<SEC-DOCUMENT>0001193125-25-290911.txt : 20260410
<SEC-HEADER>0001193125-25-290911.hdr.sgml : 20260410
<ACCEPTANCE-DATETIME>20251121111536
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-25-290911
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20251121
<PUBLIC-REL-DATE>20260410
DATE AS OF CHANGE:		20251121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seaport Therapeutics, Inc.
		CENTRAL INDEX KEY:			0002042347
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				992235719
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-08713
		FILM NUMBER:		251505676

	BUSINESS ADDRESS:	
		STREET 1:		6 TIDE STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-807-4062

	MAIL ADDRESS:	
		STREET 1:		6 TIDE STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on November&nbsp;21,
2025. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information
herein remains strictly confidential. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8194;&#8194;&#8194;&#8194;&#8194;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">99-2235719</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>101 Seaport Blvd., Floor 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">807-4062</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)
</B></P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Daphne Zohar </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>101 Seaport Blvd., Floor 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">807-4062</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service)
</B></P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell S. Bloom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Benjamin K. Marsh</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Kristen
M. McCarthy</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>100 Northern Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston,
Massachusetts 02210</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Nathan Ajiashvili</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Salvatore Vanchieri</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Sandy
Kugbei</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1271 Avenue of the Americas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10020</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">906-1200</FONT></B></P></TD></TR>
</TABLE> <center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after this registration statement becomes
effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, as amended, check the following box:&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state or other jurisdiction where the
offer or sale is not permitted.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>Subject to Completion, Dated
&#8195;&#8195;&#8195;&#8195;, 2026 </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;&#8195;Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00a03.jpg" ALT="LOGO" STYLE="width:2.98667in;height:1.12833in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is an initial public offering of shares of common stock of Seaport Therapeutics, Inc. We are offering &#8195;&#8195;&#8195;&#8195;&#8195;
shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. It is currently estimated that
the initial public offering price per share will be between $&#8195;&#8195;&#8195;&#8195;&#8195; and $&#8195;&#8195;&#8195;&#8195;&#8195;. We intend to apply to list our common stock on the Nasdaq Global Market under the symbol &#8220;SPTX.&#8221;
We believe that upon the completion of this offering, we will meet the standards for listing on the Nasdaq Global Market, and the completion of this offering is contingent upon such listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; as defined under the U.S. federal securities laws
and, as such, we have elected to comply with certain reduced public company reporting requirements in this prospectus. For additional information, see the section titled &#8220;Prospectus Summary&#8212;Implications of Being an Emerging Growth
Company and a Smaller Reporting Company.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See the section titled
&#8220;<A HREF="#toc73463_4">Risk Factors</A>&#8221; beginning on page 14 to read about factors you should consider before deciding to invest in shares of our common stock. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to Seaport Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For additional information regarding compensation payable to the underwriters, see the section titled
&#8220;Underwriting.&#8221; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters the option to purchase up to an additional
&#8195;&#8195;&#8195;&#8195; shares of common stock from us, at the initial public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to &#8195;&#8195;% of the shares offered by this prospectus for sale, at the initial public
offering price, to our directors, officers, certain employees and certain other persons associated with us. See the section &#8220;<I>Underwriting&#8212;Directed Share Program</I>.&#8221;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares against payment on or about &#8195;&#8195;&#8195;&#8195;, 2026. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Leerink&nbsp;Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Stifel</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated &#8195;&#8195;&#8195;&#8195;, 2026 </B></P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_13">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_14">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_15">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_16">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_17">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_18">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_19">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_20">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_22">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_23">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_24">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all references in this prospectus to &#8220;Seaport,&#8221; the
&#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221;, or similar terms refer to Seaport Therapeutics, Inc. and its wholly owned subsidiaries, or either or all of them as the context may require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained
in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information
that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable
free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of our common stock, and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own, have applied for, or have rights to use one or more registered and common law trademarks, service marks, and/or trade names in
connection with our business in the United States, which may be used throughout this prospectus. This prospectus also includes trademarks, tradenames, and service marks of third parties which are the property of their respective owners. Our use or
display of third-parties&#8217; trademarks, service marks, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tradenames, or products in this prospectus and our other public filings is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience,
the trademarks, service marks, logos and trade names referred to in this prospectus and our other public filings may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, TM or SM symbols, but the omission of such references
is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable owner of or licensor to these trademarks, service marks, and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET, INDUSTRY, AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market data and certain other statistical information used throughout this prospectus are based on independent industry publications,
governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that their information has been
obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe that these sources are
reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as
they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this
prospectus. Some data are also based on our good faith estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRESENTATION OF FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the applicable provisions of the Fixing America&#8217;s Surface Transportation Act, we are omitting our audited financial
statements as of and for the year ended December&nbsp;31, 2023 and our unaudited financial statements as of and for the nine months ended September&nbsp;30, 2024 and 2025 because they relate to historical periods that we believe will not be required
to be included in the prospectus at the time of the contemplated offering. We intend to amend this registration statement to include all financial information required by Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities
Act of 1933, as amended, at the date of such amendment before distributing a preliminary prospectus to investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware as SP Therapeutics, Inc. on April&nbsp;1, 2024 and changed our name to Seaport
Therapeutics, Inc. on April&nbsp;2, 2024. Our wholly owned subsidiary, SPTX, Inc., was a result of the incorporation of a predecessor company under the laws of the State of Delaware in February 2024 under the name Seaport Therapeutics, Inc., which
subsequently changed its name to Seaport Therapeutics Holdings, Inc. in March 2024 and to SPTX, Inc. in April 2024. In April 2024, we entered into a share exchange agreement, or the Share Exchange Agreement, with SPTX, Inc., which resulted in SPTX,
Inc. becoming our wholly owned subsidiary. On April&nbsp;8, 2024, or the Asset Transfer Date, we entered into an Asset Transfer Agreement, or the Asset Transfer Agreement, with PureTech Health LLC, or PureTech Health, and PureTech LYT Inc., or
PureTech LYT, pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of their right, title, and interest in, to and under the assets related to its Glyph<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP><SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> technology or products, subject to the terms set forth in the Asset Transfer Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements presented in this prospectus for periods prior to the Asset Transfer Date, which are included in the consolidated
financial statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis from the financial statements of PureTech Health plc, or PureTech, to represent our
financial position and performance as if we had existed on a standalone basis. The financial statements presented in this prospectus for periods from and after the Asset Transfer Date reflect our financial position and performance as a standalone
entity. All of our assets, liabilities and expenses as of and for the periods prior to the Asset Transfer Date were identified based on the assets and liabilities contributed to us from PureTech, as well as indirect costs that were not specifically
identifiable to us or our related programs but were considered necessary to operate as a standalone company. Management believes the assumptions underlying our <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements are reasonable.
Nevertheless, the <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements may not include all of the actual expenses that would have been incurred had we operated as a standalone company during the periods presented, and may not
reflect our results of operations, financial position, and cash flows had we operated as a standalone company during the periods presented. Actual costs that would have been incurred if we had operated as a standalone company would depend on
multiple factors, including organizational structure and strategic decisions made in various areas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information
you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections of this prospectus titled &#8220;Risk Factors,&#8221; &#8220;Special Note Regarding Forward-Looking Statements,&#8221;
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated
mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary
Glyph<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> platform to overcome those limitations and invent innovative oral therapies. Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby
enhance a drug&#8217;s oral bioavailability and reduce side effects. This process, which we call &#8220;Glyphing,&#8221; also creates new composition of matter intellectual property. Our experienced team of industry leaders has a proven track record
in neuropsychiatry drug discovery and development and delivering successful business outcomes. We aim to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment options that will make a significant impact for patients and their families. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, GlyphAllo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300</FONT>
or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects.
GlyphAllo is designed to overcome bioavailability limitations of allopregnanolone and deliver rapid and durable efficacy in major depressive disorder, or MDD. We have demonstrated in a Phase 1 clinical trial that GlyphAllo reaches therapeutically
relevant exposures with oral dosing, and in a Phase 2a clinical trial, GlyphAllo demonstrated initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> with an objective biomarker of stress in healthy
volunteers and a favorable tolerability profile. We have initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress and anticipate topline data in &#8195;&#8195;&#8195;&#8195; .
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>
<FONT STYLE="white-space:nowrap">(SPT-320</FONT> or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder, or GAD,
in Australia and MDD in Australia and the European Union, or EU. We have initiated a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 1 trial for the treatment of GAD and expect topline data in
&#8195;&#8195;&#8195;&#8195; . We are also advancing Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-348</FONT> or Glyph
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD),</FONT></FONT> a novel, Glyphed oral prodrug of the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> LSD analog <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> in preclinical studies for depressive disorders, including treatment-resistant depression, or TRD, post-traumatic stress disorder, or PTSD, and headache disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Globally, over one billion people are living with mental illness as of 2021, comparable in prevalence to obesity or hypertension. According to
the World Health Organization, as of 2021, depression affects approximately 332&nbsp;million people worldwide and anxiety affects approximately 359 million people worldwide, and there is a significant need for novel treatment options. Currently
approved drugs for MDD and GAD have significant limitations, including modest efficacy, slow onset of action, and unfavorable side effects. Advancement of novel therapies has been limited by a lack of understanding of disease pathophysiology, poor
drug-like properties, and challenges in clinical trial design and execution leading to high clinical development failure rates. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our differentiated approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are uniquely positioned to overcome the challenges of developing medicines for depression, anxiety, and other neuropsychiatric disorders by
leveraging our differentiated, three-pillar approach: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Identify clinically validated mechanisms held back by issues that can be
addressed by our proprietary </I></B><B><I>Glyph</I></B><B><I> platform. </I></B>We select our product candidates based on well-established clinical data, defined as demonstrated meaningful benefits compared to placebo in multiple randomized,
placebo-controlled clinical trials in a large number of patients. We identify drugs matching this profile where clinical and commercial potential have been limited by high first-pass metabolism, low bioavailability, and/or side effects. We advance
candidates that have the potential to be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> new medicines
and to impact<I> </I>a large number of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Create novel medicines with strong intellectual property using
</I></B><B><I>Glyph</I></B><B>.</B> Glyph is our proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. Typically, <FONT STYLE="white-space:nowrap">non-Glyphed</FONT> oral small
molecules undergo first-pass metabolism, where the concentration of drug is significantly reduced by metabolic enzymes in the liver prior to systemic circulation. First-pass metabolism can lead to low bioavailability (i.e., reduced concentration of
active drug available to target organs) and/or side effects, including liver enzyme elevations or hepatotoxicity. Glyph leverages a separate absorption path taken by dietary fats. A Glyphed molecule uses this alternative route via the intestinal
lymphatic system to bypass first-pass metabolism and transit directly into systemic circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism. For each program, we use
Glyph to create unique sets of prodrugs with differentiated profiles, and evaluate these prodrugs as potential candidates to advance into preclinical and clinical studies. Glyph has been applied to create novel product candidates for our pipeline
resulting in new intellectual property, including composition of matter patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Benefits of Our Proprietary Glyph Platform </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00n11.jpg" ALT="LOGO" STYLE="width:6.33333in;height:3.21778in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Apply our team</I></B><B><I>&#8217;</I></B><B><I>s expertise to optimize the design and execution of
clinical trials and drive successful business outcomes</I></B><B>.</B> Our team is comprised of industry leaders with a proven track record of building successful companies that have developed and commercialized innovative neuropsychiatric
medicines. This includes </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Zyprexa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Cymbalta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
Latuda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Zurzuvae<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, and Cobenfy<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (xanomeline-trospium or KarXT), which was approved
by the FDA in September 2024 and is the first new class of medicines in over 30 years for patients living with schizophrenia. Leveraging our team&#8217;s track record of success in neuropsychiatry discovery and clinical development is important as
we select new product candidates and as we implement key design elements in our clinical trials to<B><I> </I></B>optimize treatment effect and duration and reduce placebo response. In parallel, we apply our deep experience in building successful
companies to establish clear goals, drive strategic decision-making, and maintain financial discipline. Drawing on our track record of success in neuropsychiatry, we aim to drive successful outcomes for patients and shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a
pipeline of potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicines to treat
neuropsychiatric disorders with significant unmet need. We retain exclusive, worldwide development and commercialization rights to all of our product candidates and discovery programs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00n12.jpg" ALT="LOGO" STYLE="width:6.33333in;height:2.88in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAllo: Potential First- and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-Class</FONT></FONT> Therapy for MDD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo is a
novel, Glyphed oral prodrug of allopregnanolone, an endogenous neurosteroid and gamma-aminobutyric acid A, or GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB>, positive allosteric modulator, or PAM. Allopregnanolone is a naturally
occurring molecule that reduces stress, with levels that peak during the third trimester of pregnancy. An intravenous infusion formulation of allopregnanolone was approved for the treatment of postpartum depression, or PPD, a form of MDD.
Allopregnanolone has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects, but its scope of clinical use has been constrained by oral bioavailability limitations that the
Glyph platform is uniquely designed to solve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 1 clinical trial, GlyphAllo demonstrated a greater than nine-fold increase in
bioavailability compared to the previously reported bioavailability of oral allopregnanolone, enabling therapeutically relevant exposures with a favorable tolerability profile that supports chronic dosing. GlyphAllo has also demonstrated initial <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in a Phase 2a randomized, placebo-controlled trial using the Trier Social Stress Test, or TSST, a validated clinical model of anxiety in healthy volunteers.
Based on these Phase 1 and Phase 2a data, we believe GlyphAllo has the potential to become a first- and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for MDD. We advanced GlyphAllo into the
potentially registration-enabling Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in July 2025. <FONT STYLE="white-space:nowrap">BUOY-1</FONT> is a global, randomized, double-blind, placebo-controlled trial evaluating the efficacy,
safety, and tolerability of GlyphAllo </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in adults with MDD, with or without anxious distress. MDD with anxious distress is a form of MDD characterized by significant anxiety. Approximately 60% of patients with MDD meet the criteria for
anxious distress. This trial is expected to enroll up to approximately 360 patients, randomized 1:1 to receive either GlyphAllo or placebo once-daily over a <FONT STYLE="white-space:nowrap">six-week</FONT> treatment period. The primary endpoint of
the trial is the change from baseline at six weeks in the Hamilton Depression Rating Scale-17, or <FONT STYLE="white-space:nowrap">HAMD-17,</FONT> a regulatory-standard depression severity rating scale. Following the initial treatment period,
eligible patients may enter an open-label extension trial, in which all participants will receive GlyphAllo for up to six additional weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previous clinical development of allopregnanolone and its synthetic analogs in indications beyond PPD has been hindered by poor oral
bioavailability, safety concerns, and clinical trial design limitations. GlyphAllo is designed to enhance the oral bioavailability of allopregnanolone and achieve systemic exposures comparable to an intravenous infusion of allopregnanolone, with
once-daily oral dosing. We believe our ongoing Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial improves upon the design of previous third-party clinical trials that evaluated a synthetic analog of allopregnanolone in several important
ways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are improving durable efficacy by treating patients for the full <FONT STYLE="white-space:nowrap">six-week</FONT> duration of
the primary endpoint time frame, as opposed to previous trials that treated patients for only the first two weeks and assessed efficacy after six weeks. As allopregnanolone also has an anxiolytic effect, we are also enrolling patients that have MDD
with or without anxious distress. To reduce placebo response, we are optimizing the frequency of clinician-administered assessments, as our comprehensive meta-analysis of recent antidepressant trials demonstrated that the frequency of these
assessments is positively correlated with the magnitude of the placebo response in MDD trials. We are also including a single treatment arm and will flex dose to a target dose, similar to the strategy implemented at Karuna Therapeutics, since the
number of active arms is positively associated with increased placebo response. Additionally, we are scrutinizing site selection and patient enrollment to ensure appropriate diagnosis and exclude inappropriate patients, including those with inflated
baseline ratings and those who are concurrently participating in other studies. We expect topline data from the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAgo: Potential First- and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-class</FONT></FONT> Therapy for
GAD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAgo is a novel, Glyphed oral prodrug of agomelatine that we are advancing in a key Phase 1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial for the treatment of GAD. Agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C
<FONT STYLE="white-space:nowrap">(5-HT2C)</FONT> receptor antagonist, is an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and MDD in Australia and the European Union, or EU. In GAD, agomelatine has
demonstrated statistically significant separation from placebo in all four third-party <FONT STYLE="white-space:nowrap">placebo-controlled</FONT> studies and has better efficacy and tolerability &#8211; including reduced risk of abuse potential,
sexual dysfunction, and weight gain &#8211; than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs, like selective serotonin-reuptake inhibitors, or SSRIs, or benzodiazepines. However, over 90% of
unmodified agomelatine is lost to first-pass liver metabolism and its use has been limited by dose-dependent liver enzyme elevations. Its label in both Australia and the EU requires liver function testing before initiating treatment, during
treatment, and upon increasing the dose. Agomelatine is not approved in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using our proprietary Glyph platform, GlyphAgo
is designed to avoid first-pass liver metabolism and increase systemic exposure of agomelatine, enabling exposure levels of agomelatine that are effective in GAD but at a lower dose that reduces liver exposure and reduces or eliminates the need for
liver function testing. Based on internal analyses, we believe a <FONT STYLE="white-space:nowrap">two-fold</FONT> increase in the bioavailability of agomelatine with GlyphAgo dosing will reduce or eliminate liver enzyme elevations. In a series of
preclinical studies in <FONT STYLE="white-space:nowrap">non-human</FONT> primates, or NHPs, we showed that oral dosing of GlyphAgo increased plasma exposure of agomelatine versus agomelatine alone above this
<FONT STYLE="white-space:nowrap">two-fold</FONT> target. Therefore, based on the data we have generated to date, we believe GlyphAgo has the potential to become a first- and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for GAD. The ongoing Phase 1 trial </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be conducted in multiple parts to evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo and compare the pharmacokinetics of GlyphAgo to agomelatine alone. It will include
single- and multiple-ascending dose cohorts, as well as a food-effect crossover portion, using both open-label and placebo-controlled designs. We expect topline data from our Phase 1 trial of GlyphAgo in&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Glyph2BLSD and Additional Applications of the Glyph Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph2BLSD is our novel, Glyphed oral prodrug of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> a
differentiated <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen. Glyph2BLSD is designed to harness the differentiated and <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> which has rapidly acting clinical activity and has not exhibited the fibrosis, cardiovascular effects, or hallucinations characteristic of some other
neuroplastogens. Glyph2BLSD is designed to improve the pharmacokinetic and tolerability profile of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> while maintaining therapeutic exposure levels.
Glyph2BLSD&#8217;s <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile unlocks the potential to enable convenient outpatient and repeat dosing to improve efficacy. We are advancing Glyph2BLSD through preclinical studies and are
developing Glyph2BLSD for the treatment of depressive disorders, including TRD, PTSD, and headache disorders with significant unmet need. We are also leveraging the power of the Glyph platform to explore additional applications in central nervous
system, or CNS, and <FONT STYLE="white-space:nowrap">non-CNS</FONT> diseases and advance programs that address significant unmet needs in these areas.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport was founded by pioneers
in the neuropsychiatry field and is led by a team of seasoned industry veterans with a shared mission to transform the treatment of neuropsychiatric disorders and improve patients&#8217; lives. We have assembled an experienced group of individuals
with a proven track record of building successful companies that have developed and commercialized innovative neuropsychiatric medicines. Members of our leadership team have collaborated successfully over several decades on the discovery,
development, and commercialization of neuropsychiatric medicines including Cobenfy, Latuda, Zyprexa, Cymbalta, and Zurzuvae. Our <FONT STYLE="white-space:nowrap">co-founders,</FONT> Daphne Zohar and Dr.&nbsp;Steven Paul, were central to the success
of Karuna Therapeutics, which invented and advanced the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicine Cobenfy, and was acquired by Bristol Myers Squibb in March 2024 for $14&nbsp;billion.
Cobenfy was approved by the FDA in September 2024 and is the first drug to provide a new mechanism of action for schizophrenia in over 30 years. Cobenfy is estimated to achieve annual peak sales of over $5&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have raised $325&nbsp;million in net proceeds from leading life science investors, including shareholders with
holdings greater than 5%: ARCH Venture Partners, General Atlantic, Sofinnova Investments, Third Rock Ventures, and our founder, PureTech. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We founded our company with a mission to develop life-changing treatments for patients with depression, anxiety, and other
neuropsychiatric disorders. The key elements of our business strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Successfully advance GlyphAllo through clinical development for the treatment of patients with MDD with or
without anxious distress. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Successfully advance GlyphAgo through clinical development for the treatment of patients with GAD.<B> </B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop a robust pipeline of differentiated programs for neuropsychiatric and other CNS disorders by leveraging
our Glyph platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opportunistically pursue strategic partnerships to maximize the value of our Glyph platform.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach</B><B><I> </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are uniquely positioned to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicines that will make a significant impact for patients and their families through our differentiated, three-pillar approach: 1) identify clinically validated
mechanisms held back by issues that can be addressed by our proprietary Glyph platform, 2) create novel medicines with strong intellectual property using Glyph, and 3) apply our team&#8217;s expertise to optimize the design and execution of clinical
trials and drive successful business outcomes. We believe our approach will enable us to develop transformative treatments for patients and build a leading neuropsychiatry company.<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated With Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business is subject to a number of risks of which you should be aware before making an investment decision. These risks include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage therapeutics company with a limited operating history, which may make it difficult to
evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require additional funding in order to finance operations. If we are
unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business is highly dependent on the success of our product candidates, particularly GlyphAllo for the
treatment of MDD with or without anxious distress and GlyphAgo for the treatment of generalized anxiety disorder, or GAD, and MDD. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize one or
more of our product candidates, or if we experience delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical and preclinical development involves a lengthy and expensive process and is highly uncertain. Any
difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our
commercial prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA and other comparable regulatory authorities are lengthy,
time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary Glyph platform is based on a novel approach that may not result in approvable or marketable
products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials
conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates may be associated with adverse events, or AEs, or other undesirable properties or safety
risks, which could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials or abandon a product candidate, limit the commercial profile of an approved label, or result in significant negative consequences
following regulatory approval, if obtained, or result in other significant negative consequences that could severely harm our business, financial condition, results of operations, and prospects.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have concentrated our research and development efforts on the treatment of disorders of the brain and central
nervous system, a field that faces certain challenges in drug development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Existing and potential future competitive products may reduce or eliminate the commercial opportunity for our
product candidates, if approved. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully
commercialize our product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to develop product candidates, leverage our Glyph platform and our future growth depends on
attracting, hiring, and retaining our key personnel and recruiting additional qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to assist in conducting our clinical trials and preclinical studies. If they do not
successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or
commercialization may be delayed, and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our
intellectual property and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates
similar to ours and our ability to successfully develop and commercialize our product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are heavily reliant upon the Amended and Restated License Agreement with Monash University, or the Monash
License Agreement, pursuant to which we have been granted an exclusive, royalty-bearing license to certain patent rights that are important or necessary to the development of our proprietary technology and product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">While we may in the future seek designations for our product candidates with the FDA and other comparable
regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such designations. In addition,
even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our results of operations for the period from January&nbsp;1, 2024 to April&nbsp;7, 2024, which are included in
the consolidated financial statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis based on management estimates, assumptions, and judgments about
appropriate allocation and may not be indicative of what they would have been had we actually been an independent standalone entity throughout such period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There has been no prior public market for our common stock, and an active trading market may not develop or be
sustained. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary risk factors described above should be read together with the text of the full risk factors in
the section titled &#8220;Risk Factors&#8221; and the other information set forth in this prospectus, including our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange
Commission, or the SEC. The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial may
also materially adversely affect our business, financial condition, results of operations, and future growth prospects. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware as SP Therapeutics, Inc. on April&nbsp;1, 2024 and changed our name to Seaport
Therapeutics, Inc. on April&nbsp;2, 2024. Our wholly owned subsidiary, SPTX, Inc., was a result of the incorporation of a predecessor company under the laws of the State of Delaware in February 2024 under the name Seaport Therapeutics, Inc., which
subsequently changed its name to Seaport Therapeutics Holdings, Inc. in March 2024 and to SPTX, Inc. in April 2024. In April 2024, we entered into a share exchange agreement, or the Share Exchange Agreement, with SPTX, Inc., which resulted in SPTX,
Inc. becoming our wholly owned subsidiary. At the time of the Share Exchange Agreement, we were a wholly-owned subsidiary of PureTech. Our principal executive offices are located at 101 Seaport Blvd., Floor 12, Boston, Massachusetts 02210, and our
telephone number is (617) <FONT STYLE="white-space:nowrap">807-4062.</FONT> We have three subsidiaries, Seaport Therapeutics Securities Corporation, formed in December 2024 under the laws of the Commonwealth of Massachusetts, SPTX, Inc., formed in
February 2024 under the laws of the State of Delaware, and Seaport Therapeutics Australia Pty Ltd, formed in February 2025 under the laws of Australia. Our website address is <I>www.seaporttx.com</I>. The information contained in or accessible from
our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS
Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited
interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any
golden parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may remain an
emerging growth company for up to five years from the date of the first sale in this offering. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual
gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these exemptions. We have taken
advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides
that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we may not
be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of
other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We have in the past chosen and may in the future choose to early adopt any new or revised accounting standards whenever such early
adoption is permitted for private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our
shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million
during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250&nbsp;million measured on the last business day of our second fiscal quarter or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may
continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial
statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;&#8195;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of common stock offered by us </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days to purchase up to &#8195;&#8195;&#8195;additional shares of common stock from us at the public offering price, less underwriting discounts and commissions on the same terms as
set forth in this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;&#8195;shares (or &#8195;&#8195;&#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase additional shares of common stock in full) </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from the sale of our common stock in this offering will be approximately $ &#8195;&#8195;&#8195;&#8195;&#8195;million (or approximately $ million if the underwriters exercise their option to purchase
additional&#8195;&#8195;&#8195;&#8195;&#8195; shares of common stock in full), based on the assumed initial public offering price of $ &#8195;&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price range set forth on the cover page
of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds we receive from this offering, together with our existing cash, cash
equivalents, and investments, to advance development of GlyphAllo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300),</FONT> GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT
STYLE="white-space:nowrap">(SPT-320),</FONT> and Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP><FONT STYLE="white-space:nowrap">(SPT-348)</FONT> and other candidates, as well
as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purposes. For additional information, see the section titled &#8220;Use of Proceeds.&#8221; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Directed share program </P></TD>
<TD>At our request, the underwriters have reserved up to &#8195;&#8195;% of the shares of common stock being offered by this prospectus for sale at the initial public offering price to our directors, officers, certain employees, and certain other
persons associated with us. We do not know if these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Any
reserved shares not so purchased will be offered by the underwriters to the general public on the same terms as the other shares of common stock. Except for reserved shares purchased by our executive officers and directors, these reserved shares
will not be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described elsewhere in this prospectus. For additional information, see the section titled &#8220;Underwriting&#8212;Directed Share Program.&#8221;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">For a discussion of factors you should carefully consider before deciding whether to invest in our common stock, see the section titled
&#8220;Risk Factors.&#8221; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market trading symbol </P></TD>
<TD>&#8220;SPTX&#8221; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise noted, the number of shares of our common stock that will be outstanding
after this offering is based on&#8195;&#8195;&#8195;&#8195;shares of common stock (which includes &#8195;&#8195;&#8195;&#8195;shares of unvested restricted common stock) outstanding as of December&nbsp;31, 2025, after giving effect to the conversion
of all outstanding shares of our convertible preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195; shares of common stock immediately prior to the completion of this offering, or the Preferred Stock Conversion, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock issuable upon exercise of outstanding stock options as of
December&nbsp;31, 2025 under our 2024 Equity Incentive Plan, as amended, or the 2024 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share, and&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon
exercise of outstanding stock options granted after December&nbsp;31, 2025 pursuant to our 2024 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance as of December&nbsp;31, 2025
under the 2024 Plan, which will cease to be available for issuance at the time that our 2026 Stock Option and Incentive Plan, or the 2026 Plan, becomes effective; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock to be granted to an executive officer and a director
under the 2026 Plan, issuable upon the exercise of stock options, with an exercise price that is equal to the initial public offering price in this offering, or a number of shares of restricted common stock, as applicable, or the IPO Grants, equal
to approximately 12.5% of the number of shares of our common stock to be outstanding upon the closing of this offering calculated on a fully diluted basis; see the sections titled &#8220;Executive Compensation&#8212;Narrative disclosure to the 2025
Summary Compensation Table&#8212;Equity Incentive Compensation&#8221; and &#8220;Director Compensation&#8221; for more information on such grants, including a description of how the number of shares issuable pursuant to such grants will be
determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our
2026 Plan, including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the
number of shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock reserved for future issuance under our 2026 Employee Stock
Purchase Plan, or the ESPP, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common
stock reserved for future issuance under the ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the information in this prospectus
reflects or assumes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">1-for-&#8195;&#8195;&#8195;&#8195;reverse</FONT> stock split of our common
stock, which will become effective prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding stock options described above after December&nbsp;31, 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the underwriters&#8217; option to purchase up to an additional shares of common stock in this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no purchases by existing stockholders or their affiliates pursuant to the directed share program; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the
completion of this offering and the adoption of our amended and restated bylaws to be in effect upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth our summary consolidated statements of operations data for the years ended December&nbsp;31, 2024 and 2025 and
our summary consolidated balance sheet data as of December&nbsp;31, 2025. We have derived the summary consolidated statements of operations data for years ended December&nbsp;31, 2024 and 2025, and the summary consolidated balance sheet data as of
December&nbsp;31, 2025, from our audited consolidated financial statements included elsewhere in this prospectus. The historical results for the period from January&nbsp;1, 2024 to April&nbsp;7, 2024, which are included in the consolidated financial
statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis and are not necessarily indicative of results that may be expected in the future, nor are our other
historical results necessarily indicative of the results that may be expected for any period in the future. You should read the following summary financial data together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus. The summary consolidated financial data included in this section are not intended to replace the consolidated
financial statements and are qualified in their entirety by our consolidated financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (including stock-based compensation of $0.7&nbsp;million)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative (including stock-based compensation of $15.2&nbsp;million)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense), net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212; &#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss and comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted <SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,961,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited) <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding, basic and diluted (unaudited) <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Notes 2 and 15 to our consolidated financial statements included elsewhere in this prospectus for details
on the calculation of basic and diluted net loss per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give
effect to adjustments to our capital structure arising in connection with the completion of this offering </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and is calculated by dividing the pro forma net loss attributable to common stockholders by the pro forma weighted-average common shares outstanding for the period. Pro forma weighted-average
common shares outstanding is computed by adjusting the weighted-average common shares outstanding to give pro forma effect to the Preferred Stock Conversion as if such conversion had occurred on January&nbsp;1, 2025. Pro forma basic and diluted net
loss per share attributable to common stockholders does not include the effect of the shares expected to be sold in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>As</B><br><B>adjusted&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma balance sheet data give effect to (i)&nbsp;the Preferred Stock Conversion and (ii)&nbsp;the
filing and effectiveness of our amended and restated certificate of incorporation in Delaware immediately prior to the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted balance sheet data give effect to (i)&nbsp;the pro forma adjustments set forth in
footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;<I>&#8195;&#8195; </I>per share, which is the midpoint of the price range
set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Pro forma as adjusted balance sheet data is illustrative only and will change based
on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;<I>&#8195;&#8195; </I>per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and investments, working capital, total assets, and total stockholders&#8217;
equity by approximately $&#8195;&#8195;&#8195;<I>&#8195;&#8195; </I>, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Each 1,000,000 increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of
each of cash, cash equivalents, and investments, working capital, total assets and total stockholders&#8217; equity by approximately $&#8195;&#8195;&#8195;<I>&#8195;&#8195; </I>million, assuming no change in the assumed initial offering price per
share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements
appearing elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties
described below, as well as the other information in this prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus and &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; before deciding whether to invest in our common stock. The risks described below are not the only ones facing us. The following risks or additional risks and uncertainties not presently known to us or that
we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations, and growth prospects. In such an event, the trading price of our common stock could decline, and you may lose all
or part of your investment. This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our
actual results could differ materially from those anticipated in our forward-looking statements as a result of specific factors, including the risks and uncertainties described below. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Condition, and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage therapeutics company with a limited operating history, which may make it difficult to evaluate our current
business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage therapeutics company with a limited operating history. We were formed by PureTech Health plc, or PureTech, in April
2024 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, advancing our Glyph<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform and technology, identifying
potential product candidates, securing intellectual property rights, and planning and undertaking preclinical studies and clinical trials. Our Glyph platform was being developed by members of our current team during their tenure at PureTech up to
the date of our entry into an Asset Transfer Agreement , or the Asset Transfer Agreement, with PureTech Health LLC, or PureTech Health, and PureTech LYT, Inc., or PureTech LYT, at which time we became a standalone company. As such, our results of
operations for the period from January&nbsp;1, 2024 to April&nbsp;7, 2024, which are included in the consolidated financial statements for the year ended December&nbsp;31, 2024, have been carved out from the results of operations of PureTech that
were attributable to operations related to our Glyph platform and our product candidates, based on management estimates, assumptions, and judgments about appropriate allocation and may not be indicative of what they would have been had we actually
been an independent standalone entity throughout such period, nor are they necessarily indicative of our future results of operations, financial position, and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At Seaport, we have not yet demonstrated an ability to generate product or collaboration revenues, obtain regulatory approvals, manufacture
any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. All preclinical and early clinical development of GlyphAllo<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300),</FONT> certain preclinical development of GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>
<FONT STYLE="white-space:nowrap">(SPT-320)</FONT> and our other candidates prior to our formation was conducted when we were part of PureTech. Despite our affiliation with PureTech, and members of our current team&#8217;s involvement in the
development of the Glyph platform while at PureTech, our limited operating history as a standalone company makes any reliance on past performance uncertain. We will encounter risks and difficulties frequently experienced by early-stage therapeutics
companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop, and commercialize product candidates based on our Glyph
platform. We do not know whether we will be able to develop any product candidates that succeed through clinical development or to develop products of commercial value. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have no products approved for commercial sale and have not generated any revenue from product sales or collaboration arrangements to date. We will continue to incur significant research and
development and other expenses related to our preclinical and clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Net losses and negative cash flows have had,
and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. Our net losses totaled $46.9 and $&#8195;&#8195;&#8195;&#8195;million for the years ended December&nbsp;31, 2024 and 2025, respectively. As of
December&nbsp;31, 2025, we have not yet generated product or collaboration revenue and had an accumulated deficit of $&#8195;&#8195;&#8195;&#8195;. We expect to continue to incur significant losses for the foreseeable future, and we expect these
losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates. The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful initiation and completion of preclinical studies with favorable results, including toxicology and
other studies designed to be compliant with good laboratory practice, or GLP, requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allowance to proceed with clinical trials under Investigational New Drug applications, or INDs, by the United
States Food and Drug Administration, or the FDA, or of similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful initiation, enrollment, and completion of clinical studies in accordance with good clinical practice,
or GCPs, requirements and other applicable rules and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the frequency and severity of adverse events, or AEs, observed in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and establishing relationships with contract research organizations, or CROs, and clinical sites for
the clinical development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating the safety and efficacy of our product candidates to the satisfaction of the FDA and other
applicable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of regulatory approvals from applicable regulatory authorities, including approvals of New Drug
applications, or NDAs, from the FDA, and maintaining any such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with third-party manufacturers for, or establishing, clinical or commercial manufacturing
capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing, and distribution capabilities and launching commercial sales of our product
candidates, if and when approved, either alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, establishing, and maintaining patent and trade secret protection or regulatory exclusivity for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining an acceptable safety profile of our product candidates following regulatory approval, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of people who can develop and, if approved, commercialize, market and
sell our product candidates, if approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our product candidates, if approved, by patients, the medical community and third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our expenses will increase substantially if, and as, we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our product candidates through preclinical and clinical development, including advancing GlyphAllo<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>and GlyphAgo through later-stage clinical trials, and other candidates through discovery and early clinical and preclinical stages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for our product candidates that successfully complete clinical trials from the U.S.
Food and Drug Administration, or the FDA, and/or other foreign comparable regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, quality control, medical, scientific, and other technical personnel to support the
clinical development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our internal capabilities to support clinical-stage development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase our headcount as we expand our research and development organization, and
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> planning activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undertake any activities to establish sales, marketing, and distribution capabilities in preparation for
commercialization, as applicable, including hiring additional personnel to support such operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, acquire, and develop additional product candidates where we can leverage our Glyph platform,
including through business development efforts to invest in or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience heightened regulatory scrutiny; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments due under the Asset Transfer Agreement and/or the License Agreement
with Monash University, or the Monash License Agreement, and any future <FONT STYLE="white-space:nowrap">in-license</FONT> or collaboration agreements with third parties; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therapeutic product development entails substantial upfront capital expenditures and significant risk that any
potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, secure market access, and reimbursement and become commercially viable, and therefore any investment in us is highly
speculative. Accordingly, before making an investment in us, you should consider our prospects, factoring in the costs, uncertainties, delays, and difficulties frequently encountered by companies in clinical development, especially clinical-stage
therapeutics companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they would otherwise be if we had a longer operating history or a history of successfully developing and commercializing
pharmaceutical products. We may encounter unforeseen expenses, difficulties, complications, delays, and other known or unknown factors in achieving our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our expenses could increase beyond our expectations if we are required by the FDA or other comparable regulatory authorities to
perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will require additional funding in order to finance operations. If we are unable to raise
capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing therapeutic products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and
uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory approval for, our product candidates. Even
if our current or future product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally through
private financings. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development of our product candidates, continue to identify additional targets using our Glyph
platform, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acquisitions or
<FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, we had $&#8195;&#8195;&#8195;&#8195;million of cash, cash
equivalents and investments. Based upon our current operating plan, we believe that our existing cash, cash equivalents, and investments, together with the net proceeds from this offering, will enable us to fund our operating expenses and capital
expenditure requirements through&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We may also raise additional financing
on an opportunistic basis in the future. For example, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to
secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop our product candidates. Our
future capital requirements will depend on many factors, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, costs, and results of discovery, preclinical development and clinical trials for our
current or future product candidates and effectiveness of our Glyph platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including
the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and
distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses to attract, hire, and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of macroeconomic trends including inflation, tariffs, and fluctuating interest rates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any potential supply chain interruptions or delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological, and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with research and development of product candidates, we are unable to predict the
timing or amount of our working capital requirements. In addition, if we obtain regulatory approval for our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and
distribution which make it difficult to predict when or if we will be able to achieve or maintain profitability. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company.
Accordingly, we will need to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial additional funding in order to support our continuing operations. Our ability to raise additional funds will depend on financial, economic, political and market conditions and other
factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it
could force us to delay, limit, reduce, or terminate our product development programs, future commercialization efforts or other operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our
product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations
with our existing cash, cash equivalents, and investments, the net proceeds from this offering, any future equity, debt, royalty, or other financings and upfront and milestone and royalty payments, if any, received under any future licenses or
collaborations. If we raise additional capital through the sale of equity or convertible debt securities, or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your
ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market
price of our common stock to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures, declaring dividends, or acquiring, selling, or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business. If we raise additional funds through
collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams, or product candidates, or
grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators, or others at an earlier stage than otherwise would be desirable. Attempting to secure additional financing may
also divert management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities. Any of these occurrences may have a material adverse effect on our business, financial condition, results of
operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business is highly dependent on the success of our product candidates, particularly GlyphAllo for the treatment of major depressive
disorder, or MDD, with or without anxious distress and GlyphAgo for the treatment of generalized anxiety disorder, or GAD, and MDD. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize one
or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, as an
organization, we have not completed the development of any product candidates and nearly all of our candidates remain in early-stage clinical or preclinical development. Our future success and ability to generate revenue from our product candidates
is dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize one or more of our product candidates. All of our product candidates that we pursue will require substantial additional investment for clinical
development, regulatory review, and approval in one or more jurisdictions. If any of our product candidates, particularly GlyphAllo for MDD with or without anxious distress, and GlyphAgo for GAD and MDD, encounters safety or efficacy problems,
development delays or regulatory issues, or other problems, our development plans, and business would be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not
have the financial resources to continue development of our product candidates if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA or other comparable regulatory authorities that our
product candidates are safe and effective; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficiency of our financial and other resources to complete the necessary clinical trials and preclinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from our clinical trials, preclinical studies, or the clinical trials of others
for product candidates similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies, or abandon a program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related AEs experienced by subjects in our clinical trials, including unexpected toxicity results, or by
individuals using drugs or therapeutic biologics similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting an IND application, a New Drug Application, or an NDA, or other regulatory submission to the
FDA or other comparable regulatory authorities, delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension, termination, or hold, of a clinical trial once commenced; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA or other comparable regulatory authorities regarding the scope or design of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">poor effectiveness of our product candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in enrolling subjects in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of subjects from our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher than anticipated clinical trial or manufacturing costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA or other comparable regulatory authority inspection and review of our clinical trial sites,
manufacturing sites, or those of our partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or the clinical
trial protocol or otherwise meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition with existing platforms, product candidates, or therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policies, and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our therapies in particular; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficiency of our financial and other resources to complete the necessary activities to prepare for launch,
commercialization and/or resources to address coverage and reimbursement matters to the extent any of our products receive approval; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of data by the FDA or other comparable regulatory authorities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical and preclinical development involves a lengthy and expensive process and is highly uncertain. Any difficulties or delays in the
commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining approval from regulatory authorities for the commercialization of any of our product candidates, we must conduct extensive
clinical trials to demonstrate the safety and efficacy of the product candidate in humans. Before we can initiate clinical trials for any product candidates, we must submit the results of preclinical studies to the FDA or other comparable regulatory
authorities along with other information, including information about product candidate chemistry, manufacturing and controls, and our proposed clinical trial protocol, as part of an IND or similar regulatory submission. The FDA or other comparable
regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our preclinical development programs. Moreover, even if we commence
clinical trials, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our product candidates could
significantly affect our product development timelines and product development costs and harm our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know
whether our planned clinical trials will begin on time or be completed on schedule, if at all. The timing for commencement, data readouts, and completion of clinical trials can be delayed for a number of reasons, including delays related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro</I> data to
support the initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining allowance or approval from regulatory authorities to commence a trial or reaching a consensus with
regulatory authorities on trial design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities disagreeing as to the design or implementation of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval from one or more institutional review boards, or IRBs, or ethics committees at clinical trial
sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending, or terminating the trial at an investigational site, precluding enrollment
of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or amendments to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from the trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs to perform in accordance with GCP requirements or applicable regulatory rules and guidelines
in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of our product candidates for use in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up,</FONT> including subjects failing to remain in our trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients choosing an alternative product for the indications for which we are developing our product candidates,
or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue a clinical trial or costs being greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects experiencing severe or serious unexpected drug-related AEs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious AEs in trials of the same class of agents conducted by other companies that could be
considered similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of
the resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization,
or CMO, delays or failure by our CMOs or us to make any necessary changes to such manufacturing process, or failure of our CMOs to produce clinical trial materials in accordance with current Good Manufacturing Practice, or cGMP, regulations or other
applicable requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials must be conducted in accordance with the FDA and other comparable regulatory
authorities&#8217; legal requirements, regulations, and guidelines, and remain subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where such clinical trials are conducted. We could also
encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial, or by the FDA or other comparable regulatory
authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or applicable clinical trial protocols, adverse findings
from inspections of clinical trial sites by the FDA or other comparable regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may
require us to resubmit our clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, conducting clinical trials in foreign countries, as we are currently doing and may do for our current or future product candidates,
presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled subjects in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural
customs, managing additional administrative burdens associated with foreign regulatory schemes, and political and economic risks, including war, relevant to such foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many of the factors that cause or lead to the termination, suspension of, or a delay in the commencement or completion of
clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any resulting delays to our clinical trials could shorten any period during which we may have the exclusive right to commercialize our product
candidates. In such cases, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial
condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Due to the significant resources required for the development of our pipeline and
uncertainty regarding our ability to access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more
profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to invent and develop new medicines for patients with
depression, anxiety, and other debilitating neuropsychiatric disorders. Our lead product candidate, GlyphAllo for the treatment of MDD, with or without anxious distress, has been evaluated in Phase 1 and Phase 2a studies in healthy volunteers and is
currently in Phase 2b clinical development in our <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial. Our second product candidate, GlyphAgo, is being evaluated in a key
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 1 clinical study, our third product candidate, Glyph2BLSD is in preclinical studies and our other programs are at various stages of discovery and
preclinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the significant resources required for the development of our product candidates, we must decide which
product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management, and financial resources toward particular product
candidates, therapeutic areas, or indications may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the viability or market potential of
any of our product candidates or misread trends in the pharmaceutical industry, in particular for disorders of the brain and nervous system, our business, financial condition, and results of operations could be materially and adversely affected. As
a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing, or royalty arrangements in
cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We, third parties on which we rely, and our service providers are, or may become, subject to a variety of stringent and evolving privacy
and data security laws, regulations, and rules, contractual obligations, industry standards, policies, and other obligations related to privacy and data security. Any actual or perceived failure to comply with such obligations could expose us to
significant fines or other penalties and otherwise harm our business and operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we
and the third parties upon which we rely (such as our third-party CROs, and other contractors and consultants) collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share,
or, collectively, process, personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, financial information,
and data we collect about trial participants in connection with clinical trials, or, collectively, sensitive data. Our data processing activities subject us to numerous evolving privacy and data security obligations, such as various laws,
regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to privacy and data security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legislative and regulatory framework for the processing of personal data worldwide is rapidly evolving and is likely to remain uncertain
for the foreseeable future. Numerous federal, state, and local laws and regulations, including federal and state information security and data breach notification laws and regulations, federal and state consumer protection laws (e.g., Section&nbsp;5
of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws) govern the processing of health-related and other personal data. Many of these laws and regulations differ from each other and from the Health Insurance
Portability and Accountability Act of 1996, or HIPAA, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties, private litigation, and
injunctive relief. In the event that we are subject to or affected by HIPAA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses,
including providing specific disclosures in privacy notices and affording individuals certain rights concerning their personal data. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect
more states to pass similar laws in the future. While the comprehensive privacy laws that are in effect at the state level generally exempt certain data processed in the context of clinical trials, the continued development of new privacy laws at
the state level may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. Further proposed privacy legislation, if enacted, may add additional complexity, variation in
requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of data and information that could be of potential use to the growth and development of
our business, and could result in increased compliance costs and/or the necessity of making changes in our business practices and policies. The continued further development of privacy laws in different states in the country would make our
compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may be subject to new laws governing the privacy of certain specific types of data, including, most notably, consumer health
data. For example, Washington State&#8217;s My Health My Data Act broadly defines consumer health data, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent consent requirements, and grants
consumers certain rights with respect to their health data, including to request deletion of their information. Connecticut and Nevada have also passed similar laws </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulating consumer health data. State laws are changing rapidly and there is ongoing discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we would likely
become subject, if enacted. These various privacy and data security laws may impact our business activities, including our identification of research subjects, relationships with business partners, and ultimately the marketing and distribution of
our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, an increasing number of laws, regulations, and industry standards may govern privacy and data
security. For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s, or UK&#8217;s, GDPR, or UK GDPR, impose strict requirements for processing personal data. The EU GDPR and the UK GDPR,
or together, GDPR, establish stringent requirements regarding the processing of personal data, including strict requirements relating to processing of sensitive data (such as health data), ensuring there is a legal basis or condition to justify the
processing of personal data, where required strict requirements relating to obtaining consent of individuals, expanded disclosures about how personal data is to be used, limitations on retention of information, implementing safeguards to protect the
security and confidentiality of personal data, where required providing notification of data breaches, maintaining records of processing activities, and documenting data protection impact assessments where there is high risk processing and taking
certain measures when engaging third-party processors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under GDPR, companies may face temporary or definitive bans on data processing and
other corrective activities, fines of up to &#128;20&nbsp;million (&pound;17.5&nbsp;million GBP) or 4% of annual global revenues, whichever is greater, and private litigation related to processing of personal data brought by classes of data subjects
or consumer protection organizations authorized at law to represent their interests. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> could also result in a material adverse effect on our business, financial condition, and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other
countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular,
the European Economic Area, or EEA, and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly
stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law,
such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, and the UK extension thereto (which allows for
transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully
transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally compliant transfer are too onerous, we
could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant
expense, increased exposure to regulatory actions, substantial fines, and penalties, the inability to transfer data and work with partners, vendors, and other third parties, and injunctions against our processing or transferring of personal data
necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and
activities activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to privacy and data security laws, we are contractually subject to industry standards adopted by industry groups and may
become subject to such obligations in the future. We are also bound by other contractual obligations related to privacy and data security, and our efforts to comply with such obligations may not be successful. We may publish privacy policies and
marketing materials, and other statements, such as compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with certain certifications or self-regulatory principles, regarding privacy and data security. If these policies, materials or statements are found to be deficient, lacking in transparency,
deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. Obligations related to privacy and data security (and consumers&#8217; data privacy
expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.
Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data
on our behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may at times fail (or be perceived to have failed) in our efforts to comply with our privacy and data security
obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are
perceived to have failed, to address or comply with applicable privacy and data security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties,
audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In
particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per
violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, financial
condition, or results of operations, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain
jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery and Development of Our Current or Future Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA and other comparable regulatory authorities are lengthy, time-consuming and inherently
unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not permitted to commercialize, market, promote, or sell any product candidate in the United States without obtaining regulatory
approval from the FDA. Other comparable regulatory authorities impose similar requirements. The time required to obtain approval by the FDA or other comparable regulatory authorities is inherently unpredictable, but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For instance, jurisdictions outside of the United States, such as the EU, may have different requirements for regulatory
approval, which may require us to conduct additional clinical, nonclinical, or chemistry, manufacturing, and control studies. To date, we have not submitted an NDA to the FDA or similar drug approval submissions to other comparable regulatory
authorities for any product candidate. We must complete additional preclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is inherently uncertain as to outcome.
We cannot guarantee that our clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our initial and potential additional product candidates is susceptible to the risk of failure inherent at any
stage of development, including failure to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of AEs that are severe or medically or commercially unacceptable, failure to comply with
protocols or applicable regulatory requirements and determination by the FDA or other comparable regulatory authorities that a product candidate may not continue development or is not approvable. It is possible that even if any of our product
candidates have a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct, or analysis of our clinical trials.
Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of such product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect
toxicity of, or intolerability caused by, such product candidate, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case. Serious AEs or other AEs, as well as tolerability issues, could
hinder or prevent market acceptance of the product candidate at issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future product candidates could fail to receive
regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree as to the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or other comparable regulatory authorities that a
product candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or other
comparable regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our interpretation of data from clinical
trials or preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of an NDA to the FDA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may find deficiencies with or fail to approve the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or other comparable regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process as well as the
unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would substantially harm our business, results of operations and prospects. The FDA and other
comparable regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from future
clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or other comparable regulatory authorities. Furthermore, the U.S. Supreme Court&#8217;s July 2024 decision to overturn prior
established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies, and decisions may become subject to
increasing legal challenges, delays, and/or changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to obtain approval, regulatory authorities may approve any of our
product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a
product candidate with a label that does not include the labeling claims necessary or desirable for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, FDA and foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the
EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for
revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April&nbsp;26, 2023. The proposed
revisions remain to be agreed and adopted by the European Parliament and Council of the EU and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a
significant impact on the pharmaceutical industry and our business in the long term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The FDA or other comparable regulatory
authorities may disagree with our regulatory plan for our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general approach for FDA approval of a new drug
is dispositive data from two or more adequate and well-controlled clinical trials of the product candidate in the relevant patient population. Adequate and well-controlled clinical trials typically involve a large number of patients, have
significant costs and take years to complete. The FDA or other comparable regulatory authorities may disagree with us about whether a clinical trial is adequate and well-controlled or may request that we conduct additional clinical trials prior to
regulatory approval. In addition, there is no assurance that the doses, endpoints, and trial designs that we intend to use for our planned clinical trials, including those that we have developed based on feedback from regulatory agencies or those
that have been used for the approval of similar drugs, will be acceptable for future approvals. For instance, if we elect to pursue an indication of MDD with anxious distress, we will need to be able to reliably and consistently identify this <FONT
STYLE="white-space:nowrap">sub-population</FONT> of MDD patients, and we will need to demonstrate that GlyphAllo has a differentiated effect in these patients. However, the FDA may not agree with our proposed development plans, and our clinical
trial results may not support approval of our product candidates for our target indications. In addition, our product candidates could fail to receive regulatory approval, or regulatory approval could be delayed, for many reasons, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may not file or accept our NDA or marketing application for
substantive review; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with the dosing regimen, design, or
implementation of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may determine there is not substantial evidence of
effectiveness to support approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or other comparable regulatory authorities that
our product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our clinical trials may not meet the level of statistical significance required by the FDA or
other comparable regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their
safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our interpretation of data from preclinical
studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of
the FDA or other comparable regulatory authorities to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may find deficiencies with or fail to approve the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or other comparable regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our proprietary Glyph platform is based
on a novel approach that may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is utilizing our proprietary Glyph platform, which is designed to leverage the lymphatic system to enable and
enhance the oral administration of drugs, avoid first-pass liver metabolism and reduce side effects that have previously impeded the development of certain active drugs. Despite favorable results in third-party clinical trials of the active moiety
that is chemically identical to the active moiety within our product candidates and the favorable results in clinical trials of our molecules and mechanisms to date, the scientific research that forms the basis of our approach is still ongoing. Each
of our current product candidates utilizes our Glyph platform. As a result, we are exposed to a number of unforeseen risks related to our Glyph platform, and these risks could impact each of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our research and development efforts to date have resulted in a development portfolio of programs and product candidates, we may not
be able to discover or identify additional candidates that could appropriately utilize our Glyph platform and thus not be able to develop product candidates to expand our development portfolio. Even if we are successful in continuing to build and
expand our development portfolio, the potential product candidates that we identify may not be successful in clinical development. For example, even though our Glyph platform is intended to reduce certain side effects, our product candidates may
nonetheless be shown to have harmful side effects or other characteristics that indicate that they are unlikely to offer an improvement over standard of care or receive marketing approval and achieve market acceptance. If we do not successfully
develop and commercialize product candidates, we will not be able to obtain drug revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third
parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
results observed from preclinical studies or early-stage clinical trials of our product candidates may not necessarily be predictive of the results of later-stage clinical trials that we conduct. Similarly, positive results from such preclinical
studies or early-stage clinical trials may not be replicated in our subsequent preclinical studies or clinical trials. For instance, results seen in preclinical animal models may not translate to similar results in patients, and results from our
initial studies in healthy volunteers may not translate to clinical trials in patients with MDD or GAD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that
any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs proceeding through clinical trials. Many companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused
by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported AEs. Additionally, GlyphAllo is a novel,
Glyphed oral prodrug of allopregnanolone, an endogenous neurosteroid with a well-established, clinically validated antidepressant, anxiolytic, and sleep-promoting effect, and GlyphAgo is a novel, Glyphed oral prodrug of agomelatine, a clinically
validated antidepressant and anxiolytic. We may be unable to replicate the previous clinical efficacy observed with such molecules in clinical trials utilizing our Glyph platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may in the future utilize an &#8220;open-label&#8221; clinical trial design
for certain of our future clinical trials. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or
placebo. Most open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as
patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of
receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have
received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results of a product candidate when studied in a
controlled environment with a placebo or active control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, preclinical and clinical data are often susceptible to varying
interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other comparable regulatory authority approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals to commercialize any of our product
candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. We have and may in the future experience delays in our clinical trials or preclinical studies and
initiating or completing additional clinical trials or preclinical studies, including as a result of regulators not allowing or delay in allowing clinical trials to proceed under an IND or similar foreign authorization (e.g. regulatory hold), or not
approving or delaying approval for any clinical trial grant or similar approval we need to initiate a clinical trial or a hold on an ongoing clinical trial. We may also experience numerous unforeseen events during our clinical trials that could
delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs, or other reviewing bodies may not authorize us or our investigators to commence a clinical
trial, to conduct, or continue a clinical trial at a prospective or specific trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects or patients required for clinical trials of our product candidates may be larger than we
anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or
patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials
on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies
to reflect changes in regulatory requirements or guidance, which may be required to resubmit to an IRB and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or other reviewing bodies may find deficiencies with, fail to approve, or subsequently find fault with
the manufacturing processes or facilities of third-party manufacturers with which we enter </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
into agreements for clinical and commercial supplies, or the supply or quality of any product candidate or other materials necessary to conduct clinical trials of our product candidates may be
insufficient, inadequate, or not available at an acceptable cost, or we may experience interruptions in supply; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for approval policies or regulations of the FDA, or other comparable regulatory authorities to
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulators or IRBs of the
institutions in which clinical trials are being conducted may suspend, limit, or terminate a clinical trial, or data monitoring committees may recommend that we suspend or terminate a clinical trial, due to a number of factors, including failure to
conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other comparable regulatory authorities resulting in the imposition of a
clinical hold, safety issues, or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations, or administrative actions or lack of adequate funding to continue the clinical trial. Negative or
inconclusive results from our clinical trials or preclinical studies could mandate repeated or additional clinical trials and, to the extent we choose to conduct clinical trials in other indications, could result in changes to or delays in clinical
trials of our product candidates in such other indications. We do not know whether any clinical trials that we conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our product candidates for the
indications that we are pursuing. If later-stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to successfully initiate and complete clinical trials and to demonstrate the efficacy and safety necessary to obtain regulatory
approval to market our product candidates would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds
to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure or otherwise modify our trials after they have begun. Significant
clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully
commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may be associated with adverse side effects, AEs, or other undesirable properties or safety
risks, which could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials or abandon a product candidate, limit the commercial profile of an approved label, or result in significant negative consequences
following regulatory approval, if obtained, or result in other significant negative consequences that could severely harm our business, financial condition, results of operations, and prospects.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by any of our product candidates could cause us or regulatory authorities to interrupt, delay, or
halt clinical trials and could result in a more restrictive label, the inclusion of a Risk Evaluation and Mitigation Strategy, or REMS, or the delay or denial of regulatory approval by the FDA or other comparable regulatory authorities. Any
treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial, or could result in potential product liability claims. Any of these occurrences may harm our business, financial
condition, and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may observe safety or tolerability issues beyond those we anticipate with our product
candidates in ongoing or future clinical trials. For example, to date, we have only completed clinical studies evaluating GlyphAllo in healthy volunteers, and it is possible that serious AEs related to GlyphAllo may occur in this clinical program or
in our clinical programs for other product candidates. Additionally, it is possible that human subjects with MDD may experience greater side effects in our clinical program for GlyphAllo than observed in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthy volunteers. We continue to learn more about our product candidates, and unfavorable profiles could lead to adverse outcomes or concerns by the FDA or other comparable regulatory
authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many compounds that initially showed promise in clinical or earlier-stage testing are later found to cause undesirable or
unexpected side effects that prevented further development of the compound. Results of future clinical trials of our product candidates could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics,
despite a favorable tolerability profile observed in earlier-stage testing. At any time, we may decide to terminate or greatly narrow the target population for a clinical development program due to unacceptable side effects or safety concerns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If unacceptable side effects arise in the development of our product candidates, we, the FDA or other comparable regulatory authorities, the
IRBs, or independent ethics committees at the institutions in which our trials are conducted, could suspend, limit, or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit, or terminate
our trials, or the FDA or other comparable regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. We may be unable to overcome any such suspensions or holds that
are placed on our clinical trials. Treatment-emergent side effects that are deemed to be drug-related could delay recruitment of clinical trial subjects or may cause subjects that enroll in our clinical trials to discontinue participation in our
clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using our product candidates to understand the side effect profiles for our
clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in harm to patients that are administered our product
candidates. Any of these occurrences may materially adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, some of our product candidates utilize prodrugs of drugs that have been approved by regulatory authorities, such as the FDA and
other comparable regulatory authorities, which if such approval is revoked, could negatively impact the success of our own products. For example, GlyphAllo is an oral prodrug of allopregnanolone, and brexanolone, a synthetic formulation of
allopregnanolone, is currently approved by FDA for the treatment of postpartum depression. GlyphAgo is an oral prodrug of agomelatine, which has been approved for the treatment of GAD in Australia and MDD in Australia and Europe. It is possible that
one or more of the active moieties of our product candidates has also been approved by FDA or other comparable regulatory authorities. In addition, even if our product candidates were to receive marketing approval or be commercialized, we would
continue to be subject to the risks that the FDA or other comparable regulatory authorities could revoke approval of an active moiety that is chemically identical to the active moiety within our product candidates or any active moiety as our product
candidates, if applicable, or that efficacy or safety issues could arise with any active moiety that is chemically identical to the active moiety within our product candidates or active moiety as our product candidates, if applicable, which could
negatively impact the commercial opportunity for our own products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any of our product candidates receives regulatory
approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS, to ensure that the benefits of
treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems
and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone. Other
potentially significant negative consequences associated with AEs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to suspend marketing of a product, or we may decide to remove such product from the
marketplace; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw or change their approvals of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label or limit access of a product to selective
specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of a product for patients, or to conduct
post-marketing studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held
liable for harm caused to subjects or patients; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product may become less competitive, and our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving
or maintaining market acceptance of our product candidates, if approved by the FDA or other regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we
complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and may prevent us from obtaining approvals for the commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate we develop and the activities associated with its development and commercialization, including its design, testing,
manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other comparable regulatory authorities in the United States, and by
other comparable foreign regulatory authorities. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product
candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we are developing or may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team expects to rely, in addition to <FONT STYLE="white-space:nowrap">in-house</FONT> regulatory personnel, on third-party CROs and
regulatory consultants to assist us in submitting and supporting the applications necessary to gain marketing approvals. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to
the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to,
and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or
other characteristics that may preclude its obtaining marketing approval or prevent or limit commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining
marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type,
complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted
product application, may cause delays </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the approval or rejection of an application. The FDA and other comparable regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or
may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent
marketing approval of a product candidate. Any marketing approval that we may ultimately obtain could be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial
prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interim,
topline, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the
final data. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim, topline, or preliminary data from our clinical trials and preclinical
studies. Such announcements or publications are typically based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to
the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the
interim, topline, or preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.
Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline, and preliminary
data should be viewed with caution until the final data are available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim data from clinical trials that we may complete are further
subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, topline, or preliminary data, and final data could
significantly harm our business prospects. Further, disclosure of such data by us or by our competitors could result in volatility in the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or
analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities, or otherwise regarding a particular product candidate
or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
our product candidates may be harmed, which could harm our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If
we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our product candidates may be delayed, and our business, financial condition, and results of
operations may be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific,
clinical, regulatory and other product development objectives. These milestones may include our expectations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly
announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a product. The achievement of many of
these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which, if not realized as expected, may cause the timing of achievement of the milestones to vary considerably from our estimates,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including
the extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our receipt of approvals by the FDA and other comparable regulatory authorities and the timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other actions, decisions, or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and
marketing activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve announced milestones in the timeframes we expect, the development and
commercialization of our product candidates may be delayed, and our business, financial condition, and results of operations may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have concentrated our research and development efforts on the treatment of disorders of the brain and central nervous system, a field
that faces certain challenges in drug development. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have focused our research and development efforts on addressing disorders
of the brain and central nervous system. Developing a product candidate for treatment of these diseases is difficult and subjects us to a number of challenges specific to central nervous system, or CNS, companies. In particular, many
neuropsychiatric disorders, such as MDD and GAD, rely on subjective patient-reported outcomes as key clinical endpoints. This makes them more vulnerable to the placebo effect as compared to evaluating outcomes with more objective endpoints. For
example, our Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial of GlyphAllo is using endpoints based on subjective assessment scales such as the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> and the Clinical Global Impressions-Severity
scale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, given the history of clinical failures in this field, future clinical or regulatory failures by us or others may result
in further negative perception of the likelihood of success in this field, which may significantly and adversely affect the market price of our common stock. We intend to work closely with the FDA and other comparable regulatory authorities to
perform the requisite scientific analyses and evaluation in an effort to obtain regulatory approval for our product candidates; however, the process of developing our product candidates may be complex and time-consuming for the reasons described
herein. We cannot be certain that our approach will lead to the development of product candidates that effectively and safely address the underlying diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or
otherwise adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is a significant factor impacting the duration of our clinical trials, along
with treatment duration and completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. We may experience difficulties in patient enrollment in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with our protocols depends, among other things, on our ability to enroll a sufficient number
of patients who remain in the study until its conclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient misrepresentation of their eligibility or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the
clinical trial protocol, resulting in the need to drop such patients from the clinical trial, increase the needed enrollment size for the clinical trial, or extend the clinical trial&#8217;s duration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of new indications for existing therapies or approval of new therapies in general;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages
and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued enrollment of prospective patients by clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in our clinical trials will drop out of the trials before completion.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience challenges in recruiting principal investigators and patients to participate in ongoing and future
clinical trials for such product candidates if we are unable to sufficiently demonstrate the potential of such product candidates to them. Furthermore, we may experience difficulties in reliably and consistently identifying the subpopulation of MDD
patients with anxious distress, which may delay our recruitment efforts for our Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial. We also plan to take additional screening steps for patients beyond what certain other sponsors have done
in similar trials, which may further narrow the eligible population of patients for our trials and cause delays in our recruitment efforts. In addition, our clinical trials may compete with other clinical trials for product candidates that are in
the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being
conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of
patients who are available for our clinical trials in such clinical trial site. Furthermore, if significant AEs or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our trials and patients
may drop out of our trials. Additionally, patients, including patients in any control groups, may withdraw from the clinical trial for various reasons, including but not limited to if they are not experiencing improvement in their underlying disease
or condition, or if they experience other difficulties or issues relating to their underlying disease or condition. Participants with neuropsychiatric disorders such as MDD and GAD constitute a vulnerable patient population and may withdraw from the
clinical trial if they are not experiencing improvement in their underlying disease or condition or if they experience other difficulties or issues relating to their underlying disease or condition or otherwise, which may or may not be related to
our product candidate in clinical trial. Withdrawal of patients from our clinical trials may compromise the quality of our data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on, and will continue to rely on, CROs and clinical trial sites to ensure
proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of
patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials or our development efforts altogether. Delays in patient enrollment may result in increased costs, affect the timing or
outcome of the planned clinical trials, product candidate development and approval process, and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion
of these trials, adversely affect our ability to advance the development of our product candidates, cause our value to decline, and limit our ability to obtain additional financing if needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may conduct clinical trials for our product candidates outside of the United States and the FDA may not accept data from such trials,
in which case our development plans may be delayed, which could materially harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted and are
conducting clinical trials for our product candidates outside the United States. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or other comparable regulatory authorities may be
subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally not approve the application on
the basis of foreign data alone unless (i)&nbsp;the data are applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and
(iii)&nbsp;the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT
STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the study was not otherwise subject to an IND, the FDA will
not accept the data as support for an application for regulatory approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection
if deemed necessary. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign
jurisdictions where the trials are conducted. There can be no assurance that the FDA or any other comparable regulatory authorities will accept data from trials conducted outside of the United States or the relevant jurisdiction. If the FDA or any
other comparable regulatory authority does not accept such data, it may result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not
receiving approval for commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if any of our product candidates receives regulatory
approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become
profitable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never commercialized a product, and even if any of our product candidates are approved by the appropriate
regulatory authorities for marketing and sale, it may nonetheless fail to achieve sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. The commercial success of any of our product candidates
will depend significantly on the broad adoption and use of the resulting product by these individuals and organizations for approved indications. For example, Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT
STYLE="white-space:nowrap">(SPT-348),</FONT> in development for the treatment of depressive disorders, including treatment-resistant depression, or TRD, post-traumatic stress disorder, or PTSD, and headache disorders, is a Glyphed oral prodrug of
the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD.</FONT></FONT> There has been recent interest in psychedelics in part because of their
potential to demonstrate therapeutic effects in neuropsychiatric disorders. Although Glyph2BLSD is not a psychedelic, there is a risk that it will be viewed as such by investors and the public, or could be classified as such by regulatory
authorities based on its final structure. Treatments containing controlled substances or drugs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that have similar effects or characteristics of controlled substances may generate public controversy or unfavorable views, which could lead to delays in, and increased expenses for, and limit or
restrict the introduction and marketing of such types of therapeutic candidates. For more information on controlled substances, see subsection titled &#8220;&#8212;Certain of our product candidates may be regulated as controlled substances, the
making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration and other regulatory agencies.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the indications for our product candidates have well-established standards of care that physicians, patients and payors are familiar
with and, in some cases, are available generically. Even if our product candidates are successful in registrational clinical trials, they may not be successful in displacing these current standards of care if we are unable to demonstrate superior
efficacy, safety, ease of administration, and/or cost-effectiveness. For example, physicians may be reluctant to take their patients off their current medications and switch their treatment regimen to our product candidates. Further, patients often
acclimate to the treatment regimen that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch due to inadequate coverage or reimbursement by third-party payors. Even
if we are able to demonstrate our product candidates&#8217; safety and efficacy to the FDA and other comparable regulatory authorities, safety or efficacy concerns in the medical community may hinder market acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources,
including management time, and financial resources, and may not be successful. If any product candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become
profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of the product, including as compared to any more-established products or other
alternative products that may later be approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of the product compared to competitive therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indications for which the product is approved, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line
therapy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product&#8217;s convenience and ease of administration compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try, and of physicians to prescribe, the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with the product in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product&#8217;s acceptance into standard of care treatment algorithms by medical societies that could limit
payor and physician uptake; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings, including distribution or use restrictions contained in the product&#8217;s approved
labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of sales, marketing, and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care for the targeted indications for the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and adequacy of coverage and reimbursement from government payors, managed care plans, and other
third-party payors, including any price concessions required by third-party payors to obtain coverage; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to the product, or favorable publicity about competitive products.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure by one or more of our product candidates that obtains regulatory approval to achieve market acceptance or
commercial success would adversely affect our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to discover, develop, and commercialize other product
candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although
the development and commercialization of our current product candidates are our initial focus, as part of our longer-term growth strategy, we may seek to develop other product candidates leveraging our Glyph platform. We intend to evaluate internal
opportunities from our existing product candidates or other potential product candidates, and also may choose to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates to treat patients suffering from other disorders
with significant unmet medical needs and limited treatment options. Any other potential product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials, and
approval by the FDA or other comparable regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown
to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in
the marketplace or be more effective than other commercially available alternatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we intend to devote capital and
resources for basic research to discover and identify additional product candidates. These research programs require substantial technical, financial, and human resources, whether or not any product candidates are ultimately identified. Our research
programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our product candidates obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates that we develop may nevertheless be covered by third parties&#8217; patents or other exclusive
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that
indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire product
candidates or the underlying technology. The process of proposing, negotiating, and implementing a license or acquisition is lengthy and complex. Other companies, including some with substantially greater financial, marketing, and sales resources,
may compete with us for the license or acquisition of product candidates. We have limited resources to identify and execute the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of third-party products, businesses, and technologies
and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities that are never completed, or we may fail to realize the anticipated
benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, future acquisitions may entail numerous operational and financial risks,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposure to unknown liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption of our business and diversion of management&#8217;s time and attention to develop acquired products or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher than expected acquisition and integration costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in combining the operations and personnel of any acquired businesses with our operations and
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased amortization expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in
management and ownership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with entering new markets in which we have limited or no experience; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to motivate key employees of any acquired businesses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To finance any acquisitions, we may choose to issue shares of our common stock as consideration, which could dilute the ownership of our
stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions using our common stock as consideration. Additional funds may not be available on terms that are favorable to us, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in identifying and developing additional product candidates, either through internal development or licensing or
acquisition from third parties, our potential for growth and achieving our strategic objectives may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The number of
patients with the diseases and disorders for which we are developing our product candidates has not been established with precision. If the actual number of patients with the diseases or disorders we elect to pursue with our product candidates is
smaller than we anticipate, we may have difficulties in enrolling patients in our clinical trials, which may delay or prevent development of our product candidates. Even if such product candidates are successfully developed and approved, the markets
for our product candidates may be smaller than we expect and our revenue potential and ability to achieve profitability may be materially adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pipeline includes product candidates for a variety of neuropsychiatric disorders, including MDD and GAD. There is no precise method of
establishing the actual number of patients with any of these disorders in any geography over any time period. With respect to many of the indications in which we have developed, are developing, or plan to develop our product candidates, we have
estimates of the prevalence of the disease or disorder. Our estimates as to prevalence may not be accurate, and the actual prevalence or addressable patient population for some or all of those indications, or any other indication that we elect to
pursue, may be significantly smaller than our estimates. In estimating the potential prevalence of indications we are pursuing, or may in the future pursue, including our estimates as to the prevalence of MDD and GAD, we apply assumptions to
available information that may not prove to be accurate. In each case, there is a range of estimates in the published literature and in marketing studies, which include estimates within the range that are lower than our estimates. The actual number
of patients with these disease indications may, however, be significantly lower than we believe. Even if our prevalence estimates are correct, our product candidates may be developed for only a subset of patients with the relevant disease or
disorder or our product candidates, if approved, may be indicated for or used by only a subset. In the event the number of patients with the diseases and disorders we are studying is significantly lower than we expect, we may have difficulties in
enrolling patients in our clinical trials, which may delay or prevent development of our product candidates. If any of our product candidates are approved and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our prevalence estimates with respect to any indication or our other market assumptions are not accurate, the markets for our product candidates for these indications may be smaller than we
anticipate, which could limit our ability to generate revenues and achieve profitability or to meet our expectations with respect to the foregoing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Competitive products may reduce or eliminate the commercial opportunity for our product candidates, if approved. If our competitors
develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize our product candidates may be adversely
affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical and commercial landscapes for the treatment of neuropsychiatric disorders are highly competitive and
subject to rapid and significant technological change. We face competition with respect to our indications for our product candidates and will face competition with respect to any other drug candidates that we may seek to develop or commercialize in
the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing
the development of drug candidates for the treatment of the CNS indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct
research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware that a significant number of product candidates are currently under development for MDD, GAD, and other indications that we are
currently pursuing and may pursue, and some or all may become commercially available in the future for the treatment of conditions for which we are trying or may try to develop product candidates. Additionally, if our product candidates were to be
approved, they would likely compete with historical standard of care therapies. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions,
government agencies, and research institutions. For examples of the competition that our product candidates face, see the section titled &#8220;Business&#8212;Competition&#8221; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In most cases, we do not currently plan to run <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT>
clinical trials evaluating our product candidates against the current standards of care, which may make it more challenging for our product candidates to compete against the current standards of care due to the lack of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trial data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may
have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals, and reimbursement, and marketing approved
products than we do. Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving widespread market acceptance. Our competitors&#8217; products may be more effective, or more
effectively marketed and sold, than any product candidate we may commercialize and may render our therapies obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> before we can recover development and commercialization expenses. If any
of our product candidates are approved, it could compete with a range of therapeutic treatments that are in development. In addition, our competitors may succeed in developing, acquiring, or licensing technologies and drug products that are more
effective or less costly than our product candidates, which could render our product candidates obsolete and noncompetitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain
approval for any of our product candidates, we may face competition based on many different factors, including the efficacy, safety, and tolerability of our products, the ease with which our products can be administered, the timing and scope of
regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage, and patent position. Existing and future competing products could present superior treatment
alternatives, including being more effective, safer, less expensive, or marketed and sold more effectively than any products we may develop. Competitive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit
our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our
competitors may obtain patent protection, regulatory exclusivities, or FDA approval and commercialize products more rapidly than we do, which may impact future approvals or sales of any of our product candidates that receive regulatory approval. If
the FDA approves the commercial sale of any product candidate, we will also be competing with respect to marketing capabilities and manufacturing efficiency. We expect competition among products will be based on product efficacy and safety, the
timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement coverage by government and private third-party payors, regulatory exclusivities, and patent position. Our profitability
and financial position will suffer if our product candidates receive regulatory approval but cannot compete effectively in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a
smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in
recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to develop our sales, marketing, and distribution capability on our own or through collaborations with marketing
partners, we will not be successful in commercializing our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales, or
distribution capabilities. We intend to establish a sales and marketing organization, either on our own or in collaboration with third parties, with technical expertise and supporting distribution capabilities to commercialize one or more of our
product candidates that may receive regulatory approval in key territories. These efforts will require substantial additional resources, some or all of which may be incurred in advance of any approval of the product candidate. Any failure or delay
in the development of our or third parties&#8217; internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our product candidates on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to or our failure to educate an adequate number of physicians
on the benefits of any future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our existing and future product candidates, we may choose to collaborate with third parties that have
direct sales forces and established distribution systems to serve as an alternative to our own sales force and distribution systems. Our future product revenue may be lower than if we directly marketed or sold our product candidates, if approved. In
addition, any revenue we receive will depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are not successful in commercializing any approved products, our
future product revenue will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to
develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
States or overseas. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing
our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our
operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, we had 55 full-time employees. We expect to experience significant growth in the number
of our employees and the scope of our operations over time. To manage these growth activities, we must continue to implement and improve our managerial, operational, quality, and financial systems, expand our facilities and continue to recruit and
train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a
company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit, and train additional qualified personnel. Our inability to manage the expansion
or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth
could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may
increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to develop product candidates, leverage our Glyph platform and our future growth depends on attracting, hiring, and
retaining our key personnel and recruiting additional qualified personnel. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends upon the continued contributions
of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the clinical
development of our product candidates. Given the specialized nature of neuropsychiatric disorders and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our
pipeline, we will require personnel with medical, scientific, or technical qualifications specific to each program. The loss of key personnel, in particular our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer, <FONT
STYLE="white-space:nowrap">Co-Founder,</FONT> and Chair of the Board, Chief Financial Officer, Chief Medical Officer, <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Scientific Officer, Chief Operating Officer, General Counsel, and
clinical development personnel, would delay our research and development activities. The competition for qualified personnel in the therapeutics, biotechnology and biopharmaceutical industries is intense, and our future success depends upon our
ability to attract, retain, and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If our
recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical operations and research and development programs depend on our ability to attract and retain highly skilled
employees across multiple functions, particularly in Massachusetts. There is powerful competition for skilled personnel in this geographical market, and we have from time to time experienced, and we expect to continue to experience, difficulty in
hiring and retaining employees with appropriate qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources than we do, and any of our employees may terminate their
employment with us at any time. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources
and, potentially, damages. Furthermore, job candidates and existing employees often consider the value of the stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, either because we are a public company or for other reasons, it may harm our
ability to recruit and retain highly skilled employees. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of
the options they hold are significantly below the market price of our common stock, particularly after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described herein. If we fail to attract new personnel or fail to
retain and motivate our current personnel, our business and future growth prospects would be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to assist in conducting our clinical trials and preclinical studies. If they do not successfully carry
out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed,
and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely on third parties, such as CROs,
clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and preclinical studies and expect to rely on these third parties to conduct clinical trials and preclinical studies of any other
product candidate that we develop. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory, and IRB approval, patient enrollment rates, and compliance with
GCPs. In most cases, we use the services of third parties, including CROs, to carry out our clinical trial-related activities and rely on such parties to accurately report their results. Our reliance on third parties for clinical development
activities may impact or limit our control over the timing, conduct, expense, and quality of our clinical trials. Moreover, the FDA requires us to comply with GCPs for conducting, recording, and reporting the results of clinical trials to assure
that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of clinical trial sponsors, principal
investigators, clinical trial sites, and IRBs. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable
systems for product tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen, and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory
requirements and scientific standards. Our failure or the failure of third parties to comply with the applicable protocol, legal and regulatory requirements and scientific standards can result in rejection of our clinical trial data or other
sanctions. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials, or the potential regulatory approval of a product candidate may be delayed or be
unsuccessful. Additionally, if we or our third-party contractors fail to comply with applicable GCPs for any reason, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional
clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under
our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill, and resources to our ongoing development programs. Moreover, many CROs, including some of those that we have engaged to conduct our clinical
trials, are experiencing enrollment challenges as a result of, among other things, high employee turnover driven by macroeconomic environment and the inexperience of new employees. Additionally, at clinical trial sites, the availability of staff and
trial participants has been limited due to a decrease in the number of clinical investigative sites across the globe. These contractors may also have relationships with other commercial entities, including our competitors, for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third
parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to
obtain, or may be delayed in obtaining, regulatory approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial
results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired, or foreclosed. In addition, principal investigators
for our clinical trials may be asked to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in
perceived or actual conflicts of interest, or the FDA or foreign regulatory authorities conclude that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial
site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA or foreign regulatory authorities of any NDA or foreign application we submit. Any such delay or
rejection could prevent us from commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on other third parties to store and distribute drug
supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses,
and depriving us of potential product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the third-party organizations we utilize may terminate their engagements with us
under certain circumstances. The replacement of an existing CRO or other third party may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates. We
may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, even if there are suitable replacements for one or more of these service providers, there is a natural transition period when a new
service provider begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we currently and may in the future rely on foreign CROs and CMOs. Such foreign CROs and CMOs may be subject to U.S. legislation,
sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to
secure significant commitments from governments to purchase our potential therapies. For example, in January 2024, there was congressional activity, including the introduction of the BIOSECURE Act (H.R. 7085) in the House of Representatives and a
substantially similar Senate bill (S.3558). In September 2024, the U.S. House of Representatives passed a version of the BIOSECURE Act (H.R. 8333), however, the Senate did not approve that legislation. In October 2025, both the U.S. House of
Representatives and Senate passed their respective versions of the National Defense Authorization Act of 2026 (NDAA), each including an amendment often referred to as &#8220;BIOSECURE 2.0.&#8221; While BIOSECURE 2.0 has not yet been enacted and must
still be reconciled in conference, the current text would establish federal government contracting, grant, and loan restrictions similar in effect to prior BIOSECURE proposals. However, unlike earlier versions of BIOSECURE that named specific
Chinese companies, BIOSECURE 2.0 would implement a process-based designation system through which biotechnology companies &#8220;of concern&#8221; would be identified based on whether companies fall within statutorily define categories, including
entities identified on the Department of Defense&#8217;s Section&nbsp;1260H list of &#8220;Chinese military companies&#8221; and other entities that are subject to the direction, control, or jurisdiction of a foreign adversary&#8217;s government
which pose national security risks based on specified criteria. If BIOSECURE 2.0 becomes law or similar laws are passed, they would have the potential to severely restrict the ability of therapeutics companies like us to purchase services or
products from, or otherwise collaborate with, certain Chinese biotechnology companies &#8220;of concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We do business with companies in
China, and it is possible some of our contractual counterparties could be impacted by this legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our use of third parties to manufacture our product candidates, including those
located outside of the United States, may increase the risk that we will not have sufficient quantities of our product candidates, raw materials, active pharmaceutical ingredients, or APIs, or drug products when needed or at an acceptable cost.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product
candidates, and we lack the resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of our product candidates to third parties, including in jurisdictions outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on and engage third-party manufacturers to provide all of the API and the final drug product formulation of all of our
product candidates that are being used in our clinical trials and preclinical studies. If we were to need an alternate manufacturer, we would incur added costs and delays in identifying and qualifying any such replacement. In addition, we typically
order raw materials, API, and drug product and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. We may not be able to timely secure needed supply
arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of our product candidates or, to commercialize them, if approved. We
may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial quantities and formulation of our product candidates, and
the costs of manufacturing could be prohibitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the third-party manufacturers we rely on have only recently begun working with
us and have limited experience manufacturing our API and final drug products. If our manufacturers have difficulty or suffer delays in successfully manufacturing material that meets our specifications, it may limit supply of our product candidates
and could delay our clinical trials.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to establish and maintain
arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on
third parties for manufacturing process development, regulatory compliance, and quality assurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over
our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on supply availability resulting from capacity and scheduling constraints of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of the third-party manufacturer to produce materials with acceptable quality on a larger scale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of manufacturing agreements by third parties because of factors beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements
by the third party, at a time that is costly or inconvenient to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not maintain our key manufacturing relationships, we may fail to
find replacement manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for our product candidates. If we do find replacement manufacturers, we may not be able to enter into
agreements with them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other comparable regulatory authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any third-party manufacturer with whom we contract fails to perform its
obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different manufacturer. In either scenario, our clinical trials supply could be delayed
significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be proprietary to the original manufacturer and we may have difficulty, or there may be contractual
restrictions prohibiting us from transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party
manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a
manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or other comparable regulatory authorities. We may be unsuccessful in
demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical trials. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product
candidates or commercialize our products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third party owns independently. This would
increase our reliance on such third-party manufacturer or require us to obtain a license from such third-party manufacturer in order to have another third party manufacture our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates is approved by any regulatory agency, we intend to utilize arrangements with third-party contract
manufacturers for the commercial production of those products. This process is difficult and time-consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under
cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our manufacturers are located outside of the United States. There is currently significant uncertainty about the future relationship
between the United States and various other countries with respect to trade policies, treaties, government regulations, and tariffs. Increased tariffs or pending legislation that would impose federal contracting or federal funding limitations on
parties directly using or connected to those using the services or equipment of certain foreign entities with known or alleged associations with foreign adversaries could potentially disrupt our existing supply chains and impose additional costs on
our business. Additionally, it is possible further tariffs may be imposed that could affect imports of any APIs used in our product candidates in the future, or our business may be adversely impacted by retaliatory trade measures taken by China or
other countries, including restricted access to such raw materials used in our product candidates. Given the uncertainty regarding how the U.S. or foreign governments will act with respect to tariffs, international trade agreements, and policies,
further governmental action related to tariffs, additional taxes, contracting matters, regulatory changes, or other retaliatory trade measures in the future could occur with a corresponding detrimental impact on our business and financial condition.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure, or the failure of our third-party manufacturers, to comply with applicable
regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of product candidates, operating restrictions, and
criminal prosecutions, any of which could significantly affect supplies of our product candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be evaluated by the FDA and are required to register
their facilities with the FDA, subjecting them to inspections to assess whether these facilities are in compliance with cGMPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs and comparable foreign requirements. If our contract manufacturers cannot successfully manufacture material that
conforms to our specifications and the strict regulatory requirements of the FDA or other comparable regulatory authorities, we may not be able to secure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or maintain regulatory approval for our product candidates manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers to maintain
adequate quality control, quality assurance, and qualified personnel. If the FDA finds deficiencies or the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it
withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved. Contract
manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP and comparable foreign
requirements. Any failure to comply with cGMP requirements or other FDA and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products,
if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment
delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA and other comparable regulatory requirements could adversely affect
our clinical research activities and our ability to develop our product candidates and market our products following approval, if obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, should we decide to use any APIs in any of our product candidates that are proprietary to one or more third parties, we would
need to maintain licenses to those APIs from those third parties. If we are unable to gain or continue to access rights to such APIs prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop
alternate product candidates from these programs by either accessing or developing alternate APIs, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued
access rights to the desired APIs on commercially reasonable terms or develop suitable alternate APIs, we may not be able to commercialize product candidates from these programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter
our development and commercialization plans. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future opportunistically pursue strategic partnerships or
collaborations, as the advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. If we believe that
partnerships or collaborations can accelerate the development or maximize the market potential of our product candidates, we will consider entering into product, target and/or geographic specific strategic partnerships or collaborations on an
opportunistic basis. Likely collaborators may include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies. In addition, if we are able to
obtain regulatory approval for product candidates from foreign regulatory authorities, we may enter into partnerships or collaborations with international biotechnology or pharmaceutical companies for the commercialization of such product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
partnership or collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed partnerships or collaboration, and the proposed collaborator&#8217;s
evaluation of a number of factors. Those factors may include the potential differentiation of our product candidate from competing product candidates, design, or results of clinical trials, the likelihood of approval by the FDA or other comparable
regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients, and the potential of competing products. The
collaborator may also consider alternative product candidates or technologies for similar indications that may be available for partnership or collaboration and whether such a partnership or collaboration could be more attractive than the one with
us for our product candidate. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or
bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Partnerships and collaborations are each complex and time-consuming to negotiate and
document. Further, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any partnership or collaboration agreements that
we enter into in the future may contain restrictions on our ability to enter into potential partnerships or collaborations or to otherwise develop specified product candidates. We may not be able to negotiate partnerships or collaborations on a
timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce, or delay its development program or one or more of our other
development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if conflicts arise between our collaborators and us, the other party may act in a manner adverse to us and could limit our
ability to implement our strategies. Our collaborators could conduct multiple product development efforts and could develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that
are the subject of these partnerships or collaborations with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competing products may preclude us from entering into partnerships or
collaborations with their competitors, fail to obtain timely regulatory approvals, prevent us from obtaining timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the partnership or
collaboration efforts, including development, delivery, manufacturing, and commercialization of products. Any of these developments could harm our company and product development efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we enter into collaborations with third parties for the development and/or commercialization of our product candidates, our prospects
with respect to those product candidates will depend in significant part on the success of those collaborations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter
into collaborations with third parties for the development and/or commercialization of certain of our product candidates. If we enter into such collaborations, we will have limited control over the amount and timing of resources that our
collaborators will dedicate to the development or commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations involving our product
candidates pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and/or commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, which divert resources or create
competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources
to the marketing and distribution of such product or products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and
intellectual property rights, contract interpretation, or the preferred course of development might cause delays or termination of the research, development, or commercialization of product candidates, might lead to additional responsibilities for
us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to
development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination, it could decide to delay, diminish, or terminate the development or
commercialization of any product candidate licensed to it by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If any third-party manufacturer of our product candidates is
unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product
candidates, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of our product candidates. The transition to larger scale production could prove
difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates
while maintaining the same quality then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business, financial condition, and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or
delay. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and
commercialization, it is common that various aspects of the development program, such as the vendors used to manufacture drug product or manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results.
Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials
conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval and similar foreign notifications and approvals. This could delay or prevent completion of clinical
trials, require conducting bridging clinical trials, or the repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of our product candidates, and jeopardize our ability to commence sales and generate
revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in
obtaining regulatory approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of
our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a
product candidate, the European Commission or comparable foreign regulatory authorities must also approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve
requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by
regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend
to charge for our products is also subject to approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also submit marketing authorization applications in other countries.
Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with
foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in
international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued
regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, distribution, AE reporting, advertising, promotion, sampling, import, export, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state
requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP (and comparable foreign requirements) and GCP requirements for any clinical trials
that we conduct post-approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the
approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and
efficacy of the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA
may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician communication plans or
additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. In addition, if the FDA or other comparable regulatory authority approves our product candidates, we will have to
comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may
impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product
candidates, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety
information, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market, or
voluntary product recalls; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or withdrawal of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response and could generate negative publicity. The policies of the FDA and other comparable regulatory authorities may change and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or
abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and
we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>While we may in the future seek designations for our product candidates with the FDA
and other comparable regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway, or regulatory exclusivity, there can be no assurance that we will successfully obtain such
designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other comparable regulatory authorities offer certain designations for product candidates that are designed to encourage the
research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated
regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations could expedite the development or approval process, they
generally do not change the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we may seek a Fast Track Designation for future product candidates we develop. If a product is intended for the treatment of a
serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or
not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a
faster development process, review, or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek Breakthrough Therapy Designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is
intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and
the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible
for accelerated approval and priority review. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even
if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a
product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product
candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even in the absence of obtaining Fast Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review at the time of
submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other
available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination, or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient
compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications,
and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Where appropriate, we may secure approval from the FDA or other comparable regulatory authorities through the use of the accelerated
approval pathway. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of,
necessary marketing approvals. Even if we receive accelerated approval from the FDA or other comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing
requirements, the FDA or such other comparable regulatory authorities may seek to withdraw any accelerated approval we have obtained. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek an accelerated approval pathway for our one or more of our therapeutic candidates from the FDA or other comparable regulatory
authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate designed to treat a serious or
life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the therapeutic candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to
predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated
approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical
endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct
therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a
specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor
fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. The FDA
is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to seeking accelerated approval, we would seek feedback from the FDA or other
comparable regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no
assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review, or approval. Similarly, there can be no assurance that after
subsequent feedback from the FDA or other comparable regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review, or approval, even if we initially decide to do so.
Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA or other comparable regulatory
authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA
to full approval. A failure to obtain accelerated approval or any other form of expedited development, review, or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic candidate, could
increase the cost of development of such therapeutic candidate, and could harm our competitive position in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain
of our product candidates may be regulated as controlled substances, the making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration and other regulatory
agencies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not yet fully understand the potential for GlyphAllo or Glyph2BLSD to be classified as controlled substances, but
brexanolone is currently classified as a Schedule IV controlled substance under the Controlled Substances Act, or CSA and although <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> is not a controlled substance, it is an analogue of LSD, which is a Schedule I controlled substance under the CSA. Accordingly, we may need to conduct studies to assess the abuse potential of
GlyphAllo and/or Glyph2BLSD, and pending the outcome of such evaluations, we may be required to provide a proposal for scheduling by the Drug Enforcement Administration, or the DEA, when submitting an NDA, which could cause delays in our development
process or commercialization timing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DEA regulates controlled substances as Schedule I, II, III, IV, or V substances. Schedule I
substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV, or V, with Schedule II substances considered to present the highest risk
of abuse and Schedule V substances the lowest relative risk of abuse among such substances. If any of our product candidates were to become subject to DEA oversight, such product candidates would be subject to additional restrictions regarding their
manufacture, shipment, storage, sale, and use, depending on the scheduling of the active ingredients, and may limit the commercial potential of any of our product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various states also independently regulate controlled substances. Though state controlled substances laws often mirror federal law, because
the states are separate jurisdictions, they may separately schedule drugs as well. While some states automatically schedule a drug when the DEA does so, in other states there must be rulemaking or a legislative action. State scheduling may delay
commercial sale of any controlled substance drug product for which we obtain federal regulatory approval and adverse scheduling could impair the commercial attractiveness of such product. If any of our product candidates is classified as a
controlled substance, we or our collaborators would also be required to obtain separate state registrations in order to be able to obtain, handle, and distribute controlled substances for clinical trials or for commercial sale, and failure to meet
applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any of our product candidates that may be classified as controlled substances, we and our suppliers, manufacturers, contractors,
customers, and distributors are required to obtain and maintain applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registrations from state, federal, and foreign law enforcement and regulatory agencies and comply with state, federal, and foreign laws and regulations regarding the manufacture, use, sale,
importation, exportation and distribution of controlled substances. There is a risk that DEA regulations may limit the supply of the compounds used in clinical trials for our product candidates, and, in the future, the ability to produce and
distribute our products in the volume needed to meet commercial demand. Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production, and procurement quotas, recordkeeping, reporting,
handling, storage, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates including controlled substances. The DEA, and some states, conduct
periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or comply with any applicable regulations could delay or preclude us from developing and commercializing our
product candidates containing controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In some circumstances,
violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of any of our products or product candidates that are classified as controlled substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with healthcare providers and physicians and third-party payors subject us to anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could increase our compliance costs, and expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits, and future earnings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, pharmacies, consultants, marketing
personnel, third-party payors, patient organizations, and customers expose us to broadly applicable foreign, federal and state fraud and abuse, and other healthcare laws and regulations. These laws include foreign, federal, and state anti-kickback
laws, false claims statutes, civil monetary penalties laws, healthcare data privacy, and security laws, and consumer protection and unfair competition laws, as well as transparency laws regarding payments or other items of value provided to
healthcare providers, and laws related to price reporting. Healthcare providers, physicians, and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. These laws
may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute any product for which we obtain regulatory approval. For more information on
healthcare laws and regulations that may impact our company, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Other Healthcare Laws&#8221; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements both internally and with third parties will comply with applicable
healthcare and privacy laws and regulations will involve ongoing substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations,
or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which
they are subject, it is possible that some of our current or future practices or arrangements might be challenged under one or more of these laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of
investigations, prosecutions, convictions, and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be
time-consuming, resource-intensive, and can divert a company&#8217;s attention from the business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our business practices or operations
are found to be in violation of any of fraud and abuse, or other healthcare laws or governmental laws, regulations, agency guidance, or case law that may apply to us, we may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to significant penalties, including administrative, civil, and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs,
such as Medicare and Medicaid, integrity oversight, and reporting obligations, contractual damages, individual imprisonment, reputational harm, diminished profits, and future earnings, and the curtailment or restructuring of our operations, as well
as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, defending against
any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be
impaired. If any of the physicians, or other providers, or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions
from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of any of our product candidates, if approved, will depend in part on the extent to which governmental
authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it
difficult for us to sell any approved product candidates profitably. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our product candidates, if approved, depends
on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors. Patients who are provided medical
treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Our ability to achieve coverage and acceptable levels of reimbursement for our product candidates by
third-party payors will have an effect on our ability to successfully commercialize those products. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, any product that we may
develop. For more information on the laws and regulations that may impact coverage and reimbursement of our product candidates, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Coverage and Reimbursement&#8221; included
elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and other third-party payors, such as private health insurers and health maintenance
organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use
of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective, and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining
coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the
use of our products, if approved, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. Furthermore, rules and
regulations regarding reimbursement change frequently, and, in some cases, at short notice, and we believe that additional changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain coverage for a given product, if approved, the resulting reimbursement payment rates might not be adequate for us to achieve
or sustain profitability or may require cost-sharing (e.g., <FONT STYLE="white-space:nowrap">co-payments</FONT> or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coinsurance) that patients find unacceptably high. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. In the United States, the principal
decisions about reimbursement for new medicines are typically made by U.S. Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare, and private
payors tend to follow CMS coverage determinations to a substantial degree. Additionally, third-party payors may not cover or provide adequate reimbursement for a given product or, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT>
evaluations, or other ancillary services required following the use of product candidates, once approved. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage or implement prior authorization or step
therapy programs for new or innovative drug therapies before they will reimburse patients who use such therapies which may be time-consuming or costly for patients and lead to a reduction in revenue. Patients are unlikely to use our product
candidates, once approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and
reimbursement for our product candidates. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented
in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for therapeutics products and services, and many
third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as
substitutable and offer to reimburse patients only for a less expensive competitor product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs
may limit the amount we will be able to charge for our products, if approved. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable
us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products, if approved, and may not be able
to obtain a satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net prices for drugs may be reduced by mandatory discounts or
rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product
candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price
and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment
methodologies may be subject to changes in healthcare legislation and regulatory initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by
governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not
cover or provide adequate payment for our product candidates. If, for example, we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products, if approved, would be subject to
ceiling prices set by such programs, which could reduce the revenue we may generate from any such products. Participation in such programs would also expose us to the risk of significant civil monetary penalties, sanctions, and fines should we be
found to be in violation of any applicable obligations thereunder. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent
U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between
pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that healthcare reform measures that may be adopted in the future may result in
more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability, or commercialize our products, if approved. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot
be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of our product candidates, if
any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed pricing for a product must be approved before it may be lawfully
marketed. The requirements governing product pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems
provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a
particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product
candidates. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing healthcare legislative and regulatory reform measures and cost containment initiatives may have a material adverse effect on our
business and results of operations and increase the difficulty and cost for us to obtain coverage for and commercialize any of our current or future product candidates and may adversely affect the prices we may set. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for
example, (1)&nbsp;changes to our manufacturing arrangements, (2)&nbsp;additions or modifications to product labeling, (3)&nbsp;the recall or discontinuation of our products, or (4)&nbsp;additional record-keeping requirements. Current and future
legislation and regulations may increase the difficulty and cost for us to commercialize our drugs, if approved, and affect the prices we may obtain, including changes in coverage and reimbursement policies in certain market segments for our product
candidates, which could make it difficult for us to sell our product candidates, if approved, profitably. If any such changes were to be imposed, they could adversely affect the operation of our business. See the section titled
&#8220;Business&#8212;Current and Future U.S. Healthcare Reform&#8221; included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among policy makers and
payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, and/or expanding access. For example, in March 2010, the
ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. Since its enactment, certain provisions of the ACA have
been subject to judicial, executive, and legislative challenges and may be subject to additional challenges in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers, effective April&nbsp;1, 2013, which, due to subsequent
legislative amendments, will stay in effect through 2032 unless additional congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several
providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the
funding of the Medicaid program. Such reductions are expected to apply significant funding pressure on state Medicaid budgets, decrease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the number of persons enrolled in Medicaid, and reduce the services covered by Medicaid, which could adversely affect our sales of any of our product candidates that we commercialize. These laws
and regulatory changes may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on prescribers of our product candidates, if approved, and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state, and foreign governments, and the prices of products have been a
focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage, and the amount of reimbursement for drugs and other medical products,
government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for
substitution of generic products. For example, the American Rescue Plan Act of 2021 eliminated the Medicaid statutory rebate cap of 100% of average manufacturer price as of January&nbsp;1, 2024. Elimination of this cap may require pharmaceutical
manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
cost of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States. There have been several Congressional inquiries, as well as legislative and regulatory initiatives and executive
orders designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most
significantly, in August 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in
2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price
increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new manufacturer discount program (beginning in 2025). CMS has published
the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation. The IRA permits the Secretary of the Department of Health and Human
Services, or the HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented, although the Medicare drug price
negotiation program is currently subject to legal challenges. The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, but is likely to be significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trump administration is pursuing a <FONT STYLE="white-space:nowrap">two-fold</FONT> strategy to reduce drug costs in the U.S. While it is
unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for product candidates, if approved. On the one
hand, the Trump administration has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price
in a group of other countries. In response, multiple manufacturers have reportedly entered into confidential pricing agreements with the federal government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to
impose drug pricing policies, although proposed regulations have not yet been published. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. In
addition, pharmaceutical pricing and marketing has long been the subject of considerable discussion in Congress and among policymakers. Additional drug pricing proposals could appear in future legislation and it is possible that Congress could enact
additional laws that negatively affect the pharmaceutical industry. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our
revenue generated from the sale of any approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare
legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional
inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, state governments have become increasingly active in developing proposals, passing legislation, and implementing
regulations designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discounts, formulary flexibility, restrictions on certain product access and marketing cost disclosure, drug price increase
reporting, and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating <FONT STYLE="white-space:nowrap">so-called</FONT> prescription drug
affordability boards with the goal of imposing price limits on certain drugs in these states, while some states are also seeking to implement general, across the board price caps for pharmaceuticals, or are seeking to regulate drug distribution.
These types of initiatives may result in additional reductions in Medicare, Medicaid, and other healthcare funding. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial
condition, results of operations, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their
prescription drug and other healthcare programs. These measures could reduce the ultimate demand for any of our current and future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that these and other state and federal healthcare reform measures may
be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies, impose price controls, and additional downward pressure on the price
that we receive for any approved product candidate for which we may obtain regulatory approval, and the frequency with which any such product candidate is prescribed or used. Any reduction in reimbursement from Medicare or other government programs
may result in a similar reduction in payments from private payors. The implementation of cost containment measures, changes in healthcare spending and policy, or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our product candidates, and materially affect our business. If additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. We cannot predict with certainty what impact any federal or state health reforms will have on
us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new
interpretations of existing laws, regulations, or decisions, related to healthcare availability, the method of delivery, or payment for healthcare products and services could negatively impact our business, operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing
negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares
the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become
profitable could be impaired. For more details concerning the risks related to pricing and reimbursement in the EU, please refer to the discussion in the risk factor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar political, economic, and regulatory developments are occurring in the EU and may affect the ability of pharmaceutical companies to
profitably commercialize their products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the
pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the
pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service
providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and
affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on
specific products and therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending
Directive 2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e. oncology and advanced therapy medicinal products as of
2025, orphan medicinal products as of 2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for
cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment
of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising
technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of
health technology, and making decisions on pricing and reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business could be affected by litigation, government
investigations and enforcement actions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate in a number of jurisdictions in a highly regulated industry and we
could be subject to litigation, government investigation and enforcement actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability,
environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings that may arise from conducting our business. Any determination that our operations or
activities are not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, equitable
remedies, including disgorgement, injunctive relief and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal proceedings, government investigations and enforcement actions can be expensive and time-consuming. An adverse outcome resulting from
any such proceedings, investigations, or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive relief, product recalls, integrity oversight
and reporting obligations, reputational damage and modifications of our business practices, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if such a proceeding,
investigation, or enforcement action is ultimately decided in our favor, the investigation and defense thereof could require substantial financial and management resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities, including
noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other illegal activity
by our current and any future employees, independent contractors, consultants, CMOs, and vendors. Misconduct by these parties could include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intentional, reckless, and/or negligent conduct that fails to comply with the regulations set forth by the FDA or other comparable regulatory authorities, provide true, complete, and accurate
information to the FDA and other comparable regulatory authorities, comply with manufacturing standards we may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose
unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated
with compliance with these laws are likely to increase. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions
are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations, and prospects, including,
without limitation, the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs,
imprisonment, contractual damages, reputational harm, diminished profits, and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other comparable regulatory authorities actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising, and promotion of
prescription drugs. These regulations include standards and restrictions for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, industry-sponsored scientific and educational activities,
promotional activities involving the internet and <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe
and effective by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and
approved by the regulatory authorities, we may only promote or market our products in a manner that is consistent with their <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. Similar requirements may apply in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability.
The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> use and has enjoined several companies from engaging in <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage
the promotion any product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. In addition, any such
<FONT STYLE="white-space:nowrap">off-label</FONT> use of our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our
product candidates for these uses for which they are not approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Inadequate funding for the FDA or other comparable regulatory authorities or government agencies could hinder their ability to hire and
retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our
business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be
affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and accept the payment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government
agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA or other comparable regulatory authorities or government agencies may also slow the time necessary for new drugs to be
reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to
furlough critical employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with U.S.
administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA&#8217;s ability to conduct routine activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a prolonged government shutdown occurs, including as a result of reaching the debt ceiling, it could significantly impact the ability of
the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in
order to properly capitalize and continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>EU drug marketing and reimbursement regulations may materially affect our
ability to market and receive coverage for our products in the EU Member States. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our product
candidates in both the United States and potentially in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In
some foreign countries, particularly those in the European Union, the pricing of products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these
countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the
availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce
or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to reward improper performance generally is typically
governed by the national anti-bribery laws of EU Member States and the Bribery Act 2010 in the United Kingdom. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive
governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered, or promised
to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the United Kingdom despite its departure from
the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with
physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU Member States. These requirements are
provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or
imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, including some countries in the European Union, the proposed pricing for a product
must be approved before it may be lawfully marketed. The requirements governing product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pricing and reimbursement vary widely from country to country. For example, some EU Member States have the option to restrict the range of medicinal products for which their national health
insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between
<FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls
on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other
available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for therapeutics products will allow favorable reimbursement and
pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party
payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited
in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to export and import controls, economic sanctions, and anti-corruption laws and regulations of the United States and
other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which can harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs
regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the
provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. We are also subject to anti-corruption and anti-bribery
laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and other state and national anti-bribery laws in the countries in which we conduct
activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything
else of value to recipients in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate
system of internal accounting controls. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities.
Any violation of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation,
reputational harm, and other consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or any third-party manufacturer we engage now or in the future fail to comply with
environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous
environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and
flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of
contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur
significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain general liability insurance as well as
workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in
connection with our storage or disposal of biological, hazardous, or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs
in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or commercialization efforts. Failure to comply with these laws and
regulations also may result in substantial fines, penalties, or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, with respect to the operations of our current
and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations, or properly dispose of wastes associated with our products, we could
be held liable for any resulting damages, suffer reputational harm, or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party
contract manufacturers become subject to injunctions or other sanctions as a result of their <FONT STYLE="white-space:nowrap">non-compliance</FONT> with environmental, health, and safety laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property and
proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates similar to ours and our
ability to successfully develop and commercialize our product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success
depends, in large part, on our ability to obtain and maintain intellectual property rights protection through patents, trademarks, and trade secrets in the United States and other countries with respect to our technology and product candidates. If
we do not adequately protect our intellectual property rights, competitors or other third parties may be able to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability. To
protect our proprietary position, we and our licensors have filed patent applications and may file other patent applications in the United States or abroad related to our product candidates that are important to our business. In particular, we are
heavily reliant on patent rights we have exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Monash University pursuant to the Monash License Agreement. The patent application process is expensive, time-consuming and complex. We may
not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may not be able to obtain patents on certain inventions if those inventions are publicly disclosed prior to our filing a
patent application covering them. We enter into nondisclosure and confidentiality agreements with parties who have access to confidential information, including confidential information regarding inventions not yet disclosed in patent applications.
We cannot guarantee that any of these parties will not breach these confidentiality agreements and publicly disclose any of our inventions before a patent application is filed covering such inventions. If such confidential information is publicly
disclosed, we may not be able to successfully patent the inventions and consequently, we may not be able to prevent third parties from using such inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the scope of the patent protection we obtain is not sufficiently broad, we may not be able to prevent others from developing and
commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our
rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents have, or that any of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications that mature into issued patents will include claims with a scope sufficient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to protect our product candidates or otherwise provide any competitive advantage. Other parties have developed or may develop technologies that may be related to or competitive with our approach,
and may have filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or conflict with our patent portfolio, either by claiming the same compounds, formulations, or methods or by claiming
subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States,
the natural expiration of a patent is generally twenty years after the first <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application has been filed. Various extensions may be available; however, the life of a patent, and the
protection it affords, is limited. Given the amount of time required for the development, testing, and regulatory review of product candidates, patents protecting such product candidates might expire before or shortly after such product candidates
are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if they are unchallenged, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and pending patent applications, if
issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patent portfolio by developing similar or alternative product candidates in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a product candidate that provides benefits similar to one of our product candidates but falls outside the scope of our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent rights. If the patent protection provided by the patent and patent applications we hold or pursue with respect to such product candidate is not sufficiently broad to impede such competition, our
ability to successfully commercialize our product candidate could be negatively affected, which would harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, or any
future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss
potential opportunities to strengthen our patent position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patent
portfolio may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, or licensees, whether now or in the
future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or licensees are not fully cooperative or disagree with us as to the
prosecution, maintenance, or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patent portfolio, such patents may be held to be
invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and/or applications will be due to be paid to the
U.S. Patent and Trademark Office, or the USPTO, and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and patent applications. We rely on our outside counsel or our licensing partners
to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with several procedural,
documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can, and in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT
STYLE="white-space:nowrap">Non-compliant</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with certain foreign
filing requirements during the patent application process. For example, in some countries, including the U.S., China, India and some European countries, a foreign filing license is required before certain patent applications are filed. The foreign
filing license requirements vary by country and depend on various factors, including where the inventive activity occurred, citizenship status of the inventors, the residency of the inventors and the invention owner, the place of business for the
invention owner and the nature of the subject matter to be disclosed (e.g., items related to national security or national defense). In some, but not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all cases, for example in China and India, a foreign filing license cannot be obtained retroactively in accordance with the applicable rules. There are situations, however, in which <FONT
STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment of a pending patent application or can be grounds for revoking or invalidating an issued patent, resulting in the loss of patent rights in the relevant jurisdiction. In such
an event, potential competitors might be able to enter the relevant markets with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects. We
may also be dependent on our licensors to take the necessary actions to comply with these requirements with respect to our licensed intellectual property. Any of these outcomes could impair our ability to prevent competition from third parties,
which may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical and biotechnology companies carries uncertainty.
As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are characterized by uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a
patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the
first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are not published until 18 months
after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patent portfolio, or that we were the first to file for patent protection of such inventions. If third parties
have filed prior patent applications on inventions claimed in our patent portfolio that were filed on or before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the
first to invent any of the subject matter covered by our patent portfolio. If third parties have filed such prior applications after March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to
determine whether our invention was derived from theirs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because the issuance of a patent is not conclusive as to its
inventorship, scope, validity or enforceability, any patents we may own or license may be challenged in the courts or patent offices in the United States and abroad. There is no assurance that all the potentially relevant prior art relating to our
patent portfolio has been published or found. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patent portfolio, or that we were the first to file for patent protection of such inventions. If
such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of prior art to the USPTO, or to other
patent offices around the world. Alternatively or additionally, we may become involved in post-grant review procedures, oppositions, derivation proceedings, ex parte reexaminations, inter partes review, supplemental examinations, or interference
proceedings or challenges before the USPTO or in district court in the United States, or similar proceedings in various foreign jurisdictions, including both national and regional, challenging patents or patent applications in which we have rights,
including patents on which we rely to protect our business. An adverse determination in any such challenge may result in loss of the patent or claims in the patent portfolio being narrowed, invalidated or held unenforceable, in whole or in part, or
in denial of the patent application or loss or reduction in the scope of one or more claims of the patent portfolio, any of which could limit our ability to stop others from using or commercializing similar or identical technology and products, or
limit the duration of the patent protection of our technology and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our or our licensors&#8217; pending and future patent
applications may not result in patents being issued that protect our business, in whole or in part, or which effectively prevent others from commercializing competitive products. For example, our or our licensors&#8217; provisional applications may
never result in issued patents. A provisional patent application is not eligible to become an issued patent until, among other things, we or our licensors file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12
months of filing the provisional patent application. If we or our licensors do not timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we or our licensors may lose the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
priority dates with respect to such provisional patent applications and any patent protection on the inventions disclosed in such provisional patent applications. While we intend to timely file <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications relating to our current and future provisional patent applications, we cannot predict whether any of our or our licensors&#8217;
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications directed to our technology and product candidates will result in the issuance of patents that effectively protect our technology and product candidates. Further, competitors
may be able to design around our patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries also may diminish the value of our patents or narrow the scope of our patent protection. In
addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including jurisdictions that coincide with significant
commercial markets, such as the European Patent Office, China, and Japan, restrict the patentability of methods of treatment of the human body more than United States law does, and India does not permit the patenting of methods of treatment at all.
These differences in patent protection may have a material adverse effect on our ability to adequately protect our inventions against unauthorized use by third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future
development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance, whether intentional or not, can result in abandonment or lapse of a patent or patent application, resulting in partial or complete
loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued, or even if issued may not provide adequate patent
coverage to prevent a competitor from developing a competing product or otherwise provide us with any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">company-owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that have been issued or may be
issued in the future may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, some of which may have substantially greater resources, may seek or may have already obtained
patents that will limit, interfere with or eliminate our ability to make, use, and sell our product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the U.S. may, under certain circumstances, force us to grant a license under our patents to
a competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there could also be delays at the USPTO caused by staffing cuts and other U.S. government actions as a result of
the U.S. Department of Government Efficiency or other executive actions to reduce the size of the U.S. government. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
competitors may also seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our patents, or both, including by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our
competitors do not infringe our patents. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain certain information as company trade secrets. This information may relate to inventions that are not patentable or not optimally
protected with patents. We use commercially acceptable practices to protect this information, including, for example, limiting access to the information and requiring passwords for our computers. Additionally, we execute confidentiality agreements
with any third parties to whom we may provide access to the information and with our employees, consultants, scientific advisors, collaborators, vendors, contractors, and advisors. We cannot provide any assurances that all such agreements have been
duly executed, and third parties may still obtain this information or may come upon this or similar information independently. It is possible that technology relevant to our business will be independently developed by a person who is not a party to
such a confidentiality or invention assignment agreement. If any of our trade secrets were to be independently developed by a competitor or other third party, we would have no right to prevent such competitor or third party, or those to whom they
communicate such independently developed information, from using that information to compete with us. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by contract manufacturers,
consultants, collaborators, vendors, advisors, former employees and current employees. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies will be
effective. Furthermore, if the parties to our confidentiality agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a consequence of
such breaches or violations. Our trade secrets could otherwise become known or be independently discovered by our competitors. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse
against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets, our business, financial condition, results of operation and prospects may be materially and
adversely harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily reliant on <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property, and if we
fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our current and future licensors, we could lose
license rights that are important to our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are heavily reliant upon the rights granted to us under the Asset Transfer
Agreement and the Monash License Agreement pursuant to which, for the latter, we have been granted an exclusive, royalty-bearing license to certain patent rights that are important or necessary to the development of our proprietary technology and
product candidates. Termination of the Asset Transfer Agreement or the Monash License Agreement or reduction or elimination of our licensed rights could lead to the loss of our ability to develop and commercialize our proprietary technology and
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may need to obtain licenses to intellectual property rights necessary to develop and commercialize
our product candidates or may need to amend existing or future licenses. If we are unable to obtain or amend such licenses at a reasonable cost or on reasonable terms, we may be unable to develop or commercialize our product candidates, which could
harm our business significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, the Monash License Agreement imposes, and we expect that future license agreements will
impose, diligence obligations, milestone and royalty payments, indemnification and other obligations on us. If we fail to comply with our obligations under one or more of these licenses, our licensors, including Monash University, may have the right
to terminate the license agreement at issue. If one or more of these licenses is terminated, we may be unable to develop or commercialize our product candidates. Termination of any of our current or future license agreements or reduction or
elimination of our licensed rights may require us to negotiate new or reinstated licenses with less favorable terms, even if available at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our license agreements are, and future license agreements are likely to be,
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of the licensed rights, or
increase what we believe to be our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition, if disputes over the license agreements or the
<FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property prevent or impair our ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the
affected product candidate. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">License agreements we may enter into in the future may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> or may not include all
territories or fields of use of interest to us. Accordingly, third parties may also obtain licenses from such licensors to the same intellectual property rights they have licensed to us. As a result, the licenses granted to us may not provide us
with exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our product candidates, which may permit competitors to develop and
commercialize a competitive product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in some cases, we may not have the right to control the preparation, filing and
prosecution of patent applications, or to maintain the patents, covering technology that we <FONT STYLE="white-space:nowrap">in-license</FONT> from third parties. Therefore, we cannot be certain that any
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our future licensors or collaboration partners fail to obtain, maintain
or protect any patents or patent applications licensed to us, decide not to pursue litigation against third-party infringers, fail to prosecute infringement, or fail to defend against counterclaims of patent invalidity and unenforceability, our
rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our current or future licensors regarding intellectual property subject to a license agreement, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate
intellectual property of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our current or future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite our best efforts, our current or future licensors might conclude that we materially breached our license agreements and might
therefore terminate the license agreements, thereby removing our ability to develop and commercialize products, if approved, and technology covered by these license agreements. As a result, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be required to cease our development and commercialization of our product candidates and use of our proprietary technologies covered by the patent rights owned by the licensors. Furthermore,
if the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights fail to provide the intended exclusivity, competitors will have the freedom to seek regulatory approval of, and to market, products identical to ours. These events could have a
material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. For a more complete description of our license agreements, see the section titled &#8220;Business&#8212;License
Agreement.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may need to acquire or license additional intellectual property from third parties, and such licenses may not
be available or may not be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold intellectual property, including
patent rights that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more
established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and
greater clinical development. If we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize our
product candidates, if approved, would likely be delayed or we may have to abandon development of that product candidate and our business and financial condition could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates in the future, we might become dependent on proprietary rights
from third parties with respect to those product candidates. Any termination of such licenses could result in the loss of significant rights and would cause material adverse harm to our ability to develop and commercialize any product candidates
subject to such licenses. Even if we are able to <FONT STYLE="white-space:nowrap">in-license</FONT> any such necessary intellectual property, it could be on nonexclusive terms, including with respect to the use, field or territory of the licensed
intellectual property, thereby giving our competitors and other third parties access to the same intellectual property licensed to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us
to make an appropriate return on our investment or at all. If we are unable to license such intellectual property, or if we are forced to license such intellectual property on unfavorable terms, our business could be materially harmed. <FONT
STYLE="white-space:nowrap">In-licensing</FONT> IP rights could require us to make substantial licensing and royalty payments. Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against
our licensors or another licensee or in administrative proceedings. If any <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents are invalidated or held unenforceable, we may not be able to prevent competitors or other third parties from
developing and commercializing competitive products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, intellectual property rights that we may
<FONT STYLE="white-space:nowrap">in-license</FONT> in the future may be sublicensed under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our
sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to
which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have the right to control the prosecution, maintenance, enforcement or defense of patents and patent applications that we license
from third parties, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents. In such cases, we would be reliant on the licensor to take any necessary actions. We
cannot be certain that such licensor would act with our best interests in mind, or in compliance with applicable laws and regulations, or that their actions would result in valid and enforceable patents. For example, it is possible that a
licensor&#8217;s actions in enforcing and/or defending a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent licensed by us may be less vigorous than had we conducted them ourselves. We cannot be certain that such activities by our licensors have been or will be conducted in compliance with
applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents
or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property
that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents or defense of claims asserting the invalidity of those
patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to or after our assuming control. This could cause us to lose rights in any applicable intellectual property
that we <FONT STYLE="white-space:nowrap">in-license,</FONT> and as a result our ability to develop and commercialize product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing
products. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our present or future licensors may have relied upon or may rely upon third-party consultants or collaborators or on funds from third parties
such that our present or future licensors may not be the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> If other third parties have ownership rights to our present or future <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive
position, business, financial conditions, results of operations, and prospects. Furthermore, government agencies may provide, funding or other assistance in connection with the development of the intellectual property rights owned by or licensed to
us. In addition, the U.S. federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive,
nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with <FONT STYLE="white-space:nowrap">&#8220;march-in</FONT> rights.&#8221; <FONT
STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a
&#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. If we choose to collaborate with academic institutions to accelerate our preclinical research or development, we
cannot be sure that any <FONT STYLE="white-space:nowrap">co-developed</FONT> intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we <FONT STYLE="white-space:nowrap">co-own</FONT> or license in
technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their
protection. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection
for our product candidates, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our product candidates from unauthorized making, using, selling, offering to sell or importing by third
parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and have in recent years been the subject of
much litigation. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and biotechnology patents during litigation often based on changing interpretations of patent law.
Further, the determination that a patent application or patent claim meets all the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the USPTO or by a court
or other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications,
patents and other information that may affect the patentability of claims in our patent portfolio, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or
enforced in our own patent portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot provide assurances that any of our or our licensors&#8217; pending patent applications
will be found to be patentable, including over our own prior art publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims of the issued patents that we own or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> or any claims that may issue from our or our licensors&#8217; pending and future patent applications nor to the outcome of any proceedings by any potential third parties that could challenge the
patentability, validity or enforceability of our patent portfolio in the United States or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our product candidates and/or materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not
adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire
breadth of developments in one or more of our programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that one or more of our pending patent applications will not become an issued patent or, if
issued, that the patent claims will not have sufficient scope to protect our technology, provide us with commercially viable patent protection or provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable
under United States or foreign laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not successfully commercialize our product candidates, if approved, before our relevant patents expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be the first to file patent applications for the inventions covered by our patent portfolio; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are separately patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent that we are unable to obtain and maintain patent protection for our product candidates, or in the event that such
patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of any of our product candidates for <FONT STYLE="white-space:nowrap">follow-on</FONT> indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited term. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
twenty years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the
USPTO in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent having an earlier expiration date. Even if patents covering our drug candidates are obtained, once the patent life has expired for a drug
candidate, we may be open to competition from competitive medications, including generic versions. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents directed towards such drug
candidates might expire before or shortly after such drug candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with sufficient rights to exclude others from commercializing drug candidates similar or identical to ours for a meaningful amount of time, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required
for the development, testing and regulatory review of product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a Patent Term Extension, or PTE, of up to
five years beyond the normal expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process. A PTE grant cannot extend the remaining term of a patent beyond a total of 14 years
from the date of the product approval. Further, PTE may only be applied once per product, and only with respect to an approved indication&#8212;in other words, only one patent (for example, covering the product itself, an approved use of said
product, or a method of manufacturing said product) can be extended by PTE. Moreover, the scope of protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. We
anticipate applying for PTE in the United States. Similar extensions may be available in other countries where we are prosecuting patents and we likewise anticipate applying for such extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The granting of such patent term extensions is not guaranteed and is subject to numerous requirements. We might not be granted an extension
because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents, failure to exercise due diligence during the testing phase or regulatory review process or any other failure to
satisfy any of the numerous applicable requirements. In addition, to the extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of
that third party. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and
may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and
preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug
Products with Therapeutic Equivalence Evaluations, or the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our
product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA
to obtain permission to sell a generic version of such drug candidate. Where patents are listed, an ANDA or 505(b)(2) applicant seeking approval before patent expiry must submit a Paragraph IV certification; if we sue within 45 days of notice,
approval of the ANDA or 505(b)(2) application may be stayed for up to 30 months, though the patent can still be invalidated or found not infringed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general,
thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily
dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in
either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and,
more generally, could affect the value of our intellectual property or narrow the scope of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
owned and licensed patents. The U.S. Congress is responsible for passing laws establishing patentability standards. As with any laws, implementation is left to federal agencies and the federal
courts based on their interpretations of the laws. Interpretation of patent standards can vary significantly within the USPTO, and across the various federal courts, including the U.S. Supreme Court. Recently, the Supreme Court has ruled on several
patent cases, generally limiting the types of inventions as well as the scope of inventions that can be patented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to
increasing uncertainty with regard to our ability to obtain patents in the future, the legal landscape in the U.S. has created uncertainty with respect to the value of patents. Depending on any proposed or already implemented actions by U.S.
Congress, and future decisions by the lower federal courts and the U.S. Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new
patents or to enforce our existing patents and patents that we might obtain in the future as well as the cost associated with the filing, prosecution and maintenance of our or our licensors patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent reform legislation in the United States and other countries could increase those uncertainties and costs. For example, the Leahy-Smith
America Invents Act of 2011, or the Leahy-Smith Act, included a number of significant changes to United States patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and
cost-effective avenues for competitors to challenge the validity of patents, for example, via post grant review and inter partes review proceedings at the USPTO. Because of a lower evidentiary standard in USPTO proceedings compared to the
evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be
insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or any
patents we may license in the future that would not have been invalidated if first challenged by the third party as a defendant in a district court action. In addition, the Leahy-Smith Act transformed the United States patent system into a
&#8220;first to file&#8221; system. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant
<FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and
patents that we might obtain in the future. The U.S. Supreme Court has ruled on several patent cases in recent years; these cases often narrow the scope of patent protection available to inventions in the pharmaceutical and biotechnology industries.
We cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. For example, in 2023, the Federal Circuit issued a decision in <I>In re Cellect, LLC</I> involving the interaction of patent
term adjustment, or PTA, terminal disclaimers, and obviousness-type double patenting which may affect the patent term of any issued patents that rely on any PTA. In 2022, the U.S. Congress passed the Inflation Reduction Act, or IRA, which authorizes
the Secretary of the Department of Health and Human Services, or HHS, to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. For small
molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain that it will not affect our
patent strategy in the long run. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a new court system recently became operational in the European Union. The Unified Patent Court,
or UPC, began accepting patent cases on June&nbsp;1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple member states of the European Union. The broad geographic reach
of the UPC could enable third parties to seek revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Union member states in which the European patent is validated. Under the UPC, a successful revocation proceeding for a European Patent under the UPC would result in loss of patent protection in
those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse
impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will
develop over time and we cannot predict what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely affect our ability to enforce or defend the validity of our European patents. Patent owners have the option to <FONT
STYLE="white-space:nowrap">opt-out</FONT> their European Patents from the jurisdiction of the UPC, defaulting to <FONT STYLE="white-space:nowrap">pre-UPC</FONT> enforcement mechanisms. We have not opted out our existing European patents and patent
applications but we may in the future decide to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents could be subject to the jurisdiction of the
UPC. We cannot be certain that our European patents will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, enforcing, and defending patents protecting our product candidates in all countries throughout the world
would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries,
particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. Further, the standards applied by the USPTO and foreign
patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies, products and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign
intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Geopolitical actions in the
United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our
issued patents or those of any current or future licensors. Many companies have encountered significant problems in protecting, enforcing and defending intellectual property rights in certain foreign jurisdictions, such as China and Russia. For
example, further to the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine, the Kremlin issued Decree 299 stating that Russian companies and individuals can use patented inventions without the owner&#8217;s
permission or compensation, if the patent is held by owners from &#8220;unfriendly countries,&#8221; which include the United States. As a result, we would not be able to enforce our otherwise valid patent rights against an infringer in Russia.
These and other restrictions could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights in such countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties.
Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe or from selling or importing products made from our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and market their own products and, further, may export otherwise infringing products to territories where we have patent
protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights, whether successful or not, could result in substantial costs and divert our
efforts and resources from other aspects of our business. Further, such proceedings could put our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents at risk of being invalidated, held unenforceable or interpreted narrowly; put our pending patent applications at risk of not issuing; and provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be
able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, we may
decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as
patents in some jurisdictions, such as in the U.S., but may issue as patents with claims of different scope or may even be refused in other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>In order to protect our competitive position around our product candidates, we may become involved in lawsuits to protect or enforce our
patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we
may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to
assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide
that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court
will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation
or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products.
Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid
or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. We may find it impractical or
undesirable to enforce our intellectual property against some third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not
to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue
such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a result of the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors are larger than we are and have
substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed
intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or otherwise violating our intellectual property. Even if resolved in our favor, litigation or other
legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our
internal research programs, or <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for infringing
intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing current and future product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to develop, manufacture, and market our current as well as any future product
candidates, without infringing the intellectual property and other proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual
property rights. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. If any third-party patents
or patent applications are found to cover our current or any future product candidates or their methods of use, or other aspects of our current or future product candidates, we may not be free to manufacture or market such product candidates as
planned without obtaining a license, which may not be available on commercially reasonable terms, or at all, or we may incur significant legal fees or damages. We may in the future become party to, or be threatened with, adversarial proceedings or
litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert
infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Moreover, in recent years, individuals and groups that are <FONT STYLE="white-space:nowrap">non-practicing</FONT>
entities, commonly referred to as &#8220;patent trolls,&#8221; have acquired patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive
threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. If a patent infringement suit were
threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the actual or threatened suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our efforts to avoid obstacles and disruptions arising from third-party intellectual property, it is impossible to establish with
certainty that our programs directed to our current and any future product candidates will be free of claims by third-party intellectual property holders. We cannot guarantee that any of our patent searches or analyses, including the identification
of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad
that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Even with modern databases and <FONT STYLE="white-space:nowrap">on-line</FONT> search engines, literature searches are imperfect and may fail
to identify relevant patents and published applications. Even when a third-party patent is identified, we may conclude upon a thorough analysis, that we do not infringe the patent or that the patent is invalid. The scope of a patent claim is
determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively
impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope.
Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. If the third-party patent owner disagrees with our conclusion and we continue with the business activity in
question, patent litigation may be initiated against us. Alternatively, we might decide to initiate litigation in an attempt to have a court declare the third-party patent invalid or <FONT STYLE="white-space:nowrap">non-infringed</FONT> by our
activity. In either scenario, patent litigation typically is costly and time-consuming, and the outcome is uncertain. The outcome of patent litigation is subject to uncertainties that cannot be quantified in advance, for example, the credibility of
expert witnesses who may disagree on technical interpretation of scientific data. Ultimately, in the case of an adverse outcome in litigation, we could be prevented from commercializing a product or using certain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aspects of our technology platform as a result of patent infringement claims asserted against us. This could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the pharmaceutical and biotechnology industries, and we may become party
to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our current or future product candidates, including interference proceedings before the USPTO. Third parties may assert
infringement claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and
biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to
interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that any current or future product candidates, products, methods, processes, modeling or similar work
either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to
infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product or
cease some of our business operations, which could harm our business. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the
infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby
giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found
liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could
prevent us from commercializing any future product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third
parties could have a similar negative impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our involvement in litigation, and in, e.g., any interference, derivation,
reexamination, inter partes review, opposition or post-grant proceedings or other intellectual property proceedings in the United States, or other jurisdictions, may divert management time from focusing on business operations, could cause us to
spend significant amounts of money and may have no guarantee of success. Any current and potential intellectual property litigation also could force us to do one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop selling, manufacturing or using our products in the United States or other jurisdictions that use the
intellectual property at issue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant
technology, which license may not be available on reasonable terms, or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> thereby giving our competitors access to the same technologies licensed to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign those products or processes that use any allegedly infringing or misappropriated technology, which may
result in significant cost or delay to us, or which redesign could be technically infeasible; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully
infringed certain intellectual property rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Others may challenge inventorship or claim an ownership interest in our intellectual
property which could expose it to litigation and have a significant adverse effect on its prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent
application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors or the effects of foreign laws where foreign
nationals are involved in the development of the subject matter of the patent. Furthermore, ownership disputes may arise from alleged contributions of third parties involved in developing our product candidates and may result in joint ownership of
our inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Any disagreement over inventorship could result in our being forced to defend our determination of inventorship in a legal
action which could result in substantial costs and be a distraction to our senior management and scientific personnel. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material
adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we typically require employees, consultants and contractors who may develop intellectual property on our behalf to execute agreements
assigning such intellectual property to us, we may be unsuccessful in obtaining execution of assignment agreements with each party who in fact develops intellectual property that we regard as our own. Moreover, even when we obtain agreements
assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached. In either case, we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic
institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. If we are unsuccessful in obtaining assignment agreements from an employee, consultant or contractor who develops
intellectual property on our behalf, the employee, consultant or contractor may later claim ownership of the invention. Any disagreement over ownership of intellectual property could result in our losing ownership, or exclusive ownership, of the
contested intellectual property, paying monetary damages and/or being enjoined from clinical testing, manufacturing and marketing of the affected product candidate(s). Even if we are successful in prosecuting or defending against such claims,
litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any
intellectual property litigation could lead to unfavorable publicity that could harm our reputation and cause the market price of our common stock to decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of any patent litigation, there could be public announcements of the results of hearings, rulings on motions, and other
interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our products, programs, or intellectual property could be diminished. In such event, the market price of our
common stock may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees or we have misappropriated intellectual property from a
competitor or third parties or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our current and
former employees and our licensors&#8217; current and former employees, including our senior management, were previously employed at other pharmaceutical or biotechnology companies, including some which may be competitors or potential competitors.
Although we take commercially reasonable steps to ensure that our employees do not use the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, including incorporating such
intellectual property into our product candidates, we may be subject to claims that we or these employees have misappropriated the intellectual property of a third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any of our employees are accused of misappropriating the proprietary information, <FONT
STYLE="white-space:nowrap">know-how</FONT> or trade secrets of a third party, we may be forced to defend such claims in litigation. If we are found to have misappropriated the intellectual property rights of a third party, we may be forced to pay
monetary damages, sustain reputational damage, lose key personnel, or lose valuable intellectual property rights. Further, it may become necessary for us to obtain a license from such third party to commercialize any of our product candidates. Such
a license may not be available on commercially reasonable terms or at all. Any of the aforementioned could materially affect the commercialization of any of our product candidates. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of
our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Along
with patent protection, we also rely on trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, including, for example, certain aspects of our manufacturing
processes. We seek to protect these trade secrets, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent
contractors, CROs, advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> are difficult to maintain as confidential. Although we use
reasonable efforts to protect our trade secrets, any party with whom we have executed a confidentiality agreement may breach that agreement and disclose our proprietary information, including our trade secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the
outcome is unpredictable. Accordingly, we may not be able to obtain adequate remedies for such breaches, despite any legal action that we might take against persons making such unauthorized disclosures. In addition, courts outside the United States
sometimes are less willing than United States courts to protect trade secrets. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such
third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business
and competitive position could be harmed. For example, we may choose not to file a patent application for certain inventions, instead choosing to rely on trade secret protection, and a third party may subsequently file a patent application covering
such intellectual property. Although certain defenses maybe available to us, those defenses may not be available to a commercial partner or acquiror. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Those with whom we collaborate on research and development related to current and future product candidates may have rights to publish data
and other information to which we have rights. In addition, we sometimes engage individuals or entities to conduct research relevant to our business. The ability of these individuals or entities to publish or otherwise publicly disclose data and
other information generated during the course of their research is subject to certain contractual limitations. These contractual provisions may be insufficient or inadequate to protect our confidential information. If we do not apply for patent
protection prior to such publication, or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information
may be jeopardized. We may also need to share our trade secrets and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft
of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be
able to build name recognition in our trademarks of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current or future
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims
against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to protect our rights to our trademarks and trade names or may be forced to stop
using these names, which we need for name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and
possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered
trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. During trademark
registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign
jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not
survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in
Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our
proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be
acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. If we are unable to
establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to
develop and commercialize our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future collaborations that we enter into may not be successful. The success of our
collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business
combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that causes the delay or termination of the research,
development or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to
collaborations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit
sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may use our intellectual property or proprietary information in a way that gives rise to actual or
threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability or business risk; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable current or future product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and a collaborator&#8217;s sales and marketing activities or other
operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering
and Ownership of Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior public market for our common stock, and an active trading market may
not develop or be sustained. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no public market for our common stock prior to this offering. Although we intend to
apply to list our common stock on The Nasdaq Global Select Market, an active or liquid market in our common stock may not develop upon closing of this offering or, if it does develop, it may not be sustainable. The initial public offering price for
our common stock was determined through negotiations among the underwriters and us and may vary from the market price of our common stock following this offering. This price will not necessarily reflect the price at which investors in the market
will be willing to buy and sell our shares following this offering. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you wish to sell them and the prices that you may obtain for your
shares. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products, or technologies by using our common stock as consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our common stock may be volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in
response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this section and elsewhere in this prospectus, these factors include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment, completion, or results of our current or future preclinical and clinical trials for
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in identifying and advancing a clinical candidate for our other programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse
development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results or delays, suspensions, or terminations in future preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical
trial; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates, or the
failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial
requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse developments concerning our manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of the healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable
prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to establish strategic partnerships or collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to commercialize our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">introduction of new products or services offered by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us
or our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry, or product candidates in particular, or positive or
negative recommendations or withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and the market for therapeutics companies in particular, have experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the
market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our
operating results to fall below expectations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual operating results may fluctuate significantly, due to a
variety of factors, many of which are outside of our control and may be difficult to predict, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development and, if approved, commercialization
activities relating to our current and future product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and status of enrollment for clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary
depending on the quantity of production and the terms of our agreements with manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop, or commercialize additional product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and amount of any milestone, royalty, or other payments due under any collaboration or license agreement,
including the Asset Transfer Agreement and/or the Monash License Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies and clinical trials for our product candidates or
competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States
and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our product candidates, if approved, which may vary significantly over time.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and
annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results
as an indication of our future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This variability and unpredictability could also result in our failing to meet the
expectations of industry or financial analysts or investors for any period. If our future revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we
provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings
guidance we may provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research
about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend in part
on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our common stock would likely be negatively impacted. In the
event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these
analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors, principal stockholders, and their respective affiliates own a significant percentage of our stock and
will be able to exert significant control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the beneficial ownership of our
common stock as of &#8195;&#8195;&#8195;&#8195;, 2026, prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately &#8195;% of our voting
stock and, upon the completion of this offering, that same group will hold approximately &#8195;% of our outstanding voting stock (assuming no exercise of the underwriters&#8217; option to purchase additional shares, no exercise of outstanding
options and no purchases of shares in this offering by any of this group), in each case assuming the conversion of all outstanding shares of our convertible preferred stock into shares of our common stock. In particular, PureTech will own
approximately &#8195;% of our common stock following this offering and will be our largest stockholder following this offering. As a result, PureTech along with stockholders who own more than 5% or more of our capital stock, if acting together, will
continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation, or sale of all or substantially
all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our
company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the
prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock in the public market could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price could decline as a result of sales of a large number of shares of common stock after this offering or the perception that
these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, &#8195;&#8195;&#8195;&#8195; shares of common stock will be outstanding (or &#8195;&#8195;&#8195;&#8195;
shares if the underwriters exercise their option to purchase additional shares from us in full), based on the number of shares outstanding as of &#8195;&#8195;&#8195;&#8195;, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the
Securities Act of 1933, as amended, or the Securities Act, unless held by our &#8220;affiliates&#8221; as defined in Rule 144 under the Securities Act. The resale of the remaining &#8195;&#8195;&#8195;&#8195; shares, or &#8195;&#8195;&#8195;&#8195;%
of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain
of our stockholders with us or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters in connection with this offering. However, subject to applicable securities law restrictions, these
shares will be able to be sold in the public market beginning on the 181<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity
incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market
<FONT STYLE="white-space:nowrap">stand-off</FONT> agreements and/or <FONT STYLE="white-space:nowrap">lock-up</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled &#8220;Shares Eligible for Future Sale&#8221; included elsewhere in this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, the holders of approximately &#8195;&#8195;&#8195; shares, &#8195;&#8195;&#8195; or
&#8195;% &#8195;&#8195;&#8195; of &#8195;&#8195;&#8195; our outstanding shares following this offering, of our common stock will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares
or to include their shares in registration statements that we may file for ourselves or our other stockholders. We also intend to register the offer and sale of all shares of common stock that we may issue under our equity compensation plans. Once
we register the offer and sale of shares for the holders of registration rights and shares that may be issued under our equity incentive plans, these shares will be able to be sold in the public market upon issuance, subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described under the section titled &#8220;Underwriting&#8221; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock,
in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect
our results of operations and cause our stock price to decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have considerable discretion in the application of the
net proceeds of this offering and, including for any of the purposes described in the section titled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are
being used appropriately. As a result, investors will be relying upon management&#8217;s judgment with only limited information about our specific intentions for the use of the net proceeds of this offering. We may use the net proceeds for purposes
that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our common stock in our initial public offering, you will experience substantial and immediate dilution.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the price range
set forth on the cover page of this prospectus, is substantially higher than the pro forma as adjusted net tangible book value per share of our outstanding common stock immediately following the completion of this offering. If you purchase shares of
common stock in this offering, you will experience substantial and immediate dilution in the pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195; per share as of December&nbsp;31, 2025. That is because the price
that you pay will be substantially greater than the pro forma as adjusted net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than
the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution if the underwriters exercise their option to purchase additional shares in this offering, when those holding stock
options exercise their right to purchase common stock under our equity incentive plans, upon the vesting of outstanding restricted stock awards or when we otherwise issue additional shares of common stock. For more information, see the section
titled &#8220;Dilution&#8221; included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participation in this offering by our existing stockholders
and/or their affiliated entities will reduce the public float for our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent our existing stockholders who
are our affiliates or their affiliated entities participate in this offering, such purchases would reduce the <FONT STYLE="white-space:nowrap">non-affiliate</FONT> public float of our common stock after this offering, which is the number of shares
of common stock that are not held by our officers, directors, and affiliated stockholders. As a result, the number of freely tradeable shares of our common stock following this offering will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be reduced relative to what it would have been had these shares been sold to investors that were not existing stockholders, affiliates, or purchasers. This could adversely impact the liquidity of
our common stock and depress the price at which you may be able to sell shares of common stock purchased in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our
issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to issue additional capital stock in the future and to grant equity awards to employees, directors, and consultants under our stock
incentive plans. We may also raise capital through equity financings in the future. Additionally, as part of our business strategy, we may acquire or make investments in complementary companies, products, or technologies and issue equity securities
to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#8217; ability to achieve a return
on their investment will depend on appreciation of the value of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends
on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital
stock in the foreseeable future. In addition, any future debt agreements may preclude us from paying dividends. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not
certain. For more information on our dividend policy, see the section titled &#8220;Dividend Policy&#8221; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial
to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and
our amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, will contain provisions that may discourage, delay, or prevent a merger, acquisition or other
change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be
willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may
frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by
our stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all
our stockholders would be entitled to cast to amend or repeal specified provisions of our amended and restated certificate of incorporation or amended and restated bylaws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our
outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated bylaws that
will become effective upon the effectiveness of this registration statement designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our
stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws that will become effective upon effectiveness of the registration statement of which this prospectus forms a
part provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our
behalf, (ii)&nbsp;any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising
pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv)&nbsp;any action asserting a claim that is
governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting
a cause or causes of action arising under the Securities Act, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock
is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on
stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or
our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, Section&nbsp;22 of the Securities Act
creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. While the Delaware Supreme Court and other state courts have
upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal
Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not
enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an
action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to satisfy listing requirements of The Nasdaq Stock Market, or
Nasdaq, or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our common stock is listed on Nasdaq, we must meet
certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#8217;s listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#8217;s listing standards, our common stock may be delisted. In
addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our
stockholders&#8217; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our
ability to raise capital and the value of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other General Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of actual or
perceived changes in interest rates, inflation, and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty
about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the
ongoing conflicts in the Middle East and between Russia and Ukraine, terrorism, political unrest, or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine,
may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further
deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our drug
candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. For example, there has been proposed U.S. legislation that may have the effect of restricting the ability of U.S. biopharmaceutical companies to
purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies that the government name as &#8220;companies of concern&#8221; without losing the ability to contract with, or otherwise receive funding from,
the U.S. government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships. Furthermore, any disruptions to our supply chain as a result of unfavorable global economic
conditions, including due to geopolitical conflicts, political unrest, tariff, and other trade-related cost pressures or public health crises, could negatively impact the timely execution of our ongoing and future clinical trials. In addition,
inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent events of political unrest and/or potential future disruptions in access to bank deposits or lending
commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We, or the third parties upon whom we depend, may be adversely affected by natural disasters, public health crises, or
other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Natural disasters or public health crises could severely disrupt our operations and the operations of our suppliers, CROs, and clinical sites,
which would have a material adverse impact on our business, financial condition, results of operations, and prospects. If a natural disaster, power outage, public health crisis, or other event occurred that prevented us from conducting our clinical
trials, releasing clinical trial results, or delaying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our ability to obtain regulatory approval for our product candidates, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are eligible to be treated as an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and our election
of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we
may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements in addition to any required unaudited
interim financial statements and a correspondingly reduced &#8220;<I>Management</I><I>&#8217;</I><I>s Discussion and Analysis of Financial Condition and Results of Operations</I>&#8221; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting pursuant to of Section&nbsp;404 of the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus,
we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be an emerging growth company for up to five years following the completion of this offering, although circumstances could cause us
to lose that status earlier, including if we are deemed to be a &#8220;large accelerated filer,&#8221; which occurs when the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter, or if we have total annual gross revenue of $1.235&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be
an emerging growth company as of the last day of our fiscal year, or if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period before that time, in which case we would no
longer be an emerging growth company immediately. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not
emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can also take advantage of an extended
transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we
may not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even
after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed
fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. We cannot predict if investors will find our common
stock less attractive because we may rely on these exemptions. If some investors find our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote
substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant
legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current
reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose
significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street
Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in
these areas such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this offering. Stockholder
activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the
manner in which we operate our business in ways we cannot currently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public
companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they
could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For
example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to establish and maintain an effective system of
internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and
the trading price of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that we have adequate internal financial and accounting controls and procedures
in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be reevaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with this offering, we began the process of documenting, reviewing, and
improving our internal controls and procedures for compliance with Section&nbsp;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. Under current
rules, we will be subject to these requirements beginning with our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ending 2026. Any failure to implement required new or improved controls, or difficulties encountered
in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public
accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Internal control deficiencies could also cause investors to lose
confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be
required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company or a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&nbsp;404(b) of
the Sarbanes-Oxley Act. We could be an emerging growth company for up to five years following completion of this initial public offering. An independent assessment of the effectiveness of our internal controls over financial reporting could detect
problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We must design our
disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the
time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently
fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or
by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and
our financial condition and results of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain the majority of our cash, cash equivalents, and investments in
accounts with major U.S. and multi-national financial institutions, and our cash equivalents are invested in U.S. government money market funds and our investments are invested in U.S. Treasury obligations. Our deposits at certain of these
institutions exceed insured limits, unless subject to a &#8220;sweep.&#8221; Market conditions and changes in financial regulations and policies can impact the viability of these institutions. Adverse developments that affect financial institutions,
such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&nbsp;10, 2023, Silicon Valley Bank was closed by the California Department of
Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit
arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that us, the financial institutions with which we may have future credit agreements or
arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial,
credit, or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. Any
inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to predict; consequently, the
impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may
be limited. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, we had approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million of federal net
operating losses, or NOLs. Federal NOLs generated in taxable years beginning after December&nbsp;31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOL carryforwards in a taxable year is limited to 80% of our
taxable income in such year. As of December&nbsp;31, 2025, we had approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million of state NOLs. Of the state NOLs, some are of indefinite life, but most expire at various dates, beginning in
&#8195;&#8195;&#8195;&#8195;. As of December&nbsp;31, 2025, we had approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million of federal research and development tax credit carryforwards. Federal tax credit carryforwards expire at various dates,
beginning in &#8195;&#8195;&#8195;&#8195;. As of December&nbsp;31, 2025, we had approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million of state research and development tax credit carryforwards. The state tax credits, which have various
carryforward rules, begin to expire in &#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as
amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by &#8220;5&nbsp;percent shareholders&#8221; over a three-year
period, the corporation&#8217;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to offset its
post-change income or taxes may be limited. A corporation that experiences an ownership change will generally be subject to an annual limitation on the use of its <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs equal to the value
of the corporation immediately before the ownership change, multiplied by the long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate (subject to certain adjustments). We may have experienced ownership changes in the past and may
experience ownership changes as a result of this offering and/or subsequent shifts in our stock ownership (some of which are outside our control). There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs by federal
or state taxing authorities or other unforeseen reasons, portions of our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities. As a result, our ability to use our
<FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and tax credits to offset future taxable income, if any, or taxes could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain
profitability, we may be unable to use a material portion of our NOLs and tax credits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax law could adversely affect
our business and financial condition. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. federal, state, local, and foreign tax laws, regulations and administrative guidance
are subject to change as a result of the legislative process and review and interpretation by the U.S. Internal Revenue Service, the U.S. Treasury Department and other taxing authorities. Changes to tax laws (which changes may have retroactive
application), including with respect to net operating losses and research and development tax credits, could adversely affect us or holders of our common stock. For example, on July&nbsp;4, 2025, President Donald Trump signed the One Big Beautiful
Bill Act into law. Key tax provisions included the restoration of 100% bonus depreciation for certain qualified property, immediate expensing for domestic research and experimental expenditures and the ability to make elective adjustments for prior
years, changes to the Section&nbsp;163(j) interest limitations and updates to net CFC tested income (formerly GILTI) and FDII rules. In recent years, many other such changes have been made and changes are likely to continue to occur in the future.
Future changes in tax laws could have a material adverse effect on our business, financial condition, results of operations, or cash flow. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes
in tax laws on an investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our information technology systems and infrastructure, or those of our
collaborators and service providers, or our data, may be subject to cyberattacks, security breaches, compromises or other incidents, which could impact the confidentiality, integrity, and availability of our operational system and result in
additional costs, loss of revenue, significant liabilities, harm to our brand, material disruption of our development programs and operations, or other adverse consequences.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and the third parties upon which we rely, process sensitive data, and, as a result, we and the
third parties upon which we rely face a variety of evolving threats that could cause </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cyber-attacks, security breaches, compromises, or other incidents that impact the confidentiality, integrity, and availability of our operational systems. Although we, and the third parties upon
which we rely, take steps to develop and maintain systems and controls designed to protect our sensitive data, systems, and infrastructure, there can be no assurance that our internal technology systems, and infrastructure, or those of third parties
upon which we rely, will be sufficient to protect against a cyber-attack, security breach, compromise, or other incident such as an industrial espionage attack, ransomware, or insider threat attack, which may compromise the confidentiality,
integrity, and availability of our system infrastructure, or those of third parties upon which we rely, or lead to the loss, destruction, alteration, or dissemination of, or damage to, our sensitive data. Such threats are prevalent and continue to
rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or
misuse), sophisticated nation states, and nation-state-supported actors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk of a cyber-attack, security breach, compromise, or
other adverse impact to our and our third-party service provider&#8217;s information technology systems and sensitive data has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world
have increased. Such risks come from a variety of evolving threats, including but not limited to, social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks),
malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, credential stuffing,
credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware errors (including vulnerabilities in commercial software that is integrated into our information
technology systems and those of third parties upon which we rely), failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods, and other
similar threats. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individuals engage in and are expected to continue to engage in cyber-attacks, including without limitation nation-state
actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely, may be vulnerable to a heightened risk of cyber-attacks,
including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell, and distribute our products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also face increased risks of a cyber-attack, security breach, compromise, or adverse impact to our and our third-party service
provider&#8217;s information technology systems and sensitive data incident due to our reliance on internet technology and the number of our employees who work on a hybrid basis at home, in the office, or other public spaces. This may create
additional opportunities for cybercriminals to exploit vulnerabilities. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be
negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies that were not found during due diligence of such acquired or integrated entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain
attacks. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts and our ability to monitor these third parties&#8217; information security practices is
limited. These third parties may not have adequate information security measures in place and if our third-party service providers experience a cyber-attack, security breach, compromise or incident, or other interruption, we could experience adverse
consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such
award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to detect vulnerabilities in our information technology systems and infrastructure on a timely basis or until
after a cyber-attack, security breach, compromise, or other incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to adequately address any such identified vulnerabilities. In addition, we
may be unable to comprehensively apply patches or confirm that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measures are in place to mitigate all such vulnerabilities, or that patches will be applied before vulnerabilities are exploited by a threat actor. If attackers are able to exploit critical
vulnerabilities before patches are installed or mitigating measures are implemented, significant compromises could impact our and our customers&#8217; systems and data. Any integration of artificial intelligence in our or any third party&#8217;s
operations, products, or services is expected to pose new or unknown cybersecurity risks and challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can also be no assurance
that our cybersecurity risk management program and processes, including our policies, controls, or procedures, will be fully implemented, complied with, or effective in protecting our information technology systems (and those of third parties upon
which we rely) and sensitive data. We and certain of our third-party service providers regularly experience cyberattacks and other incidents, and we expect such attacks and incidents to continue in varying degrees. While to date no incidents have
had a material impact on our operations or financial results, we cannot guarantee that material incidents will not occur in the future. We may in the future experience additional threats, compromises, breaches, or incidents. If we, or a third party
upon whom we rely, experience a cyber-attack, security breach, compromise, or other adverse impact to the confidentiality, integrity and availability of our system infrastructure, or those of third parties upon which we rely, or sensitive data, or
are perceived to have experienced a cyber-attack, security breach, compromise, or other adverse impact to our and our third-party service provider&#8217;s information technology systems and sensitive data, we may experience adverse consequences,
such as government enforcement actions (e.g., investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including
individual and class action claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); significant incident response, system restoration,
or remediation and future compliance costs; financial loss; and other potentially significant harms. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our
contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Additionally, we cannot guarantee that any costs and liabilities incurred in relation to an attack or incident will be
covered by our existing insurance policies or that applicable insurance will be available to us in the future on economically reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, applicable privacy and data security obligations may require us to notify relevant stakeholders of a cyber-attack, security breach,
compromise, or other adverse impact to our and our third-party service provider&#8217;s information technology systems and sensitive data. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to
adverse consequences. In addition, cyber-attacks, security breaches, compromises, or other incidents may cause stakeholders (including investors and potential customers) to stop supporting our business, deter new customers from using our products,
and negatively impact our ability to grow and operate our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to experience a cyber-attack, security breach, compromise,
or other adverse impact to our and our third-party service provider&#8217;s information technology systems and sensitive data that causes interruptions in our operations, it could result in a material disruption of our product development programs,
business, financial condition, and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may use artificial intelligence in our business, and challenges with
properly managing its use, as well as uncertainty regarding the legal landscape surrounding the use of AI could result in reputational harm, competitive harm, legal liability, and adversely affect our results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use artificial intelligence, or AI, machine learning, and automated decision-making technologies, or, collectively, AI Technologies,
throughout our business, and are making investments in this area. We expect that increased investment will be required in the future to continuously improve our use of AI Technologies. As with many technological innovations, there are significant
risks involved in developing, maintaining and deploying these technologies, including that <FONT STYLE="white-space:nowrap">AI-generated</FONT> content, analyses, or recommendations we utilize could be deficient, that our competitors may more
quickly or effectively adopt AI capabilities, or that our use of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
AI or other emerging technologies increases regulatory, cybersecurity and other significant risks. There can be no assurance that the usage of, or our investments in such technologies will always
enhance our products or services or be beneficial to our business, including our efficiency or profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, if the
models underlying our AI Technologies are: incorrectly designed or implemented; trained or reliant on incomplete, inadequate, inaccurate, biased or otherwise poor quality data, or on data to which we do not have sufficient rights or in relation to
which we and/or the providers of such data have not implemented sufficient legal compliance measures; used without sufficient oversight and governance to ensure their responsible use; and/or adversely impacted by unforeseen defects, technical
challenges, cybersecurity threats or material performance issues, the performance of our products, services and business, as well as our reputation, could suffer or we could incur liability resulting from the violation of laws or contracts to which
we are a party or civil claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be successful in our development and maintenance of these technologies in the face of novel
and evolving technical, reputational and market factors. Our efforts to develop proprietary AI models in the future could increase our operating costs. Our future ability to develop proprietary AI models may be limited by our access to processing
infrastructure or training data, and we may be dependent on third party providers for such resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to keep pace with
rapidly evolving AI Technologies, especially in the medical device industry, our competitive position and business results may suffer. The introduction and use of AI Technologies, particularly generative AI, into new or existing offerings may result
in new or expanded risks and liabilities, including due to enhanced governmental or regulatory scrutiny, litigation, compliance issues, ethical concerns, confidentiality or security risks, as the well as other factors that could adversely affect our
reputation, as the well as our business, operating results, and financial condition. For example, AI Technologies can lead to unintended consequences, including generating content that appears correct but is factually inaccurate, misleading, or
otherwise flawed, which could negatively impact our customers, harm our reputation and business, and expose us to liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use AI
Technologies from third parties. If we are unable to obtain or maintain rights to use these AI Technologies on commercially reasonable terms, or if any such third-party AI tools become incompatible with our products, we may be forced to acquire or
develop alternate AI Technologies, which may limit or delay our ability to provide competitive offerings and may increase our costs. These AI Technologies also may incorporate data from third party sources, which may expose us to risks associated
with data rights and protection. The legal and regulatory landscape surrounding AI Technologies is rapidly evolving and uncertain, including with respect to intellectual property ownership and license rights, cybersecurity, and data protection laws,
among others, and has not yet been fully addressed by courts or regulators. The evolving legal, regulatory, and compliance framework for AI Technologies may also impact our ability to protect our own data and intellectual property against infringing
use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory framework for AI Technologies is rapidly evolving as many federal, state, and foreign government bodies and agencies
have introduced or are currently considering additional laws and regulations and we expect to see increasing government and supranational regulation related to AI use and ethics, which may also significantly increase the burden and cost of research,
development and compliance in this area. In the U.S., a number of states have proposed and passed laws regulating various uses of AI, and federal regulators have issued guidance affecting the use of AI in regulated sectors. The FDA, for example,
also issued guidance on the use of AI in medical devices, requiring detailed risk management and review processes to obtain approvals. If we develop or use AI systems governed by these laws or regulations, we will need to apply significant resources
to design, develop, test and maintain such systems in accordance with applicable laws and regulations, with the potential for significant enforcement or litigation in the event of any perceived <FONT STYLE="white-space:nowrap">non-compliance.</FONT>
It is possible that new laws and regulations will be adopted in the U.S. and in other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, or that existing laws and regulations, including competition and antitrust laws, may be interpreted
in ways that would limit our ability to use AI Technologies for our business, or require us to change the way we use AI Technologies in a manner that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negatively affects the performance of our products, services, and business and the way in which we use AI Technologies. We may need to expend resources to adjust our products or services in
certain jurisdictions if the laws, regulations, or decisions are not consistent across jurisdictions. Further, the cost to comply with such laws, regulations, or decisions and/or guidance interpreting existing laws, could be significant and would
increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in operating expenses, as well as any actual or perceived failure to comply with such laws and regulations,
could adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even in the absence of dedicated AI laws and
regulations, we may be subject to novel legal and business risks relating to our adoption of these new technologies. Vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or
rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft
and misuse of personal information, confidential information, and intellectual property. Our use of AI Technologies may also, in the future, result in cybersecurity incidents that implicate the personal information of customers or patients. Any such
cybersecurity incidents related to our use of AI applications could adversely affect our reputation and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities
and to limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of clinical trial and product
liability exposure related to the testing of our product candidates in clinical trials, and we will face an even greater risk if we commercially sell any products that we develop. While we currently have no products that have been approved for
commercial sale, the ongoing, planned, and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the
product, healthcare providers, pharmaceutical companies, or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities.
Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently hold clinical trial liability insurance, we will need to maintain such insurance coverage as we expand our clinical
trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to obtain and maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability
that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business
operations could be impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in litigation that could divert management&#8217;s attention
and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may be
subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal data, contractual relations with collaborators
and licensors, and intellectual property rights. In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, the
announcement of negative events, such as negative results from clinical trials, or periods of volatility in the market price of a company&#8217;s securities. These events may also result in or be concurrent with investigations by the SEC. We may be
exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our business and cash resources and
our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials,
results of preclinical studies, clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking
statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any
future results, performance, or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify
forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221;
&#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking
statements contained in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our current and future clinical trials, preclinical studies, and
research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of announcement of results from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully complete our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance other product candidates that we may identify and successfully complete any clinical
studies, including the manufacture of any such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to quickly leverage programs within our initial target indications and to progress additional
programs to further develop our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence of certain disorders we intend to treat and the size of the market opportunity for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of the number of patients with certain disorders we intend to treat and the number of patients that we
will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our investigational new drug applications, or INDs, submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, platform, and our programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to leverage the clinical, regulatory, and manufacturing advancements to accelerate our clinical
trials and approval of product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to meet future regulatory standards with respect to our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our existing license agreements and identify and enter into future license agreements and
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties for the manufacture of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our platform; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing, and manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS
Act or a smaller reporting company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated cash runway, use of proceeds from this offering, our financial performance, estimates of our
expenses, capital requirements, and needs for additional financing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements
largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these
forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in
&#8220;<I>Risk Factors</I>&#8221; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking
statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events, or otherwise. Our
forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments that we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not
be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the
registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of our common stock in this offering will be approximately
$&#8195;&#8195;&#8195;&#8195;million (or approximately $&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise their option to purchase additional shares of our common stock in full) based on an assumed initial public offering price of
$&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint
of the price range set forth on the cover of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by $&#8195;&#8195;&#8195;&#8195;million, assuming the number of shares offered by us, as set forth on
the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the
number of shares of common stock offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by $&#8195;&#8195;&#8195;&#8195;million, assuming the assumed
initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to create a public market for our common stock and thereby facilitate future access to the public
equity markets, increase our visibility in the marketplace, and obtain additional capital to support our operations. We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents, and investments, as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to advance development of GlyphAllo<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300)</FONT> through &#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to advance development of GlyphAgo<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-320)</FONT> through&#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to advance development of Glyph2BLSD<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP><FONT STYLE="white-space:nowrap">(SPT-348)</FONT> and other candidates, as well as fund research and development activities for additional
programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use a portion of the remaining net proceeds and our existing cash, cash equivalents, and investments to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products, or assets. However, we have no current commitments, agreements, understandings, or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe, based on our current operating plan, that the net proceeds from this offering, together with our existing cash, cash equivalents
and investments, will be sufficient to fund our operations through&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.
We do not have any committed external source of funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expected use of proceeds from this offering along with our existing cash, cash
equivalents, and investments described above represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to
be received upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. We expect that we will require additional funds in order to fully accomplish the specified uses of the proceeds of this offering.
The amounts and timing of our actual expenditures will depend on numerous factors, including progress of our research and development, the status of and results from preclinical studies and clinical trials that we are conducting or may conduct in
the future, and other factors described in the section titled &#8220;Risk Factors,&#8221; as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual expenditures may differ materially from the estimates
described above. Moreover, our estimates of the costs to fund our trials are based on the current designs of the trials. If we were to modify the design of any of these trials, for instance, to increase the number of patients in the trials, our
costs to fund the trials could increase. We may find it necessary or advisable to use the net proceeds for other purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have broad discretion over how to use the net proceeds to us from this offering and
investors will be relying on the judgment of our management regarding the application of the net proceeds. Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation instruments,
including short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We do not anticipate declaring or paying, in the foreseeable future, any
cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration and payment of dividends, if any,
will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects,
and other factors our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends. In addition, our ability to pay cash dividends on our capital stock in the future may be
limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our existing cash, cash equivalents, and investments and our capitalization as of December&nbsp;31, 2025: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis, giving effect to (i)&nbsp;the Preferred Stock Conversion and (ii)&nbsp;the filing and
effectiveness of our amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis, giving effect to (i)&nbsp;the pro forma adjustments set forth above and
(ii)&nbsp;the issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of common stock in this offering at the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price range set forth on the
cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be
adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. Cash, cash equivalents, and investments are not components of our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this information together with our consolidated financial statements and the related notes included elsewhere in this
prospectus, and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations<I>.</I>&#8221; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma<BR>As<BR>adjusted<SUP STYLE="font-size:75%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (Series A and B), $0.0001 par value; 113,921,040 shares authorized and
113,921,036 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; no shares authorized, issued, or outstanding, actual;
&#8195;&#8195;&#8195;shares authorized, and no shares issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 159,070,000 shares authorized and &#8195;&#8195;&#8195;shares
issued and outstanding, actual; &#8195;&#8195;&#8195;shares authorized, issued and outstanding, pro forma; &#8195;&#8195;&#8195;shares authorized, &#8195;&#8195;&#8195;shares &#8195;&#8195;&#8195;issued and outstanding, pro forma as
adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and investments, additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#8217; equity and total capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming that the number of shares of common stock offered by us, as set forth on the cover
page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares
of common stock offered by us would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#8217; equity and
total capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming no change in the assumed initial public offering price per share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock that will be outstanding after this offering on a pro forma and pro
forma as adjusted basis is based on &#8195;&#8195;&#8195;&#8195; shares of common stock (which includes &#8195;&#8195;&#8195;&#8195;shares of unvested restricted common stock) outstanding as of December&nbsp;31, 2025, after giving effect to the
Preferred Stock Conversion, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock issuable upon exercise of outstanding stock options as of
December&nbsp;31, 2025 under our 2024 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195; per share, and&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon exercise of outstanding stock options granted after
December&nbsp;31, 2025 pursuant to our 2024 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock reserved for future issuance as of December&nbsp;31, 2025
under the 2024 Plan, which will cease to be available for issuance at the time that our 2026 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock issuable upon the exercise or grant of the IPO Grants,
equal to approximately 12.5% of the number of shares of our common stock to be outstanding upon the closing of this offering calculated on a fully diluted basis (after giving effect to the number of shares of our common stock to be sold in this
offering, not including the exercise in full of the underwriters&#8217; option to purchase additional shares), to be granted to an executive officer and a director under the 2026 Plan; see the sections titled &#8220;Executive
Compensation&#8212;Narrative Disclosure to the 2025 Summary Compensation Table&#8212;Equity Incentive Compensation&#8221; and &#8220;Director Compensation&#8221; for more information on such grants, including a description of how the number of
shares issuable pursuant to such grants will be determined;&#8195;&#8195;&#8195;&#8195; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our
2026 Plan, including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the
number of shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock reserved for future issuance under the ESPP, which will become
effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of December&nbsp;31, 2025 was $&#8195;&#8195;&#8195;&#8195; million, or
$&#8195;&#8195;&#8195;&#8195; per share of our common stock. Our historical net tangible book value (deficit) represents the amount of our total tangible assets less our total liabilities and the carrying value of our convertible preferred stock,
which is not included within stockholders&#8217; deficit. Historical net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by&#8195;&#8195;&#8195;&#8195;shares of our common stock outstanding as
of December&nbsp;31, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value (deficit) as of December&nbsp;31, 2025 was
$&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195; per share. Pro forma net tangible book value (deficit) per share represents the amount of our total tangible assets less our total liabilities, divided by the number of shares of
our common stock outstanding as of December&nbsp;31, 2025, after giving effect to (i)&nbsp;the Preferred Stock Conversion and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, which will occur
immediately prior to the completion of this offering. Pro forma net tangible book value (deficit) per share represents pro forma net tangible book value (deficit) divided by the total number of shares outstanding as of December&nbsp;31, 2025, after
giving effect to the pro forma adjustments described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to the issuance and sale
of&#8195;&#8195;&#8195;&#8195;shares of common stock that we are offering at the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value (deficit) as of December&nbsp;31, 2025 would have been
$&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195;per share. This amount represents an immediate increase in pro forma net tangible book value (deficit) of $&#8195;&#8195;&#8195;&#8195; per share to our existing stockholders and
an immediate dilution in pro forma net tangible book value (deficit) of $&#8195;&#8195;&#8195;&#8195; per share to new investors purchasing shares of common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value (deficit) per share after this
offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share as of December&nbsp;31, 2025 attributable to the pro forma adjustment described
above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value (deficit) per share as of December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value (deficit) per share attributable to new
investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value (deficit) per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and may change based on the actual initial
public offering price and other terms of this offering. Each $1.00 increase or decrease, as applicable, in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price range set forth on the
cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;, and dilution per share to new investors purchasing common stock in this offering by
$&#8195;&#8195;&#8195;&#8195;, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. Similarly, each increase or decrease, as applicable, of 1.0&nbsp;million shares in the number of shares of common stock offered by us would increase or decrease, as applicable, our pro forma as adjusted net
tangible book value (deficit) per share after this offering by $&#8195;&#8195;&#8195;&#8195;per share, in each case, and increase or decrease, as applicable, the dilution to investors participating in this offering by
$&#8195;&#8195;&#8195;&#8195;per share, assuming no change in the assumed initial public offering price, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of our common stock in full, our pro forma as adjusted net tangible
book value (deficit) after the offering would be $&#8195;&#8195;&#8195;&#8195; per share, representing an immediate increase in pro forma as adjusted net tangible book value (deficit) of $&#8195;&#8195;&#8195;&#8195; per share to existing
stockholders and immediate dilution in pro forma as adjusted net tangible book value (deficit) dilution of $&#8195;&#8195;&#8195;&#8195; per share to new investors, in each case assuming an initial public offering price of
$&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes on the pro forma as adjusted basis described above, as of December&nbsp;31, 2025, the total number of
shares of common stock purchased from us on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, the total consideration paid or to be paid to us, and the average price per share paid by existing stockholders or to be paid by new investors
in this offering, based on the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. New investors purchasing shares of our common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#8217; option to purchase additional shares in this
offering. If the underwriters exercise their option to purchase additional shares of common stock from us in full, our existing stockholders would own &#8195;%, and new investors purchasing shares of our common stock in this offering would own
&#8195;%, of the total number of shares of our common stock outstanding immediately after the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of
shares of our common stock that will be outstanding after this offering is based on&#8195;&#8195;&#8195;&#8195;shares outstanding as of December&nbsp;31, 2025, after giving effect to the Preferred Stock Conversion, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock issuable upon exercise of outstanding stock options as of
December&nbsp;31, 2025 under our 2024 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share, and&#8195;&#8195;&#8195;&#8195;shares of common stock issuable upon exercise of outstanding stock options granted after
December&nbsp;31, 2025 pursuant to our 2024 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock reserved for future issuance as of December&nbsp;31, 2025
under the 2024 Plan, which will cease to be available for issuance at the time that our 2026 Plan, becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock issuable upon the exercise or grant of the IPO Grants,
equal to approximately 12.5% of the number of shares of our common stock to be outstanding upon the closing of this offering calculated on a fully diluted basis (after giving effect to the number of shares of our common stock to be sold in this
offering, not including the exercise in full of the underwriters&#8217; option to purchase additional shares), to be granted to an executive officer and a director under the 2026 Plan; see the sections titled &#8220;Executive
Compensation&#8212;Narrative Disclosure to the 2025 Summary Compensation Table&#8212;Equity Incentive Compensation&#8221; and &#8220;Director Compensation&#8221; for more information on such grants, including a description of how the number of
shares issuable pursuant to such grants will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock that will become available for future issuance under our
2026 Plan, including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the
number of shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock reserved for future issuance under our ESPP, which will become
effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any outstanding options are exercised, new options or other equity awards are issued under our equity
incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if
we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_10"></A>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations in conjunction with our audited consolidated financial statements and related notes and other financial information included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain
forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, strategies, objectives, expectations, intentions and beliefs. Financial results
through April&nbsp;8, 2024, which are included in the consolidated financial statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis and our full year
results for the year ended December&nbsp;31, 2024 are not necessarily indicative of results that may be expected in the future, nor are our other historical results necessarily indicative of the results that may be expected for any period in the
future. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this
prospectus. You should carefully read the &#8220;Risk Factors&#8221; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also
see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Unless otherwise indicated, all references in this section to &#8220;Seaport,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
&#8220;us,&#8221; or similar terms refer to Seaport Therapeutics, Inc. and its wholly owned subsidiaries, or either or all of them, before the Asset Transfer (as defined below) and after the Asset Transfer, as applicable and as the context may
require. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated
mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary Glyph platform to overcome those limitations and invent
innovative oral therapies. Our lead product candidate, GlyphAllo <FONT STYLE="white-space:nowrap">(SPT-300</FONT> or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically
validated in third-party trials as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. We have initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress
and anticipate topline data in &#8195;&#8195;&#8195;&#8195;&#8195;. Our second product candidate, GlyphAgo <FONT STYLE="white-space:nowrap">(SPT-320</FONT> or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically
validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder, or GAD, in Australia and MDD in Australia and the European Union, or EU. We have initiated a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 1 trial for the treatment of GAD and expect topline data in &#8195;&#8195;&#8195;&#8195;&#8195;. We are also advancing Glyph2BLSD <FONT STYLE="white-space:nowrap">(SPT-348</FONT> or
Glyph <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD),</FONT></FONT> a novel, Glyphed oral prodrug of the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> LSD analog <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> in preclinical studies for depressive disorders, including treatment-resistant depression, or TRD, post-traumatic stress disorder, or PTSD, and headache disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in April 2024 by PureTech LYT Inc., or PureTech LYT, as our sole stockholder, and upon formation we entered into an asset
transfer agreement, or the Asset Transfer Agreement, with PureTech LYT and PureTech Health LLC, or PureTech Health, pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of its
right, title and interest in, to, and under the assets related to its Glyph technology or products, or the Asset Transfer. See <FONT STYLE="white-space:nowrap">sub-section</FONT> titled &#8220;Asset Transfer Agreement and Financings&#8221; below.
Our historical consolidated financial statements up to April&nbsp;8, 2024, or the Asset Transfer Date, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis and are derived from the financial statements of
PureTech Health plc and its consolidated subsidiaries, or PureTech, to represent our financial position and performance as if we had existed on a standalone basis. Prior to the Asset Transfer, our combined financial statements included the assets,
liabilities, and expenses of PureTech that management determined were specifically identifiable to us and our related programs, as well as indirect costs that were not specifically identifiable to us or our related programs but were considered
necessary to operate as a standalone company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Management believes the assumptions underlying our <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements are reasonable. Nevertheless, the
<FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements may not include all of the actual expenses that would have been incurred, and may not reflect our results of operations, financial position, and cash flows, had we operated as a
standalone company for the period prior to the Asset Transfer. Effective April&nbsp;8, 2024, the Company&#8217;s financial statements are presented on a consolidated basis, as PureTech Health LLC and PureTech LYT completed the transfer of the Glyph
platform business, or the Seaport Business, on such date. The audited financial statements presented, including the historical results of the Company prior to April&nbsp;8, 2024, are referred to as the consolidated financial statements. Our
consolidated financial statements are presented in conformity with accounting principles generally accepted in the U.S., or GAAP. See Note 1&#8212;Nature of Business and Basis of Presentation, in the notes to the consolidated financial statements
appearing elsewhere in this prospectus for additional information on the preparation and basis of presentation of the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have devoted substantially all of our efforts to organizing and staffing our company, business planning, research and development
activities, building and strengthening our intellectual property portfolio, and providing general and administrative support for these operations. Subsequent to the Asset Transfer Date and to date, we have funded our operations with proceeds from
the issuance and sale of convertible preferred stock, including the $100.1&nbsp;million gross proceeds we received in April 2024 from our Series <FONT STYLE="white-space:nowrap">A-2</FONT> Financing (as defined below) and the $226.0&nbsp;million
gross proceeds we received in October 2024 from our Series B Financing (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses
since the inception of our business and expect to continue to generate operating losses for the foreseeable future. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual
commercialization of any product candidates we may develop. During the year ended December&nbsp;31, 2024, we had a net loss of $46.9&nbsp;million and as of December&nbsp;31, 2024 we had an accumulated deficit of $39.2&nbsp;million. We expect our
expenses and operating losses will increase substantially as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our product candidates through preclinical and clinical development, including advancing GlyphAllo<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>and GlyphAgo through later-stage clinical trials, and other candidates through discovery and clinical and preclinical stages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for our product candidates that successfully complete clinical trials from the U.S.
Food and Drug Administration, or the FDA, and/or other foreign comparable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, quality control, medical, scientific, and other technical personnel to support the
clinical development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our internal capabilities to support clinical-stage development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase our headcount as we expand our research and development organization, and
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> planning activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undertake any activities to establish sales, marketing, and distribution capabilities in preparation for
commercialization, as applicable, including hiring additional personnel to support such operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, acquire, and develop additional product candidates where we can leverage our Glyph platform,
including through business development efforts to invest in or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience heightened regulatory scrutiny; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments due under the Asset Transfer Agreement and/or the License Agreement
with Monash University, or the Monash License Agreement, and any future <FONT STYLE="white-space:nowrap">in-license</FONT> or collaboration agreements with third parties; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, and other expenses associated with operating as a public company.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our preclinical studies and planned clinical trials and our
expenditures on other research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate any revenue from product sales unless and until
we successfully complete development and obtain regulatory approval for one or more of our potential future product candidates, which may not be for at least the next several years, if ever. If we obtain regulatory approval for any of our existing
or future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from our existing or
future product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements. See the section titled
&#8220;Liquidity and Capital Resources.&#8221; However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our inability to raise capital or enter into such other arrangements
when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market potential future product
candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe, based on our current operating plan, that the net
proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through &#8195;&#8195;&#8195;&#8195;&#8195;. See sections titled &#8220;Use of
Proceeds,&#8221; &#8220;Liquidity and Capital Resources&#8221; and &#8220;Risk Factors&#8212;Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset Transfer Agreement and Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in April 2024 by PureTech LYT, as our sole stockholder, and upon formation issued 1,000 shares of our common stock to
PureTech LYT. In April 2024, we entered into an Asset Transfer Agreement, or the Asset Transfer Agreement, with PureTech Health and PureTech LYT pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and
deliver to us all of PureTech Health and PureTech LYT&#8217;s right, title, and interest in, to, and under the assets related to its Glyph technology or products, including the Monash License Agreement, subject to the terms set forth in the Asset
Transfer Agreement. In exchange, we issued 40,000,000 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 949,000 shares of our common stock to PureTech LYT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Transfer Agreement, we have agreed to make milestone payments of up to an aggregate of $10.0&nbsp;million for the
first product covered by assets transferred through the Asset Transfer Agreement, or the Seaport Glyph Product, and up to an aggregate of $5.0&nbsp;million for each subsequent Seaport Glyph Product that achieves certain developmental and commercial
milestones. In addition, we are obligated to pay low single digit tiered royalties on the annual net sales of each Seaport Glyph Product and a percentage of net income generated by the Company from third parties on any products licensed under
agreements which were transferred as part of the Asset Transfer Agreement. The royalty term will expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Seaport Glyph Product on
the later of the ten year anniversary of the first commercial sale of such Seaport Glyph Product in such country or the date on which the last valid claim of patent rights of such Seaport Glyph Product expires in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon entry into the Asset Transfer Agreement, we entered into a stock purchase agreement with PureTech LYT and other third-party
investors, pursuant to which we issued 26,342,102 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred stock, or the Series A Financing, of which 8,421,052 shares were issued and sold to PureTech LYT, at a
purchase price of $3.80 per share for gross aggregate proceeds of $100.1&nbsp;million. PureTech LYT remained a majority investor of Seaport, until the completion of our Series B convertible preferred stock financing, or the Series B Financing, in
October 2024, upon which we issued and sold an aggregate amount of 47,578,934 shares of its Series B convertible preferred stock, of which 3,031,578 shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
were issued to PureTech LYT, and an aggregate of 494,734 shares issued to certain of our management and Board of Directors, or the Board, at a purchase price of $4.75 per share, for gross
aggregate proceeds of $226.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Monash License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, PureTech Health exclusively assigned to us, and we assumed, all rights and obligations under a license agreement entered into in
August 2017 between PureTech Health and Monash University, or the Original License Agreement. In March 2025, we entered into the Monash License Agreement, which amended and restated the Original License Agreement. Pursuant to the Monash License
Agreement, Monash University has granted us (i)&nbsp;a worldwide, exclusive, sublicensable license under certain Monash University intellectual property rights, including patent rights related to the Glyph platform, or the Licensed Patents, <FONT
STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities, for the purpose of developing and commercializing products in all fields with one exception, (ii)&nbsp;a worldwide, <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under certain background technology and certain other intellectual property strictly to the extent necessary to exercise the license described in subclause (i)&nbsp;above, and
(iii)&nbsp;a first right and an exclusive option to obtain an exclusive license to any invention generated by Monash University outside of the Licensed Patents and pertaining to certain prodrug technology. Additionally, we and Monash University
agreed to collaborate in conducting research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, we have agreed to use
reasonable commercial endeavors to (i)&nbsp;develop at least one Licensed Product (as defined therein), (ii) seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or
Europe, promote and develop the sale of at least one Licensed Product in such territory. Monash University has agreed to provide reasonable technical assistance and advice based on Monash University&#8217;s
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the Monash License Agreement. We have granted Monash University a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, royalty-free license under
the Licensed Patents, related <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities solely for academic, teaching, and
<FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research uses, which includes the right to sublicense for <FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research to other academic institutions or <FONT
STYLE="white-space:nowrap">non-commercial</FONT> research entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional discussion around the obligations under the Monash
License Agreement, see the subsection titled &#8220;&#8212;Contractual Obligations and Commitments&#8221; and &#8220;Business&#8212;Agreements&#8212;Monash University Exclusive License Agreement&#8221; included elsewhere in this prospectus </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, our operations were managed as part of PureTech prior to the Asset Transfer Date. Accordingly, certain shared costs have been
allocated to us and reflected as expenses in our standalone consolidated financial statements, as described in greater detail in the notes to our consolidated financial statements appearing elsewhere in this prospectus. We considered the allocation
methodologies used to be a reasonable and appropriate reflection of the historical PureTech expenses attributable to us for purposes of our standalone consolidated financial statements. The expenses reflected in our consolidated financial statements
may not be indicative of expenses that will be incurred by us in the future. The following discussion summarizes the key factors we believe are necessary for an understanding of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not
recognized any revenue and do not expect to generate any revenue from the sale of products in the near term, if at all. If our development efforts for our current or potential future product candidates are successful and result in regulatory
approval or if we enter into additional license or collaboration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements with third parties, we may generate revenue in the future from product sales, payments from such license or collaboration agreements, or any combination thereof. However, there can be
no assurance as to when we will generate such revenue, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development, or R&amp;D, expenses consist primarily of costs incurred in connection with the discovery, <FONT
STYLE="white-space:nowrap">non-clinical</FONT> development, and clinical development of our lead product candidates and potential future product candidates. R&amp;D expenses include direct costs specifically attributable to our programs including
external fees to conduct certain clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research and development activities, preclinical and early discovery assets, such as costs paid to contract research and manufacturing organizations,
consulting fees, laboratory services and supplies, and costs incurred in connection with the Monash License Agreement, as well as indirect costs that are not directly attributable to a specific program such as personnel related expenses, including
stock-based compensation, facility expenses, depreciation, and information technology costs. Prior to the Asset Transfer Date, R&amp;D expenses also included allocated indirect R&amp;D costs from PureTech, including personnel related expenses,
stock-based compensation, facility expenses, depreciation, and information technology costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as
incurred. We recognize direct development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors or our estimate of the level of service that has been performed at each reporting
date. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the inherently unpredictable nature of preclinical and clinical development, we do not allocate all of our internal
research and development expenses on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis as these expenses primarily relate to personnel and other overhead costs that are deployed across
multiple programs under development. Our research and development expenses also include external costs, which we do track on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis following the
program&#8217;s nomination as a product candidate. We began tracking such external costs upon the nomination for GlyphAllo in 2020, GlyphAgo at the end of our fiscal year ended December&nbsp;31, 2023 and Glyph2BLSD at the end of our fiscal year
ended December&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We expect that our research and
development expenses will continue to increase for the foreseeable future as we advance our current and any future product candidates into and through clinical development and as we continue to develop additional product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of salaries and personnel-related costs, including stock-based compensation expense, for our
personnel in executive, business development, legal, finance and accounting, human resources and other administrative functions, consulting fees, facility costs not otherwise included in R&amp;D expenses, fees paid for accounting and tax services,
insurance expenses, legal costs consisting of general corporate legal fees and patent legal fees, and allocated expenses from PureTech prior to our formation in April 2024. Allocated PureTech expenses included employee-related costs, including
salaries, bonuses, benefits, and stock-based compensation expenses for PureTech personnel and our personnel in executive, finance, accounting, human resources, and other administrative functions. Allocated expenses from PureTech also included
corporate overhead expenses and shared costs, such as general management and executive oversight, facilities, compliance, human resources, legal, including intellectual property costs, finance, risk management, and information technology all of
which supported the operations of PureTech as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future as we
increase our headcount to support the expansion of our business, particularly in support of development of product candidates and our continued research and clinical development activities. We will also incur significant costs associated with being
a public company, including increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs, as well as expenses related to services associated with maintaining compliance with the requirements of the Nasdaq
Stock Market, the Securities and Exchange Commission, and investor relations costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the completion of this offering, we continued
to grant additional equity awards to certain individuals to maintain in total an aggregate of 12.5% ownership on a fully diluted basis as specified by underlying agreements. Upon the completion of the offering, we will
issue&#8195;&#8195;&#8195;&#8195;&#8195; equity awards to certain individuals to maintain an aggregate of 12.5% ownership and we will recognize total stock-based compensation expense of $&#8195;&#8195;&#8195;&#8195;&#8195; over the remaining vesting
period. In addition, certain individuals have accelerated vesting associated with the successful completion of an IPO which will result in &#8195;&#8195;&#8195;&#8195;&#8195;equity awards vesting and recognition of stock-based compensation expense
of &#8195;&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Provision for Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provision for income taxes consists of United States federal and state income taxes in jurisdictions in which we conduct business. The
provision for income taxes is based on our taxable income. Our loss before income taxes is adjusted for permanent and temporary tax differences, primarily related to capitalized research and development expenses, resulting in taxable income or loss.
We recorded a full valuation allowance of our deferred tax asset position as of December&nbsp;31, 2024 as we believe it was more likely than not that we would not be able to utilize our deferred tax assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the years
ended December&nbsp;31, 2024 and 2025 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (including stock-based compensation of $0.7&nbsp;million)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative (including stock-based compensation of $15.2&nbsp;million)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;&#8199;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Direct costs:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAllo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAgo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and early discovery assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Indirect costs:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation (excluding stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8201;&#8199;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8199;&#8199;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the year ended December&nbsp;31, 2024 were $25.1&nbsp;million and were
primarily attributable to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$7.4&nbsp;million in direct costs associated with our lead program GlyphAllo, which includes clinical
manufacturing, preclinical studies and start up activities related to our <FONT STYLE="white-space:nowrap">BUOY-1</FONT> (Phase 2b) trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$5.2&nbsp;million in direct costs associated with GlyphAgo, which includes manufacturing and preclinical studies
as we prepare to enter the clinic in 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$5.9&nbsp;million in direct costs associated with preclinical and other early discovery assets, including
Glyph2BLSD; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$5.0&nbsp;million in employee compensation, consisting of payroll, bonus, and benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.7&nbsp;million of stock-based compensation of which $0.6&nbsp;million related to the 2024 Plan and
$0.1&nbsp;million allocated from the PureTech stock-based compensation plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.9&nbsp;million in other research and development expenses included allocated facility, depreciation,
information technology, and other costs. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation (excluding stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, depreciation, IT, and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8201;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8201;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses for the year ended December&nbsp;31, 2024 were $27.3&nbsp;million and were
primarily attributable to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15.2&nbsp;million of stock-based compensation expense of which $14.0&nbsp;million related to the 2024 Plan and
$1.2&nbsp;million allocated from the PureTech stock-based compensation plan. Accelerated vesting associated with the close of the Series B Financing accounted for $9.6&nbsp;million; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$5.5&nbsp;million in employee compensation expenses consisting of payroll, bonus, and benefits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$5.2&nbsp;million in professional fees primarily related to legal fees for general corporate and intellectual
property matters and building our administrative infrastructure; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.5&nbsp;million in facilities, depreciation, information technology, and other costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income, Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net,
consists primarily of interest and investment income on our cash and cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary
source of liquidity for our business prior to our formation was funding by PureTech of the expenses allocated to the Seaport business. Prior to the Asset Transfer Date, transfers of cash to and from PureTech have been reflected in Net transfers from
PureTech in the statement of cash flows and net parent investment in the statement of convertible preferred stock and stockholders&#8217; deficit. Since the Asset Transfer Date, we have funded our operations with the aggregate gross proceeds of
$326.1&nbsp;million from the Series A and Series B Financings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding our cash flows for the period presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8201;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2024, net cash used in operating activities was $29.6&nbsp;million, primarily consisting of our net
loss of $46.9&nbsp;million, offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $14.5&nbsp;million in stock-based compensation expense, and $0.2&nbsp;million of depreciation expense and $2.5&nbsp;million resulting from changes in
operating assets and liabilities which was generally due to the growth in our business, the advancement of our clinical programs, and the timing of vendor invoicing and payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2024, our investing activities primarily consisted of leasehold improvements in our corporate
headquarters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&nbsp;31, 2024 included $100.1&nbsp;million of gross proceeds received in
April 2024 from our Series A Financing and $226.0&nbsp;million of gross proceeds received in October 2024 from our Series B Financing, which were partially offset by payments of issuance costs of $0.8&nbsp;million. In addition, as PureTech managed
our cash and financing arrangements through April&nbsp;8, 2024, our financing activities include $14.0&nbsp;million of net transfers from PureTech. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, we had cash and cash equivalents of $309.1&nbsp;million. We expect that our cash and cash equivalents as of
December&nbsp;31, 2024, will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the date our consolidated financial statements were available to be issued. We believe that the net
proceeds from this offering, together with our existing cash, cash equivalents, and investments will enable us to fund our operations and capital expenditure requirements through&#8195;&#8195;&#8195;&#8195;&#8195;. We have based this estimate on
assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the inherently
unpredictable nature of preclinical and clinical development and given the early stage of our programs and product candidates, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development,
obtain any marketing approval, and commercialize our products, if and when approved. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve
profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which products, if approved, may be subject to future
collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We will need to raise substantial additional capital in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of capital are to fund research and development activities, compensation and related expenses, and general overhead costs. We
expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our current and future product candidates through discovery, preclinical studies, and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, costs, and results of discovery, preclinical development and clinical trials for our
current or future product candidates and effectiveness of our Glyph platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including
the timing and amount of any milestones, royalties, or other payments due in connection with our acquisitions and licenses, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and
distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses to attract, hire, and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of macroeconomic trends including inflation, tariffs, and fluctuating interest rates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any potential supply chain interruptions or delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, that we can generate substantial product revenue, we expect to finance our operations through a combination of
public and private equity offerings, debt and royalty financings, or other sources of capital, which may include additional collaborations with other companies, or licensing arrangements with third parties, or other similar arrangements. However, we
may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest
of our stockholders will or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt or royalty financing and preferred equity financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures, or declaring dividends. If we raise additional
funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, product candidates, or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional capital or obtain adequate funding when needed or on acceptable terms, we may be required to delay, scale back, or discontinue our research, product development,
or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations and Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Asset
Transfer Agreement and Transition Services Agreement with PureTech </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Asset Transfer Agreement, we have agreed to
contingent payments to PureTech Health upon successful development and commercialization of products developed using the Glyph platform. For more information, refer to the subsection titled &#8220;Asset Transfer Agreement and Financings&#8221;
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Transfer Agreement, we entered into a transition services agreement, or the TSA, with PureTech Health
and PureTech LYT, or the PureTech TSA Parties, pursuant to which the PureTech TSA Parties agreed to provide us with certain services and resources related to corporate functions for an initial 12 month period following the Asset Transfer Date,
subject to extension. Under the TSA, we were obligated to pay to the PureTech TSA Parties $0.5&nbsp;million upon closing of the Asset Transfer. We further agreed to pay the PureTech TSA Parties monthly fees for services that were mutually agreed
upon by us and the PureTech TSA Parties as provided under the TSA, which were based on the PureTech TSA Parties&#8217; cost of providing the services, throughout the term of the TSA. In 2025, the TSA was amended to extend through July 2026 to
provide <FONT STYLE="white-space:nowrap">ad-hoc</FONT> support as needed; however, the services to be provided under the amended TSA are expected to be de minimis. For more information, refer to the subsection titled <I>&#8220;</I><I>Transition From
PureTech and Costs to Operate as an Independent Company.</I><I>&#8221;</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Monash License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, we have agreed to use reasonable commercial endeavors to (i)&nbsp;develop at least one Licensed Product,
(ii)&nbsp;seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or Europe, promote and develop the sale of at least one Licensed Product in such territory. Monash
University agrees to provide reasonable technical assistance and advice based on Monash University&#8217;s <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the Monash License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licenses granted by Monash University, we are required to pay
Monash University: <FONT STYLE="white-space:nowrap">(i)&nbsp;low-single</FONT> digit royalties with a rate based on net sales per calendar year (subject to certain reductions); (ii) a <FONT STYLE="white-space:nowrap">low-double</FONT> digit
percentage of any net income received under a sublicense (subject to a license payment stacking reduction) with the percentage varying based on the development stage of the licensed products at the time the sublicense is granted during the term of
the Monash License Agreement; (iii)&nbsp;an agreed to research funding amount to progress mutually agreed research and development or commercialization activities; (iv)&nbsp;a <FONT STYLE="white-space:nowrap">mid-five-figure</FONT> annual
maintenance fee during the term of the agreement commencing on the third anniversary of the execution date of the Original License Agreement until the first commercial sale of a Licensed Product creditable against net income sharing, royalties, and
milestone payments; (v)&nbsp;milestone payments in the event of successful development milestones of up to $1.075&nbsp;million per Licensed Product for the first three Licensed Products; and (vi)&nbsp;milestone payments in the event of successful
commercial milestones of up to $7.25&nbsp;million per Licensed Product for the first three Licensed Products. We are also obligated to (a)&nbsp;pay all costs incurred for the prosecution and maintenance of the Licensed Patents and patent filings
stemming from collaboration activities and (b)&nbsp;reimburse Monash University for all patent prosecution costs of the Licensed Patents prior to the execution date of the Original License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monash License Agreement commenced on the execution date of the Original License Agreement and will expire seven years after the last of
the Licensed Patents expires, unless terminated earlier. Either party may terminate for due cause, including for material breach and bankruptcy. Monash University may terminate if we fail to meet our diligence requirements. Either party may
terminate the Monash License Agreement if we determine that the activities are no longer commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31,
2025, three development milestones have been paid and expensed under the Monash License Agreement totaling $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
additional information see the section titled &#8220;Business&#8212;Agreements&#8212;Monash License Agreement&#8221;, included elsewhere in this prospectus.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase and Other Obligations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter
into contracts in the normal course of business with contract research organizations, or CROs, and other third-party vendors for preclinical and commercial supply manufacturing, support for <FONT STYLE="white-space:nowrap">pre-commercial</FONT>
activities, research, and development activities, and other services and products for our operations. These contracts are generally cancelable upon written notice. Payments due upon cancellation consist generally of payments for services provided
and expenses incurred up to the date of cancellation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lease Obligations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, we entered into a lease agreement with a third party for our corporate office space located in Boston, Massachusetts. The
lease commenced in December 2024 and has an initial term of approximately six years, expiring in October 2030. The aggregate payments under the lease total approximately $6.1&nbsp;million, which will be recognized over the term of the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, we entered into a laboratory license with a third party for lab space located in Boston, Massachusetts. The license
commenced in January 2025 and is for an initial term of 24 months from the commencement date. The aggregate payments under the license total approximately $1.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information on our contractual obligation and commitments please see Note 7&#8212;Monash License Agreement, Note
13&#8212;Commitments and Contingencies and Note 17&#8212;Subsequent Events, to our consolidated financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates and Significant Judgments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the related disclosure
of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and judgments on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in Note 2 to our
consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses as of each balance sheet date. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase
orders, communicating with internal personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise
notified of the actual cost. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. The majority of our service providers invoice us monthly in arrears for services performed or when
contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">contract-to-contract</FONT></FONT> and may result
in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, we record a prepaid expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although
we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting
amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized that are expected to vest over
the requisite service period of the awards, which is usually the vesting period of the respective award. For stock-based awards with service-based vesting conditions, we recognize compensation expense on a straight-line basis. For stock-based awards
with performance-based vesting conditions, we recognize compensation expense over the requisite service period using the accelerated attribution method, commencing when achievement of the performance condition becomes probable. Subsequent to our
formation and the Asset Transfer, we estimated the fair value of stock option awards using the Black-Scholes option pricing model. Estimating the fair value of equity awards as of the grant date using valuation models, such as the Black-Scholes
option pricing model, is affected by assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the
underlying common stock on the date of grant. These inputs are subjective and generally require significant analysis and judgment to develop. Forfeitures are accounted for as they occur. Changes in the assumptions can materially affect the fair
value and ultimately how much stock-based compensation expense is recognized. The fair value of time-vesting restricted stock unit awards is equal to the common stock price on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock-based compensation expense we recognized in our financial statements prior to our
formation and the Asset Transfer Date, and separate from our 2024 Plan, has been determined based on the fair value of the underlying award as determined by PureTech, the total expense calculated for the period under GAAP, and the relative amount
allocated to Seaport associated with each employee. The assumptions used in the Black-Scholes option pricing model for these awards were those of PureTech, including the fair value of PureTech&#8217;s common stock, expected volatility, expected
term, expected dividend yield, and risk-free interest rates as of the grant date. Seaport employees continued to vest in their PureTech equity awards up until the completion of our Series B Financing in October 2024 at which time PureTech no longer
maintained a controlling interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Determination of the Fair Value of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our common stock subsequent to the Asset Transfer and to date, the estimated fair value of our common
stock has been determined by our Board , as of the date of each option grant with input from management, considering our most recently available third-party valuations of common stock, and our Boards&#8217; assessment of additional objective and
subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the
American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,<I> Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common stock valuation was prepared using a market approach to
estimate our enterprise value and either an option pricing method, OPM, or a hybrid method to allocate value to the common stock. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company,
with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders
exceeded the value of the convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighed expected return method, or PWERM, where the equity
value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of the future value of our common stock, assuming various outcomes. The
value of a share of common stock is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the
common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. In each case, a discount for lack of
marketability of the common stock is then applied to arrive at an indication of value for the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These third-party valuations
were performed at various dates, which resulted in valuations of our common stock of $2.35 per share as of October&nbsp;18, 2024 and $2.53 per share as of July&nbsp;16, 2025. Given the absence of a public trading market, our Board, with input from
management, considered the results of these third-party valuations in addition to numerous objective and subjective factors to determine the fair value of common stock. The factors included, but were not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold convertible preferred stock to new and existing investors and the rights and
preferences of the convertible preferred stock relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise future financings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development efforts, including the status of clinical development for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our equity as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of enterprise milestones, including entering into license agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently
completed mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any external market conditions affecting the biotechnology industry and trends within the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our convertible preferred stock and holders of
our common stock, such as an initial public offering, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical
industry. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations were highly complex and subjective and represented
management&#8217;s best estimates, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our
stock-based compensation expense could have been materially different. Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our Board to
estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted market price of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes by grant date the number of shares subject to awards granted under our equity incentive plan
through the date of this prospectus, the per share exercise price of the awards or purchase price of the common stock awards and weighted average grant date fair value on each grant date: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Type of Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;Subject<BR>to Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Exercise&nbsp;or<BR>Purchase&nbsp;Price<BR>of Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;26, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock&nbsp;Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;25, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;3, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;25, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;15, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;11, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;7, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition From PureTech and Costs to Operate as an Independent Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our formation and the Asset Transfer, the financial statements reflect our operating results and financial position as our business
was operated by PureTech, rather than as an independent company. We may incur additional ongoing operating expenses to operate as an independent company. These costs will include the cost of various corporate functions, incremental information
technology-related costs and incremental costs to operate standalone accounting, legal and other administrative functions. We may also incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> expenses and
<FONT STYLE="white-space:nowrap">non-recurring</FONT> capital expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of building our administrative infrastructure, we
entered into the TSA in connection with the Asset Transfer with PureTech that provided us with certain services and resources related to corporate functions for an initial 12 month period following the Transfer Date as amended. We pay PureTech fees
for the services as mutually agreed upon by us and PureTech as provided under the Transition Services Agreement, which fees are based on PureTech&#8217;s cost of providing the services. This Transition Services Agreement allowed us to operate our
business independently prior to completing the establishment of a standalone infrastructure. Actual costs that would have been incurred if we operated as a standalone company during these periods would have depended on various factors, including
organizational design, outsourcing, and other strategic decisions related to corporate functions, information technology and back-office infrastructure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions with Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Asset Transfer Date, we began incurring additional operating expenses necessary to operate as an independent company, including
various corporate functions and incremental costs to operate standalone accounting, legal, and other administrative functions. These functions were provided to us from PureTech prior to the Asset Transfer Date and continued under the TSA discussed
above. Substantially all of these activities will be performed using our own resources at this time. The terms of the TSA are discussed in the section captioned &#8220;Certain Relationships and Related Person Transactions.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, or the Securities
Act, as modified by the Jumpstart Our Business Startups Act, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements in addition to any required unaudited
interim financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration
statement declared effective or do not have a class of securities registered under the Exchange Act of 1934, as amended, or the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that
an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable.
We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, will adopt the new or
revised standard whenever such early adoption is permitted for private companies. This may make comparison of our financial statements with another public company, which is neither an emerging growth company nor an emerging growth company that has
opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of
the completion of this initial public offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.235&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a
&#8220;large accelerated filer&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of the common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities
during the prior three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may
continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled
disclosures for so long as (i)&nbsp;the market value of our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the
last business day of our second fiscal quarter, or (ii)(a) our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year, and (b)&nbsp;the market value of our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with
established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary Glyph<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> platform to
overcome those limitations and invent innovative oral therapies. Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby enhance a drug&#8217;s oral bioavailability and reduce side effects.
This process, which we call &#8220;Glyphing,&#8221; also creates new composition of matter intellectual property. Our experienced team of industry leaders has a proven track record in neuropsychiatry drug discovery and development and delivering
successful business outcomes. We aim to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
treatment options that will make a significant impact for patients and their families. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging our proprietary Glyph platform
to advance a pipeline of novel therapies to address the significant unmet needs in depression and anxiety. Our lead product candidate, GlyphAllo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300</FONT>
or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects.
GlyphAllo is designed to overcome bioavailability limitations of allopregnanolone and deliver rapid and durable efficacy in major depressive disorder, or MDD. We have demonstrated in a Phase 1 clinical trial that GlyphAllo reaches therapeutically
relevant exposures with oral dosing, and in a Phase 2a clinical trial, GlyphAllo demonstrated initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> with an objective biomarker of stress in healthy
volunteers and a favorable tolerability profile. We have initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress and anticipate topline data in &#8195;&#8195;&#8195;&#8195; .
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>
<FONT STYLE="white-space:nowrap">(SPT-320</FONT> or Glyph Agomelatine), is a novel, Glyphed, oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder, or GAD
in Australia and MDD in Australia and the European Union, or the EU. Due to extensive liver first-pass metabolism, agomelatine can cause dose-dependent liver enzyme elevations, and its use has been limited by the need for frequent liver function
testing. GlyphAgo is designed to overcome this limitation by avoiding first-pass metabolism and achieving therapeutic exposures of agomelatine while reducing or eliminating the need for liver monitoring. We have initiated a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 1 trial for the treatment of GAD and expect topline data in &#8195;&#8195;&#8195;&#8195; . We are also advancing Glyph2BLSD<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-348</FONT> or Glyph <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD),</FONT></FONT> a novel, Glyphed oral prodrug of the <FONT
STYLE="white-space:nowrap">non-hallucinogenic</FONT> LSD analog <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> in preclinical studies for depressive disorders, including treatment-resistant depression,
or TRD, post-traumatic stress disorder, or PTSD, and headache disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Globally, over one billion people are living with mental illness
as of 2021, comparable in prevalence to obesity or hypertension. According to the World Health Organization, as of 2021, depression affects approximately 332&nbsp;million people worldwide and anxiety affects approximately 359 million people
worldwide, and there is a significant need for novel treatment options. Currently approved drugs for MDD and GAD have significant limitations, including modest efficacy, slow onset of action, and unfavorable side effects. Advancement of novel
therapies has been limited by a lack of understanding of disease pathophysiology, poor drug-like properties, and challenges in clinical trial design and execution leading to high clinical development failure rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our differentiated approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
uniquely positioned to overcome the challenges of developing medicines for depression, anxiety, and other neuropsychiatric disorders by leveraging our differentiated, three-pillar approach: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Identify clinically validated mechanisms held back by issues that can be addressed by our proprietary </I></B><B><I>Glyph</I></B><B><I>
platform. </I></B>We select our product candidates based on well-established clinical data, defined as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demonstrated meaningful benefits compared to placebo in multiple randomized, placebo-controlled clinical trials in a large number of patients. We identify drugs matching this profile where
clinical and commercial potential have been limited by high first-pass metabolism, low bioavailability, and/or side effects. We advance candidates that have the potential to be
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> new medicines and to impact<I> </I>a large number of
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Create novel medicines with strong intellectual property using </I></B><B><I>Glyph</I></B><B>.</B> Glyph is our
proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. Typically, <FONT STYLE="white-space:nowrap">non-Glyphed</FONT> oral small molecules undergo first-pass metabolism, where the
concentration of drug is significantly reduced by metabolic enzymes in the liver prior to systemic circulation. First-pass metabolism can lead to low bioavailability (i.e., reduced concentration of active drug available to target organs) and/or side
effects, including liver enzyme elevations or hepatotoxicity. Glyph leverages a separate absorption path taken by dietary fats. A Glyphed molecule uses this alternative route via the intestinal lymphatic system to bypass first-pass metabolism and
transit directly into systemic circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism. For each program, we use Glyph to create unique sets of prodrugs with
differentiated profiles, and evaluate these prodrugs as potential candidates to advance into preclinical and clinical studies. Glyph has been applied to create novel product candidates for our pipeline resulting in new intellectual property,
including composition of matter patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Benefits of Our Proprietary Glyph Platform </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00n11.jpg" ALT="LOGO" STYLE="width:6.33333in;height:3.21778in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Apply our team</I></B><B><I>&#8217;</I></B><B><I>s expertise to optimize the design and execution of
clinical trials and drive successful business outcomes</I></B><B>.</B> Our team is comprised of industry leaders with a proven track record of building successful companies that have developed and commercialized innovative neuropsychiatric
medicines. This includes Zyprexa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Cymbalta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Latuda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Zurzuvae<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, and Cobenfy<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (xanomeline-trospium or KarXT), which was approved by the FDA in September 2024 and is the first new class of medicines in over 30
years for patients living with schizophrenia. Leveraging our team&#8217;s track record of success in neuropsychiatry discovery and clinical development is important as we select new product candidates and as we implement key design elements in our
clinical trials to<B><I> </I></B>optimize treatment effect and duration and reduce placebo response. In parallel, we apply our deep experience in building successful companies to establish clear goals, drive strategic decision-making, and maintain
financial discipline. Drawing on our track record of success in neuropsychiatry, we aim to drive successful outcomes for patients and shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicines to treat neuropsychiatric disorders with significant unmet need. We retain exclusive, worldwide development and commercialization rights to all of our
product candidates and discovery programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00n12.jpg" ALT="LOGO" STYLE="width:6.33333in;height:2.88in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also leveraging the power of the Glyph platform to advance programs that address significant unmet
needs in other central nervous system, or CNS, and <FONT STYLE="white-space:nowrap">non-CNS</FONT> diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAllo: Potential First- and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-Class</FONT></FONT> Therapy for MDD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo is a novel,
Glyphed oral prodrug of allopregnanolone, an endogenous neurosteroid and gamma-aminobutyric acid A, or GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB>, positive allosteric modulator, or PAM. Allopregnanolone is a naturally occurring
molecule that reduces stress, with levels that peak during the third trimester of pregnancy. An intravenous infusion formulation of allopregnanolone was approved for the treatment of postpartum depression, or PPD, a form of MDD. Allopregnanolone has
been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects, but its scope of clinical use has been constrained by oral bioavailability limitations that the Glyph platform is
uniquely designed to solve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 1 clinical trial, GlyphAllo demonstrated a greater than nine-fold increase in bioavailability
compared to the previously reported bioavailability of oral allopregnanolone, enabling therapeutically relevant exposures with a favorable tolerability profile that supports chronic dosing. GlyphAllo has also demonstrated initial <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in a Phase 2a randomized, placebo-controlled trial using the Trier Social Stress Test, or TSST, a validated clinical model of anxiety in healthy volunteers.
Based on these Phase 1 and Phase 2a data, we believe GlyphAllo has the potential to become a first- and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for MDD. We advanced GlyphAllo into the
potentially registration-enabling Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in July 2025. <FONT STYLE="white-space:nowrap">BUOY-1</FONT> is a global, randomized, double-blind, placebo-controlled trial evaluating the efficacy,
safety, and tolerability of GlyphAllo in adults with MDD, with or without anxious distress. MDD with anxious distress is a form of MDD characterized by significant anxiety. Approximately 60% of patients with MDD meet the criteria for anxious
distress. This trial is expected to enroll up to approximately 360 patients, randomized 1:1 to receive either GlyphAllo or placebo once-daily over a <FONT STYLE="white-space:nowrap">six-week</FONT> treatment period. The primary endpoint of the trial
is the change from baseline at six weeks in the Hamilton Depression Rating Scale-17, or <FONT STYLE="white-space:nowrap">HAMD-17,</FONT> a regulatory-standard depression severity rating scale. Following the initial treatment period, eligible
patients may enter an open-label extension trial, in which all participants will receive GlyphAllo for up to six additional weeks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previous clinical development of allopregnanolone and its synthetic analogs in indications
beyond PPD has been hindered by poor oral bioavailability, safety concerns, and clinical trial design limitations. GlyphAllo is designed to enhance the oral bioavailability of allopregnanolone and achieve systemic exposures comparable to an
intravenous infusion of allopregnanolone, with once-daily oral dosing. We believe our ongoing Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial improves upon the design of previous third-party clinical trials that evaluated a synthetic
analog of allopregnanolone in several important ways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are improving durable efficacy by treating patients for the full <FONT
STYLE="white-space:nowrap">six-week</FONT> duration of the primary endpoint time frame, as opposed to previous trials that treated patients for only the first two weeks. As allopregnanolone also has an anxiolytic effect, we are also enrolling
patients that have MDD with or without anxious distress. To reduce placebo response, we are optimizing the frequency of clinician-administered assessments, as our comprehensive meta-analysis of recent antidepressant trials demonstrated that the
frequency of these assessments is positively correlated with the magnitude of the placebo response in MDD trials. We are also including a single treatment arm and will flex dose to a target dose, similar to the strategy implemented at Karuna
Therapeutics, since the number of active arms is positively associated with increased placebo response. Additionally, we are scrutinizing site selection and patient enrollment to ensure appropriate diagnosis and exclude inappropriate patients,
including those with inflated baseline ratings and those who are concurrently participating in other studies. We expect topline data from the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAgo: Potential First- and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-class</FONT></FONT> Therapy for GAD
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAgo is a novel, Glyphed oral prodrug of agomelatine that we are advancing in a key Phase 1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial for the treatment of GAD. Agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C <FONT STYLE="white-space:nowrap">(5-HT2C)</FONT> receptor antagonist,
is an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and MDD in Australia and the European Union, or EU. In GAD, agomelatine has demonstrated statistically significant separation from placebo in all four
third-party placebo-controlled studies and has better efficacy and tolerability&#8212;including reduced risk of abuse potential, sexual dysfunction, and weight gain&#8212;than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs, like selective serotonin-reuptake inhibitors, or SSRIs, or benzodiazepines. However, over 90% of unmodified agomelatine is lost to first-pass
liver metabolism and its use has been limited by dose-dependent liver enzyme elevations. Its label in both Australia and the EU requires liver function testing before initiating treatment, during treatment, and upon increasing the dose. Agomelatine
is not approved in the United States. Using our proprietary Glyph platform, GlyphAgo is designed to avoid first-pass liver metabolism and increase systemic exposure of agomelatine, enabling exposure levels of agomelatine that are effective in GAD
but at a lower dose that reduces liver exposure and reduces or eliminates the need for liver function testing. Based on internal analyses, we believe a <FONT STYLE="white-space:nowrap">two-fold</FONT> increase in the bioavailability of agomelatine
with GlyphAgo dosing will reduce or eliminate liver enzyme elevations. In a series of preclinical studies in <FONT STYLE="white-space:nowrap">non-human</FONT> primates, or NHPs, we showed that oral dosing of GlyphAgo increased plasma exposure of
agomelatine versus agomelatine alone above this <FONT STYLE="white-space:nowrap">two-fold</FONT> target. Therefore, based on the data we have generated to date, we believe GlyphAgo has the potential to become a first- and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for GAD. The ongoing Phase 1 trial will be conducted in multiple parts to evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo and
compare the pharmacokinetics of GlyphAgo to agomelatine alone. It will include single- and multiple-ascending dose cohorts, as well as a food-effect crossover portion, using both open-label and placebo-controlled designs. We expect topline data from
our Phase 1 trial of GlyphAgo in&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Glyph2BLSD and Additional Applications of the Glyph Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph2BLSD is our novel Glyphed oral prodrug of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> a
differentiated <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen. Glyph2BLSD is designed to harness the differentiated and <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> which has rapidly acting clinical activity and has not exhibited the fibrosis, cardiovascular effects, or hallucinations characteristic of some other
neuroplastogens. Glyph2BLSD is designed to improve the pharmacokinetic and tolerability profile of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> while maintaining therapeutic exposure levels.
Glyph2BLSD&#8217;s <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile unlocks the potential to enable convenient outpatient and repeat dosing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to improve efficacy. We are advancing Glyph2BLSD through preclinical studies and are developing Glyph2BLSD for the treatment of depressive disorders, including TRD, PTSD, and headache disorders
with significant unmet need. We are also leveraging the power of the Glyph platform to explore additional applications in CNS and <FONT STYLE="white-space:nowrap">non-CNS</FONT> diseases and advance programs that address significant unmet needs in
these areas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport was founded by pioneers in the neuropsychiatry field and is led by a team of seasoned industry veterans with a shared mission to
transform the treatment of neuropsychiatric disorders and improve patients&#8217; lives. We have assembled an experienced group of individuals with a proven track record of building successful companies that have developed and commercialized
innovative neuropsychiatric medicines. Members of our leadership team have collaborated successfully over several decades on the discovery, development, and commercialization of neuropsychiatric medicines including Cobenfy, Latuda, Zyprexa,
Cymbalta, and Zurzuvae. Our <FONT STYLE="white-space:nowrap">co-founders,</FONT> Daphne Zohar, and Dr.&nbsp;Steven Paul, were central to the success of Karuna Therapeutics, which invented and advanced the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicine Cobenfy, and was acquired by Bristol Myers Squibb in March 2024 for $14&nbsp;billion. Cobenfy was approved by the FDA in September 2024 and is the first drug to provide a new mechanism
of action for schizophrenia in over 30 years. Cobenfy is estimated to achieve annual peak sales of over $5&nbsp;billion. The core members of our leadership team include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Daphne Zohar</I></B>, Founder, Chief Executive Officer and Board Member, previously founded and led
PureTech Health for 20 years as CEO. She also <FONT STYLE="white-space:nowrap">co-founded</FONT> PureTech&#8217;s entities, including Karuna Therapeutics. Ms.&nbsp;Zohar was a key driver in PureTech&#8217;s productive R&amp;D engine, which led to 28
new medicines and a clinical success rate at PureTech and founded entities that was around six times better than the industry average during her tenure. PureTech programs, including Cobenfy (invented at PureTech) and deupirfenidone, met with
clinical success pursuing the same three pillar strategy of identifying clinically validated medicines with previous issues that held back their development, applying new technology to address previous limitations, and leveraging the team&#8217;s
expertise to optimize the design and execution of clinical trials and drive successful business outcomes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Steven Paul, M.D., </I></B><FONT STYLE="white-space:nowrap">Co-founder</FONT> and the Chair of the board of
directors, brings over 40 years of experience as a physician-scientist specializing in CNS drug discovery and development and was previously the President, Chief Executive Officer, and Chair of the Board and Chief Scientific Officer and President of
Research and Development at Karuna Therapeutics. He was also formerly the Executive Vice President for Science and Technology and President of the Lilly Research Laboratories at Eli Lilly. Prior to his tenure at Eli Lilly, Dr.&nbsp;Paul spent 18
years at the National Institute of Health and served as the Scientific Director of the National Institute of Mental Health. Dr.&nbsp;Paul played a key role in the development of several important neuropsychiatric drugs, including Zyprexa, Cymbalta,
Cobenfy, and Zurzuvae. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Antony Loebel, M.D.</I></B>, Chief Medical Officer and President of Clinical Development, brings over
20&nbsp;years of leadership experience in the biopharmaceutical industry and is a board-certified psychiatrist. He was formerly the President and Chief Executive Officer and Chief Medical Officer of Sunovion Pharmaceuticals. Dr.&nbsp;Loebel was
instrumental in the growth of Sunovion to a company with over $3.5&nbsp;billion in total revenue and played a key role in the development and commercialization of Latuda for the treatment of patients with bipolar depression and schizophrenia.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Michael Chen, Ph.D.</I></B>, <FONT STYLE="white-space:nowrap">Co-founder</FONT> and Chief Scientific
Officer, has over 20 years of experience in various research and leadership roles in the neuropsychiatry field. He was formerly the Head of Innovation at PureTech Health where he oversaw the rapid advancement of neuropsychiatric medicines and Glyph
platform translation and validation that led to the founding of Seaport Therapeutics. At PureTech, Dr.&nbsp;Chen played a key role in the clinical advancement of deupirfenidone, which recently demonstrated strong and durable efficacy with favorable
tolerability as a monotherapy in a Phase 2b trial in idiopathic pulmonary fibrosis. Dr.&nbsp;Chen was previously <FONT STYLE="white-space:nowrap">Co-founder</FONT> and Head of Research and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Strategy at Sonde Health, a leader in voice-based health monitoring developing artificial intelligence powered-vocal biomarkers for depression and other neuropsychiatric disorders.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Lauren White</I></B>, Chief Financial Officer, has over 22 years of corporate finance, accounting,
strategic partnering and investor relations experience. Most recently, she served as the Chief Financial Officer at ImmunoGen prior to and through its acquisition by AbbVie for $10.1&nbsp;billion in 2024. Before that she was the Chief Financial
Officer, Treasurer, and Principal Accounting Officer at C4 Therapeutics, responsible for developing and leading the company&#8217;s financial and capital strategies. Prior to that, Ms.&nbsp;White spent ten years at Novartis in various finance roles.
Ms.&nbsp;White started her career at General Electric and Boston Consulting Group in strategy and marketing roles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Lana Gladstein, J.D.</I></B>, General Counsel, has over 25 years of legal expertise including corporate
governance and M&amp;A transactions, licensing and partnerships, and intellectual property matters. Most recently, Ms.&nbsp;Gladstein was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage company developing therapeutics and
diagnostics for neurodegenerative diseases. Prior to APRINOIA, she was Chief Legal Officer at Arranta Bio and Executive Vice President and General Counsel at Brammer Bio until their acquisitions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Eric Green</I></B>, Chief Operating Officer, has diverse expertise with over 25 years of experience across
R&amp;D process engineering, pharmaceutical manufacturing, operations, and global development and commercialization strategy. Most recently, he was Senior Vice President, Head of Development Programs at Alnylam Pharmaceuticals where he led a team
responsible for global development and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities for a portfolio of development stage programs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors brings together seasoned leaders in the biopharmaceutical industry, with expertise spanning neuropsychiatry research
and development, regulatory affairs, financial operations, and commercialization. Our team is united by a shared commitment to develop transformative treatments for patients to address the significant unmet need in neuropsychiatry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have raised $325&nbsp;million of net proceeds from leading life science investors, including shareholders with
holdings greater than 5%: ARCH Venture Partners, General Atlantic, Sofinnova Investments, Third Rock Ventures, and our founder, PureTech. Prospective investors should not rely on the investment decisions of our existing investors, as these investors
may have different risk tolerances and in certain cases received their shares in prior offerings at prices lower than the price offered to the public in this offering. See the sections titled &#8220;Certain Relationships and Related Person
Transactions&#8221; and &#8220;Principal Stockholders&#8221; for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We founded our company with a mission to develop life-changing treatments for patients with depression, anxiety, and other neuropsychiatric
disorders. The key elements of our business strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Successfully advance </B><B>GlyphAllo</B><B> through clinical development for the treatment of patients with
MDD with or without anxious distress</B>. GlyphAllo is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic and
sleep-promoting effects. GlyphAllo is designed to overcome bioavailability limitations of allopregnanolone and deliver rapid and durable efficacy in MDD. We have demonstrated in a Phase 1 clinical trial that GlyphAllo reaches therapeutically
relevant exposures with oral dosing, and in a Phase 2a clinical trial, GlyphAllo demonstrated initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> with an objective biomarker of stress in healthy
volunteers and a favorable tolerability profile that supports chronic dosing. We have initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress and anticipate topline data
in&#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Successfully advance </B><B>GlyphAgo</B><B> through clinical development for the treatment of patients with
GAD</B>.<B> </B>GlyphAgo is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
antidepressant that is approved for the treatment of GAD in Australia and MDD in Australia and the EU. Due to extensive first-pass metabolism, agomelatine can cause dose-dependent liver enzyme
elevations, and its use has been limited by the need for frequent liver function testing. GlyphAgo is designed to overcome this limitation by avoiding first-pass metabolism and achieving therapeutic exposures of agomelatine while reducing or
eliminating the need for liver monitoring. We have initiated a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 1 trial for the treatment of GAD and expect topline data in .
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop a robust pipeline of differentiated programs for neuropsychiatric and other CNS disorders by
leveraging our </B><B>Glyph</B><B> platform</B>. We have used Glyph to create over 24 different small molecules based on the broad compatibility of our platform with a range of small molecule physicochemical properties. Given the novel prodrug
modifications to these drugs and resulting improvements in drug properties, we create new composition of matter intellectual property for these therapies. In addition to GlyphAllo and GlyphAgo, we have multiple preclinical programs, including
Glyph2BLSD, and are also evaluating the application of our Glyph platform in therapeutic areas beyond neuropsychiatry. Our team has a track record of building revolutionary biopharmaceutical companies that have developed successful medicines for
neuropsychiatric disorders, and we believe that our scientific expertise and world-class technical capabilities will enable us to identify and develop high value targets in the future. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically pursue strategic partnerships to maximize the value of our </B><B>Glyph</B><B> platform.</B>
We have exclusive global rights to develop and commercialize our product candidates and pursue various discovery programs using our Glyph platform. We may seek strategic collaborations where we believe the resources and expertise of third-party
biopharmaceutical companies could accelerate the clinical development or maximize the commercial potential of our product candidates and/or discovery programs, or where such collaborations could expand the capabilities of our Glyph platform. We may
also opportunistically evaluate partnerships in therapeutic areas outside neuropsychiatry where our Glyph platform has demonstrated potential applicability, such as oncology, immunology and inflammation, metabolic disease, and obesity.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unmet Patient Need in Neuropsychiatry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the World Health Organization, as of 2021, depression affects approximately 332&nbsp;million people worldwide and anxiety affects
approximately 359 million people worldwide. Quality of life can be severely impacted and the societal economic burden of MDD totals over $300&nbsp;billion in the United States alone as of 2023. According to the National Institute of Mental Health,
MDD affects approximately 21&nbsp;million adults in the United States, as of 2021. According to the National Institute of Mental Health, approximately 4 in 10 people with MDD do not receive treatment, and for those that do, currently approved drugs
often have significant limitations, including modest efficacy, slow onset of action, and unfavorable side effects. Anxiety disorders are even more prevalent than MDD and affect approximately 350&nbsp;million people worldwide. Of these, approximately
100&nbsp;million adults suffer from GAD, including more than seven million adults in the United States, according to JAMA Psychiatry, as of 2017. There have been no new therapies approved for GAD in almost two decades, and the medicines currently
used for GAD have modest efficacy, slow onset, and/or unfavorable side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the shortcomings of existing therapies, there has
been limited innovation in neuropsychiatric treatment options over the last 30 years and there remains a significant need for novel mechanisms and additional treatment options. The unmet need for improved therapies to treat depression and anxiety is
so great that even approved drugs with limited efficacy and significant tolerability issues have become widely prescribed drugs. For instance, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT>
therapies, such as Zoloft<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Zyprexa, and Cymbalta, have each generated $3&nbsp;billion to $5&nbsp;billion in peak annual sales between 2005 and 2012, despite significant limitations, such as
modest efficacy, slow onset, and undesirable side effects. SSRIs and serotonin-norepinephrine reuptake inhibitors, or SNRIs,&nbsp;both first-line treatments for MDD and GAD, can take weeks to improve symptoms, and often do not lead to complete
remission of symptoms. In addition, patients with MDD with anxious distress, a subtype of MDD representing approximately 60% of patients with MDD, have even lower rates of treatment response and remission, and there are no approved therapies
indicated for MDD with anxious distress. Patients with MDD have an increased </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
likelihood of both suicidal ideation and suicide attempts, which is further increased in patients with MDD with anxious distress. Even for patients who benefit from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs, many experience challenging side effects, such as unintended weight gain, sexual dysfunction, and sleep disturbances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GAD is characterized by excessive anxiety and worry that is difficult to control, and presents with associated symptoms such as restlessness,
sleep disturbance, and irritability. More than half of GAD patients are untreated, and of those that are treated, only half respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> treatments like
SSRIs and SNRIs. Current therapies provide limited efficacy and can cause significant adverse effects, including weight gain, sexual dysfunction, and sleep disturbances. There is a clear unmet need for novel therapies that provide improved efficacy
and reduce unfavorable side effects for patients suffering from GAD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Challenges in Neuropsychiatric Drug Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the significant unmet need in neuropsychiatry, over 90% of neuropsychiatry product candidates fail in clinical trials, according to the
Biotechnology Innovation Organization. The challenges that have held back the development of novel treatments for neuropsychiatric disorders include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Fundamental pathophysiology is unknown:</B> High failure rates in clinical trials evaluating investigational
therapies without prior clinical validation can reflect an incomplete understanding of the underlying pathophysiology of depression and anxiety. Translation of data from animal models to humans is difficult due to the complexity of the CNS.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Poor drug-like properties:</B> Drugs for neuropsychiatric disorders have had low oral bioavailability and/or
significant side effects due in part to poor drug-like properties, often due to high first-pass metabolism in the liver. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Challenges with clinical trial design and execution:</B> Suboptimal trial design and execution of
neuropsychiatry clinical trials can lead to failed studies and prevent drug approvals. A key challenge in neuropsychiatry clinical development is the placebo effect, which can be impacted by the frequency of clinician-administered assessments, the
number of treatment arms, the number of sites, and the inclusion of inappropriate patients, including those with inflated baseline ratings and those who are concurrently participating in other studies. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach</B><B><I> </I></B><B></B><I></I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are uniquely positioned to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicines that will make a significant impact for patients and their families through our differentiated, three-pillar approach: 1) identify clinically validated
mechanisms held back by issues that can be addressed by our proprietary Glyph platform, 2) create novel medicines with strong intellectual property using Glyph, and 3) apply our team&#8217;s expertise to optimize the design and execution of clinical
trials and drive successful business outcomes. We believe our approach will enable us to develop transformative treatments for patients and build a leading neuropsychiatry company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1) Identify clinically validated mechanisms held back by issues that can be addressed by our proprietary Glyph platform. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our team&#8217;s deep expertise in neuropsychiatry drug discovery and development to analyze data generated from prior clinical trials
of investigational therapies for depression, anxiety, and other neuropsychiatric disorders. Of the investigational therapies that have demonstrated clinical efficacy, we analyze the factors that have held these molecules back from achieving
regulatory or commercial success and identify those that we can address with our Glyph platform, including poor oral bioavailability and/or liver-related adverse events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We select product candidates that have the potential to become high-impact,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> and/or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapies and design and conduct early derisking <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies that validate the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fundamental hypotheses underlying each program. Molecules that meet all the above criteria become candidates for our Glyph platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2) Create novel medicines with strong intellectual property using Glyph. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph is a lymphatic-targeting prodrug platform that has been clinically validated. We can apply Glyph to molecules to overcome limitations
such as low oral bioavailability, liver related adverse events, and other side effects. Importantly, every time we Glyph a molecule, it results in the creation of a novel molecule and, therefore, new composition of matter intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of the Glyph platform has been a culmination of over 50 years of work since researchers began exploring the potential of
lymphatic transport to improve drug delivery. Since the 1970s, research has been conducted on highly lipophilic molecules, or molecules that can be dissolved in lipids or fats, that could take advantage of the lymphatic route to bypass first-pass
metabolism and target lymphatic tissues. However, this approach was limited by the need for chemical properties like lipophilicity, which can negatively affect drug absorption and metabolism. To overcome these limitations, Dr.&nbsp;Christopher
Porter, the <FONT STYLE="white-space:nowrap">co-inventor</FONT> of Glyph and Director of the Monash Institute of Pharmaceutical Sciences, advanced cleavable prodrugs with lipophilic moieties to promote lymphatic transport and the release of parent
drug. Simple triglyceride-based prodrugs with direct conjugation of a desired drug with a lipophilic moiety were explored but did not fully capture the potential of lymphatic targeting prodrugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Porter, in collaboration with our Head of Chemistry, Dr.&nbsp;Jamie Simpson, then invented our Glyph platform, which advanced the
creation of a new type of prodrug that significantly improved lymphatic transport. This proprietary prodrug chemistry is designed to promote enhanced lymphatic uptake while maintaining gut stability and the release of the parent drug. Our Glyph
platform enables the design of various linkers, glyceride moieties, and self-immolative groups tailored for each active pharmaceutical ingredient, or API, candidate, to allow for the release of the API. An illustration of an exemplary lymphatic
targeting lipid prodrug is below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g13a34.jpg" ALT="LOGO" STYLE="width:6.30571in;height:2.77429in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When taken orally, conventional small molecule drugs are absorbed in the gut, enter the portal vein, and
travel to the liver, where they can undergo high first-pass metabolism before entering systemic circulation. This can result in low bioavailability, or very little of the drug actually circulating in the body or brain and can also increase the risk
of liver-related adverse events. In contrast, dietary fats enter systemic circulation through a completely different pathway: they enter the mesenteric lymphatic system of the gut and traffic into the thoracic duct, bypassing the liver on their way
into systemic circulation. With Glyph, we cloak drugs so that the body recognizes them as if they were dietary fats, and traffics them through the lymphatic system, avoiding the liver </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and transporting them directly into the bloodstream. This improves a molecule&#8217;s bioavailability and thereby enables drugs that otherwise need to be given intravenously, to be dosed orally.
Glyph also helps to overcome other issues&#8212;such as liver toxicity&#8212;by avoiding the liver on the first pass and reducing dose while maintaining therapeutic exposure levels. Glyph is, to our knowledge, the only clinically validated
lymphatic-targeting platform. Previous examples of oral lymphatic-targeting therapies have yet to result in efficient lymphatic transport, generalized across molecules, or translated to humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have pioneered the use of preclinical models to test and validate our lymphatic transport approach. We are able to use a streamlined series
of <I>in vitro</I> and <I>in vivo</I> assays, which are efficient, repeatable, and highly translatable, and customize prodrug chemistry to each unique active drug. The translatability of these models is illustrated by our GlyphAllo program, which
was predicted to have enhanced bioavailability based on our preclinical data. This was confirmed in a Phase 1 trial of GlyphAllo in healthy volunteers, which showed that the systemic exposure of allopregnanolone achieved following dosing of
GlyphAllo was nine-fold greater than that of unmodified allopregnanolone. Similarly, our GlyphAgo program has demonstrated a substantial increase in bioavailability compared to agomelatine alone in <FONT STYLE="white-space:nowrap">non-human</FONT>
primates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have used Glyph to create over 24 different small molecules based on our Glyph platform&#8217;s compatibility with a range
of physiochemical properties of small molecules. Our Glyph platform can be used with a range of small molecules, including for indications beyond neuropsychiatry, including oncology, immunology and inflammation, metabolic disease, and obesity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3) Apply our team&#8217;s expertise to optimize the design and execution of clinical trials and drive successful business outcomes.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our experienced team has a proven track record of building successful companies that have developed and commercialized innovative
neuropsychiatric medicines. We are led by the team that discovered and advanced Cobenfy, which was first approved by the FDA in September 2024 and is the first new mechanism in over 30&nbsp;years for patients living with schizophrenia. Within each
of our programs, we are implementing key learnings from our collective experience to improve the probability of success. For instance, to optimize the design and execution of the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial of
GlyphAllo in MDD, we aim to implement learnings from the prior trials of allopregnanolone and its synthetic analogs such as zuranolone. These include key design elements to improve durable efficacy and reduce the placebo effect, namely treating
patients for the full duration of the primary endpoint, limiting the frequency of clinical assessments, randomizing patients 1:1 to either a single active treatment arm or placebo, and using rigorous patient inclusion criteria. Our strategy to
optimize the frequency of clinical assessments is supported by a recent meta-analysis we conducted of major MDD trials over the last 10 years to identify clinical design factors associated with the magnitude of the placebo response. A key finding
from this analysis was that the number and frequency of clinician-administered assessments were significantly associated with greater placebo response. Thus, reducing the number and frequency of clinician-administered assessments may decrease the
placebo response in MDD trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the key design elements we are incorporating into our clinical
trials to improve durable efficacy and minimize the placebo effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g04c52.jpg" ALT="LOGO" STYLE="width:5.59667in;height:3.09499in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging our Glyph platform to advance a pipeline of novel candidates to address the significant unmet need for patients with
depression and anxiety. Our lead product candidates include GlyphAllo for the treatment of MDD and GlyphAgo for the treatment of GAD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAllo:
Potential First- and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-Class</FONT></FONT> Therapy for MDD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo, is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous neurosteroid and GABA<SUB
STYLE="font-size:75%; vertical-align:bottom">A</SUB> PAM that has been clinically validated as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. The scope of allopregnanolone&#8217;s clinical use has been constrained by
oral bioavailability limitations that GlyphAllo is specifically designed to solve. We are currently advancing GlyphAllo in the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in MDD with or without anxious distress, that we believe has
the potential to be registration-enabling. We believe that GlyphAllo has the potential to be a first- and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for MDD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Background on MDD and Market Opportunity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MDD is one of the most disabling neuropsychiatric disorders and ranks among the leading causes of disease burden worldwide. As of 2023, 29% of
adults in the United States reported having been diagnosed with depression at some point in their life, more than diabetes (16%) or chronic kidney disease (14%).<I> </I>Depression is often characterized by persistent low mood or anhedonia&#8212;loss
of interest in normally enjoyable activities&#8212;as well as changes in sleep, appetite, cognition, psychomotor function, fatigue, feelings of worthlessness, inappropriate guilt, or suicidal ideation. Depression can be debilitating to daily
functioning, including school, work, and interpersonal relationships, and it significantly reduces quality of life. Individuals with depression are 20&nbsp;times more likely to commit suicide than those without depression. According to the CDC, in
2022, suicide was the second leading cause of death for people ages 10-14 and 20-34, the third leading cause of death for people ages 15-19, and there were over 32,000 total suicides in the United States caused by depression. This exceeded the
number of deaths from leukemia, according to SEER. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MDD is a highly heterogeneous disease that manifests in myriad ways, with variations in
symptoms, severity, and duration. Furthermore, the underlying causes are multifaceted, encompassing genetic, biological, environmental, and psychological factors. For example, according to The American Journal of Psychiatry, more than half of adults
diagnosed with MDD also experience notable concurrent anxiety. Individuals with MDD with anxious distress have worse depressive symptoms, higher likelihood of suicidal ideation, and attempted suicide, increased functional and physical impairment,
reduced quality of life, and lower response to treatments for MDD. In recognition of the clinical impact of anxious distress, the <FONT STYLE="white-space:nowrap">DSM-5</FONT> added in 2013 a specifier for anxious distress in the context of MDD.
There are no drugs specifically approved for MDD patients with anxious distress. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations of the Current Standard of Care in MDD
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are multiple approved antidepressant therapies, only 61% of adults with MDD in the United States received treatment in
2021, according to the National Institute of Mental Health. Of MDD patients who do receive treatment, approximately <FONT STYLE="white-space:nowrap">one-half</FONT> fail to achieve remission with first-line therapies. Current standard of care for
those who respond poorly to initial antidepressant monotherapy treatment relies on polypharmacy and treatment-switching strategies between current options including SSRIs, SNRIs, dopaminergic/noradrenergic drugs, and atypical antipsychotics. Current
treatments are also in many cases associated with significant negative side effects such as sexual dysfunction, weight gain, gastrointestinal issues, insomnia, fatigue, nausea, emotional blunting, and others, which limit medication adherence and can
negatively impact treatment outcomes. Even when patients achieve symptom remission, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapies may take weeks to yield effect and can even make symptoms
like insomnia worse. Therefore, there is a significant unmet need for novel therapies that are more effective and better tolerated for the treatment of people with MDD. <B></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Validation of Allopregnanolone and GABA Modulation in MDD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allopregnanolone is an endogenous neurosteroid that is synthesized in the periphery and brain and binds selectively with high affinity to GABA<SUB
STYLE="font-size:75%; vertical-align:bottom">A</SUB> receptors. Allopregnanolone has a rapid onset of action and a well-established, clinically validated antidepressant, anxiolytic, and sleep-promoting effect. GlyphAllo retains the activity and
potency of endogenous allopregnanolone in oral form. Levels of allopregnanolone peak during the third trimester of pregnancy, and an intravenous infusion formulation of allopregnanolone was approved for the treatment of PPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GABA is the primary inhibitory neurotransmitter in the brain and is a pivotal component of the etiology of depression and anxiety disorders.
Reduced GABA levels in the brain are associated with MDD, and cerebrospinal fluid, or CSF, GABA levels are highly correlated with anxiety in patients with MDD and tend to normalize with successful treatment. Other drugs that target GABA, such as
benzodiazepines, have been investigated for MDD; however, these have been largely ineffective as they lack antidepressant effects driven by specific GABA receptor subtypes and can lead to dependence and abuse. Importantly, allopregnanolone binds to
GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB> receptors at distinct sites compared to benzodiazepines and thereby modulates GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB> signaling in a manner distinct from
benzodiazepines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Prior Clinical Studies of Allopregnanolone and its Synthetic Analogs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allopregnanolone and its synthetic analogs, including zuranolone, have been tested in multiple studies in MDD and PPD and have demonstrated
rapidly acting antidepressant and anxiolytic effects. An IV formulation of allopregnanolone, brexanolone, was developed and approved by the FDA in 2019 for the treatment of PPD and marketed under the trade name Zulresso. In two positive Phase 3
trials, brexanolone demonstrated statistically significant and clinically meaningful and rapid reductions in the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> as compared to placebo in patients with PPD. In addition, brexanolone demonstrated rapid
and statistically significant anxiolytic effects and improvement in insomnia symptoms from baseline, according to pooled <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses of three placebo-controlled trials of brexanolone in PPD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After oral administration, unmodified allopregnanolone is rapidly and nearly completely
metabolized via liver first-pass metabolism, resulting in only a small percentage reaching the systemic circulation and CNS. As a result, oral administration of allopregnanolone does not produce adequate exposure levels for efficacy and is poorly
suited for chronic treatment of depression and anxiety disorders. Due to the poor oral bioavailability of allopregnanolone, brexanolone was only available via a <FONT STYLE="white-space:nowrap">60-hour</FONT> IV infusion, requiring the presence of a
health care provider to continuously monitor the patient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To overcome the poor bioavailability of brexanolone and the challenges
associated with IV administration, an oral synthetic analog of allopregnanolone, zuranolone, was developed. In two Phase 3 studies in PPD, zuranolone met the primary endpoint and also demonstrated a statistically significant improvement in symptoms
of anxiety. Zuranolone was approved by the FDA for the treatment of PPD in 2023 and is marketed under the trade name Zurzuvae. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to its development in PPD, zuranolone was tested in four placebo-controlled clinical trials in patients with MDD. In these trials, patients received either zuranolone or placebo once daily for two weeks. The primary endpoint in these trials
was change from baseline in <FONT STYLE="white-space:nowrap">HAMD-17</FONT> score at Day 15 or Day 3. Change from baseline in <FONT STYLE="white-space:nowrap">HAMD-17</FONT> score was also assessed at Day 42, when patients had not received treatment
for four weeks. Zuranolone demonstrated a rapid antidepressant effect that deepened while patients were on drug and met the primary endpoint in three of the four trials. In the trial that did not meet its primary endpoint, zuranolone showed
statistically significant reductions in the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> total score at Days 3, 8 and 12, but not at Day 15. Zuranolone also demonstrated a statistically significant anxiolytic effect in the WATERFALL trial. We
believe the negative results of these trials at Day 42 was primarily due to two key factors related to clinical trial design and execution. First, as patients received treatment for only the first two weeks of the study, patients had not received
treatment for approximately four weeks when the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> score was assessed at Day 42. Second, these studies showed a high placebo response, likely driven by the elevated frequency of clinician-administered
assessments. Indeed, according to our meta-analysis of recent antidepressant trials, zuranolone&#8217;s WATERFALL trial had approximately double the placebo response and double the frequency of clinician-administered assessments compared to typical
antidepressant trials. Zuranolone was generally safe and well tolerated in 2,005 treated patients across seven randomized control<B> </B>trials, with the most common treatment-emergent adverse event being somnolence, an <FONT
STYLE="white-space:nowrap">on-target</FONT> effect of GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB>. Despite its demonstrated antidepressant and anxiolytic activity, zuranolone was not approved in MDD, potentially due to lack of
efficacy at later timepoints. Development of zuranolone for MDD was discontinued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Overcomes Limitations of Allopregnanolone
and its Synthetic Analogs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo is a novel, Glyphed oral prodrug of allopregnanolone designed to increase the oral bioavailability
of allopregnanolone. After oral dosing, GlyphAllo is metabolized to the parent API, allopregnanolone, chemically identical to the endogenous neurosteroid, which we believe can overcome safety limitations of synthetic analogs of allopregnanolone.
Additionally, we believe GlyphAllo may have additional benefits compared to other MDD drugs, including a rapid onset of action, anxiolytic activity, and sleep-promoting effects. Paired with our expertise in designing and executing neuropsychiatry
clinical trials, we believe we can overcome the historical limitations seen in the development of allopregnanolone and its synthetic analogs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Phase 1 and Phase 2a Trial in Healthy Volunteers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As initial proof of concept for GlyphAllo, we conducted a trial in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics
of GlyphAllo, which included both Phase 1 and Phase 2a portions. Phase 1 was a multi-part trial with single ascending, multiple ascending, and food effect parts with doses ranging from 70 mg to 1,000 mg daily for up to 7 days. The goal of this trial
was to demonstrate that orally dosed GlyphAllo can safely achieve therapeutically relevant exposures and demonstrate pharmacodynamic effects consistent with allopregnanolone activity in the brain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase 1 trial, we observed that GlyphAllo resulted in dose-dependent levels of
allopregnanolone in plasma with no accumulation and minimal evidence of a clinically meaningful food effect. Across dose groups, the estimated time to peak exposure was between three to four hours, and the terminal half-life after single or multiple
doses was approximately 24 hours. Unlike synthetic analogs of allopregnanolone that can exhibit delayed elimination rates compared to endogenous allopregnanolone, levels of allopregnanolone dropped to 15% of Cmax by eight hours post-dose following
administration of GlyphAllo, which we believe will reduce or eliminate <FONT STYLE="white-space:nowrap">next-day</FONT> somnolence or drowsiness. GlyphAllo achieved exposures that are nine-fold greater than those reported without Glyph, reaching
therapeutically relevant levels that are comparable to those that occur naturally during the third trimester of pregnancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At these
therapeutically relevant levels, GlyphAllo also demonstrated pharmacodynamic effects consistent with allopregnanolone activity in the brain (upper panel of figure below). These measures include increased beta electroencephalogram, or beta EEG, power
versus placebo (lower left panel of figure below) and reduced saccadic eye velocity, or SEV (lower right panel of figure below), at four hours post dose, consistent with the pharmacology of IV allopregnanolone. Both allopregnanolone blood
concentrations and brain activity signals peaked at <FONT STYLE="white-space:nowrap">3-5</FONT> hours post-dose and declined by <FONT STYLE="white-space:nowrap">6-8</FONT> hours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAllo Provided Therapeutically Relevant Allopregnanolone Exposures and Demonstrated Pharmacodynamic Effects </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01n38.jpg" ALT="LOGO" STYLE="width:4.61in;height:3.63333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo was generally well-tolerated with no serious or severe adverse events, or AEs, including no
events of excessive sedation, altered state of consciousness, loss of consciousness, <FONT STYLE="white-space:nowrap">pre-syncope,</FONT> syncope, falls, or suicidal ideation or behavior. These data were consistent with the safety profile seen in
our extensive <FONT STYLE="white-space:nowrap">non-clinical</FONT> dog toxicity studies. All treatment-related AEs were transient, mild or moderate, and were consistent with the known pharmacology profile of allopregnanolone. These events were
generally dose- and time-dependent, occurring more frequently at high doses and early in dosing. The most common AE was mild and transient somnolence, an <FONT STYLE="white-space:nowrap">on-target</FONT> effect of GABA<SUB
STYLE="font-size:75%; vertical-align:bottom">A</SUB>. Furthermore, Stanford Sleepiness Score, or SSS, scores returned to baseline by six hours post-dosing, and this effect decreased after Day 1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the demonstration of therapeutically relevant plasma exposures of allopregnanolone
and pharmacodynamic markers of allopregnanolone activity in the brain observed in Phase 1, we evaluated an active, well-tolerated dose of GlyphAllo in an initial
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in healthy volunteers. As allopregnanolone is an anti-stress hormone and has demonstrated clinical efficacy in PPD, a form of major depression
that is also characterized by high anxiety, we conducted a Phase 2a initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial using a validated clinical model of anxiety in healthy volunteers
called the Trier Social Stress Test, or TSST. This randomized, double-blind, placebo-controlled trial evaluated a single dose of GlyphAllo (375 mg) or placebo given in the morning to 80 healthy volunteers. The TSST involves preparing a speech and
delivering it in front of a panel of judges, followed by a mental math test judged by the panel. Typically, participants will have a robust increase in salivary cortisol, the body&#8217;s primary stress hormone, in response to the TSST. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Design of Phase 2a Trial of GlyphAllo Using the TSST in Healthy Volunteers </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01n39.jpg" ALT="LOGO" STYLE="width:6.33333in;height:2.61556in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this trial, individuals receiving placebo exhibited a robust increase in salivary cortisol in response
to the TSST. In contrast, this increase in the physiological stress response was potently blunted by a single dose of GlyphAllo, with a <FONT STYLE="white-space:nowrap">p-value</FONT> of 0.0001. To date, the only compound to demonstrate reduced
salivary cortisol levels in response to the TSST is alprazolam, a benzodiazepine that has been marketed as Xanax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAllo Potently Blunted Salivary Cortisol Response to the TSST </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g02n39.jpg" ALT="LOGO" STYLE="width:4.50667in;height:3.45in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Self-reported assessments of anxiety were also collected using the State-Trait Anxiety Inventory which
confirmed that the TSST transiently and modestly increased self-reported anxiety in both the placebo and GlyphAllo groups. These results are consistent with previous data showing that healthy volunteers are less likely to self-report anxiety
symptoms following the TSST compared to patients with an anxiety disorder, who may experience a heightened negative psychological response to social stress. These results are also consistent with previously published self-reported assessments during
the TSST using known anxiolytic drugs such as alprazolam in healthy volunteers, in which self-reported anxiety increased in both drug and placebo groups in response to the TSST. Treatment-emergent related adverse events occurring at &gt;5% were
somnolence (29% GlyphAllo vs. 13% placebo) dizziness (20% GlyphAllo vs. 3% placebo), and headache (7.3% GlyphAllo vs. 7.7% placebo), all of which were transient and mild or moderate in severity. No treatment-related severe or serious adverse events
(AEs) were reported. The results of these Phase 1 and Phase 2a trials support the continued development of GlyphAllo as a first- and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicine for MDD with
or without anxious distress.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> Trial in MDD) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2025, we initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial of GlyphAllo in adults with MDD with or without
anxious distress. <FONT STYLE="white-space:nowrap">BUOY-1</FONT> is a global, randomized, double-blind, placebo-controlled trial with an open-label extension to evaluate the efficacy, safety, and tolerability of GlyphAllo. Patients will be
randomized to GlyphAllo or placebo during the double-blind period. In the active treatment arm, GlyphAllo will be administered once daily at bedtime at flexible fixed doses ranging from 125 mg to 375 mg. On Day 42, patients completing the
double-blind period will be eligible to enter a <FONT STYLE="white-space:nowrap">six-week</FONT> open label extension, or OLE, trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Design of Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> Trial of GlyphAllo in
MDD </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00n40.jpg" ALT="LOGO" STYLE="width:6.33333in;height:1.70333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect topline data from the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial
in&#8195;&#8195;&#8195;&#8195;. Based on the results of our Phase 2b clinical trial, we intend to consult with the FDA about the potential to use this trial to support our registrational filing for MDD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Opportunities to Expand the Potential for GlyphAllo in MDD and Other Indications </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the development and commercialization of GlyphAllo for the treatment of MDD with or without anxious distress is our primary focus, we
plan to evaluate GlyphAllo in additional indications as part of our longer-term growth strategy. For instance, since allopregnanolone is a rapidly acting antidepressant with anxiolytic and sleep-promoting effects, we may also evaluate GlyphAllo as a
treatment for other stress-related mood and anxiety disorders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAgo: Potential First- and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Best-in-Class</FONT></FONT> Therapy for GAD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAgo is a novel, Glyphed oral prodrug of agomelatine
that we are developing for the treatment of GAD. We are currently progressing a key Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial of GlyphAgo in healthy volunteers. Agomelatine, a
clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist, is an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and MDD in Australia and the EU. With GlyphAgo, we aim to achieve the
exposure levels of agomelatine that are effective in GAD, but at a lower dose that reduces or eliminates the need for liver function testing, while creating new composition of matter IP.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g14k41.jpg" ALT="LOGO" STYLE="width:6.30571in;height:2.71143in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Background on GAD and Market Opportunity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the World Health Organization, anxiety disorders affect 359&nbsp;million people worldwide, as of 2021. Of these, 100&nbsp;million
adults suffer from GAD, including more than seven million adults in the United States, according to JAMA Psychiatry as of 2017. As there have been no new approved therapies for GAD in almost two decades, and the current standards of care for GAD are
characterized by modest efficacy, slow onset, and/or unfavorable side effects, there is a significant unmet need for novel treatments. GAD results in excessive, obsessive, and continuous stress to the point where patients are incapable of living
normal lives or carrying out standard daily routines. GAD patients typically have uncontrollable symptoms of restlessness, fatigue, inability to focus, irritability, muscle tension, and sleep disturbance. GAD places substantial strain on the broader
healthcare system, with patients with GAD having more than twice as many health care visits and almost nine times more mental health care visits than those without GAD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Current Standard of Care and Limitations in GAD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Anxiety &amp; Depression Association of America, as of 2025, more than approximately half of GAD patients do not receive
treatment, and those that do typically are prescribed SSRI or SNRI agents, which can have significant AEs including weight gain, sexual dysfunction, emotional blunting, and insomnia. These AEs, coupled with the observation that only half of patients
respond to these medications, lead many patients to pursue augmentation therapies including benzodiazepines, buspirone, gabapentin, mirtazapine, or antipsychotics&#8212;each with its own risks. For example, benzodiazepines are widely used and can
result in dependence and abuse in just a few weeks. Despite this, approximately 1 in 8 adults in the United States use benzodiazepines each year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Validation of Agomelatine in GAD</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agomelatine is a clinically validated anxiolytic and antidepressant and is approved in Australia for the treatment of GAD. Agomelatine has
demonstrated clinical efficacy compared to placebo in four out of four third-party, randomized, placebo-controlled studies in GAD, and its efficacy in GAD is better than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs like benzodiazepines or SSRIs. These studies demonstrate a favorable efficacy and tolerability profile, with the only key exception being
dose-dependent elevations in liver enzymes in a small but notable percentage of patients. As a result, frequent liver function testing is required prior to and during use of agomelatine. Agomelatine is also approved in the EU and Australia for the
treatment of MDD, but it has never been approved in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The favorable efficacy and safety profile of agomelatine in GAD is
supported by a recent meta-analysis of 22 pharmacological treatments evaluated in randomized trials of adult outpatients with GAD. This meta-analysis, which was based on data collected from 25,441 patients across 89 trials, found that agomelatine
demonstrated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
superior efficacy compared to SSRIs and benzodiazepines. In addition, agomelatine demonstrated a superior tolerability profile compared to both benzodiazepines, which have abuse potential, and
SSRIs, which can have significant AEs, including insomnia, sexual dysfunction, emotional blunting, weight gain, and even withdrawal symptoms in the event of discontinuation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, agomelatine&#8217;s favorable tolerability profile consists of no statistically significant difference in overall adverse events or
dropout rate and no association with clinically significant somnolence compared to placebo. Agomelatine does not cause sexual dysfunction. Specifically, no deleterious effect on sexual function was observed during agomelatine treatment over 12 or <FONT
STYLE="white-space:nowrap">24-week</FONT> treatment periods in a specific sexual dysfunction comparative trial in remitted depressed patients. Agomelatine also does not exhibit the &#8220;hangover&#8221; effects (e.g., lethargy, fatigue, decreased
motivation, anxiety, etc.) caused by various antidepressants and antipsychotics. Agomelatine also improves sleep latency, sleep architecture, and daytime sleepiness compared to SSRIs, which can worsen sleep and cause insomnia. This makes agomelatine
well-suited for GAD, where sleep disturbance is a core symptom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the superior tolerability profile of agomelatine, clinical uptake
has been limited by the requirement for frequent liver function monitoring. Due to extensive first-pass liver metabolism, the oral bioavailability of agomelatine is very low (~1%), and the frequency of liver transaminase elevations with agomelatine
treatment is two to five-fold greater than placebo. As a result, patients in Australia and the EU&#8212;where agomelatine is approved&#8212;are required to undergo frequent liver function tests. Specifically, liver function tests must be performed
before starting treatment, after 3, 6, 12, and 24 weeks, and when increasing dose. This burdensome liver testing, combined with a lack of patent protection, has limited clinical and commercial adoption of agomelatine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph enables bypass of liver first-pass metabolism, improving oral bioavailability and enabling the potential to achieve therapeutic
exposures at a lower dose. As the increases in liver transaminase levels observed with agomelatine are dose-dependent, our goal is to achieve the exposure levels of agomelatine that are effective in GAD, but at a higher bioavailability and thus
lower dose that reduces or eliminates the need for liver function testing. Based on internal analyses, we believe a <FONT STYLE="white-space:nowrap">two-fold</FONT> increase in the bioavailability of agomelatine will reduce or eliminate liver enzyme
elevations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAgo in Preclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As validation for GlyphAgo and further validation for our Glyph platform, we conducted in vivo studies in NHPs to evaluate the potential for
GlyphAgo to achieve therapeutic exposure levels at a lower dose that may reduce or eliminate the need for liver function testing. In these studies, we dosed NHPs with either GlyphAgo or an equivalent (i.e., equimolar) amount of agomelatine alone.
GlyphAgo was shown to enhance lymphatic absorption and provide significantly higher systemic exposures of agomelatine compared to agomelatine alone. Oral dosing of GlyphAgo in a rat model resulted in over 50% of agomelatine being transported through
the mesenteric lymphatics versus less than 1% for orally dosed agomelatine alone. Following administration of agomelatine alone, levels of agomelatine in plasma were below the limit of quantification, consistent with the low oral bioavailability of
agomelatine in humans and NHPs (Valdoxan EPAR). In contrast, administration of GlyphAgo substantially increased plasma exposures of agomelatine compared with agomelatine alone, demonstrating the potential of GlyphAgo to achieve therapeutic exposures
of agomelatine while minimizing the dose impacting the liver. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAgo Substantially Increased Plasma Agomelatine Levels in <FONT
STYLE="white-space:nowrap">Non-Human</FONT> Primates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g14k43.jpg" ALT="LOGO" STYLE="width:4.54286in;height:4.12286in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the therapeutic exposures achieved with GlyphAgo in our NHP studies, we modelled the clinical
implications of these data with respect to potential liver enzyme elevations using DILIsym, an analytical, computational model-based software capable of predicting and explaining Drug-Induced Liver Injury, or DILI. The FDA uses and cites DILIsym in
drug approvals as the standard software for the quantitative prediction and investigation of DILI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One useful output of DILIsym is an
eDISH (Evaluation of Drug-Induced Serious Hepatotoxicity) plot. eDISH plots are a standard way that the FDA evaluates liver safety of new drug candidates in clinical trials. eDISH graphs the peak serum alanine aminotransferase (ALT; a liver enzyme)
value and peak serum bilirubin value observed in each patient (or simulated patient) in a clinical trial along the <FONT STYLE="white-space:nowrap">x-axis</FONT> and <FONT STYLE="white-space:nowrap">y-axis,</FONT> respectively. Each patient (or
simulated patient) is represented by a single point on the graph, and liver enzyme elevations (&gt;3x upper limit of normal) are indicated by the presence of points on the right half of the graph. We first simulated the relationship between
agomelatine dose and liver enzyme elevations using available clinical data for two approved doses of agomelatine (25 and 50 mg). Next, we simulated potential liver enzyme elevations following administration of an equimolar dose of GlyphAgo, using
assumptions derived from our in vivo study in NHPs described above. The results are shown in the four eDISH plots below. The eDISH plots in the upper row represent approved doses of agomelatine (25 mg and 50 mg) and recapitulate the liver enzyme
elevations observed in previous clinic trials of agomelatine. The eDISH plots in the lower row represent doses of GlyphAgo with enhanced bioavailability and thus lower dose, which in contrast show no liver enzyme elevations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DILIsym Simulations Demonstrate that GlyphAgo is Not Projected to Cause Liver Enzyme
Elevations </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00n44.jpg" ALT="LOGO" STYLE="width:6.334in;height:3.914in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, our DILIsym simulations demonstrated that, with conservative estimates, clinically relevant
doses of GlyphAgo are not projected to cause liver enzyme elevations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan of GlyphAgo in GAD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are advancing a Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial of GlyphAgo
that we believe has the potential to be highly clinically derisking for the GlyphAgo program. In this trial, we aim to demonstrate that GlyphAgo can achieve exposure levels that have demonstrated efficacy in GAD at a lower dose that does not cause
an increase in liver enzymes and reduces or eliminates the need for liver function testing. This Phase 1 trial will be conducted in multiple parts to evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo compared to agomelatine. It
will include single- and multiple-ascending dose phases, as well as a food-effect crossover portion, using both open-label and placebo-controlled designs. We expect topline data in &#8195;&#8195;&#8195;&#8195;&#8195; . </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Opportunities to Expand the Potential for GlyphAgo in GAD and Other Indications </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the development and commercialization of GlyphAgo for the treatment of GAD is our primary focus, as part of our longer-term growth
strategy, we may evaluate GlyphAgo in other indications as well, including MDD. Indeed, agomelatine is approved for MDD in Australia and the EU, but it is constrained by similar liver function testing requirements in MDD as well. As agomelatine also
improves sleep latency, sleep quality, and daytime sleepiness compared to SSRIs, which can worsen sleep and cause insomnia, we may also evaluate GlyphAgo for the treatment of insomnia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Glyph2BLSD: <FONT STYLE="white-space:nowrap">Non-Hallucinogenic</FONT> Neuroplastogen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph2BLSD is our novel, Glyphed oral prodrug of the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> which we are developing for the treatment of depressive disorders, including TRD, PTSD, and headache disorders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with significant unmet need. Neuroplastogens are compounds that enhance neuroplasticity, the brain&#8217;s ability to form, reorganize, and strengthen neural connections, and include psychedelics
and ketamine. They offer the potential to repair disrupted brain circuits and have demonstrated efficacy for treating neuropsychiatric disorders. However, significant challenges remain, including functional unblinding of clinical trials due to the
production of hallucinations and sensory disturbances, the accompanying need for supervised administration, and concerns over long-term safety, such as the risk of fibrosis. Leveraging our Glyph platform, we have designed Glyph2BLSD to harness the
efficacy of psychedelics while eliminating hallucinations to enable the execution of placebo-controlled trials, outpatient dosing, and an enhanced dosing regimen to optimize efficacy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Potential Indications for Glyph2BLSD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 3&nbsp;million adults in the United States have TRD, according to The Journal of Clinical Psychiatry, as of 2021. Unlike MDD,
which, according to the National Institute of Mental Health, as of 2021, impacts an estimated 21&nbsp;million adults annually, TRD is characterized by the failure to achieve an adequate response after two or more antidepressant treatments. Patients
with TRD face severe challenges, including a significantly lower likelihood of responding to subsequent therapies, a reduced quality of life, and an increased risk of attempting suicide, more than double the rate seen in <FONT
STYLE="white-space:nowrap">non-resistant</FONT> depression. Many of these individuals experience chronic disability, relying heavily on social support systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PTSD affects approximately 12&nbsp;million individuals in the United States and is also characterized by significant unmet need. There are
currently only two approved therapies for PTSD, both of which are SSRIs. We believe Glyph2BLSD has the potential to restore function and improve outcomes to address the significant unmet medical need in TRD and PTSD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trigeminal autonomic cephalalgias, notably cluster headaches, are severe neurological conditions linked to the trigeminal nerve. Cluster
headaches affect approximately 150,000 patients in the United States and cause the most severe pain known to humans, greater than labor pain or gunshot wounds. Individuals with cluster headache experience intense pain and autonomic symptoms
including eye watering, swelling, and redness, as well as nose congestion. Headache attacks may last for up to 3 hours per episode and occur up to 8 times a day, disrupting patients&#8217; lives. Cluster headache has also been called &#8220;suicide
headache&#8221; due to the increased risk of suicide during headache periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A small trial by Karst et al. showed that three doses of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> over a <FONT STYLE="white-space:nowrap">10-day</FONT> period significantly reduced the frequency and intensity of chronic cluster headaches, with effects lasting
weeks to months. Importantly, the treatment did not induce hallucinations, making it a safer alternative to traditional psychedelics. While the trial was not placebo-controlled, and thus requires additional clinical investigation, we believe that
Glyph2BLSD has the potential to optimize the pharmacokinetics of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> to ensure precise and sustained dosing, while preserving its
<FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage therapeutics company focused on inventing and developing novel medicines for patients with depression, anxiety, and
other debilitating neuropsychiatric disorders. While we believe our Glyph platform can produce small molecules that offer an attractive alternative to branded and generic therapeutics treating neuropsychiatric diseases if they are approved, today we
face competition from major pharmaceutical and biopharmaceutical companies, academic institutions, governmental agencies, consortiums, and public and private research institutions, among others. Many of our potential competitors, either alone or
with collaboration partners, have significantly greater financial resources than we do, as well as equal or greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products, and the
commercialization of those products. Accordingly, our potential competitors may be more successful than we are in achieving regulatory approvals and commercializing their neuropsychiatric products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the key competitive factors affecting the success of our lead product candidates
GlyphAllo and GlyphAgo, that we are developing to address MDD and GAD, respectively, if approved, are likely to be efficacy, safety, and frequency of dosing, convenience, price, the level of generic competition, and the availability of reimbursement
from government and other third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing GlyphAllo for the treatment of MDD. We believe, if approved, that
GlyphAllo would compete with several currently approved therapeutics, including: Caplyta and Spravato (marketed by Janssen Pharmaceuticals), Vraylar (AbbVie and Gideon Richert Plc.), Trintellix (Takeda Pharmaceuticals and Lundbeck), Auvelity (Axsome
Therapeutics), and Rexulti and Abilify (Ostuka Pharmaceuticals). We are also aware of multiple potentially competitive late-clinical-stage assets, including azetukalner (Xenon Pharmaceuticals), <FONT STYLE="white-space:nowrap">ALTO-300</FONT> and <FONT
STYLE="white-space:nowrap">ALTO-203</FONT> (Alto Neuroscience) and CYB003 (Cybin). We also face competition from branded and generic atypical antipsychotics and SSRI/SNRIs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing GlyphAgo for the treatment of GAD. We believe, if approved, that GlyphAgo would compete with several currently marketed
therapeutics, including: Lyrica and Buspirone (marketed by Viatris) and marketed generic SSRI/SNRIs and benzodiazepines. In relation to both GlyphAgo and Glyph2BLSD, we are also aware of multiple potentially competitive late-clinical-stage assets,
including an LSD program (Mind Medicine, MindMed), <FONT STYLE="white-space:nowrap">ENX-102</FONT> (Engrail Therapeutics), CYB004 (Cybin), and <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogens (Gilgamesh Pharma and AbbVie).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect the proprietary technology, inventions and improvements that are commercially important to the development of our business, by seeking, maintaining and standing ready to defend patent rights, whether developed internally or licensed from
third parties. We also rely on trademarks, trade secrets and other intellectual property rights relating to our proprietary Glyph platform and product candidates, and on continuing technological innovation and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary and intellectual property position. We may also rely on regulatory and other protections afforded through data and marketing
exclusivities, where available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to protect the intellectual property and proprietary technology that we consider important to our
business by pursuing patent applications that cover our technologies (including the Glyph platform) and product candidates and methods of using the same, as well as any other relevant inventions and improvements that are considered commercially
important to the development of our business. We likewise seek to protect the intellectual property to which we obtain rights through licenses and sublicenses and work collaboratively with our licensors to ensure patent prosecution and protection.
Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for our product candidates, commercially important technologies (including the Glyph platform), inventions and trade secrets
related to our business, defend and enforce our intellectual property rights, particularly our patent rights and any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future, preserve the confidentiality of our trade
secrets and operate without infringing valid and enforceable intellectual property rights of others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions for
therapeutics companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can
be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents that we own or <FONT STYLE="white-space:nowrap">in-license</FONT>
now or in the future. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from
competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. Notwithstanding the scope of the patent protection available to us, a competitor could develop competitive technologies and products that are not
covered by our patents, and we may be unable to stop such competitor from commercializing such technologies and products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio includes a combination of patents and pending patent applications
solely owned by us or <FONT STYLE="white-space:nowrap">co-owned</FONT> with Monash University where Monash University&#8217;s rights are exclusively licensed to us, and patents and pending patent applications owned by Monash University that are
exclusively licensed to us. As of November&nbsp;12, 2025, our owned and exclusively licensed patent estate contains eleven patent families comprising five issued U.S. patents, thirteen issued patents in Australia, Canada, China, Europe (validated in
Great Britain and through a Unitary Patent in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia, and Sweden), Japan and New Zealand, seven
pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, two allowed European applications, 37 pending patent applications in various jurisdictions outside of the U.S., as further described below, and four pending
PCT international applications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the Glyph platform patents and applications discussed below, as of November&nbsp;12, 2025, with regard to the GlyphAllo program,
we <FONT STYLE="white-space:nowrap">co-own</FONT> with and exclusively license from Monash University one issued U.S. patent relating to composition of matter coverage of GlyphAllo, which is expected to expire in 2041. We also <FONT
STYLE="white-space:nowrap">co-own</FONT> with and exclusively license from Monash University three pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, one allowed European application and nineteen pending patent
applications in Australia, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, New Zealand, and Singapore, relating to the composition of matter and methods of treatment which, if issued, will be expected to expire between 2039 and 2041.
The foregoing expiration dates may not account for potentially available patent term adjustments or extensions and terminal disclaimers, and assume payment of all appropriate maintenance, renewal, and annuity fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also solely own two international patent applications filed under the Patent Cooperation Treaty (PCT), one directed to methods of treating
MDD with and without anxious distress using our GlyphAllo product candidate and the other directed to an intermediate for GlyphAllo. We expect that any issued patents claiming priority to these applications will expire in 2044, without taking into
account any possible patent term adjustments or extensions and if all maintenance and annuity fees are paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAgo Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the Glyph platform patents and applications discussed below, we also solely own one international patent application filed under
the PCT, directed to the composition of matter of our GlyphAgo product candidate and its use. We expect that any issued patents claiming priority to the international patent application will expire in 2044, without taking into account any possible
patent term adjustments or extensions and if all maintenance and annuity fees are paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Glyph2BLSD Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the Glyph platform patents and applications discussed below, we also solely own one international patent application filed under
the PCT, directed to the composition of matter of our Glyph2BLSD product candidate and its use. We expect that any issued patents claiming priority to this international patent application will expire in 2044, without taking into account any
possible patent term adjustments or extensions and if all maintenance and annuity fees are paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Glyph Platform </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With regard to the Glyph platform, we exclusively license from Monash University two issued U.S. patents, twelve issued patents in Australia,
Canada, China, Europe (validated in Great Britain and through a Unitary Patent in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia and
Sweden), Japan, and New Zealand, and one allowed European patent application, relating to platform coverage of GlyphAllo, GlyphAgo and Glyph2BLSD, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as well as design-around coverage, which are expected to expire between 2035 and 2037. We also exclusively license from Monash University three pending U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications and 14 pending patent applications in Australia, Canada, China, Europe, Hong Kong, Japan, and New Zealand, relating to platform coverage of GlyphAllo, GlyphAgo and
Glyph2BLSD, as well as design-around coverage, which are expected to expire between 2035 and 2036 We also <FONT STYLE="white-space:nowrap">co-own</FONT> and exclusively license from Monash University one issued U.S. patent, two pending U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications and four pending patent applications in Australia, Canada, Europe, and Hong Kong, relating to platform coverage of Glyph2BLSD, as well as design-around coverage, which are
expected to expire in 2039. The foregoing expiration dates may not account for potentially available patent term adjustments or extensions and terminal disclaimers, and assume payment of all appropriate maintenance, renewal, and annuity fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in
which we file, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which
compensates a patentee for administrative delays by the United States Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier expiring patent. Our patent applications
may not issue as patents, and even if issued, the scope or term of any issued patent may not afford sufficient protection or competitive advantage to our existing or future products. See the section titled &#8220;Risk Factors&#8212;Risks related to
our intellectual property&#8221; for a more comprehensive description of risks related to our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United
States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review
process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an
extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. If our product candidates receive FDA
approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however,
there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November<B></B>&nbsp;12, 2025, we have no outstanding litigation related to our intellectual property nor any threat to initiate claims
against us. In the future, we may need to engage in litigation to enforce patents issued or licensed to us, to protect our trade secrets or <FONT STYLE="white-space:nowrap">know-how</FONT> or to defend against claims of infringement of the rights of
others. Such litigation could be costly and could divert our attention from other functions and responsibilities. We may not receive adequate remedies even if we prevail in such litigation and adverse determinations could subject us to significant
liabilities to third parties, which could severely harm our business. See the section titled &#8220;Risk Factors&#8212;Risks related to our intellectual property&#8221; for a more comprehensive description of risks related to our intellectual
property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we rely on intellectual property rights, including patents, trademarks and trade secrets, as well as contractual
protections to establish and protect our proprietary rights, we believe that factors such as the technological and creative skills of our personnel, creation of new solutions, features and functionality, and frequent enhancements to our platform are
also essential to establishing and maintaining our technology leadership position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secret protection for our proprietary information to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect our
proprietary information, including restricting and monitoring access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result,
we may be unable to meaningfully protect our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secret information. See the section titled &#8220;Risk Factors&#8212;Risks related to our intellectual property&#8221; for a more comprehensive
description of risks related to our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we plan to rely on regulatory protection based on orphan drug
exclusivities, data exclusivities, and market exclusivities. See the section titled &#8220;&#8212;Government Regulation&#8221; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we have and will continue to pursue trademark protection for our company name and brand. As of November&nbsp;14, 2025, we own fifteen
pending trademark applications in the United States and foreign jurisdictions, including four allowed trademarks in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Transfer Agreement with PureTech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we entered into an Asset Transfer Agreement, or the Asset Transfer Agreement, with PureTech Health LLC, or PureTech Health, and
PureTech LYT, Inc., or PureTech LYT, pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of PureTech Health&#8217;s and PureTech LYT&#8217;s right, title, and interest in, to, and
under the assets related to its Glyph technology or products, including the Monash License Agreement, subject to the terms set forth in the Asset Transfer Agreement. In exchange, we issued 40,000,000 shares of our Series <FONT
STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 949,000 shares of our common stock to PureTech LYT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with the Asset Transfer Agreement, we have agreed to make milestone payments of up to an aggregate of $10.0&nbsp;million for the first product covered by assets transferred through the Asset Transfer Agreement, or the Seaport Glyph Product, and up
to an aggregate of $5.0&nbsp;million for each subsequent Seaport Glyph Product that achieves certain developmental and commercial milestones. In addition, we are obligated to pay tiered royalties on potential annual net sales of each Seaport Glyph
Product as follows: less than $500 million: 3%; $500&nbsp;million to $1 billion: 3.5%; $1&nbsp;billion to $2.5 billion: 4%; $2.5&nbsp;billion to $3.5 billion: 4.5%; $3.5&nbsp;billion or greater: 5%. The royalty term will expire on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Seaport Glyph Product on the later of the ten year anniversary of the first commercial sale of such Seaport Glyph Product in such country
or the date on which the last valid claim of patent rights of such Seaport Glyph Product expires in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent we
license to a third-party rights under the Glyph intellectual property transferred to us through the Asset Transfer Agreement, we have also agreed to pay a percentage of net income we receive from such third party under such a license, with such
percentage in the <FONT STYLE="white-space:nowrap">low-double</FONT> digits to <FONT STYLE="white-space:nowrap">mid-single</FONT> digits. Any such amount of net income are creditable against royalty payments. Other than the upfront equity grant, we
have not made any payments to date pursuant to the Asset Transfer Agreement. Upon a change of control with respect to our controlled affiliate that has exclusive rights to utilize any Seaport Glyph Product, we are obligated to pay a low double-digit
percentage of the value of the aggregate amount of all change of control consideration paid to us.<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Monash University Exclusive
License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, PureTech Health exclusively assigned to us, and we assumed, all rights and obligations under the
Original License Agreement. In March 2025, we entered Monash License Agreement. Pursuant to the Monash License Agreement, Monash University grants us (i)&nbsp;a worldwide, exclusive, sublicensable license under certain Monash University intellectual
property rights, including patent rights related to the Glyph platform, or the Licensed Patents, <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development activities, for the purpose of developing and commercializing products in all fields with one exception, (ii)&nbsp;a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
sublicensable license under certain background technology and certain other intellectual property strictly to the extent necessary to exercise the license described in subclause (i)&nbsp;above, and (iii)&nbsp;a first right and an exclusive option to
obtain an exclusive license to any invention generated by Monash University outside of the Licensed Patents and pertaining to certain prodrug technology. Additionally, we and Monash University agreed to collaborate in conducting research and
development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, we have agreed to use reasonable commercial endeavors to (i)&nbsp;develop at
least one Licensed Product, (ii)&nbsp;seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or Europe, promote and develop the sale of at least one Licensed Product
in such territory. Monash University agrees to provide reasonable technical assistance and advice based on Monash University&#8217;s <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the Monash License
Agreement. We grant Monash University a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, royalty-free license under the Licensed Patents, related <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming
from joint research and development activities solely for academic, teaching, and <FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research uses, which includes the right to sublicense for
<FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research to other academic institutions or <FONT STYLE="white-space:nowrap">non-commercial</FONT> research entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licenses granted by Monash University, we are required to pay Monash University:
<FONT STYLE="white-space:nowrap">(i)&nbsp;low-single</FONT> digit royalties with a rate based on net sales per calendar year (subject to certain reductions); (ii) a <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentage of any net
income received under a sublicense (subject to a license payment stacking reduction) with the percentage varying based on the development stage of the Licensed Products at the time the sublicense is granted during the term of the Monash License
Agreement; (iii)&nbsp;an agreed to research funding amount to progress mutually agreed research and development or commercialization activities; (iv)&nbsp;a <FONT STYLE="white-space:nowrap">mid-five-figure</FONT> annual maintenance fee during the
term of the agreement commencing on the third anniversary of the execution date of the Original License Agreement until the first commercial sale of a Licensed Product creditable against net income sharing, royalties, and milestone payments;
(v)&nbsp;milestone payments in the event of successful development milestones of up to $1.075&nbsp;million per Licensed Product for the first three Licensed Products; and (vi)&nbsp;milestone payments in the event of successful commercial milestones
of up to $7.25&nbsp;million per Licensed Product for the first three Licensed Products. We are also obligated to (a)&nbsp;pay all costs incurred for the prosecution and maintenance of the Licensed Patents and patent filings stemming from
collaboration activities and (b)&nbsp;reimburse Monash University for all patent prosecution costs of the Licensed Patents prior to the execution date of the Original License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monash License Agreement commenced on the execution date of the Original License Agreement and will expire seven years after the last of
the Licensed Patents expires, unless terminated earlier. Either party may terminate for due cause, including for material breach and bankruptcy. Monash University may terminate if we fail to meet our diligence requirements. Either party may
terminate the Monash License Agreement if we determine that the activities are no longer commercially viable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state, and local level, and in other countries and jurisdictions, including the
European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacturing, quality control, safety, effectiveness, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution,
marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance
with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval of Drugs in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.
The failure to comply with applicable U.S. requirements at any time during the product development process, approval process, or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including
refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, and other types of letters, product seizures, total or partial suspension of production or distribution,
injunctions, fines, product recalls, and other post-market actions, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations, and penalties brought by the FDA and the U.S. Department of Justice or
other governmental entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a new drug product in the United States must
typically undertake the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of nonclinical, or preclinical, laboratory tests, animal studies, and formulation studies in
compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an investigational new drug application, or IND, which must take effect before human
clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board, or IRB, representing each clinical site before each clinical trial may
be initiated at that site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or
GCPs, to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of a New Drug Application, or NDA, and payment of user fees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of the product by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the
product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity,
strength, quality, and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of
the clinical data; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before an
applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include, among other things, laboratory evaluation of the purity and stability of the manufactured drug substance or active
pharmaceutical ingredient, or API, and the formulated drug or drug product, as well as <I>in vitro</I> and animal studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for
therapeutic use. The conduct of certain preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term preclinical testing, such as animal tests of reproductive adverse effects, or AEs, and
carcinogenicity, may continue after the IND is submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The IND and IRB Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that allows an investigational drug to be shipped in interstate commerce for use in a clinical trial and a
request for FDA authorization to administer such investigational drug to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
humans. Such authorization must be secured prior to interstate shipment and administration of the investigational drug. In an IND, applicants must submit a protocol for each clinical trial and
any subsequent protocol amendments. In addition, the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA
as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. The FDA
also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing
investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold) may only resume after the FDA has notified the sponsor that the
investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under
an IND, all FDA IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with GCP, among other things, including review and approval
by an independent ethics committee and obtaining informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trials,
as well as the quality and integrity of the resulting data. FDA must also be able to validate the data from the study through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and
approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review of the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent
information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not
being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety
monitoring board or committee. This group provides advice to the sponsor as to whether or not a trial may move forward at designated check points based on <FONT STYLE="white-space:nowrap">pre-specified</FONT> criteria and access that only the group
maintains to available data from the study. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public
dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Human Clinical Trials in Support of an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical trial. Clinical
trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, which may overlap
or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1</I>. The product candidate is initially introduced into healthy human subjects or, in certain
indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness, and to determine
maximal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2</I>. The product candidate is administered to a limited patient population with the specified disease
or condition to identify possible AEs and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3</I>. The product candidate is administered to an expanded patient population, generally at
geographically dispersed clinical trial sites, in well-controlled clinical trials with the intent to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product
candidate and to provide adequate information for the labeling of the product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, sometimes
referred to as Phase 4 studies, may be conducted after initial regulatory approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase 4 clinical trials as a condition of approval of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the IND is active, progress reports detailing the
results of the clinical trials, among other information, must be submitted at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be
submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or <I>in vitro</I> testing that suggest a significant risk in humans exposed to the drug; and any clinically
important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within
seven calendar days after the sponsor&#8217;s initial receipt of the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies often
complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of
the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review of an NDA by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials,
together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more
indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically increased annually. Certain exceptions and
waivers are available for some of these fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct
pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
route of administration. Under PREA, NDAs, and certain supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate
the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is deemed safe and effective. The sponsor
or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the product candidate is ready for approval for use in adults before
pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before any pediatric clinical trials begin. The FDA must send a <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor
that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of an NDA within 60 days of its receipt, before accepting the NDA for filing, to determine whether the
application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to determine, among
other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the performance goals and policies
implemented by the FDA under the Prescription Drug User Fee Act, or PDUFA, FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed within 10
months from the date of filing, and applications for &#8220;priority review&#8221; products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional
months if FDA requests or the applicant otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date or is otherwise deemed a &#8220;major
amendment&#8221; to the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During its review of an NDA, the FDA typically will inspect the facility or facilities where the
product is or will be manufactured. These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs), finished drug product manufacturing,
and control testing laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within
required specifications. In addition, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a condition of approval, the FDA may require an applicant to develop a risk evaluation and mitigation strategy, or REMS. REMS
use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the
product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician
communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an
advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is
not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fast Track, Breakthrough Therapy, and Priority Review </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a number of programs intended to facilitate and expedite development and review of investigational drugs if they are intended to
address an unmet medical need in the treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy Designation, and priority review designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">First, the FDA may designate a product candidate for Fast Track review if it is intended, whether alone or in combination with one or more
other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such disease or condition. For Fast Track product candidates, sponsors may have greater
interactions with the FDA and the FDA may initiate review of sections of a Fast Track product candidate&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation
of clinical data submitted by the sponsor, that a Fast Track product candidate may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable
user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track Designation may be withdrawn by the FDA if the FDA
believes that the designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Second, a product candidate may be
designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other drugs products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product
candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy Designation includes all of
the benefits associated with Fast Track Designation, including the potential for rolling review of an NDA submission. In addition, the FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor
throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking
other steps to design the clinical trials in an efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third, the FDA may designate an NDA review for a priority review if it
is for a product candidate that treats a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in safety or effectiveness compared to available therapies. The FDA determines, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the product candidate may represent a significant improvement when compared with other available therapies. Significant improvement may be
illustrated, among other things, by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to
improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s
goal for taking action on a marketing application from 10 months to six months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accelerated Approval Pathway </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may grant accelerated approval to a product candidate intended to treat a serious or life-threatening condition that provides
meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on an intermediate clinical
endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical
sign, or other measure that is thought to predict clinical benefit, but is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a
therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated
that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect
is reasonably likely to predict the ultimate clinical benefit of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway is often used in settings in
which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway is typically contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the product&#8217;s anticipated clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the
completion of Phase 4 or other post-approval clinical trials to verify and describe the anticipated the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is permitted to require, as appropriate,
that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such
studies, including progress toward enrollment targets, and the FDA must post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated
approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA
generally requires, unless otherwise informed by the agency, <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials for product candidates approved under accelerated regulations, which could adversely impact the timing of the
commercial launch of the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA&#8217;s Decision on an NDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of any inspections of the
manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific
indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a complete response letter is issued,
the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have
been addressed to the FDA&#8217;s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA approves a product, it may limit the
approved indications for use for the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the
drug&#8217;s safety or effectiveness after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms,
including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising, and promotion, reporting of adverse experiences with the product and applicable product tracking and tracing requirements.
After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are annual prescription drug product program fee requirements for certain
marketed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs, and
those supplying products, ingredients, and components of them are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with
cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
and documentation requirements upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with
product tracking and tracing requirements and notify the FDA of counterfeit, diverted, stolen, and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must
continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is
granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including
AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or
clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market, or voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning, or untitled letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted
only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA
and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted
<FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of
prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug
distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing
authorization for a new drug. A Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy
but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the
investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. The FDA may also
require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference drug. The FDA may then approve the new product candidate for all, or some, of the labeled
indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant. Section&nbsp;505(j) establishes an abbreviated approval process for a generic version of approved drug products
through the submission of an Abbreviated New Drug Application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance
characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug, or RLD. ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include preclinical (animal) and
clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through <I>in vitro</I>, <I>in
vivo</I>, or other testing. In certain situations, an applicant may obtain ANDA approval of a generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability
Petition. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Patent</FONT> Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any applicable
period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the RLD has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity for a new drug containing a new
chemical entity, or NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or
pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, which
states the proposed generic drug will not infringe one or more of the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following the
original product approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA also provides for a period of three years of exclusivity for
<FONT STYLE="white-space:nowrap">non-NCE</FONT> drugs if the NDA or a supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the
applicant and are essential to the approval of the application or supplement. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination, or
indication, but it generally would not protect the original, unmodified product from generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic
versions of the drug as of the date of approval of the original drug product; it only prevents FDA from approving such ANDAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug
product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and to patent terms.
This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#8220;Written Request&#8221; for
such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hatch-Waxman Patent
Certification and the <FONT STYLE="white-space:nowrap">30-Month</FONT> Stay </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In seeking approval of an NDA or a supplement thereto,
NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Upon approval of an NDA, each of the patents listed in the application for the drug is
published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Upon submission of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents
listed for the RLD in the Orange Book that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no patent information on the drug product that is the subject of the application has been submitted to the FDA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent has expired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which such patent expires; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent is invalid, unenforceable, or will not be infringed upon by the manufacture, use, or sale of the drug
product for which the application is submitted. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all
listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or
indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant
has provided a paragraph IV certification, the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a
patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA
may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the
applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an ANDA or 505(b)(2) NDA
applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take many months or years
to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. If the
drug has NCE exclusivity and the ANDA is submitted four years after approval, the <FONT STYLE="white-space:nowrap">30-month</FONT> stay is extended so that it expires seven and a half years after approval of the innovator drug, unless the patent
expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Extension
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which
permits a patent term restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the
effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the remaining
term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the application for the extension must be submitted prior to the expiration of the patent in question and within 60 days of drug approval. A patent that covers multiple drugs for which approval
is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office, or USPTO, reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Enforcement Administration Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our product candidates have the potential to be regulated as controlled substances by the U.S. Drug Enforcement Administration, or
DEA. The Controlled Substances Act of 1970, or CSA, establishes registration, security, recordkeeping, reporting, storage, distribution, and other requirements administered by the DEA. The DEA is concerned with the control of handlers of controlled
substances, and with the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. The DEA regulates controlled substances as Schedule I, II, III, IV, or V
substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV, or V, with Schedule II substances considered to
present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual registration
is required for any facility that manufactures, distributes, dispenses, imports, or exports any controlled substance. The registration is specific to the particular location, activity, and controlled substance schedule. For example, separate
registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized. The DEA typically inspects a facility to review its security measures prior to issuing a registration.
Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. Required security measures include background checks on employees and physical control of inventory
through measures such as cages, surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and periodic reports made to the DEA. Reports must also be made for thefts or losses of any
controlled substance, and authorization must be obtained to destroy any controlled substance. In addition, special authorization and notification requirements apply to imports and exports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To meet its responsibilities, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to
maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those
registrations. In certain circumstances, violations can lead to criminal prosecution. Individual states also regulate controlled substances, and manufacturers are also subject to state regulation on distribution of these products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rest of the World Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
other countries outside of the United States, such as those in Europe, Latin America, or Asia, the requirements governing product development, the conduct of clinical trials, product marketing, product licensing, pricing and reimbursement can vary
from country to country. Failure to comply with applicable foreign regulatory requirements may subject sponsors, manufacturers, or marketers of pharmaceutical products to, among other things, fines, suspension, or withdrawal of regulatory
authorizations and approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval of
Medicinal Products in the European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply
with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy, and governing, among other things, clinical trials, obtaining marketing authorization, or MA, commercial sales and
distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows similar lines as in the
United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the
relevant competent authorities of an MA application, or MAA, and granting of an MA by these authorities before the product can be marketed and sold in the EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-clinical</FONT> Studies and Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly to the United States, the various phases of <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research in the EU are
subject to significant regulatory controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are performed to demonstrate the
health or environmental safety of new chemical or biological substances. <FONT STYLE="white-space:nowrap">Non-clinical</FONT> (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice, or GLP,
as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). These GLP standards reflect the Organization for Economic <FONT
STYLE="white-space:nowrap">Co-operation</FONT> and Development requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials of medicinal products in the EU must be
conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on Good Clinical Practices, or GCP, as well as the applicable
regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The
sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR,
which was adopted in April 2014 and repealed the EU Clinical Trials Directive, became applicable on January&nbsp;31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further
implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the EU Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state in which
the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single
application for multi-center trials. The CTR allowed sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other
things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as
well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is
communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicines
used in clinical trials must be manufactured in accordance with Good Manufacturing Practice, or GMP. Other national and <FONT STYLE="white-space:nowrap">EU-wide</FONT> regulatory requirements may also apply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Marketing Authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market our product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More
concretely, in the EU, medicinal product candidates can only be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialized after obtaining an MA. To obtain an MA, an applicant must submit an MAA either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the
procedures administered by competent authorities in the EU member states (decentralized procedure or mutual recognition procedure) for obtaining an MA in multiple EU Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure based on the opinion of the Committee
for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the EU. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines
produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products) and products with a new active substance
indicated for the treatment of certain diseases, including products for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for
products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific, or technical innovation or which are in the interest of public health in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the maximum timeframe for the evaluation of an MAA by the EMA is 210&nbsp;days, excluding clock stops, when
additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated evaluation
might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from a public health perspective and in particular from the point of view of therapeutic innovation. If the CHMP accepts such request, the time limit of
210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.
At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 67 days from the date of the CHMP opinion, the European Commission will adopt
its final decision on the MAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover
their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be
recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the
decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member
state. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Periods of Authorization and Renewals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A MA has an initial validity of five years. The MA may be renewed after five years on the basis of a
<FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the relevant EU member state for a nationally authorized product. To this end, the MA holder must provide the EMA or the
competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. Once renewed, the MA is
valid for an unlimited period, unless the European Commission or the competent authorities of the relevant member states decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period. Any
authorization which is not followed by the actual placing of the medicinal product on the EU market (for centrally-authorized products) or on the market of the authorizing EU member state (for nationally-authorized products) within three years after
authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> &#8220;sunset clause&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Data and Market Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, innovative medicinal products approved on the basis of a complete and independent data package generally receive eight years of data
exclusivity and an additional two years of market exclusivity upon grant of an MA. The data exclusivity period prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the innovator&#8217;s
preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar (abbreviated) MA, for a period of eight years from the date on which the reference product was first authorized in the
EU. During an additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar medicinal product
can be placed on the EU market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">10-year</FONT> period will be extended to a maximum of 11 years if, during the first eight years of those 10 years, the MA
holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. There is no
guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the
prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained an MA based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical
tests and clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan Medicinal Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A
medicinal product can be designated as an orphan if its sponsor can establish that: (1)&nbsp;the product is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition, (2) either (i)&nbsp;such
condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii)&nbsp;without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate sufficient
return to justify the necessary investment in its development; (3)&nbsp;there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the EU or, if such method exists, the product
would be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An orphan designation provides a number of benefits, including fee
reductions, regulatory assistance, and the possibility to apply for a centralized EU MA. Upon grant of an MA, orphan medicinal products are entitled to a <FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity, which means that
the EMA and the competent authorities of the EU member states cannot accept another MAA, or grant an MA, or accept an application to extend an MA for a similar medicinal product for the same indication for a period of ten years. A &#8220;similar
medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of market
exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan, or PIP. No extension to any supplementary protection certificate, or SPC, can be granted on the basis of
pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The orphan exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets
the criteria for which it received orphan destination, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the
threshold. Additionally, an MA may be granted to a similar product for the same indication as an authorized orphan product at any time if (i)&nbsp;a second applicant can establish that its product, although similar to the authorized orphan product,
is safer, more effective or otherwise clinically superior; (ii)&nbsp;the MA holder for the authorized orphan product consents to a second medicinal product application; or (iii)&nbsp;the MA holder for the authorized product cannot supply enough
orphan medicinal product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pediatric Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No 1901/2006 provides that prior to obtaining an MA in the EU, applicants have to demonstrate compliance with all measures
included in a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO, and covering all subsets of the pediatric population, unless the PDCO has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class
waiver, or (3)&nbsp;a deferral for one or more of the measures included in the PIP. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which an MA is being sought. Products that
are granted an MA with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a <FONT STYLE="white-space:nowrap">six-month</FONT> extension of the protection under a SPC provided an application for such
extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a <FONT
STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and
submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the European Commission and/or the competent regulatory authorities of the member states. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, or QPPV, who
is responsible for the establishment and maintenance of that system, and oversees the safety profiles of medicinal products and any emerging safety concerns. Key obligations include expedited reporting of suspected serious adverse reactions and
submission of periodic safety update reports, or PSURs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new MAA must include a risk management plan, or RMP, describing the risk
management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or
post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with
physicians, misleading and comparative advertising, and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited in the EU. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in the EU.
Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the EU member states plus
Norway, Liechtenstein, and Iceland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with EU and member state laws that apply to the conduct of clinical trials,
manufacturing approval, authorization of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption, or with other
applicable regulatory requirements may result in administrative, civil, or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant an MA, product withdrawals and recalls, product
seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing, or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Reform of the Regulatory Framework in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe
initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data
protection, revising the eligibility for expedited pathways, etc.) was published on April&nbsp;26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and Council of the EU and the proposals may therefore be
substantially revised before adoption, which is not anticipated before early 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Brexit and the Regulatory Framework in the United
Kingdom </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the end of the Brexit transition period on January&nbsp;1, 2021 and the implementation of the Windsor Framework on
January&nbsp;1, 2025, the United Kingdom, or UK, is not generally subject to EU laws in respect of medicines. The EU laws that have been transposed into UK law through secondary legislation remain applicable in the UK however, new legislation such
as the (EU) CTR is not applicable in the UK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Medicines and Medical Devices Act 2021, the Secretary of State or an
&#8216;appropriate authority&#8217; have delegated powers to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which
aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials, and medical devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the UK&#8217;s standalone medicines and
medical devices regulator. As a result of the Ireland/Northern Ireland protocol, different rules applied in Northern Ireland than in England, Wales, and Scotland (together, &#8220;Great Britain&#8221;, or GB), which continued to follow the EU
regulatory regime. However, on January&nbsp;1, 2025 a new arrangement called the &#8220;Windsor Framework&#8221; came into effect and reintegrated Northern Ireland under the regulatory authority of the MHRA with respect to medicinal products. The
Windsor Framework removes EU licensing processes and EU labeling and serialization requirements in relation to Northern Ireland and introduces a <FONT STYLE="white-space:nowrap">UK-wide</FONT> licensing process for medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as
amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. In April 2025, the UK introduced the Medicines for Human Use (Clinical Trials) (Amendment) Regulations. These changes, which will take full
effect from April 2026, aim to create a streamlined, risk-proportionate system that accelerates approvals while maintaining robust safety standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and
risk-proportionate approach to initial clinical trial applications for Phase 4 and <FONT STYLE="white-space:nowrap">low-risk</FONT> Phase 3 clinical trial applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAs in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. All existing EU MAs for centrally authorized
products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January&nbsp;1, 2021, unless the MA holder chose to <FONT STYLE="white-space:nowrap">opt-out.</FONT> Under the terms of the Windsor
Framework, these licenses became valid for the whole of the UK from January&nbsp;1, 2025. In order to use the centralized procedure to obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, after
Brexit, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the
UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, a
<FONT STYLE="white-space:nowrap">150-day</FONT> assessment (subject to clock-stops) and a rolling review procedure. The rolling-review procedure permits the separate or joint submission of quality,
<FONT STYLE="white-space:nowrap">non-clinical,</FONT> and clinical data to the MHRA which can be reviewed on a rolling basis. After an application under the rolling-review procedure has been validated, the final decision should be received within
100 days (subject to clock-stops). In addition, since January&nbsp;1, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of MAAs. Pursuant to the IRP, the MHRA will take into account the
expertise and decision-making of trusted regulatory partners (e.g. the medicines regulatory authorities in Australia, Canada, Switzerland, Singapore, Japan, the U.S.A. and the EMA in the EU). The MHRA will conduct a targeted assessment of IRP
applications but retain the authority to reject applications if the evidence provided is considered insufficiently robust. Applications should be decided within a maximum of 60 days if there are no major objections identified that cannot be resolved
within such 60 day period and the approval from the trusted regulatory partner selected has been granted within the previous 2 years. If there are such major objections identified or such approval hasn&#8217;t been granted within the previous 2
years, then the relevant timeframe for the MHRA decision is within 110 days. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line
extensions, variations, and renewals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the UK, the initial duration of an MA is five years and following renewal will be valid for an
unlimited period unless the MHRA decides on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Any authorization which is not followed by the actual placing of the medicine on the market in the UK
(or GB, if the MA is only valid in GB) within three (3)&nbsp;years shall cease to be in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no
<FONT STYLE="white-space:nowrap">pre-MA</FONT> orphan designation in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored
for the market, i.e., the prevalence of the condition in the UK, rather than the EU, must not be more than five in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the
product in the UK. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect our ability to operate, and our proposed sales, marketing, and distribution strategies,
include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order, or recommendation of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved,
imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the federal False Claims Act, or FCA (discussed below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the FCA and civil monetary penalty laws, which impose
criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal healthcare programs that are false or
fraudulent; knowingly making or causing a false </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an
obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private
individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty
of violating these statutes without actual knowledge of the statutes or specific intent to violate them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failing to take appropriate steps to keep consumers&#8217; personal information secure could constitute an unfair
act or practice in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act, 15 U.S.C. &#167; 45(a) or similar state laws. The Federal Trade Commission, or FTC, and state regulators expect a company&#8217;s data
security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities.
Individually identifiable health information is considered sensitive data that merits stronger safeguards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations requires manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to physicians (defined to
include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other licensed healthcare professionals (i.e., physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered
nurse anesthetists, and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require manufacturers to calculate and report complex pricing
metrics in an accurate and timely manner to government programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or services
reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing
information, such as the tracking and reporting of gifts, compensations, and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales
representatives. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal, state, and foreign enforcement bodies are continuing to increase their scrutiny of
interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. If our operations are found to be in violation of any of such
laws or any other governmental regulations that apply, we may be subject to significant penalties, including, without limitation, administrative, civil, and criminal penalties, damages, fines, disgorgement, contractual damages, the curtailment or
restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs, reputational harm, diminished profits and future earnings, and individual imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Privacy and Data Security </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
ordinary course of business, we and the third parties upon which we rely collect, receive, store, or otherwise process personal data, including information we may collect about participants in our clinical trials. This personal data can also include
data that is considered &#8220;sensitive&#8221; personal data under privacy laws, policies, or agreements to which we are subject. Accordingly, we are, or may be become, subject to numerous, evolving privacy and data security obligations, including
global, federal, state, and local laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations related to privacy and data security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These privacy and data security laws are evolving and may impose potentially conflicting obligations. Such obligations may include, without
limitation, federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., the Federal Trade Commission Act). At the
state level, numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording individuals certain rights concerning their
personal data. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. Additionally, a smaller number of states have passed or are
considering laws governing the privacy of consumer health data. While existing state consumer privacy laws provide exemptions for data processed in the context of clinical trials, the continued development of complex requirements at the state level
may further complicate compliance efforts and may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products, and are examples
of the increasingly stringent and evolving regulatory frameworks related to personal data processing, as more fully discussed in the section titled &#8220;Risk Factors.&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, to the extent we collect personal data outside of the United States, through clinical trials or otherwise, we are, or may
become, subject to foreign data and data security laws, such as the European Union&#8217;s General Data Protection Regulation 2016/679, or EU GDPR, and other national data protection legislation in force in relevant EEA Member States, and the EU
GDPR as it forms part UK law by virtue of section 3 of the European Union (Withdrawal) Act 2018, or UK GDPR. Foreign privacy and data security laws impose significant and complex compliance obligations on entities that are subject to those laws and
may impose significant sanctions for <FONT STYLE="white-space:nowrap">non-compliance</FONT> (including fines of up to the greater of 20&nbsp;million Euros (17.5&nbsp;million GBP for the UK) or 4% of worldwide annual revenue), as more fully discussed
in the section titled &#8220;Risk Factors.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the costs associated with their prescription. Therefore, adequate coverage and reimbursement from such third-party payors are critical to new and ongoing product
acceptance. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement
levels, for the product. Factors payors consider in determining coverage and reimbursement are based on whether the product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective, and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage
and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement
rate that the payor will pay for the product once coverage is approved. A third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Therefore, even if coverage is
provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment. Further, one payor&#8217;s determination to provide coverage for a product does not
assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost- effectiveness of
medical products and services and imposing controls to manage costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining coverage and
reimbursement, as the process of determining coverage and reimbursement is often time consuming and costly. In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Moreover, coverage may be more limited than the
purposes for which the product is approved by FDA or regulatory authorities in other countries. Additionally, companies may also need to provide discounts to purchasers, private health plans, or government healthcare programs. Third-party payors may
limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. Third-party payors could determine that our product candidates are not medically
necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and our financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state, and foreign governments, and the prices of products have
been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products,
government control, and other changes to the healthcare system in the United States including the relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.
Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Net prices for drugs may be reduced by mandatory
discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United&nbsp;States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, third-party payors are increasingly reducing reimbursements for drugs and services and implementing measures to control
utilization of drugs (such as requiring prior authorization or step therapy for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage, among other things). Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged
for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Even if favorable coverage and reimbursement status is
attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Moreover, payment methodologies may be subject to changes in healthcare
legislation and regulatory initiatives. For example, the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened
governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things,
bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will
continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many pharmaceutical manufacturers must calculate and report
certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by
mandatory discounts or rebates required by government healthcare programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit
a company&#8217;s revenue generated from the sale of any approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring coverage and adequate
payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval
for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only
after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or
<FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU Member States have the option to restrict the range of products for which their national
health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the
profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions.
Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises
experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political,
economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage
between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will
allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and Future Healthcare Reform
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system
that could impact our ability to sell our products profitably. For example, in March 2010, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA
contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and changes to fraud and abuse laws. For example, the ACA, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%
of the average manufacturer price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required collection of rebates for drugs paid by Medicaid managed care organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer
50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (later increased to 70%); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or
importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its
enactment, there have been judicial, administrative, executive, and legislative challenges to certain aspects of the ACA as well as executive orders related to the ACA&#8217;s implementation. It is unclear how healthcare reform measures of the
current presidential administration or other efforts, if any, to challenge repeal or replace the ACA, will impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers and health plans (including Part D prescription drug
plans) of up to 2% per fiscal year, effective April&nbsp;1, 2013, and which will stay in effect through 2032, unless Congress takes additional action. Additionally, American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare
payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Moreover, the One Big Beautiful Bill Act, which was enacted in July 2025, imposes
significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid. These new laws and regulatory changes may result in
additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on prescribers of our drugs, if approved, and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically,
there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, as of January&nbsp;1, 2024, the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug
rebate cap of 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs. More recently, the Inflation Reduction Act of 2022, or IRA, among other things, directed HHS to negotiate the price of certain
high-expenditure, single-source drugs and biologics covered under Medicare, and created civil monetary penalties and an excise tax for manufacturers that fail to comply with the drug price negotiation requirements. The IRA also imposed rebates for
certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation, and, beginning in 2025, replaced the Part D coverage gap discount program with a new discounting program. The IRA
permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August&nbsp;15, 2024, HHS announced the negotiated prices for the first ten drugs that will be subject to price negotiations, and
on January&nbsp;17, 2025, HHS announced 15 additional drugs subject to negotiations. The Medicare drug price negotiation program is currently subject to multiple legal challenges. The impact of these challenges, as well as any other future
challenges, is uncertain, and it is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Trump administration is pursuing a
<FONT STYLE="white-space:nowrap">two-fold</FONT> strategy to reduce drug costs in the U.S. While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical
industry and on our ability to receive adequate revenues for product candidates, if approved. On the one hand, President Trump has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as
most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries. In response, multiple manufacturers have reportedly entered into confidential pricing agreements with the federal
government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to impose drug pricing policies, although proposed regulations have not yet been published. Even regulatory proposals or executive actions that are
ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. In addition, pharmaceutical pricing and marketing has long been the subject of considerable discussion in Congress and among policymakers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, FDA released its implementing regulations regarding section 804 Importation Programs under the Medicare Prescription Drug Improvement
and Modernization Act of 2003, which create a pathway for states to submit proposals to import certain drugs from Canada. On January&nbsp;5, 2024, the FDA authorized a Florida program to import prescription drugs from Canada for a period of two
years to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. If broadly implemented, importation of drugs under this program from Canada may materially and
adversely affect the price we receive for any of our product candidates. Additionally, it is unclear what steps the current presidential administration will take with respect to increasing importation of drugs at the state or federal level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states have also been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their
prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although a number of these and other proposed measures
may require authorization through additional legislation to become effective, and the current presidential administration may reverse or otherwise change these measures, both the current presidential administration and Congress have indicated that
they will continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar political, economic, and regulatory developments are
occurring in the EU and may affect the ability of pharmaceutical companies to profitably commercialize their products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state
level may result in significant additional requirements or obstacles. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter
for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general,
however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens
on those wishing to develop and market products, this could restrict or regulate post-approval activities and affect the ability of pharmaceutical companies to commercialize their products. In international markets, reimbursement and healthcare
payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, potential reductions in prices and changes in reimbursement levels could be the
result of different factors, including reference pricing systems, parallel distribution, and parallel trade. It could also result from the application of external reference pricing mechanisms, which consist of arbitrage between <FONT
STYLE="white-space:nowrap">low-priced</FONT> and high-priced countries. Reductions in the pricing of our medicinal products in one EU member state could affect the price in other EU member states and, thus, have a negative impact on our financial
results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Technology Assessment, or HTA, of medicinal products in the EU is an essential element of the pricing and reimbursement
decision-making process in a number of EU member states. The outcome of HTA has a direct impact on the pricing and reimbursement status granted to the medicinal product. A negative HTA by a leading and recognized HTA body concerning a medicinal
product could undermine the prospects to obtain reimbursement for such product not only in the EU member state in which the negative assessment was issued, but also in other EU member states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, Directive 2011/24/EU was adopted at the EU level. This Directive establishes a voluntary network of national authorities or bodies
responsible for HTA in the individual EU member states. The network facilitates and supports the exchange of scientific information concerning HTAs. Further to this, on December&nbsp;13, 2021, Regulation No 2021/2282 on HTA, amending Directive
2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e. oncology and advanced therapy medicinal products as of 2025, orphan
medicinal products as of 2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at
the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the
innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies
early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health
technology, and making decisions on pricing and reimbursement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Boston, Massachusetts, where we lease and occupy approximately 25,265 square feet of office space.
Our Boston lease expires in October 2030. We also license and occupy approximately 1711 square feet of lab space in Boston, Massachusetts. This license will expire in January 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our existing facilities in Boston are sufficient for our needs for the foreseeable future. To meet the future needs of our
business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of September&nbsp;30, 2025, we had 55 full-time employees. Within our workforce, 36 employees are engaged in research and development and 19 are engaged in business development, finance, legal, and general management and administration. Our human
capital resources objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward
personnel through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. None of our
employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal
proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and
prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information regarding our executive officers and directors as of the date of this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael C. Chen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lana Gladstein, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Green</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony Loebel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lauren A. White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director and Board Chair</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Daphne
Zohar</B><B>.</B> Ms.&nbsp;Zohar was our founder and has served as our President and Chief Executive Officer and as a member of our board of directors since April 2024. Prior to joining us, Ms.&nbsp;Zohar served as Founder, Chief Executive Officer
and as a member of the board of directors of PureTech (Nasdaq/LSE: PRTC), since its formation in June 2015 to April 2024, and since 2005 at PureTech&#8217;s predecessor entity. A successful entrepreneur, Ms.&nbsp;Zohar created PureTech, assembling a
leading team and scientific network to help implement her vision for the company, and was a key participant in fundraising, business development and establishing the underlying programs and platforms that have resulted in PureTech&#8217;s
substantial pipeline of products and product candidates. She also <FONT STYLE="white-space:nowrap">co-founded</FONT> PureTech&#8217;s entities, including Karuna Therapeutics, Inc. (formerly Nasdaq: KRTX), which was acquired by Bristol Myers Squibb
in March 2024. Ms.&nbsp;Zohar was a key driver in PureTech&#8217;s productive R&amp;D engine, which led to 28 new medicines and a clinical success rate at PureTech and founded entities that was around six times better than the industry average
during her tenure. Ms.&nbsp;Zohar is a senior advisor to PureTech and serves on the BIO (Biotechnology Innovation Organization) Board Executive Committee. Ms.&nbsp;Zohar is also founder&nbsp;&amp; <FONT STYLE="white-space:nowrap">co-host</FONT> of
the weekly podcast &#8220;Biotech Hangout.&#8221; Ms.&nbsp;Zohar received a B.S. from Northeastern University. Our board of directors believes that Ms.&nbsp;Zohar is qualified to serve as a member of our board of directors because of her extensive
experience and leadership in the biopharmaceutical industry and her role as our company&#8217;s founder and chief executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Michael C. Chen, Ph.D.</B><I></I>&nbsp;Dr. Chen has served as our Chief Scientific Officer since May 2024. Prior to joining us, Dr. Chen
served various roles at PureTech from 2016 to May 2024, most recently as Head of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Innovation from 2016 to May 2024, where he oversaw the rapid advancement of the neuropsychiatric medicines that led to our launch. From 2016 to 2019, Dr. Chen was also <FONT
STYLE="white-space:nowrap">co-founder</FONT> and Head of Research and Strategy at Sonde Health, Inc., a company developing vocal biomarkers for depression and other neuropsychiatric disorders. He was a postdoctoral fellow at Beth Israel Deaconess
Medical Center and Harvard Medical School, Department of Neurology. Dr. Chen completed his Ph.D. at Stanford University, focusing on the neurobiological mechanisms of depression and sleep disorders. He received a B.A. from Yale University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Lana Gladstein, J.D.</B> Ms.&nbsp;Gladstein has served as our General Counsel since June 2024. Prior to joining us, she served as the Group
General Counsel at APRINOIA Therapeutics, Inc. (Nasdaq: APRI) from May 2023 to June 2024. From June 2022 to May 2023, she also served as Chief Legal Officer of Recipharm AB North America from June 2022 to May 2023, Chief Legal Officer and General
Counsel of Arranta Bio (acquired by Recipharm) from November 2019 to May 2023 and Executive Vice President and General Counsel of Brammer Bio (acquired by Thermo Fisher Scientific) from March 2017 to October 2019. Prior to that, Ms.&nbsp;Gladstein
was a partner at the law firm of Nutter McClennen&nbsp;&amp; Fish LLP and Pepper Hamilton LLP. Ms.&nbsp;Gladstein holds a J.D. from Northeastern University School of Law and a B.A. in Biology from Brandeis University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Eric Green. </B>Mr.&nbsp;Green has served as our Chief Operating Officer since May 2024. Prior to joining us, Mr.&nbsp;Green was Senior
Vice President, Head of Development Programs at Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), or Alnylam, from February 2021 to April 2024 where he led a team responsible for global development and
<FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities for a portfolio of development stage programs. From February 2019 to January 2021 he served as Senior Vice President, Global General Manager for the TTR Franchise at Alnylam.
Mr.&nbsp;Green held former roles at biopharmaceutical companies such as Synageva BioPharma Corp., Infinity Pharmaceuticals, Inc., Genzyme Corporation, and Pfizer Inc. (NYSE: PFE). He received an M.B.A. from MIT Sloan School of Management and an M.S.
in chemical engineering from MIT School of Engineering. He earned a B.S. in chemical engineering from University of Michigan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Antony
Loebel, M.D. </B>Dr.&nbsp;Loebel has served as our Chief Medical Officer and President of Clinical Development since June 2024. He was previously the President and Chief Executive Officer of Sunovion Pharmaceuticals Inc. from April 2019 to June
2023, and served as Chief Medical Officer from 2011 to March 2019. During his tenure at Sunovion, Dr.&nbsp;Loebel played a key role in the company&#8217;s growth to over $3.5&nbsp;billion in total revenue and was instrumental in the development and
commercialization of Latuda for the treatment of bipolar depression and schizophrenia. Prior to his time at Sunovion, he held senior roles in research and development and medical affairs at Dainippon Sumitomo Pharma America and Pfizer Inc. (NYSE:
PFE). Dr.&nbsp;Loebel earned his M.D. from the University of Washington in Seattle, completed his psychiatry residency at the Zucker Hillside Hospital in New York, and is board certified in psychiatry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Lauren A. White.</B><I></I>&nbsp;Ms.&nbsp;White has served as our Chief Financial Officer since November 2024. Prior to joining us,
Ms.&nbsp;White served as the Chief Financial Officer and Treasurer of ImmunoGen, Inc. (formerly Nasdaq: IMGN), or ImmunoGen, from September 2023 to June 2024 prior to its acquisition by AbbVie. Prior to that, she served as Chief Financial Officer,
Treasurer, and Principal Accounting Officer at C4 Therapeutics, Inc. (Nasdaq: CCC) from June 2021 to September 2023, and held roles of increasing responsibility at Novartis AG (NYSE: NVS), most recently as Vice President, Finance, and Global Head of
Business Planning and Analysis at Novartis Institutes for BioMedical Research from July 2017 to June 2021. Ms.&nbsp;White earned an M.B.A. from Harvard Business School and a B.S. from the Carroll School of Management at Boston College. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Steven M. Paul, M.D.</B> Dr. Paul has been a member and chair of our board of directors since April 2024. Dr.&nbsp;Paul was one of our
founders and has also served as our senior advisor since February 2024. From August 2018 to January 2024, Dr. Paul served in senior leadership roles at Karuna Therapeutics, Inc. (Nasdaq: KRTX, prior to its recent acquisition by Bristol Myers Squibb
Company), including as Chief Scientific Officer and President of Research and Development from January 2023 to January 2024, and President, Chief Executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Officer, and Chairman of the board of directors from August 2018 to January 2023. Dr. Paul has also served as a Venture Partner at Third Rock Ventures since 2010. Dr. Paul is also board certified
by the American Board of Psychiatry and Neurology. Dr. Paul has served on the board of directors of Rapport Therapeutics, Inc. (Nasdaq: RAPP) since December 2022 and Sage Therapeutics, Inc. (Nasdaq: SAGE) from September 2011 until June 2024 and is
also the chairman of the board of directors of the Foundation for the National Institutes of Health (FNIH). Previously, Dr. Paul served on the boards of directors of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) from September 2010 to April 2022,
Voyager Therapeutics, Inc. (Nasdaq: VYGR) from September 2014 to June 2022 and Karuna Therapeutics, Inc. from March 2018 to March 2024. Dr. Paul also previously spent 17 years at Eli Lilly and Company (NYSE: LLY), during which time he held several
leadership roles, including Executive Vice President for Science and Technology, and President of the Lilly Research Laboratories. Prior to Lilly, Dr. Paul spent 18 years at the National Institute of Mental Health (NIMH) where he served as
Scientific Director. Dr. Paul received a Bachelor of Arts degree in biology and psychology from Tulane University and Master of Science and Doctor of Medicine degrees from the Tulane University School of Medicine. Our board of directors believes
that Dr. Paul is qualified to serve on our board of directors due to his numerous leadership roles and experience in the pharmaceutical industry and his expertise in neuroscience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>James I. Healy, M.D, Ph.D.</B> Dr. Healy has been a member of our board of directors since April 2024. Dr.&nbsp;Healy has served as
Managing Partner of Sofinnova Investments, Inc. since June 2000. Dr. Healy has served on the boards of directors of Rapport Therapeutics, Inc. (Nasdaq: RAPP) since August 2023, ArriVent Biopharma, Inc. (Nasdaq: AVBP) since March 2023 and BioAge
Labs, Inc. (Nasdaq: BIOA) since February of 2024. , Previously, Dr. Healy served on numerous public company boards of directors including Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) from January 2021 until September 2024, Natera, Inc. (Nasdaq: NTRA)
from November 2014 until June 2025, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) from November 2017 until September 2025, Ascendis Pharma A/S (Nasdaq: ASND) from November 2014 to May 2022, Amarin Corporation PLC (Nasdaq: AMRN) from May 2008 to December
2016, CinCor Pharma, Inc. (Nasdaq: CINC, prior to its recent acquisition by AstraZeneca PLC) from May 2019 to February 2023, Coherus BioSciences, Inc. (Nasdaq: CHRS) from February 2014 to February 2022, Karuna Therapeutics, Inc. (Nasdaq: KRTX, prior
to its recent acquisition by Bristol Myers Squibb Company) from June 2019 to March 2024, Iterum Therapeutics plc (Nasdaq: ITRM) from November 2015 to February 2020, ObsEva SA (Nasdaq: OBSEF) from August 2013 to May 2021, and NuCana PLC (Nasdaq:
NCNA) from March 2014 to April 2022. He also previously served as a director on the Board of the National Venture Capital Association (NVCA) and the Board of the Biotechnology Industry Organization (BIO). Dr. Healy holds Bachelor of Arts degrees in
molecular biology and Scandinavian studies from the University of California, Berkeley, and Doctor of Medicine and Doctor of Philosophy degrees in immunology from Stanford University School of Medicine. Our board of directors believes that Dr. Healy
is qualified to serve on our board of directors due to his extensive experience and leadership roles in the biopharmaceutical industry and expertise in healthcare investing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Robert J. Hombach.</B> Mr.&nbsp;Hombach has been a member of our board of directors since March 2025. Mr.&nbsp;Hombach served as the
Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta (NYSE: BXLT), a global biopharmaceutical company, until it was acquired by Shire plc. in 2016. Mr.&nbsp;Homach has served on the board of directors of Henry
Schein Inc (Nasdaq: HSIC) since February, 2025, BioMarin Pharmaceutical Inc (Nasdaq: BMRN) since September 2017, Embecta Corp. (Nasdaq: EMBC) since April, 2022, Aptinyx Inc. from April, 2018 to December, 2023, CarMax Inc, (NYSE: KMX) from March,
2018 to June, 2022. He was instrumental in Baxalta&#8217;s successful spin off from its parent company, Baxter (NYSE: BAX), where he previously served as Corporate Vice President and Chief Financial Officer. In addition to his board positions at
BioMarin and Henry Schein, Mr.&nbsp;Hombach is the Chair of the Audit Committee at Embecta, a global diabetes care company spun out of Becton Dickinson, and has held previous board positions at several other companies including Naurex, Inc., which
was acquired by Allergan in 2015. Mr.&nbsp;Hombach received an MBA from Northwestern University&#8217;s J.L. Kellogg Graduate School of Management, and a BS in Finance cum laude from the University of Colorado. Our board of directors believes that
Mr.&nbsp;Hombach is qualified to serve on our board of directors due to his significant leadership experience in the biopharmaceutical industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Robert Nelsen.</B> Mr.&nbsp;Nelsen has been a member of our board of directors since
April 2024. Mr.&nbsp;Nelsen <FONT STYLE="white-space:nowrap">co-founded</FONT> ARCH Venture Partners, L.P., a venture capital firm focused on early-stage technology companies, in 1986 and has served as a Managing Director of ARCH Venture Partners or
its affiliated entities since 1994. Mr.&nbsp;Nelsen has served on the board of directors of Prime Medicine, Inc. (Nasdaq: PRME) since September 2020, Vir Biotechnology, Inc. (Nasdaq: VIR) since April 2016, Sana Biotechnology, Inc. (Nasdaq: SANA)
from since October 2018, Lyell Immunopharma, Inc. (Nasdaq: LYEL) since September 2018, each a U.S. publicly traded biotechnology company. Mr.&nbsp;Nelsen has served as the Chairman and as a member of the boards of directors of Hua Medicine, Inc., a
drug development company, since April 2010 and Brii Biosciences, Inc., a biotechnology company, since June 2018, each a Hong Kong publicly listed company, and currently serves on the board of directors of a number of private companies.
Mr.&nbsp;Nelsen previously served on the board of directors of a number of public biotechnology companies, including Revolution Healthcare Acquisition Corp. from 2021 to 2022, Denali Therapeutics Inc. from 2015 to 2022, Unity Biotechnology, Inc.
from 2015 to December 2020, Agios Pharmaceuticals, Inc. from 2007 to June 2017, Syros Pharmaceuticals, Inc. from 2012 to June 2018, Juno Therapeutics, Inc. (acquired by Celgene Corporation in January 2018) from 2013 to March 2018, Sienna
Biopharmaceuticals, Inc. from 2015 to September 2018 and Gossamer Bio, Inc. from 2017 to December 2018 (prior to its initial public offering). Mr.&nbsp;Nelsen received his M.B.A. from the University of Chicago and his B.S. from the University of
Puget Sound in Economics and Biology. Our board of directors believes that Mr.&nbsp;Nelsen is qualified to serve on the Board due to his significant venture capital experience as a director and investor in the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Sandra E. Peterson.</B> Ms.&nbsp;Peterson has been a member of our board of directors since November 2024. She has served as an Operating
Partner at Clayton Dubilier&nbsp;&amp; Rice, or CD&amp;R, a private investment firm, since April 2019 where she invests in life sciences and consumer companies and oversees technology initiatives to enhance performance of the firm&#8217;s portfolio
companies. Prior to joining CD&amp;R, Ms.&nbsp;Peterson was the Group Worldwide Chair for Johnson&nbsp;&amp; Johnson, or J&amp;J, where she led J&amp;J&#8217;s consumer and medical devices businesses and was responsible for global operating
infrastructure, technology, supply chain, quality, and key strategic initiatives from 2012 to 2018. Ms.&nbsp;Peterson currently serves as Lead Independent Director of Microsoft Corp. (Nasdaq: MSFT) since March 2023 and a member of its board of
directors since December 2015. She also serves as Executive Chairwoman of the board of directors of Volastra Therapeutics since October 2019. Ms.&nbsp;Peterson received her M.P.A. from Princeton University and a B.A. from Cornell University. Our
board of directors believes that Ms.&nbsp;Peterson is qualified to serve on our board of directors due to her extensive knowledge of strategy and business development in the life sciences industry and her wide-ranging experience in leadership
positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Denice Torres, J.D.</B> Ms. Torres has been a member of our board of directors since May 2024. Ms. Torres is the founder
and Chief Executive Officer of The Ignited Company, a consulting firm she founded in November 2017, and is also the founder of The Mentoring Place, a nonprofit organization established in 2017. From December&nbsp;2004 to December&nbsp;2017, Ms.
Torres served in senior leadership roles at Johnson &amp; Johnson, including President of J&amp;J Neuroscience, President of J&amp;J Consumer Health, and Chief Strategy and Transformation Officer of the J&amp;J Medical Device Sector. Prior to that,
from 1990 to 2004, Ms. Torres held various leadership positions at Eli Lilly and Company, including Executive Director of Global Neuroscience and Director of U.S.&nbsp;Women&#8217;s Health. Ms. Torres currently serves on the board of directors of
Celldex Therapeutics Inc. (Nasdaq: CLDX), Glaukos&nbsp;Corp. (Nasdaq: GKOS), National Resilience Inc., and ByHeart Inc. Ms. Torres previously served on the boards of Karuna Therapeutics, Inc., 2seventy bio, Inc., Thirty Madison, bluebird bio, Inc.,
and Surface Oncology, Inc. Ms.&nbsp;Torres holds an M.B.A. from the University of Michigan, a J.D. from Indiana University School of Law, a B.S. in Psychology from Ball State University, and an M.A. in the Study of Happiness from Centenary
University. She is currently pursuing a Ph.D. in Happiness Studies at Centenary University. Our board of directors believes that Ms. Torres is qualified to serve on our board of directors due to her extensive leadership experience in the
pharmaceutical, biotechnology, and consumer health industries and her expertise in neuroscience, strategy, and business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>David Wheadon, M.D.</B> Dr.&nbsp;Wheadon has been a member of our board of directors since July 2024. He served as Senior Vice President,
Global Regulatory Affairs, Patient Safety, and Quality Assurance for AstraZeneca Pharmaceuticals from 2014 to 2019 and as Executive Vice President, Research and Advocacy at the Juvenile </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Diabetes Research Foundation from 2013 to 2014. From 2009 to 2013, Dr.&nbsp;Wheadon served as Senior Vice President, Scientific and Regulatory Affairs and as a member of the Management Committee
of the Pharmaceutical Research and Manufacturers of America, or PhRMA. Prior to his joining PhRMA, Dr.&nbsp;Wheadon held senior regulatory and clinical development leader roles at Abbott Laboratories and GlaxoSmithKline plc. Dr.&nbsp;Wheadon began
his career as a clinical research physician in neuroscience at Eli Lilly&nbsp;&amp; Company. Dr.&nbsp;Wheadon has served on the board of directors of Indivior, PLC (Nasdaq: INDV) since June 2024, Vaxart, Inc. (Nasdaq: VXRT) since April 2021,
and&nbsp;Sotera Health, Inc. (Nasdaq:&nbsp;SHC) since May 2021. He formerly served on the board of directors of Assertio Holdings, Inc. (formerly Assertio Therapeutics, Inc.), Karuna Therapeutics, Inc., and Chemocentryx, Inc. Dr.&nbsp;Wheadon holds
an A.B. from Harvard College and an M.D. from Johns Hopkins University School of Medicine. He completed his fellowship training in Psychiatry at the Tufts, New England Medical Center. Our board of directors believes that Dr.&nbsp;Wheadon is
qualified to serve as a member of the board of directors due to his leadership roles in the pharmaceutical industry and his extensive experience in regulatory affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Eric Elenko, Ph.D.</B> Dr.&nbsp;Elenko has been a member of our board of directors since April 2024. Dr.&nbsp;Elenko is the <FONT
STYLE="white-space:nowrap">co-founder</FONT> of PureTech Health (Nasdaq: PRTC) where he has served as the President since April 2024. Prior to his current role, Dr.&nbsp;Elenko previously served as PureTech Health&#8217;s Chief Innovation Officer
from June 2015 through April 2024. Prior to serving as Chief Innovation Officer, Dr. Elenko held multiple other leadership roles within PureTech. Prior to joining PureTech Health, Dr.&nbsp;Elenko was a consultant with McKinsey and Company. Dr.
Elenko has served on the Board of Directors of multiple PureTech portfolio companies during his tenure with PureTech. Dr.&nbsp;Elenko received his Ph.D. in biomedical sciences from the University of California, San Diego and his B.A. in biology from
Swarthmore College. Our board of directors believes that Dr.&nbsp;Elenko is qualified to serve on our board of directors because of his extensive understanding of the biotechnology and pharmaceutical industries and his senior management experience.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Jason Pitts, Ph.D.</B> Dr.&nbsp;Pitts has been a member of our board of directors since October 2024. Dr.&nbsp;Pitts has served as
Principal at General Atlantic since December 2024, and prior to such role served in various roles, including Vice President, since March 2021 at General Atlantic, and focuses on investments in the life sciences sector. Prior to joining General
Atlantic, he was a Principal at Sofinnova Investments focused on therapeutics investments from June 2019 to January 2021. Dr.&nbsp;Pitts has also served as a board member of Solve Therapeutics since December 2024, CinCor Pharma, Inc. from October
2021 to February 2023 and Bolt Biotherapeutics, Inc. from July 2020 to January 2021. He received his Ph.D. in neuroscience from The Rockefeller University and a B.S. in neuroscience from Cornell University. Our board of directors believes that
Dr.&nbsp;Pitts is qualified to serve on our board of directors due to his extensive expertise in healthcare investing and experience as a board member of other biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Robert Lyne, LLB.</B> Mr.&nbsp;Lyne is the interim chief executive officer and chief portfolio officer at PureTech. Mr.&nbsp;Lyne is a
seasoned executive with deep experience in life sciences, including his prior role as Chief Executive Officer at Arix Bioscience plc, a transatlantic venture capital company focused on investing in innovative biotechnology companies from April 2021
to December 2023. Mr.&nbsp;Lyne brings more than a decade of experience leading London-listed life science companies and portfolio management, with a strong track record in governance and executive team leadership. Mr.&nbsp;Lyne began his career as
a lawyer at international law firm Bird&nbsp;&amp; Bird LLP in London before moving to Touchstone Innovations, a London listed biotech and technology investor, which was acquired in 2017. Mr.&nbsp;Lyne has a BA from the University of Oxford and an
LLB from Oxford Brookes University. Our board of directors believes that Mr.&nbsp;Lyne is qualified to serve as a member of the board of directors due to his extensive experience and leadership roles in the pharmaceutical industry. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family
relationships among any of our executive officers or directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our board of directors, which currently consists of ten members. The primary
responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain members of our board of directors were elected under the provisions of our amended and restated certificate of incorporation and
agreements with our stockholders. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our
directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance
committee&#8217;s and our board of directors&#8217; priority in selecting board members is the identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability
to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences, and expertise relevant to our growth strategy. Our directors
hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this
offering, and our amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, will also provide that our directors may be removed only for cause by the
affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors,
including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Staggered Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this
prospectus forms a part, will permit our board of directors to establish the authorized number of directors from time to time by resolution. Each director serves until the expiration of the term for which such director was elected or appointed, or
until such director&#8217;s earlier death, resignation or removal. In accordance with our amended and restated certificate of incorporation, our board of directors will be divided into three classes with staggered three-year terms. At each annual
meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three
classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be &#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and their terms
will expire at our first annual meeting of stockholders following this offering, to be held in &#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be &#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and their terms
will expire at our second annual meeting of stockholders following this offering, to be held in &#8195;&#8195;&#8195;&#8195;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will be &#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and their terms
will expire at our third annual meeting of stockholders following this offering, to be held in &#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes
so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the listing standards, requirements and rules of The Nasdaq Stock Market LLC, or the Nasdaq Listing Rules, independent directors must
comprise a majority of our board of directors as a listed company within one year of the listing date. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation,
and nominating and governance committees be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under the
Nasdaq Listing Rules, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of an audit committee of a listed company may not,
other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any
of its subsidiaries, other than compensation for board service; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule
<FONT STYLE="white-space:nowrap">10C-1</FONT> under of the Exchange Act, the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a
relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the
director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
her or his background, employment, and affiliations, including family relationships, our board of directors has determined that&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;do not have relationships that
would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the Nasdaq Listing Rules. Our board of directors
has determined that &#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;, and &#8195;&#8195;&#8195;&#8195; are not independent under applicable rules and regulations of the SEC and the Nasdaq Listing Rules. In making these determinations, our
board of directors considered the current and prior relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in
determining their independence, including the beneficial ownership of our shares by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and the transactions described in the section titled &#8220;Certain Relationships and Related
Person Transactions.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt policies and procedures for director candidates for our nominating and corporate
governance committee, which will provide that factors, such as a candidate&#8217;s character, judgment, skills, education, expertise, and absence of conflicts of interest should be considered in determining director candidates. Our priority in
selection of board members will be identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture
among board members, and their knowledge of our business and understanding of the competitive landscape in which we operate and adherence to high ethical standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure and Board&#8217;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, the role of chair of our board of directors is separated from the role of chief executive officer. We believe that separating these
positions allows our chief executive officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business, while allowing the chairman of our board to lead the board of directors in its
fundamental role of providing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the chief executive officer is required to devote to her position in the
current business environment, as well as the commitment required to serve as our chair of our board of directors, particularly as the board of directors&#8217; oversight responsibilities continue to grow. While our amended and restated bylaws and
corporate governance guidelines will not require that our board chair and chief executive officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and
demonstrates our commitment to good corporate governance. Our board of directors will adopt, effective prior to the completion of this offering, corporate governance guidelines that will provide that the board of directors may appoint a lead
independent director. The lead independent director will be responsible for calling and presiding over separate meetings of the independent directors. The lead independent director will preside over periodic meetings of independent directors, serve
as a liaison between the chair and the independent directors and perform such additional duties as the board of directors may otherwise determine and delegate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks,
including risks relating to our financial condition, development, and commercialization activities, operations, strategic direction, and intellectual property as more fully discussed in the section titled &#8220;Risk Factors.&#8221; Management is
responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of
risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of
directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a
particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or
risks, the chairperson of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk
oversight role, particularly with respect to risk interrelationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will establish upon the completion of this offering an audit committee, a compensation committee, and a nominating and
corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of
directors. Each committee will operate under a written charter that satisfies the application rules and regulation of the SEC and the Nasdaq Listing Rules, which we will post to our website at <I>www.seaporttx.com</I> upon the completion of this
offering. Information contained on, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference. Our board of directors may establish other
committees as it deems necessary or appropriate from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our audit committee will consist
of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and the chair of our audit committee will be&#8195;&#8195;&#8195;&#8195;. Our board of directors has determined that each member of the audit committee is
independent under Nasdaq Listing Rules and Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act and can read and understand fundamental financial statements in accordance with applicable requirements. Our board of directors
has also determined that&#8195;&#8195;&#8195;&#8195;is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. In arriving at these determinations, our board of directors has examined each audit committee
member&#8217;s scope of experience and the nature of their employment in the corporate finance sector. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the audit committee will be to discharge the responsibilities of our
board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered public accounting firm. Specific responsibilities of
our audit committee will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing insurance coverage for our officers and directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the preparation of our annual proxy statement, reviewing with management our financial statements to
be included in our quarterly reports to be filed with the SEC, and reviewing with management the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosures in
our periodic reports filed with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving, or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our major risk exposures, including financial, operational, cybersecurity, competition, legal, and
regulatory exposures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee will operate under a written charter, which will be effective upon the
completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our compensation committee will consist of &#8195;&#8195;&#8195;&#8195;,
&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and the chair of our compensation committee will be&#8195;&#8195;&#8195;&#8195;. Our board of directors has determined that each member of the compensation committee is independent under
the Nasdaq Listing Rules and is a <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT> director&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of our compensation committee will be to discharge the responsibilities of our board of directors in overseeing our
compensation policies, plans, and programs and to review and determine the compensation to be paid to our executive officers, directors, and other senior management, as appropriate. Specific responsibilities of our compensation committee will
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of our chief executive officer, other executive officers, and senior
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation paid to our directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation arrangements with our executive officers and other senior management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, adopting, amending, and terminating incentive compensation and equity plans, severance agreements,
profit sharing plans, bonus plans, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections, and any other compensatory arrangements for our executive officers and other senior management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating, and recommending to our board of directors succession plans for our executive officers;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees, including our
overall compensation philosophy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee will operate under a written charter, which will be
effective upon the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our nominating and corporate governance committee will consist
of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and the chair of our nominating and corporate governance committee will be&#8195;&#8195;&#8195;&#8195;. Our board of directors has determined that each
member of the nominating and corporate governance committee is independent under the Nasdaq Listing Rules, a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and free from any relationship that would interfere with the exercise of his
or her independent judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the nominating and corporate governance committee will be to discharge the
responsibilities of our board of directors with respect to our corporate governance functions and to identify, communicate with, evaluate and recommend candidates for our board of directors. Specific responsibilities of our nominating and corporate
governance committee will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and
nominees recommended by stockholders, to serve on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and making recommendations to our board of directors regarding the composition and chairmanship of
the committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instituting plans or programs for the continuing education of our board of directors and orientation of new
directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and
matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing periodic evaluations of the board of directors&#8217; performance, including committees of the board
of directors and management. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee will operate under a written charter,
which will be effective upon the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt a written code of business conduct and ethics that applies to all our employees,
officers, and directors. This includes our principal executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar functions. The full text of our code of business conduct and ethics
will be posted on our website at <I>www.seaporttx.com</I>. We intend to disclose on our website any future amendments of our code of business conduct and ethics or waivers that exempt any principal executive officer, principal financial officer,
principal accounting officer or controller, persons performing similar functions, or our directors from provisions in the code of business conduct and ethics. Information contained on, or accessible through, our website is not a part of this
prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of the compensation committee is currently, or has been at any time, one of our officers or employees. None of our officers
currently serves, or has served during the last calendar year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation
committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Recovery </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with this offering, we intend to adopt a compensation recovery policy that is compliant with the Nasdaq Listing Rules, as required by the Dodd-Frank Act, to be effective in connection with the effectiveness of the registration statement
of which this prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, provisions in our amended and restated certificate of incorporation and amended and restated bylaws, which will
become effective immediately prior to the completion of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part, respectively, limit or eliminate the personal liability of directors and officers
for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when acting on behalf of the corporation, a director and, or officer exercise an informed business judgment based on all material
information reasonably available to him or her. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director or officer&#8217;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the Delaware General Corporation Law, or DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not limit or eliminate our rights or any stockholder&#8217;s rights to seek
<FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, such as injunctive relief or rescission. These provisions will not alter a director or officer&#8217;s liability under other laws, such as the federal securities laws or other state or
federal laws. Our amended and restated certificate of incorporation that will become effective upon the closing of this offering also will authorize us to indemnify our officers, directors, and other agents to the fullest extent permitted under
Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, our amended and restated bylaws to be effective immediately upon effectiveness of the
registration statement will provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers, employees, and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other
agents, in connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then
the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
secure insurance on behalf of any officer, director, employee, or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether
our amended and restated bylaws permit such indemnification. We intend to obtain such insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the indemnification that
will be provided for in our amended and restated certificate of incorporation and amended and restated bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the
specific indemnification provisions contained in the DGCL. These indemnification agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#8217; fees, expenses,
judgments, fines, and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides
services at our request. We believe that these provisions and agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws
and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we
aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations, and
determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from the programs as summarized in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an emerging growth company and a smaller reporting company, we have opted to comply with the executive compensation disclosure rules
applicable to &#8220;smaller reporting companies,&#8221; as such terms are defined in the rules promulgated under the Securities Act. The compensation provided to our named executive officers for the fiscal year ended December&nbsp;31, 2025, or
Fiscal Year 2025, is detailed in the 2025 Summary Compensation Table and accompanying footnotes and narrative that follow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named
executive officers for Fiscal Year 2025 are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daphne Zohar, our Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;, our&#8195;&#8195;&#8195;&#8195;; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;, our&#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the compensation of our named executive officers has consisted of a combination of base salary, cash incentive compensation, and
long-term incentive compensation, as more fully described below. Our executive officers, like all full-time employees, are eligible to participate in our health, welfare, and retirement benefit plans. As we transition from a private company to a
publicly traded company, we intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2025 Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during Fiscal Year 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)&#8201;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)&#8201;<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation<BR>($)&#8201;<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)&#8201;<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Daphne Zohar</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the aggregate grant date fair value of the shares of restricted stock awarded to
the named executive officers during Fiscal Year 2025, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or FASB ASC Topic 718. Such grant date fair values do not take into account any
estimated forfeitures related to service-based vesting. A discussion of the assumptions used in determining grant date fair value may be found in Note&nbsp;&#8195; to our financial statements for Fiscal Year 2025, included elsewhere in this
prospectus. The amounts reported in this column reflect the accounting cost for the restricted stock award and does not correspond to the actual economic value that may be received by our named executive officers upon the vesting of the awards or
any sale of the underlying securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the aggregate grant date fair value of stock option awards granted to our named
executive officers in Fiscal Year 2025, computed in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. The assumptions used in calculating the grant
date fair values of the option awards reported in this column are set forth in Note&nbsp;&#8195; of our consolidated financial statements for Fiscal Year 2025, included elsewhere in this
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
prospectus. The amounts reported in this column reflect the accounting cost for these option awards and do not correspond to the actual economic value that may be received by our named executive
officers upon the exercise of the option awards or any sale of the underlying securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annual cash incentive bonuses for performance during Fiscal Year 2025 are not calculable as of the latest
practicable date prior to the filing of this prospectus. We expect that such amounts will be determined later in the first quarter of the fiscal year ending December&nbsp;31, 2026 and we will disclose the amount of such bonuses when they are
determined. For more information on these bonuses, see the description of the 2025 cash bonuses below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent &#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to the 2025 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2025 Base Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named
executive officers each receive a base salary to compensate them for services rendered to us. Base salaries are intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, and responsibilities.
Base salaries are expected to be reviewed annually, typically in connection with our annual performance review process, approved by our board of directors or the compensation committee of the board of directors, and may be adjusted from time to time
to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Fiscal
Year 2025, the base salaries for Ms.&nbsp;Zohar,&#8195;&#8195;&#8195;&#8195;, and&#8195;&#8195;&#8195;&#8195;were $&#8195;&#8195;&#8195;&#8195;, $&#8195;&#8195;&#8195;&#8195; and $&#8195;&#8195;&#8195;&#8195; , respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2025 Cash Bonuses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Fiscal Year
2025, each of the named executive officers was eligible to earn an annual performance bonus based on the achievement of certain corporate performance and individual performance goals. For Fiscal Year 2025, the target annual bonus for
Ms.&nbsp;Zohar,&#8195;&#8195;&#8195;&#8195;, and&#8195;&#8195;&#8195;&#8195;were&#8195;&#8195;&#8195;&#8195;%,&#8195;&#8195;&#8195;&#8195;% and&#8195;&#8195;&#8195;&#8195;%, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Incentive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe equity
grants provide our executives with a strong link to our long-term performance, create an ownership culture, and help to align the interests of our executives and our stockholders. In addition, we believe equity grants promote executive retention
because they incentivize our executive officers to remain in our service during the vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Fiscal Year 2025, we granted
each of our named executive officers options to purchase common stock of the Company under our 2024 Equity Incentive Plan, as amended from time to time. For additional information regarding outstanding equity awards held by our named executive
officers as of December&nbsp;31, 2025, see the &#8220;<I>Outstanding Equity Awards at 2025 Fiscal Year End</I>&#8221; table below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan and
Health and Welfare Benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently participate in a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) retirement
savings plan, or the 401(k) Plan, for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) Plan on the same terms as other
full-time employees. Our 401(k) Plan is intended to qualified for favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. We
provide matching contributions under the 401(k) Plan equal to 100% of each employee&#8217;s contributions up to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum of 3% of the employee&#8217;s annual eligible compensation, subject to the safe harbor limit. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT>
retirement savings though our 401(k) Plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. Other than
the 401(k) plan, we do not provide any qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> retirement or deferred compensation benefits to our employees, including our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans, including
medical dental, and vision benefits, short-term and long-term disability insurance, and basic life and AD&amp;D insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements for
Named Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into offer letters with each of our named executive officers in connection with their commencement
of employment, which set forth the terms and conditions of their employment, including base salary, target annual bonus opportunity, initial equity awards and eligibility to participate in our employee benefit plans generally offered to our
employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2025 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of
December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)</B><br><B>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2024 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
2024 Equity Incentive Plan, or the 2024 Plan, was approved by the Company&#8217;s subsidiary&#8217;s Board and Stockholders and became effective for the Company in April 2024 and was subsequently amended in April 2024 and October 2024 to increase
the number of shares reserved for issuance thereunder. Under the 2024 Plan, as amended, we have reserved for issuance an aggregate of 38,607,011 shares of our common stock. These numbers are subject to adjustment in the event of a stock dividend,
stock split, <FONT STYLE="white-space:nowrap">spin-off,</FONT> recapitalization, or other similar equity restructuring. Our board of directors has determined not to make any further awards under the 2024 Plan following the closing of this offering,
but all outstanding awards under the 2024 Plan will continue to be governed by their existing terms. In connection with this offering, we intend to adopt a new incentive equity plan under which we will grant equity-based awards following this
offering, as described below under &#8220;<I>2026 Equity Incentive Plan</I>.&#8221; The following summary describes the material terms of the 2024 Plan. This summary is not a complete description of all provisions of the 2024 Plan and is qualified
in its entirety by reference to the 2024 Plan, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock underlying any awards that are expired, lapsed, terminated, surrendered, cancelled without having been fully
exercised, or is forfeited in whole or in part (including repurchased by us at or below the original issuance price), and shares that are withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding
under our 2024 Plan are currently added back to the shares of common stock available for issuance under our 2024 Plan (and, following the completion of this offering, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be added back to the shares of common stock available for issuance under the 2026 Equity Incentive Plan, or the 2026 Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has acted as administrator of the 2024 Plan. The administrator has full power to, among other things, select, from
among the individuals eligible for awards, determine the specific terms and conditions of each award, and accelerate at any time the exercisability or vesting of any award, subject to the provisions of the 2024 Plan. Persons eligible to participate
in our 2024 Plan are our employees, consultants and directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Plan permits the granting of (1)&nbsp;options to purchase common
stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and (2)&nbsp;options that do not so qualify. The option exercise price of each option is determined by the administrator but may not be less than 100% of the
fair market value of the common stock on the date of grant or, in the case of an incentive stock option granted to a 10% owner, the exercise price shall not be less than 110% of the fair market value of our common stock on the date of grant. The
term of each option is fixed by the administrator and may not exceed ten years from the date of grant (or five years in the case of certain incentive stock option grants). The administrator determines at what time or times each option may be
exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator of the 2024 Plan may award restricted shares of common stock and restricted stock units subject to such
conditions and restrictions as it determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator of the 2024 Plan may also grant other stock-based awards to be delivered
in the future. The awards may be paid in shares of common stock, cash, or other forms of property, as determined by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the event of certain equity restructuring, including stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off,</FONT> recapitalization, or other similar change to the Company&#8217;s capital structure, the administrator of the 2024
Plan shall make appropriate adjustments to the maximum number of shares reserved for issuance under the 2024 Plan, the number and type of securities subject to outstanding awards under the 2024 Plan, and the exercise price of any outstanding awards
under the 2024 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Plan provides that in the event of a &#8220;change in control&#8221; (as defined in the 2024 Plan), the
administrator is authorized to take various actions, including, but not limited to: (i)&nbsp;canceling any award in exchange for cash or property, (ii)&nbsp;accelerating the vesting of any award, (iii)&nbsp;providing for the assumption or
substitution of awards by the successor entity, (iv)&nbsp;adjusting the number and type of shares subject to outstanding awards, (v)&nbsp;replacing the award with other rights or property selected by the administrator, and (vi)&nbsp;terminating the
award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may amend, suspend, or terminate the 2024 Plan at any time, subject to stockholder approval where required
by applicable law. The administrator of the 2024 Plan may also amend, modify, or terminate any outstanding award. The participant&#8217;s consent to such action will be required unless (i)&nbsp;the administrator determines that the action would not
materially and adversely affect the participant, or (ii)&nbsp;the change is permitted under the 2024 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No awards may be granted under
our 2024 Plan after the date that is ten years from the date our 2024 Plan was adopted by our board of directors. As described above, our board of directors has determined not to make any further awards under our 2024 Plan following the completion
of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, options to purchase up to&#8195;&#8195;&#8195;&#8195;shares of common stock at a weighted
average exercise price of $&#8195;&#8195;&#8195;&#8195;per share and&#8195;&#8195;&#8195;&#8195;shares of restricted stock were outstanding under the 2024 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2026 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2026 Plan was adopted by our board of directors on&#8195;&#8195;&#8195;&#8195;2026, approved by our stockholders
on&#8195;&#8195;&#8195;&#8195; , 2026 and will become effective on the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. The 2026 Plan will allow us to make
equity-based and cash-based incentive awards to our officers, employees, directors, and consultants. The following summary describes the material terms of the 2026 Plan. This summary is not a complete description of all provisions of the 2026 Plan
and is qualified in its entirety by reference to the 2026 Plan, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. We have initially reserved&#8195;&#8195;&#8195;&#8195;shares of our common stock for the issuance of awards under
the 2026 Plan, or the Initial Limit. The 2026 Plan provides that the number of shares reserved and available for issuance under the 2026 Plan will automatically increase on January&nbsp;1, 2027 and each January thereafter during the term of the 2026
Plan, by&#8195;% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee, or the Annual Increase. The number of shares reserved
for issuance under the 2026 Plan will be subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares we issue under the 2026 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock
underlying any awards under the 2026 Plan and the 2024 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the
issuance of stock, expire, or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2026 Plan. The maximum number of shares of common stock that may be issued pursuant to
incentive stock options shall not exceed the Initial Limit, cumulatively increased on January&nbsp;1, 2027 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or&#8195;&#8195;&#8195;&#8195;shares of common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Limit</I>. The grant date fair value of all awards under the 2026 Plan
and all other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any one calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may not exceed $&#8195;;
provided, however, that such amount shall be $&#8195;&#8195;&#8195;&#8195;for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. The 2026 Plan will be administered by our compensation committee. Our compensation committee will have full power
to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the
exercisability or vesting of any award, and to determine the specific terms and conditions of each award, subject to the provisions of the 2026 Plan. The compensation committee is specifically authorized to exercise its discretion to reduce the
exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Persons eligible to participate in the 2026 Plan will be those employees,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and consultants selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. The 2026 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock
options under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on
the date of grant unless the option (i)&nbsp;is granted pursuant to a transaction described in and in a manner consistent with, Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to United States income tax, or
(iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code. The term of each option will be fixed by our compensation committee and may not exceed ten years from the date of grant (or five years in the case of certain incentive stock
options). Our compensation committee will determine at what time or times each option may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Our compensation committee may award stock appreciation
rights under the 2026 Plan subject to such conditions and restrictions as it determines. Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise
price. The exercise price of each stock appreciation right may not be less than 100% of the fair market value of our common stock on the date of grant unless the stock appreciation right (i)&nbsp;is granted pursuant to a transaction described in,
and in a manner consistent with, Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to United States income tax, or (iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code. The term of each
stock appreciation right will be fixed by our compensation committee and may not exceed ten years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and Restricted Stock Units</I>. Our compensation committee may award restricted shares of common stock and restricted
stock units to participants subject to such conditions and restrictions as it determines. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment or other service relationship with us
through a specified vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unrestricted Stock Awards</I>. Our compensation committee may grant shares of common stock that
are free from any restrictions under the 2026 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Equivalent Rights</I>. Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient
to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cash-Based
Awards</I>. Our compensation committee may grant cash bonuses under the 2026 Plan to participants, subject to the achievement of certain performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale Event</I>. The 2026 Plan provides that, upon the effectiveness of a &#8220;sale event&#8221; (as defined in the 2026 Plan), an
acquirer or successor entity may assume, continue, or substitute outstanding awards under the 2026 Plan. To the extent that awards granted under the 2026 Plan are not assumed, continued, or substituted by the successor entity, the 2026 Plan and all
awards granted under the 2026 Plan will terminate. In such case, except as may be otherwise provided in the relevant award agreement, all awards with time-based vesting, conditions, or restrictions will become fully vested and exercisable or
nonforfeitable as of the effective time of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and exercisable or nonforfeitable in connection with the sale event in the
plan administrator&#8217;s discretion or to the extent specified in the relevant award agreement. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise any options and
stock appreciation rights (to the extent exercisable) within a specified time period, as determined by the compensation committee, prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants holding
vested and exercisable options and stock appreciation rights equal to the difference between the per share consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights; provided, that any
options or stock appreciation rights with exercise prices equal to or greater than such per share consideration will be cancelled for no consideration. In addition, we may make or provide for a payment, in cash or in kind, to the participants
holding other awards in an amount equal to the per share consideration payable to stockholders in the sale event multiplied by the number of vested shares of common stock under such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our board of directors may amend or discontinue the 2026 Plan and our compensation committee may amend or cancel outstanding
awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may materially and adversely affect rights under an award without the holder&#8217;s consent. Certain amendments to the 2026 Plan require the approval
of our stockholders. The compensation committee is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options and stock appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No awards may be granted under the 2026 Plan after the date that is ten years from the effective date of the 2026 Plan. No awards have been
made under the 2026 Plan prior to the date hereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2026 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP was adopted by our board of directors on&#8195;&#8195;&#8195;&#8195;, 2026, approved by our stockholders
on&#8195;&#8195;&#8195;&#8195;, 2026, and will become effective on the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The ESPP has two components: a
component intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&nbsp;423 of the Code, or the 423 Component, and a component that is not intended to so qualify, or the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Except as otherwise provided, the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component will be operated and administered in the same manner as the 423 Component, except where prohibited
by law. The following summary describes the material terms of the ESPP. This summary is not a complete description of all provisions of the ESPP and is qualified in its entirety by reference to the ESPP, which will be filed as an exhibit to the
registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. The ESPP initially reserves and authorizes the
issuance of up to a total of&#8195;&#8195;&#8195;&#8195; shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January&nbsp;1, 2027 and
each January&nbsp;1 thereafter through January&nbsp;1, 2036, by the least of (i)&#8195;&#8195;&#8195;&#8195; % of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31, (ii)&#8195;&#8195;&#8195;&#8195;
shares of common stock, or (iii)&nbsp;such number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other
change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. All individuals classified as employees on the payroll records of the Company or a
&#8220;designated company&#8221; (as defined in the ESPP) as of the first day of the applicable offering period are eligible to participate in the ESPP, provided that the ESPP administrator may determine in advance of an offering that employees are
eligible only if, as of the first day of the offering, they (a)&nbsp;are customarily employed by us or a designated company for more than 20 hours a week (or such lesser amount determined by the ESPP administrator), (b) are customarily employed by
us or a designated company for more than five months per calendar year, (c)&nbsp;have completed a minimum period of employment as determined by the ESPP administrator, provided such service requirement does not exceed two years of employment, and/or
(d)&nbsp;they are not highly compensated employees. However, any employee who owns, or as a result of participation in the ESPP would own or hold, 5% or more of the total combined voting power or value of all classes of our stock will not be
eligible to purchase shares of common stock under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offerings</I>. We may make one or more offerings each year to our
employees to purchase shares of our common stock under the ESPP, each of which may consist of one or more purchase periods. Offerings will begin and end on the dates determined by the ESPP administrator, except that no offering will exceed 27 months
in duration. Each eligible employee may elect to participate in any offering by submitting an enrollment form by the deadline established by the ESPP administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each employee who is a participant in the ESPP may purchase shares by authorizing payroll deductions at a minimum
of&#8195;&#8195;&#8195;&#8195;% and up to a maximum of&#8195;&#8195;&#8195;&#8195;% of such participant&#8217;s eligible compensation during an offering period (or such other minimum and maximum as determined by the administrator in advance of an
offering). Unless the participating employee has previously withdrawn from the offering, such participant&#8217;s accumulated payroll deductions will be used to purchase shares of our common stock on the last day of each purchase period at a price
equal to 85% of the fair market value of the shares on the first day or the last day of the purchase period, whichever is lower, provided that no more than the number of shares of common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined by dividing $25,000 by the fair market value of our common stock on the first day of such offering period (or such other maximum number of shares as may be established by the
administrator) may be purchased by any one employee during any purchase period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the offering period, under the ESPP
for each calendar year during which any option granted to the employee is outstanding at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accumulated payroll deductions of
any employee who is not a participant on the last day of an offering period will be refunded. An employee&#8217;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale Event.</I> In the case of and subject to the consummation of a &#8220;sale event&#8221; (as defined in the ESPP), the
administrator of the ESPP, in its discretion, and on such terms and conditions as it deems appropriate, is authorized to take any one or more of the following actions under the ESPP or with respect to any right under the ESPP to facilitate such
transactions or events: (i)&nbsp;provide for either (A)&nbsp;termination of any outstanding option in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such option had such option been
currently exercisable or (B)&nbsp;the replacement of such outstanding option with other options or property selected by the administrator of the ESPP in its sole discretion; (ii)&nbsp;provide that the outstanding options under the ESPP shall be
assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for similar options covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate
adjustments as to the number and kind of shares and prices; (iii)&nbsp;make adjustments in the number and type of shares of common stock (or other securities or property) subject to outstanding options under the ESPP and/or in terms and conditions
of outstanding options and options that may be granted in the future; (iv)&nbsp;provide that the offering with respect to which an option relates will be shortened by setting a new exercise date on which such offering period will end; and
(v)&nbsp;provide that all outstanding options shall terminate without being exercised and all amounts in the accounts of participants shall be promptly refunded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of
shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_14"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2025 Director Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table presents the compensation awarded to, earned by, or paid to each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors for their services to us during Fiscal Year 2025. During
Fiscal Year 2025, Ms.&nbsp;Zohar served as a member of our board of directors and received no additional compensation for her service as a member of our board of directors. The compensation for Fiscal Year 2025 received by Ms.&nbsp;Zohar as our
Chief Executive Officer is presented in the &#8220;<I>2025 Summary Compensation Table</I>&#8221; above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.<B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne, LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bharatt Chowrira, Ph.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy
that will become effective upon the completion of this offering and is designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each
director who is not an employee will be paid cash compensation from and after the completion of this offering, as set forth below, which amounts will be payable quarterly in arrears and prorated for partial years of service: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for lead independent director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will
provide that, upon initial election to our board of directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an equity award with a fair market value of $&#8195;&#8195;&#8195;&#8195;or an option to
purchase&#8195;&#8195;&#8195;&#8195; shares of our common stock, or the Initial Grant. The Initial Grant will vest on&#8195;&#8195;&#8195;&#8195; , subject to continued service as a director through the applicable vesting date. Furthermore, on the
date of each annual meeting of stockholders following the completion of this offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director following such
meeting will be granted an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
annual equity award with fair market value of $&#8195;&#8195;&#8195;&#8195;or option to purchase&#8195;&#8195;&#8195;&#8195; shares of our common stock, or the Annual Grant. The Annual Grant will
vest&#8195;&#8195;&#8195;&#8195;. These awards are subject to full accelerated vesting upon the sale of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate amount
of compensation, including both equity compensation and cash compensation, paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director in a calendar year
period will not exceed $&#8195;&#8195;&#8195;&#8195; (or $&#8195;&#8195;&#8195;&#8195;for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board of
directors). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will reimburse all reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in attending meetings of the board of directors and committees thereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_15"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, and
indemnification arrangements discussed, when required, in the sections titled &#8220;Management,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; and the registration rights described in the section titled
&#8220;Description of Capital Stock&#8212;Registration Rights,&#8221; the following is a description of all transactions since our date of incorporation in April 2024 and each currently proposed transaction in which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been or are to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at <FONT
STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or holders of more than 5% or more of our outstanding capital stock, or
any immediate family member of, or person sharing the household with, any of these individuals or entities or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset Transfer Agreement with PureTech and Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we entered into an Asset Transfer Agreement, or the Asset Transfer Agreement, with PureTech Health LLC, or PureTech Health, and
PureTech LYT, Inc., or PureTech LYT and together with PureTech Health, PureTech, pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of PureTech Health and PureTech LYT&#8217;s
right, title and interest in, to, and under the assets related to its Glyph technology or products, including the Monash License Agreement, subject to the terms set forth in the Asset Transfer Agreement. In exchange, we issued 40,000,000 shares of
our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 949,000 shares of our common stock to PureTech LYT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Transfer Agreement, we have agreed to make milestone payments of up to an aggregate of $10.0&nbsp;million for the
first product covered by assets transferred through the Asset Transfer Agreement, or the Seaport Glyph Product, and up to an aggregate of $5.0&nbsp;million for each subsequent Seaport Glyph Product that achieves certain developmental and commercial
milestones. In addition, we are obligated to pay tiered royalties on potential annual net sales of each Seaport Glyph Product as follows: less than $500 million: 3%; $500&nbsp;million to $1 billion: 3.5%; $1&nbsp;billion to $2.5 billion: 4%;
$2.5&nbsp;billion to $3.5 billion: 4.5%; $3.5&nbsp;billion or greater: 5%. The royalty term will expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Seaport Glyph Product on
the later of the ten year anniversary of the first commercial sale of such Seaport Glyph Product in such country or the date on which the last valid claim of patent rights of such Seaport Glyph Product expires in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon entry into the Asset Transfer Agreement, we entered into a stock purchase agreement with PureTech LYT and other third-party
investors, in which we issued 26,342,102 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, or the Series A Financing, of which 8,421,052 shares were issued and sold to PureTech LYT. PureTech LYT remained a
majority investor of Seaport, until the completion of our Series B convertible preferred stock financing, or the Series B Financing, in October 2024, upon which we issued and sold an aggregate amount of 47,578,934 shares of its Series B convertible
preferred stock, of which 3,031,578 shares were issued to PureTech LYT, and an aggregate of 494,734 shares issued to certain of our management and board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition Services Agreement with PureTech </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with entry into the Asset Transfer Agreement, we also entered into a Transition Services Agreement with PureTech pursuant to
which PureTech agreed to provide us certain services relating to the orderly transition and continued operation on a transitional basis for one year following the entry into the Transition Services Agreement, as amended (unless extended by mutual
agreement of the parties or the earlier </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination of all services provided under the Transition Services Agreement) in consideration of our payment of all fees associated with the transitioned services. Pursuant to the Transition
Services Agreement, we made an up-front payment of $0.5 million to reimburse PureTech for work performed by certain third-parties prior to the closing and have paid an aggregate of $14.2&nbsp;million of expenses since the Asset Transfer Date. In
2025, the TSA was amended to extend through July 2026 to provide ad-hoc support as needed; however, the services to be provided under the amended TSA are expected to be de minimis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we issued and sold to certain investors an aggregate of 26,342,102 of Series <FONT STYLE="white-space:nowrap">A-2</FONT>
convertible preferred stock at a price per share of $3.80, for an aggregate purchase price of approximately $100.1&nbsp;million. Each outstanding share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock will convert
into one share of common stock immediately prior to the completion of this offering. The following table summarizes the shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred stock issued to our related parties:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchasers&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech LYT, Inc. <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,421,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARCH Venture Fund XII, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,894,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners XI, L.P.
<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,052,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,947,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#8220;Principal Stockholders.&#8221; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PureTech LYT beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Elenko and
Mr.&nbsp;Lyne, members of our board of directors, were designated to our board of directors by PureTech LYT and are executive officers at PureTech. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ARCH Venture Fund XII, L.P. beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Nelsen, a
member of our board of directors, was designated to our board of directors by ARCH Venture Fund XII, L.P. and is a Managing Director of ARCH Venture Partners. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sofinnova beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Healy, a member of our
board of directors, was designated to our board of directors by Sofinnova and is a Managing Director of Sofinnova. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Third Rock Ventures beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024 and November 2024, we issued and sold to certain investors an aggregate of 47,578,934 shares of Series B convertible preferred
stock at a price per share of $4.75, for an aggregate purchase price of approximately $226.0&nbsp;million. Each outstanding share of Series B convertible preferred stock will convert into one share of common stock immediately prior to the completion
of this offering. The following table summarizes the shares of our Series B convertible preferred stock issued to our related parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchasers&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Atlantic (SP), L.P. <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,526,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARCH Venture Fund XII, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,421,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,999,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech LYT, Inc. <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,399,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners XI, L.P.
<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,526,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,526,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul <SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lana Gladstein <SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony Loebel <SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric D. Green and Jessica Santiago-Green, Trustees, or their Successors in interest, of the Eric
D. Green Living Trust dated November&nbsp;12, 2010&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice M. Torres Revocable Trust
<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#8220;Principal Stockholders.&#8221; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General Atlantic beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Pitts, a member of
our board of directors, was designated to our board of directors by General Atlantic and is a Vice President of General Atlantic. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ARCH Venture Fund XII, L.P. beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Nelsen, a
member of our board of directors, was designated to our board of directors by ARCH Venture Fund XII, L.P. and is a Managing Director of ARCH Venture Partners. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PureTech LYT beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Elenko and
Mr.&nbsp;Lyne, members of our board of directors, were designated to our board of directors by PureTech LYT and are executive officers at PureTech. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sofinnova beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Healy, a member of our
board of directors, was designated to our board of directors by Sofinnova and is a Managing Director of Sofinnova. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Third Rock Ventures beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Steven M. Paul is Chairman and a member of our board of directors and a senior advisor to the Company.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lana Gladstein is our General Counsel. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Antony Loebel is our Chief Medical Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Eric Green is our Chief Operating Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Denice Torres is a member of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with our Series <FONT STYLE="white-space:nowrap">A-2</FONT> and Series B convertible preferred stock financings, we entered into investors&#8217; rights, voting, and right of first refusal and
<FONT STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights and information rights, among other things, with certain holders of our preferred stock and certain holders of our common stock, including holders of more than
5% of our capital stock and entities with which certain of our directors or officers are affiliated. These agreements will terminate upon the closing of this offering, except for the registration rights granted under our amended and restated
investors&#8217; rights agreement, as more fully described in &#8220;Description of Capital Stock&#8212;Registration Rights.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year-ended December&nbsp;31, 2024, we made payments of $0.2 million to Third Rock Ventures for professional fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&nbsp;Rights&nbsp;and Side Letters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the initial issuance and sale of our convertible preferred stock, we entered into management rights and side letters with
certain purchasers of our convertible preferred stock, including holders of more than 5% of our capital stock and entities with which certain of our directors or officers are affiliated, pursuant to which such entities were granted
certain&nbsp;management&nbsp;rights, among other things, including the right to consult with and advise our management on significant business issues, review our operating plans, examine our books, and records and inspect our facilities. These
management rights letters will terminate upon completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steven M. Paul Advisor Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2024, we entered into a senior advisor agreement with Steven M. Paul, the chair of our board of directors, whereby we pay
Dr.&nbsp;Paul an annual fee of $500,000 and agreed that if at any time while Dr.&nbsp;Paul is providing services to us up to and including the closing of an initial public offering, Dr.&nbsp;Paul&#8217;s ownership reduces to below 5% of our total
outstanding capital on a fully diluted basis including all outstanding options and restricted common stock, we will grant him an additional equity award to maintain his ownership at the 5% threshold. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment and Benefit Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer letter or employment agreements with certain of our executive officers, and granted restricted stock and stock
options to our executive officers, including an agreement with our Chief Executive Officer pursuant to which we have agreed to maintain our Chief Executive Officer&#8217;s ownership at a certain percentage of our shares on a fully diluted basis and
an agreement pursuant to which we&#8217;ve extended additional benefits to our Chief Executive Officer, as more fully described in the section titled &#8220;Executive Compensation.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Grants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted restricted
stock and options to purchase shares of our common stock to certain of our executive officers and directors. For more information regarding the options granted to our executive officers and directors, see the sections titled &#8220;Executive
Compensation&#8221; and &#8220;Director Compensation.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will contain provisions limiting the liability of directors and officers, and our amended
and restated bylaws will provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide
our board of directors with discretion to indemnify our employees and other agents when determined appropriate by our board of directors. In addition, we have entered into or intend to enter into an indemnification agreement with each of our
directors and executive officers, which will require us to indemnify them. For more information regarding these agreements, see the section titled &#8220;Management&#8212;Limitations on Liability and Indemnification Agreements.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request,
the underwriters have reserved for sale, at the initial public offering price, up to approximately &#8195;&#8195;&#8195;&#8195;shares of our common stock being offered hereby (approximately &#8195;&#8195;&#8195;&#8195;%) for directors, executive
officers, employees and business associates. The directed share program will not limit the ability of our directors, officers, and their family members, or holders of more than 5% of our capital stock, to purchase more than $120,000 in value of our
common stock. We do not currently know the extent to which these related persons will participate in our directed share program, if at all, or the extent to which they will purchase more than $120,000 in value of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Transactions with Related Persons </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to completion of this offering, we intend to adopt a written policy that our executive officers, directors, nominees for election as a
director, beneficial owners of more than 5% of any series of our common stock, and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or
ratification of our board of directors or our audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any series of our common
stock, or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and such person would have a direct or indirect
interest, must be presented to our board of directors or our audit committee for review, consideration, and approval. In approving or rejecting any such proposal, our board of directors or our audit committee is to consider the material facts of the
transaction, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the
transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding beneficial ownership of our capital stock as of&#8195;&#8195;&#8195;&#8195;, 2026 by:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Under these rules, beneficial ownership includes any shares
of common stock as to which the individual or entity has sole or shared voting power or investment power. Unless otherwise indicated below, to our knowledge the persons and entities named in the table have sole voting and sole investment power with
respect to all shares that they beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60 days
of&#8195;&#8195;&#8195;&#8195;to be outstanding and to be beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person but have not treated them as outstanding for the purpose of computing
the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership before the offering is based on an aggregate
of&#8195;&#8195;&#8195;&#8195;shares of common stock (which includes&#8195;&#8195;&#8195;&#8195;shares of restricted common stock) deemed to be outstanding as of&#8195;&#8195;&#8195;&#8195;, after giving effect to the Preferred Stock Conversion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership after the offering is based on&#8195;&#8195;&#8195;shares of common stock assumed to be outstanding
immediately after the completion of this offering (assuming the sale of &#8195;shares of common stock in this offering based on an initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, and no exercise of the underwriters&#8217; option to purchase additional shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table does not reflect
any shares of common stock that may be purchased pursuant to our directed share program described under &#8220;Underwriting&#8212;Directed Share Program.&#8221; If any shares are purchased by our existing principal stockholders, directors or their
affiliated entities, the number and percentage of shares of our common stock beneficially owned by them after this offering will differ from those set forth in the following table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o Seaport Therapeutics, Inc., 101 Seaport
Blvd., Floor 12, Boston, Massachusetts 02210. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech LYT, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARCH Venture Fund XII, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Atlantic (SP), L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners XI, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar,<I> Chief Executive Officer and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne, LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (16 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our
capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation, which will become
effective immediately prior to the completion of this offering, and the amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents
have been filed with the SEC as exhibits to our registration statement of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion
of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon filing of our amended and restated certificate of incorporation and the completion of this offering, our
authorized capital stock will consist of &#8195;&#8195;&#8195;&#8195;shares of common stock, par value $0.0001 per share, and shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, there were &#8195;&#8195;&#8195;&#8195;shares of common stock outstanding (which includes
&#8195;&#8195;&#8195;&#8195;shares of unvested restricted common stock), held of record by&#8195;&#8195;&#8195;&#8195;stockholders, 40,000,000 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock, 26,342,102 shares of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred stock and 47,578,934 shares of Series B preferred stock outstanding and held of record by 34 stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock
are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends
declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription
rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our common stock
will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and
paid for, validly issued, fully paid, and <FONT STYLE="white-space:nowrap">non-assessable.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the completion of this offering, all outstanding shares of our convertible preferred stock will be converted into shares
of our common stock. Upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to&#8195;&#8195;&#8195;&#8195;shares of preferred stock in one or more series and to
fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, and the
number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the
likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our Company or other
corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025,&#8195;&#8195;&#8195;&#8195;shares of common stock were issuable upon the exercise of outstanding stock options
under the 2024 Plan, at a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; no shares of common stock were issuable upon exercise of outstanding stock options outside of our 2024 Plan; and&#8195;&#8195;&#8195;&#8195; shares
of our common stock that will become available for future issuance under our 2026 Plan, including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of
which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that
expire or are repurchased, forfeited, cancelled, or withheld; and For additional information regarding terms of our equity incentive plans, see the section titled &#8220;Executive Compensation&#8212;Employee Benefit and Equity Compensation
Plans.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering and subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into in connection
with this offering and federal securities laws, certain holders of shares of our common stock, including those shares of our common stock that will be issued upon the Preferred Stock Conversion in connection with this offering, will initially be
entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities will possess these registration rights pursuant to
the terms of our second amended and restated investors&#8217; rights agreement and are described in additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration rights described below would
enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay all registration expenses, other than underwriting discounts, selling commissions,
and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to
limit the number of shares the holders may include. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will expire no later than four years after the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
the completion of this offering, holders of &#8195;&#8195;&#8195;&#8195;shares of our common stock, including those issuable upon the Preferred Stock Conversion, will be entitled to certain demand registration rights pursuant to that certain
Investors&#8217; Rights Agreement, by and between us and the investors party thereto, dated as of October&nbsp;18, 2024, or the investors&#8217; rights agreement. At any time beginning 180 days after the completion of this offering, the holders of
at least 9% of these registrable securities may request that we register all or a portion of their shares. We are not required to effect more than two registration statements which are declared or ordered effective pursuant to these demand
registration rights. Such request for registration must cover shares with an anticipated aggregate offering price of at least $15&nbsp;million, net of any underwriting discounts, selling commissions, and other related expenses. With certain
exceptions, we are not required to effect the filing of a registration statement during the period starting with the date of the filing of, and ending on a date 60 days following the effective date of the registration statement for this offering.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, holders of &#8195;&#8195;&#8195;&#8195;shares of our common stock, including those issuable upon the
Preferred Stock Conversion, were entitled to, and the necessary percentage of holders waived, their rights to notice of this offering and to include their shares of registrable securities in this offering pursuant to the investors&#8217; rights
agreement. After this offering, in the event that we propose to register any of our securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Securities Act, either for our own account or for the account of other security holders, the holders of these registrable securities will be entitled to certain piggyback registration
rights allowing such holders to include their shares in such registration, subject to certain marketing and other limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT
STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, holders of
&#8195;&#8195;&#8195;&#8195;shares of our common stock, including those issuable upon the Preferred Stock Conversion, will be entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights pursuant to the investors&#8217;
rights agreement. Holders of at least 9% of these registrable securities can make a request that we register their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (which qualification may occur no sooner than twelve calendar months after the date of this offering) and if the reasonably anticipated aggregate net proceeds of the shares offered would equal or exceed
$5&nbsp;million, net of any underwriting discounts, selling commissions and other related expenses. We will not be required to effect more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within any twelve-month period. The
right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand registration rights and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights granted under our Investor Rights
Agreement will terminate upon the earliest of (i)&nbsp;the closing of a &#8220;Deemed Liquidation Event,&#8221; as such term is defined in our amended and restated certificate of incorporation (as currently in effect), (ii) such date after the
completion of this offering when each holder (A)&nbsp;together with its affiliates (as determined under Rule 144 of the Securities Act) holds less than 1% of our outstanding capital stock and (B)&nbsp;may immediately sell all registrable securities
held by such holder pursuant to Rule 144 of the Securities Act without any volume limitations, or another similar exemption, during any three month period without registration, and (iii)&nbsp;the third anniversary of the completion of this offering.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws will include a number of provisions that may have the
effect of delaying, deferring, or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT
STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and
Filling Vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide for the division of our board of directors
into three classes serving staggered three-year terms, with one class being elected each year. Our amended and restated certificate of incorporation also will provide that directors may be removed only for cause and then only by the affirmative vote
of the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from
an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and
treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Written
Consent of Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide that all stockholder actions are
required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder
actions and would prevent the amendment of our amended and restated bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that only a majority of the members of our
board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and restated bylaws
will limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance
Notice Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws will establish advance notice procedures with regard to stockholder proposals
relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures will provide that notice of stockholder proposals must be timely given in writing to our corporate
secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual
meeting for the preceding year. Our amended and restated bylaws will specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an
annual or special meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment to our amended and restated certificate of incorporation must first be approved by a majority of our board of directors and, if
required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote
thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding
shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our amended and restated bylaws may be amended by the
affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the amended and restated bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the
amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as
a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation will provide for &#8195;&#8195;&#8195;&#8195; authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage
an attempt to obtain control of us by means of a merger, tender offer, proxy contest, or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the
best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the
proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation will grant our board of directors broad power to establish the rights and preferences of authorized and unissued
shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers,
including voting rights, of these holders and may have the effect of delaying, deterring, or preventing a change in control of us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits
a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the
business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of
the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated
bylaws will provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on
our behalf, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii)&nbsp;any action
asserting a claim arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or amended and restated bylaws (including the interpretation, validity, or enforceability thereof) or as to which the DGCL
confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder. Consequently, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts
have exclusive jurisdiction or the Securities Act. Moreover, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or
the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated bylaws will provide that, unless we consent in writing to the
selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising
under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to
any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to
bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with
the federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our amended and restated bylaws will provide that any
person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#8220;Management&#8212;Limitations on Liability and Indemnification Agreements.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
currently not listed on any securities exchange. We intend to apply to have our common stock approved for listing on the Nasdaq Global Market under the symbol &#8220;SPTX.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the
completion of this offering, the transfer agent and registrar for our common stock will be&#8195;&#8195;&#8195;&#8195;. The transfer agent&#8217;s address is&#8195;&#8195;&#8195;&#8195;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of our common stock,
including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our
ability to raise equity capital. Although we intend to apply to list our common stock on the Nasdaq Global Market, we cannot assure you that there will be an active public market for our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, based on our shares outstanding as of December&nbsp;31, 2025, a total of
&#8195;&#8195;&#8195;&#8195;shares of common stock will be outstanding, assuming no exercise of the underwriters&#8217; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in
this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the limitations described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as
currently in effect, once we have been subject to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with
the manner of sale, volume limitation, or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one
of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than
our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without
complying with any of the requirements of Rule 144, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell
shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Beginning 90 days after the date of this prospectus, within any three-month period, such stockholders may sell a number of shares that does not
exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of common stock then outstanding, which will equal approximately
&#8195;&#8195;&#8195;&#8195;shares immediately after this offering, assuming no exercise of the underwriters&#8217; option to purchase additional shares of common stock from us; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates or
persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities
Act, or Rule 701, generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in
reliance on Rule 144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144
without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to wait until 90 days after the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act with the SEC
to register the offer and sale of shares of our common stock that are issuable under the 2024 Plan, the 2026 Plan, and the ESPP. These registration statements will become effective immediately upon filing. Shares covered by these registration
statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below, and Rule 144 limitations applicable to affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or
exchangeable for our capital stock have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any
of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180 days from the date of this prospectus without the prior written consent of&#8195;&#8195;&#8195;&#8195;, subject
to certain exceptions. For more information, see the section titled &#8220;Underwriting.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their
shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. For more
information, see the section titled &#8220;Description of Capital Stock&#8212;Registration Rights.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the purchase, ownership, and disposition of our common stock issued pursuant to this offering. This discussion is based on the Internal Revenue Code of
1986, as amended, or the Code, Treasury Regulations promulgated thereunder, published rulings, and administrative pronouncements of the U.S. Internal Revenue Service, or IRS, and judicial decisions, all as in effect on the date hereof. These
authorities are subject to differing interpretations and may change, possibly with retroactive effect, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the IRS with respect
to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our common stock pursuant to this offering
and who hold our common stock as a &#8220;capital asset&#8221; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion is not a complete analysis of all potential U.S. federal income tax
consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Code, and also
does not address any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences, such as estate or gift tax consequences, or any tax consequences arising under any state, local, or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject
to special rules under the U.S. federal income tax laws, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens, or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as pass-through or disregarded entities for U.S. federal
income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;controlled foreign corporations&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;passive foreign investment companies&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, mutual funds, financial institutions, investment funds, insurance companies, brokers, dealers, or traders
in stock, securities, commodities or currencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise of an option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction or straddle, or synthetic
security or a constructive sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement
that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status of the partner, the activities of the
partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them
of owning and disposing of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE
INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS OR UNDER ANY APPLICABLE INCOME TAX TREATY. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder is any beneficial owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or any organization taxable as a corporation for U.S. federal income taxes that is not created or
organized under the laws of the United States, any state thereof, or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign trust or estate, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described under &#8220;<I>Dividend Policy</I>,&#8221; we do not currently anticipate declaring or paying, for the foreseeable future, any
distributions on our capital stock. However, if we were to distribute cash or other property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will then constitute a return of capital and will first be applied against and reduce a
holder&#8217;s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under &#8220;&#8212;Gain on sale or other taxable
disposition of our common stock&#8221; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding
and FATCA (as defined below), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such
lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish to us or our withholding agent with a timely and valid IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying such
holder&#8217;s qualification for the reduced rate. This certification must be provided to us or our withholding agent before the payment of the dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder holds our common stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to
provide appropriate documentation to the agent, which then will be required to provide certification to us or our withholding agent, either directly or through other intermediaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade or business in
the United States, and dividends paid on our common stock are effectively connected with such holder&#8217;s U.S. trade or business (and, if required by an applicable tax treaty, are attributable to such holder&#8217;s permanent establishment or
fixed base in the United States), such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally
must furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form), certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#8217;s conduct of
a trade or business within the United States to the applicable withholding agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends paid
on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation also may be subject to an additional branch profits tax equal
to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected dividends, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but that qualify
for a reduced treaty rate, may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any
applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and FATCA (as defined below), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
conduct of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the
United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for a period or periods aggregating 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#8220;United States real property interest&#8221; by reason of our status as a
United States real property holding corporation, or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
holding period for our common stock, and our common stock is not &#8220;regularly traded&#8221; on an &#8220;established securities market&#8221; within the meaning of applicable Treasury Regulations, during the calendar year in which the sale or
other disposition occurs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal
income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation also may be
subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by
an applicable income tax treaty), but may be offset by certain U.S.- source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (even though the individual is not considered a resident of the United States), provided that
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining whether we are a USRPHC depends on the fair market value of our United States real property interests relative to the fair market
value of our worldwide real property interests and our other trade or business assets. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we have
not been, are not currently or will not in the future become a USRPHC. Even if we are treated as a USRPHC, gain realized by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on a disposition of our common stock will not be subject to U.S.
federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (a)&nbsp;the five-year period
preceding the disposition or (b)&nbsp;the holder&#8217;s holding period and (2)&nbsp;our common stock is &#8220;regularly traded&#8221; on an &#8220;established securities market,&#8221; within the meaning of applicable Treasury Regulations. There
can be no assurance that our common stock qualifies as regularly traded on an established securities market for purposes of the rules described above. Prospective investors are encouraged to consult their own tax advisors regarding the possible
consequences to them if we have been, are or were to become a USRPHC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors
regarding any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating
the amount of distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required because the distributions
were effectively connected with the holder&#8217;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement
with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of distributions on or the gross proceeds of a disposition of our common stock provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption, and if the payor does not have actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding on Foreign Entities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal withholding tax of 30% on certain
payments made to a &#8220;foreign financial institution&#8221; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S.
tax authorities substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or
an exemption applies. FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">&#8220;non-financial</FONT> foreign entity&#8221; (as specially defined under these rules) unless
such entity provides the withholding agent a certification that it does not have any &#8220;substantial United States owners&#8221; or provides information identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An
intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of
such taxes. FATCA currently applies to dividends paid on our common stock and would have applied also to payments of gross proceeds from the sale or other disposition of our common stock. However, proposed regulations under FATCA provide for the
elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other disposition of from property of a type that can produce U.S.-source dividends or interest. Under these proposed Treasury Regulations (which may be
relied upon by taxpayers prior to finalization), FATCA withholding does not apply to gross proceeds from sales or other dispositions of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are encouraged to consult with their tax advisors regarding the possible implications of FATCA on their investment in
our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF ACQUIRING, OWNING, AND DISPOSING OF OUR
COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.,</FONT> OR U.S. FEDERAL <FONT
STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC are the representatives of the underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other
than the shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have an option to buy
up to an additional &#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30 days.
If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total estimated underwriting discounts and commissions to be paid to the underwriters by us. Such
amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase &#8195;&#8195;&#8195;&#8195;&nbsp;additional shares of our common stock from us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares sold by the underwriters to the public will initially be offered at the initial public offering price
set forth on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&#8195;&#8195;&#8195;&#8195;per share from the initial public offering price. After the initial offering of the
shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or
in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our officers, directors, and holders of substantially all of our common stock and securities convertible into or
exchangeable for our common stock have agreed or will agree with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for shares of common stock,
or collectively, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent
of&#8195;&#8195;&#8195;&#8195;. This agreement does not apply to any existing employee benefit plans. See the section titled &#8220;Shares Available for Future Sale&#8221; for a discussion of certain transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the offering, there has been no public market for the shares of our common stock. The initial public offering price has been
negotiated among us and the representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing market conditions, will be our historical performance, estimates of the
business potential and earnings prospects of us, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common stock on the Nasdaq Global Market under the symbol
&#8220;SPTX.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell shares of our common stock in the open
market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase
in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#8220;covered short position&#8221; is a short position that is not greater than the amount of additional shares for
which the underwriters&#8217; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market.&#8195;In
determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional
shares pursuant to the option described above. &#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must
cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open
market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion
of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may
have the effect of preventing or retarding a decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain, or otherwise affect the market price of our common stock. As a result, the
price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected
on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our share of the total expenses of the offering, excluding the estimated underwriting discounts and commissions, will be
approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $&#8195;&#8195;&#8195;&#8195;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial, and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage, and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT>
activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for which they received or
will receive customary fees and expenses.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters, and their
respective affiliates, officers, directors, and employees may purchase, sell, or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps, and other financial instruments for
their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of ours (directly, as collateral securing other obligations or otherwise) and/or
persons and entities with relationships with us. The underwriters and their respective affiliates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may also communicate independent investment recommendations, market color, or trading ideas and/or publish or express independent research views in respect of such assets, securities, or
instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities, and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to &#8195;% of the common stock offered by this prospectus for sale at the initial public
offering price for sale at the initial public offering price to our directors, officers, certain employees and certain other persons associated with us. The sales will be made by&#8195;&#8195;&#8195;&#8195; through a directed share program. We do
not know if these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Any reserved shares not so purchased will
be offered by the underwriters to the general public on the same terms as the other shares of common stock. Except for reserved shares purchased by our executive officers and directors, these reserved shares will not be subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> restrictions described elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in the European Economic Area </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the EEA, or, each, a Relevant Member State, an offer to the public of any shares may not be made in that
Relevant Member State, except that an offer to the public in that Relevant Member State of any shares may be made at any time under the following exemptions under the EU Prospectus Regulation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a &#8220;qualified investor&#8221; as defined under the EU Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than &#8220;qualified investors&#8221; as defined under the
EU Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the EU Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall result in a requirement for the Company or any of the underwriters to publish a prospectus pursuant to Article 3
of the Prospectus Regulation or a supplemental prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, warranted and agreed to
and with each of the underwriters and the Company that it is a qualified investor within the meaning of Article 2 of the EU Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 1(4) of the EU Prospectus Regulation, each
financial intermediary will also be deemed to have represented, warranted, and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they
been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public, other than their offer or resale in a Relevant Member State to qualified investors as so defined or in
circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the
underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, warranties, and agreements. Notwithstanding the above, a person who is not a &#8220;qualified investor&#8221; and who has notified the
underwriters of such fact in writing may, with the prior consent of the Notwithstanding the above, a person who is not a &#8220;qualified investor&#8221; and who has notified the underwriters of such fact in writing may, with the prior consent of
the underwriters, be permitted to acquire shares in the offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in
relation to any shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe
for any shares, and the expression &#8220;EU Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective
Investors in the United Kingdom </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An offer to the public of any shares may not be made in the UK, except that an offer to the public in
the UK of any shares may be made at any time under the following exemptions under the UK Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a &#8220;qualified investor&#8221; as defined under the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than &#8220;qualified investors&#8221; as defined under the
UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within section 86 of the Financial Services and Markets Act 2000, as
amended, or the FSMA, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall result in a requirement for the Company or any
Bookrunner to publish a prospectus pursuant to section 85 of the FSMA or a supplemental prospectus pursuant to Article 23 of the UK Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed
to have represented, warranted and agreed to and with each of the underwriters and the Company that it is a qualified investor within the meaning of Article 2 of the UK Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 1(4) of the UK Prospectus Regulation, each
financial intermediary will also be deemed to have represented, warranted, and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they
been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public, other than their offer or resale in the UK to qualified investors as so defined or in circumstances in which
the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their
affiliates will rely upon the truth and accuracy of the foregoing representations, warranties, and agreements. Notwithstanding the above, a person who is not a &#8220;qualified investor&#8221; and who has notified the underwriters of such fact in
writing may, with the prior consent of underwriters, be permitted to acquire shares in the offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the
expression an &#8220;offer to the public&#8221; in relation to any shares in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to
decide to purchase or subscribe for any shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Prospectus is only being distributed to and is only directed at: (A)&nbsp;persons
who are outside the UK; or (B)&nbsp;qualified investors who are also (i)&nbsp;investment professionals falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005, or the Order, or (ii)&nbsp;high net worth companies, and other persons
to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order, or, all such persons falling within (1)-(3) together being referred to as, relevant persons. The shares are only available to, and any invitation,
offer, or agreement to subscribe, purchase, or otherwise acquire the shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this Prospectus or any of its contents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Canada </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection&nbsp;73.3(1) of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions, and Ongoing
Registrant Obligations. Any resale of the shares must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Hong Kong </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong), or the Companies (Winding Up and Miscellaneous Provisions) Ordinance, or which do not constitute an
invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the Securities and Futures Ordinance, or (ii)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and
Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no
advertisement, invitation, or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are
likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only
to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Singapore </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, under
Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions
specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an
accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as
defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under
Section&nbsp;274 of the SFA or to a relevant person (as defined in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#8217;s securities pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no consideration
is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments)
(Shares and Debentures) Regulations 2005 of Singapore, or Regulation 32. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an
accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an
institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a
consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for
the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation&nbsp;32. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Japan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as
amended), or the FIEA. The shares may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of
Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any
relevant laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in the Dubai International Financial Centre </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or the DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any
documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares of common stock to which this prospectus
relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares of common stock offered should conduct their own due diligence on the shares of common stock. If you do not understand the contents of this
prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Australia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement, or other disclosure document has been lodged with the Australian Securities
and Investments Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not
purport to include the information required for a prospectus, product disclosure statement, or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares of common stock may only be made to persons, the Exempt Investors, who are &#8220;sophisticated
investors&#8221; (within the meaning of section 708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in
section 708 of the Corporations Act so that it is lawful to offer the shares of common stock without disclosure to investors under Chapter 6D of the Corporations Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock applied for by Exempt Investors in Australia must not be offered
for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under
section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares of common stock must observe such Australian <FONT
STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of
the investment objectives, financial situation, or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether
the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Israel </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, and has not been
filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares of common stock is directed only at, (i)&nbsp;a limited number of persons in
accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks,
portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as
it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the
Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Brazil </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer and sale of the shares have not been and will not be registered with the Brazilian securities commission (Comiss&atilde;o de Valores
Mobili&aacute;rios, or CVM) and, therefore, will not be carried out by any means that would constitute a public offering in Brazil under CVM Resolution No.&nbsp;160, dated 13&nbsp;July 2022, as amended, or CVM Resolution 160, or unauthorized
distribution under Brazilian laws and regulations. The shares may only be offered to Brazilian professional investors (as defined by applicable CVM regulation), who may only acquire the shares through a
<FONT STYLE="white-space:nowrap">non-Brazilian</FONT> account, with settlement outside Brazil in <FONT STYLE="white-space:nowrap">non-Brazilian</FONT> currency. The trading of these shares on regulated securities markets in Brazil is prohibited.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common stock being offered in this prospectus will be passed upon for us by Goodwin Procter LLP. Certain
legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2024 and for the year then ended included in this prospectus have been so included in
reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_23"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File Number <FONT
STYLE="white-space:nowrap">333-&#8195;&#8195;&#8195;&#8195;)</FONT> under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not
contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common
stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily
complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an
exhibit is qualified in all respects by the filed exhibit. The SEC also maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is
<I>www.sec.gov/edgar.</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not file periodic reports with the SEC. On the completion of this offering, we will be subject
to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements, and other information with the SEC. These reports, proxy statements and other information will be available for review at the website of the
SEC referred to above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at <I>www.seaporttx.com</I>. Information contained in, or accessible through, our
website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference. Upon completion of this offering, you may access, free of charge, our annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_24"></A>INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements as of and for the Year Ended December&nbsp;31, 2024 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_2">Consolidated Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_3">Consolidated Statement of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_4">Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_5">Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of Seaport Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated balance sheet of Seaport Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&nbsp;31, 2024, and the related consolidated statements of operations and comprehensive loss, of
convertible preferred stock and stockholders&#8217; deficit and of cash flows for the year then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2024, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles
generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the
Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards
generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error
or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating
the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ PricewaterhouseCoopers LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Boston, Massachusetts</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">March&nbsp;31, 2025, except for the segment information discussed in Note 2 and the effects of disclosing net loss per share information discussed in Note 15 to the consolidated financial statements, as to which the date is
November&nbsp;21, 2025</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor since 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_2"></A>Consolidated Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets&#8212;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, convertible preferred stock and stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, par value $0.0001;
40,000,000 shares authorized, issued, and outstanding as of December&nbsp;31, 2024; liquidation preference of $4,000 as of December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, par value $0.0001;
26,342,102 shares authorized, issued and outstanding as of December&nbsp;31, 2024; liquidation preference of $100,100 as of December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, par value $0.0001; 47,578,938 shares authorized as of
December&nbsp;31, 2024; 47,578,934 shares issued and outstanding as of December&nbsp;31, 2024; liquidation preference of $226,000 as of December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.0001; 159,070,000 shares authorized as of December&nbsp;31, 2024;
8,150,000 shares issued and outstanding as of December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, convertible preferred stock and stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_3"></A>Consolidated Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (including stock-based compensation of $0.7 million) <SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative (including stock-based compensation of $15.2 million) <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,961,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related-party amounts of $14.2&nbsp;million for research and development expense for the year ended
December&nbsp;31, 2024. See Note 16&#8212;Related Parties. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related-party amounts of $5.8&nbsp;million for general and administrative expense for the year ended
December&nbsp;31, 2024. See Note 16&#8212;Related Parties. </P></TD></TR></TABLE> <P STYLE="margin-top:240pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these
consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_4"></A>Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT><BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT><BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Parent</B><br><B>Investment</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss attributable to Seaport</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net transfers from PureTech Health plc prior to formation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense allocated from PureTech Health plc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock to PureTech Health plc upon formation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible
preferred stock to PureTech Health plc upon Asset Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Reclassification of net investments from PureTech Health plc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, net of
issuance costs of $343</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock, net of issuance costs of $429</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_5"></A>Consolidated Statement of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from PureTech Health plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible
preferred stock <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance costs associated with issuance of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series B convertible preferred stock <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance costs associated with issuance of Series B convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> operating,
financing, and investing information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets obtained in exchange for lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes proceeds from certain related parties of $32.0&nbsp;million. See Note 16&#8212;Related Parties.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes proceeds from certain related parties of $16.7&nbsp;million. See Note 16&#8212;Related Parties.
</P></TD></TR></TABLE> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Background </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport
Therapeutics, Inc., and its consolidated subsidiaries, Seaport or the Company, is a clinical-stage therapeutics company focused on inventing and developing medicines for patients with depression, anxiety, and other debilitating neuropsychiatric
disorders using the Company&#8217;s proprietary Glyph Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements include the historical financial
position, results of operations, and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit, and cash flows of the Glyph platform business, or the Seaport Business, which was a business of PureTech Health plc and its
consolidated subsidiaries, or PureTech, a public company incorporated, domiciled and registered in the United Kingdom. The Seaport Business was historically managed as part of PureTech prior to the completion of the
<FONT STYLE="white-space:nowrap">spin-off</FONT> of the Seaport Business from PureTech in April 2024, pursuant to the Asset Transfer Agreement (as defined below). The Company, which holds the assets, liabilities, and operations associated with the
Seaport Business, was incorporated under the laws of the State of Delaware as SP Therapeutics, Inc. on April&nbsp;1, 2024, and changed its name to Seaport Therapeutics, Inc. on April&nbsp;2, 2024. Its wholly owned subsidiary, SPTX, Inc.
(&#8220;SPTX&#8221;), was a previously created entity in February 2024 under the laws of the State of Delaware under the name Seaport Therapeutics, Inc. and changed its name to SPTX, Inc. in April 2024. In April 2024, the Company entered into a
share exchange agreement with SPTX, which resulted in SPTX becoming the Company&#8217;s wholly owned subsidiary. See Note 9&#8212;Common Stock, for further disclosure regarding the share exchange with SPTX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited
to, completion of preclinical studies and clinical trials, obtaining regulatory approvals for product candidates, dependence on key personnel, protection of intellectual property, compliance with government regulations, and ability to secure capital
necessary to fund operations. Product candidates currently under development by the Company will require significant additional research and development efforts, including preclinical and clinical development, and regulatory approval prior to
commercialization. There can be no assurance that the Company&#8217;s research and development efforts will be successfully completed, that any product candidates developed will obtain necessary government regulatory approval, or that any products,
if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnology companies. Even if the Company&#8217;s product development efforts
are successful, it is uncertain when, if ever, the Company will realize significant product revenue from product sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Asset
Transfer and Series A Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was incorporated in April 2024 by PureTech LYT Inc., or PureTech LYT, a wholly owned
subsidiary of PureTech, as the sole stockholder, and the Company issued 1,000 shares of its common stock to PureTech LYT. On April&nbsp;8, 2024, or the Asset Transfer Date, the Company entered into the Asset Transfer Agreement with PureTech Health
LLC, or PureTech Health, and PureTech LYT, pursuant to which PureTech Health and PureTech LYT, agreed to contribute, convey, assign, transfer, and deliver to the Company all of its right, title, and interest in, to and under the assets related to
its Glyph technology and products, or the Asset Transfer. As consideration, the Company issued to PureTech LYT 40,000,000 shares of its Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 949,000 shares of its common
stock on the Asset Transfer Date, and also agreed to contingent payments to PureTech upon successful development and commercialization of products developed using the Glyph platform, each of which is referred to as a Seaport Glyph Product,
including; (i)&nbsp;low single digit tiered royalties; (ii)&nbsp;milestone payments up to $15.0&nbsp;million upon achievement of specified milestones; and (iii)&nbsp;a percentage of net income generated by the Company from third parties on any
products licensed under agreements which were transferred as part of the Asset Transfer Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the Asset Transfer and related
<FONT STYLE="white-space:nowrap">spin-off</FONT> transaction represented the transfer of a business between entities under common control. As a result, the net liabilities were transferred from PureTech to the Company at PureTech&#8217;s carrying
amounts on the Asset Transfer Date, and the Company ascribed a nil value to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and common stock issued to PureTech Health and PureTech LYT. The consolidated financial
statements for the period prior to the Asset Transfer Date, were prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis from the consolidated financial statements of PureTech to represent Seaport Business&#8217;
financial position, results of operations, changes in net parent investment and cash flows as if the Seaport Business existed on a standalone basis. Effective April&nbsp;8, 2024, the Company&#8217;s financial statements are presented on a
consolidated basis, as PureTech Health and PureTech LYT completed the transfer of the Seaport Business on such date. The audited financial statements for the year presented, including the historical results of the Company prior to April&nbsp;8,
2024, are referred to as the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon entry into the Asset Transfer Agreement, the Company
entered into a stock purchase agreement with PureTech LYT and other third-party investors, pursuant to which the Company issued and sold shares of its Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, or the Series A
Financing, and together with the Asset Transfer, the Transaction. Subsequent to the Transaction, PureTech LYT remained the controlling investor of the Company, until the completion of the Company&#8217;s Series B convertible preferred stock
financing, or the Series B Financing (as further discussed herein), in October 2024. The Series B Financing resulted in a decrease to PureTech LYT&#8217;s fully diluted ownership, resulting in PureTech LYT no longer maintaining a controlling
interest in the Company. See Note 8&#8212;Convertible Preferred Stock, for further disclosure regarding issuances of the Company&#8217;s convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United
States of America, or GAAP. These consolidated financial statements include the accounts of Seaport Therapeutics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period prior to the Transaction, the accompanying consolidated financial statements of the Company have been prepared on a standalone
basis and are derived from PureTech&#8217;s consolidated financial statements and accounting records. The consolidated financial statements reflect PureTech&#8217;s historical accounting policies, adjusting for differences between International
Financial Reporting Standards and GAAP as appropriate. These consolidated financial statements do not purport to reflect what the Company&#8217;s results of operations, financial position, or cash flows would have been had the Company operated as a
standalone company during the period prior to the Transaction, nor are they indicative of the Company&#8217;s future results of operations, financial position, or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s operations were not historically conducted by a single legal entity, net parent investment is shown in lieu of
stockholders&#8217; equity in the historical consolidated financial statements for the period prior to the Transaction. Net parent investment represents the cumulative investment by PureTech in the Seaport Business through the Transaction date,
inclusive of operating results. All transactions between the Seaport Business and PureTech were effectively settled in the consolidated financial statements at the time the Transaction was recorded. The effects of the settlement of such transactions
between the Seaport Business and PureTech are reflected in the consolidated statement of cash flows as &#8220;Net transfers from PureTech Health plc&#8221; within financing activities and in the statement of convertible preferred stock and
stockholders&#8217; deficit as &#8220;Net parent investment.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was dependent upon PureTech for all of its working
capital and financing requirements through the date of the Transaction. PureTech used a centralized approach for cash management and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financing of its operations. There were no cash amounts specifically attributable to the Seaport Business prior to the Transaction; therefore, cash and cash equivalents were excluded in the
consolidated financial statements prior to the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company include, for the period
prior to the Transaction, the assets, liabilities, and expenses of PureTech that Seaport management determined were specifically identifiable to the Seaport Business and its related programs, as well as indirect costs that are not specifically
identifiable to the Seaport Business or its related programs but are deemed necessary to operate as a standalone entity. The assets and liabilities in the consolidated financial statements for the period prior to the Transaction were recorded based
on their legal title or related to the exclusive use of the Seaport Business. Shared assets were not included on the consolidated balance sheet, but costs reflecting the use of such assets by the Seaport Business were reflected in the consolidated
statement of operations and comprehensive loss. Indirect costs are the costs of support functions that are provided on a centralized basis by PureTech prior to the Transaction, which include, but are not limited to, facilities, information
technology, insurance, quality, compliance, finance, human resources, legal, corporate strategy, corporate governance, and other general and administrative type functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company also include, for the period prior to the Transaction, indirect costs that have been
allocated to the Seaport Business for the purposes of preparing the consolidated financial statements based on proportional cost allocation methods using headcount, proportional time spent, and other organizational activities, as applicable, which
were considered to be reasonable reflections of the utilization of services provided to or benefit received by the Seaport Business for the period prior to the Transaction. Seaport management considers that such allocations were made on a reasonable
basis; however, these allocations may not necessarily be indicative of the costs that would have been incurred if the Seaport Business had operated on a standalone basis for the full year ended December&nbsp;31, 2024 and, therefore, may not be
indicative of the Company&#8217;s results of operations, financial position, and cash flows had the Company operated as a standalone entity prior to the Transaction. See Note 16&#8212;Related Parties, for additional information regarding
related-party transactions with PureTech. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, PureTech continued to provide various research and development
and corporate services under the transition services agreement, or the TSA, which was initially set to terminate one year following the date of the Asset Transfer Agreement. In 2025, the TSA was amended to extend through July 2026 to provide <FONT
STYLE="white-space:nowrap">ad-hoc</FONT> support; however, the value of services to be provided under the amended TSA are expected to be de minimis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the
Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements were available to be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s ability to fund operations and capital needs depended on funding from PureTech through the date of the Transaction. The
Company&#8217;s future operations will be dependent on its ability to raise additional capital to finance such operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
has incurred losses and negative cash flows from operations, including a net loss of $46.9&nbsp;million for the year ended December&nbsp;31, 2024, and cash flows used in operations of $29.6&nbsp;million for the year ended December&nbsp;31, 2024. The
Company expects to continue to generate operating losses and negative cash flows for the foreseeable future as the Company continues to develop its product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements have been prepared assuming it will
continue as a going concern, which presumes it will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. The Company believes its
cash and cash equivalents of $309.1&nbsp;million as of December&nbsp;31, 2024 will be sufficient to fund its expected operating expenses and capital expenditure requirements for at least 12 months from the date these consolidated financial
statements were available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time that the Company can generate significant product revenue, if ever, the Company
expects to fund its operations through equity offerings or debt financings, credit or loan facilities, collaborations, <FONT STYLE="white-space:nowrap">out-license</FONT> arrangements, other capital resources, or a combination of one or more of
these funding sources. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. The Company&#8217;s failure to raise or secure capital as and when needed could have a negative impact on its
financial condition and its ability to pursue its business strategies. If adequate funds are not available to the Company, the Company may be required to delay, reduce, or eliminate clinical programs, obtain funds through arrangements with
collaborators on terms unfavorable to the Company, or pursue merger or acquisition strategies. There can be no assurances the Company will be able to obtain additional funding. There is no assurance that the Company will be successful in obtaining
sufficient capital on acceptable terms to fund continuing operations, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting year
presented. Management of the Company evaluates its estimates which include, but are not limited to, accrued research and development expenses and stock-based compensation expense for periods after the Transaction. For the period before the
Transaction, Management included allocations of direct expenses and indirect expenses, such as personnel-related expenses, including stock-based compensation, facility, information technology and other general overhead expenses from PureTech. The
Company based its estimates on the historical experience of PureTech and on various other assumptions that are believed to be reasonable. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents, and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash with original maturities of three months or less at
the date of purchase to be cash equivalents. The Company invests excess cash primarily in overnight cash sweeps and money market funds which are highly liquid and have high credit ratings. Such investments are subject to minimal credit and market
risks. The Company classifies all cash of which use is limited by contractual provisions as restricted cash. Restricted cash is recorded on the consolidated balance sheet as of December&nbsp;31, 2024 within other
<FONT STYLE="white-space:nowrap">non-current</FONT> assets and includes amounts held as a security deposit for a letter of credit in connection with leased facilities and its corporate card program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s cash and cash equivalents, and restricted
cash as of (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash within other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash per the consolidated statement of cash
flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash and cash
equivalents. All of the Company&#8217;s cash, cash equivalents, and restricted cash are deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits. The Company invests its excess cash, in
line with its investment policy, in money market funds. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting Standards Codification, or ASC, Topic 820, Fair Value Measurement, or ASC 820, identifies fair value as the exchange price, or exit
price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, or in the absence of a principal market, the most advantageous market for the investment or
liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2 inputs are inputs other than quoted prices included within Level&nbsp;1 that are observable for the
asset or liability, either directly or indirectly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the
assumptions market participants would use in pricing the asset or liability. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based
on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments
categorized in Level&nbsp;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, less accumulated depreciation, and consists of lab equipment and leasehold improvements.
Depreciation of property and equipment are calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or
extend the life of the respective assets, are charged to expense as incurred. The estimated useful lives of the Company&#8217;s respective assets are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Estimated Useful Life</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">The&nbsp;lesser&nbsp;of&nbsp;5&nbsp;years&nbsp;or&nbsp;the&nbsp;remaining&nbsp;term&nbsp;of&nbsp;the&nbsp;lease</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon retirement or disposal of property and equipment, the cost, and related accumulated depreciation are
removed from the consolidated balance sheet and any gain or loss is reflected in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry
or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the recoverability of the asset group to be held and used is
measured by a comparison of the carrying amount of an asset group to future undiscounted cash flows expected to be generated by the asset group. If the carrying amounts of the asset group is less than its future undiscounted cash flows, an
impairment loss is then measured by comparing the fair value of asset group to its respective carrying amount. There has been no impairment of long-lived assets recorded for the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for leases in accordance with ASC 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the relevant facts and circumstances present in the arrangement.
Leases with a term greater than one year are recognized on the consolidated balance sheet as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and short-term and long-term lease liabilities, as
applicable. The Company typically only includes an initial lease term in its assessment of a lease arrangement, and options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company
will renew. The Company has elected not to recognize leases with an original term of one year or less on the consolidated balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leases contain both lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. <FONT STYLE="white-space:nowrap">Non-lease</FONT>
components may include common area maintenance, utilities, and other operating costs. The Company combines the lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components in its lease arrangements as a single lease component. Variable
costs are not included in the measurement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities and are expensed when incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating lease liabilities and their corresponding
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are initially recorded at the lease commencement date based on the present value of lease payments measured over the expected remaining lease term.
Certain adjustments to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets may be required for items such as prepaid lease payments or any incentives received. The Company measures the net present
value of lease payments using a discount rate based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the interest rate implicit in the lease or an incremental borrowing rate if the rate implicit in the lease is not readily determinable. The interest rate implicit in the lease contracts is
typically not readily determinable, and as a result, the Company estimates an incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same
currency, for a similar term, in a similar economic environment. To estimate the incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have
any outstanding third-party debt or a rating agency-based credit rating. Operating lease costs are expensed using the straight-line method over the lease term and are classified within research and development or general and administrative expense
based on the use of the underlying facility or using a reasonable allocation method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assumptions that the Company made at the
commencement date are <FONT STYLE="white-space:nowrap">re-evaluated</FONT> upon occurrence of certain events, including a lease modification. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified its convertible preferred stock as temporary equity on the Company&#8217;s consolidated balance sheet due to the
terms that allow for redemption of the shares in cash upon certain deemed liquidation events that are not solely within the control of the Company. The Company initially recorded its Series <FONT STYLE="white-space:nowrap">A-2</FONT> and Series B
convertible preferred stock at fair value, net of issuance costs. The occurrence of such deemed liquidation event is not currently probable and thus the carrying values of the convertible preferred stock are not being adjusted to their redemption
values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development, or R&amp;D, costs are expensed as incurred. Internal costs include personnel related expenses, stock-based
compensation, facility and IT costs, and depreciation. External costs include fees for goods and services to conduct clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> activities, such as costs paid to contract research organizations,
consulting fees, laboratory services and supplies, and costs incurred in connection with license agreements. Prior to the Transaction, these expenses included allocations from PureTech. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to estimate its accrued R&amp;D costs as of the end of the reporting period. In accruing R&amp;D costs, the Company
estimates the period over which services will be performed or goods will be provided and the level of effort to be performed in each period. The financial terms of the R&amp;D contracts vary and may result in payments that do not match the periods
over which the goods or services are provided. The Company accrues costs under its contracts based on analyzing the work performed and amounts paid. In circumstances where amounts have been paid in excess of costs incurred, the Company records the
excess as prepaid expense and recognizes research and development expense as the goods are received or the related services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses are primarily comprised of employee-related expenses, including stock-based compensation and occupancy
costs, depreciation, and third-party expenses related to finance, legal and other general and administrative functions. Prior to the Transaction, these expenses included allocations from PureTech. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses costs associated with intellectual property-related matters as incurred and classifies such costs as general and
administrative expenses within the consolidated statement of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Asset Acquisitions and Acquired <FONT
STYLE="white-space:nowrap">In-Process</FONT> Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for acquisitions of assets or
a group of assets that do not meet the definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to
the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are acquired in an asset acquisition for use in research and
development activities that have an alternative future use are capitalized as <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, or IPR&amp;D. Acquired IPR&amp;D that has no alternative future use as of the acquisition date
is recognized as research and development expense as of the acquisition date. The Company will recognize additional research and development expenses in the future or capitalize such amounts for completed technology if and when the Company becomes
obligated to make contingent milestone payments under the terms of the agreements by which it acquired the IPR&amp;D assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingent
consideration in asset acquisitions is measured and recognized when payment becomes probable and reasonably estimable. Subsequent changes in the accrued amount of contingent consideration are measured and recognized at the end of each reporting
period and upon settlement as an adjustment to the cost basis of the acquired asset or group of assets, or, if related to IPR&amp;D with no alternative future use, charged to expense. The Company did not recognize any IPR&amp;D expense for the year
ended December&nbsp;31, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees of the Company participate in the Company&#8217;s stock-based compensation plans and prior to the Transaction, participated in
PureTech&#8217;s stock-based compensation plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense allocated to the Company for the period prior to the
Transaction relates to equity awards issued by PureTech, including stock options, service-based restricted stock unit awards and performance-based restricted stock unit awards with both market and performance conditions. Stock-based compensation
expense recorded during the period prior to the Transaction was recognized through allocations, based on the proportion of time the employee spent on the Seaport Business during the year presented and PureTech&#8217;s estimate of fair value.
Stock-based compensation expense associated with service-based awards granted by PureTech was recognized over the requisite service period of the awards, which is generally the vesting period, on a straight-line basis. Service-based awards granted
to employees under the PureTech plans generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed during the applicable vesting period.
Performance-based restricted stock unit awards granted under the PureTech plans to its executives included both performance and market conditions, which performance conditions were based on the achievement of PureTech&#8217;s strategic targets and
market conditions were based on PureTech&#8217;s achievement of the absolute total shareholder return, or TSR, and TSR as compared to various market indexes. The performance-based restricted stock awards have been liability classified by PureTech,
as PureTech has historically settled the awards in cash. Stock-based compensation expense for liability-classified awards that contain performance conditions is recognized once the performance condition is deemed probable of being achieved. Once the
performance conditions are considered probable of being achieved, the amount of stock-based compensation expense recognized is measured based on the requisite service period completed and the fair value of the award, which is remeasured at fair
value at each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting date until the date of settlement. Cumulative adjustments to stock-based compensation expense for awards with performance conditions are recorded to reflect subsequent changes to the
estimated outcome of the performance criteria over the requisite service period. Stock-based compensation expense for liability classified awards that contain market conditions is initially measured based on the grant date fair value of the award
and is remeasured at fair value at each reporting date until the date of settlement, with the determination of the fair value reflecting such conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense of the Company for periods subsequent to the Transaction relates to equity awards issued by the Company to
its employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> under its 2024 Equity Incentive Plan, or the 2024 Plan, including stock options and restricted stock awards with both service and performance-based vesting conditions.
Stock-based compensation expense is measured at estimated fair value on the grant date and is recognized as compensation expense over the requisite service period, which is the vesting period during which an employee provides service in exchange for
the award. Compensation expense for awards to <FONT STYLE="white-space:nowrap">non-employees</FONT> is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of
the award. Forfeitures are accounted for as they occur. Stock-based compensation expense for service-only based awards is recognized on a straight-line basis. Stock-based compensation expense for awards with both performance and service-based
vesting conditions is recognized over the requisite service period using an accelerated attribution method, once the performance conditions are considered probable of being achieved, using management&#8217;s best estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model, which requires
inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. The fair value of each restricted stock award granted is measured on
the date of grant at the estimated fair value of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there has not historically been a public market for the
Company&#8217;s common stock, the estimated fair value of common stock was determined by the Company&#8217;s Board of Directors as of the date of each option grant, with inputs from management, considering third-party valuations of its common stock
as well as the Company&#8217;s Board of Directors&#8217; assessment of additional objective and subjective factors that it believed were relevant. These third-party valuations were performed in accordance with the guidance outlined in the American
Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies. The expected
term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for time periods
approximately equal to the expected term of the award. There is no expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies stock-based compensation expense in the consolidated statement of operations and comprehensive loss in the same manner
in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. See Note 10&#8212;Stock-Based Compensation, for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Transaction, the Company was included in PureTech&#8217;s income tax returns, and all income taxes were paid by PureTech. Income
tax expense and other income tax related information contained in these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consolidated financial statements prior to the Transaction are presented on a separate return approach as if the Company filed its own tax return for those periods. Under this approach, the
provision for income taxes represents income tax paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year calculated as if the Company were a standalone taxpayer filing hypothetical income
tax returns. Current income tax liabilities were assumed to be immediately settled with PureTech and were relieved through the &#8220;Net parent investment&#8221; account and were reflected as &#8220;Net transfers from PureTech Health plc&#8221;
within financing activities in the consolidated statement of cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes income taxes under the asset and
liability method. Deferred income taxes are recognized for differences between the financial reporting and tax basis of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse.
The effect on deferred taxes of a change in tax rates are recognized in income in the period that includes the enactment date. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company considers all available positive
and negative evidence including its past operating results, the existence of cumulative losses in the most recent fiscal years, changes in the business in which the Company operates and its forecast of future taxable income. In determining future
taxable income, the Company is responsible for assumptions utilized, including the amount of <FONT STYLE="white-space:nowrap">pre-tax</FONT> operating income, the reversal of temporary differences and the implementation of feasible and prudent tax
planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions using a <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold for
recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the
effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax
expense. For the year ended December&nbsp;31, 2024, the Company had no tax reserves accrued for uncertain tax positions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is comprised of net loss and other comprehensive loss. The Company has no components of other comprehensive loss. Therefore,
net loss equals comprehensive loss for the year presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net loss per share attributable to common
stockholders as the Company has issued shares that meet the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net loss per share for each class of common and participating securities
according to dividends declared or accumulated and participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income (loss) available to common stockholders for the period to be allocated
between common and participating securities based upon their respective rights to share in the undistributed earnings as if all income (loss) for the period had been distributed. The Company considers its convertible preferred stock to be
participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock would be entitled to receive dividends on a basis consistent with the common stockholders. There is no allocation required under
the <FONT STYLE="white-space:nowrap">two-class</FONT> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing the net loss in each period by the weighted average number of shares of common stock
outstanding during such period, excluding potentially dilutive common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have
been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. The shares of common stock and convertible preferred stock distributed to PureTech upon the formation of the Company
and on the effective date of the Asset Transfer were considered as outstanding in the calculation of basic and diluted earnings per share for the period prior to the formation of the Company and the Asset Transfer, as the formation and Asset
Transfer were deemed to be common control transactions. Additionally, the SPTX March 2024 Shares were considered outstanding in the calculation of basic and diluted earnings per share as of their date of issuance and the SPTX February 2024 Shares
were considered outstanding in the calculation of diluted earnings per share as of their date of issuance (See Note 9&#8212;Common Stock, for definitions and further disclosure regarding these SPTX shares). The Company had no additional shares of
common stock outstanding or any potentially dilutive equity instruments other than described above prior to its formation and the Asset Transfer Date. See Note 15&#8212;Net Loss per Share for definitions and further disclosure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the
chief operating decision-maker, or CODM, in deciding how to allocate resources and assess performance. The Company has one operating and reportable segment, which is the business focused on advancing the development of neuropsychiatric medicines in
areas of high unmet patient needs using the Company&#8217;s proprietary Glyph<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Platform. The Company&#8217;s CODM, its chief executive officer, manages the Company&#8217;s operations on a
consolidated basis for the purpose of allocating resources. All of the Company&#8217;s long-lived assets are held in the United States. See Note 14&#8212;Segments, for further disclosure regarding the Company&#8217;s segment information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2023, the Company early adopted Accounting Standard Update, or ASU, <FONT STYLE="white-space:nowrap">2020-06,</FONT>
<I>Debt&#8212;Debt with Conversion and Other Options</I><I>, </I>or<I> </I>ASU <FONT STYLE="white-space:nowrap">2020-06,</FONT> which reduces complexity in applying GAAP to certain financial instruments with characteristics of liability and equity.
The ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> removed the guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock.
The adoption did not have any impact on the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the Financial Accounting Standards Board, or
the FASB, issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments</I><I> &#8211; </I><I>Credit Losses</I><I> (Topic 326): Measurements of Credit Losses on Financial Instruments</I>, or ASU <FONT
STYLE="white-space:nowrap">2016-13,</FONT> which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> replaces the existing incurred loss
impairment model with an expected loss model. It also eliminates the concept of other-than temporary impairment and requires credit losses related to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in the earlier recognition of credit losses, if any. In May 2019, the FASB
issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-05,</FONT> Financial Instruments&#8212;Credit Losses (Topic 326): Targeted Transition Relief, or ASU <FONT STYLE="white-space:nowrap">2019-05,</FONT> which provides additional implementation
guidance on the previously issued ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> For the Company, both ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU <FONT STYLE="white-space:nowrap">2019-05</FONT> were effective for fiscal years
beginning after December&nbsp;15, 2022. The Company adopted the standard effective January&nbsp;1, 2023 on a modified-retrospective basis which did not have a material impact on the Company&#8217;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment Reporting</I><I> (Topic 280): Improvements
to </I><I>Reportable Segment Disclosures</I>, or ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> which requires public entities to disclose information about </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their reportable segments&#8217; significant expenses on an interim and annual basis. All disclosure requirements under ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> are also required for
public entities with a single reportable segment. This standard became effective for the Company for the annual reporting period ended December&nbsp;31, 2024, using the retrospective method. The adoption of this standard resulted in additional
disclosure on the significant expenses reviewed by the Company&#8217;s CODM. See Note 14&#8212;Segments, for the Company&#8217;s segment presentation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards Updates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB, or other standard-setting bodies that are adopted by Seaport as of the
specified effective date. The Company qualifies as an &#8216;&#8216;emerging growth company&#8217;&#8217; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8216;&#8216;opt out&#8217;&#8217; of the extended
transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and <FONT STYLE="white-space:nowrap">non-public</FONT> companies, the
Company can adopt the new or revised standard at the time <FONT STYLE="white-space:nowrap">non-public</FONT> companies adopt the new or revised standard and can do so until such time that the Company either (i)&nbsp;irrevocably elects to
&#8216;&#8216;opt out&#8217;&#8217; of such extended transition period or (ii)&nbsp;no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is
permitted for <FONT STYLE="white-space:nowrap">non-public</FONT> companies. Unless otherwise discussed, Seaport believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial
position or results of operations upon adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> <I>Income Taxes</I><I> (Topic 740): Improvements to Income Tax Disclosures</I>, or ASU <FONT STYLE="white-space:nowrap">2023-09.</FONT> This amended guidance applies to all entities and
broadly aims to enhance the transparency and decision usefulness of income tax disclosures. For public entities, the amendments in this update are effective for fiscal years beginning after December&nbsp;15, 2024 and for entities other than public
entities, the amendments in this update are effective for fiscal years beginning after December&nbsp;15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The
Company is currently analyzing the impact that ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> may have on the consolidated financial statements for fiscal years beginning after December&nbsp;15, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03,</FONT> <I>Income Statement&#8212;Reporting Comprehensive
Income&#8212;Expense Disaggregation Disclosures</I><I> (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of Income Statement Expenses</I>, or ASU <FONT STYLE="white-space:nowrap">2024-03,</FONT> which is intended to provide
more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, and amortization) included in certain expense captions presented on the statement of operations. The guidance in ASU <FONT
STYLE="white-space:nowrap">2024-03</FONT> is effective for fiscal years beginning after December&nbsp;15, 2026, and interim periods within fiscal years beginning after December&nbsp;15, 2027. Early adoption is permitted. The amendments may be
applied either (1)&nbsp;prospectively to financial statements issued for periods after the effective date of ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> or (2)&nbsp;retrospectively to all prior periods presented in the financial statements.
The Company is currently evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> may have on its consolidated financial statements and disclosures for fiscal years beginning after December&nbsp;15, 2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. PREPAID EXPENSES AND OTHER CURRENT ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid, other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth by level, within the fair value hierarchy, the financial assets, and liabilities carried at fair value on a
recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;prices&nbsp;in<BR>active&nbsp;markets&nbsp;for<BR>identical assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;other<BR>observable&nbsp;inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>unobservable<BR>inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds included in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company&#8217;s cash equivalents consisted of money market funds, classified
as Level&nbsp;1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment.&nbsp;As of December&nbsp;31, 2024, the Company had no financial liabilities that required fair value
measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts
payable, related party payable and accrued expenses and other current liabilities approximate fair value due to their short-term nature. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. PROPERTY
AND EQUIPMENT, NET </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8199;&#8201;240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.3&nbsp;million for the year ended December&nbsp;31, 2024, which consisted of
$0.2&nbsp;million of depreciation expense on the Company&#8217;s assets included on the consolidated balance sheet as of December&nbsp;31, 2024 and $0.1&nbsp;million of allocated depreciation expense from PureTech associated with shared assets. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued personnel and bonus expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional and legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;5,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. MONASH LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, PureTech Health exclusively assigned to the Company, and the Company assumed, all rights and obligations under a license
agreement entered into in August 2017 between PureTech Health and Monash University, or the Original License Agreement. In March 2025, the Company entered into an amended and restated license agreement with Monash University, which amended and
restated the Original License Agreement, or the Monash License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Monash License Agreement, Monash University
grants the Company (i)&nbsp;a worldwide, exclusive, sublicensable license under certain Monash University intellectual property rights, including patent rights related to the Glyph platform, or the Licensed Patents,
<FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities, for the purpose of developing and commercializing products in all fields with one exception, (ii)&nbsp;a worldwide, <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under certain background technology and certain other intellectual property strictly to the extent necessary to exercise the license described in subclause (i)&nbsp;above, and
(iii)&nbsp;a first right and an exclusive option to obtain an exclusive license to any invention generated by Monash University outside of the Licensed Patents and pertaining to certain prodrug technology. Additionally, the Company and Monash
University agreed to collaborate in conducting research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, the Company has
agreed to use reasonable commercial endeavors to (i)&nbsp;develop at least one Licensed Product, (ii)&nbsp;seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or
Europe, promote, and develop the sale of at least one Licensed Product in such territory. Monash University agrees to provide reasonable technical assistance and advice based on Monash University&#8217;s
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the Monash License Agreement. The Company granted Monash University a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, royalty-free license
under the Licensed Patents, related <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities solely for academic, teaching, and non-commercial collaborative research uses,
which includes the right to sublicense for <FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research to other academic institutions or <FONT STYLE="white-space:nowrap">non-commercial</FONT> research entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licenses granted by Monash University, the Company is required to pay Monash University: <FONT
STYLE="white-space:nowrap">(i)&nbsp;low-single</FONT> digit royalties with a rate based on net sales per calendar year (subject to certain reductions); (ii) a <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentage of any net income
received under a sublicense (subject to a license payment stacking reduction) with the percentage varying based on the development stage of the Licensed Products at the time the sublicense is granted during the term of the Monash License Agreement;
(iii)&nbsp;an agreed to research funding amount to progress mutually agreed research and development or commercialization activities; (iv)&nbsp;a <FONT STYLE="white-space:nowrap">mid-five-figure</FONT> annual maintenance fee during the term of the
agreement commencing on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third anniversary of the execution date of the Original License Agreement until the first commercial sale of a Licensed Product creditable against net income sharing, royalties, and milestone
payments; (v)&nbsp;milestone payments in the event of successful development milestones of up to $1.075&nbsp;million per Licensed Product for the first three Licensed Products; and (vi)&nbsp;milestone payments in the event of successful commercial
milestones of up to $7.25&nbsp;million per Licensed Product for the first three Licensed Products. We are also obligated to (a)&nbsp;pay all costs incurred for the prosecution and maintenance of the Licensed Patents and patent filings stemming from
collaboration activities and (b)&nbsp;reimburse Monash University for all patent prosecution costs of the Licensed Patents prior to the execution date of the Original License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monash License Agreement commenced on the execution date of the Original License Agreement and will expire seven years after the last of
the Licensed Patents expires, unless terminated earlier. Either party may terminate for due cause, including for material breach and bankruptcy. Monash University may terminate if the Company fails to meet its diligence requirements. Either party
may terminate the Monash License Agreement if the Company determines that the activities are no longer commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monash
License Agreement was determined to represent an asset acquisition, as the acquired licenses and intellectual property did not meet the definition of a business. All upfront consideration paid in exchange for the Monash License Agreement was
expensed as research and development upon execution of the agreement, as the Licensed Patents and intellectual property was determined to represent in-process research and development with no alternative future use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the first development milestone of $50,000 and the second development milestone of $175,000 were achieved and
paid by PureTech as they occurred prior to the formation of the Company. No other milestones have occurred or have been paid under the Monash License Agreement as of December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2024, the Company incurred no expense associated with annual research funding fees and $30,000 in
annual maintenance fees under the Monash License Agreement, which was accrued on the consolidated balance sheet as of December&nbsp;31, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.
CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, or
the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred stock, or the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, and Series B
convertible preferred stock, or the Series B Preferred Stock, and collectively with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred Stock, the Preferred
Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, the Company issued to PureTech LYT, a wholly owned subsidiary of PureTech, 40,000,000 shares of its Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, as part of the consideration for the assets contributed to the Company as part of the Asset Transfer Agreement. No value was assigned to the Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred Stock as it represented consideration paid as part of a common control transaction. See Note 1&#8212;Nature of Business and Basis of Presentation, for further disclosure of the Asset Transfer Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon the issuance of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock to PureTech LYT, the Company entered
into a Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock Purchase Agreement, or the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Financing, with PureTech LYT and other third-party investors pursuant to which the Company issued
and sold 26,342,102 shares of its <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred Stock at a price of $3.80 per share for gross aggregate proceeds of $100.1&nbsp;million. See Note&nbsp;16&#8212;Related Parties, for further
disclosure of the issuances of the Company&#8217;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock to related parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company entered into a stock purchase agreement with new and existing investors, or the Series B Financing, pursuant to
which the Company issued and sold an aggregate amount of 47,578,934 shares of its Series B Preferred Stock at a purchase price of $4.75 per share, for gross aggregate proceeds of $226.0&nbsp;million. See Note 16&#8212;Related Parties, for further
disclosure around the issuances of the Company&#8217;s Series B Preferred Stock to related parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the Preferred Stock,
the Company assessed the embedded conversion and liquidation features of the securities and determined that such features did not require the Company to separately account for these features. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, Preferred Stock consisted of the following (in thousands, except share and per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Price per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,921,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,921,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8194;325,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8194;330,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,921,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the holders of the Preferred Stock have the following rights and preferences:
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of the Preferred Stock are entitled to vote, together with the holders of common stock, as a single class, on all matters submitted to the shareholders for a vote and are entitled to the number of votes equal to the number of shares of
common stock into which the Preferred Stock would convert on the record date for determination of shareholders entitled to vote. The holders of the Preferred Stock generally vote together as a single class with holders of common stock except that,
(i)&nbsp;the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, exclusively and voting together as a separate class on an as converted basis, shall be entitled to elect two (2)&nbsp;directors of the Company, each, a
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director, (ii)&nbsp;the holders of record of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, exclusively and voting together as a separate class on an as converted
basis, shall be entitled to elect two (2)&nbsp;directors of the Company, each, a Series <FONT STYLE="white-space:nowrap">A-2</FONT> Director, (iii)&nbsp;the holders of record of the shares of Series B Preferred Stock, exclusively and voting together
as a separate class on an as converted basis, shall be entitled to elect one (1)&nbsp;director of the Company, or the Series B Director and, together with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Directors and Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Directors, each, a Preferred Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a majority vote of the holders of the
Company&#8217;s Preferred Stock is required to, among others, liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank
senior to or authorize additional shares of Preferred Stock, declare a dividend or make a distribution, or change the authorized number of directors constituting the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of the Preferred Stock are entitled to participate in any dividends payable to common stockholders on an as converted basis and have priority over the payment of dividends to holders of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a dividend on common stock or any class of stock that is convertible into
common stock, the dividend per share of Preferred Stock would equal the product of (A)&nbsp;the dividend payable on each share of such class or series as if all shares of such class or series had been converted into common stock and (B)&nbsp;the
number of shares of common stock issuable upon conversion of such share of Preferred Stock. In the case of a dividend on any class or series that is not convertible into common stock, the dividend per share of Preferred Stock would be determined by
(A)&nbsp;dividing the amount of dividend payable on each share of such class or series of capital stock by the original issue price of such class or series and (B)&nbsp;multiplying such fraction by the original issue price of the applicable class or
series of Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding share of Preferred Stock is convertible, at any time, at its holder&#8217;s discretion, and without the payment of additional
consideration, into such whole number of fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock, at the applicable conversion ratio then in effect. The conversion price for each share of Preferred Stock shall
initially be equal to the original issuance price for such series of Preferred Stock and is subject to standard anti-dilutive adjustments for share splits and similar transactions. In the event certain conditions are not met prior to March&nbsp;31,
2026, the conversion price of the Series B Preferred Stock will be reduced to $3.80. As of December&nbsp;31, 2024, these conditions have not been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding share of Preferred Stock shall automatically be converted into fully-paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock upon the earliest to occur of (i)&nbsp;the consummation of a qualified initial public offering at a public offering price of at least $5.70 per share, in a firm commitment
resulting in at least $100.0&nbsp;million of gross proceeds or (ii)&nbsp;the date specified by vote or written consent of the holders of at least a majority of the outstanding shares of the Preferred Stock, voting together as a single class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, and the holders of a majority of the outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and Series B Preferred Stock, which majority must include at least
one new investor from the Series B Financing that holds at least 2,100,000 shares of Series B Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, or the Requisite Holders, and the
holders of at least 65% of the then-outstanding shares of Series B Preferred Stock, or the Series B Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There shall be no
adjustment in the conversion price of the Preferred Stock as a result of the issuance or deemed issuance of additional shares of the Company&#8217;s common stock if the Company receives written notice from the holders of at least a majority of the
then outstanding shares of Preferred Stock, voting together as a single class, and, solely in the respect of an adjustment in the conversion price of the Series B Preferred Stock, the Series B Majority, agreeing that no such adjustment shall be made
as the result of the issuance or deemed issuance of additional shares of the Company&#8217;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the occurrence of a Deemed
Liquidation Event (as defined below), the holders of shares of Preferred Stock then outstanding shall be entitled, on a pari passu basis among the series of Preferred Stock, to be paid out of the assets or funds of the Company available for
distribution to stockholders before any payment is made to the holders of common stock. The holders of Preferred Stock are entitled to an amount per share equal to the greater of (i)&nbsp;the original issue price for such series, plus any dividends
declared but unpaid thereon, or (ii)&nbsp;the amount that would have been payable had all shares of each series of Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation
Event. After the payment in full of the Preferred Stock preference amount, the remaining assets of the Company available for distribution to stockholders shall be distributed among the holders of common stock on a pro rata basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the following events shall be considered a &#8220;Deemed Liquidation Event,&#8221;
unless the Requisite Holders, elect otherwise; a merger, consolidation, statutory conversion, transfer, domestication, continuance involving the Company or a subsidiary, or a sale, lease, or transfer of substantially all of the assets of the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preferred Stock does not have any redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation
Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. COMMON STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting,
dividend, and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers, and preferences of the holders of the Preferred Stock set forth above. Each share of common stock entitles the
holder to one vote, together with the holders of the Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s board of
directors, subject to the preferential dividend rights of Preferred Stock. As of December&nbsp;31, 2024, no dividends have been declared or paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company had authorized 159,070,000 shares of common stock, of which 8,150,000 were issued and outstanding,
including 902,778 unvested shares of restricted common stock that are subject to service-based vesting as of December&nbsp;31, 2024. Concurrent with the Transaction, the Company issued 2,500,000 shares of restricted common stock in exchange for
shares of restricted common stock of SPTX. Such shares were originally issued upon the formation of SPTX in February 2024 (the &#8220;SPTX February 2024 Shares&#8221;). SPTX subsequently became a subsidiary of the Company upon the formation date.
See Note 10&#8212;Stock-Based Compensation for further disclosure of restricted common stock issued by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the
Transaction, the Company issued 950,000 shares of common stock to a board member in exchange for shares of common stock of SPTX issued in March 2024 (the &#8220;SPTX March 2024 Shares,&#8221; and together with the SPTX February 2024 Shares, the
&#8220;Exchange Shares&#8221;). SPTX had no other material activity beyond its previously issued shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the SPTX
March 2024 Shares, the Company recognized $0.9&nbsp;million of stock-based compensation expense in its consolidated statement of operations and comprehensive loss for the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had no shares of common stock outstanding or any potentially dilutive equity instruments for any period prior to its formation and
the Asset Transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. STOCK-BASED COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>PureTech Stock-based Compensation Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PureTech has stock-based compensation plans which provide for granting equity awards, including
<FONT STYLE="white-space:nowrap">non-qualified</FONT> and incentive stock options, restricted stock, restricted stock units, cash-based awards, and performance shares to employees, officers, and directors of, and consultants to, PureTech. All
stock-based compensation plans were managed on a consolidated basis by PureTech. Stock-based compensation expense was allocated to the Company based on the proportion of time each employee or <FONT STYLE="white-space:nowrap">non-employee</FONT>
spent on the Seaport Business in the period. Accordingly, the amounts presented are not necessarily indicative of future stock-based compensation of Seaport and do not necessarily reflect the amount that Seaport would have issued as an independent
company for the year presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options Issued by PureTech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the stock option award activity issued to the Company&#8217;s employees transferred pursuant to the Asset
Transfer under PureTech&#8217;s stock-based compensation plans during the year ended December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(525,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">873,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PureTech utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options
issued under PureTech&#8217;s stock-based compensation plans on each grant date. The following table presents the assumptions used by PureTech in the Black-Scholes option-pricing model during the year ended December&nbsp;31, 2024: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted by PureTech during the year ended
December&nbsp;31, 2024 was $1.02. The aggregate intrinsic value is calculated as the difference between the exercise price and the market price of PureTech&#8217;s common stock at December&nbsp;31, 2024. As of December&nbsp;31, 2024, all outstanding
stock options issued by PureTech to the Company&#8217;s employees were fully vested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units Issued by PureTech
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the restricted stock unit activity issued to the Company&#8217;s employees transferred pursuant to the
Asset Transfer under PureTech&#8217;s stock-based compensation plans during the year ended December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Fair&nbsp;Value*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at January&nbsp;1, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,211,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(541,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(990,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,678,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on the fair value as of the reporting date as the awards were liability-classified. Such awards were not
assumed by the Company. While the recipient of these PureTech awards will be eligible to continue vesting as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of December&nbsp;31, 2024, pursuant to the terms of the PureTech equity plan, as long as services continue to be provided to PureTech, the Company will not recognize any stock-based compensation
expense associated with such awards in the periods after PureTech no longer maintained a controlling interest in the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport employees continued to vest in their PureTech equity awards until the completion of the Company&#8217;s Series B Financing (as
discussed in Note 8) in October 2024 at which time PureTech no longer maintained a controlling interest in the Company. Accordingly, Seaport employees forfeited their unvested awards in October 2024 as the employees were no longer deemed to be
continuing service providers under PureTech&#8217;s plan, except for restricted stock units granted to an employee of Seaport for services performed to PureTech. As of December&nbsp;31, 2024, Seaport employees held 873,617 of outstanding vested
options that Seaport employees had 90 days to exercise from October 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2024 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Equity Incentive Plan, or the 2024 Plan, was approved by the Company&#8217;s subsidiary&#8217;s Board and Stockholders and became
effective for the Company in April 2024 and was subsequently amended in April 2024 and October 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2024 Plan, the Company can
issue incentive stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards to employees, directors, and consultants of the Company. The 2024 Plan is administered by the Company&#8217;s Board of
Directors, or by a committee at the discretion of the Board of Directors. The exercise prices, vesting, and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that exercise prices
of each stock option shall not be less than 100% of the fair market value of the Company&#8217;s common stock and that each stock option term cannot exceed 10 years. The Company&#8217;s Board of Directors determines the fair market value of the
Company&#8217;s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional factors which may have changed since the date of the most recent contemporaneous valuation
through the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 10,000,000 shares of common stock were initially reserved for issuance under the 2024 Plan, and it
was subsequently amended to allow for the issuance of up to 38,607,011 shares of common stock. As of December&nbsp;31, 2024, there were 7,102,683 awards available for future grants under the 2024 Plan. Shares of common stock underlying any awards
that are forfeited, canceled, or reacquired by the Company prior to vesting will again be available for the grant of awards under the 2024 Plan. Through the completion of an Initial Public Offering, the Company will continue to grant additional
equity awards to certain individuals to maintain in total a 12.5% ownership on a fully diluted basis as specified by underlying agreements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vesting periods for stock options issued under the 2024 Plan generally vest over four years with a
<FONT STYLE="white-space:nowrap">one-year</FONT> cliff and equal monthly installments thereafter and may be subject to accelerated vesting. Performance-based options vest in three annual installments that are contingent upon the achievement of the
Company&#8217;s annual goals. For restricted stock awards, the vesting periods can vary and may contain accelerated vesting that would result in unvested shares becoming fully vested upon the occurrence of certain events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2024 Plan Stock Option Activity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the Company&#8217;s stock option award activity under the 2024 Plan during the year ended December&nbsp;31, 2024:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,564,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,535,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;9.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;23,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,535,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;10,033,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above excludes the 718,500 performance-based options which have an exercise price of $2.35 per
share, that were approved to be issued by the Company&#8217;s Board of Directors in December 2024, but which have not yet been deemed granted from an accounting perspective as of December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options issued under the 2024 Plan on
each grant date. The following table presents the ranges of assumptions used by the Company in the Black-Scholes option-pricing model during the year ended: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2024</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.19&#8201;-&#8201;6.08</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3.7%&#8201;-&#8201;4.39%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">87.10%&#8201;-&#8201;92.33%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0%&#8201;-&#8201;0%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted during the year ended December&nbsp;31, 2024 was
$1.02 per share. The aggregate intrinsic value is calculated as the difference between the exercise price and the fair value of the Company&#8217;s common stock at December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, there was $16.0&nbsp;million in unrecognized stock-based compensation expense associated with issued and
outstanding service-based stock options, which is expected to be recognized over a weighted-average period of 1.6 years and is partially subject to future accelerated vesting upon the close of an initial public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2024 Plan Restricted Stock Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has granted restricted stock awards to certain members of the Company&#8217;s Board of Directors and Chief Executive Officer. Of
the total 6,250,000 restricted stock awards granted: (i) 2,500,000 have service-based vesting in equal monthly installments over a three-year period, of which 50% of the unvested amount was subject to accelerated vesting upon the close of the Series
B Financing and 50% of any unvested amounts is subject to future acceleration upon the close of an initial public offering; and (ii) 3,750,000 have performance based vesting which vested in full upon the close of the Series B Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the Company&#8217;s restricted stock award activity under the
2024 Plan during the year ended December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8196;6,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,347,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total fair value of restricted stock awards granted during the year ended December&nbsp;31, 2024 was
$6.1&nbsp;million. The total fair value of the restricted stock awards that vested during the period was $5.2&nbsp;million and the total stock-based compensation associated with the restricted stock awards during the year ended December&nbsp;31,
2024 was $5.2&nbsp;million. As of December&nbsp;31, 2024, there was $0.9&nbsp;million in unrecognized stock-based compensation expense associated with issued and outstanding restricted stock awards, which is expected to be recognized over a
weighted-average period of 1.1 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents stock-based compensation expense recorded in the Company&#8217;s consolidated statement of operations and
comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;14,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense for the year ended December&nbsp;31, 2024 of $14.5&nbsp;million
included $14.4&nbsp;million of stock-based compensation expense for Seaport employees, of which $9.6&nbsp;million was due to accelerated vesting of certain awards upon the close of the Series B Financing, and $0.1&nbsp;million of stock-based
compensation expense associated with awards issued to Seaport employees prior to the Asset Transfer under PureTech&#8217;s stock-based compensation plans. Seaport employees continued to vest in their PureTech equity awards until October 2024, at
which time PureTech no longer maintained a controlling interest and the Seaport employees ceased to vest in their PureTech awards. No related tax benefits from stock-based compensation expense were recognized for the year ended 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2024, the Company allocated stock-based compensation of $1.3&nbsp;million, associated with PureTech
employees equity awards who spent a proportion of time providing services to the Company through the Asset Transfer, which is excluded from the table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. INCOME TAXES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
Transaction, income taxes and related income tax accounts have been calculated using the separate return method as if the Company filed income tax returns on a standalone basis. Prior to the Transaction, the Company&#8217;s operations were
calculated on a <FONT STYLE="white-space:nowrap">carve-out</FONT> basis and included certain hypothetical tax attributes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Following the Transaction, these hypothetical tax attributes are not available for future utilization by the Company and were removed from the tax provision. Furthermore, the Company operated as
part of PureTech until the completion of the Asset Transfer on April&nbsp;8, 2024, and therefore the Company will be included in PureTech&#8217;s U.S. Federal consolidated income tax return until that date. The Company will then file a standalone
U.S. Federal consolidated income tax return for the remainder of fiscal year 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the components of loss
before income taxes (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before the provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no income tax expense or benefit for the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal statutory income tax rate to the effective tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8196;21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. state income taxes, net of U.S. federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective income tax rate differs from the U.S. federal statutory rate of 21.0% primarily as a result of
the valuation allowance maintained against the Company&#8217;s net deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities reflect the net tax effects of temporary differences
between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8196;&#8199;1,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use lease asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s change in its valuation allowance account with respect to deferred tax assets is as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8196;10,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The valuation allowance decreased during the year ended December&nbsp;31, 2024 primarily as a result of the
hypothetical tax attributes which are not available for future utilization by the Company as a result of the Transaction, partially offset by U.S. operating losses incurred, research credits generated, and capitalized research and other expenses
generated after the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the need for a valuation allowance, the Company considers the cumulative book income and
loss position. The Company has assessed, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carryback net operating losses, or NOLs, the existence of reversing taxable temporary differences,
the availability of tax planning strategies, and forecasted future taxable income. At December&nbsp;31, 2024, the Company maintained a full valuation allowance against its net deferred tax assets, as it has concluded that it is more likely than not
that the deferred assets will not be utilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company had U.S. federal NOLs, of $7.2&nbsp;million. The
U.S. federal NOLs do not expire. As of December&nbsp;31, 2024, the Company had U.S. federal tax credit carryforwards of $1.5&nbsp;million that expire at various dates through 2043 and $0.7&nbsp;million that expire at various dates through 2044,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company had $6.9&nbsp;million of state NOLs. These NOLs
were generated in Massachusetts and expire at various dates through 2044. As of December&nbsp;31, 2024, the Company had U.S. state tax credit carryforwards of $0.3&nbsp;million that expire at various dates through 2038, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation undergoes an ownership change, the corporation&#8217;s ability
to use its <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs and other <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change tax attributes, such as research tax credits, to offset its post-change income and taxes may be
limited. In general, an ownership change occurs if there is a cumulative change in an entity&#8217;s ownership by 5% stockholders that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under U.S. state tax laws.
Under the Tax Cuts and Jobs Act of 2017, the use of federal NOLs arising in taxable years beginning after December&nbsp;31, 2017 is limited to 80% of current year taxable income and NOLs arising in taxable years ending after December&nbsp;31, 2017
may not be carried back (though any such NOLs may be carried forward indefinitely). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may have experienced an ownership change
in the current period and may experience ownership changes in the future as a result of future transactions in its share capital, some of which may be outside of the control of the Company. As a result, if the Company earns net taxable income, its
ability to use its <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs, or other <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change tax attributes, to offset U.S. federal and state taxable income and taxes may be subject to
significant limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States. At December&nbsp;31, 2024, the Company is no longer
subject to examination by taxing authorities in the United States for years prior to 2021. NOLs and tax credits in the United States may be subject to adjustments by taxing authorities in future years in which they are utilized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. LEASES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company
entered into an operating lease for office space in Boston, Massachusetts, which commenced in December 2024 and has an initial lease term that continues through October&nbsp;20, 2030, with no options to extend. In conjunction with entering into the
lease, the Company paid a security deposit of $0.2&nbsp;million in the form of a letter of credit, which is recorded as restricted cash within other <FONT STYLE="white-space:nowrap">non-current</FONT> assets on the Company&#8217;s consolidated
balance sheet as of December&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, the Company entered into a laboratory license agreement with a third party
for lab space located in Boston, Massachusetts. The license commenced in January 2025 and is for an initial term of 24 months from the commencement date, with no renewal option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to entering into the lease and laboratory license agreement, the Company did not have any leases as it shared office and lab space with
PureTech and made payments to PureTech under the TSA. See Note&nbsp;16&#8212;Related Parties for further disclosure of transactions with PureTech. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table contains a summary of the components of lease costs recognized pertaining to the Company&#8217;s operating lease for the
year ended December&nbsp;31, 2024 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease Cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table contains a summary of other supplemental lease information pertaining to
the Company&#8217;s operating lease for the year ended December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Lease Information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liability&#8212;operating leases (in
thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term&#8212;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate&#8212;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;6.61</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below reconciles future minimum payments under
<FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases as of December&nbsp;31, 2024 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: impact of leases not yet commenced</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;4,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Legal Matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company, from time to time, may be involved with lawsuits arising in the ordinary course of business. The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition,
results of operations, or cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with various third parties for preclinical research studies, clinical
trials, testing, manufacturing, and other services. These contracts generally provide for termination upon notice and are cancellable without significant penalty or payment, and do not contain any minimum purchase commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees and Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners
and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties. In addition, the Company has entered into indemnification agreements with all&nbsp;board of directors that will require the Company, among other things, to indemnify them against certain
liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the
Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements that could have a material effect on its financial position, results of operations, or cash
flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company participates in the PureTech defined-contribution plan under Section&nbsp;401(k) of the Internal Revenue Code of 1986, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows
participants to defer a portion of their annual compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis. The Company will make a contribution of 3% of each employee&#8217;s annual compensation up to annual safe harbor limits. The
Company has accrued $0.1&nbsp;million in 401(k) contribution liabilities as of December&nbsp;31, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 12&#8212;Leases, for information related to the Company&#8217;s lease obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. SEGMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has one
operating and reportable segment focused on inventing and developing novel medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders using the Company&#8217;s proprietary Glyph<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CODM manages the Company&#8217;s operations on a consolidated basis,
and assesses performance based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. The CODM makes decisions about allocating resources and assessing performance for the entire company. The
measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain significant segment expenses that are regularly provided
to the CODM (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAllo direct research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAgo direct research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and early discovery assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation of $0.7 million)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other indirect research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation of $15.2 million)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other segment items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8201;46,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Company&#8217;s formation on April&nbsp;1, 2024, the Company issued 1,000 shares of its common stock to PureTech and on April&nbsp;8,
2024, the effective date of the Asset Transfer, an additional 949,000 shares of its common stock were issued to PureTech. The aggregate 950,000 shares were considered outstanding for the full year and the Exchange Shares were considered outstanding
based on their issuance or vesting dates, as applicable, in the calculation of basic and diluted earnings per share for the year ended December&nbsp;31, 2024, as the formation, Asset Transfer and Exchange Shares were deemed to be common control
transactions. There were no shares of the Company outstanding prior to the Company&#8217;s formation and the Asset Transfer Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period,
without consideration for potentially dilutive securities. The net loss available to common stockholders was not allocated to the Preferred Stock as the holders did not have a contractual obligation to share in losses. Diluted net loss per share is
the same as basic net loss per share for the years presented since the effects of any potentially dilutive securities, would be antidilutive given the net loss of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is calculated as follows (in thousands except share and per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;2,961,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For accounting purposes, the computation of basic and diluted weighted-average common shares
outstanding for the year ended December&nbsp;31, 2024&nbsp;excludes all shares of unvested restricted common stock as such shares are not considered outstanding. See Note 10&#8212;Stock-Based Compensation, for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share attributable
to common stockholders, as their effect is antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,535,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (as converted to common
stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock (as converted to common
stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;139,359,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The table above excludes the performance-based options, as they were not yet been deemed granted from an
accounting perspective. See Note 10&#8212;Stock-Based Compensation, for more information. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. RELATED PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During&nbsp;the year ended December&nbsp;31, 2024, there was $5.5&nbsp;million of corporate expense allocations from PureTech Health plc prior
to the Transaction and $14.2&nbsp;million of expenses incurred pursuant to the TSA after the Asset Transfer Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
Transaction, the Company historically operated as part of PureTech and not as a separate entity. Accordingly, for the period prior to the Transaction, certain corporate expenses represent shared costs of PureTech that were allocated to the Company
based on a systematic and rational methodology and are reflected as expenses in these consolidated financial statements. These amounts include, but are not limited to, items such as payroll, general management and executive oversight, costs to
support Seaport&#8217;s information technology infrastructure, facilities, compliance, human resources, legal, and finance functions, risk management, and stock-based compensation, all of which supported the operations of PureTech as a whole.
Corporate expense and shared cost allocations are generally allocated to the Company based on proportional cost allocation methods using headcount or proportional time worked supporting the Seaport Business and other organizational activities, as
applicable, which were considered to be reasonable reflections of the utilization of services provided or benefit received by the Company during the periods presented prior to the Transaction. Total corporate expense allocations were
$1.7&nbsp;million in research and development and $3.8&nbsp;million in general and administrative expenses during the year ended December&nbsp;31, 2024. Net transfers from PureTech Health plc within financing activities in the consolidated statement
of cash flows and the consolidated statement of convertible preferred stock and stockholders&#8217; deficit consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate cost allocations from PureTech</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General finance activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from PureTech</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed in Note 1&#8212;Nature of Business and Basis of Presentation, the Company
entered into the Asset Transfer Agreement with PureTech and issued 40,000,000 shares of its Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock to PureTech LYT. In connection with entering into the Asset Transfer Agreement, the
Company entered into the TSA with PureTech, under which the Company made an <FONT STYLE="white-space:nowrap">up-front</FONT> payment of $0.5&nbsp;million to reimburse PureTech for work performed by certain third-parties prior to the closing of the
Asset Transfer Agreement to advance the Company&#8217;s programs and activities. During the year ended December&nbsp;31, 2024, the Company incurred $14.2&nbsp;million of expenses from PureTech under the TSA of which $12.4&nbsp;million related to
research and development and $1.8&nbsp;million related to general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, as part of its Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Financing, the Company issued and sold 8,421,052 shares of its Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock to PureTech LYT, at a purchase price of $3.80 per share for gross aggregate
proceeds of $32.0&nbsp;million. Subsequent to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing, PureTech LYT remained the controlling investor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, as part of its Series B Financing, the Company issued and sold an aggregate 3,031,578 and 494,734 shares of its Series B
Preferred Stock to PureTech LYT and to certain of the Company&#8217;s management and board of directors, respectively, at a purchase price of $4.75 per share, for gross aggregate proceeds of $14.4&nbsp;million and $2.3&nbsp;million, respectively.
Subsequent to the Series B Financing, PureTech LYT was no longer a controlling investor of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2024, the Company made payments of $0.2&nbsp;million to Third Rock Ventures for professional fees, which were included within general and administrative expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
evaluated subsequent events through March&nbsp;31, 2025, the date these consolidated financial statements were available to be issued. There were no subsequent events that require adjustments to or disclosure in the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. SUBSEQUENT EVENTS (UNAUDITED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with the reissuance of the financial statements, the Company has evaluated subsequent events through November&nbsp;21, 2025, the date the financial statements were available to be reissued. The Company has concluded that no subsequent
events have occurred that require disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;Shares </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00a03.jpg" ALT="LOGO" STYLE="width:2.98667in;height:1.12833in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>J.P.&nbsp;Morgan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Leerink&nbsp;Partners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Citigroup </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel
</B></P> <P STYLE="margin-top:48pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Through and including &#8195;&#8195;&#8195;&#8195;, 2026 (the 25th day after the date of this prospectus), all dealers effecting
transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter
and with respect to an unsold allotment or subscription. </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all references to &#8220;Seaport,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
&#8220;us&#8221;, or similar terms refer to Seaport Therapeutics, Inc. and its wholly owned, consolidated subsidiaries, or either or both of them as the context may require. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection with this
offering. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Market, or Nasdaq, listing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Custodian transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> *</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be provided by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against
liabilities arising out of actions, suits, and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may
cover expenses (including attorneys&#8217; fees) judgments, fines, and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit, or proceeding. Section&nbsp;145 permits
corporations to pay expenses (including attorneys&#8217; fees) incurred by directors and officers in advance of the final disposition of such action, suit, or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to
purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the
corporation would have the power to indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will adopt
provisions in our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which will become effective upon the effectiveness of the
registration statement of which this prospectus forms a part, that will limit or eliminate the personal liability of our directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended.
Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as directors or officers, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our directors, any unlawful payments related to dividends or unlawful stock purchases, redemptions or other
distributions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which they derived an improper personal benefit; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our officers, any derivative action by or in the right of the corporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect the
availability of equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated bylaws will provide that:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to
the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will advance reasonable expenses, including attorneys&#8217; fees, to our directors and, in the discretion of
our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our executive
officers. These agreements provide that we will indemnify each of our directors, our executive officers, and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#8217; fees (but
excluding judgments, fines, and settlement amounts), to each indemnified director, executive officer, or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any
action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification,
advancement of expenses, or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s or officer&#8217;s services as a director
referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide
indemnification for the expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain general liability insurance
which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended, or Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for indemnification of us and our directors and
officers by the underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Recent Sales
of Unregistered Securities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding securities we have issued within the past three years that were
not registered under the Securities Act.<B><I>&nbsp;</I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Preferred Stock Issuances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we issued an aggregate of 40,000,000 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock in
connection with entry into an asset transfer agreement, dated as of April&nbsp;8, 2024, or the Asset Transfer Agreement, with PureTech LYT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also issued and sold to accredited investors an aggregate of 26,342,102 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT>
convertible preferred stock at a price per share of $3.80, for an aggregate purchase price of $100.1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October and November 2024, we issued and sold to accredited investors an aggregate of
47,578,934 shares of Series B convertible preferred stock at a price per share of $4.75, for an aggregate purchase price of approximately $226.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Common Stock Issuances </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2024, we issued an aggregate of 1,000 shares of common stock to PureTech LYT in connection with our formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we
issued an aggregate of 949,000 shares of common stock to PureTech LYT in connection with the Asset Transfer Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since April 2024,
we have sold or issued by exchange to our founders an aggregate of 7,200,000 shares of restricted common stock under our 2024 Plan or pursuant to agreement, at a purchase price of $0.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c) Grants and exercises of stock options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since April 2024, we have granted certain employees, consultants, and directors options to purchase an aggregate of 28,120,752 shares of our
common stock under our 2024 Plan, at exercise prices ranging from $0.97 to $2.53 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since April 2024, 1200 stock options have
been exercised under out 2024 plan at a weighted average purchase price of $0.97 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved
any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, the Registrant believes these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2)
of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts
relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any
distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with the Registrant, to information about the Registrant. The sales of
these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation, as amended, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws, to be in effect as of the effectiveness of the registration statement of which this prospectus forms a part.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Specimen Common Stock Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2+&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#8217; Rights Agreement, by and between the Registrant and certain of its stockholders, dated as of October&nbsp;18, 2024.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Goodwin Procter LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2024 Equity Incentive Plan, as amended, and form of award agreements thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2026 Equity Incentive Plan and form of award agreements thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2026 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, by and between the Registrant and its directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Executive Cash Incentive Bonus Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, by and between the Registrant and Daphne Zohar, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, by and between the Registrant and &#8195;&#8195;&#8195;&#8195;, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, by and between the Registrant and &#8195;&#8195;&#8195;&#8195;, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*&#134;+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Asset Transfer Agreement by and between the Registrant, PureTech Health LLC and PureTech LYT, Inc., dated April&nbsp;8, 2024.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*&#134;+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated License Agreement between Monash University, ABN 12 377 614 012, a body politic and corporate constituted in accordance with the Monash University Act 2009 of Wellington Road, Clayton, Victoria, Australia 3800
and the Registrant, dated March&nbsp;12, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Laboratory License Agreement, by and between the Registrant and Eli Lilly and Company, dated December&nbsp;10, 2024.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Sub-Sublease</FONT> Agreement, by and among the Registrant, Enel North America, Inc. and Enel x Federal LLC, dated November&nbsp;27, 2024.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Goodwin Procter LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Filing Fee Table.</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain portions of this document that constitute confidential information have been redacted pursuant to Item
601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601(a)(5) and (6)&nbsp;of
Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the
financial statements or the notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful
defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act of 1933, as amended, the information omitted
from a form of prospectus filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act of 1933,
as amended, shall be deemed to be part of this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Massachusetts, on the &#8195;&#8195;&#8195;&#8195; of &#8195;&#8195;&#8195;&#8195;, 2026. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SEAPORT THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:&#8194; Chief Executive Officer and Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY AND SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each individual whose signature appears below hereby constitutes and appoints Daphne Zohar and Lauren A. White as such person&#8217;s true and
lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent with full power of substitution and resubstitution, for such person in such person&#8217;s name, place, and stead, in any and all
capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act
of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or any substitute
or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act
of 1933, as amended, this Registration Statement and Power of Attorney has been signed by the following person in the capacities and on the date indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lauren A. White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer (<I>Principal Financial Officer and Principal Accounting Officer</I>)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director and Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne, LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2026</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections&nbsp;242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the
State of Delaware (the &#8220;<B>General Corporation Law</B>&#8221;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of this corporation is Seaport Therapeutics, Inc., and that this corporation was originally incorporated pursuant to
the General Corporation Law on April&nbsp;1, 2024 under the name SP Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That the Board of Directors of this
corporation (the &#8220;<B>Board of Directors</B>&#8221;) duly adopted resolutions proposing to further amend and restate the Amended and Restated Certificate of Incorporation of this corporation, declaring said amendment and restatement to be
advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and
restatement is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Amended and Restated Certificate of Incorporation of this corporation be further
amended and restated in its entirety to read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>: The name of this corporation is Seaport Therapeutics, Inc. (the
&#8220;<B>Corporation</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: The address of the registered office of the Corporation in the State of Delaware is
1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD</B>: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH</B>: The total number of shares of all classes of stock which
the Corporation shall have the authority to issue is 272,991,040. The Corporation has two classes of stock, referred to as Common Stock and Preferred Stock. There are 159,070,000 shares of authorized Common Stock, $0.0001 par value per share
(&#8220;<B>Common Stock</B>&#8221;), and 113,921,040 shares of authorized Preferred Stock, $0.0001 par value per share (&#8220;<B>Preferred Stock</B>&#8221;), 40,000,000 of which are hereby designated as &#8220;<B>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#8221;, 26,342,102 of which are hereby designated as &#8220;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</B>&#8221;, and 47,578,938 of which are hereby designated as
&#8220;<B>Series B Preferred Stock</B>&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, preferences and special
rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.
COMMON STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and
qualified by the powers, preferences and special rights of the holders of the Preferred Stock set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. Except
as otherwise provided herein or by applicable law, the holders of the Common Stock shall be entitled to one vote for each share of Common Stock held as of the applicable record date for each meeting of stockholders (and written actions in lieu of
meetings); <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (this
&#8220;<B>Certificate of Incorporation</B>&#8221;) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or
more other such series, to vote thereon pursuant to this Certificate of Incorporation or pursuant to the General Corporation Law. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares
thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of
the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares
of the Preferred Stock shall have the powers, preferences and special rights set forth in this Part&nbsp;B of this <U>Article</U><U></U><U>&nbsp;Fourth</U>. Unless otherwise indicated, references to &#8220;sections&#8221; or &#8220;Sections&#8221;
in this Part&nbsp;B of this <U>Article</U><U></U><U>&nbsp;Fourth</U> refer to sections of Part&nbsp;B of this <U>Article</U><U></U><U>&nbsp;Fourth</U>. References to &#8220;<B>Preferred Stock</B>&#8221; mean, together, the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, and the Series B Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the
obtaining of any consents required elsewhere in this Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall, on a <I>pari passu</I> basis, first receive, or simultaneously receive, a dividend on each outstanding
share of Preferred Stock in an amount at least equal to (i)&nbsp;in the case of a dividend on Common Stock, the product of (A)&nbsp;the dividend declared, paid or set aside on such Common Stock and (B)&nbsp;the number of shares of Common Stock
issuable upon conversion of a share of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock; (ii)&nbsp;in the case of a dividend on a class or series of capital stock that is convertible into Common Stock, the product of (A)&nbsp;the dividend declared, paid or set aside
per share of such class or series of capital stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of such Preferred Stock, <U>divided</U> by the number of shares of Common Stock issuable upon conversion of a
share of such class or series of capital stock; or (iii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, the product of (A)&nbsp;the amount of the dividend payable on each share of such class or
series of capital stock divi<U>d</U>ed by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with
respect to such class or series) and (B)&nbsp;the applicable Original Issue Price (as defined below); <U>provided</U> that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of
capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in
the highest Preferred Stock dividend for the applicable series of Preferred Stock, The &#8220;<B>Original Issue Price</B>&#8221; shall mean, with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, $0.10 per share,
with respect to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, $3.80 per share, and with respect to the Series B Preferred Stock, $4.75 per share, subject to, in each case, appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the applicable Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation,
Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Preferred
Stock</U>. In the event of (a)&nbsp;any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of each series of Preferred Stock then outstanding shall be entitled to be paid out of the assets of
the Corporation available for distribution to its stockholders, and (b)&nbsp;a Deemed Liquidation Event (as defined below), the holders of shares of each series of Preferred Stock then outstanding shall be entitled to be paid out of the
consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, on a <I>pari passu</I> basis based on their respective Liquidation Amounts (as defined below) and before any
payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share of each such series of Preferred Stock equal to the greater of (i)&nbsp;the Original Issue Price for such series, plus any dividends
declared but unpaid thereon, and (ii)&nbsp;such amount per share as would have been payable had all shares of such series of Preferred Stock (and all shares of all other series of Preferred Stock that would receive a larger distribution per share if
such series of Preferred Stock were converted into Common Stock) been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount
payable pursuant to this sentence is hereinafter referred to, for each series of Preferred Stock, as applicable, as the &#8220;<B>Liquidation Amount</B>&#8221;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed
Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled under this
<U>Section</U><U></U><U>&nbsp;2.1</U>, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of
the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Payments to Holders of Common Stock</U>. In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for
distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or the remaining Available Proceeds, as the
case may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares of Common Stock held by each such holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Definition</U>. Each of the following events shall be considered a &#8220;<B>Deemed Liquidation Event</B>&#8221; unless (x)&nbsp;the
holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, and (y)&nbsp;the holders of a majority of the
outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and Series B Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, which majority
must include at least one New Series B Investor (as defined in the Amended and Restated Investors&#8217; Rights Agreement, dated on or about the Original Issue Date (as defined below), by and among the Corporation and the other parties thereto, as
such agreement may be amended and/or restated from time to time (the &#8220;<B>Investors&#8217; Rights Agreement</B>&#8221;)) (together, the &#8220;<B>Requisite Holders</B>&#8221;), elect otherwise by written notice sent to the Corporation at least
10 days prior to the effective date of any such event: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) a merger, consolidation, statutory conversion, transfer, domestication, or
continuance in which </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger, consolidation, statutory conversion, transfer, domestication, or continuance, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger,
consolidation, statutory conversion, transfer, domestication, or continuance involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger, consolidation, statutory
conversion, transfer, domestication, or continuance continue to represent, or are converted into or exchanged for shares of capital stock or other equity interests that represent, immediately following such merger, consolidation, statutory
conversion, transfer, domestication, or continuance, a majority, by voting power, of the capital stock or other equity interests of (1)&nbsp;the surviving or resulting corporation or entity; or (2)&nbsp;if the surviving or resulting corporation or
entity is a wholly owned subsidiary of another corporation or entity immediately following such merger, consolidation, statutory conversion, transfer, domestication, or continuance, the parent corporation or entity of such surviving or resulting
corporation or entity; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) (i)&nbsp;the sale, lease, transfer, exclusive license or other disposition, in a single
transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or (ii)&nbsp;the sale, lease, transfer, exclusive
license or other disposition (whether by merger, consolidation, statutory conversion, domestication, continuance or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Corporation if
substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of
the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in
<U>Section</U><U></U><U>&nbsp;2.3.1(a)(i)</U> unless the agreement or plan with respect to such transaction, or terms of such transaction (any such agreement, plan or terms, the &#8220;<B>Transaction Document</B>&#8221;), provide that the
consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated to the holders of capital stock of the Corporation in accordance with <U>Sections</U><U></U><U>&nbsp;2.1</U> and <U>2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event referred to in <U>Section</U><U></U><U>&nbsp;2.3.1(a)(ii)</U> or <U>2.3.1(b)</U>, if the
Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later
than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) to require the redemption of such shares of Preferred Stock, and (ii)&nbsp;if the Requisite Holders so
request in a written instrument delivered to the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained
liabilities associated with the assets sold or technology licensed, any other expenses reasonably related to such Deemed Liquidation Event or any other expenses incident to the dissolution of the Corporation as provided herein, in each case as
determined in good faith by the Board of Directors), together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the
&#8220;<B>Available Proceeds</B>&#8221;) on the 150th day after such Deemed Liquidation Event (the &#8220;<B>DLE Redemption Date</B>&#8221;), to redeem all outstanding shares of Preferred Stock at a price per share equal to the applicable
Liquidation Amount; <U>provided</U>, that if the definitive agreements governing such Deemed Liquidation Event contain contingent indemnification obligations on the part of the Corporation and prohibit the Corporation from distributing all or a
portion of the Available Proceeds while such indemnification obligations remain outstanding, then the DLE Redemption Date shall automatically be extended to the date that is ten business days following the date on which such prohibition expires.
Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall redeem a pro rata portion of each
holder&#8217;s shares of Preferred Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem
all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders. Prior to the distribution or redemption provided for in this <U>Section</U><U></U><U>&nbsp;2.3.2(b)</U>, the Corporation shall not expend or dissipate the Available Proceeds for any
purpose, except to discharge expenses incurred in connection with such Deemed Liquidation Event. In connection with a distribution or redemption provided for in <U>Section</U><U></U><U>&nbsp;2.3.2</U>, the Corporation shall send written notice of
the redemption (the &#8220;<B>Redemption Notice</B>&#8221;) to each holder of record of Preferred Stock. Each Redemption Notice shall state: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the date
specified in the Redemption Notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the redemption date and the price per share at which the shares of Preferred Stock are being redeemed; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner
and at the place designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
the Redemption Notice shall have been duly given, and if payment is tendered or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of
Preferred Stock so called for redemption shall not have been surrendered, all rights with respect to such shares shall forthwith after the date terminate, except only the right of the holders to receive the payment without interest upon surrender of
any such certificate or certificates therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to
the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities to be paid or distributed to
such holders pursuant to such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to
<U>Section</U><U></U><U>&nbsp;2.3.1(a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#8220;<B>Additional Consideration</B>&#8221;), the Transaction
Document shall provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#8220;<B>Initial Consideration</B>&#8221;) shall be allocated among the holders of capital stock of the Corporation in
accordance with <U>Sections</U><U></U><U>&nbsp;2.1</U> and <U>2.2</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes
payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Sections</U><U></U><U>&nbsp;2.1</U> and <U>2.2</U> after taking
into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Section</U><U></U><U>&nbsp;2.3.4</U>, consideration placed into escrow or retained as a holdback to be available for
satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Voting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of
stockholders of the Corporation (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into
which the shares of Preferred Stock held by such holder are convertible (as provided in <U>Section</U><U></U><U>&nbsp;4</U> below) as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by
the other provisions of this Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.1 (i)&nbsp;At all times when at least 10,000,000 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock remain
outstanding (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock), the holders of
record of the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, exclusively and voting together as a separate class, shall be entitled to elect two&nbsp;(2) directors of the Corporation (each, a &#8220;<B>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Director</B>&#8221;), (ii)&nbsp;at all times when at least 6,578,947 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock remain outstanding (subject to appropriate adjustment in the
event of any stock dividend, stock split, combination, or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock), the holders of record of the shares of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, exclusively and voting together as a separate class, shall be entitled to elect two&nbsp;(2) directors of the Corporation (each, a &#8220;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Director</B>&#8221;), (iii)&nbsp;at all times when at least 11,894,734 shares of Series B Preferred Stock remain outstanding (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar
recapitalization with respect to the Series B Preferred Stock), the holders of record of the shares of Series B Preferred Stock, exclusively and voting together as a separate class, shall be entitled to elect one&nbsp;(1) director of the Corporation
(the &#8220;<B>Series B Director</B>&#8221; and, together with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Directors and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Directors, each, a &#8220;<B>Preferred Director</B>&#8221;), and
(iv)&nbsp;the holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, shall be entitled to elect the balance of the total number of directors of the Corporation (the &#8220;<B><FONT STYLE="white-space:nowrap">At-Large</FONT>
Directors</B>&#8221;); <U>provided</U>, <U>however</U>, for administrative convenience, the initial Series B Director may also be appointed by the Board of Directors in connection with the approval of the initial issuance of the Series B Preferred
Stock without a separate action by the holders of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.2 Any director elected as provided in <U>Sections</U><U></U><U>&nbsp;3.2.1(i)</U>,<U>
3.2.1(ii)</U> or <U>Section</U><U></U><U>&nbsp;3.2.1(iii)</U> may be removed without cause by, and only by, the affirmative vote of the holders of a majority of the shares of the class or series of capital stock entitled to elect such director or
directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.3 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the holders of shares of Preferred Stock fail to elect a sufficient number of directors to fill all
directorships for which they are entitled to elect directors pursuant to <U>Section</U><U></U><U>&nbsp;3.2.1</U> (and to the extent any of such directorships is not otherwise filled by a director appointed in accordance with the proviso in
<U>Section</U><U></U><U>&nbsp;3.2.1)</U>, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock fill such directorship in accordance with <U>Section</U><U></U><U>&nbsp;3.2.1</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A vacancy in any <FONT STYLE="white-space:nowrap">At-Large</FONT> Director seat can be filled by either the
vote or written consent in lieu of a meeting of the stockholders entitled to elect the <FONT STYLE="white-space:nowrap">At-Large</FONT> Directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority in voting power of
the outstanding shares of the class or series of capital stock entitled to elect such director shall constitute a quorum for the purpose of electing such director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.4 The &#8220;<B>Requisite Directors</B>&#8221; shall mean a majority of the Board of Directors, including a majority of the Preferred
Directors then seated (or three&nbsp;(3) Preferred Directors if greater), and including at least two (2)&nbsp;Preferred Directors that are not Series <FONT STYLE="white-space:nowrap">A-1</FONT> Directors, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when at least 28,480,260 shares of Preferred Stock (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock and calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) are
outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect any of the
following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the Requisite Holders and any such act or transaction that has not been approved
by such consent or vote prior to such act or transaction being effected shall be null and void <I>ab initio,</I> and of no force or effect: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the Corporation or effect any Deemed
Liquidation Event or any other merger, consolidation, statutory conversion, transfer, domestication or continuance; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 amend, alter or repeal any provision of this Certificate of Incorporation or Bylaws
of the Corporation in a manner that adversely affects the special rights, powers and preferences of the Preferred Stock (or any series thereof); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 create, or authorize the creation of, or issue, or obligate itself to issue, shares of, or reclassify, any capital stock or any
security convertible into or exercisable for any equity security, in each case, unless the same ranks junior to the Preferred Stock with respect to its special rights, powers and preferences; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 increase or decrease the authorized number of shares of Preferred Stock or of any series of Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 without the approval of the Requisite Directors, sell, issue, sponsor, create or distribute, or cause or permit any of its subsidiaries
to sell, issue, sponsor, create or distribute, any digital tokens, cryptocurrency or other blockchain-based assets (collectively, &#8220;<B>Tokens</B>&#8221;), including through a <FONT STYLE="white-space:nowrap">pre-sale,</FONT> initial coin
offering, token distribution event or crowdfunding, or through the issuance of any instrument convertible into or exchangeable for Tokens; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any
shares of capital stock of the Corporation other than: (i)&nbsp;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein; (ii)&nbsp;dividends or other distributions payable on the Common Stock solely in the
form of additional shares of Common Stock; (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such
employment or service, at no greater than the original purchase price thereof; and (iv)&nbsp;as otherwise approved by the Requisite Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 without the approval of the Requisite Directors, (i)&nbsp;adopt, amend, terminate or repeal any equity (or equity-linked) compensation
plan, or (ii)&nbsp;amend any such plan to increase the number of shares authorized for issuance thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 unless the aggregate
indebtedness of the Corporation and its subsidiaries for borrowed money following such action would not exceed $1,000,000, create, or issue, any debt security, create any lien or security interest (except for purchase money liens or statutory liens
of landlords, mechanics, materialmen, workmen, warehousemen and other similar persons arising or incurred in the ordinary course of business), or incur other indebtedness for borrowed money, including but not limited to obligations and contingent
obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security lien, security interest or other indebtedness for borrowed money, unless approved by the Requisite Directors in each case, and other
than equipment leases, bank lines of credit or trade payables incurred in the ordinary course of business and approved by the Requisite Directors; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 create, or hold capital stock in, any subsidiary that is not wholly owned (either
directly or through one or more other subsidiaries) by the Corporation, or permit any subsidiary to create, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any
capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all
or substantially all of the assets of such subsidiary; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 increase or decrease the authorized number of directors constituting
the Board of Directors, change the number of votes entitled to be cast by any director or directors on any matter, or adopt any provision inconsistent with <U>Article</U><U></U><U>&nbsp;Sixth</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock Protective Provisions</U>. At any time when at least 10,000,000
shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock are outstanding (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the
Preferred Stock and calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance,
recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or
affirmative vote of the holders of a majority of the then-outstanding shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and any such act or transaction that has not been approved by such consent or vote prior to such act
or transaction being effected shall be null and void <I>ab initio,</I> and of no force or effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.1 amend, alter or repeal any
provision of this Certificate of Incorporation or Bylaws of the Corporation in a manner that adversely affects the special rights, powers and preferences of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.2 increase or decrease the authorized number of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock Protective Provisions</U>. At any time when at least 6,578,947
shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock are outstanding (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the
Preferred Stock and calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance,
recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or
affirmative vote of the holders of a majority of the then-outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and any such act or transaction that has not been approved by such consent or vote prior to such act
or transaction being effected shall be null and void <I>ab initio,</I> and of no force or effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.1 amend, alter or repeal any
provision of this Certificate of Incorporation or Bylaws of the Corporation in a manner that adversely affects the special rights, powers and preferences of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.2 increase or decrease the authorized number of shares of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.6 <U>Series B Preferred Stock Protective Provisions</U>. At any time when at
least 11,894,734 shares of Series B Preferred Stock are outstanding (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock and calculated
on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization,
reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of
the holders of at least 65% of the then-outstanding shares of Series B Preferred Stock (the &#8220;<B>Series B Majority</B>&#8221;) and any such act or transaction that has not been approved by such consent or vote prior to such act or transaction
being effected shall be null and void <I>ab initio,</I> and of no force or effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.6.1 amend, alter or repeal any provision of this
Certificate of Incorporation or Bylaws of the Corporation in a manner that adversely affects the special rights, powers and preferences of the Series B Preferred Stock; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.6.2 increase or decrease the authorized number of shares of Series B Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional Conversion</U>. The holders of the Preferred Stock shall have conversion rights as follows (the &#8220;<B>Conversion
Rights</B>&#8221;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, and
without the payment of additional consideration by the holder thereof, into such whole number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (calculated as provided in
<U>Section</U><U></U><U>&nbsp;4.2</U> below), as is determined by dividing the applicable Original Issue Price by the applicable Conversion Price (as defined below) in effect at the time of conversion. The &#8220;<B>Conversion Price</B>&#8221;
applicable to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, and the Series B Preferred Stock as of the Original Issue Date shall be equal to $0.10,
$3.80, and $4.75, respectively, per share. Such initial Conversion Price for the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, and the Series B Preferred
Stock, and the rate at which shares of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, and the Series B Preferred Stock may be converted into shares of
Common Stock, shall be subject to adjustment as provided in this <U>Section</U><U></U><U>&nbsp;4</U>. In the event that, on or prior to March&nbsp;31, 2026, the first patient is not dosed in a placebo-controlled phase 2 study for <FONT
STYLE="white-space:nowrap">SPT-300</FONT> in major depressive disorder (which study includes activated sites in the United States) and the Conversion Price for the Series B Preferred Stock at such time exceeds $3.80 per share, then the Conversion
Price for the Series B Preferred Stock will be automatically reduced to $3.80 per share (in each case, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to
the Common Stock and calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a notice of redemption of
any shares of Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;2.3.2(b)</U>, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the date fixed for
redemption, unless the redemption price is not fully paid on such redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the
Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred
Stock; provided that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with <U>Section</U><U></U><U>&nbsp;2.1</U> to the holders of Preferred Stock pursuant to such liquidation,
dissolution or winding up of the Corporation or a Deemed Liquidation Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Number of Shares Issuable Upon Conversion</U>. The
number of shares of Common Stock issuable to a holder of Preferred Stock upon conversion of such Preferred Stock shall be rounded to the nearest whole share, after aggregating all fractional interests in shares of Common Stock that would otherwise
be issuable upon conversion of all shares of that same series of Preferred Stock being converted by such holder (with any fractional interests after such aggregation representing 0.5 or greater of a whole share being entitled to a whole share). For
the avoidance of doubt, no fractional interests in shares of Common Stock shall be created or issuable as a result of the conversion of the Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;4.1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common S tock, such holder shall (a)&nbsp;provide written notice to the Corporation&#8217;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its
own transfer agent) that such holder elects to convert all or any number of such holder&#8217;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&#8217;s shares are certificated,
surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the
Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the
principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&#8217;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required
by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its
attorney duly authorized in writing. Unless a later time and date is otherwise specified by the Corporation, the close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer
agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &#8220;<B>Conversion Time</B>&#8221;), and the shares of Common Stock issuable upon conversion of the specified
shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate
or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and, a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered
certificate that were not converted into Common Stock, and (ii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when the Preferred
Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time
to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the
Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation,
engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action that would cause an adjustment reducing the Conversion Price for any series of Preferred
Stock below the then par value of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the
Corporation may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no
longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor and to
receive payment of any dividends declared but unpaid thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no
adjustment to the applicable Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or
delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer
involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity
requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments to Preferred Stock Conversion Price for Diluting Issues</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this <U>Article</U><U></U><U>&nbsp;Fourth</U>, the following definitions shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<B>Additional Shares of Common Stock</B>&#8221; means all shares of Common Stock issued (or, pursuant to
<U>Section</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Original Issue Date (as defined below), other than (1)&nbsp;the following shares of Common Stock and (2)&nbsp;shares of Common Stock deemed issued
pursuant to the following Options and Convertible Securities (clauses&nbsp;(1) and (2), collectively, &#8220;<B>Exempted Securities</B>&#8221;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to any series of Preferred Stock, shares of Common Stock, Options or Convertible Securities issued as a
dividend or distribution on such series of Preferred Stock (including dividends payable in connection with dividends on other classes or series of stock) or Common Stock issued upon conversion of such series of Preferred Stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Section</U><U></U><U>&nbsp;4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Requisite Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Requisite Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the
acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided that such issuances are approved by the Requisite Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock issued in connection with an IPO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements, or strategic partnerships approved by the Requisite Directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities deemed at the time of issuance to be Exempted
Securities by the consent of the Requisite Holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#8220;<B>Convertible Securities</B>&#8221; means any
evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#8220;<B>IPO</B>&#8221; means the Corporation&#8217;s first underwritten public offering of its Common Stock under the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#8220;<B>Option</B>&#8221; means any rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or
Convertible Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#8220;<B>Original Issue Date</B>&#8221; means the date on which the first share of Series B Preferred Stock
is issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Preferred Stock Conversion Price</U>. No adjustment in the Conversion Price of a series of
Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least a majority of the outstanding shares of such series of
Preferred Stock, voting together as a single class, and, solely in respect of an adjustment in the Conversion Price of the Series B Preferred Stock, the Series B Majority, agreeing that no such adjustment shall be made as the result of the issuance
or deemed issuance of such Additional Shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the
maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a
subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of
Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price of any series
of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding
automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise,
conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease
becoming effective, the Conversion Price of such series of Preferred Stock computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion
Price for such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this
<U>Section</U><U></U><U>&nbsp;4.4.3(b)</U> shall have the effect of increasing the Conversion Price applicable to a series of Preferred Stock to an amount which exceeds the lower of (i)&nbsp;the Conversion Price for such series of Preferred Stock in
effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the Conversion Price for such series of Preferred Stock that would have resulted from any issuances of
Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted
Securities), the issuance of which did not result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U> (either because the consideration per share (determined
pursuant to <U>Section</U><U></U><U>&nbsp;4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the
provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of
shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such
Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto determined in the manner provided in <U>Section</U><U></U><U>&nbsp;4.4.3(a)</U> shall be deemed to have been issued effective upon
such increase or decrease becoming effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option or unconverted or
unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of
<U>Section</U><U></U><U>&nbsp;4.4.4</U>, the Conversion Price of such series of Preferred Stock shall be readjusted to such Conversion Price for such series of Preferred Stock as would have obtained had such Option or Convertible Security (or
portion thereof) never been issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange
of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is potentially subject to
adjustment based upon subsequent events, any adjustment to the Conversion Price of a series of Preferred Stock provided for in this Section<U>&nbsp;4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares
or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in <U>clauses</U><U></U><U>&nbsp;(b)</U> and <U>(c)</U>&nbsp;of this
<U>Section</U><U></U><U>&nbsp;4.4.3</U>). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise,
conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Conversion Price of a series of Preferred Stock that would result under the terms of this
<U>Section</U><U></U><U>&nbsp;4.4.3</U> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming
for purposes of calculating such adjustment to the Conversion Price for such series of Preferred Stock that such issuance or amendment took place at the time such calculation can first be made. In the event an Option or Convertible Security contains
alternative conversion terms, such as a cap on the valuation of the Corporation at which such conversion will be effected, or circumstances where the Option or Convertible Security may be repaid in lieu of conversion, then the number of shares of
Common Stock issuable upon the exercise, conversion and/or exchange of such Option or Convertible Security shall be deemed not calculable until such time as the applicable conversion terms are determined. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Conversion Price Upon Issuance of Additional Shares of Common
Stock</U>. In the event the Corporation shall at any time after the Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;4.4.3</U>),
without consideration or for a consideration per share less than the Conversion Price of a series of Preferred Stock in effect immediately prior to such issuance or deemed issuance, then the Conversion Price for such series of Preferred Stock shall
be reduced, concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> = CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> * ((A + B) / (A +
C)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#8220;CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>&#8221; shall mean the Conversion Price of such series of Preferred
Stock in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#8220;CP<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>&#8221; shall mean the Conversion Price of such series of Preferred Stock in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#8220;A&#8221; shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of
Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible
Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#8220;B&#8221; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had
been issued or deemed issued at a price per share equal to CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#8220;C&#8221; shall mean the number of such Additional Shares of Common
Stock issued in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this
<U>Section</U><U></U><U>&nbsp;4.4.5</U>, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and Property</U>. Such consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Requisite Directors; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in <U>clauses (i)</U>&nbsp;and <U>(ii)</U> above, as determined in good faith by the Requisite Directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for Additional
Shares of Common Stock deemed to have been issued pursuant to <U>Section</U><U></U><U>&nbsp;4.4.4</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration)
payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities, by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than
one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of
<U>Section</U><U></U><U>&nbsp;4.4.4</U>, and such issuance dates occur within a period of no more than 180 days from the first such issuance to the final such issuance, then, upon the final such issuance, the Conversion Price for such series of
Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such
period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any time or from time to time after the
Original Issue Date effect a subdivision of the outstanding Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common
Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original
Issue Date combine the outstanding shares of Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable
on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this <U>Section</U><U></U><U>&nbsp;4.5</U> shall become effective at the
close of business on the date the subdivision or combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and
Distributions</U>. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other
distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Conversion Price of each series of Preferred Stock in effect immediately before such event shall be decreased as of the time of such
issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Conversion Price of each such series of Preferred Stock then in effect by a fraction: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common
Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully
made on the date fixed therefor, the Conversion Price of each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Price of each series of Preferred Stock shall be
adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U> as of the time of actual payment of such dividends or distributions; and (b)&nbsp;no such adjustment shall be made if the holders of such series of Preferred Stock simultaneously
receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock
on the date of such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation
at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation
(other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then and in each
such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities
or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Section</U><U></U><U>&nbsp;2.3</U>, if there shall
occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than
a transaction covered by <U>Sections</U><U></U><U>&nbsp;4.5</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be
convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon
conversion of one share of such Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate
adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of the Preferred
Stock, to the end that the provisions set forth in this <U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to changes in and other adjustments of the Conversion Price of each series of Preferred Stock) shall thereafter be
applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Conversion Price of a series of
Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten days thereafter, compute such adjustment or readjustment in
accordance with the terms hereof and furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of
Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock
(but in any event not later than 10 days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the Conversion Price then in effect for each series of Preferred Stock held by such holder, and (ii)&nbsp;the
number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of each such series of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or series or any other
securities, or to receive any other security; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the
Common Stock of the Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or
other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange
applicable to the Preferred Stock and the Common Stock, Such notice shall be sent at least 10 days prior to the record date or effective date for the event specified in such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. All outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the
then effective conversion rate as calculated pursuant to <U>Sections</U><U></U><U>&nbsp;4.1.1</U> and <U>4.2</U>, upon the earliest to occur of (the time of such conversion is referred to herein as the &#8220;<B>Mandatory Conversion
Time</B>&#8221;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) immediately prior to the closing of the sale of shares of Common Stock to the public at a price of at least $5.70
per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended (the &#8220;<B>Securities Act</B>&#8221;), resulting in at least $100,000,000 of gross proceeds to the Corporation and in connection with such offering the shares of Common Stock
are listed for trading on the Nasdaq Stock Market, the New York Stock Exchange or another exchange or marketplace approved by the Requisite Directors; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the date and time, or upon the occurrence of an event, specified by vote or written
consent of the Requisite Holders and the Series B Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. All holders of record of shares of
Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice need not be sent
in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock being converted that holds such shares of Preferred Stock in certificated form shall surrender his, her or its
certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation
against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates
surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing.
All rights with respect to the Preferred Stock converted pursuant to <U>Section</U><U></U><U>&nbsp;5.1</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory
Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders
(or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Section</U><U></U><U>&nbsp;5.2</U>. As soon as practicable after the Mandatory Conversion Time and, if applicable, the
surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or
certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof, and (b)&nbsp;pay any declared but unpaid dividends on the shares of Preferred Stock converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption</U>. Other than as set forth in <U>Article</U><U></U><U>&nbsp;Fourth</U>, <U>Part</U><U></U><U>&nbsp;B</U>,
<U>Section</U><U></U><U>&nbsp;2.3.2(b)</U>, the Preferred Stock is not redeemable at the option of the holder or the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.
<U>Redeemed or Otherwise Acquired Shares</U>. Unless approved by the Board of Directors and the Requisite Holders, any shares of Preferred Stock that are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall
be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following
redemption, conversion or acquisition. The Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Except as otherwise set forth herein, (a)&nbsp;any of the rights, powers, preferences and other terms of the Preferred Stock
set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the holders that would otherwise be required to amend such right, powers, preferences, and other terms and (b)&nbsp;at any time
more than one series of Preferred Stock is issued and outstanding, any of the rights, powers, preferences and other terms of any series of Preferred Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by
the affirmative written consent or vote of the holders of such series that would otherwise be required to amend such right, power, preference, or other term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Any notice required or permitted by the provisions of this
<U>Article</U><U></U><U>&nbsp;Fourth</U> to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in
compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH</B>: Subject to any additional vote required by this Certificate of Incorporation or the Bylaws of the Corporation, in furtherance
and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH</B>: Subject to any additional vote required by this Certificate of Incorporation, the number of directors of the Corporation shall
be determined in the manner set forth in the Bylaws of the Corporation, Each director shall be entitled to one vote on each matter presented to the Board of Directors; provided, however, that, for so long as the holders of Preferred Stock are
entitled to elect a Preferred Director, the approval of the Requisite Directors shall be required hereunder for the authorization by the Board of Directors of any matter that requires the Requisite Director Vote under the terms of the
Investors&#8217; Rights Agreement, to the extent that Preferred Directors are then serving. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH</B>: Elections of directors need
not be by written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH</B>: Meetings of stockholders may be held
within or outside of the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such
manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH</B>: To
the fullest extent permitted by law, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the General
Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this <U>Article</U><U></U><U>&nbsp;Ninth</U> to authorize corporate action further eliminating or limiting the personal liability of directors
or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or elimination of the foregoing provisions of this <U>Article</U><U></U><U>&nbsp;Ninth</U> by the stockholders of the
Corporation shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of, or increase the liability of any director or officer of the Corporation with respect to any acts or omissions of such
director or officer occurring prior to, such amendment, repeal or elimination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH</B>: To the fullest extent permitted by applicable law, the Corporation is
authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which the General Corporation Law permits the Corporation to provide indemnification) through Bylaw
provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal, modification or elimination of the foregoing provisions of this <U>Article</U><U></U><U>&nbsp;Tenth</U> shall not
(a)&nbsp;adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal, modification or elimination; or (b)&nbsp;increase the liability of any director, officer or
agent of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to such amendment, repeal, modification or elimination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH</B>: The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in
being offered an opportunity to participate in, any Excluded Opportunity. An &#8220;<B>Excluded Opportunity</B>&#8221; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into
the possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent
of any such holder, other than someone who is an officer or employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in <U>clauses</U><U></U><U>&nbsp;(i)</U> and <U>(ii)</U>&nbsp;are &#8220;<B>Covered
Persons</B>&#8221;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#8217;s capacity as a
director of the Corporation while such Covered Person is performing services in such capacity. Any repeal or modification of this <U>Article</U><U></U><U>&nbsp;Eleventh</U> will only be prospective and will not affect the rights under this
<U>Article</U><U></U><U>&nbsp;Eleventh</U> in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, in
addition to any other vote required by law or this Certificate of Incorporation, the affirmative vote of (i)&nbsp;the Requisite Holders and (ii)&nbsp;the holders of at least 80% of the outstanding shares of Series B Preferred Stock, will be required
to amend or repeal, or to adopt any provisions inconsistent with this <U>Article</U><U></U><U>&nbsp;Eleventh</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH</B>: Unless
the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative
action or proceeding brought on behalf of the Corporation; (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#8217;s
stockholders; (iii)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the General Corporation Law or the Corporation&#8217;s certificate of incorporation or bylaws;
or (iv)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of the Corporation, except for, as to each of
(i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable patty not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal
jurisdiction of the Court of Chancery within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter
jurisdiction, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRTEENTH</B>: If any provision or provisions of this Certificate of Incorporation shall
be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other
circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any sentence of this Certificate of Incorporation containing any such provision held to be invalid, illegal or
unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> That the
foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> That this Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of the
Corporation&#8217;s Amended and Restated Certificate of Incorporation, has been duly adopted in accordance with Sections&nbsp;242 and 245 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation has been executed
by a duly authorized officer of this corporation on October&nbsp;17, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BYLAWS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SEAPORT THERAPEUTICS, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a
Delaware corporation) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adopted as of April&nbsp;1, 2024 </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TABLE OF CONTENTS </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE I IDENTIFICATION; OFFICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NAME</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PRINCIPAL AND BUSINESS OFFICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REGISTERED AGENT AND OFFICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CORPORATE RECORDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE II STOCKHOLDERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ANNUAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SPECIAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PLACE OF STOCKHOLDER MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NOTICE OF MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>QUORUM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADJOURNED MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FIXING OF RECORD DATE.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VOTING LIST</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VOTING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PROXIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RATIFICATION OF ACTS OF DIRECTORS AND OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CONDUCT OF MEETINGS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ACTION WITHOUT MEETING.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE III DIRECTORS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GENERAL POWERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NUMBER AND TENURE OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ELECTION OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CHAIRMAN OF THE BOARD; VICE CHAIRMAN OF THE BOARD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>QUORUM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VOTING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VACANCIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REMOVAL OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RESIGNATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REGULAR MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SPECIAL MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NOTICE OF SPECIAL MEETINGS OF THE BOARD OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>WRITTEN ACTION BY DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PARTICIPATION BY CONFERENCE TELEPHONE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMMITTEES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMPENSATION OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV OFFICERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GENERAL PROVISIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ELECTION AND TERM OF OFFICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RESIGNATION AND REMOVAL OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VACANCIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE CHIEF EXECUTIVE OFFICER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE PRESIDENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE VICE PRESIDENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE SECRETARY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE ASSISTANT SECRETARY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE TREASURER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>THE ASSISTANT TREASURER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>OTHER OFFICERS, ASSISTANT OFFICERS AND AGENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ABSENCE OF OFFICERS, DELEGATION OF AUTHORITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMPENSATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE V CAPITAL STOCK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ISSUANCE OF STOCK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CERTIFICATES OF SHARES; UNCERTIFICATED SHARES.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SIGNATURES OF FORMER OFFICER, TRANSFER AGENT OR REGISTRAR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TRANSFER OF SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LOST, DESTROYED OR STOLEN CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REGULATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI RESTRICTIONS ON TRANSFER AND RIGHT OF FIRST REFUSAL.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TRANSFERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CONSENT TO TRANSFER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RIGHT OF FIRST REFUSAL.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXCEPTIONS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VOID TRANSFERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LEGENDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VII INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RIGHT TO INDEMNIFICATION OF DIRECTORS AND OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PREPAYMENT OF EXPENSES OF DIRECTORS AND OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CLAIMS BY DIRECTORS AND OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INDEMNIFICATION OF EMPLOYEES AND AGENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADVANCEMENT OF EXPENSES OF EMPLOYEES AND AGENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">NON-EXCLUSIVITY</FONT> OF RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>OTHER INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INSURANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>AMENDMENT OR REPEAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VIII DIVIDENDS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DECLARATIONS OF DIVIDENDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SPECIAL PURPOSES RESERVES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX NOTICE BY ELECTRONIC TRANSMISSION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NOTICE BY ELECTRONIC TRANSMISSION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEFINITION OF ELECTRONIC TRANSMISSION; ELECTRONIC MAIL; ELECTRONIC MAIL ADDRESS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INAPPLICABILITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE X GENERAL PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FISCAL YEAR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>WRITTEN WAIVER OF NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ATTENDANCE AS WAIVER OF NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>WAIVER OF SECTION 1501</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CONTRACTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LOANS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CHECKS, DRAFTS, ETC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEPOSITS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ANNUAL STATEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VOTING OF SECURITIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EVIDENCE OF AUTHORITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CERTIFICATE OF INCORPORATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEVERABILITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PRONOUNS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE XI AMENDMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>BY THE BOARD OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>BY THE STOCKHOLDERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IDENTIFICATION; OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. NAME. The name of the corporation is Seaport Therapeutics, Inc. (the &#8220;<U>Corporation</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. PRINCIPAL AND BUSINESS OFFICES. The Corporation may have such principal and other business offices, either within or outside
of the state of Delaware, as the Board of Directors may designate or as the Corporation&#8217;s business may require from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. REGISTERED AGENT AND OFFICE. The Corporation&#8217;s registered agent may be changed from time to time by or under the
authority of the Board of Directors. The address of the Corporation&#8217;s registered agent may change from time to time by or under the authority of the Board of Directors, or the registered agent. The business office of the Corporation&#8217;s
registered agent shall be identical to the registered office. The Corporation&#8217;s registered office may be but need not be identical with the Corporation&#8217;s principal office in the state of Delaware. The Corporation&#8217;s initial
registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. CORPORATE RECORDS. Any
records and documents required by law to be kept by the Corporation permanently or administered by the Corporation in the regular course of business may be kept on, or by means of, or be in the form of, any information storage device, method, or one
more electronic networks or databases, provided that the records so kept can be converted into clearly legible paper form within a reasonable time and, with respect to the stock ledger, the records so kept comply with Section&nbsp;224 of the
Delaware General Corporation Law. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to applicable law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. ANNUAL MEETING. An annual meeting of the stockholders shall be held on such date as may be designated by the Board of
Directors, the Chairman of the Board, the Chief Executive Officer or the President. At each annual meeting, the stockholders shall elect directors to hold office for the term provided in <U>Section</U><U></U><U>&nbsp;2</U> of Article III of these
Bylaws and transact such other business as may properly be brought before the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. SPECIAL MEETING. A special meeting
of the stockholders for any purpose or purposes may be called at any time only by the President, the Board of Directors, the Chairman of the Board, the Chief Executive Officer or any other person designated by the Board of Directors. The Board of
Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. PLACE OF STOCKHOLDER MEETINGS. The Board of Directors, the Chairman of the Board, the Chief Executive Officer or
the President may designate any place, either within or without the State of Delaware, as the place of meeting for any annual meeting or for any special meeting. If no such place is designated by the Board of Directors, the place of meeting will be
the principal business office of the Corporation or the Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but will instead be held solely by means of remote communication as provided under
Section&nbsp;211 of the Delaware General Corporation Law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. NOTICE OF MEETINGS. Except as otherwise provided by law or waived as herein
provided, whenever stockholders are required or permitted to take any action at a meeting, whether annual or special, notice of the meeting shall be given stating the place, if any, date and hour of the meeting, the means of remote communications,
if any, by which stockholders may be deemed to be present in person and vote at such meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Such notice shall be given unless otherwise required by law
not less than 10 days nor more than 60 days before the date of the meeting to each stockholder entitled to vote at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When a meeting is
adjourned to reconvene at the same or another place, if any, or by means of remote communications, if any, in accordance with <U>Section</U><U></U><U>&nbsp;6</U> of Article II of these Bylaws, notice need not be given of the adjourned meeting if the
time and place thereof are announced at the meeting at which the adjournment is taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5. QUORUM. Unless otherwise provided
by law, the Corporation&#8217;s Certificate of Incorporation or these Bylaws, the holders of a majority in voting power of the shares of the capital stock of the Corporation issued and outstanding and entitled to vote at the meeting, present in
person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum for the transaction of business; <U>provided</U>, <U>however</U>,
that where a separate vote by a class or classes or series of capital stock is required by law or the Certificate of Incorporation, the holders of a majority in voting power of the shares of such class or classes or series of the capital stock of
the Corporation issued and outstanding and entitled to vote on such matter, present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall
constitute a quorum entitled to take action with respect to the vote on such matter. If a quorum is present in person or represented by proxy at such meeting, such stockholders may continue to transact business until adjournment, notwithstanding the
withdrawal of such number of stockholders as may leave less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6. ADJOURNED MEETINGS. Any meeting of
stockholders may be adjourned from time to time to any other time and to any other place (or by means of remote communications, if any) at which a meeting of stockholders may be held under these Bylaws by the chairman of the meeting or by a majority
of the stockholders present or represented at the meeting and entitled to vote, although less than a quorum. It shall not be necessary to notify any stockholder of any adjournment of less than 30 days if the time and place, if any, of the adjourned
meeting, and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which adjournment is taken, unless after the
adjournment a new record date is fixed for the adjourned meeting. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7. FIXING OF RECORD DATE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Board of Directors may fix in advance a date as a record date for the determination of the stockholders entitled to notice of or to
vote at any meeting of stockholders or any adjournment thereof. Such record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 days
nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business
on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote
at a meeting of stockholders shall apply to any adjournment of the meeting; <U>provided</U>, <U>however</U>, that the Board of Directors may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For the purpose of determining stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors
may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is established by the Board of Directors, and which date shall not be more than 10 days after the date on which the resolution
fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior
action by the Board of Directors is required by law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in the State
of Delaware, its principal office, or an officer or agent of the Corporation having custody of the book in which the proceedings of meetings of stockholders are recorded. Delivery to the Corporation&#8217;s registered office shall be by hand or by
certified or registered mail, return receipt requested. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by law, the record date for determining stockholders&#8217; consent to
corporate action in writing without a meeting shall be the close of business on the day on which the Board of Directors adopts the resolution taking such prior action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For the purpose of determining the stockholders entitled to receive payment of any dividend or other distribution or allotment of any
rights or the stockholders entitled to exercise any rights in respect to any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix the record date, which record date shall not precede
the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining the stockholders for any such purpose shall
be the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8. VOTING LIST.
The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of stockholders entitled to vote at the meeting, arranged in alphabetical order, and
showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, for a period of at least 10 days
prior to the meeting, (i)&nbsp;by a reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii)&nbsp;during ordinary business hours, at the
principal place of business of the Corporation. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to the
stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present. If the
meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to
access such list shall be provided with the notice of the meeting. Except as otherwise provided by law, such list shall be the only evidence as to the identity of stockholders entitled to examine the list of stockholders required by this
<U>Section</U><U></U><U>&nbsp;8</U> or to vote in person or by proxy at any meeting of the stockholders. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9. VOTING. Unless otherwise provided by the Certificate of Incorporation, each stockholder shall be entitled to one vote for each
share of capital stock held by each stockholder. When a quorum is present at any meeting, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person or represented by proxy at the meeting
and entitled to vote on the subject matter shall be the act of the stockholders, except when a different vote is required by law, the Certificate of Incorporation or these Bylaws. When a quorum is present at any meeting, directors shall be elected
by plurality of the votes of the shares present in person or represented by a proxy at the meeting entitled to vote on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10. PROXIES. Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action
in writing without a meeting (including by means of remote communications, if any, by which stockholders may be deemed to be present in person and vote at such meeting) may authorize another person or persons to act for him or her by proxy (executed
or transmitted in a manner permitted by the Delaware General Corporation Law), but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A duly executed proxy shall be irrevocable
if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A proxy may remain irrevocable regardless of whether the interest with which it is coupled is an
interest in the stock itself or an interest in the Corporation generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11. RATIFICATION OF ACTS OF DIRECTORS AND
OFFICERS. Except as otherwise provided by law or by the Certificate of Incorporation of the Corporation, any transaction or contract or act of the Corporation or of the directors or the officers of the Corporation may be ratified by the affirmative
vote of the holders of the number of shares which would have been necessary to approve such transaction, contract or act at a meeting of stockholders, or by the written consent of stockholders in lieu of a meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12. CONDUCT OF MEETINGS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Chairman of Meeting</U>. Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in the
Chairman&#8217;s absence by the Vice Chairman of the Board, if any, or in the Vice Chairman&#8217;s absence by the Chief Executive Officer, or in the Chief Executive Officer&#8217;s absence, by the President, or in the President&#8217;s absence by a
Vice President, or in the absence of all of the foregoing persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen by vote of the stockholders at the meeting. The Secretary shall act as
secretary of the meeting, but in the Secretary&#8217;s absence the chairman of the meeting may appoint any person to act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Rules, Regulations and Procedures</U>. The Board of Directors may adopt by resolution such rules, regulations and procedures for the
conduct of any meeting of stockholders of the Corporation as it shall deem appropriate including, without limitation, such guidelines and procedures as it may deem appropriate regarding the participation by means of remote communication of
stockholders and proxyholders not physically present at a meeting. Except to the extent inconsistent with such rules, regulations and procedures as adopted by the Board of Directors, the chairman of any meeting of stockholders shall have the right
and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the
Board of Directors or prescribed by the chairman of the meeting, may include, without limitation, the following: (i)&nbsp;the establishment of an agenda or order of business for the meeting; (ii)&nbsp;rules and procedures for maintaining order at
the meeting and the safety of those present; (iii)&nbsp;limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as shall be
determined; (iv)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v)&nbsp;limitations on the time allotted to questions or comments by participants. Unless and to the extent determined by the Board of
Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13. ACTION WITHOUT MEETING. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any action required or permitted to be taken at any annual or special meeting of stockholders of the Corporation, may be taken without a
meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be delivered to the Corporation signed by the holders of outstanding stock having not less than the minimum number of
votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prompt notice of the taking of the corporate action without a meeting by less than unanimous consent shall be given to those stockholders
who have not consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of
holders to take the action were delivered to the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) An electronic transmission consenting to an action to be taken and transmitted by a
stockholder or proxy holder, or by a person or persons authorized to act for a stockholder or proxy holder, shall be deemed to be written, signed and dated for the purposes of this section, provided that any such electronic transmission sets forth
or is delivered with information from which the Corporation can determine (i)&nbsp;that the electronic transmission was transmitted by the stockholder or proxy holder or by a person or persons authorized to act for the stockholder or proxy holder
and (ii)&nbsp;the date on which such stockholder or proxy holder or authorized person or persons transmitted such electronic transmission. A consent given by electronic transmission is delivered to the Corporation upon the earliest of: (i)&nbsp;when
the consent enters an information processing system, if any, designated by the Corporation for receiving consents, so long as the electronic transmission is in a form capable of being processed by that system and the Corporation is able to retrieve
that electronic transmission; (ii)&nbsp;when a paper reproduction of the consent is delivered to the Corporation&#8217;s principal place of business or an officer or agent of the Corporation having custody of the book in which proceedings of
meetings of stockholders or members are recorded; (iii)&nbsp;when a paper reproduction of the consent is delivered to the Corporation&#8217;s registered office in this State by hand or by certified or registered mail, return receipt requested; or
(iv)&nbsp;when delivered in such other manner, if any, provided by resolution of the Board of Directors or governing body of the Corporation. Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in
lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. GENERAL POWERS. The business and affairs of the Corporation shall be managed by or under the direction of a Board of
Directors, who may exercise all of the powers of the Corporation except as otherwise provided by law or the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. NUMBER AND TENURE OF DIRECTORS. Subject to the rights of holders of any class or series of capital stock of the Corporation to
elect directors, the number of directors of the Corporation shall be determined from time to time by the stockholders or the Board of Directors in a resolution adopted by the Board of Directors. Each director shall hold office until the next annual
meeting of stockholders and until such director&#8217;s successor is elected and qualified or until such director&#8217;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. ELECTION OF DIRECTORS. Except as otherwise provided in these Bylaws, directors shall be elected at the annual meeting of
stockholders by such stockholders as have the right to vote on such election. Directors need not be residents of the State of Delaware. Directors need not be stockholders of the Corporation. Elections of directors need not be by written ballot. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. CHAIRMAN OF THE BOARD; VICE CHAIRMAN OF THE BOARD. The Board of Directors
may appoint from its members a Chairman of the Board and a Vice Chairman of the Board, neither of whom need be an employee or officer of the Corporation. If the Board of Directors appoints a Chairman of the Board, such Chairman shall perform such
duties and possess such powers as are assigned by the Board of Directors. If the Board of Directors appoints a Vice Chairman of the Board, such Vice Chairman shall perform such duties and possess such powers as are assigned by the Board of
Directors. Unless otherwise provided by the Board of Directors, the Chairman of the Board or, in the Chairman&#8217;s absence, the Vice Chairman of the Board, if any, shall preside at all meetings of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5. QUORUM. The greater of (a)&nbsp;a majority of the directors at any time in office and
<FONT STYLE="white-space:nowrap">(b)&nbsp;one-third</FONT> of the number of directors fixed pursuant to <U>Section</U><U></U><U>&nbsp;2</U> of Article III of these Bylaws shall constitute a quorum of the Board of Directors. If less than a quorum are
present at a meeting of the Board of Directors, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until such quorum shall be present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6. VOTING. The vote of the majority of the directors present at a meeting at which a quorum is present shall be the act of the
Board of Directors, unless the Delaware General Corporation Law or the Certificate of Incorporation requires a vote of a greater number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7. VACANCIES. Subject to the rights of holders of any series of Preferred Stock to elect directors, unless and until filled by
the stockholders, any vacancy or newly-created directorship on the Board of Directors, however occurring, may be filled by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director. A director
elected to fill a vacancy shall be elected for the unexpired term of such director&#8217;s predecessor in office, and a director chosen to fill a position resulting from a newly-created directorship shall hold office until the next annual meeting of
stockholders and until a successor is elected and qualified, or until such director&#8217;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8. REMOVAL OF DIRECTORS. Except as otherwise provided by the General Corporation Law of the State of Delaware, a director, or the
entire Board of Directors, may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except that the directors elected by the holders of a particular class or series of stock
may be removed without cause only by vote of the holders of a majority of the outstanding shares of such class or series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.
RESIGNATION. Any director may resign by delivering a resignation in writing or by electronic transmission to the Corporation at its principal office or to the Chairman of the Board, the Chief Executive Officer, the President or the Secretary. Such
resignation shall be effective upon delivery unless it is specified to be effective at some later time or upon the happening of some later event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10. REGULAR MEETINGS. Regular meetings of the Board of Directors may be held without notice at such time, place and manner as
shall be determined from time to time by the Board of Directors; provided that any director who is absent when such a determination is made shall be given notice of the determination. A regular meeting of the Board of Directors may be held without
notice immediately after and at the same place as the annual meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11. SPECIAL MEETINGS. Special meetings of the Board of Directors may be called
by or at the request of the Chairman of the Board, the Chief Executive Officer, the President, two or more directors or by one director in the event that there is only a single director in office. The person or persons authorized to call special
meetings of the Board of Directors may fix any time, date or place, either within or without the State of Delaware, for holding any special meeting of the Board of Directors called by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12. NOTICE OF SPECIAL MEETINGS OF THE BOARD OF DIRECTORS. Notice of the date, place, if any, and time of any special meeting of
the Board of Directors shall be given to each director by the Secretary or by the officer or one of the directors calling the meeting. Notice shall be duly given to each director (a)&nbsp;in person, by telephone, fax or by electronic transmission at
least 24 hours in advance of the meeting, (b)&nbsp;by sending written notice by reputable overnight courier or delivering written notice by hand, to such director&#8217;s last known business, home or facsimile address at least 48 hours in advance of
the meeting, or (c)&nbsp;by sending written notice by first-class mail to such director&#8217;s last known business or home address at least 72 hours in advance of the meeting. A notice or waiver of notice of a meeting of the Board of Directors need
not specify the purposes of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13. WRITTEN ACTION BY DIRECTORS. Unless otherwise restricted by the Certificate of
Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or committee, as the case may
be, consent thereto in writing, or by electronic transmission. Without limiting the manner by which consent may be given, members of the Board of Directors may consent by delivery of an electronic transmission when such transmission is directed to a
facsimile number or electronic mail address at which the Corporation has consented to receive such electronic transmissions, and copies of the electronic transmissions are filed with the minutes of proceedings of the Board of Directors or committee.
After an action is taken, the consent or consents relating thereto shall be filed with the minutes of the proceedings of the Board of Directors, or the committee thereof, in the same paper or electronic form as the minutes are maintained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14. PARTICIPATION BY CONFERENCE TELEPHONE. Members of the Board of Directors, or any committee designated by such board, may
participate in a meeting of the Board of Directors, or committee thereof, by means of conference telephone or similar communications equipment as long as all persons participating in the meeting can speak with and hear each other, and participation
by a director pursuant to this section shall constitute presence in person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;15. COMMITTEES. The Board of
Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation with such lawfully delegable powers and duties as the Board of Directors thereby confers, to serve at the pleasure of the
Board of Directors. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member at any meeting
of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting
in the place of any such absent or disqualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
member. Any such committee, to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the
management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it, but no such committee shall have the power or authority in reference to the following matters:
(i)&nbsp;approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by law to be submitted to stockholders for approval or (ii)&nbsp;adopting, amending or
repealing any bylaw of the Corporation. Each such committee shall keep minutes and make such reports as the Board of Directors may from time to time request. Except as the Board of Directors may otherwise determine, any committee may make rules for
the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these Bylaws for the Board of Directors. Except as otherwise
provided in the Certificate of Incorporation, these Bylaws, or the resolution of the Board of Directors designating the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the
committee, and delegate to a subcommittee any or all of the powers and authority of the committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;16. COMPENSATION OF
DIRECTORS. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, the Board of Directors shall have the authority to fix the compensation of directors. The directors may be paid their expenses, if any, of attendance at each
meeting of the Board of Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as director. No such payment shall preclude any director from serving the Corporation in any other capacity and
receiving compensation therefore. Members of special or standing committees may be allowed like compensation for attending committee meetings. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. GENERAL PROVISIONS. The officers of the Corporation shall consist of a Chief Executive Officer, a President, a
Secretary, a Treasurer and such other officers with such other titles as the Board of Directors shall determine, including one or more Vice Presidents, Assistant Treasurers and Assistant Secretaries. The Board of Directors may appoint such other
officers as it may deem appropriate. No officer need be a stockholder. Any two or more offices may be held by the same person. The officers elected by the Board of Directors shall have such duties as are hereafter described and such additional
duties as the Board of Directors may from time to time prescribe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. ELECTION AND TERM OF OFFICE. The Chief Executive
Officer, President, Treasurer and Secretary shall be elected annually by the Board of Directors at the regular meeting of the Board of Directors held after each annual meeting of the stockholders. If the election of officers is not held at such
meeting, such election shall be held as soon thereafter as may be convenient. Other officers may be appointed at any time, at a meeting or by the written consent of the Board of Directors. Except as otherwise provided by law, by the Certificate of
Incorporation or by these Bylaws, each officer shall hold office until his or her successor has been duly elected and qualified, unless a different term is specified in the resolution electing or appointing such officer, or until his or her earlier
death, resignation or removal. Election or appointment of an officer or agent shall not of itself create contract rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. RESIGNATION AND REMOVAL OF OFFICERS. Any officer may resign by delivering a
written resignation to the Corporation at its principal office or to the Chief Executive Officer, the President or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some later time or upon the
happening of some later event. Any officer may be removed at any time, with or without cause, by vote of a majority of the directors then in office. Except as the Board of Directors may otherwise determine, no officer who resigns or is removed shall
have any right to any compensation as an officer for any period following such officer&#8217;s resignation or removal, or any right to damages on account of such removal, whether such officer&#8217;s compensation be by the month or by the year or
otherwise, unless such compensation is expressly provided for in a duly authorized written agreement with the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. VACANCIES. The Board of Directors may fill any vacancy occurring in any office for any reason and may, in its discretion,
leave unfilled for such period as it may determine any offices other than those required by the Delaware General Corporation Law. Each such successor shall hold office for the unexpired term of such officer&#8217;s predecessor and until a successor
is elected and qualified, or until such officer&#8217;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5. THE CHIEF EXECUTIVE
OFFICER. Unless the Board of Directors has designated another person as the Corporation&#8217;s Chief Executive Officer, the President shall be the Chief Executive Officer of the Corporation. The Chief Executive Officer shall have general charge and
supervision of the business and affairs of the Corporation subject to the direction of the Board of Directors, and shall perform all duties and have all powers that are commonly incident to the office of chief executive or that are delegated to such
officer by the Board of Directors. The Chief Executive Officer shall preside at all meetings of the Board of Directors and shall see that orders and resolutions of the Board of Directors are carried into effect. The Chief Executive Officer may sign
bonds, mortgages, certificates for shares and all other contracts and documents whether or not under the seal of the Corporation except in cases where the signing and execution thereof shall be expressly delegated by law, by the Board of Directors
or by these Bylaws to some other officer or agent of the Corporation. The Chief Executive Officer shall have general powers of supervision and shall be the final arbiter of all differences between officers of the Corporation and his or her decision
as to any matter affecting the Corporation shall be final and binding as between the officers of the Corporation subject only to the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6. THE PRESIDENT. In the absence of the Chief Executive Officer or in the event of his or her inability or refusal to act, the
President shall perform the duties of the Chief Executive Officer, and when so acting, shall have all the powers of and be subject to all the restrictions upon the Chief Executive Officer. At all other times the President shall have the active
management of the business of the Corporation under the general supervision of the Chief Executive Officer or the Board of Directors. The President shall have concurrent power with the Chief Executive Officer to sign bonds, mortgages, certificates
for shares and other contracts and documents, whether or not under the seal of the Corporation except in cases where the signing and execution thereof shall be expressly delegated by law, by the Board of Directors, or by these Bylaws to some other
officer or agent of the Corporation. In general, the President shall perform all duties incident to the office of president and such other duties as the Chief Executive Officer (if the President is not the Chief Executive Officer) or the Board of
Directors may from time to time prescribe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7. THE VICE PRESIDENT. In the absence of the President or in the event of his
or her inability or refusal to act, the Vice President (or in the event there be more than one Vice President, the Executive Vice President and then the other Vice President or Vice Presidents in the order designated, or in the absence of any
designation, then in the order of their election) shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions upon the President. The Vice Presidents shall perform such other
duties and have such other powers as the Chief Executive Officer or the Board of Directors may from time to time prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8. THE SECRETARY. The Secretary shall perform such duties and shall have such powers as the Board of Directors or the Chief
Executive Officer may from time to time prescribe. The Secretary shall perform such duties and have such powers as are incident to the office of the secretary, including without limitation the duty and power to attend all meetings of the Board of
Directors and all meetings of the stockholders and record all the proceedings in a book to be kept for that purpose and shall perform like duties for the standing committees when required and to maintain a stock ledger and prepare lists of
stockholders and their addresses as required. The Secretary shall give, or cause to be given, notice of all meetings of the stockholders and special meetings of the Board of Directors, and shall perform such other duties as may be prescribed by the
Board of Directors or the Chief Executive Officer, under whose supervision he or she shall be. The Secretary shall have custody of the corporate records and the corporate seal of the Corporation and the Secretary, or an Assistant Secretary, shall
have authority to affix the same to any instrument requiring it and when so affixed, it may be attested by his or her signature or by the signature of such Assistant Secretary. The Board of Directors may give general authority to any other officer
to affix the seal of the Corporation and to attest the affixing by his or her signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9. THE ASSISTANT SECRETARY. The
Assistant Secretary, or if there be more than one, the Assistant Secretaries in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election), shall, in the absence of the Secretary or in
the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Secretary and shall perform such other duties and have such other powers as the Chief Executive Officer, the Board of Directors or the Secretary
may from time to time prescribe. In the absence of the Secretary or any Assistant Secretary at any meeting of stockholders or directors, the chairman of the meeting shall designate a temporary secretary to keep a record of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10. THE TREASURER. The Treasurer shall perform such duties and shall have such powers as may from time to time be assigned by the
Board of Directors or the Chief Executive Officer. In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including without limitation, the duty and power to have the custody of the
corporate funds and securities and to keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such
depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation as may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ordered by the Board of Directors, taking proper vouchers for such disbursements, and shall render to the President and the Board of Directors, as required by the Board of Directors, an account
of all his or her transactions as Treasurer and of the financial condition of the Corporation. If required by the Board of Directors, the Treasurer shall give the Corporation a bond (which shall be renewed every six years) in such sum and with such
surety or sureties as shall be satisfactory to the Board of Directors for the faithful performance of the duties of his or her office and for the restoration to the Corporation, in case of his or her death, resignation, retirement or removal from
office, of all books, papers, vouchers, money and other property of whatever kind in his or her possession or under his or her control belonging to the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11. THE ASSISTANT TREASURER. The Assistant Treasurer, or if there shall be more than one, the Assistant Treasurers in the order
determined by the Board of Directors (or if there be no such determination, then in the order of their election), shall, in the absence of the Treasurer or in the event of his or her inability or refusal to act, perform the duties and exercise the
powers of the Treasurer and shall perform such other duties and have such other powers as the Chief Executive Officer, the Board of Directors or the Treasurer may from time to time prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12. OTHER OFFICERS, ASSISTANT OFFICERS AND AGENTS. Officers, Assistant Officers and Agents, if any, other than those whose duties
are provided for in these Bylaws, shall have such authority and perform such duties as may from time to time be prescribed by resolution of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13. ABSENCE OF OFFICERS, DELEGATION OF AUTHORITY. In the absence of any officer of the Corporation, or for any other reason the
Board of Directors may deem sufficient, the Board of Directors may from time to time delegate the powers or duties, or any of such powers or duties, of any officers or officer to any other officer or to any director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14. COMPENSATION. The Board of Directors shall have the authority to establish reasonable salaries, compensation or reimbursement
of all officers for services to the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. ISSUANCE OF STOCK. Subject to the provisions of the Certificate of Incorporation, the whole or any part of any unissued
balance of the authorized capital stock of the Corporation or the whole or any part of any shares of the authorized capital stock of the Corporation held in the Corporation&#8217;s treasury may be issued, sold, transferred or otherwise disposed of
by vote of the Board of Directors in such manner, for such lawful consideration and on such terms as the Board of Directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. CERTIFICATES OF SHARES; UNCERTIFICATED SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The shares of the Corporation shall be represented by certificates, provided that the Board of Directors of the Corporation may provide by
resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the
Corporation. Every holder of stock represented by certificates shall be entitled to have a certificate, in such form as may be prescribed by law and by the Board of Directors, signed in a manner that complies with Section&nbsp;158 of the Delaware
General Corporation Law, representing the number of shares held by such holder registered in certificate form. Any or all the signatures on the certificate may be a facsimile or pdf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each certificate for shares of stock which are subject to any restriction on transfer
pursuant to the Certificate of Incorporation, these Bylaws, applicable securities laws or any agreement among any number of stockholders or among such holders and the Corporation shall have conspicuously noted on the face or back of the certificate
either the full text of the restriction or a statement of the existence of such restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the Corporation shall be authorized
to issue more than one class of stock or more than one series of any class, the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications,
limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of each certificate representing shares of such class or series of stock, provided that in lieu of the foregoing requirements
there may be set forth on the face or back of each certificate representing shares of such class or series of stock a statement that the Corporation will furnish without charge to each stockholder who so requests a copy of the full text of the
powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send to the registered owner
thereof a written notice containing the information required to be set forth or stated on certificates pursuant to Sections 151, 156, 202(a) or 218(a) of the General Corporation Law of the State of Delaware or, with respect to Section&nbsp;151 of
the General Corporation Law of the State of Delaware, a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights
of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. SIGNATURES OF FORMER OFFICER, TRANSFER AGENT OR REGISTRAR. In case any officer, transfer agent, or registrar who has signed or
whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person or entity
were such officer, transfer agent or registrar at the date of issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. TRANSFER OF SHARES. Transfers of shares of the
Corporation shall be made only on the books of the Corporation, or by transfer agents designated to transfer shares of the Corporation. Subject to applicable law, shares of stock represented by certificates shall be transferred only on the books of
the Corporation by the surrender to the Corporation or its transfer agent of the certificate representing such shares properly endorsed or accompanied by a written assignment or power of attorney properly executed, and with such proof of authority
or the authenticity of signature as the Corporation or its transfer agent may reasonably require. Except as may be otherwise required by law, by the Certificate of Incorporation or by these Bylaws, the Corporation shall be entitled to treat the
record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect to such stock, regardless of any transfer, pledge or other disposition of such stock
until the shares have been transferred on the books of the Corporation in accordance with the requirements of these Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5. LOST, DESTROYED OR STOLEN CERTIFICATES. Whenever a certificate representing
shares of the Corporation has been lost, destroyed or stolen, the holder thereof may file in the office of the Corporation an affidavit setting forth, to the best of his or her knowledge and belief, the time, place, and circumstance of such loss,
destruction or theft together with a statement of indemnity and posting of such bond sufficient in the opinion of the Board of Directors to indemnify the Corporation against any claim that may be made against it on account of the alleged loss of any
such certificate. Thereupon the Board may cause to be issued to such person or such person&#8217;s legal representative a new certificate or a duplicate of the certificate alleged to have been lost, destroyed or stolen. In the exercise of its
discretion, the Board of Directors may waive the indemnification and bond requirements provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6. REGULATIONS. The
issue, transfer, conversion and registration of shares of stock of the Corporation shall be governed by such other regulations as the Board of Directors may establish. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTIONS
ON TRANSFER AND RIGHT OF FIRST REFUSAL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. TRANSFERS. If a holder of any shares of stock of the Corporation (a
&#8220;<U>Holder</U>&#8221;) proposes to, directly or indirectly, sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively &#8220;<U>Transfer</U>&#8221;) any such shares, or any right or
interest therein (including, without limitation, the entering into of any swap or other arrangement that Transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock of the Corporation, whether any
such transaction described above is to be settled by delivery of common stock of the Corporation or other securities, in cash or otherwise), pursuant to a bona fide offer acceptable to such Holder, then Holder shall first give written notice of the
proposed Transfer (the &#8220;<U>Transfer Notice</U>&#8221;) to the Corporation. The Transfer Notice shall state the name of the proposed transferee, the number of shares Holder proposes to Transfer (the &#8220;<U>Offered Shares</U>&#8221;), whether
the Offered Shares are vested or unvested shares, the price per share and all other material terms and conditions of the Transfer, including any available exemption set forth in Section&nbsp;4 below from the restrictions set forth in Sections 2 and
3 below and shall include a confirmation from the Holder that the proposed transferee is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended (the &#8220;<U>Securities
Act</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. CONSENT TO TRANSFER. Except as specifically provided herein, the prior written consent of the
Corporation (upon duly authorized action of its Board of Directors) shall be required for any Transfer of any shares of the Corporation. The Corporation may withhold consent for any legitimate corporate purpose, as determined by the
Corporation&#8217;s Board of Directors. The Corporation shall notify Holder within 30 days of receipt of the Transfer Notice indicating whether consent has been provided for the proposed Transfer (a &#8220;<U>Transfer Approval</U>&#8221;) or
withheld (a &#8220;<U>Transfer Denial</U>&#8221; and together with &#8220;Transfer Approval&#8221;, the &#8220;<U>Transfer </U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Determination</U>&#8221;). For purposes of clarity, a Holder shall not be entitled to Transfer any shares if such proposed Transfer results in a Transfer Denial. Any Transfer made following a
Transfer Determination that results in a Transfer Approval shall be effected pursuant to a transfer agreement in a form reasonably acceptable to the Corporation (which form shall include, without limitation, a release in favor of the Corporation and
representations from the Holder and transferee that the Corporation is not a party to the transaction and has made no representations to the transferee). This provision shall not apply to any Transfer of Preferred Stock of the Corporation or the
shares of Common Stock issued upon conversion thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. RIGHT OF FIRST REFUSAL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the exceptions set forth in Section&nbsp;3(e) below, for 30 days following a Transfer Determination that results in a Transfer
Approval, the Corporation or its assigns shall have the option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice (the &#8220;<U>Right of First Refusal</U>&#8221;). In the event the
Corporation or its assigns, as applicable, elects to purchase all or part of the Offered Shares, it shall give written notice of such election to the Holder within such 30 day period. Within 10 days after Holder&#8217;s receipt of such notice,
Holder shall tender to the Corporation at its principal offices the certificate or certificates representing the Offered Shares to be purchased by the Corporation, duly endorsed in blank by Holder or with duly endorsed stock powers attached thereto,
all in a form suitable for Transfer of the Offered Shares to the Corporation. Promptly following receipt of such certificate or certificates, the Corporation or its assigns, as applicable, shall deliver or mail to Holder a check in payment of the
purchase price for such Offered Shares; <U>provided that</U> if the terms of payment set forth in the Transfer Notice were other than cash against delivery, the Corporation or its assigns, as applicable, may pay for the Offered Shares on the same
terms and conditions as were set forth in the Transfer Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Corporation or its assigns, as applicable, does not elect to
acquire any of the Offered Shares, Holder may, within the <FONT STYLE="white-space:nowrap">30-day</FONT> period following the expiration of the option granted to the Corporation under Section&nbsp;3(a) above, Transfer the Offered Shares that the
Corporation has not elected to acquire to the proposed transferee, <U>provided that</U> such Transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice, such Transfer shall be only to a
prospective transferee that is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act and such Transfer shall comply with the Securities Act. Notwithstanding any of the above, all Offered Shares
transferred pursuant to this Section&nbsp;3 shall remain subject to these Bylaws and any equity grant agreement such Offered Shares were subject to and such transferee shall, as a condition to such Transfer, deliver to the Corporation a written
instrument confirming that such transferee shall be bound by all of the terms and conditions of these Bylaws and any applicable equity grant agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) After the time at which the Offered Shares are required to be delivered to the Corporation for Transfer to the Corporation pursuant to
subsection 3(a) above, the Corporation shall not pay any dividend to Holder on account of such Offered Shares or permit Holder to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar as
permitted by law, treat the Corporation as the owner of such Offered Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Corporation may assign its Right of First Refusal in any particular transaction
under this Section&nbsp;3 to one or more persons or entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The provisions of this Section&nbsp;3 shall not apply to any Transfer
of Preferred Stock of the Corporation or the shares of Common Stock issued upon conversion thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the extent the Corporation has
entered into any written agreement with the stockholder attempting to Transfer shares that grants the Corporation a right of first refusal with respect thereto (&#8220;<U>Separate ROFR Terms</U>&#8221;), then such Separate ROFR Terms shall supersede
this Section&nbsp;3 of Article VI and shall control such stockholder&#8217;s proposed Transfer of shares following a Transfer Determination that results in a Transfer Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. EXCEPTIONS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Article VI may be waived with respect to any Transfer upon duly authorized action of its Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The following transaction shall be exempt from the consent requirements set forth in Article VI, Section&nbsp;2: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) any Transfer made for bona fide estate planning purposes to or for the benefit of (i)&nbsp;any spouse, children, parents, uncles, aunts,
siblings or grandchildren of the Holder or any other relatives of the Holder that have been approved by the Board of Directors (collectively, &#8220;<U>Approved Relatives</U>&#8221;), (ii) a custodian or trustee of any trust established solely for
the benefit of the Holder and/or Approved Relatives or (iii)&nbsp;where the Holder is a trust, (x)&nbsp;a custodian or trustee of any trust established solely for the benefit of one or more beneficiaries of the Holder trust and/or Approved Relatives
of any such beneficiaries or (y)&nbsp;one or more beneficiaries of the Holder trust and/or Approved Relatives of any such beneficiaries; provided however, such shares shall remain subject to these Bylaws and any existing equity grant agreement and
such transferee shall, as a condition to such Transfer, deliver to the Corporation a written instrument confirming that such transferee shall be bound by all of the terms and conditions of these Bylaws and any applicable equity grant agreement and
there shall be no further Transfer of such shares except in accordance with these Bylaws; and provided further that such Transfer is made pursuant to a transaction in which there is no consideration actually paid for such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The following transactions shall be exempt from the restrictions set forth in Article VI, Section&nbsp;3: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) any Transfer made for bona fide estate planning purposes to or for the benefit of (i)&nbsp;any Approved Relatives, (ii)&nbsp;a custodian
or trustee of any trust established solely for the benefit of the Holder and/or Approved Relatives or (iii)&nbsp;where the Holder is a trust, (x)&nbsp;a custodian or trustee of any trust established solely for the benefit of one or more
beneficiaries of the Holder trust and/or Approved Relatives of any such beneficiaries or (y)&nbsp;one or more beneficiaries of the Holder trust and/or Approved Relatives of any such beneficiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) any Transfer made as part of the sale of all or substantially all of the shares of capital stock of the Corporation (including pursuant
to a merger or consolidation); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C) any Transfer pursuant to an effective registration statement filed by the Corporation
under the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D) a stockholder&#8217;s bona fide pledge or mortgage of any Common Stock with a commercial lending
institution; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(E) a corporate stockholder&#8217;s Transfer of any or all of its shares pursuant to and in accordance with the terms of
any merger, consolidation, reclassification of common stock or capital reorganization of the corporate stockholder, or pursuant to a sale of all or substantially all of the stock or assets of a corporate stockholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(F) a corporate stockholder&#8217;s Transfer of any or all of its shares to any or all of its stockholders; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(G) a Transfer of any or all of the shares held by a stockholder which is a limited or general partnership to any or all of its partners.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the case of a Transfer pursuant to Sections 4(c)(A) and (D)-(G) above, such shares shall remain subject to these Bylaws and any
existing equity grant agreement and such transferee shall, as a condition to such Transfer, deliver to the Corporation a written instrument confirming that such transferee shall be bound by all of the terms and conditions of these Bylaws and any
applicable equity grant agreement and there shall be no further Transfer of such shares except in accordance with these Bylaws; provided further in the case of any Transfer pursuant to Section&nbsp;4(c)(A), that such Transfer is made pursuant to a
transaction in which there is no consideration actually paid for such Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5. TERMINATION. The provisions of Article VI
shall terminate upon the closing of the sale of shares of common stock in an underwritten public offering pursuant to an effective registration statement filed by the Corporation under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6. VOID TRANSFERS. The Corporation shall not be required (a)&nbsp;to Transfer on its books any shares which shall have been sold
or otherwise transferred in violation of any of the provisions of this Article VI or (b)&nbsp;to treat as owner of such shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom any such shares shall have
been so sold or transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7. LEGENDS. The books and records of the Corporation and any certificates representing shares
of stock of the Corporation shall contain or bear the following legend so long as the foregoing Transfer restrictions are in effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO (i)&nbsp;TRANSFER RESTRICTIONS AND (ii)&nbsp;A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE CORPORATION AND/OR ITS ASSIGNEE(S), EACH AS PROVIDED IN THE BYLAWS OF THE CORPORATION. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. RIGHT TO INDEMNIFICATION OF DIRECTORS AND OFFICERS. The Corporation shall indemnify and hold harmless, to the fullest extent
permitted by applicable law as it presently exists or may hereafter be amended, any person (an &#8220;<U>Indemnified Person</U>&#8221;) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or
proceeding, whether civil, criminal, administrative or investigative (a &#8220;<U>Proceeding</U>&#8221;), by reason of the fact that such person, or a person for whom such person is the legal representative, is or was a director or officer of the
Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, limited liability company,
trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#8217; fees) reasonably incurred by such Indemnified Person in such
Proceeding. Notwithstanding the preceding sentence, except as otherwise provided in Section&nbsp;3 of this Article VII, the Corporation shall be required to indemnify an Indemnified Person in connection with a Proceeding (or part thereof) commenced
by such Indemnified Person only if the commencement of such Proceeding (or part thereof) by the Indemnified Person was authorized in advance by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. PREPAYMENT OF EXPENSES OF DIRECTORS AND OFFICERS. The Corporation shall pay the expenses (including attorneys&#8217; fees)
incurred by an Indemnified Person in defending any Proceeding in advance of its final disposition, <U>provided</U>, <U>however</U>, that, to the extent required by law, such payment of expenses in advance of the final disposition of the Proceeding
shall be made only upon receipt of an undertaking by the Indemnified Person to repay all amounts advanced if it should be ultimately determined that the Indemnified Person is not entitled to be indemnified under this Article VII or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. CLAIMS BY DIRECTORS AND OFFICERS. If a claim for indemnification or advancement of expenses under this Article VII is not paid
in full within 30 days after a written claim therefor by the Indemnified Person has been received by the Corporation, the Indemnified Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be
entitled to be paid the expense of prosecuting such claim. In any such action the Corporation shall have the burden of proving that the Indemnified Person is not entitled to the requested indemnification or advancement of expenses under applicable
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. INDEMNIFICATION OF EMPLOYEES AND AGENTS. The Corporation may indemnify and advance expenses to any person who was or
is made or is threatened to be made or is otherwise involved in any Proceeding by reason of the fact that such person, or a person for whom such person is the legal representative, is or was an employee or agent of the Corporation or, while an
employee or agent of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, limited liability company, trust, enterprise or nonprofit
entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#8217; fees) reasonably incurred by such person in connection with such Proceeding. The ultimate
determination of entitlement to indemnification of persons who are <FONT STYLE="white-space:nowrap">non-director</FONT> or officer employees or agents shall be made in such manner as is determined by the Board of Directors in its sole discretion.
Notwithstanding the foregoing sentence, the Corporation shall not be required to indemnify a person in connection with a Proceeding initiated by such person if the Proceeding was not authorized in advance by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5. ADVANCEMENT OF EXPENSES OF EMPLOYEES AND AGENTS. The Corporation may pay the
expenses (including attorneys&#8217; fees) incurred by an employee or agent in defending any Proceeding in advance of its final disposition on such terms and conditions as may be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6. <FONT STYLE="white-space:nowrap">NON-EXCLUSIVITY</FONT> OF RIGHTS. The rights conferred on any person by this Article VII
shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these bylaws, agreement, vote of stockholders or disinterested directors or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7. OTHER INDEMNIFICATION. The Corporation&#8217;s obligation, if any, to indemnify any person who was or is serving at its
request as a director, officer or employee of another corporation, partnership, limited liability company, joint venture, trust, organization or other enterprise shall be reduced by any amount such person may collect as indemnification from such
other corporation, partnership, limited liability company, joint venture, trust, organization or other enterprise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.
INSURANCE. The Board of Directors may, to the full extent permitted by applicable law as it presently exists, or may hereafter be amended from time to time, authorize an appropriate officer or officers to purchase and maintain at the
Corporation&#8217;s expense insurance: (a)&nbsp;to indemnify the Corporation for any obligation which it incurs as a result of the indemnification of directors, officers and employees under the provisions of this Article VII; and (b)&nbsp;to
indemnify or insure directors, officers and employees against liability in instances in which they may not otherwise be indemnified by the Corporation under the provisions of this Article VII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9. AMENDMENT OR REPEAL. Any repeal or modification of the foregoing provisions of this Article VII shall not adversely affect any
right or protection hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification. The rights provided hereunder shall inure to the benefit of any Indemnified Person and such person&#8217;s
heirs, executors and administrators. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.
DECLARATIONS OF DIVIDENDS. Dividends upon the capital stock of the Corporation, subject to the provisions of the Certificate of Incorporation, if any, may be declared by the Board of Directors at any regular or special meeting, pursuant to law.
Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. SPECIAL PURPOSES RESERVES. The Board of Directors may set apart out of any of the funds of the Corporation available for
dividends a reserve or reserves for any proper purpose and may abolish any such reserve. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE BY ELECTRONIC TRANSMISSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. NOTICE BY ELECTRONIC TRANSMISSION. Without limiting the manner by which notice otherwise may be given effectively to
stockholders, any notice to stockholders given by the Corporation under the Delaware General Corporation Law, the Certificate of Incorporation, or these Bylaws may be given in writing directed to the stockholder&#8217;s mailing address (or by
electronic transmission directed to the stockholder&#8217;s electronic mail address, as applicable) as it appears on the records of the Corporation and shall be given (1)&nbsp;if mailed, when the notice is deposited in the U.S. mail, postage
prepaid, (2)&nbsp;if delivered by courier service, the earlier of when the notice is received or left at such stockholder&#8217;s address or (3)&nbsp;if given by electronic mail, when directed to such stockholder&#8217;s electronic mail address
unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by Section&nbsp;3 of this Article. A notice by electronic mail must
include a prominent legend that the communication is an important notice regarding the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Without limiting the manner by which
notice otherwise may be given effectively to stockholders, but subject to Section&nbsp;3 of this Article, any notice to stockholders given by the Corporation under any provision of the Delaware General Corporation Law, the Certificate of
Incorporation or these Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice or electronic
transmission to the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice given pursuant to the preceding paragraph shall be deemed given: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of
(A)&nbsp;such posting and (B)&nbsp;the giving of such separate notice; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) if by any other form of electronic transmission, when
directed to the stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a notice may not be given by an electronic transmission from and after the time that
(1)&nbsp;the Corporation is unable to deliver by such electronic transmission 2 consecutive notices given by the Corporation and (2)&nbsp;such inability becomes known to the secretary or an assistant secretary of the Corporation or to the transfer
agent, or other person responsible for the giving of notice, provided, however, the inadvertent failure to discover such inability shall not invalidate any meeting or other action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the Corporation that the notice has been given shall, in
the absence of fraud, be <I>prima facie</I> evidence of the facts stated therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. DEFINITION OF ELECTRONIC TRANSMISSION; ELECTRONIC MAIL; ELECTRONIC MAIL
ADDRESS. An &#8220;electronic transmission&#8221; means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be
directly reproduced in paper form by such a recipient through an automated process. An &#8220;electronic mail&#8221; means an electronic transmission directed to a unique electronic mail address (which electronic mail shall be deemed to include any
files attached thereto and any information hyperlinked to a website if such electronic mail includes the contact information of an officer or agent of the Corporation who is available to assist with accessing such files and information). An
&#8220;electronic mail address&#8221; means a destination, commonly expressed as a string of characters, consisting of a unique user name or mailbox (commonly referred to as the &#8220;local part&#8221; of the address) and a reference to an internet
domain (commonly referred to as the &#8220;domain part&#8221; of the address), whether or not displayed, to which electronic mail can be sent or delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. INAPPLICABILITY. Notice by a form of electronic transmission shall not apply to Sections 164, 296, 311, 312 or 324 of the
Delaware General Corporation Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. FISCAL YEAR. The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2. SEAL. The corporate seal shall have inscribed thereon the name of the Corporation, the year of its organization and the words
&#8220;Corporate Seal, Delaware&#8221; or such other form as shall be approved by the Board of Directors. Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3. WRITTEN WAIVER OF NOTICE. A written waiver of any notice required to be given by law, the Certificate of Incorporation or by
these Bylaws, signed by or electronically transmitted by the person entitled to notice, whether before, at or after the time of the event for which notice is to be given, shall be deemed equivalent to notice required to be given to such person.
Neither the business to be transacted at, nor the purpose of, any regular or special meeting of stockholders, directors or members of a committee of directors need be specified in any written waiver of notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4. ATTENDANCE AS WAIVER OF NOTICE. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting,
except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, and objects, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5. WAIVER OF SECTION 1501. To the fullest extent provided by the law, the Corporation shall not be required to cause annual
reports to be delivered to its stockholders under Section&nbsp;1501 of the California General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6. CONTRACTS.
The Board of Directors may authorize any officer or officers, agent or agents, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined to
specific instances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7. LOANS. No loans shall be contracted on behalf of the Corporation and no
evidences of indebtedness shall be issued in its name unless authorized by a resolution of the Board of Directors. Such authority may be general or confined to specific instances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8. CHECKS, DRAFTS, ETC. All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness
issued in the name of the Corporation shall be signed by one or more officers or agents of the Corporation and in such manner as shall from time to time be determined by resolution of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9. DEPOSITS. The funds of the Corporation may be deposited or invested in such bank account, in such investments or with such
other depositaries as determined by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10. ANNUAL STATEMENT. The Board of Directors shall present at
each annual meeting, and at any special meeting of the stockholders when called for by vote of the stockholders, a full and clear statement of the business and condition of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11. VOTING OF SECURITIES. Except as the Board of Directors may otherwise designate, the Chief Executive Officer, the President or
the Treasurer may waive notice of, vote, or appoint any person or persons to vote, on behalf of the Corporation at, and act as, or appoint any person or persons to act as, proxy or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for this Corporation (with or without power of substitution) at, any meeting of stockholders or securityholders of any other entity, the securities of
which may be held by this Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12. EVIDENCE OF AUTHORITY. A certificate by the Secretary, or an Assistant Secretary,
or a temporary Secretary, as to any action taken by the stockholders, directors, a committee or any officer or representative of the Corporation shall as to all persons who rely on the certificate in good faith be conclusive evidence of such action.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13. CERTIFICATE OF INCORPORATION. All references in these Bylaws to the Certificate of Incorporation shall be deemed to
refer to the Certificate of Incorporation of the Corporation, as amended and in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14. SEVERABILITY.
Any determination that any provision of these Bylaws is for any reason inapplicable, illegal or ineffective shall not affect or invalidate any other provision of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;15. PRONOUNS. All pronouns used in these Bylaws shall be deemed to refer to the masculine, feminine or neuter, singular or
plural, as the identity of the person or persons may require. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1. BY THE BOARD OF DIRECTORS. These Bylaws may be altered, amended or repealed, in whole or in part, or new Bylaws may be adopted
by the Board of Directors, when such power is conferred upon the Board of Directors by the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.
BY THE STOCKHOLDERS. These Bylaws may be altered, amended or repealed, in whole or in part, or new Bylaws may be adopted, by the affirmative vote of the holders of a majority of the shares of the capital stock of the Corporation issued and
outstanding and entitled to vote at any annual meeting of stockholders, or at any special meeting of stockholders, provided notice of such alteration, amendment, repeal or adoption of new Bylaws shall have been stated in the notice of such special
meeting. If the power to adopt, amend or repeal Bylaws is conferred upon the Board of Directors by the Certificate of Incorporation it shall not divest or limit the power of the stockholders to adopt, amend or repeal Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL, AND THE REGISTRANT TREATS SUCH INFORMATION AS
PRIVATE AND CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN <B>REDACTED</B>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED INVESTORS&#8217; RIGHTS
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS AMENDED AND RESTATED INVESTORS&#8217; RIGHTS AGREEMENT (this &#8220;<B>Agreement</B>&#8221;) is made as of October&nbsp;18, 2024, by
and among Seaport Therapeutics, Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), and the Investors (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
certain of the Investors (the &#8220;<B>Existing Investors</B>&#8221;) hold shares of Preferred Stock and possess registration rights, information rights, rights of first offer, and other rights pursuant to that certain Investors&#8217; Rights
Agreement dated as of April&nbsp;8, 2024, by and among the Company and such Existing Investors (the &#8220;<B>Prior Agreement</B>&#8221;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Existing Investors and the Company desire to induce certain of the Investors to purchase shares of Series B Preferred
Stock of the Company, par value $0.0001 per share (&#8220;<B>Series B Preferred Stock</B>&#8221;), pursuant to that certain Series B Preferred Stock Purchase Agreement dated as of the date hereof by and among the Company and such Investors (the
&#8220;<B>Purchase Agreement</B>&#8221;) by amending and restating the Prior Agreement in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the
parties agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For purposes of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 &#8220;<B>Affiliate</B>&#8221; means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or other investment fund now or hereafter
existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser (or <FONT STYLE="white-space:nowrap">sub-adviser</FONT> or affiliate adviser) with,
such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 &#8220;<B>Approved Annual Budget</B>&#8221; means an annual budget and business plan for the next fiscal year, prepared
on a monthly basis, as approved by the Requisite Director Vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 &#8220;<B>ARCH</B>&#8221; means ARCH VENTURE FUND XII, L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 &#8220;<B>Board of Directors</B>&#8221; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 &#8220;<B>Certificate of Incorporation</B>&#8221; means the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended
and/or restated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 &#8220;<B>Common Stock</B>&#8221; means shares of the Company&#8217;s common stock, par value
$0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 &#8220;<B>Competitor</B>&#8221; means any Person engaged, directly or indirectly (including through any
partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in biotechnology focusing on neurological and/ or psychiatric conditions with products or product candidates
targeting similar diseases or indications to the Company; but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than 20% of the outstanding equity of any Competitor and
does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor. Notwithstanding the above, the Company and the Investors acknowledge and agree that each of ARCH, CPPIB, Foresite, General
Atlantic, [***], Invus, PureTech, Sofinnova, Third Rock, [***] and [***] is a financial investor and shall not be deemed a Competitor (notwithstanding the fact that its Affiliates and/or portfolio companies may be engaged, or may in the future
engage, in activities some of which may be deemed competitive with the Company&#8217;s business). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 &#8220;<B>CPPIB</B>&#8221; means CPP Investment Board Holdings (4)&nbsp;Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 &#8220;<B>Damages</B>&#8221; means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject
under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i)&nbsp;any untrue statement or alleged untrue statement
of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii)&nbsp;an omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii)&nbsp;any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act,
the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 &#8220;<B>Deemed Liquidation Event</B>&#8221; shall have the meaning ascribed to it in the Company&#8217;s Certificate of Incorporation,
as in effect on the date of this Agreement and regardless of the date on which such event occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 &#8220;<B>Derivative
Securities</B>&#8221; means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12 &#8220;<B>Exchange Act</B>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13 &#8220;<B>Excluded Registration</B>&#8221; means (i)&nbsp;a registration relating to the sale or grant of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii)&nbsp;a registration relating to an SEC Rule 145 transaction; (iii)&nbsp;a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv)&nbsp;a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 &#8220;<B>Foresite</B>&#8221; means Foresite Capital Fund VI,
L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15 &#8220;<B>Form <FONT STYLE="white-space:nowrap">S-1</FONT></B>&#8221; means such form under the Securities Act as in effect on
the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16 &#8220;<B>Form <FONT
STYLE="white-space:nowrap">S-3</FONT></B>&#8221; means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of
substantial information by reference to other documents filed by the Company with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17 &#8220;<B>GAAP</B>&#8221; means generally
accepted accounting principles in the United States as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18 &#8220;<B>General Atlantic</B>&#8221; means
General Atlantic (SP), L.P. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.19 [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20 &#8220;<B>Holder</B>&#8221; means any holder of Registrable Securities who is a party to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.21 &#8220;<B>Immediate Family Member</B>&#8221; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner
or similar statutorily-recognized domestic partner, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships of a natural person referred to herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22 &#8220;<B>Initiating Holders</B>&#8221; means, collectively, Holders who properly initiate a registration request under this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23 &#8220;<B>Investors</B>&#8221; means the persons named on <U>Schedule A</U> hereto, each person to whom the rights of an Investor
are assigned pursuant to <U>Section</U><U></U><U>&nbsp;6.1</U>, and each person who hereafter becomes a party to this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;6.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.24 &#8220;<B>Invus</B>&#8221; means Invus Public Equities, L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.25 &#8220;<B>IPO</B>&#8221; means the Company&#8217;s first underwritten public offering of its Common Stock under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.26 &#8220;<B>Major Investor</B>&#8221; means any Investor that, individually or together with such Investor&#8217;s Affiliates, holds at
least 2,100,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.27 &#8220;<B>New Securities</B>&#8221; means, collectively, equity securities of the Company, whether or not currently authorized, as well
as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.28 &#8220;<B>New Series B Investor</B>&#8221; means any Major Investor whose holdings of Preferred Stock as of the date of this Agreement
consist entirely of shares of Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.29 &#8220;<B>Person</B>&#8221; means any individual, corporation, partnership,
trust, limited liability company, association, or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.30 &#8220;<B>PureTech</B>&#8221; means PureTech LYT, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.31 &#8220;<B>Preferred Director</B>&#8221; means any director of the Company that the holders of record of a class, classes or series of
Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.32
&#8220;<B>Preferred Stock</B>&#8221; means, collectively, shares of the Company&#8217;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and Series B Preferred
Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.33 &#8220;<B>Registrable Securities</B>&#8221; means (i)&nbsp;the Common Stock issuable or
issued upon conversion of the Preferred Stock; (ii)&nbsp;any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, held by the Investors from time to
time; and (iii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the
shares referenced in clauses (i)&nbsp;and (ii) above; excluding in all cases (other than the restrictions on transfer and legend requirements in <U>Section</U><U></U><U>&nbsp;2.12</U>), however, any Registrable Securities sold by a Person in a
transaction in which the applicable rights under this Agreement are not assigned pursuant to <U>Section</U><U></U><U>&nbsp;6.1</U>, and excluding for purposes of <U>Section</U><U></U><U>&nbsp;2</U> any shares for which registration rights have
terminated pursuant to <U>Section</U><U></U><U>&nbsp;2.13</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.34 &#8220;<B>Registrable Securities then outstanding</B>&#8221; means
the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible
securities that are Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.35 &#8220;<B>Requisite Holder Vote</B>&#8221; means (i)&nbsp;prior to an IPO, the approval
of (x)&nbsp;Investors holding a majority of the Registrable Securities issued or issuable upon conversion of the Preferred Stock, voting together as a single class, and (y)&nbsp;the holders of a majority of the Registrable Securities issued or
issuable upon conversion of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and Series B Preferred Stock, voting together as a single class, which majority must include at least one New Series B Investor, and
(ii)&nbsp;following an IPO, the approval of Investors holding a majority of the Registrable Securities issued or issuable upon conversion of the Preferred Stock, voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.36 &#8220;<B>Requisite Director Vote</B>&#8221; means the approval of a majority of the Board of Directors, including a majority of the
Preferred Directors then seated (or three (3)&nbsp;Preferred Directors if greater), and including at least two (2)&nbsp;Preferred Directors that are not Series <FONT STYLE="white-space:nowrap">A-1</FONT> Directors (as defined in the Certificate of
Incorporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.37 &#8220;<B>Restricted Securities</B>&#8221; means the securities of the Company required to be notated with the
legend set forth in <U>Section</U><U></U><U>&nbsp;2.12(b)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.38 &#8220;<B>SEC</B>&#8221; means the Securities and Exchange
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.39 &#8220;<B>SEC Rule 144</B>&#8221; means Rule 144 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.40 &#8220;<B>SEC Rule 145</B>&#8221; means Rule 145 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.41 &#8220;<B>Securities Act</B>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.42 &#8220;<B>Selling Expenses</B>&#8221; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in <U>Section</U><U></U><U>&nbsp;2.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.43 &#8220;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#8221; means shares of the Company&#8217;s Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.44 &#8220;<B>Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</B>&#8221; means shares of the Company&#8217;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.45 &#8220;<B>Sofinnova</B>&#8221; means Sofinnova Venture Partners XI, L.P. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.46 &#8220;<B>Third Rock</B>&#8221; means Third Rock Ventures VI, L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.47 [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.48 [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Registration Rights</U>. The Company covenants and agrees as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Demand Registration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand</B>. If at any time after the earlier of (i)&nbsp;five (5) years after the date
of this Agreement or (ii) 180 days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least 9% of the Registrable Securities then outstanding that the Company file a Form <FONT
STYLE="white-space:nowrap">S-1</FONT> registration statement with respect to Registrable Securities then outstanding having an anticipated aggregate offering price (as adjusted for any stock split, stock dividend, combination, or other
recapitalization or reclassification effected after the date hereof), net of Selling Expenses, of at least $15,000,000, then the Company shall: (x)&nbsp;within ten days after the date such request is given, give notice thereof (the &#8220;<B>Demand
Notice</B>&#8221;) to all Holders other than the Initiating Holders; and (y)&nbsp;as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form
<FONT STYLE="white-space:nowrap">S-1</FONT> registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included
in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Sections 2.1(c)</U> and <U>2.3</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand</B>. If at any time when it is eligible to use a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement, the Company receives a request from Holders of at least 9% of the Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-3</FONT>
registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5,000,000, then the Company shall (i)&nbsp;within ten days after the date
such request is given, give a Demand Notice to all Holders other than the Initiating Holders, and (ii)&nbsp;as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Sections 2.1(c)</U> and <U>2.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1</U> a certificate signed by the Company&#8217;s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company for such registration
statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i)&nbsp;materially interfere with a significant acquisition, corporate
reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render the Company
unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be
tolled correspondingly, for a period of not more than 90 days after the request of the Initiating Holders is given; <U>provided</U>, <U>however</U>, that the Company may not invoke this right more than twice in any
<FONT STYLE="white-space:nowrap">12-month</FONT> period; and <U>provided further</U> that the Company shall not register any securities for its own account or that of any other stockholder during such 90 day period other than an Excluded
Registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1(a)</U>, (i) during the period that is 60 days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a
Company- initiated registration, <U>provided</U> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii)&nbsp;after the Company has effected two
registrations pursuant to <U>Section</U><U></U><U>&nbsp;2.1(a)</U>; or (iii)&nbsp;if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
pursuant to a request made pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)</U>. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)</U>, (i) during the
period that is 30 days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, a Company- initiated registration, <U>provided</U> that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has effected two registrations pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)</U> within the <FONT
STYLE="white-space:nowrap">12-month</FONT> period immediately preceding the date of such request. A registration shall not be counted as &#8220;effected&#8221; for purposes of this <U>Section</U><U></U><U>&nbsp;2.1(d) </U>until such time as the
applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement pursuant to <U>Section</U><U></U><U>&nbsp;2.6</U>, in which case such withdrawn registration statement shall be counted as &#8220;effected&#8221; for purposes of this <U>Section</U><U></U><U>&nbsp;2.1(d)</U>; <U>provided</U>,
that if such withdrawal is during a period the Company has deferred taking action pursuant to <U>Section</U><U></U><U>&nbsp;2.1(c)</U>, then the Initiating Holders may withdraw their request for registration and such registration will not be counted
as &#8220;effected&#8221; for purposes of this <U>Section</U><U></U><U>&nbsp;2.1(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Company Registration</U>. If the Company
proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for
cash (other than in an Excluded Registration or a registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within
20 days after such notice is given by the Company, the Company shall, subject to the provisions of <U>Section</U><U></U><U>&nbsp;2.3</U>, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in
such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this <U>Section</U><U></U><U>&nbsp;2.2</U> before the effective date of such registration, whether or not any Holder has elected to
include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with <U>Section</U><U></U><U>&nbsp;2.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Underwriting Requirements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If, pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, and the Company shall include such information in the Demand Notice. The underwriter(s)
will be selected by the Board of Directors and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&#8217;s Registrable Securities in such registration
shall be conditioned upon such Holder&#8217;s participation in such underwriting and the inclusion of such Holder&#8217;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall (together with the Company as provided in <U>Section</U><U></U><U>&nbsp;2.4(e)</U>) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting; <U>provided</U>,
<U>however</U>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that no Holder (or any of their assignees) shall be required to make any representations, warranties or indemnities except as they relate to such Holder&#8217;s ownership of shares and authority
to enter into the underwriting agreement and to such Holder&#8217;s intended method of distribution, and the liability of such Holder shall be several and not joint, and limited to an amount equal to the net proceeds from the offering received by
such Holder. Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;2.3</U>, if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten,
then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such
Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling
Holders; <U>provided</U>, <U>however</U>, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To
facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with any offering involving an underwriting of shares of the Company&#8217;s capital stock pursuant to
<U>Section</U><U></U><U>&nbsp;2.2</U>, the Company shall not be required to include any of the Holders&#8217; Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and
its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance
with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i)&nbsp;the number of Registrable Securities included in
the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii)&nbsp;the number of Registrable Securities included in the offering be reduced below 30% of
the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder&#8217;s
securities are included in such offering. For purposes of the provision in this <U>Section</U><U></U><U>&nbsp;2.3(b)</U> concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners,
members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the
foregoing Persons, shall be deemed to be a single &#8220;selling Holder,&#8221; and any pro rata reduction with respect to such &#8220;selling Holder&#8221; shall be based upon the aggregate number of Registrable Securities owned by all Persons
included in such &#8220;selling Holder,&#8221; as defined in this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of <U>Section</U><U></U><U>&nbsp;2.1</U>, a
registration shall not be counted as &#8220;effected&#8221; if, as a result of an exercise of the underwriter&#8217;s cutback provisions in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>, fewer than 50% of the total number of Registrable Securities that
Holders have requested to be included in such registration statement are actually included. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Obligations of the Company</U>. Whenever required under this <U>Section</U>&nbsp;2 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the
Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U>,
<U>however</U>, that (i)&nbsp;such <FONT STYLE="white-space:nowrap">120-day</FONT> period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the
Company, from selling any securities included in such registration, and (ii)&nbsp;in the case of any registration of Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that are intended to be offered on a continuous or
delayed basis, subject to compliance with applicable SEC rules, such <FONT STYLE="white-space:nowrap">120-day</FONT> period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) promptly make available for
inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all
financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company&#8217;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller,
underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) notify each selling Holder, promptly after the Company receives notice thereof, of the
time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#8217;s directors may implement a trading program under Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Furnish Information</U>. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder&#8217;s Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Expenses of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, including all registration, filing, and qualification fees; printers&#8217; and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $50,000 per registration, of one counsel for the selling Holders selected by Holders of a majority of the Registrable Securities to be registered (&#8220;<B>Selling Holder Counsel</B>&#8221;), shall be borne and paid by
the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> if the registration request is subsequently withdrawn
at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn
registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to <U>Sections 2.1(a)</U> or <U>2.1(b)</U>, as the case may be; <U>provided further</U> that if, at the time of
such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to <U>Sections</U><U></U><U>&nbsp;2.1(a)</U> or <U>2.1(b)</U>. All
Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> (other than fees and disbursements of counsel to any Holder, other than the Selling Holder Counsel, which shall be borne solely by
the Holder engaging such counsel) shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Delay of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this <U>Section</U><U></U><U>&nbsp;2</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <U>Indemnification</U>. If any Registrable Securities are included in a registration
statement under this <U>Section</U><U></U><U>&nbsp;2</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each
Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person
any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement
contained in this <U>Section</U><U></U><U>&nbsp;2.8(a)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder,
underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration except to the extent such information has been corrected in a subsequent writing prior to the sale of Registrable Securities to
the Person asserting the claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and
hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent
that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration and that
has not been corrected in a subsequent writing prior to the sale of Registrable Securities to the Person asserting the claim; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this
<U>Section</U><U></U><U>&nbsp;2.8(b)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and
<U>provided further</U> that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under <U>Sections 2.8(b)</U> and <U>2.8(d</U>) exceed the proceeds from the offering received by such Holder (net of any
Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an
indemnified party under this <U>Section</U><U></U><U>&nbsp;2.8</U> of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a
claim in respect thereof is to be made against any indemnifying party under this <U>Section</U><U></U><U>&nbsp;2.8</U>, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in
such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties;
<U>provided</U>, <U>however</U>, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be
paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party
represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under
this <U>Section</U><U></U><U>&nbsp;2.8</U>, only to the extent that such failure materially prejudices the indemnifying party&#8217;s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any
liability that it may have to any indemnified party otherwise than under this <U>Section</U><U></U><U>&nbsp;2.8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To provide for just and equitable contribution to joint liability under the Securities
Act in any case in which either: (i)&nbsp;any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section</U><U></U><U>&nbsp;2.8</U> but it is judicially determined (by the entry of a final
judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
<U>Section</U><U></U><U>&nbsp;2.8</U> provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
<U>Section</U><U></U><U>&nbsp;2.8</U>, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties&#8217; relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; <U>provided</U>, <U>however</U>, that, in any such case (x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by
such Holder pursuant to such registration statement, and (y)&nbsp;no Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation; and <U>provided further</U> that in no event shall a Holder&#8217;s liability pursuant to this <U>Section</U><U></U><U>&nbsp;2.8(d)</U>, when combined with the amounts paid or payable by such Holder pursuant to
<U>Section</U><U></U><U>&nbsp;2.8(b)</U>, exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; <U>provided</U>, <U>however</U>, that any matter expressly provided
for or addressed by the provisions of this <U>Section</U><U></U><U>&nbsp;2.8</U> that is not expressly provided for or addressed by the underwriting agreement shall be controlled by the foregoing provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this <U>Section</U><U></U><U>&nbsp;2.8</U> shall survive the completion of any offering of Registrable Securities in a registration under this <U>Section</U><U></U><U>&nbsp;2</U>, and otherwise shall survive the
termination of this Agreement or any provision(s) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <U>Reports Under Exchange Act</U>. With a view to making
available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the Company shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) make and keep available adequate current public information, as those terms
are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i)&nbsp;to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90)&nbsp;days after the effective date of the registration statement
filed by the Company for the IPO, the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies), and (ii)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such
securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to
use such form). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <U>Limitations on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall
not, without a prior Requisite Holder Vote, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i)&nbsp;provide to such holder or prospective holder the right to include securities in any
registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that
they wish to so include, or (ii)&nbsp;allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; <U>provided</U> that this limitation shall not apply to Registrable
Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;6.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <U>&#8220;Market <FONT STYLE="white-space:nowrap">Stand-off&#8221;</FONT> Agreement</U>. Each Holder hereby agrees that it will not,
without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity
securities under the Securities Act on a registration statement (other than an Excluded Registration) on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> and ending on the date specified by the Company and the managing underwriter (such period not
to exceed 180 days in the case of the IPO), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or
dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for
such offering, or (ii)&nbsp;enter into any swap, hedging, or other transaction or arrangement that transfers, or is designed to transfer, to another, in whole or in part, any of the economic consequences of ownership, directly or indirectly, of such
securities, whether or not any such transaction or arrangement described in <U>clause (i)</U>&nbsp;or <U>(ii)</U> above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this
<U>Section</U><U></U><U>&nbsp;2.11</U> shall apply only to the IPO, shall not apply to shares purchased in the IPO or on the open market following the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting
agreement or to the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1,</FONT> <U>provided</U> that such plan does not permit transfers during the restricted period, or the transfer of any shares to any trust
for the direct or indirect benefit of the Holder or one or more of the Holder&#8217;s Immediate Family Members, <U>provided</U> that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and that any such
transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors of the Company are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a
similar agreement from all stockholders individually owning more than one percent (1%) of the Company&#8217;s outstanding Common Stock (after giving effect to the conversion into Common Stock of all outstanding Preferred Stock). The Company shall
work in good faith with PureTech and the managing underwriter with the aim of providing PureTech with such exceptions to the restrictions set forth herein as are necessary for PureTech to maintain an exemption from registration under the Investment
Company Act of 1940. The underwriters in connection with such registration are intended third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;2.11</U> and shall have the right, power and authority to enforce the provisions hereof as though
they were a party hereto. Each Holder further agrees to execute </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this <U>Section</U><U></U><U>&nbsp;2.11</U> or that are necessary
to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements,
based on the number of shares subject to such agreements, except that, notwithstanding the foregoing, the Company and the underwriters may, in their sole discretion, waive or terminate these restrictions with respect to up to an aggregate of 100,000
shares of Common Stock (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 <U>Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act and all other applicable U.S. laws and regulations. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree
to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or,
following the IPO, SEC Rule 144, in each case, to be bound by the terms of this <U>Section</U><U></U><U>&nbsp;2.12</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each
certificate, instrument, or book entry representing (i)&nbsp;the Preferred Stock; (ii)&nbsp;the Registrable Securities; and (iii)&nbsp;any other securities issued in respect of the securities referenced in clauses (i)&nbsp;and (ii), upon any stock
split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of <U>Section</U><U></U><U>&nbsp;2.12(c)</U>) be notated with a legend substantially in the following form: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE
SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF
WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holders consent to the Company making a notation in its records and giving
instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this <U>Section</U><U></U><U>&nbsp;2.12</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
<U>Section</U><U></U><U>&nbsp;2</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the IPO, the
transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder&#8217;s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed
sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder&#8217;s expense by either (i)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall, be
reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction may be effected without registration under the Securities Act; (ii)&nbsp;a &#8220;no action&#8221; letter from the SEC to the effect that the proposed sale, pledge, or transfer of
such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company to the effect
that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted
Securities in accordance with the terms of the notice given by the Holder to the Company. Notwithstanding the foregoing, the Company will not require such a notice, legal opinion or &#8220;no action&#8221; letter (x)&nbsp;in any transaction in
compliance with SEC Rule 144; or (y)&nbsp;in any transaction in which such Holder distributes or transfers Restricted Securities to an Affiliate of such Holder for no consideration; <U>provided</U> that each transferee agrees in writing to be
subject to the terms of this <U>Section</U><U></U><U>&nbsp;2.12</U>. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to
SEC Rule 144, the appropriate restrictive legend set forth in <U>Section</U><U></U><U>&nbsp;2.12(b)</U>, except that such certificate, instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such
Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act and the Company will use commercially reasonable efforts to cause any such legend to be removed. In addition, subject to
compliance with applicable securities laws and regulation, and any contractual restrictions entered into by the Investor (such as a <FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff agreement), at the request of the Investor, if, in
the opinion of counsel for such Investor and the Company, the restrictive legend set forth in <U>Section</U><U></U><U>&nbsp;2.12(b)</U> is no longer required in order to establish compliance with any provisions of the Securities Act, the Company
will use commercially reasonable efforts to cause any such legend to be removed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 <U>Termination and Suspension of Registration
Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>2.2</U> shall terminate, as to such Holder, upon the earliest to occur of:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the closing of a Deemed Liquidation Event; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) such time after consummation of an IPO, when the Holder (A)&nbsp;together with together with its &#8220;affiliates&#8221; (as determined
under SEC Rule 144) holds less than 1% of the outstanding capital stock of the Company and (B)&nbsp;may immediately sell all of the Holder&#8217;s Registrable Securities under SEC Rule 144 without volume limitation, or another similar exemption
under the Securities Act is available for the sale of all of such Holder&#8217;s shares without limitation, during a three-month period without registration; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the third anniversary of the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.
<U>Information Rights</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Delivery of Financial Statements</U>. The Company shall deliver to each Major Investor, <U>provided</U>
that the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) as soon as
practicable, but in any event within one hundred eighty (180)&nbsp;days after the end of each fiscal year of the Company (i)&nbsp;a balance sheet as of the end of such year; (ii)&nbsp;statements of income and of cash flows for such year; and
(iii)&nbsp;a statement of stockholders&#8217; equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) as soon as practicable, but in any event within forty-five (45)&nbsp;days after the end
of each quarter of each fiscal year of the Company, (i)&nbsp;unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except
that such financial statements may (x)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments; and (y)&nbsp;not contain all notes thereto that may be required in accordance with GAAP) and (ii)&nbsp;an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> capitalization table; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) as soon as practicable,
but in any event within 30 days prior to the end of each fiscal year, the Company&#8217;s Approved Annual Budget for the upcoming fiscal year; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor
may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this <U>Section</U><U></U><U>&nbsp;3.1(d)</U> to provide information (i)&nbsp;that the Company reasonably determines in good
faith to be a trade secret or similar highly confidential information; or (ii)&nbsp;the disclosure of which would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else in this <U>Section</U><U></U><U>&nbsp;3.1</U> to the contrary, the Company may cease providing the information
set forth in this <U>Section</U><U></U><U>&nbsp;3.1</U> during the period starting with the date 60 days before the Company&#8217;s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to
comply with the SEC rules applicable to such registration statement and related offering; <U>provided</U> that the Company&#8217;s covenants under this <U>Section</U><U></U><U>&nbsp;3.1</U> shall be reinstated at such time as the Company is no
longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2
<U>Inspection</U>. The Company shall permit each Major Investor (<U>provided</U> that the Board of Directors has not reasonably determined that such Major Investor is a Competitor), at such Major Investor&#8217;s expense, to visit and inspect the
Company&#8217;s properties; examine its books of account and records; and discuss the Company&#8217;s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major
Investor; <U>provided</U>, <U>however</U>, that the Company shall not be obligated pursuant to this <U>Section</U><U></U><U>&nbsp;3.2</U> to provide access to any information that it reasonably and in good faith considers to be a trade secret or
confidential information or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Termination of Information Rights</U>. The covenants set forth in <U>Sections 3.1</U> and <U>3.2</U> shall terminate and be of no
further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or (iii)&nbsp;upon the
closing of a Deemed Liquidation Event, whichever event occurs first. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Confidentiality</U>. Each Investor agrees that such Investor
will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the Company (including notice of the
Company&#8217;s intention to file a registration statement), unless such confidential information (a)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this <U>Section</U><U></U><U>&nbsp;3.4</U> by such
Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company&#8217;s confidential information, or (c)&nbsp;is or has been made known or disclosed to such Investor by a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third party without a breach of any obligation of confidentiality such third party may have to the Company; <U>provided</U>, <U>however</U>, that an Investor may disclose confidential information
(i)&nbsp;to its attorneys, accountants, consultants, investment adviser or <FONT STYLE="white-space:nowrap">sub-adviser,</FONT> and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring its
investment in the Company; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this <U>Section</U><U></U><U>&nbsp;3.4</U>; (iii) to any
Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, <U>provided</U> that (A)&nbsp;such Investor informs such Person that such information is confidential and directs such Person to
maintain the confidentiality of such information, (B)&nbsp;any such disclosure to a Person that is a limited partner or equivalent equity holder that is not involved in the day to day monitoring of such Investor&#8217;s investment in the Company may
only include the types of information that the Company is obligated to provide under <U>Section</U><U></U><U>&nbsp;3.1</U>, and (C)&nbsp;such Person is not a Competitor; or (iv)&nbsp;as may otherwise be required by law, regulation, rule, court order
or subpoena, <U>provided</U> that such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Waiver of Statutory Information Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Investor hereby acknowledges and agrees that until the consummation of the IPO, such Investor shall hereby be deemed to have
unconditionally and irrevocably, to the fullest extent permitted by law, on behalf of such Investor and all beneficial owners of the shares of Common Stock or Preferred Stock owned by such Investor (a &#8220;<B>Beneficial Owner</B>&#8221;), waived,
and does hereby so waive, any rights such Investor or a Beneficial Owner might otherwise have had under Section&nbsp;220 of the Delaware General Corporation Law (or under similar rights under other applicable law) to inspect for any proper purpose
and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders and its other books and records or the books and records of any subsidiary. This waiver applies only in such Investor&#8217;s capacity as a stockholder
and does not affect any other information and inspection rights such Investor may expressly have pursuant to <U>Sections 3.1</U>, <U>3.2</U> or <U>3.5(b)</U> of this Agreement. Each Investor hereby further warrants and represents that such Investor
has reviewed this waiver with its legal counsel, and that such Investor knowingly and voluntarily waives its rights as a stockholder otherwise provided by Section&nbsp;220 of the Delaware General Corporation Law (or under similar rights under other
applicable law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Within 15 days after request by any Investor that is not a Major Investor (but no more frequently than once per each
quarter of each fiscal year of the Company), the Company shall deliver to such requesting Investor a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of
capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the
number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the relevant Investors to calculate its respective percentage equity ownership in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Rights to Future Stock Issuances</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right of First Offer</U>. Subject to the terms and conditions of this <U>Section</U><U></U><U>&nbsp;4.1</U> and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such
proportions as it deems appropriate, among (i)&nbsp;itself and (ii)&nbsp;its Affiliates; <U>provided</U> that each such Affiliate (x)&nbsp;is not a Competitor, unless such party&#8217;s purchase of New Securities is otherwise consented to by the
Board of Directors, and (y)&nbsp;agrees to enter into this Agreement and the Voting Agreement of even date herewith among the Company, the Investors and the other parties named therein (the &#8220;<B>Voting Agreement</B>&#8221;), as an
&#8220;<B>Investor</B>&#8221; under each such agreement (<U>provided</U> that any Competitor shall not be entitled to any rights as a Major Investor under <U>Sections 3.1</U>, <U>3.2</U> and <U>4.1</U> hereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall give notice (the &#8220;<B>Offer Notice</B>&#8221;) to each Major
Investor, stating (i)&nbsp;its bona fide intention to offer such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any, upon which it proposes to offer such New Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) By notification to the Company within twenty (20)&nbsp;days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming
full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20)&nbsp;day period, the Company shall promptly notify each Major Investor that elects to
purchase or acquire all the shares available to it (each, a &#8220;<B>Fully Exercising Investor</B>&#8221;) of any other Major Investor&#8217;s failure to do likewise. During the ten (10)&nbsp;day period commencing after the Company has given such
notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to
subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any
other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative
Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this <U>Section</U><U></U><U>&nbsp;4.1(b)</U> shall occur within the later of 120 days of the date that the
Offer Notice is given and the date of initial sale of New Securities pursuant to <U>Section</U><U></U><U>&nbsp;4.1(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If all New
Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in <U>Section</U><U></U><U>&nbsp;4.1(b)</U>, the Company may, during the 120 day period following the expiration of the periods provided in
<U>Section</U><U></U><U>&nbsp;4.1(b)</U>, offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer
Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30)&nbsp;days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this <U>Section</U><U></U><U>&nbsp;4.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The right of first offer in this <U>Section</U><U></U><U>&nbsp;4.1</U> shall not be applicable to (i)&nbsp;Exempted Securities (as defined
in the Certificate of Incorporation); and (ii)&nbsp;shares of Common Stock issued in the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Termination</U>. The covenants set
forth in <U>Section</U><U></U><U>&nbsp;4.1</U> shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of
Section&nbsp;12(g) or 15(d) of the Exchange Act, or (iii)&nbsp;upon the closing of a Deemed Liquidation Event, whichever event occurs first. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Additional Covenants</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Insurance</U>. Subject to <U>Section</U><U></U><U>&nbsp;5.12</U>, the Company shall obtain, within ninety (90)&nbsp;days of the date
hereof, from financially sound and reputable insurers, Directors and Officers liability insurance in an amount and on terms and conditions approved by the Requisite Director Vote and will use commercially reasonable efforts to cause such insurance
policies to be maintained until such time as the Board of Directors, including the Requisite Director Vote, determines that such insurance should be discontinued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Employee Agreements</U>. Unless otherwise approved by the Requisite Director Vote, the Company will cause each Person now or hereafter
employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure, proprietary rights assignment
agreement and, to the extent legally permissible, a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the
above-referenced agreements or any restricted stock agreement between the Company and any employee, without a Requisite Director Vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Employee Stock</U>. Unless otherwise approved by the Requisite Director Vote, all employees of the Company who purchase, receive
options to purchase, or receive awards of shares of the Company&#8217;s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i)&nbsp;vesting of shares over a four year
period, with the first 25% of such shares vesting following twelve (12)&nbsp;months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following 36 months, and (ii)&nbsp;a market <FONT
STYLE="white-space:nowrap">stand-off</FONT> provision substantially similar to that in <U>Section</U><U></U><U>&nbsp;2.11</U>. Without a prior Requisite Director Vote, the Company shall not amend, modify, terminate, waive or otherwise alter, in
whole or in part, any restricted stock agreement or option agreement. In addition, unless otherwise approved by the Requisite Director Vote, the Company (x)&nbsp;shall not offer, allow or agree to any acceleration of vesting for its employees or
consultants, and (y)&nbsp;shall retain (and not waive) a &#8220;right of first refusal&#8221; on employee transfers until the Company&#8217;s IPO, and shall have the right to repurchase unvested shares at cost upon termination of employment of a
holder of restricted stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Board Matters</U>. The Company shall reimburse the
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses incurred (consistent with the Company&#8217;s travel
policy) in connection with attending meetings of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Successor Indemnification</U>. If the Company or any of
its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, but subject to
<U>Section</U><U></U><U>&nbsp;5.12</U>, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect
immediately before such transaction, whether such obligations are contained in the Company&#8217;s Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Expenses of Counsel</U>. In the event of a Deemed Liquidation Event or a transaction that is a Sale of the Company (as defined in the
Voting Agreement) (each, a &#8220;<B>Reimbursed Transaction</B>&#8221;), the reasonable fees and disbursements, not to exceed $75,000 in the aggregate, of one counsel for the Investors (&#8220;<B>Investor Counsel</B>&#8221;), solely in their
capacities as stockholders, shall be borne and paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Indemnification Matters</U>. The Company hereby acknowledges
that one (1)&nbsp;or more of the Preferred Directors may have certain rights to indemnification, advancement of expenses and/or insurance provided by one (1)&nbsp;or more of the Investors and certain of their Affiliates (collectively, the
&#8220;<B>Investor Indemnitors</B>&#8221;). The Company hereby agrees (a)&nbsp;that it is the indemnitor of first resort (<I>i.e.</I>, its obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to any such Preferred Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such
Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Preferred Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in
settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Preferred Director), without regard
to any rights such Preferred Director may have against the Investor Indemnitors, and, (c)&nbsp;that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution,
subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Preferred Director with respect to any claim for which such Preferred
Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of
such Preferred Director against the Company. The Preferred Directors and the Investor Indemnitors are intended third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;5.7</U> and shall have the right, power and authority to enforce the
provisions of this <U>Section</U><U></U><U>&nbsp;5.7</U> as though they were a party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Right to Conduct
Activities</U>. The Company hereby agrees and acknowledges that each of ARCH, CPPIB, Foresite, General Atlantic, [***], Invus, PureTech, Sofinnova, Third Rock, [***] and [***] (each, together with Affiliates, a &#8220;<B>Professional Investment
Organization</B>&#8221;) is a professional investment organization, and as such reviews the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company&#8217;s business
(as currently conducted or as currently propose to be conducted). Nothing in this Agreement shall preclude or in any way restrict the Professional Investment Organization from evaluating or purchasing securities, including publicly traded
securities, of a particular enterprise, or investing or participating in any particular enterprise whether or not such enterprise has products or services that compete with those of the Company; and the Company hereby agrees that, to the extent
permitted under applicable law, no Professional Investment Organization shall be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by such Professional Investment Organization in any entity competitive with
the Company, or (ii)&nbsp;actions taken by any partner, officer, employee or other representative of such Professional Investment Organization to assist any such competitive company, whether or not such action was taken as a member of the board of
directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; <U>provided</U>, <U>however</U>, that the foregoing shall not contravene the confidentiality obligations in
<U>Section</U><U></U><U>&nbsp;3.4</U> or otherwise in this Agreement or relieve (x)&nbsp;any of the Investors from liability associated with the unauthorized disclosure of the Company&#8217;s confidential information obtained pursuant to this
Agreement, or (y)&nbsp;any director or officer of the Company from any liability associated with such person&#8217;s fiduciary duties to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Anti-Harassment Policy</U>. Subject to <U>Section</U><U></U><U>&nbsp;5.12</U>, the Company shall, within 60 days following the Closing
(as defined in the Purchase Agreement), adopt and thereafter maintain in effect (i)&nbsp;a code of conduct governing appropriate workplace behavior, and (ii)&nbsp;an anti-harassment and discrimination policy prohibiting discrimination and harassment
at the Company. Such code of conduct and policy shall be reviewed by the Board of Directors and its adoption shall require the approval of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>FCPA</U>. The Company covenants that it shall not (and shall not permit any of its subsidiaries or controlled Affiliates or any of its
or their respective directors, officers, managers, employees, independent contractors, representatives or agents, in their capacities as such, to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or
indirectly, to any third party, including any <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;<B>FCPA</B>&#8221;)), in each case, in
violation of the FCPA, the U.K. Bribery Act, or any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and controlled Affiliates to) cease all of its or their
respective known activities, as well as remediate any known actions taken by the Company, its subsidiaries or controlled Affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or
agents, in their capacities as such, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries to), from and
after their implementation, maintain commercially reasonable systems of internal controls (including, but not limited to accounting systems, purchasing systems and billing systems) to provide reasonable assurances regarding compliance with the FCPA,
the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request by an Investor, the Company agrees to provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws
to such Investor. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The Company shall, and shall cause any direct or indirect subsidiary or entity
controlled by it, whether now in existence or formed in the future to make commercially reasonable efforts to comply with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Termination of Covenants</U>. The covenants set forth in this <U>Section</U><U></U><U>&nbsp;5</U>, except for
<U>Sections</U><U></U><U>&nbsp;5.5</U>, <U>5.6</U> and <U>5.7</U>, shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic
reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or (iii)&nbsp;upon the closing of a Deemed Liquidation Event, whichever event occurs first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Fiduciary Duties</U>. The Company&#8217;s obligations set forth in Sections <U>5.1</U>, <U>5.5</U> and <U>5.9</U> that are qualified
by this <U>Section</U><U></U><U>&nbsp;5.12</U> shall not be applicable to the extent (and only to the extent) that the Board of Directors determine in good faith that compliance would be inconsistent with the exercise of the fiduciary duties of the
Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Successors and Assigns</U>. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i)&nbsp;is an Affiliate of a Holder; (ii)&nbsp;is a Holder&#8217;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&#8217;s Immediate Family Members; or
(iii)&nbsp;after such transfer, holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); <U>provided</U>, <U>however</U>, that
(x)&nbsp;the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y)&nbsp;such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of <U>Section</U><U></U><U>&nbsp;2.11</U>. For the purposes of determining the
number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1)&nbsp;that is an Affiliate or stockholder of a Holder; (2)&nbsp;who is a Holder&#8217;s Immediate Family Member; or (3)&nbsp;that is a trust for the
benefit of an individual Holder or such Holder&#8217;s Immediate Family Member shall be aggregated together and with those of the transferring Holder; <U>provided further</U> that all transferees who would not qualify individually for assignment of
rights shall, as a condition to the applicable transfer, establish a single <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of exercising any rights, receiving notices, or taking any
action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Governing Law</U>. This Agreement shall be governed by the internal law of the State
of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Notices</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. All notices and other communications given or made pursuant to this Agreement shall be in writing (including electronic
mail as permitted in this Agreement) and shall be deemed effectively given upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if sent by electronic mail during the recipient&#8217;s
normal business hours, and if not sent during normal business hours, then on the recipient&#8217;s next business day; (iii)&nbsp;five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(iv)&nbsp;one business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying <FONT STYLE="white-space:nowrap">next-day</FONT> delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their addresses as set forth on <U>Schedule A</U> hereto (with a copy (which copy shall not constitute notice) to be sent to such party as indicated on <U>Schedule A</U>), or (as to the
Company) to the address set forth on the signature page hereto, or in any case to such email address or address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;6.5</U>. If notice is given to the
Company, a copy (which copy shall not constitute notice) shall also be sent to Wilmer Cutler Pickering Hale&nbsp;&amp; Dorr LLP, 60 State Street, Boston, Massachusetts 02109, Attn.: Stuart M. Falber. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Consent to Electronic Notice</U>. Each party to this Agreement consents to the delivery of any stockholder notice pursuant to the
Delaware General Corporation Law (the &#8220;<B>DGCL</B>&#8221;), as amended or superseded from time to time, by electronic mail pursuant to Section&nbsp;232 of the DGCL (or any successor thereto) at the electronic mail address set forth below such
party&#8217;s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the
foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party to this Agreement
agrees to promptly notify the Company of any change in such stockholder&#8217;s electronic mail address, and that failure to do so shall not affect the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Amendments and Waivers</U>. Any term of this Agreement may be amended, modified, terminated and the observance of any term of this
Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite Holder Vote; <U>provided</U> that the Company may in its sole discretion
waive compliance with <U>Section</U><U></U><U>&nbsp;2.12(c)</U> (and the Company&#8217;s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of <U>Section</U><U></U><U>&nbsp;2.12(c)</U> shall be
deemed to be a waiver); and <U>provided further</U> that any provision hereof may be waived by any waiving party on such party&#8217;s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a)&nbsp;this Agreement may not
be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investor without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of
the provisions of <U>Section</U><U></U><U>&nbsp;4</U> with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may
nonetheless, by agreement with the Company, purchase securities in such transaction; provided, however, if, after giving effect to any waiver of <U>Section</U><U></U><U>&nbsp;4.1</U> or any provision pertaining to
<U>Section</U><U></U><U>&nbsp;4.1</U> with respect to a particular transaction, a Major Investor in fact purchases New Securities in such transaction (such Major Investor, a &#8220;<B>Participating Investor</B>&#8221;), the aforementioned waiver
shall be deemed to apply to any Major Investor only if that Major Investor has been provided the opportunity to purchase a proportional number of the New Securities in such transaction based on the pro rata purchase right of each Major Investor set
forth in <U>Section</U><U></U><U>&nbsp;4.1</U>, assuming a transaction size determined based upon the amount purchased by the Participating Investor that invested the largest percentage in such transaction (such amount with respect to a Major
Investor, the &#8220;<B>Participation Amount</B>&#8221;); and provided further that, in such event, the Company, in its sole discretion, may reduce each Major Investor&#8217;s Participation Amount by up to 50%, provided that such percentage
reduction is applied equally to each Major Investor&#8217;s Participation Amount); (b) <U>Section</U><U></U><U>&nbsp;1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to PureTech and this <U>Section</U><U></U><U>&nbsp;6.6(b)</U> may not
be amended, modified, terminated or waived, without the written consent of PureTech, for so long as PureTech continues to have rights pursuant to such <U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (c)
<U>Section</U><U></U><U>&nbsp;1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to ARCH, and this <U>Section</U><U></U><U>&nbsp;6.6(c)</U> may not be amended, modified, terminated or waived, without the written consent of ARCH, for so
long as ARCH continues to have rights pursuant to such <U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (d)<U>&nbsp;Section</U><U></U><U>&nbsp;1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to
Sofinnova, and this <U>Section</U><U></U><U>&nbsp;6.6(d)</U> may not be amended, modified, terminated or waived, without the written consent of Sofinnova, for so long as Sofinnova continues to have rights pursuant to such
<U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (e) <U>Section</U><U></U><U>&nbsp;1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to Third Rock and this <U>Section</U><U></U><U>&nbsp;6.6(e)</U> may
not be amended, modified, terminated or waived, without the written consent of Third Rock, for so long as Third Rock continues to have rights pursuant to such <U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (f)
<U>Section</U><U></U><U>&nbsp;1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to General Atlantic and this <U>Section</U><U></U><U>&nbsp;6.6(f)</U> may not be amended, modified, terminated or waived, without the written consent of
General Atlantic, for so long as General Atlantic continues to have rights pursuant to <U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (g) <U>Section</U><U></U><U>&nbsp;1.7</U> and
<U>Section</U><U></U><U>&nbsp;5.8</U> with respect to [***] and the [***] Investors and this <U>Section</U><U></U><U>&nbsp;6.6(g)</U> may not be amended, modified, terminated or waived, without the written consent of the [***], for so long as the
[***] continue to have rights pursuant to <U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (h) <U>Section</U><U></U><U>&nbsp;1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to [***] and this
<U>Section</U><U></U><U>&nbsp;6.6(h)</U> may not be amended, modified, terminated or waived, without the written consent of [***], for so long as [***] continues to have rights pursuant to <U>Section</U><U></U><U>&nbsp;1.7</U> and/or
<U>Section</U><U></U><U>&nbsp;5.8</U>; (i)<U>&nbsp;Section 1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to Invus and this <U>Section</U><U></U><U>&nbsp;6.6(i)</U> may not be amended, modified, terminated or waived, without the
written consent of Invus, for so long as Invus continues to have rights pursuant to <U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (j) <U>Section</U><U></U><U>&nbsp;1.7</U> and
<U>Section</U><U></U><U>&nbsp;5.8</U> with respect to Foresite and this <U>Section</U><U></U><U>&nbsp;6.6(j)</U> may not be amended, modified, terminated or waived, without the written consent of Foresite, for so long as Foresite continues to have
rights pursuant to <U>Section</U><U></U><U>&nbsp;1.7</U> and/or <U>Section</U><U></U><U>&nbsp;5.8</U>; (k) <U>Section</U><U></U><U>&nbsp;1.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U> with respect to CPPIB and this
<U>Section</U><U></U><U>&nbsp;6.6(k)</U> may not be amended, modified, terminated or waived, without the written consent of CPPIB, for so long as CPPIB continues to have rights pursuant to <U>Section</U><U></U><U>&nbsp;1.7</U> and/or
<U>Section</U><U></U><U>&nbsp;5.8</U>; and (l)&nbsp;prior to an IPO, any amendment, modification, termination or waiver of <U>Section</U><U></U><U>&nbsp;2</U>, <U>Section</U><U></U><U>&nbsp;3</U>, <U>Section</U><U></U><U>&nbsp;4</U>,
<U>Section</U><U></U><U>&nbsp;5.1</U>, <U>Section</U><U></U><U>&nbsp;5.4</U>, <U>Section</U><U></U><U>&nbsp;5.7</U> or this <U>Section</U><U></U><U>&nbsp;6.6</U> that adversely affects any of the rights or obligations of any holder of Series B
Preferred Stock under such Sections shall not be effective against such holder without the prior written consent of the holders of at least 65% of the then outstanding shares of Series B Preferred Stock; provided that, no such consent shall be
required for any (1)&nbsp;amendments to any voting or approval thresholds in such Sections (other than in respect of this <U>Section</U><U></U><U>&nbsp;6.6(l)</U>) made to reflect new investors or series of the Company&#8217;s preferred stock in
connection with the issuance and sale by the Company of shares of the Company&#8217;s preferred stock for bona fide capital-raising purposes or (2)&nbsp;waivers of the timing requirements for deliverables under <U>Section</U><U></U><U>&nbsp;3.1</U>.
Notwithstanding the foregoing, <U>Schedule A</U> hereto may be amended by the Company from time to time to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and <U>Schedule A</U> hereto may also be amended by the
Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;6.9</U>. The Company shall
give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or
waiver effected in accordance with this <U>Section</U><U></U><U>&nbsp;6.6</U> shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of
this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Severability</U>. In case any provision contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and
enforceable to the maximum extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Aggregation of Stock; Apportionment</U>. All shares of Registrable Securities
held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliates may apportion such rights as among themselves in any manner they deem appropriate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Additional Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering a counterpart signature page to this Agreement, and thereafter shall be deemed an
&#8220;Investor&#8221; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all
of the obligations as an &#8220;Investor&#8221; hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Entire Agreement</U>. Upon the effectiveness of this Agreement, the
Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. This Agreement (including the Exhibits and Schedules hereto) together with the other
Transaction Agreements (as defined in the Purchase Agreement) constitute the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between or among any of the parties are expressly canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Dispute Resolution</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties (a)&nbsp;hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction
of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b)&nbsp;agree not to commence any suit, action or other proceeding arising out of
or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c)&nbsp;hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit,
action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient
forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties to this Agreement consents to personal jurisdiction for any equitable
action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WAIVER OF
JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS
WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT
CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO
HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Costs of Enforcement</U>. Each party will bear its own costs in respect of any disputes arising under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party, nor shall it be construed to be a waiver of or
acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All
remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature
Page Follows] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Amended and Restated
Investors&#8217; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY</B>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SEAPORT THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daphne Zohar</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer and President</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: <U></U>[***]</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amended and Restated Investors&#8217; Rights Agreement] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO 2024 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The first full sentence of Section&nbsp;4.1 of the 2024 Equity Incentive Plan (the &#8220;<B>Plan</B>&#8221;) of Seaport Therapeutics,
Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), is hereby deleted in its entirety and replaced with the following in lieu thereof: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8220;Subject to adjustment under Section&nbsp;8 hereof, Awards may be made under the Plan covering up to 38,607,011 shares of Common
Stock.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Except as expressly amended herein, the Plan and all of the provisions contained therein shall remain in full force and
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Approved by the Board of Directors of the Company on October&nbsp;16, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Approved by the Stockholders of the Company on October&nbsp;17, 2024 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Purpose</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The purpose
of the Plan is to advance the interests of the Company&#8217;s stockholders by enhancing the Company&#8217;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such
persons with equity ownership opportunities and thereby better aligning the interests of such persons with those of the Company&#8217;s stockholders. Capitalized terms used in the Plan are defined in Section&nbsp;11 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Eligibility</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Service
Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Administration and
Delegation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Administration</U><I>.</I> The Plan will be administered by the Administrator. The Administrator shall have
authority to determine which Service Providers will receive Awards, to grant Awards and to set all terms and conditions of Awards (including, but not limited to, vesting, exercise and forfeiture provisions). In addition, the Administrator shall have
the authority to take all actions and make all determinations contemplated by the Plan and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Administrator may correct
any defect or ambiguity, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem necessary or appropriate to carry the Plan and any Awards into effect, as determined by the
Administrator. The Administrator shall make all determinations under the Plan in the Administrator&#8217;s sole discretion and all such determinations shall be final and binding on all persons having or claiming any interest in the Plan or in any
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Appointment of Committees</U><I>.</I> To the extent permitted by Applicable Laws, the Board may delegate any or all of its
powers under the Plan to one or more Committees. The Board may abolish any Committee at any time and <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself any previously delegated authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Stock Available for Awards</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <U>Number of Shares</U><I>.</I> Subject to adjustment under Section&nbsp;8 hereof, Awards may be made under the Plan covering up to
10,000,000 shares of Common Stock. If any Award expires or lapses or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such
Award being repurchased by the Company at or below the original issuance price), in any case in a manner that results in any shares of Common Stock covered by such Award not being issued or being so reacquired by the Company, the unused Common Stock
covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including shares retained by the Company from the Award being exercised or purchased
and/or creating the tax obligation) shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be
subject to any limitations under the Code. Shares of Common Stock issued under the Plan may consist in whole or in part of authorized but unissued shares, shares purchased on the open market or treasury shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Substitute Awards</U>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of
property or stock of an entity, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted prior to such merger or consolidation by such entity or an affiliate thereof. Substitute Awards may be
granted on such terms as the Administrator deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section&nbsp;4.1
hereof, except as may be required by reason of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Stock Options</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <U>General</U><I>.</I> The Administrator may grant Options to any Service Provider, subject to the limitations on Incentive Stock Options
described below. The Administrator shall determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including
conditions relating to Applicable Laws, as it considers necessary or advisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <U>Incentive Stock Options</U><I>.</I> The
Administrator may grant Options intended to qualify as Incentive Stock Options only to employees of the Company, any of the Company&#8217;s present or future &#8220;parent corporations&#8221; or &#8220;subsidiary corporations&#8221; as defined in
Sections 424(e) or (f)&nbsp;of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. All Options intended to qualify as Incentive Stock Options shall be subject to and
shall be construed consistently with the requirements of Section&nbsp;422 of the Code. Neither the Company nor the Administrator shall have any liability to a Participant, or any other party, (i)&nbsp;if an Option (or any part thereof) which is
intended to qualify as an Incentive Stock Option fails to qualify as an Incentive Stock Option or (ii)&nbsp;for any action or omission by the Administrator that causes an Option not to qualify as an Incentive Stock Option, including without
limitation, the conversion of an Incentive Stock Option to a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements under the Code
applicable to an Incentive Stock Option. Any Option that is intended to qualify as an Incentive Stock Option, but fails to so qualify for any reason, including without limitation, the portion of any Option becoming exercisable in excess of the
$100,000 limitation described in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.422-4,</FONT> shall be treated as a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Exercise Price</U><I>.</I> The Administrator shall establish the exercise price of
each Option and specify the exercise price in the applicable Award Agreement. The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is granted. In the case of an Incentive Stock Option granted to an employee
who, at the time of grant of the Option, owns (or is treated as owning under Section&nbsp;424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a &#8220;parent corporation&#8221; or
&#8220;subsidiary corporation&#8221; thereof within the meaning of Sections 424(e) or 424(f) of the Code, respectively), the per share exercise price shall be no less than 110% of the Fair Market Value on the date the Option is granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Duration of Options</U><I>.</I> Each Option shall be exercisable at such times and subject to such terms and conditions as the
Administrator may specify in the applicable Award Agreement, <U>provided that</U> the term of any Option shall not exceed ten years. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the Option, owns (or is
treated as owning under Section&nbsp;424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof within the
meaning of Sections 424(e) or 424(f) of the Code, respectively), the term of the Option shall not exceed five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <U>Exercise of
Option; Notification of Disposition</U><I>.</I> Options may be exercised by delivery to the Company of a written notice of exercise, in a form approved by the Administrator (which may be an electronic form), signed by the person authorized to
exercise the Option, together with payment in full (i)&nbsp;as specified in Section&nbsp;5.6 hereof for the number of shares for which the Option is exercised and (ii)&nbsp;as specified in Section&nbsp;9.5 hereof for any applicable withholding
taxes. Unless otherwise determined by the Administrator, an Option may not be exercised for a fraction of a share of Common Stock. If an Option is designated as an Incentive Stock Option, the Participant shall give prompt notice to the Company of
any disposition or other transfer of any shares of Common Stock acquired from the Option if such disposition or transfer is made (i)&nbsp;within two years from the grant date with respect to such Option or (ii)&nbsp;within one year after the
transfer of such shares to the Participant (other than any such disposition made in connection with a Change in Control). Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property,
assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <U>Payment Upon
Exercise</U><I>.</I> Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for in cash or by check, payable to the order of the Company, or, to the extent permitted by the Administrator, by: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) (A) delivery of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company
sufficient funds to pay the exercise price and any required tax withholding, or (B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to
the Company cash or a check sufficient to pay the exercise price and any required tax withholding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) delivery (either by actual
delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (A)&nbsp;such method of payment is then permitted under Applicable Laws, (B)&nbsp;such Common Stock, if acquired directly from
the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Company at any time, and (C)&nbsp;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar
requirements; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) surrendering shares of Common Stock then issuable upon exercise of the Option valued at
their Fair Market Value on the date of exercise; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) delivery of a promissory note of the Participant to the Company on terms determined
by the Administrator; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) delivery of property of any other kind which constitutes good and valuable consideration as determined by the
Administrator; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) any combination of the above permitted forms of payment (including cash or check). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">5.7 <U>Early Exercise of Options</U>. The Administrator may provide in the terms of an Award Agreement that the Service Provider may exercise
an Option in whole or in part prior to the full vesting of the Option in exchange for unvested shares of Restricted Stock with respect to any unvested portion of the Option so exercised. Shares of Restricted Stock acquired upon the exercise of any
unvested portion of an Option shall be subject to such terms and conditions as the Administrator shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Restricted Stock;
Restricted Stock Units</U><I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>General</U>. The Administrator may grant Restricted Stock, or the right to purchase Restricted
Stock, to any Service Provider, subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such shares if issued at no cost) in
the event that conditions specified by the Administrator in the applicable Award Agreement are not satisfied prior to the end of the applicable restriction period or periods established by the Administrator for such Award. In addition, the
Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during applicable restriction period or periods, as set forth in an applicable Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Terms and Conditions for All Restricted Stock and Restricted Stock Unit Awards</U>. The Administrator shall determine and set forth in
the applicable Award Agreement the terms and conditions applicable to each Restricted Stock and Restricted Stock Unit Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, in each case, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3 <U>Additional Provisions Relating to Restricted Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>Dividends</I>. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to
such shares to the extent such dividends have a record date that is on or after the date on which the Participant to whom such shares of Restricted Stock are granted becomes the record holder of such shares of Restricted Stock, unless otherwise
provided by the Administrator in the applicable Award Agreement. In addition, unless otherwise provided by the Administrator, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock
of property other than an ordinary cash dividend, the shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend payment will be made as provided in the applicable Award Agreement, but in no event later than the end of the calendar year in which the dividends are paid to stockholders of that class
of stock or, if later, the 15th day of the third month following the later of (A)&nbsp;the date the dividends are paid to stockholders of that class of stock, and (B)&nbsp;the date the dividends are no longer subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I>Stock Certificates</I>. The Company may require that any stock <I>certificates</I> issued in respect of shares of Restricted Stock be
deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4
<U>Additional Provisions Relating to Restricted Stock Units</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>Settlement</I>. Upon the vesting of a Restricted Stock Unit, the
Participant <I>shall</I> be entitled to receive from the Company one share of Common Stock or an amount of cash or other property equal to the Fair Market Value of one share of Common Stock on the settlement date, as the Administrator shall
determine and as provided in the applicable Award Agreement. The Administrator may provide that settlement of Restricted Stock Units shall occur upon or as soon as reasonably practicable after the vesting of the Restricted Stock Units or shall
instead be deferred, on a mandatory basis or at the election of the Participant, in a manner that complies with Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
<I>Voting Rights</I>. A Participant shall have no voting rights with respect to any Restricted Stock Units unless and until shares are delivered in settlement thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Dividend Equivalents</I>. To the extent provided by the Administrator, a grant of Restricted Stock Units may provide a Participant
with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer
and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are paid, as determined by the Administrator, subject, in each case, to such terms and conditions as the Administrator shall establish and set forth in
the applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Other Stock-Based Awards</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Other Stock-Based Awards may be granted hereunder to Participants, including, without limitation, Awards entitling Participants to receive
shares of Common Stock to be delivered in the future. Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan, as stand-alone payments and/or as payment in lieu of
compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock, cash or other property, as the Administrator shall determine. Subject to the provisions of the Plan, the Administrator shall
determine the terms and conditions of each Other Stock-Based Award, including any purchase price, transfer restrictions, vesting conditions and other terms and conditions applicable thereto, which shall be set forth in the applicable Award
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Adjustments for Changes in Common Stock and Certain Other Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 In the event that the Administrator determines that any dividend or other distribution (whether in the form of cash, Common Stock, other
securities, or other property), reorganization, merger, consolidation, combination, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or
sale or exchange of Common Stock or other securities of the Company, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, or other similar corporate transaction or event, as determined by the
Administrator, affects the Common Stock such that an adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under
the Plan or with respect to any Award, then the Administrator may, in such manner as it may deem equitable, adjust any or all of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
the number and kind of shares of Common Stock (or other securities or property) with respect to which Awards may be granted or awarded (including, but <I>not</I> limited to, adjustments of the limitations in Section&nbsp;4 hereof on the maximum
number and kind of shares which may be issued); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the number and kind of shares of Common Stock (or other securities or property)
subject to outstanding Awards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the grant or exercise price with respect to any Award; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the terms and conditions of any Awards (including, without limitation, any applicable financial or other performance
&#8220;targets&#8221; specified in an Award Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 In the event of any transaction or event described in Section&nbsp;8.1 hereof
(including without limitation any Change in Control) or any unusual or nonrecurring transaction or event affecting the Company or the financial statements of the Company, or any change in any Applicable Laws or accounting principles, the
Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event and either automatically or upon the Participant&#8217;s request, is hereby
authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x)&nbsp;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to
be made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&nbsp;to facilitate such transaction or event or (z)&nbsp;give effect to such changes in Applicable Laws or accounting principles<B>:</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the
amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the vested portion of such Award, as applicable; <U>provided that</U>, if the amount that
could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or less than zero, then the vested portion of such Award may be terminated
without payment; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) To provide that such Award shall vest and, to the extent applicable, be exercisable as
to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) To provide that
such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate
adjustments as to the number and kind of shares and applicable exercise or purchase price, in all cases, as determined by the Administrator; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards,
and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards which may be granted in the future; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) To replace such Award with other rights or property selected by the Administrator; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to the contrary in this Section&nbsp;8, the
Administrator will equitably adjust each outstanding Award, which adjustments may include adjustments to the number and type of securities subject to each outstanding Award and/or the exercise price or grant price thereof, if applicable, the grant
of new Awards to Participants, and/or the making of a cash payment to Participants, as the Administrator deems appropriate to reflect such Equity Restructuring. The adjustments provided under this Section&nbsp;8.3 shall be nondiscretionary and shall
be final and binding on the affected Participant and the Company; <U>provided that</U> whether an adjustment is equitable shall be determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution
(other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, including any Equity Restructuring, for reasons of administrative convenience the
Administrator may refuse to permit the exercise of any Award during a period of up to thirty days prior to the consummation of any such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no Participant shall have any rights
by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the
Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any
class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Common Stock subject to an Award or the grant or exercise price of any Award. The existence of the Plan,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Award Agreements and the Awards granted hereunder shall not affect or restrict in any way the right or power of the Company to make or authorize (i)&nbsp;any adjustment, recapitalization,
reorganization or other change in the Company&#8217;s capital structure or its business, (ii)&nbsp;any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii)&nbsp;any sale or issuance of securities,
including without limitation, securities with rights superior to those of the Common Stock or which are convertible into or exchangeable for Common Stock. The Administrator may treat Participants and Awards (or portions thereof) differently under
this Section&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>General Provisions Applicable to Awards</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1 <U>Transferability</U><I>.</I> Except as the Administrator may otherwise determine or provide in an Award Agreement or otherwise, in any
case in accordance with Applicable Laws, Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and
distribution, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2 <U>Documentation</U><I>.</I> Each Award shall be evidenced in an Award Agreement, which may be in such form (written, electronic or
otherwise) as the Administrator shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3 <U>Discretion</U><I>.</I> Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any
other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.4 <U>Termination of Status</U><I>.</I> The Administrator shall determine the effect on an Award of the disability, death, retirement,
authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal representative, conservator,
guardian or Designated Beneficiary may exercise rights under the Award, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5 <U>Withholding</U><I>.</I> Each Participant
shall pay to the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with Awards to such Participant no later than the date of the event creating the tax liability.
Except as the Administrator may otherwise determine, all such payments shall be made in cash or by certified check. Notwithstanding the foregoing, to the extent permitted by the Administrator, Participants may satisfy such tax obligations in whole
or in part by delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value. The Company may, to the extent permitted by Applicable Laws, deduct any such tax obligations
from any payment of any kind otherwise due to a Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.6 <U>Amendment of Award</U><I>.</I> The Administrator may amend, modify or terminate any
outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or settlement, and converting an Incentive Stock Option to a
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. The Participant&#8217;s consent to such action shall be required unless (i)&nbsp;the Administrator determines that the action, taking into account any related action, would not
materially and adversely affect the Participant, or (ii)&nbsp;the change is permitted under Section&nbsp;8 and 10.6 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.7
<U>Conditions on Delivery of Stock</U><I>.</I> The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i)&nbsp;all conditions of
the Award have been met or removed to the satisfaction of the Company, (ii)&nbsp;in the opinion of the Company&#8217;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any
applicable securities laws and any applicable stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or
appropriate to satisfy the requirements of any Applicable Laws. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is determined by the Administrator to be necessary to the lawful issuance
and sale of any securities hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.8 <U>Acceleration</U><I>.</I> The Administrator may at any time provide that any Award shall become immediately vested and/or exercisable in
full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.
<U>Miscellaneous</U><I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1 <U>No Right To Employment or Other Status</U><I>.</I> No person shall have any claim or right to be
granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise
terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an applicable Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2 <U>No Rights As Stockholder; Certificates</U><I>.</I> Subject to the provisions of the applicable Award Agreement, no Participant or
Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. Notwithstanding any other provision of the Plan,
unless otherwise determined by the Administrator or required by any Applicable Laws, the Company shall not be required to deliver to any Participant certificates evidencing shares of Common Stock issued in connection with any Award and instead such
shares of Common Stock may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on any stock certificates issued under the Plan deemed necessary or appropriate by
the Administrator in order to comply with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.3 <U>Effective Date and Term of Plan</U><I>.</I> The Plan shall become
effective on the date on which it is adopted by the Board. No Awards shall be granted under the Plan after the completion of ten years from the earlier of (i)&nbsp;the date on which the Plan was adopted by the Board or (ii)&nbsp;the date the Plan
was approved by the Company&#8217;s stockholders, but Awards previously granted may extend beyond that date in accordance with the terms of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.4 <U>Amendment of Plan</U><I>.</I> The Administrator may amend, suspend or terminate the
Plan or any portion thereof at any time; <U>provided that</U> no amendment of the Plan shall materially and adversely affect any Award outstanding at the time of such amendment without the consent of the affected Participant. Awards outstanding
under the Plan at the time of any suspension or termination of the Plan shall continue to be governed in accordance with the terms of the Plan and the applicable Award Agreement, as in effect prior to such suspension or termination. The Board shall
obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.5 <U>Provisions for Foreign
Participants</U>. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or
customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.6 <U>Section
409A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>General</I>. The Company intends that all Awards be structured in compliance with, or to satisfy an exemption from,
Section&nbsp;409A, such that no adverse tax consequences, interest, or penalties under Section&nbsp;409A apply in connection with any Awards. Notwithstanding anything herein or in any Award Agreement to the contrary, the Administrator may, without a
Participant&#8217;s prior consent, amend this Plan and/or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and actions with retroactive effect) as are necessary or appropriate to preserve
the intended tax treatment of Awards under the Plan, including without limitation, any such actions intended to (A)&nbsp;exempt this Plan and/or any Award from the application of Section&nbsp;409A, and/or (B)&nbsp;comply with the requirements of
Section&nbsp;409A, including without limitation any such regulations, guidance, compliance programs and other interpretative authority that may be issued after the date of grant of any Award. The Company makes no representations or warranties as to
the tax treatment of any Award under Section&nbsp;409A or otherwise. The Company shall have no obligation under this Section&nbsp;10.6 or otherwise to take any action (whether or not described herein) to avoid the imposition of taxes, penalties or
interest under Section&nbsp;409A with respect to any Award and shall have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute
<FONT STYLE="white-space:nowrap">non-compliant,</FONT> &#8220;nonqualified deferred compensation&#8221; subject to the imposition of taxes, penalties and/or interest under Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I>Separation from Service</I>. With respect to any Award that constitutes &#8220;nonqualified deferred compensation&#8221; under
Section&nbsp;409A, any payment or settlement of such Award that is to be made upon a termination of a Participant&#8217;s Service Provider relationship shall, to the extent necessary to avoid the imposition of taxes under Section&nbsp;409A, be made
only upon the Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&nbsp;409A), whether such &#8220;separation from service&#8221; occurs upon or subsequent to the termination of the Participant&#8217;s Service
Provider relationship. For purposes of any such provision of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean
&#8220;separation from service.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Payments to Specified Employees</I>. Notwithstanding any contrary provision in the
Plan or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; that are otherwise required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section&nbsp;409A and determined by the
Administrator) as a result of his or her &#8220;separation from service&#8221; shall, to the extent necessary to avoid the imposition of taxes under Code Section&nbsp;409A(a)(2)(B)(i), be delayed until the expiration of the <FONT
STYLE="white-space:nowrap">six-month</FONT> period immediately following such &#8220;separation from service&#8221; (or, if earlier, until the date of death of the specified employee) and shall instead be paid (in a manner set forth in the Award
agreement) on the day that immediately follows the end of such <FONT STYLE="white-space:nowrap">six-month</FONT> period or as soon as administratively practicable thereafter (without interest). Any payments of &#8220;nonqualified deferred
compensation&#8221; under such Award that are, by their terms, payable more than six months following the Participant&#8217;s &#8220;separation from service&#8221; shall be paid at the time or times such payments are otherwise scheduled to be made.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.7 <U>Limitations on Liability</U>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer,
other employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, nor will such
individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as an Administrator, director, officer, other employee or agent of the Company. The Company will indemnify
and hold harmless each director, officer, other employee and agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be granted or delegated, against any cost or expense (including
attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising out of any act or omission to act concerning this Plan unless arising out of such person&#8217;s own fraud or bad
faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.8 <U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>. Participants shall not offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Stock (or other securities) of the
Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities) of the Company held by Participant (other than those
included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180)&nbsp;days following the effective date of any registration
statement of the Company filed under the Securities Act (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i)&nbsp;the publication or other distribution of research reports and
(ii)&nbsp;analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241, or any successor provisions or amendments thereto). Participants shall execute and deliver such other agreements as may be
reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. The obligations described in this Section&nbsp;10.8 shall not apply to a registration relating
solely to employee benefit plans on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or Form <FONT STYLE="white-space:nowrap">S-8</FONT> or similar forms that may be promulgated in the future, or a registration relating solely to a Securities and
Exchange Commission Rule 145 transaction on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or
other securities) subject to the foregoing restriction until the end of said 180 day (or other) period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.9 <U>Limitations on Transfer</U>. A Participant shall not sell, assign, transfer, pledge,
hypothecate or otherwise dispose of, by operation of law or otherwise (collectively &#8220;<U>Transfer</U>&#8221;) any interest in any shares of Common Stock held by Participant except in compliance with the provisions herein, in the Company&#8217;s
Bylaws and applicable securities laws. Furthermore, the shares of Common Stock shall be subject to a right of first refusal in favor of the Company or its assignees as set forth in the Company&#8217;s Bylaws. Notwithstanding the foregoing,
Participant may, subject to compliance with the transfer restrictions set forth in the Company&#8217;s Bylaws, transfer shares of Common Stock to or for the benefit of any spouse, children, parents, uncles, aunts, siblings, grandchildren and any
other relatives approved by the Board of Directors (collectively, &#8220;<U>Approved Relatives</U>&#8221;) or to a trust established solely for the benefit of the Participant and/or Approved Relatives, <U>provided</U> that such shares of Common
Stock shall remain subject to the provisions of this Plan and any other applicable agreements, and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be
bound by all of the terms and conditions of this Plan and any other applicable agreements. The Company shall not be required (a)&nbsp;to transfer on its books any of the shares of Common Stock that have been sold or otherwise transferred in
violation of any of the provisions of this Plan, any other applicable agreement or the provisions of the Company&#8217;s Bylaws or (b)&nbsp;to treat as owner of such shares of Common Stock or to accord the right to vote or pay dividends to any
purchaser or other transferee to whom any such shares of Common Stock shall have been so sold or transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.10 <U>Data Privacy</U>.
As a condition of receipt of any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Company
and its subsidiaries and affiliates for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan. The Company and its subsidiaries and affiliates may hold certain personal information about
a Participant, including but not limited to, the Participant&#8217;s name, home address and telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), any shares of stock
held in the Company or any of its subsidiaries and affiliates, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the &#8220;<U>Data</U>&#8221;). The Company and its subsidiaries and
affiliates may transfer the Data amongst themselves as necessary for the purpose of implementation, administration and management of a Participant&#8217;s participation in the Plan, and the Company and its subsidiaries and affiliates may each
further transfer the Data to any third parties assisting the Company in the implementation, administration and management of the Plan. These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s
country may have different data privacy laws and protections than the recipients&#8217; country. Through acceptance of an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or
other form, for the purposes of implementing, administering and managing the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
broker or other third party with whom the Company or the Participant may elect to deposit any shares of Common Stock. The Data related to a Participant will be held only as long as is necessary
to implement, administer, and manage the Participant&#8217;s participation in the Plan. A Participant may, at any time, view the Data held by the Company with respect to such Participant, request additional information about the storage and
processing of the Data with respect to such Participant, recommend any necessary corrections to the Data with respect to the Participant or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local
human resources representative. The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Administrator&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws
his or her consents as described herein. For more information on the consequences of refusal to consent or withdrawal of consent, Participants may contact their local human resources representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.11 <U>Severability</U>. In the event any portion of the Plan or any action taken pursuant thereto shall be held illegal or invalid for any
reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provisions had not been included, and the illegal or invalid action shall be null and
void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.12 <U>Governing Documents</U>. In the event of any contradiction between the Plan and any Award Agreement or any other written
agreement between a Participant and the Company or any subsidiary of the Company that has been approved by the Administrator, the terms of the Plan shall govern, unless it is expressly specified in such Award Agreement or other written document that
a specific provision of the Plan shall not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.13 <U>Submission to Jurisdiction; Waiver of Jury Trial</U>. By accepting an Award,
each Participant irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of America, in each case located in the State of Delaware, for any action arising out
of or relating to the Plan (and agrees not to commence any litigation relating thereto except in such courts), and further agrees that service of any process, summons, notice or document by U.S. registered mail to the address contained in the
records of the Company shall be effective service of process for any litigation brought against it in any such court. By accepting an Award, each Participant irrevocably and unconditionally waives any objection to the laying of venue of any
litigation arising out of Plan or Award hereunder in the courts of the State of Delaware or the United States of America, in each case located in the State of Delaware, and further irrevocably and unconditionally waives and agrees not to plead or
claim in any such court that any such litigation brought in any such court has been brought in an inconvenient forum. By accepting an Award, each Participant irrevocably and unconditionally waives, to the fullest extent permitted by applicable law,
any and all rights to trial by jury in connection with any litigation arising out of or relating to the Plan or any Award hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.14 <U>Governing Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with
the laws of the State of Delaware, disregarding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of any state that would require the application of the laws of a jurisdiction other
than such state. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.15 <U>Restrictions on Shares; Claw-back Provisions.</U> Shares of Common Stock acquired
in respect of Awards shall be subject to such terms and conditions as the Administrator shall determine, including, without limitation, restrictions on the transferability of shares of Common Stock, the right of the Company to repurchase shares of
Common Stock, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, <FONT STYLE="white-space:nowrap">tag-along</FONT> rights, bring-along rights, redemption and <FONT
STYLE="white-space:nowrap">co-sale</FONT> rights and voting requirements. Such terms and conditions may be additional to those contained in the Plan and may, as determined by the Administrator, be contained in the applicable Award Agreement or in an
exercise notice, stockholders&#8217; agreement or in such other agreement as the Administrator shall determine, in each case in a form determined by the Administrator. The issuance of such shares of Common Stock shall be conditioned on the
Participant&#8217;s consent to such terms and conditions and the Participant&#8217;s entering into such agreement or agreements. All Awards (including any proceeds, gains or other economic benefit actually or constructively received by Participant
upon any receipt or exercise of any Award or upon the receipt or resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any
claw-back policy adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such claw-back policy and/or in the applicable
Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.16 <U>Titles and Headings</U>. The titles and headings of the Sections in the Plan are for convenience of reference
only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.17 <U>Conformity to
Securities Laws.</U> Participant acknowledges that the Plan is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and
Exchange Commission thereunder, and state securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan and all Awards granted hereunder shall be administered only in such a manner as to conform to such laws, rules and
regulations. To the extent permitted by Applicable Laws, the Plan and all Award Agreements shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Definitions</U><I>.</I> As used in the Plan, the following words and phrases shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1 &#8220;<U>Administrator</U>&#8221; means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan
have been delegated to such Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2 &#8220;<U>Applicable Laws</U>&#8221; means the requirements relating to the administration of
equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable
laws and rules of any foreign country or other jurisdiction where Awards are granted or issued under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3
&#8220;<U>Award</U>&#8221; means, individually or collectively, a grant under the Plan of Options, Restricted Stock, Restricted Stock Units or Other Stock-Based Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.4 &#8220;<U>Award Agreement</U>&#8221; means a written agreement evidencing an Award,
which agreements may be in electronic medium and shall contain such terms and conditions with respect to an Award as the Administrator shall determine, consistent with and subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.5 &#8220;<U>Board</U>&#8221; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.6 &#8220;<U>Change in Control</U>&#8221; means (i)&nbsp;a merger or consolidation of the Company with or into any other corporation or
other entity or person, (ii)&nbsp;a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or substantially all of the Company&#8217;s assets, or (iii)&nbsp;any other transaction, including the sale by
the Company of new shares of its capital stock or a transfer of existing shares of capital stock of the Company, the result of which is that a third party that is not an affiliate of the Company or its stockholders (or a group of third parties not
affiliated with the Company or its stockholders) immediately prior to such transaction acquires or holds capital stock of the Company representing a majority of the Company&#8217;s outstanding voting power immediately following such transaction;
<U>provided that</U> the following events shall not constitute a &#8220;Change in Control&#8221;: (A) a transaction (other than a sale of all or substantially all of the Company&#8217;s assets) in which the holders of the voting securities of the
Company immediately prior to the merger or consolidation hold, directly or indirectly, at least a majority of the voting securities in the successor corporation or its parent immediately after the merger or consolidation; (B)&nbsp;a sale, lease,
exchange or other transaction in one transaction or a series of related transactions of all or substantially all of the Company&#8217;s assets to an affiliate of the Company; (C)&nbsp;an initial public offering of any of the Company&#8217;s
securities; (D)&nbsp;a reincorporation of the Company solely to change its jurisdiction; or (E)&nbsp;a transaction undertaken for the primary purpose of creating a holding company that will be owned in substantially the same proportion by the
persons who held the Company&#8217;s securities immediately before such transaction. Notwithstanding the foregoing, if a Change in Control would give rise to a payment or settlement event with respect to any Award that constitutes
&#8220;nonqualified deferred compensation,&#8221; the transaction or event constituting the Change in Control must also constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation
<FONT STYLE="white-space:nowrap">&#167;1.409A-3(i)(5))</FONT> in order to give rise to the payment or settlement event for such Award, to the extent required by Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.7 &#8220;<U>Code</U>&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.8 &#8220;<U>Committee</U>&#8221; means one or more committees or subcommittees of the Board, which may be comprised of one or more
directors and/or executive officers of the Company, in either case, to the extent permitted in accordance with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.9
&#8220;<U>Common Stock</U>&#8221; means the common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.10 &#8220;<U>Company</U>&#8221; means Seaport Therapeutics,
Inc., a Delaware corporation, or any successor thereto. Except where the context otherwise requires, the term &#8220;Company&#8221; includes any of the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections 424(e)
or (f)&nbsp;of the Code and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a significant interest, as determined by the Administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.11 &#8220;<U>Consultant</U>&#8221; means any person, including any advisor, engaged by
the Company or a parent or subsidiary of the Company to render services to such entity if: (i)&nbsp;the consultant or adviser renders <I>bona fide</I> services to the Company; (ii)&nbsp;the services rendered by the consultant or advisor are not in
connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company&#8217;s securities; and (iii)&nbsp;the consultant or advisor is a natural person, or such
other advisor or consultant as is approved by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.12 &#8220;<U>Designated Beneficiary</U>&#8221; means the beneficiary
or beneficiaries designated, in a manner determined by the Administrator, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#8217;s death or incapacity In the absence of an effective
designation by a Participant, &#8220;Designated Beneficiary&#8221; shall mean the Participant&#8217;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.13
<I>&#8220;</I><U>Director</U><I>&#8221;</I> means a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.14 &#8220;<U>Disability</U>&#8221; means a permanent and
total disability within the meaning of Section&nbsp;22(e)(3) of the Code, as it may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.15
&#8220;<U>Dividend Equivalents</U>&#8221; means a right granted to a Participant pursuant to Section&nbsp;6.4(c) hereof to receive the equivalent value (in cash or shares of Common Stock) of dividends paid on shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.16 &#8220;<U>Employee</U>&#8221; means any person, including officers and Directors, employed by the Company (within the meaning of
Section&nbsp;3401(c) of the Code) or any parent or subsidiary of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.17 &#8220;<U>Equity Restructuring</U>&#8221; means, as
determined by the Administrator, a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off</FONT> or recapitalization through a large, nonrecurring cash
dividend, that affects the shares of Common Stock (or other securities of the Company) or the share price of Common Stock (or other securities of the Company) and causes a change in the per share value of the Common Stock underlying outstanding
Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.18 &#8220;<U>Exchange Act</U>&#8221; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.19 &#8220;<U>Fair Market Value</U>&#8221; means, as of any date, the value of Common Stock determined as follows: (i)&nbsp;if the Common
Stock is listed on any established stock exchange, its Fair Market Value shall be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the first market trading day immediately
prior to such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or such other source as the Administrator deems reliable; (ii)&nbsp;if the Common Stock is not traded on a stock exchange but is quoted on a national
market or other quotation system, the last sales price on such date, or if no sales occurred on such date, then on the date immediately prior to such date on which sales prices are reported, as reported in <I>The Wall Street Journal</I> or such
other source as the Administrator deems reliable; or (iii)&nbsp;in the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined by the Administrator in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.20 &#8220;<U>Incentive Stock Option</U>&#8221; means an &#8220;incentive stock
option&#8221; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.21 &#8220;<U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock
Option</U>&#8221; means an Option that is not intended to be or otherwise does not qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.22
&#8220;<U>Option</U>&#8221; means an option to purchase Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.23 &#8220;<U>Other Stock-Based Awards</U>&#8221; means other
Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.24 &#8220;<U>Participant</U>&#8221; means a Service Provider who has been granted an Award under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.25 &#8220;<U>Plan</U>&#8221; means this 2024 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.26 &#8220;<U>Publicly Listed Company</U>&#8221; means that the Company or its successor (i)&nbsp;is required to file periodic reports
pursuant to Section&nbsp;12 of the Exchange Act and (ii)&nbsp;the Common Stock is listed on one or more National Securities Exchanges (within the meaning of the Exchange Act) or is quoted on NASDAQ or a successor quotation system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.27 &#8220;<U>Restricted Stock</U>&#8221; means Common Stock awarded to a Participant pursuant to Section&nbsp;6 hereof that is subject to
certain vesting conditions and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.28 &#8220;<U>Restricted Stock Unit</U>&#8221; means an unfunded, unsecured right to
receive, on the applicable settlement date, one share of Common Stock or an amount in cash or other consideration determined by the Administrator equal to the value thereof as of such payment date, which right may be subject to certain vesting
conditions and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.29 &#8220;<U>Section</U><U></U><U>&nbsp;409A</U>&#8221; means Section&nbsp;409A of the Code and all
regulations, guidance, compliance programs and other interpretative authority thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.30 &#8220;<U>Securities Act</U>&#8221; means
the Securities Act of 1933, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.31 &#8220;<U>Service Provider</U>&#8221; means an Employee, Consultant or
Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.32 &#8220;<U>Termination of Service</U>&#8221; means the date the Participant ceases to be a Service Provider. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALIFORNIA SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This supplement is intended to satisfy the requirements of Section&nbsp;25102(o) of the California Corporations Code and the regulations
issued thereunder (&#8220;<U>Section</U><U></U><U>&nbsp;25102(o)</U>&#8221;). Notwithstanding anything to the contrary contained in the Plan and except as otherwise determined by the Administrator, the provisions set forth in this supplement shall
apply to all Awards granted under the Plan to a Participant who is a resident of the State of California on the date of grant (a &#8220;<U>California Participant</U>&#8221;) and which are intended to be exempt from registration in California
pursuant to Section&nbsp;25102(o), and otherwise to the extent required to comply with applicable law (but only to such extent). Definitions in the Plan are applicable to this supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Limitation On Securities Issuable Under Plan</U>. The amount of securities issued pursuant to the Plan shall not exceed the amounts
permitted under Section&nbsp;260.140.45 of the California code of regulations to the extent applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Additional Limitations For
Grants</U><I>.</I> The terms of all Awards shall comply, to the extent applicable, with Sections 260.140.41 and 260.140.42 of the California Code of Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Additional Requirement To Provide Information To California Participants</U><I>.</I> The Company shall provide to each California
Participant, not less frequently than annually, copies of annual financial statements (which need not be audited). The Company shall not be required to provide such statements to key persons whose duties in connection with the Company assure their
access to equivalent information. In addition, this information requirement shall not apply to any plan or agreement that complies with all conditions of Rule 701 of the Securities Act (&#8220;<U>Rule 701</U>&#8221;); <U>provided that</U> for
purposes of determining such compliance, any registered domestic partner shall be considered a &#8220;family member&#8221; as that term is defined in Rule 701. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CS-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Subsidiaries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Jurisdiction of Incorporation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Seaport Therapeutics Securities Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Massachusetts</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SPTX, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Seaport Therapeutics Australia Pty Ltd</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g73463g00a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g00a03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[12:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %'T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)%)B@I.BLE6#)4,F\/'_Q  : 0$  P$! 0              ! 4& P$"_\0
M-1$!  $# 00'" (# 0$! 0    $" P01!1(A,15!87&!H;$3%#,T45*1P2+1
M,E/A\/$C0O_:  P# 0 "$0,1 #\ _5(
M
M
M
M
M
M
M
M
M                           /CWMC8KGN1K4UJJKDB$!<<7VBA<YCJE)7
MIP1>4B_>A]T6J[DZ41JY7;UNU&MRJ(6 &?56Z/'DJ4U"[/C>_P#+(CI-T2X*
MOR=/3HGMS4ET[.OSU:(%6V,6GE5KX-2!ET>Z)<$5-.G@5/9FA)4NZ-"JHE31
M.3^IK\_PR%6SK\=6KVC;&+5PWM/!?P0=MQ5::]4;'5-C?_++Y/:3;51R(K51
M47A0B5VZK<Z51HGV[U%V-;<Q+Z #X=
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MR]5BNBW3>GE/+P;9A^XLNEIIZIBZW-R<G$Y-I(F:;EUW2*IEMTJ^3+Y<>?\
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MQ#*%VJ:ON6_44WOE[$+_ &E\">^&5V-\U'=*X@ SC8               -B
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MW3Z,60V+<Z]&8NFXQTV+<Y]&8NFXN]J?!\6:V)\SX3^EF !GFN
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MJK1S+FW^A>(KE%4RT=3'40/5DD;M)JH:&[;HS+/#P9*Q=N;.R)BKJYQ]8_\
M<GZ"!$87O45[MK9FJB3-U2,XE_0ES-5T315--7.&SMW*;M,5T3K$@ /E]@
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M]NG2?$ !'2P
M
M
M
M
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MX*7D\7PCN"EY/%\(%8BQFY\C6]Q99JB?/_8N"+FB*>=*&E1<TIXD7HGH
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MLC%X6J1]RL%!7,=I0M9(OVV:E/N'K.VT4SV;YOCWKFKLLM0$J
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M;R]G4I,X;LD]KFE?/4)*CVY(B9Z@)X    !GU/Z;_P#O4T$SZG]-_P#WJ:"
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M<KJ2J1438CM2@7<&=;[?+$J.DWU8L]>?E-+=AV]QW>%WD[W.SYS,_P 4 EP
M                   'QWS5YC/<,^E3^D_M-"=\U>8S[#*+X5/U?:?V@:$
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M!%$ZIK9[C4(KE1<FJO"Y=JEW H_@M=N6L_R._0X283NCV*U]7&Y.)9'?H7L
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MR+)'"QKU^TB:SN       /DC&R,5CVHYJZE1>$^@#K@@B@14AC:Q%VHU,CL
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M3QQK_2W(](
M
M
M
M
M
M
M
M
M
1                   '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g73463g00n11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g00n11.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1R$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '&<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M   ! @,1!!(A,1-!(E%Q!3(S89$4@:&QP=$C-$)RX? &4O$5)*+_V@ , P$
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ME8'AKNHRLA9)B8G4MT3%HW B(N.B(B B(@(L*[7.FM5,)ZQSFQEP;EK<[_\
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M>]YCO/R_-=_=_D<S;5*8_P ;M/\ ^U3MAU/07@]G$XQ5'=%)C)]GBIL  8
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M'5ZD1/RUV_4MU=3W&E944D@DB=WCJ#X'P*R5SO1#GVO5-=:W.RP\S?:6G8_
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M9',/UA;+KM\HTK6.IR?6#0XC\4N&?J7+\>.NO1/PV\)8^7:,=_4CXJ>?S_\
MK!N.NJ*GG,5'!)5N!QS-/*T^SO/P6*W7[&N'I%LFC;X\_P"T!9?#B*B%F,D
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M7-R/BI3'])W&OJN<-K:Z*DGN,S</J#B/\D=?B?L6YJB&)D,3(HFAK& -:!W
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MKRP5UF8VFI;I*:6KIX]F/.V'8Z []WAYJWQ%MGSQQ(TS0ND>R*6"02\I(+F
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MC55D&H.%U-0-_AG443X7?BR-:"T_$?6@W58%5>*&ENE+;9Z@-K:H%T40:27
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M>\\7+^ZO:)J2F9'(8';L>\C#2X=^-^JW+5>F;5<=/UL#Z"E8X0N,;VQ!KF.
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MT'<@Z#27.CJ[9'<8*AAHGL[1LSO5;R^.^,>]0+^(>E&3]DZ]4_-G&0UQ;_B
MQ]:D]1TUG^89HKVV".U,P7AYY&#!R.GGW+2SK'1;8#3P6:6:EQ@&*W L</)!
MT6CJH*VFCJ*25DT$@YF2,.0X>16@PS1T_&:YRSR,CB9:V.<]YP ,C<E8W!BL
MCFJ=2T]%VK+;%5-DIHI!@QAW-D8[N@V6'>++'?>,TU+5N<:)M$R6>($@2@=&
MG'=G!]R#<&<0=*OJ>P;>J?M,XR0X-S^5C'UK9XWLEC;)&YKV.&6N:<@CQ"C)
M].V:>B=226NC-.1R\@A:-O<-EHVB*Z;3M9K"RND?-2VD>DTH<[/*PM+N7[/K
M0;O?-36:Q$"[7&"F<=PQQ)<?[HR518]4V2^2&.U7*"HE SV8):['Y)P5J?"R
MQTURM U'>8XZZZW![WNDF;S!C0X@-:#L.BO\3M/TD-@GO5KACHKK;\3Q3P-Y
M"0#N#CKMXH,OC%][^Y?W/T@INI@HZG2#H;GM0OHP)CX,Y-SMX+4M?5[KIP@-
M<\8?400R.'F2,_6MGNW\@ZO^SG?[M!>TE3VNATW1LLC\VP,YXY'$[@[Y.<*/
MJ>(.EJ:H,,MYI^<'!Y YX'O (4%%15MPX)14MKYC5R43.0,ZNP02![0"/>L?
M2NI-)4=KIK?<Z".UU44;62,K*7',X#!/-C??O*#HELN-'=*5M3;JF*I@.P?&
M[(42=9Z>;;?3W72!M+VCH@]P<"7-Z@-(R<>06;IV&TQT!?8&TPHYGF3-/CD<
MX]3LN<<%].T-5;JRYU].RIF%5)%")1S-C P3@';))Z^2#?K'JVQ7R9T-JN4,
M\P&>SW:['L< 2K5VUKIVTU3J:ONT$<[3AS "\M/GR@X6H<9[13T5EI;Q:XV4
M=QIJAK&S0-Y'$.R,;>Y;AIS2ULM-I@IO0Z>6;D!FFD8'.E>?I.).3N<H)2TW
M2BN](*JV5453 3CGC.1GP/@5F+FMDIH[!Q;JK;;1V-OK:+TAU.WZ >#U [NA
M^*Z4@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("YYJR%DW%G23)8A)&8)\AS<CZ)ZKH:808K;=1-=EM'
M3 CO$3?V+*1$&B7$']^*UG!Q\VOWQ_2*V^\V^*ZVFKH)_P"#J(G1D^&1U69A
M$',K!JFHT;;H[/K"CJ6&E')!5P1]I'+&-F].A5-ZJZGB-+1V^TTE3#8XYFRU
M=7.WL^T Z-:#N>]=/(SU1!S?CA"7:5MT$!#":Z)C#W-V< LMG$*&TQMI-4T5
M;1W&,!K^2$R1R'\9KAW%9'%6V5MTM%NBMU-)421U\4CVLZAHSDK=2 >H0<WI
MHJW7.JK;=):.:BL-K<9(.W'*^HD.-\=0!@+*U$">+>ES@X%+/OCR*WY,("Y_
MPH:16:MY@1FZ2=1UW*Z F,=$'-Z>>KT!=+DRIHIZG3E7.:B&:G;SN@<[Z37-
MZXRLZ/B+2W.1E/INW5UQK'N Y71]DQH[RYSNFRWI  .@006MK?/=M(72BIF_
MZ3- 0QN>KNN/JPM6T9KJ@AMUKLM127!ETB:RFDA$!/*1MS$],=ZZ,F!G.-T'
M--0S/TQQ(DU!<J2>HM512"!LT3.<T[AC.1UWQ]:Q]9ZR9J+25SIM.T53/%V)
M-1431F-D3!UQG=SCW +J:8&.B#5=. CAG1C!S\V=/_AJUPC!'#ZT @@\CNOY
M96WH-NB".U%;([S8ZZW3?0J(BS/@>X^XX*Y;H@5^HKY:[7>(CV.FFN[;)V?,
M'%K/;AH'P/BMJN&H=6T]55TL.E34$R.;35#*AH9R_@EW_04KH*P2V&S.;72"
M:Y54CJBJD'>]W</((-D6#?OXCN/]6D_1*SEB7B-\UHKHHFETCX'M:T=22TX"
M#D_#/4U1IG1]"+U15#[1-S/IJJG;VG)ZQYF/ W&X)SYJ5OVI)M<4#[)I2DJ3
M'58;45L\?9QQ1YWQGJ5LW#&@J;;H6U4=P@?!4Q->'QOZMR]Q^PA;0!CH@T+B
M/;V6SA544%."8Z>.&)O>2 ]H5_7=FK+YPZ;1VX<U0(X9!'G'.&X):MV1!SZW
M<2[,RD@IO0;C'6,8&>B,IB2"!]$=W<L/AP^KFX@ZLGN%-Z-/*R%YBSGD!&0"
M?'&,^:Z;@9Z!,(.<\0!-9M9634SJ::HM]/&^"?L1ET><X=CPW^I;1I?5-!J7
MTAUM95=E#C,DL18UQ.=AGKC"GD QT0<[X/@B35.01_VF_J%>U7;KE9=6Q:JL
MU*ZMC?"(*ZF8?7+!T<WQ.P^"WX#'1$&AOXG6N5IBMM%<JNO.S*84Y:2? D[!
M9G#JP5MKAN5QO'*+I=)NWF8TY$8WY6^[)6X8'@$0:-PP!$^J<@C_ +5EZCR"
MN\9 3P[NH ).8M@,_P"U:MT1!BVG^*J/\RS]$+2[H#^_-9C@X^;I-\;=7+?D
MQN@+GG!D$4%^R"/^TI>HQX+H: 8Z("Y/9+I'H"]WR'45)4\M;4NJ8:V*/M ]
MI/T3C<+K"$ ]4'&N(>HG:CI;/);J*I;;(J^+-1/&6&1YS@-;UP!G)]BW;B5I
MZKOELI)[26"YV^<5, <<!Q'5OOV^"V_ \$0:#!Q.ML,;(;O17&CN(&'T_HY=
MO_1(ZA:]'5W2Y\5=/7&XT;Z.EF9**2%_TQ&&GUG>!)/3R77\#P3""-U):8KY
M8ZVW3@<D\9:#X.[C[C@KE^AG7+4^H+33W:%[8--QN;-S;"2?):T^>  ?<?%=
MB3"#3.+%GK;OIAK;>PS24T[*A\ /\*UN<M_6L2DXFV9\3((:&Y"M#<"C93'F
M!_%ST6_)@9Z!!S7A0:MVH]7ON,(AJGU$;WQM.0TGF.,]^%(4P/[\E4<''S4W
M?&WTUO6$P@+G?!^!L^F;S!.PF.6OG8YIVR" "NB(!CH@Y?8;E5<.V3VF_4M1
M+:&R.?15E.SM &$Y+7 ;CK]JFJ'7$E\N5)!INUU-33EX-34SM[)C&=^,]3T6
M[(!CH@T+5%!<+)JZ/55KIG5E.Z#L*ZFC/W0M'1S0>N-O@O?WT;,\&.FI;E-6
M=!3BF(<7>&>@6^)@> 00+[M=(M,-N$EED?<< NH8Y6\P&?'ITWPM=GXEZ=FC
M-/<*2O;(=G4\M(7']BZ F!X!!H'"FUU%)+?:\T;Z"WW"=LE)3//K-:.;<CNS
MD?!;Y4,=)!(QCN5SFD!W@<=56B#DFBM24FA;5)9-1T=52UD4SG=I'"7MF!.S
M@0O+S=JB^:^T?6-H)Z:W">1D#YF\KY3@<SN7N'3&?-=<(!ZA,(-'U[9;B+M;
M=2:>A$]QH,LD@+L=M$<Y SW[GXJV.*%G+>S]#N@K<?ZKZ,>?F\,]%OB8&<X0
M1&G:NX7*S]O=:$4,TA=R1<_,0P_1)\#CN7.]%:DIM#6^HT_?J6M9603O=&8H
M2]LS7'(+2%UM,#P0:%Q9D](T=12L8\!]93N#7-PX9/>%O#XF3TKHI6AT;V<K
M@>\$8*NXRB#A[;;725[>'@8_T**N-2Z8]#2_3#<^.3\5V*[VR&YV:JMLHY8)
MXC$<=P(QM[%G8WRB#FMEU//HN@CL^K*.I:VF')3UD$?:1RQCIG&X*G+)K07^
MZ0P66V5<M%N9ZN9O9-8,;8!W)SA;<1GJ@&.B M)XB66XSU=JOMBC;+<+6]SC
M"3CM8SU://K\5NR(-#9Q/M&.RFH[G'7 ;TOHQ+P[PST4!I5]TJ.+[JR]4_HT
MU10.?'"#GLX\@-:3X[9/M76\#.<!,;Y0<_UR">(FB2 2!+-DXZ;!= 3"(.6V
MJMDX>7B\4]WI*F2T5M0:FGJX&<X;GJUP&_A\%A\0M4R:HTE71:?I:GT")HDJ
MJF:/D!:",,:#N23CX+KR8&,8V0:S!:(;[P^I;959$=10QMR-BT\H(/N(!4!:
M=17G2]!';M266LJC3@1Q5=$T2-E8-AD9R#A="F#S"\0N:V0M(:YPR >[(6B,
MO^L[8TPW'3+;F6["IHYVM#_,M.<(-3XI7*\7VQQ5)M\MMLL,[,"H([6=Y) /
M*.@&ZZ;J"\SV.AI9X[94UT)(;-Z/CFB&.N#U6JU%#J#6UPHF7JV"SV6DE;.Z
M)\@DDJ'#H-N@]W>NCH.;7?B!IF[T4U(ZWUE?/(PM;3.I3S$]PSW>U3_#&TUM
MFTC2TER')-S.>(N;/9M<<AJVK \ B#'N/\7U7YIWV%<AX8ZCJ-,:5A==J.HE
ML\[WOAJJ=O/V1R0YKQUZC(/FNP5S7/HJAC!ESHW  =YP5K'"RW5=LT514EQI
MWT]0QS^:-_49<2$&OW[5$^L[?)9](T=2\50Y*BKGC[..*,]>O4K+XB6N.T<(
MZJW4W,Z.FACC!QN[#ADKH0&.B=4&)9OXHH?S#/T0M+O=+7Z7U;4:BMU%)6VV
MMC:ROABWD8YO1[1W[=RW]$&AGB?:)LQ6ZDN576G9M.VG+27>!)V"W.V2U$]!
M3RUM.*:I>P&2(.YN1W>,K)P!W!$'&=60W#3E_N]IM43G0ZFY>P(Z12$XD^HG
MXA=6T_:X;+9:.W4_\'3QA@/B>\^\Y*D,(@T+1 (U_K0D$ R18)'79RQ:J&NT
M1JRY7:"CFK;%<R'U @'-)!(,^MCO!R?BNCX1!S^JXBP7*GDI=+4-=77*0%D8
M="8V,/XSB[N"D=+Z0%LT--9*F7FGJXY#42#\=XP<>S]2V\ #H$0<LTKJL:+M
M,=BU51U<$M(YS(9XXC(R5F2001[5%:ZO-7J*OTY5TU%/!9H[A&V-\S>5TTA<
M,D-Z@ #O\5V@@'J$P/!!!:HOLUB;3S"UU5;2.)$\E/@F$=QY>I6GWS7>F[[;
MYZ)ENK+A52,+(X#2D'F(P-STW/5=-3 \ @YLVU5MGX)UE#<A_I3*.4E@.>0$
MDANW@"MST@,:6M&?_98OT0I9:]JFYWNV2TK[/9OG.F(=V[62ACVG\' *#0-9
MBMTO?[K26MCG,U/&&0 =(Y^;E<?@XGW^2Z=INTQ6.Q45MI_H4\89GQ/4GWG)
M6K6.VW6_ZHBO^HJ#YNBHF%E%1F0/=S'Z3W8[_P#KN6]H"T.T _OQ7PX./F^'
M?'FM\3&Z#0KV#^_#IPX./0IM\>3E[Q"!.K-%8!(%:[.!Y!;YA,("T'1((XB:
MT)! ,D."1U]5;\F$$!K_ "=%7O )/HK^GL6)H@$<-[:""#Z#T]Q6U(@T;@F"
M.'-M!!!YI-B,?AE0=ON\>A-5ZA9?:>I%-<IQ44]1%&7M<-]CCOW750,=$(!Z
MA!INI[?^[;2-/56P24]7'(*JD[=O(0]I(&1W9_8L*'B324$3:?4M#74%R8.6
M2,0E['.\6D=0M_0@'J$&O:6U#47^:HECM=12VQH'8SSX:Z5W?ZG4#INM6>RM
MT'JBZ5XHYJRP71_;2& <SZ>3O)'>#D_]!=*1!S^IU\V]TSZ+2%'5U=PF!8U\
MD1CCB'>]Q/AX+S@:QT>BG-?GF%7*#D8ST700 .@0#'1 7((JRXVKBIJBXT5%
M)64D0B;511_3+"QN'-SUP1T\UU],(-!GXFV^HC?#9*&X5MR<,1P>CEHYN[F)
MZ!2/#G3U59+;5U%U<TW2X3&IJ T[-)Z-]V3\5MH '0!0NJ:Z[T%-!-9+8VXN
M$GW:(R!CN3'X.>]!H_$&>IT=J@ZCH8R^*XT[J25H[I@/4=]0^!6Y:#L8T_IF
MEI'_ .L.':SNSGFD=N[]BUR&AO6L;];ZJ_VMUJM-O=VT=.^4/?-+W$XZ +H:
M M N8/[\]G.#CYODWQM^$M_3&Z M X7@B\ZQR",W(]1[5OZ80:#HX$<2]9$@
M@'L,'']%6ZVVW72>JJV\V6C?<+3<,/K*6-P[1CQGUVYZ]3MYE="PM5U)5:IM
M]S%19J&EN=N+ '4Q>(I6NWR0X]>[X((Z765RNT,E+IZP7!M:\<HFK&"..'^D
M<G?'@%B<$H9*>T7F*>3M98[C(U\GXS@!D_%7JC4VKZV%]/;](RTD[_5$]34-
MY(_Z6-LK8=#Z>_<U8(Z)\W;U#GNEGEQ]-[CDG]2" TF".)VK20<<D.^/(K=;
MI_%E7^9?]A63A$&E<&@1P[M8((.9=B,?[5RW5!MT1!SOAV"->:X)! -1'@D>
M3E>XL@EVE\ G_M:+H/:M^PF$&C\: 3P_K@ 2>TAV S_M&K<;?_J%-^:;]BOH
M@TJOX@4MHK:BFOULN%%R/+8Y!'VC)&YV(+?'P6NB2EU;K6QW#3-MF@BHI#)5
MUKXNR#F]S<=Y._Q75R >J 8Z(.><11-:]4Z=U&::6HH:+M(ZCLAS.8'# =CX
M_!;)IC5=!J1\_P VQU79Q $RRPEC79[AGO4^@&.B M!XWM+M"R-'4U,0^LK?
MEIW%>VUEUTF::W4\E1/Z1$[D9UP#N4$?1ZY;IZDBM^KJ6KAKH&AAGBB,D4X'
M1S2/$=RQG2UVOK_;)8J*>DTY;YA4.DJ&ACYY1]'#>N/^:Z0P>HT$= JD'/-:
MNELFM[;J*IHI:RV1TSJ=_9-YG0.YL\^/8J+SKJ"_62OI-,T=553R0O:^26(Q
MQQ,Y3S.)/7;. .I71D  Z!!HNAZNIM_"ZW5-)0R5L\<((IV$-<X<V_7RR59G
MXEZ>DC,%RHZ^.4[.IY:0N.?#P70.G1,#P"#FF@Z2NML6H[W0VF:.CJWB2BMW
M,&/<!U.#]'*S)>)EA+#!=*.X03'9U/+2EQSX>!6_I@> 0<[X8VZ47R_7BGH9
M+?:*XL%-!(.4NQG+^7N_YKHB(@T'AN"-4:WR",UXQD=?I*?U^"=$WT $GT.3
MI^25/X1! : &-%64$$'T5G7V+7-= GB-HD@$@239..FP70DP@TO75IN+;M:]
M0V*(5%70<S)J?FP9H3U SW]?BL=O%*R !DU-<XJK&].:8\P/AX+?$P/ ((K3
M5PK;G;O2;A;WV][GGLXGO#G%G<3CH?): RYLT-KO4%3>Z>H%#="R6GJ(F<X.
M!N"!T.ZZHA /4(.>:Z;/K#0L-79J:=[8ZAL_H\S.1TK&$@['QZA7J;B;9Y(F
M04M%<GUO* VD;3$.S^+GI[UOJ8'@$'->$YJG:CUB^OA$%2^IC<^,'(:2''&>
M_"C[[+<Z3C!45MII35&GH6.F@!P9(SLX-/3F&Q]RZUA,;Y0:$_BA:7-,5+1W
M.>N(]6E%.0XGP).P5S0FFZQOSW=-0QM977EWW2!ISV<>" T^>"MYP,]$0<OT
M_<ZGAW#+9[]25,MICD<ZCKH&=H"TG/*X#<%5:@OL^O: V73%)4BFJ"WTJNG9
MV;(V Y( .Y.RZ<@&.B#0N)U$R@X7U%%3@F.".*-HZG ("GKL/_L)5C&_S<[;
M_P"&I]$&F:5K:BV\,[74TM#+731TT9[",AKB-LXSX#)6%4<2M.S1FGN%)7B4
M[.IY:0N.?#P70$P/ (-#X5VR>E%WKO1'T%OKZCM:6D?])C/$CNSX*C@D"-(S
M\P(_TV;J,=X6_H!CH@T/C4"=%X:"3Z5%T&>];VSZ#?8O<91!SV8']^Z X./F
MP[XV^D5T),;Y1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1"0.I6
M++<*2*M@HY)V"JF!,<6?6<!U./#S1R9B/+*1,HCHB(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M 1$0$1$!$1!9<W+BC8\A7L(N[1Z5AS,#=8Y(YBLFI=RM*BW2Y)4H5WG3(=(
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M4B2(P2HJVY+@[*SI7963+;IA92NY[K%1(7E8Q5YXW5 :O,M,S/=MKJ(6PO'
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M3P!5<NR]QA"<([IYA>!>.?U5!<I0YMZXJDG94Y0+L0CM[E>(G<I1"(B(%V(
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MN5?='DHQF"G5V(IW5Q,P%(6\8+_<L5HV670]7^Y4WG<-%8TRT1%2L$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M+K>21VL$6(01GFE<>5@^)"#A/&GC9?K3KBJM.D:J.*EH&B*=YA;)SR]7'<;
M9 ]H*[?PFU7^[/0ELN\A;Z4]ACJ0WNE:<.V[LXS["%P3Y.VA1JZT:OO-\!D^
M<HWT,4COQW>N]_QY/K5?R:KY5:2U]=M$7E_()I'M8WN%0S8X/])H^H(/J9?/
M/!CB;J?4_%"NLMXK8I;?$R<M8V!K3EKP!N!GHOH9?(OR</OWW3\W4_[P(/KI
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%IPR2L:9N2LT-ZJ,KY'-GY6G&RE$J[0
MN!H"$@!8+G//X15B0S;X><*6T-)$N SNK#Y1G&5%R23;^L58=*\G<E2B4)B9
M2I</% 1XJ&$SLXYBKC)';Y<5+:'0E2X#J0O.T8!NY1AD.Z]#R!U78ESH2 E9
MXJL.!Z%17:D903%=ZCHE+(HOTHCO05;L]5W<'IRDB\!4%^ZP!4$GKE762DKN
MSHEE [KT;E66O7H>I0C/9D87BM!Y/>G,4A'2XO,*V'%>\^%TTKPO<;*@/!5;
M2"%QV(T+S*]*I*&CF\5X7+Q%UQZ#NK<LF 0J^C2L.I?@.\57?39Q8F98\CN=
M^,[++AC:6C/<L&/UGJ0B! 5-*Q:6W-DFE60UP P.BK:Y8ZK82M/3&GE1DGJV
MR8V\SNBNBFYCT5RCCR.8J0@:-UBR1N7IX\DUJUJ^TQ9128'<N4W$8D.0<KM.
MH0/17^Q<>O3 )G*>-ZG%MU4W*$D(\49]$[C*2#JJ6C97M%5P$A7H272!6 /!
M9E%&3(WQ55I75\LYL3N7IC(6 *ES7$9.REY0Y@"UZJ/W5Q\5X_(MW>MQX[=V
M0ZH)ZE6S)GO6("<JL$X6.9VU0R \^*KC))6,PG*RH&]5Q./#*B)"RXYG#;*P
MV^J%Z'X4XG2FU>I)-J2 J759&5@=HJ'O4NI",4,B2J+L[E>-F*PR56TE1ZEG
MIQ$,V.=WBKS9SWK 8=U=:5*)5S2$I3R94K2 .!RH&G< 5+TDV%926+-7Y,_D
M$;\]Q5Y]/SMY@L>1_/'MU"R;=4!WJ.5T:8K=41U,?L2#C"S*5I!"S13@[]Q5
M^"E\E=2G=GOGB8>Q?15P*]'3GP1T1"UTAY^2\*&A>C="T@*US<IW5](EAS=-
MEPM5N1@<""%=8]I!W5+B"K(8K1"!N= '-) 6K5E,Z)Y("Z%(T/:5"7.A#@2
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MEN7.3%%:??GM]/FWVTW/4<'#:XWF\5+#<# Z>G;V+6]FT#U<CO)ZKGEGUQQ
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MSZ82&:27^BY^<-'LS[E](4-)3T%'#244+(*:%@9''&,-:T=  @^1;)_WJ_\
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M8M\5F3-:+3TSV9^/P\<XHG)7NYGQRM#I]&TU1"'.^;Y&EWY!'*3\<*_P1O\
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M^B?@@Z%H_B1I;5N&V6ZQ23X&8)08Y!Y<KNONRMO!!Z+XWU/P'NM%F;3U<RO
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MM4U3;)3N&@]K'\#N/BN:7+A=K;2E8:JQF:H:PY;/02ELFWBW/-\,K[/GM['
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MGXQ2VZ_T\C:BEC/J<P#CD#NW#3\5O/RAOO-ZE_-1_P"^8@W/3M1;ZNQ4-19
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M\<C*P=/:#U1JO5U%J?B7-3Q1V]Q?16B##F,=W.<1ML<'O)QW=%L_'>RW&_\
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MEH;A55CKE.)7]L[/9XS@#S]8[]3LMVYF\W+S#F\,[KBGR;'N?7Z^YW.=B[N
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M4^E;3%1153+U4.A?*9>4PX<P9Q@Y^E]2@>$>KK[!J>Y:&UU*)[W1L[:EJFM
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MIZD\SC#(#]( -'=D>]3M@XGW?0]''9.(^G[F):-O9,N=)%VL4[!LT]V_3O\
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M50*VP\R\=EZ,JX%8CZK-C9ENZE,Z9M/(SA9D)V6)C=9,?10EV(5R. :<K$E
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M***VZRXBT4%7-61T]5%$)YG\[Y.4RC+CWG94<7[G2V?CYH.NN!#::-G*]Q.
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M6"VP<KIF^!=AOZUU?3EDH-.V:EM5HIVT]%3MY6,;]9)[R3N2@Y+P8^^]Q/\
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MS.:Z6EI8H'EO0EK "1Y;*00$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M/=DN.?8@^@W:WTNVL]%.H;4*C..3TIF<_%;!&]LC&OC<',<,AS3D$+GIX+Z
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M.\2-L_%:';-*5UTXU:XM,>J[CIRLDF%5$VEV]*C.^?I#. X>/4K>OWGM1?\
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MO78XA;1;M14S\!XY3YJ^F6)\O'Y' OCG=83LM#3RCUHQ[@L&6QP/^B2%<^<
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ML*(/(V-CC:R-H:QH  '0 =RX]Q.X/2:OUW0WJFK8H**01,N4#\YG;&[(QCR
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MLEX=%:K_ !/>*QM9"6E[^8X/,1X8&.Y=EMUITU77.&_6VFMT]:QCF,JZ?E)
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M6+TZ*)SZ6I:T!\4@&1@^&1TZ(-T)P,G8+FU_XVZ'LU5)3275U7/&<.;1Q.E
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M!K;5EMT;9#=;T9A2"1L?W%G.[)Z;+7]1\7='V"ICI:VXNDK'ACO1X(C(]O,
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MV8J).3X96_66SVZQT+**ST4%'2LZ10L#1[?,^:#.7$/E9_R)LW]J1_H/7;U
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MMM%OK]$11VW4%D -$8O5#V-W[,^?@3W]>JWN?25HGU?!J>2G>;Q#!Z,R7M7
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M*UGTW *RZIB8!EW51MQGIGN&)'EQ_%.RIG),^%^/!-IU*4?.S&SQ[1NK7I;
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MM,O&-+<K*@9D9SLK$3';GN5YF1D-.WL4HA5;NRXFMZK(:!C98]'&7'UE)0L
M[E;6&3);2RV(EN2%?AB/@K[6Y"NLBSW*V(9[9'C8QCHLB%FW151Q<O?E9,#
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M]UU%4QP101CM"/PGX^BT=Y)Z!<QHM5<4=94S:_3%BMMDMCCF%]SD)DF;W'E
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M%W, [B1C_$$'2$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M7$9A(T<7JND.P6P,)DM])%$,S/)&W<%$4N'AD9'JXV'>XK8=.#$[G\O-@@-
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MAK.@SG98<3L.*O%PSE<UV4VC;8;?+'3M!#N9WBL^KKF=DT=HTY&X[UJ9G]0
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MT3.XUN)2:X!8;SQ&UAK#5U#9-3TE!2VFN? QDU%&_P!7G<&C.,[!O>N_KB/
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M  JG0M SW^U8+9MSJ'K8N)%9F]O/\H_[Y6Z<';P4O2MYHB"HV-PP I2D=EF
M%?WM7:%K1CLM&'!W2:>.!FV#A7:L]FPN/<L&"V5%SYG,<&1_C%5UQTI'7DG4
M(9N7:T=./RI%S[0XR?<LN(\PZ*1M5DIZ 9?B23Q/12G80.&\8!'@L>3[0P3;
MIHCBO>G>T[1%!1E\G,X>JI*KG;#%R-VQW!7GN9$SU< >2UZ[5/TCE>1FS6R6
MU#5CB>1?OX85QK,D[J+$G,225;GE+G%6@Y3B-0]K'BBL:9+G[%84KLE7"_98
M[SOLD+J5T\*\PO%6.BE"UX%6%X KD;4A&97(ALI6WMPX*/A:%+4#,R-&592.
M[)FMV2IC:&9QNO&;= LKLP6!78X!RC9;*TV\F<FH[K >&,<YQV 6FZCK \N
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M"NTU5#37&F;3SULH@IXWUDF9'GN RND5C;!06^BT_<7TC:::+T>"FJ7 B1K
M!CUNNV$&LV32W#&Z6Z..TVS359 6X!C9$]Y'F?I96R:.TA9M(4E336"E]&@J
M)C,]G.7 .(QMGH-NBTZZ<#M"UA=-34$UME.XEHJAS.4^(!R/J41\G^\71]ZU
M=IRMN<EWMUFG9'25DARX@EP+<]_T1]:#LZ^=>-6F;'0\3>'%/16>W4\%95R"
MICBIV-;,.>+Z8 ];J>OB5]%+AG'?[ZW"S^N2?IQ(.MVC2U@LU2:FT66VT-06
MEADIJ9D;BWPR!TV"Y7\G?^4G$;^V9?TW+MBXG\G?^4G$;^V9?TW(-;XQVJJO
MOR@=.VJBJY:0UE (I9HCAS8LR&3![B6@CWKMFEM#Z<TLV,V2T4E-.UG(:@1@
MRN!ZY>=SG'BN8ZK_ .]/I+^SG_HS+N2#YQTG%IJX\7=9.XDOI7W9E7V5!3W,
MCLA!D\O('>J=L8\O:NJ5/#70EX[">"R6QKHGMD9+1-$>X.1NS&1LLF\:=T7K
M_G=7TMONDL+G0ND:[[I&6D@C+3D8.5RGBEH6W<,=/OU-HF[5UHKZ>6,-IG5!
MDCG!=CEY3N=B3W[ H.@\<;!:*GAYJ"X5-LHIJ^GH7"&ID@:Z2,#IRN(R.JCN
M"^CM-5O#33=;6:?M,]8^F:]T\E)&Y[G9.Y<1G*D]?U-3=>!5TJZF+DJJBS]M
M)&/P7%@<X?:KW >:*3A'ILQR-<UE-RN(/0AQR"@W2LN%%0\@K:NFIN;Z/:RM
M9G'ADJW3WBV5,S8J:XT4TKOHLCG:YQ]@!4'K?0&GM;/I'ZBHW5)I0X1<LKF8
MYL9Z'?H%%:;X0Z.TY>J:ZVBVR0UM.28WFH>[&00=B<="@T+Y5?I>=%_-IQ7?
M.![ ^$GJ\OUX6\Z3X2:8M%O N=MIKS<Y?7J:ROC$SY7GJ?6S@9RM&^596NMO
M[C*YC.=U-<#,&C\+EY3CZEV?3-_MVI+/3W*T5,=133-#@6G=I\".XCP0<8XO
M:+CT$R'76@F"V2T,C374D!+8IXRX#=HVZ[$=-_)=9JH*+7>AXPZ6IIZ*Z4T<
MO-#*62,:X!V.8? ]W5:#\H_4\$&DCI:A(J;U>WLIXZ>,Y<UO,"7$=V2 ![3X
M+$XS?.6B^ U#;;?.8I8VT]#431=S,8?@]P)&,^:"9ALG"&PL-#+'I1CV[.%5
M+%))GS+R2M'ME58=+<<[)%H"XTDEFOD;HJVCHYQ)$R09P< G'<?CXK?-.<'N
M'HLM(Z.STUP:Z-KO2I9'/=+D?2R#C?JN:WJ@TG:/E :+MNCZ6FIWT\I],%.2
M6\YW )).X'VH-D^4G)SWC1U)>Y9X-)2U?_:$C,\A((P'8\L_7X+=[=I'AK=Z
M%L5MM.FZN!S0 8&1.=C\H;_6MEOTMBK'MLE\?12NJV%S:2I(^Z-!Z@'KNM$N
M_ W1$K9*BA@J+/.!S-GI*ES.S(Z'!R$$_4Z=@T9PZOE'HNE?!*V">:"-CG.=
MVI:2.7.3X8"YCP&MW#ZXZ/@DO+;/6ZDE>]]<+ER/FY^<]S]\8QN/M4YP$U77
M/M&J:74-U%9;;#5&&&Y3'Z48YLY=W@8!S_26T7KAIH36+W7&:UTE1+/ZYJJ6
M0M+_ #RTX*"0L_#S2=LO\-]LUIIJ2NC:YK7TWJLP[KZH]5;>OGF:VR<,.+6D
M[1I6\5E1;+Q(YE3;*B7M>R&0.8>'7;\DKZ&0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1!S6Z?QG5_G7?:5@OZK-NA_[3K/SKOM*PW+U*^(
M>3;S*E4G*K&X7A&ZZBD+'<C;JH/(RP[."V66[VN9A+W]V<86DD*G 5-^/6\[
MEIQ\J^.-0E;E<Q*7,IV@1]Q47G*\PF%.F.M.T0JR9KY9W:67;F=I4-'<LJ_U
M/(.1IV 2S1X$DA_!"AKS,7RNW[UYO.R:[0^H^Q./VZI1L\Q)*Q^<Y*I>[<JE
MIZKPIGN^NK74#WX5OF5,KMU:RJYG2V*KI<G,K65[E<V[I=#E6'*P"JVE-N:9
M,;E>8[=8C7*ZQZBKM5DERI!5'-E><RLK*'2O!ZR8)<#JL$%5M?YJ?E&U-I5L
M@<T@JW]$G"Q(Y=UDL>'=5&)Z9THFNF5!*05L-KN C !. M7;L5DQR<HZJRT5
MUMFS88R1J6W375CMCA8;ZL..6X6O=OD]5=9/@[E5TO:L]F>.)6D=DT)8Y!AP
M&58GI^4<S.BQ8Y@>]2-*.U'+G*UTSQ/:R$UG'W1H<0=U=9+XE7I;?,^J+&MQ
MGO/17Q9)@S/:QD^"E/(QTG4R[;)CUWE@3L$T98>A7+^(NCH[K120O&'9+HG_
M (COV+L]-9_4/;RX/@U0VJ+28Z4RQ$N:.HPM''Y^.9Z-O)Y./'DM\,]WQ)<Z
M"HMM=-25D9CGB.'#["/)8J[YKW2<-]ART-BK6?0FY?\ *?)<-N5!56VK?35T
M+X9F]0X=?,>(6N6.^.:>7T?\F[4GSGIR>RU+QZ1;B#&#U,3B<? Y'O"[*&MP
MOB'0FI:C2FI*6YTY<6,/+-&#CM(SU'Z_:%]DVBYT]TM]/6T,PFIIV!\;QW@_
MK5E;;A?QZ=<:A,-#?%95-@%1;7'Q6932$$)M;?#,-B;)_HV3X*%YN:1^.BD8
M7<].1Y*.B86SN4L?B7E<J-6B&91Q%SP<;*W>86-D!.ZE*3E$6=@HB]R9DVZ*
M$VG;1Q<43.D:XL&>@6)4D$'!W54AR59<57;(]>N"(0U?3\Y*L4E P.R6#)\E
M..C#DCC#3GHN1=RV"&*ZD#8\M 6#))-&0W (4ZXC"M"F;*>BUX[UF.[SL^"\
M3\*U0.D:T..!MX+(E>YW4E9--;Y7NY6-('B5564,M,SF=AS3WA9LV7'OICRU
M<:-=K3W8&/,JS*!@J\Y6RTNV RJ7H3'98B^D!XE3]LIW.QGHH^@MLTLP)80W
MS6XTC(*: -?C(6NN:O3V>/RJ6FW9JE]CD:S#6N.VV I"QO=';&-D;RD*6J:V
ME<X @'"C+A51]F>RP-NB\O[3Y5<N+TH=XG&M69W[DMQ:PD;+"EN1/>HB:0EQ
M)*QI:C8CO7AX<4^[V\?$K'B$M)<#@[J*K*@R$[Y6&Z8D]5X'96ZN.*M=,,5[
MJ7%6R56\[*R7+DM,0K+E;<Y4EZIRNPE$*V]%6SHK;5>:I02K8,K)CBR%8CZ]
M%+T3&OV(4ZQMFR7Z88\4)\%*T+.3+BCFL9W(9/4P%=6NF.]YO&F6:@]%E03E
MP "B&AQ.=UGT8(.>X+5CGNRY*1$(74[2\NSOX+2GC#B%N]^<"';K29MI'87T
M'&^X^5YD?&KB]6"1_N5A7I/4@:SO/K%6%HTQ@71.%NTU>WP8S[2N?1,<YX !
MW70N&+>6LN.^_)']I6?E?A2OX_XD-_1$7C/4$1$!$1 (!!! (/<5"5.D[#4S
MF:>U4CI"<D]F!GX*;12K>U/NSI"^.E^UXVLTE+!1PB*EACAB'1D;0T?4KR(H
MS.^\I1$1&H%J>C=#4.E;SJ"Y4534S2WFH])F;*6\K'9<<-P!MZQZY6V(CHM/
M.@:"+7_[K;?5U5#721]G50PEO950\7@CKTW!'1;@B##O-JH;U;9[?=:6*JHY
MV\LD4K<@_P#/S[ERJ3@'8XI"+7?M1VVF+LFGIZS#/K&5V%$&I:#X>V#1#)S9
M:9YJI\=M53O[263R+CW>04WJ*Q6W4=JFMUZHXJNCE'K1R#H?$'J#YC=22(..
M#@#9(W&.DU!J2FH2=Z2.L CQX?1Z*=?P?TW'36"GMS9Z&.T58K6F(@NJ)-MY
M'$$GIY+HR("Y;J+@CIRZ7:HN=NJKG8ZNH.93;9^R:XYR3RX.,^6RZDB#F%#P
M4TW2VNYT\D]QJZVO@-.^X5<PEFC:>O(2,-^"WG2=C@TUIRWV:DEEE@HXA$Q\
MN.9P'>< !2R(-$UUPKTYK"N9<*R.HH[HP "LHI.RD..F=L'V]5K]MX#Z=BKH
M*F\7&]7SL7<S(KA4\\?O  R/)=;1!0R*-D(B8QC8@WE# , #PQX+EMZX&Z9K
M+A/6VJINEBJ)R7/^;:CLVG)R?5(./8-EU5$'.=(<'M-Z=NC+I*ZMN]SC(,=3
M<INU=&?%HP #YJ=UWH*P:WIHH[]1]I)#GLIXW%DD>?!P[O([+:40<<' .TY[
M-^I]4/H^GHQK1R%OA]'HNCZ.TK:-(6=EML-(VGIP2YQZOD<?PG.ZDJ<1 6HZ
MPT)0:HU'IZ\5E550SV65TL+(BWE>26GUL@G\$=,+;D0%JFB-#T.D:^^55#4U
M,S[M5.JY1,6X8XDG#< ;;]^5M:(-1N.A*"NXAVW5\M55-KJ& P,A:6]FX$.&
M3MG/KGO6W(B#E=]X&Z7K[C-7VR:Y6.JE.7&VU'9MR>IY<''NV7MAX(:=M]TI
M[A<ZV[7RHIW!\0N51VC&D=/5P ?>NIH@MSP15%-)3S1M?!(PL>QPR'-(P1CP
MPN1OX Z=;4R>@W>_T-!(XN=0T]7RQ'/=TSCWKL"(+-%3,HZ."FAYC%"QL;>=
MQ<< 8&2=RKR(@X?\I(9O'#T'<&[M_2:IR]\#].UMPGK+36W:Q23N+Y66VI[-
MCB>_E(('NV6YZLT?:=4SVN:[Q22/MLXJ*<LD+</!&YQUZ!;"@T'0O"G3FD*]
M]QIF5%?='C!K*Z3M9&^);M@'SZK<[O;:.[VVHM]SIXZFCJ&%DD4@R'!9:(..
MMX!62&0MH=0ZEHZ(G/HL-9AGZ*GJ+A#IRW7/3U;;!44CK-(^5C6N#O2'NQET
MKB"2=AWA=$1!I^O>'&G-;B-][I'>EQ#ECJH'\DK1UQGO&_0Y6F#@':7N+*K4
MVIZFC/6FDK1R$>!]7HNQH@UZVZ+L%NTH[3=/;8/F=["R2!PSVF>I<>I.=\]5
MS^7@#8(I'FS7O4-IB<<]E2UF&_6"?K7840:'H;A7I[2%Q=<Z055;=7-+365T
MO:R 'KCN&?'JM\1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0<RNG\:UGYUWVE83CU6==-[I6?G7?:5A/"]2OAY%O,O&G9"5X 5X5)%5G9
M4D@JG*92!4O1N0K>5?IF\T@\%RTZA*D;G29I?N5"_P 2%J=R<3([VK8JJ7EB
M#1MMA:]<6YW"\#FVW+[W[)ITTA%/[UXSH5[)U*H:5Y;WX\+,QW5O*O2M6.=E
M7*ZOA5S+T%6UZ"N.Z7 56"K0581&87 Y7&.5EJN!(0E>:Y595EI58*G5"87
M<+T%4 IE21TN!V%D0OWZK#RKL3MUR?"-J]DES>KE4]OU!5N-^V%9F[R%R)VI
MBG?4LIL@SG*NB3(4:V3INKT;U=CB"U&?'(0>JEK;5<D@).R@ ]9,$_*4OCWX
M9\F/JC3>FUD;H_6QG'58HN$;,AKEJ[ZUQ;C*L&H<3U6+)PYM.YEBKP8]V\Q5
M\+\;X)2Y!LU(YC<.<X+3(:ES3U4G3USFC=RKPTMCMM3?@],[JUZ^6=S"7!N
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MLRX85E63-,:9LHR C&9*NR,(&P7D33G?"T1#%OLRJ> 'KT63*P10DA6H'AN
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!S"ZG_ +4K<_\
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M=^:5QR=^_&PSY+<T!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g73463g00n12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g00n12.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1< 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %N,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"C_P  1" -@!VP# 2(  A$! Q$!_\0 '  !  $% 0$
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M2HHKJ6^UENU%:Z*GX7!J2T/W-R>;L<CE>7:HU7%6U!H*>C=1M)+'/QG;CO\
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M)RM:VNBY5N:Q/A,8;5$18.H1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$)P.:
MB#GT1 1$0$1$!$1 1$0$1$!$0D#J4!$1 1,C.,C*("(B B(@(B("(B B$X'-
M <]$!$1 1$0$1$!$1 1$043&01.,(:Z3'JAQP"?-5CS5$[=\+VB1T9(QO;C+
M?/FJQT\4!$1 1$0$1$!$1 1$0$1$!$0D#J<("(B B(@(B("(B B("#T.4!$1
M 1$0$1$!$1 1$0%0YKS,QPDPP @LQ](\L'/E_%5JR_@^F1;O]?L=LZ].6?X(
M+R(B B(@(B("(B B(@(B("(B B(@(B("(F1G&>: B(@(B("(B B(@(B("(B
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M2C[RRX7/Y"CA>XN^^<7'(9.,<_:NLKG%IM&I[-5U<M!2TY$[N?$>T\@3CO\
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M.[G'A/\ I*]-DNT_;B2233LR3_5"BEPD>.U"C8'NV;!ZN>7T'*1Z.JHJK3=
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MB% *'^E2K_JG_ %GLG"Y_P#F6NWSK:__ %'W8&M:ZLH=:":B>_?%$Q^T$X(
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M*KJI'-!&U[A@Y'L4D1%G<N57)S7.9:VK-%FG=MQB!$14:B(B K+N#Z8S+O\
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MUWTN#T9M1Q!P78P[![SA7'31MF9$YV)'@EH\<=5Q[YZW_P#+O[F/[*?/6_\
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MF.F?$'??&@$C'0'I^Y4"JA-.^??]Z9G<<'ECJN0_/6__ )?_ ',?V4^>M_\
MR_\ N8_LIV5>\8]_P=N;/Y9]OR[ ^:-AC#G8,APWD>9QE>B9AF=$'??&@.(Q
MW%<>^>M__+Q^IC^RGSUO_P"7?W,?V4[*O>,>_P"#MS9_+/M^77A4PF&24/\
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M"9L1)XC@7 8/0>?O7C)F/=(&DDQG#N1Y'&?>N/\ SUO_ .7_ -S']E/GK?\
M\N_N8_LIV5>\8]_PCMS9_+/M^77O2H?1V3[CPGXVG:>\X'+JJW2L;,R(D[W
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MR)_^RX_\];_^7?W,?V4^>M__ "_^YC^RG95[QCW_  =N;/Y9]OR["V9CIGQ
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M (.W-G\L^WY=?-1&(XGG=MD(#?5/?TR.[WKTRMXO!!(D+=P]4XQTZ]/<N/\
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MX]7AG=UQTZJ\B"AT@;*R/:\EP)R&D@8\3W(R0.DD9M>-F.9;@'V'O5:(+/I
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MYIPX =3@K/M-TH;O2BIM=7!509QOB>' 'P/@5">RBW4!9?*[9'+7&YU,;W.
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M@8'((O,[1M%5^K>J>RV39:-EHW*/G/B(B+!U"(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H3?+1J&+6_RY88;;.QU
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M_$?+R[UTL<A@(!@8'1%YG:-HJOU;U3V6R;+1LM&Y1\Y\1$18.H1$0$1$!$1
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M3(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(*)A(8GB%S6R$':
M7#(!\PH5VK9^1J+/7C\_T2IG5</T:7C/,<6T[G!VW \<]RAG:KCY%H<'(X_(
M_P#25U;#_GI</ZE_Q:_[WN8HB+U#Q(B(@+Q>H@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+Q>H@(B("(B B(@(B("(B
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M&HDX-PA?1.B@>P@X?@<@YIQSY<EL==SG0]S^<]NX;HZPB&MHB[;QW8.R1O\
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MZ-K6TKF-#@>;LMSS5HIF8F8[E:JXIF(GO;%%KK]<'6RW^D,C;(>(QFTG'TG
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M;';AGP/<G5;WDGD==V?SQS2M%%7:TL3N'_I<XV'/)CN?M\5Z-:6(3&3TN;)
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MN:8\##<<P>_F@K16@V;@O'$9Q3G:[;R'AD953A(>'M>T8/KY;G(\N?)!6BH
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M%Z@(B("(B B(@(B("(B B(@(B("(B B(@+Q>H@(B("(B B(@(B("(B O%ZB
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M&;OCVG<W;G([QCO6MU-CYL7':,-]&=@8QCDM+7\Z?C#*_P#XZOA+AZ(B]<\
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M16[2U9/=JN1Y$U06[6O<X@-8P?'GSZ]4$P[9ZRH;IC1U&UY%*^C$KF]SGAC
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M.SNMTQJFKNM36T\T4T;V!D8<"-S@>_V((3>X===H\]-25=H-OHX7[OOD;HF
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MD!SG'Q)Z!;C3LENF%T%#05,3A0R[GOGWMQCH1M"CMKNM3;>*V#A/BE $D4S
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M=$_9A;KIZ.:*N^8]L_E*:[C/M,]+')$[4 IV^E;1Z[H1GU >]P&,^*T6AO\
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M:N5H9),&C<YHZ GR7CZ"D?<(ZYU/$:R-AC;,6C>UIZ@'P62B 1D8/1:9NE;
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M'J+EMCU!J.YW*C!RZF 9#')Y.V#)'O6+VPPQP:(@AA8UD4=93,8QHP&M#P
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M]>;E/W/;O^-H_P!8[[*?<]N_XVC_ %COLKJR)VG?]#L;9O7FY3]SV[_C:/\
M6.^RGW/;O^-H_P!8[[*ZLB=IW_0[&V;UYN4_<]N_XVC_ %COLI]SV[_C:/\
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M=^%JX+345ND."V)XGBK'SMC<2POQ(XXSW9!Y%6Q3VN=HA;07Q\S_ %70N=*
M/'+B=N/>NF+5N)F..L\N<<W%5>O3$3G&D>FO?W3GX)%<;I,*R*AM<,<]7(SB
METCB(XV=Q..?/N 7E#<JMEP90W:"&.:5I=#+"XEDF.HY\P0M1>[1%3W6*K?3
MU<M#P&P.%,]V^+:3@X!RX<\*[9*.W37-DM+27+[R"X3U+GAH)Y8 <<GEGN5-
MRWT>8\/?G]FD7+W2XG37AGN^&/?++BNERN3Y7V>GI?1(WE@EJ7N'%(Y': .F
M>\K&TS4R56H[T^>!T$P;"Q\9.<$ ]#WA>6BL=8*8VVOI:IPB<XQ30PND;(TN
M)'3H>?0JYIIU5/?[Q4U5+)3-E;$8VO'X(!QGNSXCN4U4Q337B-,:3XZQ_?1%
M-4U5V\U3G.L>&D\ONKUZ:H:=JO1^#P2S$V\G=C(^CC^*]%?5VN@C-934LE3,
MYL--%2Y&\X_")Z+(UE&^73->R)CGO+!AK1DGUAW*W?:6H=%;:VEB,TM#()#"
M#@O:6D. \^:K;FF;=--7C/TAI=BJF[573GA'UG/*-5$]TNEL:RHNU-2&C+@U
M[Z=[BZ+)P"01S'L5R\7>KIKM24-!31SOJ8G/:7.P&D$<R?#!/[%A7BO=?*!]
MMM]'5[ZC#9))H3&V)N>9)/4^069)3O9JNVEK'F*.CD87X. =S, GQY)%-,8F
MNG773Y:*S77.8HJF8_;K\9U]FXI./Z-'Z9PA/CU^%G;GRSS6EMIQJF_'KB.#
M_"5OUHJ"*1NI+X\QO#'QPAKBTX=AIS@]ZQMSI7\/O#INQB:/C]I8M'>Y([);
M*WT:"*EEFX4S6# C!<0'#RSC/M6UOEP?0T\(IF-DJJB5L,+7="3U)\@ 2M;I
MRW^DZ-915<;V<5CV.:X8(RX\^?Q5C3<=;77".:YPOC^3HC3LWC&^0G!>/^D#
MGYE;U44;U57EF?GX.:BY=W::?-$?+Q]M8]6?+<Z^JKJBFL\%.YM,=DLU0XAN
M_P"JT#GD*Y0W:62.NBJX&PU](S<]@=N:X$$AS3X'!6AJ;93T%TKG7&"X/IZB
M4S134KI"!GJUS6GD<]ZV%HHZ44MQJ:.DKHB^(QM=4N<72#!Z-)R.?BIJHMQ3
MIZ?WC]E;=V[->)GQTY]V/AKED:<N=QNT,%7)34\%&]O,EQ+W'Q Z 9\>:MZ\
M-4-.U7HW"$6W$Q>2'8R/HX_BL[2K'Q:<MS)&.8]L#06N&"#CO"M:QC?+IJO9
M$QSWE@PUHR3S'<LZ9B-HC$:1/W:U4U3LD[TS,S3]F*:RX6RWT\E3#0[I)H8&
M<$.^BXX.<]ZV>H*Y]LLU561-:]\+=P:[H>>%B:BI)ZFR1>BLWSP/BG;'T+MI
M!PM5J6[.N=@JZ:AH*YTSV>N'P.8& ')Z]3W8&5:BB+DTSCOU]E:[DV::Z<]V
MGQU_\;:]WB:WQ6YT-.)W54@C+!UR6DC'O ]RLRW2YV^:G?=::D]$FE;%NIWN
M+HRXX&[(YCV)>8I'S:?+(WN#*D%^&D[1L=S/@JM;12365K88WR.](B.&M).-
MP\%%$4?MIF./Y3<JN1%=<3/[<8CY+]RNE0VX-M]K@CFJ]G%>Z5VUD;<X!..9
M)\$IZB\D3PSTE*V=K0Z*9KR8G<^A'T@5B50EM-_EN!@EGHZJ)L<AA:7NB<W.
M#M',@CP6PMET-PJ)!%1U,=,QHQ-,PLW.\ T\_>HFG%,33$3&./K_ 'N6IJFJ
MN8KJF)S.GIW=WSRU&B9+I)2;JAU,^EXLH+BYYDSO/+GRQG]BS*2[0P07FHJ(
MHX8J2H<TF-N"_ ',^).5C:8J30-=;*FFJFU'I$I#A"XL+2XD.W=,85@6R>OM
MVHZ5K3')-6.=$7@@.QM(]W+JM:Z::KE4U:1IRRQMU5TVJ8HUF(GGC@S?3[[Z
M/Z9\GTO QO\ 1^*[C;?;C&?)57/4#8;)1W*BCX\<\L;=F/6P[J!_Q=RH^<4G
MHW#^3*[Y1QMX/!.W=_7^CCSRL*IMD]%IRT4I:Z29E9$^38,@$N)=T[AGJJQ1
M3F-^F(U]O[WIJN58GHZIG3E/]SHS*RZW:W0BLN%'2^@@C>V*1QDC!.,G(P<>
M2D0.0".BTNLXWS:8N$<3'/>Y@PUHR3ZP[EMZ<8@C!Y':/W+"O$T15$8G,_9U
M6]ZFY51,YC$3]?PB=!+>W:GNC&NHB6MBWM<Y^T-(.-H\<=5MZVY5;[BZ@M,$
M4D\30^:29Q$<>>@Y<R2L&6H-IU-<*BHIJJ2&JBBX;H8C)S;D$''0K$NUMC@O
ME16UD%;+1U36$/I7/W1N QAS6G)!'>NG=IKJB9CNC'K.GJXXJKMT3%,Z[TY]
M(S..Z>.C;TEWFCFJ::[0,BJ88C.#"XN9*P=2W//(\"L>AN-[KJ:*MIZ2@--*
M ]L1F=Q-IZ9.,95FR4M$*B:LHJ"XET,1:Q]2YPWYZM:UY\AS(6MJQ2<&0V2B
MNU#<W?0CBC>QF_\ XOP,>*1;HF9B(\/[QT)NW(IB:JO'A.L^VLLZODO U=$R
MG-)SIGF-CW/VENX<W ?A+:UM6^"YV:":&!\LY>'/QG80S)VGNRL*Y/FH;[;[
MA4032PBE=#(Z&,O+7D@]!SQR*N5[G5=WT]4Q0S"/=*YVYA!8"SEN\/>JS$5;
MNFF)^DKQ,T[\1,YWHY9A[57>N-]J+90TL4CV1LD;)(XM:T'.=V/=@#S5ZW7*
MK^4W6ZZ0PQU!BXT<D+B6/;G!Z\P0J:"-XU9=9"QPC=!"&N+3@D;LX*IK(I':
MQM\@C>8A2RM+PTX!);RRJS%$_MQW9^>,KQ-R/WYG^6,>F<*(KK<KE+,;-3TO
MHL3S'QJE[AQ'#KM#1T\U=LMWJ:VZ5M'5TK:=],QA(SNR3GF#WCD"%A6N6HT]
M%)05%!5U$ D<Z":F9OW-)SAPSR(RFG9:BHU1=Y:J P.=##B,D$M;ZV,X[^_W
MJU5NG=JQ$8B-)^<,Z+M6]1$U3F9UC&G"?3EXI0B(N)](1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M'CPXL<&.#7$<B1G!1@<&-#R'. YD#&2J9]G!DXIQ'M.XYQ@=_->P[>$SAG+-
MHVG.<CN05(B("(B#2ZDLLUW;!P+A-1.B).8QU)]A!_\ NJ-,:;@L0F>)75%3
M-].5PQR\ %O46O3U[G1YT8=6M=)TV/W(_JO3GR\ZD/I/ X!<?H;MV<>8\%(&
MC#0/ (BK5<JJIBF>$+TVJ*:ZJXC6>/R$1%1H(B("(B B(@(B("(B B(@(B("
M(B B(@(B("MU,+:BGDA>Y[6O:6DL=M(SX$=%<1(G")C.DM$ZR5[HS ^^51IB
M-I;PV;\>&_&?>MO1TT5'2Q4].W9#$T-:WP 5Y%>JY55&)9T6:*)S'UF?J(B*
MC41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1!IY[35BHEDH;O4T[9';G1O8V5H/\ P[N@\EDVFV,MXF=Q9)ZB
M=V^6:0^L\]W3D .X+/1:3=JF,,J;-%-6]'UD1$6;41$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$3/,#!0$5ILP
M<R5VR0<,D8+>;L>'BAFQ'$_ARG>0,!O-N?$=R"ZBHXGW\1['_1W;L>KUZ9\5
MXV7<)3PY!L)'-OTO9XH+B*T9\11R<.7UR!MV\VY\1W8[U49,3"/8_FTNW8]7
MV9\4%:*VR7=Q/4>-AQS;C=R[O%4\?[PR3A2^MCU=OK#/B$%Y%09,3-CV/.03
MN ]48[B?%&2[G2#8\;#C)&-W+/+Q05HK/'_T=LO"E];'J;?6&3WA5NDQ*R/:
M\[@3N Y#'B4%:*ADFY\C=CQL.,D8#N7=XJCTC_1A-PI>>/4V^L.>.B"\BH=)
MME8S8\[L^L!R&/$]R,DW22,VO&S',C .?#Q05HK/I'^C<;A3?U-OK=<=%6^3
M;)&S8\[\\P.0QX^""M%0R3=*]FQXV8]8CD<^![U1Z1_HQFX4W+\#;ZW7'1!>
M14/DVOC;L>=Y(R!D-Y=_@C9-TKX]CQM .XCD<^!05HK/I'^CNFX4OJY]3;ZQ
MP>X*M\FUT;=CSO.,@<F\L\_!!6BH;)F9T>QXV@'<1ZISX'W*CC_Z.^7A2^KG
MU-OK''@$%Y%;?+M=&-CSO.,AN=O+//P7HDS,Z/8\;6AVXCU3GN!\>2"M%9X_
MWB27A2^IGU=OK''@._/<JGR[3%ZDAXAQR;]'EGGX(+B*@29F,>Q_)H=NQZI\
ML^*I$_WF23A2^H3ZNWUG8\!Y]R"ZBMNEVB(\.0[R!R'T>74^"]$GWXQ['\F[
MMV/5]F?%!6BM";,<C^%*-A(VEO-V/#Q7KIL-B/#D.\@8 YMSX^""XBHXGW[A
M['_1W;L>K[,^*\;-EDCN'(-A(P6\W8\/%!<16C-B.-W#D.\@8#>;<^/@JN)]
M^$>Q_-N[=CU?9GQ0>R$B-Q#2\@?1'?Y+V,ES&DM+21G:>[R5HRN?'-L8]CV9
M +F]3CJ!WA>-F<*>)[XY'.=M! ;@@GO([D%]%09,3-CV/YM+MV/5'EGQ7C)=
MQD]1XV'',?2Y=WB@N(K/'^\,DX4OK8]3;ZPSXA5F3$S8]CSN!.X#U1CN)05H
MJ&2;G2#8\;#C)'TN7<J./_H[9>%+ZV/4V^L,GO""\BH=)MF9'L>=P)W <ACQ
M*,DW/D;L>-AQDCD[EW(*T5GTC_1A-P9N>/4V^MUQT5;I-LK&;'G?GU@.0QXH
M*T5#)-TDC-CQLQZQ')V?!4>D?Z-QN#-_R]OK]<=$%Y%0^3;+&S8\[\^L!R;C
MQ1DFZ61FQXV8]8CD[/@@K16?2/\ 1C-P9O\ E[?7ZXZ*M\FV2-FQYWY]8#DW
M [T%:*ALFZ5[-CQM ]8CD<^"HXY]&=-P9LC/WO;ZQYXZ907D5#Y-KXV['NWG
M&0.3>7>C9,RO9L>-H!W$<CGP05HK/'/H[I>#+EN?4V^L<'N&56^3:Z,;'NWG
M&0.3>7>@K14"3,SH]CQM .XCU3Y!4<<\!\G"ERW/J8]8X\/:@O(K;Y-IC^]O
M.\XY#Z/+J5Z),S&/8_D =V/5/E[4%:*T)LQ2/X4OJ9]7'-V/#VKUTNUL9X<A
MWD# 'T?,H+B*CB??N'L?]'=OQZOL]JI$V8Y'<*0;"1@CF['A[4%U%;=*0R-W
M"D.\@8 YMSWE>\3[]P]C_H[M^/5]GM05HK;9<ME/#D&PD8(YNQX+PS$11OX4
MIWD#:!S;GQ]B"ZBH,GWX1['\V[M^/5]GM7C)=W$^]R#8<<Q]+S""XBM&<\&.
M3@R^OCU,>LW/C[.]5&3$S8]CSD$[\>J/+VH*T5MDFXR#AO;L..8^ERZA4\<\
M!DO!ER['J8]89\1GN[T%Y%09,3-CV/.X$[@/5&.XHR3<Z0<-[=AQDCZ7+/)!
M6BL\<^CLEX,N78]3'K#)[QGN5;I,3,9L>=P)W <ACQ05HJ&2;GR-V/;L.,D<
MG<NY4<<^C-FX$V3C[W@;AD^&4%Y%0Z0ME8S8\AP/K <FX\49(722-X;V[,>L
M1R=R[D%:*SQSZ,)N!-G\7@;NN/'^*K=(6RL9L>0[/K <FX\4%:*ADA=)(S8\
M;,>L1R=GP5''/HW&X$V?Q>!NZ^U!>14/D+9(V['NW9]8#DWVHV0NE>S8\!N/
M6(Y.SX(*T5GCGT=TO!ER,_>\#<>?M5;Y"U\;>&]V\XR!R;R[T%:*ALA,KF;'
M@- .XCD?8J..> ^3@RY;GU,#<<>'/O07D5M\A:8QPWG><<A]'EWKT2$S.CV/
M  !WD>J?(>:"M%9XYX$DG!ERW/J8&YV/#GWJITI;P_O<AWG'(#U>74H+B*@2
M$S&/8_ ;G?CU3Y>U4B8F&1_!E!82-N!EV/#GW]R"ZBMNE(;$>%(=Y P /5SW
MGFO>(>,8]C\;=V_'J^SVH*T5ILQ,<KN%(-A(VD#+L=XY]Z&4AD3N%(=Y P ,
MMSWGGW(+J*CB'C\/8_&W=OQZO7I[52V4EDKN%(-A(P0,NQWCGWH+J*T9B(XG
M\*4[R!MP,MSX\^[O57$/&$>Q^-N[?CU>O3VH*T5MLI<)3PI!L)&"!ZWF%YQC
MP8WB&3+\99@9;GQY]W>@NHJ"\B81['X+<[^6!Y>U>,D+N)F-[=AP,X];EU""
MXBM<9W!9)P9,NQEG+<W/CS[E47D3-9L>003O'0>2"M%0R0N,@,;V[#@$X];E
MU"IXSN R3@R9=CU.6X9\>?<@NHJ'/(E:S8X@@G<.@\BC)"YT@,;V[#@$XP[E
MW(*T5GC.]'$G!EW''WOEN'/VX5;GD2L9L>0[/K#&![4%:*ACRZ21I8]H;C#C
MC#O8J.,[T?B\"7=^+Y;NOMP@O(J'/+9&-V/(=G+AT;[4:\NE>PL< W&''H[V
M(*T5GC.]',O EW#_ ,/EN//VX5;Y"U\;>&]P=U(QAOM05HJ&O)E>S8\!H!#C
MT=GP5'&=Z.Z7@2[AG[WRW'![N>$%Y%0^0M=&.&]V\X)&,-Y=Z->3,YG#> T
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M>S^*HXK_ $=TG ?O&<1Y&3@^W'-!>14/>X.C C<X.."01ZO+J4#W&5S#&X-
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M,9#  0_(P3X8ZJGB2<%[^ [>W.&;AEV.G/..:"ZBMN>\</$1=N.'<QZOG_\
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MJ<0QEZKDL#XZF2#&Z1CBP[>>2#CE\%;4Q)C BS+E;WV]\+9)8)#+&)1PG[L
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M\A^SGGGO; T,[6;*YH <64Q)'4GBN4^[4.T"#2E(:6C+)KQ*WU(SS$0^N[^
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MGFG]/:.J+A:X)F5,<D;6ETSG#!< >15'95V?V#4>D8J^Z4\SZETKV%S)G-&
M>7(*8]NG]'5;_P V'_&%;[!OZ/X?^?+_ (D$]H::.BHX*6 $10L$; 3DX P%
MK-4Z:MNIZ**EN\;Y(8Y.(T,>6G=@CJ/:5$-9Z!OE\U#45]!J:6@IY&L#:=N_
M#<- /1P',C*VUJJ*?0.F:*FU1>>/(^=T;:EX<2XN)(SDDX [^B#BG:#:M/T^
MI8;#I>$1SLE$=14U%00QK^FW+C@ =Y\>07?M#:?I=,:;IZ"EE$K1F22;/)[S
MU</ ?P7-.T:P:'EM%WO-+<X3=)MT[.%6"3B2$YQLR>1)[NBT^C/G+<NR>Y4%
MC9+,75@A9AP!;$6Y>UI)Y#./TB@OZRNU7VE:R@T]99"+13/)?,/HG')TI\AT
M;XY\UUK1M3I]ENCM>FZVEGBHV %D,@<1G\)V.\G*XWI6U:_TC2U0MEC@:)O6
MEDE#7.( Z9W]!SY+3=D]5J2GO%4=,4L=07\,5>\ [8]W49(\_%!G:JBIW]L5
M2W6KYH[8Z8D..0.#@\/!'/;TSCS\U@:_I]/1:@MK>SZ1\DSOI-IWO>!)N&S8
M3SS[#X+,HWT5^[6*QFN*@LIVRRL:V60L8TM<=C"<^JW&?;[U=[6J'3-EK+;/
MI"ICBK<ET@I)R]K,8VNSD[3GS03?MXMCZK0]!73-'I5'*SB.\GC#A^EM^"E_
M9A<GW70MHJ97%THAX3R>\L);G]BB_:/6SU'8O'/<F[:RHBIB\$8.\N:3R]Q6
MS[#8WQ]G-!OSZTDKAGPWE!.Y<&-^YVUN#EP.,>>5!^U+ L5O#7E[>,,.)SGU
M#SRIQ(0(W$M+A@Y:!G/DH/VID&QT!:TL!F&&D8(]0\EU;#_GI</ZE_Q:_P"]
M[F2]1%ZAXE,=,5D%)I:I;6,#Z2HK!#-XAI9U'L(!4;NUNEMMQEI)/6+3ZCA^
M&T]"/:MC#_,>H_M[?\!65;+M1&@AGN#=]PMS=M,".4H/T0?ZIY^Q<=.:*JJZ
M8SF?]/HU;MVBBW5.,1F)^L?>/_6SH6QVRS72U- -3Z ^>J?X/(&UGN!Y^947
MM=!%56N[5$A=Q*6-CX\'EDNP<K.TY*^=M_EE<72/H97.<>\DA>:4:*JFN]O8
MYHJ*J "$..-SFNSM]I41$VXJG.N8S]UIF+LT1C3%41'/'SS[M-;H6U%PIH9,
M[))6L..N"<+=VRF91Z[AIH=W#BK-C=QR<!RIL-BN'RO3/J::6FAAF8Y\DS2Q
MHP[ID]2>G)9$7](__P#OG_$KW+D535$3_P!996;4TQ355&)WH7]*.I!K&1L\
M4KJDU,O#<UP#6CULY&.:T%UDMSR/DZ"HB<''>99 X'V8 6ST_(R+73'2.#6^
MDRC)\3N _:5JKA:JZB,KZJDFBC:_:7N80W//H>]*(B+N9GNCO^)755-C$1WS
MW?!>U#016^>E9 78EI8YG;CGUG Y]RVUZM5FLM88ZI]5.YX#F0Q. VMP.;G$
M=2<\@L/67^UV_P#L$/[BMGK:RU<]WDJZ.-U4QS6![8AN=&[:.1 Y],'/FJ17
MG<BJK&8G[-)MQ'2313F8F/EQ:FNMM%-;'W"SRS&.)P;/!/C?'GH01U!5RZ_S
M1L7]>?\ Q!7X::6R:>N#J\<*HKFLBA@=]/ .2XCN'M5BZ_S1L/\ 7G_Q!3%6
M9C7,15IRE6JF*::IQB9IUC_^H^VI);[;:H86W<U,U9*P2&&!P:(FGIN)[U8N
M5OI3;VW&U22OI=_#ECFQOB=W9QR(/BI'=JNLK!'<+5;J*NII6-W'T8221O P
M6N[^[X+47FJND5H,590TE'3U3AZK(1&]VTY!(ZX]H5;===4Q.=>_7[+WK=NF
M*HB-(C2<<ISZHTO41=SY@B(@(B("\7J("(B B(@(B("(B B(@*6Z)U6^TR"D
MKG.?0./(]3$?$>7DHDBSNVJ;M,T5\&UB_78KBY1.KZ$BD9+&V2)S7L<,M<TY
M!"J7)M$ZK?:9&TE:YSZ!QY'J8CXCR\EU>*1DL;9(W!['#+7-.01XKS6T[-5L
M]6)X=TO9;'ME&UT;U/'OA4B(N9V"(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(!YCFH'?.RG2]UJ7S^C34<KS
MEQI9-@)_JD$#W!3.Y5U-;*&:LKYF04T+=SY'GD!_\[E&8=57>OC%1:-*U<]$
MX99+45#*=T@\6L.3@^>$%G3O9EIJQU,=3#2/J:F,Y9)5/W[3X@8#<^>%L+_H
MFS7V\TUTN,4KZNG#1&YLI:!M<7#D/,K.T[>_EB.H$M!64%33/#)8*EF""1D8
M<,M<,=X*QM$7FHO=HFJJP1-D;5S0 1@@;6/+1U)YX""#=H?:4ZV5UUL,EADJ
M(WQ&*.24N8V3<W!]7'-O/N/-5]A&D:FST-5=[G ^&JJP(X8WC#FQ#F21W9./
M< NJN8UQ!<T$CID('#E@CGT0<A_E',>^T6;8USL5#^@S^"LZR]ENFKM8K175
M--413RTD+Y1%*6M>XL&21W>["ZAEKCCD<=RT&I+Q46R[:?I:=L1CKZLP2[@2
M0T,<[ESY'("#-LEAMUCMGH%KIF4]-SR&]7$]22>9/F5KM):*LVE):F2S12QN
MJ&M:_?*7Y#<XZ^TJ1AP)P""5Z@C5^T39KY>J>ZW"*5]9 &!CFREH&UQ<.0\R
ML34/9UI_4%UEN-R@G?4R!H<63.:.0P.0657ZCKQ<:FCLVGZRO=3$-DFD>VGB
MR1G#7.YNY$=!CS5[3NI?E.X5-MKJ">VW2G8)74\K@\.83@/:X<B,\D$>^Y!I
M/\FJO_WARVUWT!8;M;;;0UD,SJ>WQF. -E((:<=3W] I6M!:KQ456KK[;)1&
M*>ACIW1D [CO:XG)SY(([]R#2?Y-5?\ [PY2+3&D+)IGB.L]$V*608=*YQ>\
MCPR>@\@M^"".1!]B9&>H00V^]FVG;Y=:BXW""=U5.07ELSF@X  Y>P!8'W(-
M)_DU5_\ O#ET'(QG/)> @]"#[$$.O_9KIN]R\:II'Q5&T-,T$A8YV!@$]Q/F
M0M=:^Q_2]#4MFD95UA:<AE3*"WWAH&?85T/(SC/-> @]"#[$&DU1I:UZEH(*
M.Z1/-/ _?&V-Y9@X([N[!4:'9!I/\EJ?_P!X<N@;AG&1GP7J#1Z:TI9=-L>+
M/0QP/?R=(27/</#<>>/);Q>!P/0@^Q>H"+3ZKO8L%J%:Z S@SQ0[ _;]-X;G
M.#TSE;A 11^_ZD^3;C!;*&@J+E=)HS,*>$M:&,!QO>YW)HSR[U1;+[=I:^&F
MNFFJJC;*2&SQSLGC;@$^L1@MZ>"#ENO8)M(=K=OU!'&_T&J>V1Y8TGNV2#VX
M.?>NCZCT#IS5$WIU92N%1*T'TB!Y8YPQR)[CR\0JKWJ>NIM3FR6NR?*,[:5M
M6YQJFQ -+BW'-I\/VJU/JVZ6V,SWW3%72T+?IU%/4,J!&/%S1@X\P"@U=N['
M=+T=0V61M;5[3D,J)AM]X:T94KU'IBUZAM4-NN,+O1(7M>QD3MFT@$#&.[!Z
M+:455!74D-51RLFIYFA\<C#D.![PKR#!L5JI;):J>W6]KFTL (8'.W$9)/7V
MDK.1$&LU'8Z+4-JDMUS8]],]S7.#'%IR#D<PO--6&ATY;&V^UL>RF:XO >\N
M.3UYE;1$!:/5.E;1JB"**\TW&X1)C>UY:YF>N"/8%O$0<UA[&-+QSB1S[C(W
M/^K=.-O[&@_M70+7;J2U4,5';J>.GIHAAL;!@#_,^:RD04RL;)&^-_T7 M/L
M*CNE-%V?2T]3-:(I6/J&AK]\I?D DCK[5)$01+579[I_4M4:JOIGQU9 #IJ=
M^QSO;U!]I"UUD[)M,6JKCJ.#45DD;MS?2I YH/\ 5  /ORI\B#CO;]7RUGR3
MIRWQ22U$LHF<U@)\6L;[R2?<%TW2EJ%CTY;K;D.--"V-Q'>[',_'*VN!G.!E
M$'C]VQVS&_'+/3*@_:IN^1*#B8W\?UMO3.T]%-Y #&X%Q:,'+@<8\U!^U( 6
M.W@.+P)AAQ.<^H>:ZMA_STN']2_XM?\ >]S-$7B]0\2K$CQ$8M[N&3NV9.,^
M./%4K91V^-VGI;@7OXC*EL(;RQ@MSGVK7!IP#@X)QG"K35$YPO5353C/>]CD
MDC#A&][0\;7;21N'@?)4@D$$'!'/(53F/9])KF^T85*M&%=5^2MJI=O%J9W[
M3ENZ0G!\1DJV)I>-QN(_BYW;]QW9\<^*]9$X2,WL<&EP',8RMQ>Z>CM^JI81
M3EU''(S,+7');@$@'JL]ZF)W8CN:Q355&],]\1SS^&C+BYQ<XDN)R23S)5V>
MJJ*AK1//+*&] ]Y=CXJJN="^LG=2Q.A@+SLC<<EH\%:$;RW<&.V^..2O&)Q,
ML]8F8B22224@RO>\@!H+B3@#H%N=2W,3WZHJK;4R"-[&-#V%S"<- /@>H6D'
M/HJG1O:,N8X#S"K-$3,3/]_N%J;E44S3'?B>6?R2RR3/+Y7OD>>KG')/O*.D
MD=&V-SWF-F=K23@9ZX'<LRS6R6Z5@IX2&DM<[<X''($_P6&6.9C>QP!\1A3$
MTYW?!$TU8WIX2J@J)J<EU/-)$3R)C<6D_!>2RR3/+YI'R//X3W$GXE95WDI)
M:PNH*9]-#M:.&]VXYQS*Q&QO<"6L<0.\!*<3&]C!5$Q.Y$YA2B*H1O+MH8[/
MACFK*J47KFEI(<"#X$+UC'/SL:YWL&4,=RE$(()!!!1$"(B B(@+Q>H@(B("
M(B B(@(B("ENB=5NM,C:2M<74#CR/4Q'Q'EY*)+H.A=([N'<KK'RY.AA<.O@
MYW\ N7;*K46IZ7@[OT^B]5>CH./MCU=$8X/8US2"TC(([PO41>7>V$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MRROA=O;"-V!N(Y G/3R*ZD@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MM;?+%;+[#'%=J..I9&=S-V06GOP1S"V2(,6UVZDM5%'26ZGCIZ:/Z,<8P!_[
M^:\J;=25-=25D\(?4TF[@/R?4W##OB/%9:("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@ID&8W#<6Y!]8=WFH/V
MIC%CH '%^)@-QZGU3S4XEV\)^]NYN#EN,Y'L4'[4=OR%;]C=K.,,-QC V'EC
MN75L/^>EP_J7_%K_ +WN9HB\7J'B7J+Q>H"(B B(@(O%Z$!$1 1>+U!XO41
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M'<,=R"M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M>OV:JXV9M35^ETU3/1U>W8Z2$CUQW!P/(JNUVB.AGEJ7S35-7* UTTQR<>
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M$0$1$!$1 1$" B(@(B("(B B(@(B("(B $1$!$1 1$0$1$!$1 1$0$1$!$1
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MP'BN:7_MGIJ>HDBLMO-5&TXX\S]C7>QN,X]I'L0=<1<2H.VVHW_Z9:()(_\
M^1,6D?$%=:TU>8;_ &6FN=+%-%%."0R5N'#!P?VCJ@V:(B B(@(B("(B B+B
M.HM>ZBH^T.IM=/7-90LK60MCX$9PPEN1DMSWGO4#MR+T]2M=J&IEH[!<JFG=
MMFAII)&.P#AP:2#@^84C8(N0]D6M+[J+4D])=ZQL].VE=(&B%C/6#FC.6@'O
M*Z\@(B("(B B(@(B("(B B(@(B("+UHR1GQ7#[/KW451VBPVJ:N:ZA=<74YC
MX$8]0/(QG;GH.N4';PB(@(O0,D+E=G[78*O4$5OKK:VD@?*834<?<&G. 2-H
MY9\^64'4T16JRIAHZ6:IJGB."%ADD>>C6@9)0747,M*]J@O^IZ:U1VK@QU#W
MM;,9\D -<X';M[\>*Z:@(B("*+]IEVK+'HVMK[9*(JJ-T8:\L#L9> >1!'0K
M1=C6IKKJ2ENS[S4B=T#XVQD1-9@$.S]$#/0(.BA%#K[VC6&R7>>VUSJOTJ$M
M#MD.YO, CGGP(4Q" BX)JJT:VEU_/+2MN#GNJ":6>)Q$3(\^J-W1H QD'S7>
M8MXB8)""_ W$>/>@J1$0$6IU;63V_3%UK*1^RH@IGR1NP#AP'(X/(KGW8]K"
M]ZCO5?3WBK;/%%3\1@$+&8=N SEH'<4'5T1$!$1 1$0$1$!$1 1$0$1$!$7-
M^V75%VTU%:#9JEL!J'2B3,3'YVAN/I XZE!TA%#M%W.[7[LZ;6NG8^[S13".
M4M:T;PYP;R P.@7/>S&TZNIM;1RU\=PBI07>F.J7.V2#:<=>3CG&",J!W-$1
M2"(N>=M%'?JRR4K;$)Y(&O=Z5%3YWO&!MY#F1UR/8@Z&B@G8[27NCTU*R_\
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M\SMEK(<31OVM:7,/(C  '(X_26Q[7-63Z9LD#;;,([C4R8C):';6-YN.",>
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MT.G^STO^)BCW\G:GC)OE06-,K>#&UV.8!W$CWX'P01^77FN-/W!@O!E!=Z_
MJZ<-#VY[L 'X%=JL5[@U%I5MSIFEC9HG;F$Y+'#(+?<5!_Y0D;#IVV2%HXC:
MLM#N\ L=D?L'P61V)$GLZJP>ZIFQ^@U!SSL4_I"H_P#E3?X"NJ]I6OH]*,CI
M:2%E3<YF[FM>?4C;S&YV.9Y]!^U<J[%/Z0Z3_E3?X"L;M:W_ '1KGZ3NV;HL
M?U-C>G[4&VI]5=HMR@]/HVULE*.8?#1M+,#P]7G^U2?LZ[4IKE<8;7J%D;9I
MG;(:E@V@N[FN;T&?$8]BZI0"G;10"AV"E$;>%P_H[,<L>6%\U=I @;VBW(6H
M#''9CA_C<#=CSW9]Z#MG:+K:#2-%&&QMJ+A/GA0EV !WN=Y?O7+:;5_:'>V/
MJ[:VJDIVN/.FHP6#RS@Y^)6+VW>D?/=WI&=OHT7#SX8.<?\ 5N7>-*BE;INU
MBW[?1/1H^'MZ8VA!S?LV[2+C<[TRS7^#B32$M9/''M<UP[GM'+'GRQWJ"]KG
M])-S_K0_]MB^B:**W,K:Q]$VE%6YX]),6W?NP,;\<\XQU7SIVODCM%NI'4<+
M_MM0=E[0]<TFE:$Q1%D]VD8#%!GZ(/X;_ >7?^U1KLRN>LM35(K:^Y<*SQNY
MGT>,&<@_1;ZO3Q/\>G'K@ZO?5PW.[PS3>ENXP?."!. <'!\.6.2^G=%7>W7K
M3M+46AC(J=K1&8&\N"0/H8\OV]4'/^T;M(N-!?7V33D;1/$YL<DQ9O<YY_!8
MWIW@=#S6G-Q[4Z1GI,D%8]F,EO C?@?U0,A;'M$[-[K5:AGO>GI&ROF>)71;
M]DC)!WM)Y=V>H*T]1JKM$TP&S7F*5U/NVYJ8&N83X;V_YH.P:+K+G<--457>
MXHXJV9N]S&-+<-)]7(/0D8/O6[49[/=5,U;8S6<$05$3^%-&#D!V <@^!!4F
M4C@^J.T;4-IUI<::*K:^AI:LM$!B8,L!^CNVY]ZL3:M[0Z^G=<Z:&KCH.;VN
M@HQPPWQR021YY*C^L!">TZYBKQZ/\I??<]-FX9_9E?3L88(VB+;P\#;MZ8[L
M>2@<J[,NTR>\7&.TWYL?I,O*"HC&W>[ZKATSX$>S"WO:5KZ+2<<=-2Q,J+I,
MW>UCSZL;>8#G8YGF.0\BN,7O@L[2Y_D; C%R;P>'T!WCIY9RLSM=W_='N7I6
MX,W1[?ZFP8Q^U!LZ?5?:+<X#7T0K9*8<P^&C:6>[U>?[5)NSOM2GN-QAM>HV
M1"69VR*J8-H+NYKV]!GQ'?W=ZZI;13MM]**+;Z*(F\'9TV8Y8]V%\U=IC86]
MHMT%N  X[.4?XS:W=C'?NS[T&Z[9:^_5%VFIKG!*RTPU+O0Y'0;6NY=SL>MR
M5K05YUE1VVGIK#1U$MK,YR]E)Q!DD;O6PI?_ "A-WR%9M_TO2'9]NQ;KL,_F
M#%_:9?WA!MM?ZPI](VMLSX^/63$M@@W8W$=23W ?Y+EU%J7M'U#&ZMM3)32@
MG' @8UF1W#=S=\2J?Y0/$^=5#OSPO0QL_3=G^"S=.3]I)L5#\C0TSK=P6B C
M@?0[NISGV\T&PT+VFUS[TVS:LB:R9\G";/LX;F29QM>WIU[^6/W;'MEU5=].
M36EMGJA3B=LIDS&U^=I;CZ0/B5!K]HK75\N;Z^X6Z-U6YK07,EB9G'(' <MU
M_* #Q\W!+_K!%+N]OWO*# IM>ZXO]-'#9*>5[H& 3S4].'N>[GS)QAOD ![T
MT[VHWZU7=M+J7,],'[)FR1!DL7/F1@#IX']BZ3V/4\=/H"VF-H:9=\CR!U<7
MD9/N "Y1VZ1L9KN0M: 7TL3G>9YC/P 03;MJN-\91""V0R262HI=U5*V#<UO
MK<LOQZO+"YAH.XZBMU75NTK32SS/C:)A'3\;#<\N6#CFNUZL)=V05!<<DVV+
M/P:H-_)W_P!\WK^SQ_XR@GUPN]XI.RZ:Z56ZFO,=-Q';X@TL?NQS:1CIY+0]
MC6K+QJ.MND=XJQ.R".-T8$368))S]$#P4I[3_P"8%\_Y'_J"YS_)W_WE?/\
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MGRW)N[AL9%Q"<M(=ZO?RRNP]@/$^:5SWYX?I9V9_J-SC]BYWV0?TCVOVR_\
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MND!>",NSC/7O[EJ^Q?2]XT_6W5]XHG4S)HHVL)>UVX@G/0GQ7544C@]W[/\
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M0R0/C<W>P'/JN:[KR..\$+O"*1PZ_6/M"U7;'.O$3610X=%2-+&&5V<9P#W
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M>W5$] 745+6 NJ ]F"P'Z6,YP>N.J[ZB@<8[7M%WZ\:G976RG=64TD3(P&O
MX1&<C!/0]<^:Z=HRW5-ITM;*"N>'U-/ &2$'(!\,]^.GN6Y12/6\G#VKAFA=
M$ZAMNOJ6X5MM?%1LFD<Z0R,. 0['('/>%W)$$;UOI&BU;00P5CWPRPOW1S,
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MY:<_D[O\2N:8T[V?WR]R4-MJKD9XB'QF20-;-CF=N6YY>!P5;_E#'-\M)_\
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M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1 @(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
,B(@(B("(B B(@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g73463g00n40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g00n40.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1544&AO=&]S:&]P(#,N,  X0DE-! 0
M    %3<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"C_P  1" '_!VP# 2(  A$! Q$!_\0 '0 !  ,! 0$! 0$
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MB2&AL>'=98*:29KJF5ZK\)S$7-J9ZNW=Y.6:YKD']"@
M
M
M
M
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MJKYU363^"$X<T7WFY8MI<4:2;S%=*ZC5'4=%3,U:>!=^>U-N2[?2B9JH&O
M
M
M
M
M                                                           ,
MMQ':-*5)B"X56%[Y9ZNVUDB/CIJ^)6K2IDB9-RSS39U[5S7(Z&C#1]/AJMN5
M\Q%<$NV)[FJ>$52-R;&S_)LSVY;$ZMR;$R-"
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MMI:M%\$J89\M_)O1V7L/L][6-5SW(UJ=*KD@$@^25,"JB)/$JKT:Z'U
M     _$DL<67*2,9GNUER/QX53_Y>+_?0#[ AKFO3-CD<G6BYD@
M JHB*JJB(G2H 'F@N%'42K'3U=/+(W>UDB.5/4BGI  'E;<:)]0L#*RG=.G_
M --)6ZWLS ]0        !#WMC;K/<UK>M5R0"0?'PJG_ ,O%_OH?2.2.1/R;
MVO\ HKF!^@          !^))HHU1))&,5?E.1#\>%4_^7B_WT ^P/FR>&1VK
M'+&YW4UR*I^I)&1HBR/:Q%Z7+D!^@?'PJG_R\7^^A^XY8Y<^3D8_+?JJBY ?
ML        $.<C6JYRHC4VJJ]!\O"J?\ R\7^^@'V!^(YHI%RCD8]?]%R*?L
M           !^721M>C7/:CG;D5=J@?H ^5140TT:R5,T<3$_2D<C4]J@?4'
MRIJF"JCUZ::.9GRHW(Y/X'U          ^2U,"*J+/$BIL5%>@;40N7)LT:K
MU(Y /J              _,DC(VZTCVL;UN7(_2+FF:;4  .5&HJN5$1-ZJ>>
MFKZ2J>YE-503.;O2.1'*GL ]
M    *!IDQ[/@/#]%<*&EIZR6>M92NCE>J(U'-<N>SI\DO<4T<C6Y/8KE3/)%
M/YF]TMH\L]FML=_I):]U=<;LULS9)]:--='N75;ELVIL-2PEH:PWAN]T5XM]
M1=G5=,JN8DU5KL55:J;4RV[%4#2S\NEC:Y$<]J*O0JY&6:9,97>CNEHP=@U6
MIB.\JOY==O@L.U%?EU['+GT(U?,>&FT!V:H@27$5\OUTNKDSEJUJU;F[K1%S
MR]:J!L8,%IZZ_:'L9VJUWF[5-YP9=Y.0@J*MRNDHY-R-5W5N\V6:HB9*;T /
MYHT=T&+=(%YQ;ECV\6N*VW!T,<<:<HBM5S\OTDRRU3^ES"?<Q?G;2)_:W_-(
M!U)-%N-(VJZDTIW=9D^"DM/FWU^6IRW8VQQHQKZ>'2/%#><.S/2-MYI&9/B<
MORT3+V9(J]"KN-V.5BNR4N(\.7&T5[$?3U<+HG9IGJJJ;')YT7)4\Z >^CJH
M*VDAJJ25DU/,Q)(Y&+FCFJF:*BGU<Y&IFY41.M5,>]RS=*BNT;24-2_66UUL
ME)&Y=OD;')[%<I]9M$-=B.X5E5CO%MTN#'RN6"DHY%IX8F9KJ^3M3/++/)$]
M*[P-;8]CTS8YKDZT7,ESFL3-SD:GG7(_GG2#@"JT66=<6:/[U<X4H7L=5T-3
M,LD4T:N1-J;,]JIL7/?FBHJ&@:0+5SD:(4GH$6.MGI([A1*CE16R:NLC<_.B
MJWU@:."AZ$,6^_#1[;ZR=ZNN%,G@E8CE\KE6(B9KZ4R7UGBT_8GFP_@.:EMN
MLZ[W=Z6^D8Q?+UG['.3IV)_%4 TAKFN3-JHJ=:*25W1WAQN%,&VNSH]9)8(D
MY:1=[Y%VN7VJOJR+$ *KC_#5TQ+1TD-GQ+66"2&17OEI6:RRHJ9:J[4]):@!
M_/=J9B7"FGC#F'+AB^YWJAJZ62HD;4>0U?)D1$5N:YY*Q%/Z$,-Q=_YJ,'_V
M:_[)S<@             #^8,&8"L6.M,&DF+$4$LS*2N5T7)RJS)7229[M^Y
M#0Y?<\X#>Q6LI*Z)W0]E6[-/;FAQM"']<VE;]\3_ (DANH'\_P!\POBW1! M
MZP;=ZN]8<I_+J[77NUW,9TN:J9;$\V2IO5%3,V;!F)*'%N&J&]6MRK353-;5
M7X3')L<U?.BYH=>:)DT,D4K4=&]JM<U4S1478J&)>Y;<ZDH,7V>-5=24%V>V
M%5ZEV?\ (GM UJ^XDLM@C1][NM%0-7=X1,UBKZ$5<U/'8<<88O\ 4>#V:_6Z
MLJ/\E',FNOH3>5V+1'A)M]N-ZO=.Z[UE9,Z36N4G*LB15V,:U=F2;DSS*GII
MT=X4BP5<+SAZDH[3>;6SPJ":@5L*KJKFJ*C=^S/)=^>0&PWR\VZPV]U=>:R&
MBHVN1KIIG:K45=R9GKIIXJJGBGIY&RPRL1['L7-'-5,T5%ZE0H=@A321H6HH
MKRK7R72W(V616[I43+7RZT<FL</W.%_J:C#-=A>\*Y+QAR=U'(URYJL>:ZBI
MYDR5OH1.L#6WN:QCG/5&M:F:JNY$.?8+Y;,04*UEDKH*ZE1ZQK+ [6;K)EFF
M?K0H7N@\23V7 ZVVV:ZWB^2I;Z5L:^5Y6QRIT[ER]+D+=@##4&$<(6NR4^JO
M@L*-D>U,N4D7:]WK<JJ!8#^?JUUTTUXXNMJIKE46_ MGDY&9]*NJ^LE3HS7?
MM1>C)$1%RS5#<[[.^ELEPJ(O\9%3R/;Z4:JH95[E&G9'HN6H;ERM57322+TJ
MJ9-V^I$ BY^YZPFM%_\  I;C:KG$FM#5Q5#G*CTW*Y%Z,^K)3V:$L8W:MK+Q
M@_&+T=B.RORY9=]3#GDC_/EFFWI1R=.9K!AE4G@/NM*-8-GA]H59LNG)K_\
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MT*BIE[%V 7V>HB@I9*F:1K8(V+(Y_0C43-5]AY+%>K;?J!*VRUT%;2*Y6I+
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M6^$-7)?/EN/7CS"=+C.PK:;A55E/3.E9(]::56*]$7:Q>M%3H7S+T''I-&6
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MVK$B[>2:O1ETY;-B)N1#U8/QS67S29BS#4]+!'36=&+%*Q5UWYY?"Z.D#00
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M^=,V^IR=.9JY_,FC&"^4'NBG5&(4;%<[Q;Y:JIIV;H&N7-L:]>2,8?TV
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M]+VIZS<TW&5X%T8UU-BCWV8\NZ7K$36ZM.C$R@I4_P!!,DV[5Z$1,UWKM-4
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MTS6ZBO1.ARJY47UHIJV&K#;<-6:GM=EI64U% F36-Z5Z55>E5ZP.F
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MF3LM?SZN7_VF]E*T=Z-;'@9*B:WI/5W*I_Q]?5OUYI-N:IGDF29[=F_IS+J
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M153TZX'6TUZ1*/"5@J+?1R)48CKV<A24D2YO17^3KJB;D3/9UKDA]M$6&Y\
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MW0\5EM5#9+73VZU4T=+14[=6.*-,D:G_ 'TGM
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MLN:>I#8@!\Z:"*FIXH*>-D4,348QC$R:UJ)DB(G0B(?0
M         #XUU,RLHJBFD=(UDT;HW.C<K7(BIEFBIN7;O,?=H.F6'Q:F.L1^
M]Q?)6VK+FFI\C6SRR_U39@!SL/66@P]9J2U6BG;3T5,S4CC;[55>M57-57I5
M3H@                           !E5^T1U53>Z^X6#&M_LB5\JS5,$,JN
M8YZ[U3RDRV;.G<6S1[@:TX&M<M):DEEFJ'\K4U4[M:6=_6Y?6N2>=>M2T@
M                         !G.-M&4U^Q!)>[-BJ]6&Y2QMAE6FE5T;F-W
M)JYIEU[\LU5>DT8 4?1WHXMV#:BKKUJZNZWNLV5%QK':TCTZDZDW=*]'4A>
M                            I^D3 T>,HJ%[;O<K374#W24U112JU6N<
MF2JJ=.[S+M7K.#A/1'!;<0P7W$M^N6)KK2IE2R5SEU(/.UJJNWU^?+,TX
M
M  <NYWJ&@J6P212O<K4=FW++;Z_,=0YEQ@M<E2CJYT239)EKR:JY>C,Z8
M
M '.NUVBMCHDECD?RF>6IELRRZ_2>VEF2HIHIFHJ-D:CD1=Z9GCND-OE=%XQ6
M)%3/4UWZOIZ?0>RF2-M/&V#+DD:B,R7-,N@#Z
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M7N5J.S;EET^?S'5.9<H+7).CJ]T*2ZN2:\FJN7M Z:+FB+U@)EDF6X
M                     !X;K<H[;$R25CWH]VJB-RZO.?:WU3:VD9/&US6O
MSR1V_?D?.Z144L3$N"QHQ'>3KOU=I]:!M.RE8VC5JP)GJZJYIOZP/N
M                     !YKA74UOIUGK)FQ1(N6:]*]2$Q$S.4(F8IC.=CQ
MV^^0UM;X-'%*UVW:[++9ZSJG(M3;/),DUNDA?*Y%RU),U\^S,ZXF)CJDB8F,
MX  0D
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MCX2]YY:O ==$]$@E;.W+-7(B-R7JVJ.9POB?!TC&^%&]>VWNU(U$\8TFQ/\
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M:&661,\U61V>WS)T(= X-41$Y4SG#ZBB9FF)JC*0 'EZ
M                                        <"^W:KHJ]L-.V-6*Q%S<
MU57/-?.=\Y=RO,%!4I#+'*YRM1V;43+;Z5\QU
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M#F[.CXJ]Q12!T&QW>)K+$][@O?.'-V='Q5[CXS:0:MRIR5'"Q,MRN5W<4L=
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M2$1$1$1,D3H0Y5!>Z>MK/!XXI6OV[7(F6SUG5/5R[7=G.N<WFS8MV:=&W&0
M"M:
M #F7*&UR5*.KEB2;53+6?DN7M.F<:[V3QA5MG\(Y/)J-U=3/<J^?SG9
M                              #^:_=H_P!"PI^TJ?LC/Q@CXH6;]UC^
MZA^_=H?T+"G[2I^R,_&"/BA9OW6/[J'4Y+^NKT<7EKZ*?5VR"0=I\\$$@
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M>@@9H:V)(! $@ ( 02$@  @D ""2"0(!(   ""0 ()   $!"002$A!) $@$
M2  !!(    7[1FD;J"[)/ER2JU'YKDF62YE!+[HUB\(MUWASU>4U6YY;LT4Q
MX_\ (J]N+H<E_J:??@M]JBM\2R>+EC551-?4?K>CI,=NOYTK/VS_ +RFNV2T
M>+'RKR_*\HB)EJY99>LR*Z_G2L_;/^\IBY+^JKV=#EKZ:/=Y2$)0'9?/@
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MCM;5SZ#KVFB\7T3:?E.4U55=;++>N9\K=^NKU?;6?RZ?2'K !6M
M                 !RZ""U,K%=1K$M1M^"_-?/LS.H<6V6+P&O\)\(U]B^3
MJ9;_ %G:
M          *_?J.XSU[7T:R)%J(BZLFJF>:]&98#@7R[U5#7-A@9&YBM1<W-
M55SS7SG?                                   #^:_=H_T+"G[2I^R,
M_&"?BA9OW6/[I^_=H_T+"G[2I^R,_&"?BA9OW6/[J'4Y+^NKT<7EKZ*?5VP
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M5'LV41&&BW;TXC+KF.W-4,4VSQ5>IZ=J91*NO%]%=WLVIZB\8>_J\D_83?\
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M763S;,RQ%?L]XJJNY^#S,C2/)VU&JB[/66
M                                     Y=RO,%!4MAEBD<Y6H[-N66W
MU^8ZAR[G!:Y*EKJ]T:3:J9:TBM7+T9^DZ@
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M:*YSJB)31?N6XRHJF(?2:62>5\L\CI)'+FYSES55])^$ />Q5GGM""02()
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MGAM0Y[$7-&)L:GJ0YQ)YBS;IG2BF,WN<1=JIT)JG+U0A(!8J0"4 $$@@"00
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MLLMGK.J<J@@M3*S6HW1K4;?@R*J^?9F=4
M                                   X]VLB7"K;.LZQY-1N6KGN5?.=
M@X%\I+E-7-?1.D2'41%U9=5,\UZ,SO@
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M20 )   (" A(! 2$H   ( D$ "0       "  )() $$D$A 02A 2E 02@
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MYQ7-7U;I%@R=L=+K)YMF98
M                        "OWV[U-#7MA@:Q6*Q'>4U5Z5+ <NYWF"@J4A
MEBD<Y6H[-N67VG4                                   #^:_=H_P!"
MPI^TJ?LC/Q@CXH6?]UC^ZA^_=H_T+"G[2I^R,_&"/BA9OW6/[IU.2_KJ]'%Y
M:^BGU=L @[3YX )"$$@!(0"0()!  D ( 02$A 0!"2"2 D!*  02 A!( 2$
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M99;/6=4
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M5RJN9SIRR^5UZU3;BF::HG.-R2 26J0 A% D @"0$ $ $@""2 )!!(  @"0
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MJF>:]&98#@7R[5=%7-AIV,5BM1<U:J[<U.^
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M'%PYB*DO4.3%2*J:GEPN7;Z4ZT.T<*NBJB=&J,I?2V[E-VG2HG.  'E[
M                            <RY7F"@J4AECE<Y6H[-J)EM]?F.F<RXQ
M6M]2BURQ)-DF6N_)<O:=,                                   /YK]
MVC_0L*?M*G[(S\8)^*%F_=8_NH?OW:']"PI^TJ?LC/Q@CXH6;]UC^Z=3DOZZ
MO1Q>6OHI]7;()!VGSR 2 ()"$!"2$!(  @)2   ()  @E     @GH  @ 2
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M:Y6QUO2J5/(AE1V>3UZ$79M\_F4ON)M(&'+#:'UDMTI*B1S<H*>GE;))4/\
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MZ/O3S&E4M1#5P,FII&R1/3-KFKL4X%_#5V)RJV=KZC"XNWB:<Z=O8^H ,[4
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MJ=/H/QAZFJZ:GF;7*Y7J_-NL_6V9'"KG2JF8?2VZ9IHBF?M#J@ \O8
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M1O7N0,6RUELN>%ZN36\"_P#%4NL[-4C<N3VIYD=DO^LH']%@
M           XN(;G4V]].E,QCD>CM;6:J[LCIT$KIZ*"61$1[V(Y43K5#RW:
M[16UT22QR/Y3/+5RV99=Y[:69*BGBF:BHV1J.1%WIF!]
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M]_']FNY[GS_3>N49\MOM'*,^6WVF"@:J_P"_C^S7<]SY_IO7*,^6WVF$U/\
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M^ZEILO*PO-GYJM/^DV#FLP-_FM:N A^7:*<"N7-<+6SU19 9%_A2TG^:\_\
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MJ2XJZ)T7AFNY<D>N>MMSV9^DZIQJ>QMANJUJ3JJZ[GZFKUY]/K.R
M                    \UQ;3/I'I7*U(,TSUER3?LV^D])Y;I1I7T;Z=7JQ
M'*BZR)GN7,"+6RC93JEO5BQ:VW5=FF?_ 'D>L\5HMZ6ZF="DBR(KM;-4RZ$[
MCV@                        "'9:JY[LMI)#DUFJG6F0'-M<5K9.];>Z)
M9=7RM1^:Y9^GT'3.19[*VVU+Y6SK)K-U<E;ETHO\CK@
M          /%=8Z%\;$N*L1B+Y.N[5VGM.?>+:VY0QL=*L>H[6S1,P/30M@;
M2QI2*U8$3R=5<T/N>>W4W@='%3H_71B9:V66>T]
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ME1?)R1.A>D"G8HKGZ2<=MGP_8%I+A<7(CZ:"3E&R2]+]R:J*FU>C>I_9VB/
M\& L&TUJ8YLE8]>6JYF[GRJB9Y>9,D1/0?G1OHTP_@&E5MHIUDK9&ZLU;/Y4
MK_-U-3S)_$NH                        '%Q#2U]0^G6@<]$:CM?5DU>K
M+I])TZ!DD=% R=565K$1V:Y[<MNTY>([G4V]].E,UBH]'9ZS57=D=2@E=/10
M2R9:[V(Y<DZ50#[@                            *_2T5S9>UFE<_P %
MY1RY++FF2YY;,_06 KU)=ZN6^+2/:SD>4>W-&KGDF>6W/S%A
M                >&]15$UODCHU5)E5,E1VJN_;M/<>&]U4M';I)H$19&JU
M$S3--JY ?BPP55/1N97*Y95>JIK/UMF2=)T3FX?K9JZB=+4(U'H]6^2F6S)#
MI                         "'HJL<B;\MA)#ER:J]2 <*P4EQIZN1U<YZ
MQJQ436DUMN:=&9WC@8?NM575LD50UB,;&KDU6JFW-$_F=\
M             !R\04]944\;:%7(]'9KJOU=F1U#EXAKIZ"FC?3HU7.?JKK)
MGLR ]-ICFAM\,=4JK,B+K*KLUWKTGK/'9ZB2KMT,\R(DCL\\DR3>J'L
M                      #RW2.:6@G93*J3.;DW)<MOI/'AZFK:>.=*]SE<
MYR:NL_6V9'MN<[Z:@GFB1%>QN:9IFAX,.7&HN#*A:EK45BHC=5JIOS ^>-_B
MM7_1;]Y#/<"_&FA]+_N.-"QO\5J_Z+?O(9[@3XTT/I?]QQUL'^EN>_!PL?\
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MB(G2=J+"E^EAY5EIJE9O3-N2^Q=H'$!])X9:>9T51$^*5JY.8]JM5/4I^ !
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MI! /3RD@D( !  $CK( D  0"0 ()  @D  02!"$@ 02  ! "$@ )"   )
M-:KE1K45578B(F\#MX;Q'56675:JRTCE\J%R_P 4ZE-7M==#<J&*JIM;DI$S
M363)4*7A7!?P*J\M\[:?_J[B^M:C&HUJ(C43)$3<AP<?<M5U?@V_>7T_)EJ_
M;H_^D]7VC[I !SW4
M    ?SW[LKXIV#]]?]Q2AZ/OB?;?H.^\I?/=E?%/#_[Z_P"XI0]'WQ/MOT'?
M>4"P@ (  $A)  $D     )( $D$@0 2! !($$D "2  )(   $@0  )(  D@
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MJN_AHZHXOI,%R;38_'<ZZN  # Z@
M                  /Y[]V5\4[!^^O^XI0]'WQ/MOT'?>4OGNROBG8/WU_W
M%*'H^^)]M^@[[R@6(@D 0  )(!($ $@0"2 !)    "2     D@$@0  !)
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MN1OLS/@2! ) $   20  !( @     !($   202! )( $D  "2  ) $  "2
M!)  $D  20 )-;T+?F:X_O*?<0R0UO0M^9KC^\I]Q +A;8K6RI<M L7+:JHN
MJ]57+IZ3 ;Y^>[A^\2?>4WFTV1+?6.G2=9,VJW5U<M_K,&OGYZN'[Q)]Y0/$
M0"0(    D"      D@ #Z<M+J:G+2ZF66KKKEEU9'S $D  ?3E9=34Y634RR
MU==<O8?F-[HWHZ-SF/3<YJJBIZS\@#[2U,\LB22U$TDB;G/D553T*JGS>]\B
MYR/>]>MSE7[2 !,4CXGH^)[V/3<YCE1?:A^YYYJAVM432RN3ID>KE_B?( #[
MLK*ID2Q,JJAL2_H-E<C?9F?  2?I997,U72R.9\E7JJ>P_) 'V=55+XDB?4S
MNB3<Q9'*WV9Y'Q)( _<,LD+]>&1\;T_28Y6K[4)FFEG?KSRR2O\ E2/5R^U3
M\ " 20 )( $D  "00      2020!_06$DC7!=K2?+DEHV:V:Y)EJ[3VVJ.W,
M67Q:L:JN6OJ.UNO+^9X<*1<O@FV19ZNO1L;GU9M/59+3XL694FY3E,OT<LLL
M^\#SXW^*U?\ 1;]Y#/<"?&FA]+_N.-"QO\5J_P"BW[R&>X%^--#Z7_<<=;!_
MI;GOP<+'_K+7MQ7S2!\5ZKZ3/O(9(:WI ^*]5])GWD,E+^3/RI]6;EC\^/3^
M5CT>_&BG^@_[I<-)/Q;_ -LS^93]'OQHI_H/^Z7#23\6_P#;,_F58C]71[<9
M7X3]!<]^$,L()!UG#  !!* =8 @D( !" "2"2 )     :%HPN#/!ZF@>J)(C
M^69YT5$1?9DGM.7CRPU%/<IJZ")TE+,NLY6IGJ.Z<^\JU)4RTE3'/32+'+&N
M;7)T%^M6/X71M9=*=['HFV2+:B^K>G\3G7;5RS=F]:C.)VPZUF]9OV(P]Z<I
MC9*A4E)45<S8:6%\LCER1K4S-<L-$S#V'D;4O1%C199G9[,^GN.=+CBSQ1JL
M*32.^2V/5S]I3L28HJKTG)(WD*1%SY)%S5R_Z2])XKB]B\J:J=&E9:JP^!B:
MZ:M*K[/UAFH6KQM#4*F2RSODRZLT<I9]*"*MKH\D5?R_1]%2CX=K8K=>:6KG
M1RQ1.57(Q,UW*A?O?Y:?\E5_[C?^HG$T5TWJ:Z*<XB'G"7+=6'KMW*\IJG^&
M9:C_ )#O8=?!Z*F)[?FBI^4Z?0I=O?Y:?\E5\-O_ %%9KK_23XOIKI&V9*:-
M&HJ*U-;8B]&?G+8NW;L54U49=4J)L6;-5-=-S/KA:M(-=5T%MIGT,SX7NFU5
M5G2FJI1/?'>_G]1_#N+NN/+2N^*K7_9M_P"HCW]VC_(U7#;_ -1DL17:HT9M
M9MV(FU>KTZ;^4=G^EF]7//53OFJGNDE?O<[>I\"SXUOE)>G4:T3)6I"C];E&
MHF_++<J]2E9.K:JFJB)F,O)Q;],4W)BFK2\P$ L5) (0"002! !($$@ ""2
M) 0 ""2 )0@D  A]*:"6IG9#3QNDE>N36M3-5-)PK@^*@U*JY(V:KWM9O;'W
MKYS/?Q%%B,ZMO8TX7"7,35E3L[7#PK@Z2MU*JZ(Z*FWMBW.?Z>I/XFD00QT\
M+(H&-CC:F36M3)$0_8.!?Q%=^<ZGU.&PEO#4Y4;>T !0T@
M                                      #^>_=E?%/#_P"^O^XI0]'W
MQ/MOT'?>4OGNROBG8/WU_P!Q2AZ/OB?;?H.^\H%A   D$ "2    $D
M) @ D 0"0(!)  DA"0(!)  D@  "0(!) $@@ "2"0(    D " !)!( @
M    $D "00   $D         D 0"0(!)  D@  20   $D  20  )(
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MH  >7L
M !_/?NROBG8/WU_W%*'H^^)]M^@[[RE\]V5\4[!^^O\ N*4/1]\3[;]!WWE
ML()(       !($ D 0  !((  $@0   !($$D$@" 2 (!($      ) $
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MT."Y+BC\=[KGL$1$1$1$1$V(B  Y;L@
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M:VV-M%7>$I.KUV^3JY;_ %G9*]9Z*Y0W-9*M9%@R=OEUD\VS,L(
M          #!ZG^DS?3=]IO!@]3_ $F;Z;OM4ZW)6VKV_=P^6ME'O^SY$@'8
M< ()  @E.I"ZX5P8^IU*J[M='#O;!N<[T]2>;>57;U%FG2KE=8P]>(JT:(<;
M#6'*J]2ZS46*D:N3YE3^"=:FIVBUTMII4@HXT:GZ3E^$]>M5/7#$R&)L<3&L
MC:F36M3)$0_1P,3BZ[\Y;(['U&$P-&&C/;5V@ ,K:
M                                             _GOW97Q3L'[Z_[B
ME#T??$^V_0=]Y2^>[*^*=@_?7_<4H>C[XGVWZ#OO*!80  )(  $@"  !((
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MHC*  %:T
M              '\]^[*^*=@_?7_ '%*'H^^)]M^@[[RE\]V5\4[!^^O^XI0
M]'WQ/MOT'?>4"PD@@   )(!($     )(  D@D@   )()(    20  ) $ D@
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M4U=NH_-<O:>;![=?!UJ9GEK4C$S_ -4^EFLJ6R=TB3K)K-U<M7+^8'7
M                        <RAAM;*O6HUA\(V_!?FOGV9G3.-;;&E#7>$I
M4*_8ODZF6_UG9                    8/4_P!)F^F[[5-X,*EC?+721Q-<
M][I%1K6IFJKFIUN2]M?M^[A\M=<4>_[/.6K"V$9KGJU-;K04>]$W.D3S=2>?
MV'=PK@QM/J55W:U\V]L&]K?I=:^;<79$R3)-QZQ7*&7X+6_^'C!<EY_CO[OY
M?&CI8*.G9!2QMBB8F2-:A]@#D3,SUR[T1$1E  "$@
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MI#M ]1753$TQ/5+Q5;IJJBJ8ZXV  /+V
M                                              #-M.&CFITC6>W4
M5)7PT3J6=9E=*Q7(Y%:J9;#'O\%NZ_YR4/\ =W]Y_50 _E3_  6[K_G)0_W=
M_>:+8]#M9;;124;[M3O=!&C%<D2Y+EZS9@!D_-55]IP<)>\<U57VG!PE[S6
M!D_-55]IP<)>\<U57VG!PU[S6 !D_-55]IP<)>\<U57VG3\)>\U@ 9/S55?:
M<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-5
M5]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\
MU@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55
M?:<'"7O'-55]IT_"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[Q
MS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"
M7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\
MU57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE
M[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:=
M/PE[S6 !D_-55]IP<)>\<U57VG!PE[S6 !D_-55]IP<)>\<U57VG3\)>\U@
M9/S55?:<'"7O'-55]IT_"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG
M!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55
M?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-
M8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57
MVG!PE[QS55?:=/PE[S6 !D_-55]IP<)>\<U57VG!PE[S6 !D_-55]IP<)>\<
MU57VG!PE[S6 !D_-55]IP<->\<U57VG!PE[S6 !D_-55]IP<)>\<U57VG!PE
M[S6 !D_-55]IP<)>\<U57VG!PE[S6 !D_-55]IP<)>\<U57VG!PE[S6 !D_-
M55]IP<)>\<U57VG!PE[S6 !D_-55]IP<)>\<U57VG!PE[S6 !D_-55]IP<)>
M\<U57VG!PE[S6 !D_-55]IP<)>\<U57VG!PE[S6 !D_-55]IP<)>\<U57VG!
MPE[S6 !D_-55]IT_"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9
M/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'
M"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]
MIP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@
M 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:
M<'"7O'-55]IP<)>\U@ 9/S55?:<'"7O'-55]IP<)>\U@ 9/S55?:4'"7O'-5
M5]IP<)>\U@ 9/S55?:=/PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O
M-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U5
M7VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[Q
MS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"
M7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VE!PE[QS55?:<'"7O-8 &3\
MU57VG!PE[QS55?:<'#7O-8 &3\U57VG!PU[QS55?:<'"7O-8 &3\U57VG!PE
M[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<
M'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[QS55?:<'"7O-8 &
M3\U57VG!PE[QS55?:<'"7O-8 &3\U57VG!PE[SB8BPE3V&/_ ,;>8'3JGDP1
MQ*KU]6>Q/.IN4B*YCD:[5<J9(O5YS+[=HSJI[A+-?*YKHE<J_DE5SY/.JJFS
M^(&>VNVUETJ4I[?3OGE7>C4W>=5W(GI-=P)@N6PO\+K*V1:AZ;8(7*D:?2^4
MI:[7;*.U4R4]OIXX(DZ&IM5>M5WJOI/6
2                    !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g73463g00n44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g00n44.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1I^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &F$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M            _^% 2FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX
M;7!T:STB061O8F4@6$U0($-O<F4@-BXP+6,P,#(@-SDN,38T-#@X+" R,#(P
M+S W+S$P+3(R.C V.C4S(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D
M;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R-2TQ,2TQ-U0Q-SHQ,SHS
M,BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y
M1&%T93XR,#(U+3$Q+3$X5#$V.C(V.C0Y*S U.C,P/"]X;7 Z36]D:69Y1&%T
M93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R-2TQ,2TQ.%0Q-CHR
M-CHT.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/&1C.F9O
M<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP:&]T;W-H
M;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @
M(#QP:&]T;W-H;W Z24-#4')O9FEL93YS4D="($E%0S8Q.38V+3(N,3PO<&AO
M=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$
M/GAM<"YI:60Z9C T-S)A,#0M8F(X.2TQ.30W+3AD.&4M.38X838W8V(P9F)E
M/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)
M1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z,&(W-#AA,F4M,3<X,2UD931D+6$P
M,S$M,#=C.6%C,69F,F8P/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z8C1A-6)E,S4M.#0S
M,BUB-#0V+6%E-&4M-#,X,C0V-38P8C@Y/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8W)E871E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F(T835B93,U+3@T,S(M8C0T-BUA931E
M+30S.#(T-C4V,&(X.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R-2TQ,2TQ-U0Q-SHQ,SHS,BLP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@:6UA9V4O<&YG('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C=F8V0R,SEB+68V,#4M-F0T8BTY,C U+38U-S,X
M.3%E,C1F8CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R-2TQ,2TQ.%0Q-CHR-CHS."LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#HX,&4T9C!E9"TV,F4R+64X-#4M.60R92TV9C$T-#0R,3<R-3D\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C4M,3$M,3A4,38Z,C8Z-#DK,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IF,#0W,F$P-"UB8C@Y+3$Y-#<M
M.&0X92TY-CAA-C=C8C!F8F4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,3$M,3A4,38Z,C8Z-#DK,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C@P931F,&5D+38R93(M93@T-2TY9#)E+39F,30T-#(Q-S(U
M.3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M
M96YT240^>&UP+F1I9#IB-&$U8F4S-2TX-#,R+6(T-#8M864T92TT,S@R-#8U
M-C!B.#D\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#IB-&$U8F4S-2TX-#,R+6(T-#8M
M864T92TT,S@R-#8U-C!B.#D\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  8$!08%! 8&!08'!P8("A *"@D)"A0.#PP0%Q08&!<4%A8:'24?&ALC
M'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_VP!# 0<'!PH("A,*"A,H&A8:*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"C_P  1" 26!VP# 2(  A$! Q$!_\0 '0 !  (# 0$! 0            4&
M P0' @$("?_$ &,0  $# P("! 4,#P0(!@  #P$  @,$!1$&$B$Q!Q-!410B
M87&!%18R-E5RD92AL;+1(S,T-3="4E-S=)*5L\'25'6TTP@D8H23PL/A%T."
M@Z+P)?$F8^(G.$1DHT=69:3C_\0 &@$!  ,! 0$               (#! $%
M!O_$ $ 1 0 " @ $ P4' @4#! $% 0 ! @,1!!(A,1-!404B87&!%#*1H;'!
MT4+A(S-2<O 5-/$D-6*"1$-35)*RPO_:  P# 0 "$0,1 #\ _5*(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B#5NE=%;;;55M2<0T\;I'X[@,KG.@.E&34FHF6RLH8:42L<8WL>22X#../
MD!63IWO+J/3<%KIW?9Z^4!S1S,;>)^$[?E5/UOIQ^C*'2=VI6!M32[65+F_C
M2 [^/PN'F 0=\1:]MK(KA;Z:LIW;H9XVRL/D(RH#7&M+?I*EB=5M?/539ZFG
MC]D[RGN'E06=%RRJZ3+W04AJ[IHVKI:,CQ9C(< GED%@QV+WT=4>HKY74>I[
MEJ 2T<F\^ Q.=L&01M(& "">1!Y(.H(J+KOI$I=-5;;=24K[A=78^P,. W/+
M) )R>X!5U_29J2V!M1?M)S0T+N<C0]FW/E(Q\.$'7$4;IV]T6H+5%7VV7K(7
M\P?9,=VM<.PA4N\=)T-GUK46:X4;(J* 9?5]<2?M>[@S;Q)/#F@Z,BY%5=)V
MHIHGUMKTG4&UM\832L>=S>_(&!\JE;?TMV>?3SZZIBDBKFOZL4+';WO=V;3P
MX>7"#I"+CU=THZDH-M76Z3EIK>78#I=[>'OBW&?0NFZ8OE+J*S4]RH2>JE'%
MKN;'#FT^4()1%1]=](5+INKCMU'2ON-VDQBGC. W/+) )R>P *NS=(^I[4UM
M5?M)R0V\D!TC2YI;GRD$>@X0=:5$TOKBHO.N;K89*.***C,H;*UQ+G;'AO$>
ME6G3MZH[_:8;A;9-\$@[>!:>UI'80N4=''X9M3>^J?XH0=I1:-[NE)9;9/7W
M"3JZ:%N7'F3W #M)7-:?I'U)>G/ETWI5\U$UV!+(XG=Z1@ ^0$H.L+4NMRH[
M31/J[E4,IZ9A =(_D"3@*DZ*Z1VWF\.LUYM[[9= 2&L<20XCFWB 0?(JUTS:
MEN,E+<K(ZQS-M[)(R+AEVT\G<MN.?#F@Z[;:^EN=%'5T$S)Z:099(SD[CA4S
MI)U?=]-5=NBM-K%8RHSO>YCG<<XVC;R/G5,T!K>]6VQ6RVTNEJFKI6G8*MKG
M[7 O.3P81PSW]BNW2-KJ32%3;HH[>RK\+#B2Z8Q[<$#\DYYH+M ]TD,;WL+'
M.:"6GFT]R]JO:WU$[36FI+JRE;4N8Y@ZHR; =QQSP?F5-'2P^LM](RRV6:OO
M$S-\E-"YSVPC)'%P;DG [D'4T7)K5TJ5U->H;?JRRNMPF< )/&:69X EKAQ&
M>T'@NL%P#2XD!H&23RP@^HN77'I0J:VZRT&CK+)=3%[*;CM/E  Y>4D+[:^D
M^II+K%;]8V:2U/E(#)N.WCPR01R\H)0=01:5XN4%JM-5<:DDT]/&97;>)('<
MJQH'I!H]7U5530TDU+/"T2!KW!P<W.,Y';Y$%T1$04?I-UUZSXZ)E/3,J:JH
M+CL>X@-8.WAY3\ZEM ZE;JK3L5P,;8IM[HY8FG(:X'ZL%<UAC;KGICG=*&S6
MRVM+,'BTM;D#X7DGS+/T4S'3>O;YIFH<1'(\N@SVEN2/A8<^A!V5$7+:+I=I
M_"[M%<K>(&T9+81'-O?4/W[0T-VC'?S0=21<AK>DS5%%'X=5Z1E@MN<[I-[2
M&GEEV,#X%T32&I*+5%H97T!(X[9(G>RC?VM/UH)I%SNX])L%LUI66:XTD<-'
M3-)=5]<23AFX ,V\R>'-1-9TE:E=&ZNM^DJCU* W-EE:_+F_E9 P!\*#K2*K
M:!UI1:OH9)(&&GJX<==3N=DMSR(/:/*H[6NOO6SJ:VVQ]%')!5-:Y]0^?9U0
M+RTG&TYP!GF$%Z1<PI>DVKNVHJ>DL-DFJ+8:AL4E8X./BEV"[ &&CMXGX%;-
M;:OH-)6]L];NDFE)$,#/9/(Y^8>5!8T7(F=)&JY(/#H]'RNM_LMP$A.WOW;?
MEPKKH76EOU=22.I0Z"KB^VTSR"YOE'>/*@M"*A677\E7KRJTU7VUE))&7MCE
M$Q=O(XCAM&,MX\U?4!%1K+KJ6\:[K+#1VYCJ6D+^LJ^N_)X'Q=OY7#FOFN.D
M.GT]7,ME!2/N5V?C[!&<!F>0. 3GR (+TBY-+TD:DM&R?46E9(*%S@TR,+FE
MN?/D9\APNEV.[4E[M<%PMTG64TPRT\B#V@CL(*#>7QYVL<>X97/]==)$-@N3
M;5:Z)URNAP'1M<0&$\AP!)=Y HRDZ2;M13L9J[3M1;J28[&U08X-83W@C^>?
M(@F>CC7%1JRX72GJ*.*G%'MVECB=V2X<<^97M<5_T?R'7K41:000P@CWSUVI
M!2>D[6D^CZ>@DIZ2*I-2Y[2)'%NW '=YU56=)NJ9(6RLTC*Z)S0YKPR4@@\B
M#CDOG^D9]P67])+\P73=*>U>S_J</T @YO;^F1D52(;_ &:>CR?91DDM\[2
M?@74;3<J.[T$59;:AE132#+7M^8]Q\A6KJ*P6[4%!)27.F9*UPPU^!O8>]I[
M"N/]&%54Z2Z1:W3-5*74TSW1C/(O RQP[LM_D@[JBB=4:@H=-VJ2ON3RV-IV
MM:T9<]W8T!<XAZ2]3W)CJJSZ2EEH03A^'OW#S@8^#*#KJ*E:$Z0:+5$\E%+
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MDW[N6-I7._\ 1]?*S2MR=('>#MJ26?L#=CY%H2:3K[I$RANO2%3U-M)&8FR
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M=HC!ZOJPUN<\LG)5Z1 5!CZ/7R=()U-77)M0!)UC*;J,;<-VM&[<>7/DK\B
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M\C^M>,GS K#JGHHIZ2F?<-)5%325]..L9$)"=^.QKLY!^%7+HP_!_8OU9O\
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M\NWF9],+<L6C:.SZFN-[@J*A]17;M['XVMR[/# RI/4]EAU#9*FV54DD<,^
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M=E/31C#6-^?RGRK;1$!$1!"W#2EAN,SI:VT44LKN;S$-Q](4S&QL;&L8 &M
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MIV"1HD86.P>\'B"N.V@55 W1-R;<[C-5WJU5$E<Z:I<]LKO!Q(TAI.&D.Y8
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M'-/X"R+)ZYN/&!SP66NK;C#?JS0K:NI%177-E53S]8=[*!P,LF'<QAT;X_\
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M 1$0$1$!$1 4#:9&#55^C+V]81 0W/$C8>.%/*OVF"(ZMOLYBC,S1 T2%HW
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M4$;(XVC#6,:  /( O:"LUFF9:[55LN%54T_J7:P7T=$RGP6RENS<Y^>( )P
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MD;-L+1M:\Y>T<.3CQ([>U;Z((>W:6L-LDCDMUEMU+)&[>Q\5,QI:[!&00.'
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M6Q.<.T@- \^T9]*O=RT=8+G4FHK+9 ^8G+GM!:7'RXQE2]!14UOIFT]%!'!
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M_-+?K[_\/,K"@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B(*Y8JAU1JW4!?3S0;(Z9@$N/' ZWQA@G@?+@^16-0=M]MU[_04O_54X
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("@]<NVZ3N;@TN(BSM;S/$< IQ0
MFM?:M<?T8^<()6CF=44L<KX98'.&3'+C<WR'!(^59D'((@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("@-%_<5Q_O.L_C.4^H#1?W%<O[SJ_XS
MD$^B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@K^OJ
MAU/I*Y[*>:?? ]AZK;X@+3XQR1P'DR5.P?:8_>A1.L_:G>/U63Z)4M!]IC]Z
M$'M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!:E;;:*NDB?6TD$[XCF-TC XM/DSY@MM%R8B>Z5;36=UG4B(BZB(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M$0$1$!$1 1$0$1$!$1 1$00=M]MU[_04O_54XH.V^VZ^?H*7_JJ<0$1$!$1
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MT%\)=0 \^M9P_;67IY^]MG_3N^9>96E8X2;1'6?Y?7WXC)?VU7%:VZQ/2/\
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MGO6]=3$STCM'R^#TN0Z[_"]8?-#]-RZ\N0Z[_"]8?-#]-RHXO[D?.'H>P_\
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M*Y(UJ-=MH8LM,V7AK<TWM%M<TQK<>F_.8:FE=!NU!:[?<]17"H>.I8*:"%P
MCC  ;Q(/8!R75VC:T <@,*#T'[3++^JQ_,IU:\&.M*1,>;Q/:/%9<^:U;STK
M,Q$>4=1$17O/$1$!$1 1$0$1$!$1 1$0$1$!$1 1%BJZF&DII:BID;%!$TN>
M]W)H':@RJ$M'MFO_ /['T"MG3MYIK_:V5]$V5L#WO8T2L+'>*XM.0>(XCM6K
M:/;-?_\ =_H%!.(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M"O:F^_FEOU]_^'F5A5>U-]_-+?K[_P##S*PH"(B B(@(B("(B B(@(B("(B
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M/".K&V,F5X+PWD<-:< ^3*GM-5E?3ZEN=@NE8ZX"&GBJX*B2-K'ECRYI:X-
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M?,!ATFP-W'OP.2S("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MH#1?W%<O[SJ_XSE/J T7]Q7+^\ZS^,Y!/HB("(B B(@(B("(B B(@(B("(B
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M./A)6#6?2!0W2T2VK38GK:VL;U66Q.&T'GP(!)PK+HRQ/T_HCP2< 5+XWRS
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MY!%AHXGP4L<4D\D[VC!ED #G>4X 'R+,@(B("(B B(@(B("(B B(@(B("(B
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MM\_>$GUJQ(@KOK4@]U;Y^\)/K3UJ0>ZM\_>$GUJ=JZF&CIWSU4K8H6#+GN.
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MCJ8:VEBJ*9XDAD;N:X=H69:'CS$Q.I$1$<$1$!$1 1$0$1$!$1!!VWVW7O\
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M1?WKQ7TZO5X6?L_"WS^=O=C]UM1$5[RA$1 1$0$1$!$1 1$0$1$!$1 1$0'
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MC;"R.FZUU$[:[89&.D& UN?9.=LR <=@?HA%Q[HRZ1JS4&H:RDK(IHFMJ,;
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M[#K*+5-DI7UD3^%3 S)=RP> XX(^ A>;KTBU-VH)*"P66O\ #YVF/<]G"//
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M+B]S87N=&7<(W@XVD;N!:3GCGR$+TBK>AM3-U+;C5!ACW8DC88W@]61XI+B
M"3Q.&Y R K(@(B("(B B(@(B("(B#F.E_L?2C<F-X!SIOG!73ES'2_V7I1N;
MQQ#73?. NG*G!VGYO4]J_P"93_; B(KGEB(B B(@(B("(B"N6.F;3:MU &R2
MOZR.F>>L>78SUO 9Y#R*QJN6*JCJM6Z@,0D CCIHW;XW,XCK<XW 9'E'!6-
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MI9'L9&1^,[802 ,G&<(.<=(C?7Y0U%'9:NKZR)LLA$+FO#1&XM:YF&DATA)
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M;JBEJGQL+,R,#,5(8' ]6"_:W.<NVEWL3CO =H1$0$1$!$1!":V:':4N@/9
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M=@^TQ^]"#VB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MH:=@F=(^7K",N#GXW8)Y X' =R#3TG8(=/6TTL0A+MQW2QQ",R >Q+@.!=C
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MB("(B B(@(B("(B J[:JJ-NLKY2G?UKFP/'B.VX##^-C /DSE6)0EH]LU_\
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MIF[6U3140.:X$.:_ #G,X'&.(!4#I6Q5NJ;F9JZ>2:GC($U6^-C))0/8M):
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M'I2AM-W9+*VV6J:&GK7#A40F6,QDG\H ;3YLKKB B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M&5$9,9>,$$<L^D*HZ0U!'8V3VV[-?#M>2';<[3V@A=#BBCAC;'"QL<;>36C
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M8 MVFIX::,1T\3(F#\5C0 NUSXL>YQQ.YZ=7+<-GRS6,UHU$[Z1UEE1$6-Z
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MTK'8I-0W*S45;)<+?$^HA;*6"B<0W(SC/6*SD9&#R7R-C8V-9&UK6-& UHP
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M+W1_92S+MIP.!&?,K!!]IC]Z$'M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MLK<#LSQ':%T5 1$0$1$!$1 1$0$1$!0&B_N*Y?WG6?QG*?4!HO[BN7]YU?\
M&<@GT1$!$1 1$0$1$!$1 1$0$1$!$1 1%3>F*JFHNC>]U%++-%-'&PM?"XM>
M/';R(07)%R'7FM)ZNSVF"EM>H;=(^YT;75$],86%O6MR"X'M[NU6677;XK9<
MMU WU8I;HVULH^M^V/>YNQV<<BQV_EV'N07E%S1UKNNBS==25E?4W2FIH:R1
MM&V1YW;Y][.>0-K>!.. Y*;T'JJKU%).)XK7)3MC;)'56VM$\9))RQP(#FN'
MFP4%P14FTU,[NE[4%,Z>4T[+72/;$7DL:XODR0.0)P%GUIJ>NLE7%#2P6N*$
MQ&5U7<ZX4\1.<=6T8)<[M[@@MZ+FULZ48JJV-KZF@$$$EIEN41$V[>^)Y9)&
M#CCQVX/:'<E):6UT^_RZ?ACM_55%=3SU%9&Z3)I.J=U9:>'$E_#LY%!=T7)^
MDVJI6=(=EI[KZM2V]UNG>8;89RXO#V8<6Q'/ $\3WK%H&ZSLFU%=M-Q7:MTQ
M%3-%/3U]0=[ZII(>&&0[F-Q@'=VH.NHN84_2;/%57.EK8+14STULFN+#;;AU
M[1U>,QR>*-IXCBI&UZWN8N%J;?[13T-#=:26JIY(JDROC$; \MD&T#.TYX$\
ML(+\BYS3:[O;H[!7SV&G99[W5Q4]/(*LF6)DF=KY&[<<0,X!X<BHZ/I?IWRL
MK-MI]1WU0I@P7!IK=I?L$O4XY9X[<YQQ07;I =2-TE<O#3 ,P/$778]GM.-N
M>WS*>@^TQ^]"A];,C?I.[=8UKL4TA;N&<':>(4Q!]IC]Z$'M$7QSVL&7N#1Y
M3A!]1>.NB_.L_:"==%^=9^T%W4N<T/:+R9&#&7M&>7'FO2XZ(B("(B B(@(B
M("(B B$@ DG "^-<UPRUP<.\'*#ZB(@(OCG-:,N( [R5]!! (((/:$!$1 1$
M0$1$!$1 1$0$1$!$1 1:SZZE96-I'U$0J7#(B+O&/H6RNS$QW<BT3V$1%QT1
M$0$1$!%YZQF[;O;N[L\5ABKJ66JDIHJB)]1'[*,.!(]"[RS+DVB/-L(B+CHB
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@*NVJDIW:ROE6Z%AJ6-@8V0CQ@TLXC*L2KMJCG.LKX]LS13AL =%LXEVPX.
M[/R8099;!UFMZ?4/A&.IH'T/4;.>Z1K]V[/^SC&.U1UUL]-;+Y?=35[Y:BDJ
MK=%12TD5.9';6N?D@#)=GK,8QV*W(@XG!I*OH.A*O@;'6NNM?)%* YFZ>.-L
MC&Q-([V1M;D=X*MM5H">_>&/U;=172RT+J"#P>GZ@0L<YKG/QEV7DL;QY<.2
MOZ(*%3:(NDK:AMUO5+(TT<M)&VDH&P!Q>TM,DG$[B!V# YK8NFC*R:CTHVV7
M=M)5V!FUDKZ?K&S?8NKPYNX8![>.5=4042GT%*:BGK[A=!470W:*Z5,S8=K)
M.KB=&R)K<^*T-<..3V]Z\0='?524SO5+/4ON#_M//PK/E_%^7R*_(@I=7HNH
M];FF**W7-L%PL'5=14/@WLD+8S&0YF1P()Y'@HJ7HYN4T=7-)J/%TJ+K!=?"
M6T@ 8^.,,# S=['@.WEW\UTE$'/JOH_JKHVMJKS=HY[M53TCS-%3;(XXJ>42
M-C:W<3Q.[))_&\BWJK1'7V+6%N\.V^N"663K.J^T;XVLQC/C8VY[%<T0<^K=
M 5D=QKZFQW2DI1<61BI%30MG+9&L#.LC)<-I+6C@<C(RI2BT:*2NND[:Y\@K
M;9#;O'9ES>K#QO)SQ)W\L#DK:B"F,T1MH]+0>'?>2CDI,]5]NW0B+=SX<LXX
MJ(INC:JH*B@FH+K1ND@MT5O<ZKH!,6!F?'BR[Q"<\1Q')=*1!!:&L#M,:7HK
M.ZJ-7X*'-$Q9L+@7%W$9Y\5.HB B(@(B("(B B(@(B(*]J;[^:6_7W_X>96%
M5[4WW\TM^OO_ ,/,K"@(B("(B B(@(B("(B B(@(B("(B H.TV#U/U1?KQX1
MUGJH(!U6S'5]4PMYYXYRIQ$'--7V&&T:6U>R85E?)?ZMTU/%24[G/CF,;1&.
M&<8=&#N. %;]#V5U@TM;[?,_K*ID>^HD_.3..Z1WI<2IQ$%&UGHNOU!45S&7
M6E]3JV(1OIZVA%0:<XP70DN&TD<>.>(RI74>EFW;055IF*J?"R6D%(VH>.L<
M   '$9&3P5D1!1)=*:FN%LJ[9>=44TUOJ:9].YM-;NID&6X!#MYY=V.*PV/0
M5;1WNR7"KN-!U=KCDB92T=O$$<C7L#2YWC$[N \GDXKH*(.5R]#]._3M5:VW
M:9CI;B*N.<1^-%#M,?4#CRZMSFY\O)=(N- VKLU5;XR(634[H&D#(8"TM'#R
M96XB"H5VB(*W0%#IN>I<)J&GB935S&X?%-$T!DK1G@<C.,]X415]'URGNEPK
M?5BC,UR@BBJ9I;>))8RUFPF%Q=X@//!!P22NC(@IVD-%NT_5P3OKQ4.CM%/:
ML"+9GJG/._F>>_EY.:JETL<NC&:<-%5UL5524\],ZXPVXU4+F.>']7)$T[@<
M\6N![#GFNN(@Y!I'0UPKK#37.>I?37F.XU59#)7T@=UL4KL$2Q9&-P =@$$<
M%T+2-DJ;-2U(KZYM955$QE<8X1#'&, !C&#. ,=I)R2IU$%<L5)3TFK=0"FA
M9$)(Z:1^T8W./6Y)\JL:KECCGCU;J#PF9LQ,=,6;6;=K?LN&\SGSJQH"(B B
M(@(B("(B B(@(B("(B B(@(B("(B H/7#&R:3N;'@.:Z+!![02%.*#UP''2=
MS#';7&+@<9P<CB@D'V^$6B2@IFM@A="Z)H:W@P$$<!Z5!-TECHW]:GAG_P"X
M&A\)ZO\ V=N[;GY,JQT;)HZ:-M3*V:8#QGM9M#CWXSP69!RS4^G8[QJ_2=JA
MCK"+7&/5"HZDMAEIVAKV,+CP<3(QAP"<>-E9WV34-5K_ %?+:;EZF4M3#21%
M\U)UK9/L;@71G(\9O+M''B%TQ$'/#T<.MDU-+IBMI:8LHHZ&5E=1BI:]K,[7
MCB"'C)\ASR4M8='NM5ZMUP?<9*I]+;WT3S)& Z5SI \OX<!Q&,85M1!S>FZ.
M[DVADL]5J!DU@FKGULM.*3;*X.E,O5!^[@S)&>&>?)2,.A.JJX)A7YZJ]R7C
M;U7/?&YG5\^S=G/DY*[H@I6E-#>H-=::CP_K_ *2>EV]5MW];*)-W/AC&,*+
MK.CJY2TM9;(-0,ALD]P-Q$'@@=*'F42EA?NXMW9[,\N/?TE$'/*O05UE=?J6
M#4+(K1>ZE\]3!X(#(QK@ YL;]W#(&"2#Y%L5?1['*;BV&N$,557T5:Q@BSU8
MI]F&<^.=G/LSVJ]H@IFI]!P:@N-UJ:FL?&VMHX:9@8P$Q/BD=(V0$\#Q(X$=
MBT9-!W*OH+I!=;S2DU="^BC;1T @C;NYR.&XESO2 %T%$%?9IS;J6VW;PG[C
MH'T75;/9[G,.[.>'L.7E58;T8@T=/3/NTC6Q45?1E\4>UW^M2!^X'/#;C'E\
MBZ.B#GECT!745XL-=4W.@$=HWM93T5O$#) Z,L+G'<3NY'NY\.*Z&B("(B B
M(@(B("(B B(@* T7]Q7+^\ZO^,Y3Z@-%_<5R_O.L_C.03Z(B B(@(B("(B B
M(@(B("(B B(@*$UI8O7+IFNM'A'@_A+6CK=F[;AP/+([E-H@K^K].>N&T4E%
MX3U'@]73U6_9NW=4\.QC(YXYJJTMG9>NF&:[P05D5!;H )NNA,<<U8-S&.;D
M>-MC<[B.'%JZ4B#1OM#+<K154E/634,TK,,J(<;HW=AP>?F[56=*:-J+7J2H
MOERJZ*6MDIA2[:&C%,QPW;B]XW'<[(Y]G%71$%(O&D[V_6%7?K!?J:WOJJ6*
MFDBFH>OX,+B"#O&/9+5J]#W>HO,-WEO-OGN)I!2323VT2-;A[G!\32_Q'>-@
M\P<!=!1!S8]%L;].:=M<MU>XVJJ?*^818-3"Z0O=$X9X9\7)_P!GDIW2FC(=
M/ZDOUV95.F-RD!BB+<"F9DN<UO'CE[G.[.:MB((.IL'7:SHK]X1CP:CEI.IV
M>RWN:[=G/9MY8[57=0='0N-3J#P&YNH:*]P-%33-BW-Z]I!$HXCF!AS?QN]7
MY$'-7]'%;55$T]9=J*,R6V>VB"CMXAB8V0#QP-Q).1QR>X<.VP5FDVSS:>ED
MGZQEHIIJ=T6S'A ?$(SQSXO+R\U:D0<*M-)=:ZMTG9Z:HNSJ*U7".=U'56TP
MFEBC#N$LWL9,<&MV\\YXJXT'1Y66]T5#1W>"*R1U/7L8*)OA0;NW]5UV?8Y[
M=N<<%T1$$!KVDIZO25T\)A9+U4#Y&;AG:X-."/*IR#[2SWH4'KV.=^DKIX-.
MV+$#R_+-VYNTY',8\ZG(/M,?O0@]J*U%9(KW3Q132R1B-VX%F./!2J*5+S2>
M:O="^.N2LUM&XER_5VF8+)013P5$LCGR;"'XQC!/\E*V_0U)54-/.ZKJ Z2-
MKR !PR%L]*'WFIOT_P#RE66Q_>>B_0L^9>C?B<L8*VB>LS+R<?!X9XF])KTB
M(4K75.VDGL5.QQ+8F[ 3S."T*Z5=WM]$\1U59#$_\ESN/P*G])C2ZNM;6G:X
M[@#W'(4U3Z-M8IBVJ9)45#QE\SWG<2>U1OX<X<<Y)GS[?-+%XM<^6N&(\N_R
M6&":.HB;)!(R2-W)S3D%8_#*;PHTWA$7A &3'O&X#S*F]'+WP5ETH"\NCB=E
MOG!(/\EH76B?<=?STD<QA$K0'N'/;L&0/.%7'"QXEJ3/2(WM=]MM.&F2M>LS
MK2_4EQHZN:2*EJ8II(^+@QV<)77&CH0#65,4.>6]V"?0HZDM5OTY1U-52Q.W
M,B)>YSR2X#CYE6=)6IFHI:JZ7G=/E^QC"2!W]G8,X4:X<=N:^YY8_%.W$9:\
MN/4<\_A$+O0W&CK@? ZF*;'$AC@2/0LU140TT1EJ)611CFY[L >E475UFBL3
M:>Z6?-.^.0-<T.)!SRYJ3U;5-KM$>$MY2B-V.[B$^SUM-9I/NVG7QAS[7>L7
MKDB.:L;^$K1!-'/$V6"1LD;N+7-.0?2L4E;2QU+::2HB;4.]C&7@./H4;HSV
ML6_WA^D57;Y^$>W>9G_,HTP1;):F^V_R3R<3-,5,FOO:_->I'LC8Y\CFL8WB
M7.. %HOO=L:R1WA],X,!<0V0$X'D57UF^2OU';;0^1S*63#G@'&[)/\ (?*M
MC56FK9!8*B6EIVP2P-WM<">/'B#WJ=,%/=YYG=O1#)Q.6>?PXC5?5LLO\=ZL
M]YZBGFBCBIGX>_\ 'RUW+X%KZ J8:73!DJIF11B9WC/=@=BSVNK?6:!FDE]F
M*65A/?AI&5!Z(T]!<[?X1<'OE@8]S8X-Q#0>&25=RTC'>L](B8^+-%\DY<=J
M^],UGX=UXH;I0U[BVCJHIG#FUKN/P+<7.-2T$&G]06RHMC3$'G):'$C@<'X0
M5T=9<^*M(K:D]);N&SVR3:F2-6KZ=E7Z1_:V?TS/YK:L5PI*'35N=65,4(,(
MQO=@GS+5Z1_:V?TS/YK3TMIFEJ[7!5W0&JDD8-C2XAL;.P#"OK%)X:.>>FV6
M\Y(XN8QQN>6._;NMM%6TU;%UE)/',P<"6.SA?(JVEFJ'T\51$^=GLHVO!</.
M%1*F :7UA2>!ES*.JP',)R "<$>C@5GU&WU%UE17)@VP5! D(Y=SODP5S[+6
M9U6>DQN/X2^VVK69O'6LZGZ^<+XM6*Y44K)7QU<#V1#,CFR AGG[EJZFK? +
M#65#3AP9M;YSP'SJL6F@%)T>U\KAB2IB=(3Y.S_[Y53BPQ:G-,^<0OR\1-,G
M)6.T3,_LN#[G0LI14NJX/!R<"3>,$]V4H;E1UX/@=3%-CF&.R1Z%2M$Z?@N5
MM957(NFA:YS88<D-;QXD^E8M56V/35PH;C:LQ-+L.9DD9'\B%?\ 9L4WG%%I
MYOR9_MF:,<9[5CEZ?/YNBG@.*C9K]:H9-DEPIP\<"-X.%IZJ975UA$=I8YSY
M]N[#@TAA&3S/F6"VZ4M4%NCCJZ9CYW,!D<]W$.[<'/#T*BF/'%>;)/TAHR9<
MLWY,41K7>=Z6*&6.>)LD+VR1NY.:<@KQ5U5/21=9531PL_*>X *E:$<ZCU!=
M+:QY=3,)<T$]H=C/P+5OSJ>;7/5WU[FT#6C8#D-QCAR[,Y5L<)'B33?2(W\5
M,\=/@QDUUF=?")^?HNU)>;;62]735L$DG8T.XGS+?5.OFFK?76TRV&*$53""
MPPR  ^?CA;-\DN,.B'F4.;6MC:V4@Y.,X)R/)\ZA.&EIKR3WG6I[K*\1DK%O
M$KVC>X[2EZB^VNGDZN:OIVO!P1O!QYUNT\\51$)*>1DL9Y.8<A4G25!IZLM4
M39FP25CA]E$CB'9SV?\ 9;VG++6V?4%6V$'U)D!+27@\>!'#X0I9,&.O-$3,
M3'KY_)##Q.6_+:8B:V]/+YMVJMEHDU+%535#1<!@B'K0-Q X';S_ /Q*8J*V
MFIY8XZBHBBDDX,:]P!=YN]4FY?A,H_,WZ+E\Z16O?>K.R)^R1W!KOR27#!4_
M \2U*VMWC?R5_:?#IDO6L;BVOFM]7>+=1R]54UL$<GY)=Q'G[EN0RQSQMDA>
MV2-W)S3D%5Z'1MJ%,65$<D\[@=T[GG<2>WN47T9S2-]4:-SB61/#F\>7,'YE
M5.'';':V.9]U=7B,M<M:9:Q$6WK7P]5QJJRFI&@U51%"#R,CPW/PJ+NNIK=0
M4S96S-J7/.UK('!Q)_DJWIZCBU'?KI574&80.#61$G !)Q\&%XU)10:?U!;*
MNVQB,2.PZ,<1S .!Y05=3AL<9/#M,S;\NV]*;\9EG%.6D1%=Z^/?6]+Q:JSP
M^WPU1B=%U@SL=S'%1>KKM'06BK9%4QLK2S#&;P'C)QD#FIY537MKHWVFJKW0
M@U;&M:),G@-P[.7:L_#Q2V6.;MMJXF<E<$\L]8C]D1HRW6N44=;4U^;D9"X1
M&49SDXX<_*K);;9::>_U-323M=7.W;XNM!V9/'AS4=HBR6]]IH;@^G!JP2[K
M-QYAQ X9PM/3OX0;K_Z_G"UY9\2V35IZ1^_;Y,&"/"IBYJQ[TQ^G?YKIX93>
M%>#>$1>$8SU6X;L<^2\4UQHZFH?!3U,4LS!ES6.S@<E0=04LE;KTTT4IA,K6
MM+QS#=O'Y%;;?8:2RT\\EMB<:HQ%H>]Q)=VCR<P%GR8,=*Q,SUF(:L7$Y<M[
M1%8U69B9_CXMZMNU!0NVU=7#$_\ )<[C\"RT5=2US"ZCJ(I@.>QV<+GFBX[1
M5/J3>W,?7.DX"<D C'P9SE3$NGIJ#4-'6V!@;2DCKFB08 SQYGB,*=^&QTF:
M3,Q/K/:4,?&9<E8R16)KZ1WAN:TOQMU"!;JN%M8V4-<SQ7.#<'.0?0I*R7>F
MK:6E:ZL@DK'Q@N8UXW;L9/ *M](]KHX:#PZ.$"JDG:US\GB-I[.78%+Z9L5N
M@I:&NBIPVJZH.W[CS+<'AG':4M3%]GBW7?T[_P .4OGGBK5Z:Z><]OY6)%JF
MY4+20:VF!' @RM^M9J>HAJ&EU/-'*T'!+'!V/@6.:S'68>C%ZSTB6&*XT4O6
M]55P/ZH9?MD!V^?N6*EO5MJI^IIZV"24\ T/XGS=ZYYI:TB[WBNBFE<VD8_?
M+&TXZSQC@>93>KM,4--:)*RW1&":GP[Q7'B,^7M6VW#8:W\.;3N?^=7FTXS/
M?%.:M8U'Q[Z]%W6C67>WT3]E5601/_)<\9^!1UAN-3<-)MJ(1UE:(W,'E>,@
M<_05&:9TK"RF?/?J<25CWDXD?N 'H.,\U37#2O-XD]NFH[M%N(O?E\&.\;W/
M:/[K515M-6QE])/',T<RQV<>=9I)&1,<^1S6,;Q+G' "Y_-31V+7-"VVG9!4
M[0Y@=D8)((_FMKI,DE M\;B]M&YY,A;VG_\ %E3^RQ;)6M9Z6ZJ_MMJXKVO7
MK6=?!96W^TNEZMMPIB[E[,8^'DI-I#@"T@@\00JK%8].7.WF.WM@+BT[7L>=
MX/><\?A6?2%)<[?:)Z>O;AS"3"-P=PQR^%0OBQ\LS69B8\I68LV6;1%XB8GS
MCLEZZZ4-"[;5U<,3OR7.X_ O=%7TM<PNHZB*8#GL=G'G7/=(1VFKJ:MU]<QU
M>Z0D"<D CM\F<J8JM/34-]HZ[3T0$&1US6R#&,\<9/:%;?AL=)FDS,3ZSV4X
M^,RY*QDBL37TCO"YHB+"](1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0% 6F:
M,:LOT1D8)2('!FX;B-AXX4^H"TPQ'5M]F,3#,! T2;1N V<L]R"?1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%>U-]_-+?K[_\ #S*PJO:F
M^_FEOU]_^'F5A0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$$!:)HYM6WTQ2,?MAIFNVN!P1UN0?*I]5^SPQ0ZMOPAC9&'0TSG;&@
M9)ZW)/E5@0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!0>MR&Z5N1<0 (\DG
MLXA3B@];M#M*7)K@"TQX(/(C(03,,C)HFR1/:^-PR'-.0?2O:\011PPLCA8R
M.-HPUK!@ >0+V@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("@-
M%_<5R_O.K_C.4^H#1?W%<O[SK/XSD$^B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@@]<31PZ2NW6R,9NII&MW. R=IX#RJ9@^TQ^]
M"AM<0Q3:2NW71LDV4TCF[V@X(:>(\JF8/M+/>A![1$04WI0^\U-^G'T2K+8_
MO/0_H6?,%HZLLC[Y0Q01S-A+)-^7-SG@1_-2E! :6B@@+@XQL#,CMP%IO>LX
M*TB>L3+'CQVCB;WF.DQ"E=(_WSM'G/T@KX.05>U/I^2\U5%*RH;$*<Y(+<YX
M@_R5A'),MZVQ4K$]8V8,=JYLMICI.M?@HFA/;)>O.[Z97V+\*#_>'^&IK3^G
MY+5=*ZK?.V05).&AN-OC97UE@>W5CKQU[=A;CJ]O'V..:T6S4G)>=]ZZ^K+C
MX?)&+'68ZQ;?TW*0U!"ZHLE=%'G>Z%P&.TX5?Z,IV/LDT(/V2.8EP\A PK>J
ME6:5J:>ODK+!7>!ODXNC(\7_ /%Y,*C#>ML=L5IUOK#3GI>N6N:D;UTF'OI(
MG9'I_JG$;Y96AH[3CB5J7B!\/1S#&\'<UD9([LG*S4VE*JKKHZK4%?X48SEL
M;?8__B\F%9Z^CBKJ&6EG'V*1NTXX85GBTQ12D3O4[E3X&3/.3):-;C41_*-T
M60=,4&#GQ"/_ )%5J\R-?TCT(8X.V[&NQV'CP^59J;2EZHRZ"CO BI"<\"X'
MX/\ NMJDT:*2\4=9#5;FPX=('@ESW<<G/8K*SBI>]^?>]_FJM7/DQTQ\FN68
MW]&MKL,JKS;:6E^QW$>,V9S@UK6YX9\N0L]7:]0W6!M)<*VCCI3C>8@2Y^.]
M:FI&-O\ JR&T[6PB!N7S8\<C&<#R<5N2:$I=AZFNJV/["2" I1>N.E(M.IUO
MMM&<=\N3)-:[C>NDZ[>2:K:.*@TM5TL /5Q4DC1GF?%/%1G1M[7/_>=_):.C
MYZNXT-YM=34=:(V&)DKN.-P<.?:.&58=+VE]FMG@LDK93O+]S1CFJ,L>'2^.
MT[G<2TX)\;)3+2-5U,?+JK'21]\K3YS](*^JO:GT_)>:JCE94-B$!X@MSGB#
M_)6%5Y;UMBI6)ZQM;@QVKFRVF.DZU^"K](_M;/Z9G\U(Z1>U^G* L<' 1 '!
MY$=B^ZGM+KS:S2QRMB=O#MQ&>2@QI6XT$;19;HZ'+1UC'9VEW:1SPK*3CO@C
M'-M3M5>,N/B)RUKN-::NM\56J;121',@+=V..,N^H94WKNW^'6"5S!F2G/6M
M\PY_(L.GM,/HJ]UPN=3X56G.#V-\O'F599MG5/ZW'5[3NSRQVI?-%+4C'.^4
MQ</;)7).6-<_Y>CF]RN3[[:[';879GE/V7CRV\./RE7+4D38-*UT48PQE.6M
M'D PJCT>6]DU\JZR,$T]/EL1/>3P^3YU<=5^UNY?H7*WB)BN6N.O:)W^,J>$
MBU\%\U^\QKZ1&D;T<R,=IMC&N!>R1X<.[)R%H=)\K3145,,&1\I<!VX Q_-1
M^F;#55%EAKK37/I*IQ<UX.=K\..%,6W2E2^YQUU\K?"I8B"Q@R1PY9S\RE/A
MX\\Y9MVF>GGM&OC9>&KABG>(Z^6GG6-QJ[9:[;24CS%+.-CI <%N !P[N?-;
M%+HR@ZIKKA)/5SD>,]TA SY%(:GL<=\HFQ.?U<T9W1OQG![CY%#PZ?OLT8IJ
M^\_ZH.!$0\9P[LX"JIDCPXBMN6>N_BMR8;>-,WISQJ->D>J-T1'#%J^Y1TN.
MH:QP9@Y&-P[58*F2SW^Y3VRI@<^II\Y<X;2,'C@\^U>-/Z8%GN]1513-,#V%
MC(\'+1D<SZ%\OVF75=P%PME4:2M'-W'#OJ7<F3'?+OFUTZ3\?BCBPY<>#EY(
MGK.X^'P0M]TL;+22W&T5T\1A\8M)XXSV$*;HM1Q#2]/<+FQSA(3$_8S()R1G
M'EPM*?3M^N3.HNEWC--G);&WB?D"GY+)1OL@M;F'P8-#1QX@\\^?*9,E)K6N
M2W-.^\>CN'#DK:UL->6-=I]?DAI](6BZ01U5()*;K6A[>K/#B,\OJ4?INHK;
M1JA]EJ*@U,!'BDD\.&01W>9;5/I_4%O9U-NN\?@X]BV1O(? 5(:>TV;?6R5]
M=5.JJZ08+R. [U*<L12U;7YHUT]4:X;6R5M3'R3$]9\M>:$N7X3*/S-^BY>]
M>^V&Q>_'TVJ9JM/23:J@NPJ&AD8 ZO;Q. 1S]*^ZAL$EUN5OJF3MC%,X$M+<
M[O&!_DN5S4B])WVKK]7;</DG'DC7>VX^6X6!43HY^^=X\X^DY7M5NP61U@?<
MJN6=LS9 7[6MP0!DK/AO$8[UGO.M?BU<1CM.;'>.T;W^"O6YM74:BN57IU\,
M#0_#V3OX/.3GAW94S26"NK;M#7WZJBD,!S'##[$%0MALD.IIJRY3N-,QTI:V
M.#AQYY/PK+J#3?J'0.N%NN-2Q\1'BN=SR<<"%NO-9OX<6U;MVZ_B\S%6T8_%
MM7==S/?4=^^G05 ZZ]J];_Z?I!;NG:R6OLE)55&.MD9EV!C)SC*^Z@M[KI:9
MZ-D@C=)CQB,@8(*\['_AY8YO*?W>OE_Q<$\GG'3ZPT="^U:B\SOI%06G?P@W
M7_W/G"M>G[>ZUVF"C?()'1Y\8# .23_-1]MT_)1ZDJ[FZ=KF3[L1AO$9(/-7
MQEIS99WWWK\6:<%^7#&ONZW^""JOPG0^8?0*N];4LI*2:HE#C'$TN=M&3@*$
MET](_53+OX0T,:!]CV\?8XYJ?D8V2-S'@.8X8(/:%#/DK;DUUU$;6<+BO3Q-
M]-VF85=MHLFJ*9U=!$^)SG%I>SQ22.\<E U4%7H^\48IJM\U).[[6[NR 01R
M[>:EFZ6N5MGE=8;F(8'G/52#('R'*S46F*N>Y0UU]K_"I(2"R-@PT$<O_N%J
MKEI3>[[IZ>;%?#>^M8^7)OO';YG27QT]&?\ ^(:?D<IW3Y!L= 1RZAGS+U>K
M;%=;?+23DAK^(<.;2.14+8-/W&UU<)==72T4>1U&" <@X[>\Y6:+4O@Y)G4Q
M._FV32].)G)%=Q,1'R>I=%6B21[W-GW.)<?LG:?0I6RVBEL\$D5$'AKW;CN=
MGCR4@BIMGR7CEM;<+Z<-BQVYJ5B)4#H[>P7NZL+@'NX@'F<..59M93,@TU7%
MY W,V#RD\%1],V@W2ON9AJ'TU5!)NBE9V9)R"IM^E+M<)8V7BZB6F8<[69)/
MR +T,]<?C\]K:UKH\KAKY?LTXZ4WO>I_EYLM5+9^C]U4P?97%Q9D<LNP#_-?
M=/:=9>+?%<+Q55%2^;+@SK" !G"M55;*>HM+K<6[:<LV -_%QR*K%)IR_4+#
M345W9'1YX>+XP'P</A5=<U;Q::VY;3._HNMP]J6I%J\U8C6OCZHNX4%#;=:6
MJGMX#6A["\;BXAV[M]"MU\N-M;50VNY0ND-3C:"S+>)QS[%%1:-$%THJR*K+
MG0O$DKI 2Z1V<Y\BEM2V"&]P,W/,-1$<QRCCCR%<R9<=[4W:9U'?XNXL.:E,
MG+6(F9[>6O1#W#0M(0Z6W5$U-,.+03EH/SKYH>]3R6ZX,N#W2BA&[?S<6X.1
MY>2]>HNIC%U#KU'U)&"['C8\^,_*IG3UB@LU ^G:XRNE.97N&-WH[DR98\.:
MY+<T]-&+#;QHOBI-(Z[^/ITVC6VNR:JIW5L4+XWEQ:9&>(XGRCDH&NIZO1UR
MI'TE8^:DF=@Q/^4$<NWFI;UK7"W5,LE@N0@BD.3%(,@?/GX%DI=+UE3<(JR_
M5_A3HCEL;!AO\OF5E,M*;W?=/2>ZJ^')?6L>LG^J.WS6T'(!"(B\M[0B(@(B
M("(B B(@(B("(B B(@(B("(B B(@*#M!'KGOXSQ^P?0*G%7;51T[M97RK=#&
M:EC8(VRD>,&EG$9[D%B1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$%>U-]_-+?K[_P##S*PJO:F^_FEOU]_^'F5A0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$';"#JZ^8_,4O_ %5.*N6*CIZ/
M5NH!2PQQ"6.FD?L&-SCUN2?*K&@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"A-:^U:X_HQ\X4VH/7#&R:3N;'@.8Z+:0>1!(X()MI!:".(7U8:.FAHZ6.GI
M8F10QC#6,& T>0+,@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"@-%_<5R_O.L_C.4^H#1?W%<?[SJ_P",]!/HB("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B((;69 TG>,G_]UD^B5+0?:8_>A06O:.GJ
M])7/PJ&.7JH'R,WC.UP:<$>53L'VF/WH0>T1$!$1 1$0$1$!$1 1$0$1$%>O
M^FFW*L974M2^DK6#'6-X@XY+2?8=03M,=1??L1X'8W!(^16Y%HKQ.2L1'I\(
M9;<'BM:;=8WWU,QM&V"S4UEI##39<YQR^1W-Q4DB*FUIO/-;NT4I7'6*UC40
M(B**0B(@*NZBT_4W>IW,N4M/ 6!KHF@D'R\U8D4\>2V.>:O=7EQ5RUY;]FA9
M+5!:*%M+39(!RYSN;CWE9;M2>'VVII-^SKF%F[&<96TBY-[3;GF>KL8ZQ3DB
M.G9&Z=MAM%KCHS+UNPN.[;C.3GDI)$2UIM,VGO+M*12L5KV@1$44A$1 1$0$
M1$!$1 0@$$'B#P1$%0=I.KHJF66Q7-]*R0Y,;AD!#I6OKY&>K=V?40-.>JC&
M ?\ [YE;T6G[7D]>OKJ-_BR?8</;73TW.OP>((HX(610M#(V -:T<@ O:(LW
M=KB-=($1$!$1 1$0$1$!$1! Z;T^;-55LQJ!+X0<XV8V\2>_RJ>1%.^2V2W-
M;NKQ8JXJ\E(Z"(B@L$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 4':/;-?_ /=_H%3B@+3+&-5WZ(R,$I$!#,\2-G/""?1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%>U-]_-+?K[_ /#S*PJO:F^_FEOU
M]_\ AYE84!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1!!VWVW7S]!2_\ 54XH"T2QRZNOO52,?MAIFNVG.".MX'RJ?0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!0FM?:M<?T8^<*;4)K8ANE;D7$ "/))[.(038
MY!%YAD9+$U\3VO8X9#FG(/I7I 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0% :+^XKC_>=7_&>I]0&B_N*Y?WG5_QG()]$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!#ZS]J=X_5)/HE2L'VF/WH4/K
M>6.+25VZV1C-U-(UNXXR=IX!3$'VF/WH0>T1$!$1 1$0$1$!$6A;;O0W*2:.
MBGZQ\7LQM(Q\(\B[%9F)F([(S>L3$3/66^B(N)"(J]2:A?/JB>TFG:&1Y^R;
MN)P,\E.F.U]S7RZJ\F6N.8BWG.H6%$106"(B BT[Q6&@ME35-8'F)A<&DXRM
M;3-U=>;6*M\0B)>6[0<\E.,=IIS^2N<M8OX?GK:510%JJ[U+?JN&NI6QT#<]
M6\#R\,'MR%/I>DTG4R8\D9(W$3'S$1%!8(B("(B B(@(B("(B B(@(J])J![
M=5LL_@[2QPSUF[C['/)6%3OCM37-Y]5>/+7)OE\IT(M*Z72CM<3)*^;JF/.U
MIVDY/H"W(WMDC:]ARUP!!\BC-9B-ZZ)1>LS-8GK#ZB@;)?GW&]7&A= V-M*Y
MP#P[.[#L*>4KX[8YU9''EKECFKV$1%!8(B("(B B(@(B("(B BK^JM0/LCZ1
MK*=LW7$@Y=C&,?6I]IRT'O"G;':M8M/:5=<M;6M2.\=_J^HB@9JN\C4T<$=*
MTVL@9DQV8XG/?GL2E)OO4]C)DC'K<3.YUT3R(B@L$1$!$4!?ZN]07&C9:Z5L
MM,['6.(SQSQ![AA3QTF\ZB5>7)&.O-,3/R3Z(B@L$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!0%IAB.K;],8V&8"!H?M&X#8>&>Y3Z@[1[9K_\ [O\ 0*"<
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%>U-]_-+?K[_\
M#S*PJO:F^_FEOU]_^'F5A0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$%?L\,4.KK\(8V1AT-,YVUH&2>MR3Y58%!VWVW7S]!2_\
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M0P,8Z7@R5G 9)X>0A26@XVQZ9I2P %^YQ\IR5(7*T4-RDADK8.L?%[ [B,?
M5"^3%6\XYI[L=/BGCPYK4KEK>>:=3J>WR5+I0.V2V$\@7'YELON.I;A%U]KH
MV4]+C+.LQO>._![UK=)WVVU^^=_)7J/[6WS!2MDC'@QSRQ/?O\T:8IR\3EB+
M3$=.WR5[1U_EO#)X:R-L=7 ?&VC (\W85CJ;Y5QZSAM;1%X,\ G+?&]B3SSY
M%%Z-X:RO0'+Q^'_K2N_";2^]'T"I3AIXMXUTY=H5SY)P4F9Z\VOGU6#5%^;9
M8(Q''UU7,<1Q_P S\BAW5.KXX35NAI7, W& #Q@/G^51^K9*CU\4?@T0FFC8
MQT<;C@$Y)4OZIZI]QH/^(/K2N**8ZS$1,SUG;M\TY,EXF;1$3J.6/U;%'J"6
MZZ<JJNWL:RM@'C1.&X9''TY"V=(7A]YM77S[!.QY8\-&!Y/D43HBUW"AK[A)
M74O@\4X!#0X$9R>' ^5:VE2;1JZXVMW"*8E\8\W$?(?D4;XL<Q>M/+K'R\X2
MQ9LL3COD\]Q/S\I^J7UA?*BU"DAH&QOJJA^ 'C/#E\Y"P:COE=:[A:Z:/J7=
M> )26GGD XX\%HQ__AGI">[V5/0-X><?_I$_ L>OO;!9O./IA2QXJ1:F.8ZZ
MF9_9#+FR33)EK/3<1'TGK^*8UM>JJRTM-)1B,ND>6NWMSPQYUHFZZBNL0FM%
M''!38\5\N-S_ "C/8L?2E]P4/Z5WS*WT Q0TX'+JV_,JXFN/#6_+$S.^Z[5\
MW$7Q\\Q6-=E>TAJ&HN4]117&)L=9!Q):,9&<'([\K[>M050NPM5EIV358&7O
M>?%9Y%%6+ATC7$#D=_\ )>73,T]KFIJ*_(IJII+9,9QDCYB,*V<-/$F8C^G<
M1\5$<1D\&(M;^K4S\/\ GF\ZAN5^I614MT?#34\[P#4TP)(':.:M]AMC+50]
M1'.^<.<9-[^9R!]2J6M+K37R.EMMI=X3.Z4/W,' <".?I^17JFCZFGBBSG8T
M-SWX"JXB9C%6)C6][C]U_"UB<]YB>:(UJ?UAD1$6%Z0B(@(B("(B B(@(B("
M(B B(@*$M'MFO_\ N_T"IL$'D05"6CVS7_\ W?Z!03:(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@KVIOOYI;]??_AYE857M3??S2WZ^_P#P
M\RL* B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@@[
M;[;KY^@I?^JIQ0=M]MU[_04O_54X@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("A-:^U:X_HQ\X4V2!C) SP"A-:^U:X_HQ\X038Y!$'((@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("@-%_<5R_O.L_C.4^H#1?W%<O[SJ_X
MSD$^B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@AM9
M^U.\?JLGT2I:#[3'[T*)UG[4[Q^JR?1*EH/M,?O0@]K0U!]XKA^@?]$K?0@$
M8/$*59Y9B4;UYJS7U5+HR^\,OZ8_,%J=(OW?9OTA^=JN[6M:,-  \@1S&NQN
M:#CED+1'$ZS3ETRSPF^'C!OTZ_5]5$T#[8;UYS],J]KXUC6DEK0">> J\>7D
MI:NNZS+@\2]+[^ZHMT;/IO53[HV%\E!4C[(6#.,\_E&5L7C6='-;Y(;7U\E7
M*W8S#""TGM\_F5R< X$. (/85ABHZ:%VZ&GAC=WM8 5;'$4MJ<E=S'Q_53/"
MY*\U<5]5M\.V_1':3IZRGL\?JE+))4O)>=YR6@\@J;::_P!:M^N,=P@EZJ4^
M*YC>?$D'RC!72E\<QKO9-!\X4:<1J;<T;BWT2R<)N*<EM37M/=0M;/=4LLUY
MAB=)2-PYS2.0R",^?DI1^M**6)K;=#/4U;QAD(81Q\JM)8TL+"T%A&,8X86.
M&E@@),$$49/,L8!E2\?'-(K:N]=NOZH_9LM;VM2^N;6^GZ*-T>=;ZN7;PAH;
M,1XX'('=Q6C-55%#KJOJZ:G=4"(ETC&\]F "0NEAC6DEK0">9 0,:'%P:,GF
M<*7VN.>UYKWC6D/L$QCK2+?=G>U*NVMJ2:W2Q4$<[JJ5NQH+<;25):'M+Z"P
MN95,+9*EQ>]A[ 1@ ^CYU/-I*9LO6MIXA)SWA@S\*S*N^:O)X>.-1/=;CX>_
MB>)EMN8Z1TTYW:*M^CKI5TEPBE-%,=T<C1GEG!^#FLNI+^-0PLM=DAEE,C@7
MO+<# _[]I5]EBCE86RL:]I['#(7F"GA@!$$4<8//8T!6?:J3;Q)K[WSZ?-5]
MBR12<-;^Y\NORVB)K2Z+23[9!AT@@+!Y7<S\)5?T#>(Z9C+/4PS1U)D<02WA
MRSQ[N2O:^;&[MVT;N_'%55S^Y:EXWOK]5UN&UDK>DZU&OHH>EO;[=O-)],+)
M47.KT[J:H?<G5,UNGR8SG<&Y.> \G+"O 8T.+@T GF0%\DC9(TMD8U[3V.&0
MISQ,6MNU>FM*XX.U::K;4Q._[*-JK4MNNMJ?14+9*BHE(VCJSXISS6Y64<E!
MT=/II^$K8LN'<2[./E5IAI*>!Q=#3Q1N/:U@!68@$8(!'<4^T5K%:TCI$[=C
MA+6FU\ENLQKI"O: ]K%-[YWTBH?57MXLOG9],J\-:&C#0 .X(6-+@2T$CD<*
M->(UEMDUWW^:=N%WAKBWVU^3Y+]J?[TJD=%WVJX^_;_-7E?&L:S.UH;GN&%"
MF7EQVIKOK\D\F#GRTR;^[O\ -]7.+'71Z:U!<8[JQ[1*3ME#<Y&2<^8Y71UB
MGIH)\=?#')CEO:#CX5W#EBD6K:-Q+G$8)R36])U-5!U;?W7BU31VZGD-"PM,
ML[VXR<\ /3A3!_!Q_N?\E:6Q1MCV-8T,_) X? ONUNW;@;>6,<%9/$5Y8K6N
MHB=JJ\);FM>]MS,:[*YT>>U>#W[_ *141KCVT67SM^FKTUH:,-  [@CF-<07
M-!(Y$A1KQ'+EG+KOO\TK\+S8(P[[:_)6.D"URU]J9-3-+YJ9Q=M',M//'P!:
ME#KJB;0QBJBG%6UNUS&MR"1W*YK#X)3"7K13Q=;^7L&?A2F:G)%,E=Z[&3A[
M^).7%;4SWZ;<ZM<U54Z^IJBNAZF64%PC_);L.!\"Z6OFQN[=M&[OQQ7U1SYO
M%F)B-:C2?"\/."+1,[W.U5Z1J&:KLL;X&%YADW.#1D[<$9^99-+ZFIKCX/0M
MBF94MB\;(&W@./'*LR\MC8TY:QH/> NQFB<7AVCMV<GA[1F\6EM;[QKT4G1O
MMOOWOW_Q"I3I"]K,_OV?.K&&-:20T GF0.:.:'##@".XKL\1O+&37;7Y(UX7
MEPVP[[[_ #5RRTSJO0L5.S@Z6F<P><Y5<TIJ2&Q4<U!<H9F21R$C:WX0?@71
MP !@  =P6&6DIY7A\L$3WCDYS 2I5XBOO5O&XF=HVX6\<EL=M36-=N[FFH;C
M47:ZVRJ?2O@I#(&P;_9/ <,D_(K3KEMQBIZ>LMTDVV!V961N(RWOP.:LQ8TX
MRUIQRX<EZ79XJ-UU7I5RO!3J\6OUMKK\E6BUQ:7TVZ4S,DQQBV9.>[/):'1]
M22ON%PN74NAIILMC:1C.79X>97!U#2.?O=2P%_/<8QE; &!@< HSGI6EJXZZ
MW\4HX;):];Y;1/+VU&A<XM-;'IK4UR;=(WM;,XEDH;GAN)!'D.?D71UCGIX9
MP!/#'(!RWM!Q\*AARQCBU;1N)6<1@G)-;4G4U4+5FH#>+5-%;*>1U&P@S5#V
MX'/@!Z5.6FA%RT+!2...M@P#W')(^56)L4;(Q&R-C6#\4# ^!>P !@  =P4[
M<1')%*1K4[5TX6WB3DR6WN-=G/\ 3>H!I^%]LO4,T1B<2QP;G@3\WE7JINM7
MJ:]4L-G-3#1Q',L@.W(SQ)Q\@5ZGIX9P!/%'(!RWM!^=>HHHX6!D3&L:.QHP
M%.>)IN<D5]Z?P0C@\G+&*;^Y'PZ_+:B])WVVU^^=_)7N/V#?,$<QKL;F@X[P
MOJHOEYL=::[;_-HQX.3+?)O[VOR4/1OMSO/_ +GTU]KOPFTOO1] J]!C6DD-
M )YD!-C=V[:-W?CBKIXKWYMKO&E$<%K'%.;M;:GZXM]3'64=YH(S))3$=8T#
M)P#D'S<\K,-=6OP7>6SB;'VK9QSY^2M:P&BI3)UAIH=^<[M@S\*C7-2U8KDK
MO79.W#Y*WM?#;7-WW&_JKFAQ<JCPNNN,DHBF/V*)Y/ 9SD \AV+2U_$^AK[=
M>*8?9(W;'GOQQ'\PKNOCFM<,. ([B%RO$:R^)KIZ? MPF\'A<W7U^/=5>CJC
M,=JEK91]FJY"[)Y[0<?/E1VOO;!9O./IA7P  8  '<%\<QKB"YH)'+(7:\3,
M9IRS#EN#B<$8(GMK^5*Z4?N"A_2N^97"@^XJ?]&WYEE<QKO9-!\X7U5VR\V.
MN/7;:VF#ERVR[^]K\E#L?X1KC_Z_Y+4NLLE+K"K/@L5V=(.$6"XQCNQV+HP8
MT.+@T!Q[<<5SVV5ATO?KEZJ4\QCJ'Y;.UN<C)/RY6W#E\6;6B.L1$:]7G9\'
M@UK69Z3:9WZ-B#43K5E\FFW4D1X.>QNW^2N-LKX+E11U5*[=$_O&"#V@JJWG
M5M'76^>CMT$]3/.TQAO5\!GM4QHRV2VNQQPU(Q,]QD<W/L<]GR*K/2/#Y[5Y
M;;]>Z_A<EO%Y*6YJZ[ZUJ?HG$1%A>D(B("(B B(@(B("*OZAN][H*QD5JTW-
M=8#&'&9E7%$&NR?%P\YY '/E56CZ2+EZYZ6Q2:3J?#I7#K&PUL4W4,) +Y-I
M.T#.>.,H.DK6N5?2VRBEK+A41T]-$-SY)'8 "V5AJZ:"JB#*F&.5C7!X:]H<
M X<0>/:$$!3ZTMD^DX=0,;4&CG?U<$89]EE>7EC6M;GF2. ^'"S6N]1ZABN%
M"QE=:KA  V6*9K6S1!PRU[<%S2#QP>/(KGU#]@Z.-+5TF124%Z%14NQD,C$\
MC2\^0%P)\G%6K3E5!=ND.]7*VRLJ*".A@I3/$=S'RASW$ \C@.&<=Z#<Z,XA
M#I;J@^1XCJZI@=(\O<0)WCB3Q)\JR4ERH:+5-]965E/ ]P@(;+(&DC8>/$JQ
MP0Q0,V01LC9DNVL&!DG)/I*K5O%/)K:]Q349D>60$3.B#FM&P\-W8?(@M ((
M!!R#R(1!P'!$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!7M3?
M?S2WZ^__  \RL*KVIOOYI;]??_AYE84!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!8ZF>&FA=+4RQQ1-YO>X- ])61>9&,D86R-:YIY
MAPR$%>L5735FJ;Y)1U$4\8AI071/#AG[+PR%8U6-.&$ZKU"(*5U,UK*=I#H]
MFX_9?&'>#WJSH"(B B(@(B("(B B(@(B("(B BPUDDL-)-)3P&HF8PN9$'!I
M>0.#<G@,]Y5(N.L]06VBEJ[AHV2FIHAN?++=*=K6CS[D%]15CH_U14:LM#[A
M-9JJUPE^(>O<#US<>R;Y/G5G0059JJUTVIJ&P&;K+G5[B(X\'JPUI=E_=D#A
MWK2NNMZ"W5M9$^DKYJ:A<UE960QAT-,2 ?&.X'@""< X!XK5U+30PZYT?)#"
MQCY:JI?(YK0"\^#N&2>WDJM<;A2VS3_2#9ZZ1K;I5U-0:>F=[.H$S (]@_&R
M3CARP@M6K:8G5>D:T54[F.KC&V$/Q$!U$Q+L#F3PXG.,<.U2^N'!FE+DYQ#6
MMCR2>0&0MVUT0CM=MBJXV/GI8F %P!+7AFTD'L/,>E:.NB!I&Z%S2]HBXM R
M2,CACM02=#<:*MW-HJNGJ"T N$4@=CSX*VEJ6QD'@L<M/2^#![?8&,,</(0M
MM 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0% :+^XKC_>=7_&<
MI]0&B_N*Y?WG5_QG()]$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1!6]<7.AATY=Z:6MIF5!I7@1.E:'$EIQPSE6&#[3'[T*N](#:>
M/2]RDDHS/(Z![0YD0>6G:<.)[ .]6*#[3'[T(/:(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("^/8UXP]H<.XC*^H@\1PQ1G,<;&G_9:
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M6LF8 71DC@X \,A4EFB]2,<'#I NY(.<.I8"/HJ[UL4D]'/%#.ZGE>PM;,T
MEA(X. /#@J=ZT=1?_P!^73XK!_2@VM!W.Z355[L]]GBJZRU3LC%7'&&==&]@
M>TN:. <,D'"MJ@]):;I].4M2V.HJ:RKJY3/55=2X.DF?C&3@      <@IQ 1
M$0%!ZX);I.YN:TN(BR&CF>(X<5.*$UN0W2MR+B !'DD]G$()6BE?/2QR2P24
M[W#)BD+2YOD.TD? 5F7B"6.:)LD+VR1N&0YIR#Z5[0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!0&B_N*X_WG6?QG*?4!HO[BN7]YU?\ &<@G
MT1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%?U[/)#
MI*Y]532U&^![7=66C8"T^,=Q' >3)\BG8/M,?O0H;7$T4.DKMUTC(]U-(UNY
MP&26G 'E4S!]IC]Z$'M1^H*QU!9:RIC]FR,[?(3P"D%%ZHIGU>GZZ&,9>8R0
M._'''R*>+4WC?;:O-,QCM->^I5'1<MDIJ)U3<IX#72O)=UO$M&?Y\UK:GJK;
M2W6AN-CFAZUKOLC(N X=N/*,A2>A*&U7&S!M11TTM5$XM>7,!=@G()_^]BV-
M1BQV1U.PV>FGEF. QK0"!W\EZG/6.(F-3,]>G33Q8QVGA:S,UB.G7KO?\L72
M36/%!1TD1(%2[<[R@8P/A/R*=MNGK=36Z.G?20R';X[GM!+CVG*KO25"YL=L
MJPT[(W%KAW<B/F*NE'4Q5-)%41/:Z)[0X.!X++DM->'IR?'?S;,5:WXK)S]9
MB(U\G/K50QVWI$92P%QB9N+ 3G +"<+:U'^$&U^:/Z16*CJHJSI*$M.\/C\9
MH<.1Q&1P635+A#KRUR2';']C\8\O9%;.LY8YN_(PQ%8PVY>WB?PO53]SR^\/
MS*E=%GW)</TC?F5ONE5!24$TU1(V.,,/$GGPY!5#HL^Y+A^D;\RQ8HG[/DGY
M/0S3'VO%'S_1CTW^$"[>>3Z07NR@677-70^QIZH99\X_F%YTW^$"[>>3Z06S
MTA4[Z=]!=X/ME/(&NQW9R/E!^%:K3O+X<_U5B/KY,5(Y</C1WK:9^GF]=(]4
MXTM);H>,E3("0.T#E\I'P+?OEEJ)M-0VRWOC9L#6O+S@$ <?E4-;WC4.N#5M
MXTM'&"W(YGL^4D^A;/236SP4E)30O=''.XB1PX9 QP^55UK:ML>&O?O/S_\
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MN%ON=-#)4QN\3K&Y.!D'&?0H\+RQCR3._+MWTGQL6G+BB-:Z]^VV76DMDJJ
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MFGJUSW %\9C:.\NX?S3-?)&>L1/H[P^/%/#7FT1Y[1&F[M(S1$M4\[I*5KV
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MHR&N$0PW=AV?Y+TJ3$WR=9F=3OT>3>MJX\4ZB(W&O7_GJZ,B(O)>X(B("(B
MB(@CM1/J8[)624%734=2QF]D]2,Q,P<^-Y" 1GLRN=6+I#N6JKI;[71,IK.]
MQZR:JJ#O;5M:[#A29 #P<>R., C@NFW*@I;G124E? RHII,;XGC+78((R/.
MM6\VRTU=)3QW6"F,$$L;H.LPT1R C9M/8<XQA!)HB("(B H"TPQG5E^E,;#*
M! T/VC<!L/#*GU7+5).-97R-L#33EL!=+OXAVS@-N./GR@L:(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@KVIOOYI;]??_AYE857M3??S2WZ
M^_\ P\RL* B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H#1?W%<O[SJ_XSE/J
MT7]Q7+^\ZO\ C.03Z(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B"&UG[4[Q^JR?1*EH/M,?O0H+7L\D&DKGU=-+4;X'L/5EHV M/C'
M)' >3BIV#[3'[T(/:(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M+"[/FKAISV6]5/1%VK;E5W%E;-UC8B P;0,<3W>9:XL-\MD9JZ6[R5,S/&=
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M=[\W(XRGAVO:-<O28^*RHJ8=,7AL)G;?:@UN,[<G;GNSG^2W]%WN:YT\]/7
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MW I?W@/Z%8$05?3,U9/J:^NN-)'2R]32@,9-UH(^R<<X"M"@[;[;KY^@I?\
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M B"O^J.HO<"E_> _H3U1U%[@4O[P']"L"(*_ZHZB]P*7]X#^A/5'47N!2_O
M?T*P(@K_ *HZB]P*7]X#^A/5'47N!2_O ?T*P(@K_JCJ+W I?W@/Z$]4=1>X
M%+^\!_0K B"O^J.HO<"E_> _H4'I&OO[:.X=58Z9X-QJB2:X#!ZYV1[!7Q0&
MB_N*Y?WG5_QG(/GJCJ+W I?W@/Z$]4=1>X%+^\!_0K B"O\ JCJ+W I?W@/Z
M$]4=1>X%+^\!_0K L554PTD#IJF5L43>)<XX"[$;Z0Y,Q$;E">J.HO<"E_>
M_H6I<-17>WQ=96VBBB;V;KB,GS#9Q4;=M95-;/X'IZ%[G...M+<N/F'9YROE
MMT555DOA-^JGESN)8UVYQ\[NST+97A8I'-GG7P\V"W&SDGEX:O-\?)C;TASR
M,(%K8R7.&_9R\'_XA?/#M6W;[GA?3Q'M# P?"[BKI;;-06UH\#IHV._+QEQ]
M)6^GVC%C_P NGUGJY'"Y\G7-D^D=/S<NKM.ZLG;Q=UQ[I*O _FM)NC]2'[91
MTV?UO/\ RKKR+GV_-Y3KZ.Q[,X?^J)GYS+D1T=J(>QHJ?/ZV/Z5GHM,:KA>2
M&,@[C%6$GY@NK(D<?F\YW]"?9G#^4:^LN=CUX6L;CUE0P<QPE_[KTW7M93L<
MRLMC73@<!O,>?/D%="6O6T-+71[*N".9O^VW.%W[3CO_ )E(^G1S['EQ_P"3
MDGY3U52UZMN5TX4=IHW/_(=<-KO@+%)^J.HO<"E_> _H45=M"PN)EM,SH)1Q
M#'DEN?(>84?2Z@O.G:@4U[A?-!V.<<NQY'=OI3[-3+&\%M_">Y'&9,,ZXFNO
MC'99?5'47N!2_O ?T)ZHZB]P*7]X#^A25INM)=:?K:*4/ ]DWDYOG"WECM6:
MSJ6^MHO'-6=PK_JCJ+W I?W@/Z$]4=1>X%+^\!_0K BXDK_JCJ+W I?W@/Z$
M]4=1>X%+^\!_0K B"O\ JCJ+W I?W@/Z$]4=1>X%+^\!_0K B"O^J.HO<"E_
M> _H3U1U%[@4O[P']"L"(*_ZHZB]P*7]X#^A/5'47N!2_O ?T*P(@K_JCJ+W
M I?W@/Z$]4=1>X%+^\!_0K B"O\ JCJ+W I?W@/Z$]4=1>X%+^\!_0K B"E:
MKK[\_3-T;/9*:.(TT@<\5P<6C:<G&SBKE!]IC]Z%$ZS]J=X_59/HE2T'VF/W
MH0>UH:@^\5P_0/\ HE;ZPUU.*JBGIW' E8YF>[(PI4G5HF4,D3:DQ'HJ_1E]
MX9?TY^8*/TA[=[MO]G]DQ^V%FTI#>K)5>I\U!UE))+DS \&CO^99K_9Z^BOK
M;U98Q,X_;8NT\,'S@KTK37Q,E=Q[T=)>12+>#CMRS[D]8TME9M\#GWXV=6[.
M>[!5.Z+P30W $9B,@ ![\<?Y+Y7W:^WBE?0TMHEIC*-LDCR> [<$XPK)IJTM
MLUJCIMP=(3ND<.UQ5$QX.&U;3UF8_)IK;[1Q%;TCW:Q/7MW\E6TQ.VQWN]4,
MKML+&NE9G_9X_,5YT_;'7'2MXJ9073UCG/;Y2W)'RY6375EK9[G'5VR"20RQ
M&.78/1Q\X/R*W62C\ M-+2]L<8#O/V_*KLN:(I&2L^];6_HSX.'M;).*\>[7
M>OK_ &407G_]7A@W?9NL\&QVXY_-P4_44+K?H"6F8/LC:?<_'>>+OYJOMTS7
M>N8P&"3U-\)ZTO\ Q2.?_9=&FB9-"^*098]I:1Y"N<1DI2:\G6)GF2X3%DR1
M;Q(U,1RQ_P _!S_2-ON]39F26ZZLIH-[AU>S.#GBMN[:;NE;$QMSO<#HVNRW
M>S;Q6.BAN^E*B>*"C=76^1VYI9S'P<CZ%\K(+MJRKIXZFB=0T$3MSB_F?AYG
MT*V;6\2;Q,17UZ;_ )VHK2D8HQVK:;]M;G7\:9NDEI98K>PNW%L@&X=OB'BK
ME1_<D'Z-OS*L:_MU366NDAH*=\ICE]BSL&TA6BE:6TT+7#!# "/0L62T3@I'
MQEZ.&LQQ%YUTU#(J"_\ "@W?Z/\ AJ_*H:QLU8^OI[M:&[JJ' <P<SCD1W]V
M$X2T1::S.MQ,''4M-*VK&^68E;U1.C?[NN^/RA\[EL"[Z@ND9I:>V&C>_P 5
M\[\@,':1E?= 6NLMM3<16021AVT-<X>RP3Q5M<?A8<D6F-SKIOXJ+9?'XC%:
MD3J-]=?!J=&H_P!?NW6?;<MSGGS.5;-1[?4"X[_8]0_YBJU<+7<;'?I;I9H/
M":>8'K81S&>?#S\5BN=;?-10> T]LDHX7D=8^0D</.<<%/)3QLL9JS&NGGV5
MXLGV?#."T3S===.^VWT=!ATU.*C;U)E<#N/#&!E:[M*UM'(^HTW<]L;OQ'.X
M>;(R#Z58(+%%%IMUI#O%=&6E_>X\<_"JW::N]:<A=0SVN2K@8XF-\7E\V>"5
MR3>U[8I[SVGSCZNVQ5QTQTS5G41WC>XGZ,]MU!<:.[PV[4-.S?*0V.5K1G).
M >' C*TM8QSR:SM[891"]S6"*0\0T[CQ^%;#:2YZCOM)65M$:.CIB" \\3@Y
MQWJ7UE8Y;I##/0N#:VG.6<<;AW9[^"E%\>/+6>D3,=?2)0FF7+@M$;F(F)C?
M>88/4C4?NZS_ (0^I-+6.2VW:KJ9J^&IEE:0]K.!SG.2%KMU)>V0F&2Q2FJ
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MOBXGB)IBKVGK,_HT:V]7^LI)J>:P/,<K2P^(_M7KHUK'Q^&6NIW,EB=O:QW
MCL<,>?'PJ\JE7&VUM%K6&XT--)+3RXZTL'+/!WUJ>/+3+2V+45\_K"O)AR8,
ME,W--NNI^4_)JWO\(]!_[?\ -7]4+5-#=!JN*X6^B?.(FL+3C+21E9_5O5?N
M,S]@_P!2[DQ3EI2:S'2/5S#GC!DR1>L]9]%V5/Z3_O)3_IQ]%REM-5MUK&U!
MN]&VF+2WJ\ C=SSVGR+2Z0*&IK[3!'1P/F>)@XM:.(&"J>'KX>>(M/9HXJWC
M<+::Q/7\>Z:L?WFH?T#/HA9ZX@4503R$;L_ 5BM$;X;51QR-+7LA8US3V$!:
MNJZD4FGJ^0G!=$6#SNX?S5,1S9-1YROFW)AW/E'[(3HP^\U3W=><?LA7!5W0
M-(:73<!>,.F)D/F)X?( K$I\5:+9K3'JAP-9KP](GT$1%G:A$1!":UI*.MTM
M<H;G5^!4O5[W5.1]A+2'!_'N(!QVKEC*BEO=TA>S4,U-17&LI(*]E3;'Q&HJ
MH6L<TL)/V(2#9S''AA=*Z0XJ6KTM5T55<:2WOJ-O4RU3PUAD:X.:#GF"6@$=
MQ5)I+%JZ\UE9#<[?;**WU]?3UU14Q59F.V(1^+$W:/9&,<21@%!UI$1 1$0%
M"6CVS7__ '?Z!4VH.T>V:_\ ^[_0*"<1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$%>U-]_-+?K[_P##S*PJNZG.+[I4=]>__#S*Q("\3S1P
M0OEF>UD;!ESG'  7V61D,3I)7!C&C+G$X "YO=*^LU?=A0V[<RA8<DG@,?E.
M_D%HP8)RS,STB.\LO$\3&"(B(W:>T,MWO]?J*K=;K&Q[8"<.>.!>.\GL"L&F
M])4EK:V6H#:BKY[G#Q6^8?S4I8[136>C$%*WQC[.0\WGO*D5/+Q/3P\/2OYR
MJP<)/-XN>=V_*/D(B+(WB(B B(@(B("(B 0""",@JH:DT;!6!U1:PVGJAQV#
M@Q_U%6]%9BS7Q3S4E3FP4SUY;QM0=/:IJ:"J%MU US2T[1*_V3>[=WCRJ^M<
M'M#FD.:1D$<BH?4E@IKW38>!'4M'V.4#B/(>\*J::O-38+@ZTWG+80<,<3D,
M[B#^25KMCIQ-9OBC5H[Q_#%3+?A+1CS3NL]I_:71$0$$ @Y![46!Z8B(@(B(
M"(B B(@(B("(B"#MOMNO?Z"E_P"JIQ0=M]MU[_04O_54X@(B("(B B(@(B("
M(B B(@(B("Y9TBBSTM\KZ:INM5#->:>&&6FIZ4S=5*) (*@N'L '<,'@['D7
M4UR?6-!<+C>KN=*26J[>%FD-73FK#)J=\$@<.PY:X#&#C!XH+#T8L,IO==5W
M:.Y7.:J$-5U=,:<0F)NP-V.)(X<<GGGAP5W57T5:KG35-WNM]930U]SE8\TU
M,\O9"QC-K1N(&YV.)./F5H0$1$!0FM?:M<?T8^<*;4)K7VK7']&/G"";'((@
MY!$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4!HO[BN7]YUG\
M9RGU7]%'-#<3_P#Y.L_CO06!$49J&\P66A=/-XTAX1Q@\7'ZE*E9O,5KW1O>
MN.LVM.H@OUZI;-2&6H=F0_:X@?&>?J\JH]/2W;656)ZEY@H&GAP\4>1H[3Y5
M[L%FJM35SKG>'.\&SP;RW^0=S5T6&)D,38X6-9&T8:UHP %NFU>$CEIUOZ^G
MR>;6E^.GFOTQ^4>OS:=GM%':8.KHX0TGV3SQ<[SE;Z(L%K3:=VGJ]*M*TCEK
M&H$1%Q(1$0$1$!$1 6&LI(*V!T-5$R6)W-KAE9D78F8G<.3$3&I<[O&FZVPU
M)N%ADD=$WB6#BYH_Y@K#I74\-Y9U,VV&M:.+,\'^5OU*QJD:NTNYKS<[,#'.
MP[WQLX9_VF^7R+=3+7B(Y,W?RG^7FWP7X2?$P=:^=?X7=%6=&ZC;=X/!ZDAM
M=&./9U@[Q_-699,F.V*TUMW;L.:N:D7IV$1%6M$1$!$1 1$0$1$!$1!#:S]J
M=X_59/HE2T'VF/WH45K/VIWC]4D^B5*P?:8_>A![1$0$1$!$1 1$0$1$!$1
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M8SP+&W83-LY9VG.?3A7E0XF*UY8K&HUOX_5/@K7OSS>=S$Z^'3T$1%E;A$1
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MMO%>]CQW^&OP>=P7N9<N/X[_ !>D1%B>B(B("(B B(@(B("(B B(@(B("(B
MA.!E%IWFI%'::NH/_EQ.(\^."[6.:8B$;6BL3:?)2-"?ZUJNYU7XN'G]I_#Y
MET-4?HNIBVDKJEP^V/:P'S<3\ZO"U<=.\TQ'EJ&+V;68X>)GSW(B(LC>(B("
M(B B(@(B(*Y8Z9E-JW4 C=*[K(Z:0]9(Y^">MY9)P/(."L:@[;[;KW^@I?\
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M65\J-\VYK8&;!(X,/B'B6YP3Y4%B1:4MVH(KO!:Y:N%EQGC=-%3N=A[V X)
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M2GZ_)_AIE8T$5J2RQ7J@,+\-E;XT<F/8GZE4M+7N:R5CK/><LC:[#'N_$/\
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M0$1>(YHY'R,CD:Y\9P\ Y+3C.#W<$'M$1 1>)I8X6!TKVL:2&Y<<#). /22
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M_(_6IVFU?9IP,U75'ND80JK\)FIWJOQ\=P^3M:/KT3Z+0%YM[XW.BK:=^!G
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M9+$R2)S7QO <US3D$'D0@](O,LC(HGR2N:R-@+G.<<  <R5Z:0YH+2"#Q!"
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M3UL6_P#.7#X]-_4IM$$!-I*US,#)O#7M#@X!U;,1D'(/LNP@%9/6Q;_SE?\
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M4]4^GZJ4@OPT Y=CD3GEV('K8M_YRX?'IOZD];%O_.5_QZ;^I3:((3UL6_\
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MC*2Z1M<SHG2^&O=$[>PNK9CM=@C(\;G@GX5/H@A/6Q;_ ,Y7_'IOZD];%O\
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MV+?^<K_CTW]2>MBW_G+A\>F_J4VB"#]:]OQC?7_'IOZEX@TE:Z>%D,'AT<3
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01 1$0$1$!$1 1$0$1$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g73463g01n38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01n38.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[27:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    );T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 /_A0$IH='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#8N,"UC,# R(#<Y+C$V-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @
M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @
M(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*
M(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @,C(N
M," H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#
M<F5A=&5$871E/C(P,C4M,3$M,3=4,3<Z,3,Z,S(K,#4Z,S \+WAM<#I#<F5A
M=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TQ,2TQ.%0Q
M-3HT,CHT."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C4M,3$M,3A4,34Z-#(Z-#@K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO
M9&,Z9F]R;6%T/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P
M:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R
M;V9I;&4^<U)'0B!)14,V,3DV-BTR+C$\+W!H;W1O<VAO<#I)0T-0<F]F:6QE
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C<V-F(T-S@S
M+3%A.6$M-&(T-BTX9C%C+65B,S<P-#$W96%F93PO>&UP34TZ26YS=&%N8V5)
M1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO
M=&]S:&]P.F1C-C<V.3EE+3)E.64M,3$T-BTY-34R+30T,S5F.6(U8S$Q8SPO
M>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YX;7 N9&ED.F%E830X,C1E+3@S,#@M-64T9BTX-C-F+69C-C X
M-&8S.3,T8CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-R96%T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#IA96$T.#(T92TX,S X+35E-&8M.#8S9BUF8S8P.#1F,SDS-&(\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C4M,3$M,3=4,3<Z,3,Z,S(K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+W!N9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU
M,C(S,3)F9"TS,#5E+3%D-#DM8C0T9"TY.#$P.&-F-C-C83(\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M
M,3$M,3A4,34Z-#(Z,SDK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R
M,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S$R.&0S,S8M,V0W
M8BTS9C1D+6%E96,M-#5F-S$S-C0P8C(T/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3$Q+3$X5#$U.C0R
M.C0X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-S8V8C0W.#,M,6$Y82TT8C0V+3AF,6,M96(S-S T,3=E869E
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(U+3$Q+3$X5#$U.C0R.C0X*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HW,3(X9#,S
M-BTS9#=B+3-F-&0M865E8RTT-68W,3,V-#!B,C0\+W-T4F5F.FEN<W1A;F-E
M240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z865A
M-#@R-&4M.#,P."TU931F+3@V,V8M9F,V,#@T9C,Y,S1B/"]S=%)E9CID;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/GAM<"YD:60Z865A-#@R-&4M.#,P."TU931F+3@V,V8M9F,V,#@T9C,Y,S1B
M/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ
M1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&
M" H0"@H)"0H4#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M
M*# E*"DH_]L 0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@$0@5G P$B  (1
M 0,1 ?_$ !P  0 " @,!               &!P0% @,( ?_$ &00  $# P(#
M P8'"0L*! ,##0$  @,$!1$&(0<2,1-!410B87&!D0@5%S*AL;(C-C="4G22
MP=(6,SA65W)S=;/1X20U0U-58H*3E*(T5,+P&-/Q)6.#A+3#)D1D996CXB>%
MX__$ !L! 0 # 0$! 0             ! P0"!08'_\0 0Q$  @$"! ,%!P,"
M P<$ @,   $" Q$$$B$Q!4%1$V%Q@9$4(C*AL<'1,T+P<N$5(U(&)#0U8I+Q
M<X*BLB530V/"_]H # ,!  (1 Q$ /P#U2B(@"(B (B( B(@"(B (B( B(@"(
MB (B( JLO&J;Q3\?;/IV*K+;//1&62#D;YSN60YSC/XH[^Y6FJ1O_P#"ET__
M %:?LS("[D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!4EQFXQ'3]R@L>EIHI+FR9HJYG,#V1#/S!XN\?#U]+,X@6>Y7_ $K66RRW
M$VVLJ"QHJ02"QO."_&-]VY'M7GCC/P^M&A-.::AMH?-5SUKO**N;!?*0!MZ!
MN=O?GJA*/5"I_BEQ2N5KU-%I31-O9<+Z]H[1SFEPB<1D-#=LGEW))P 1Z<7
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M.TA=EU.6:-PB(K3L(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B(#A/-'3P233R-CAC:7O>\X#0-R2?!4%K;X0<;:EU!HBWFNG+N5M
M5.T\KC_N1C=WK)'J*OBXT<5PH*FCJ03!41NBD ."6N&#OZBM3IK1VG]-0LCL
MEII:4L&!(&<TA];SEQ]Z \S3ZAXR:@=V\$5^BC&"!34A@9@^&PR-O$KLI]3\
M9=/<LE13WJ>(9<154)F;W9R0,CWA>LUH]7ZKL^D:"*MO]4::GED[)CA&Y^78
M)QAH/<"A)4&B?A!T\U4VAUI;S;I@>4U4(<6 _P"\P^<WU[^Q7S#*R:)DL+VR
M1O:'-<TY#@>A!49K+%I?7MCIJRKMU-7T=7$)8IG1EDG*1D$.V<%(J&FCHJ."
ME@!$,,;8V G)Y0,!"#N1$0!$1 $1$ 1$0!$1 $1$ 5(W_P#A2Z?_ *M/V9E=
MRI&__P *73_]6G[,R NY$1 $1$ 1$0!?'$-:7.( &Y)[E]6LU/&^73ETCBD$
M;W4T@:\]QY3N@*XO7&%D%?)%:K<VHIV$M$TLA;S^D#&P7#@]/3W2^7Z^W&>,
MW$^=RNV[.,[EP)[M@/0!Z56,-'&U@YQS.[RLRVCR-M>89C&)X.Q+=\N!>TD>
MK /51'!8C-&4[6Z=#GL*NDF71/Q/T_%4.B:ZKE8TX[6. EA]([R%+:"XTE?0
M1UM)41R4L@RV0';V^!]"\T+)H[+<[R'0T$=9/3L<'20PD\F3WGN!('7T+TI8
M2%M'8LJ4JD%>.OR+NO?$#3=H!$URBGD'^CIONI^C8>TJG.(FI3K2OHI:2DJ*
M:B@8YK73='$D$G;;IC;)6^LVD;Q2-+J/3%&QY=@259$CAOX.=CV@+IU[37Z%
M]$=0>3AO*YL#8 T-;TSL!ZEU25*E*\7KX_8IA@ZN)DH3:L^2_)7TEK<&99('
M.\",95HV'3FO:K3EN\COT=)1F%KH8BXL>QN-@2&YZ=V5 U9UANNL;99J-D-G
M95T0B!B<!EW+U&<'P]"[J5\\?=:?B7XG@RP[3LXW[SL;HK6I:.;6DH)&X =M
M]*I_5]JKK-J"LI+I(^:I#^<SNR>V!WY\G<Y^O*NP<0JRD=B\:>JZ<;[MS^L!
M0'7&HCJ2ZB81AM+$ V%KV-Y@._)]?I48>=52]Y*WE]C%4X;VBLG;YD,TI-#3
MZFM,U3*V*&.JC>][NC0' Y*]912,FB;)"]LD;AEKFG((\05YSTY#2U5QBMU?
M3LDI*U[8G8: ]CCLU[7=003ZCWY4HIJV]\+;@RDN//<--2OY8Y6C>/O./ ]?
M-.Q[DQ4.V:MOTZE<*,L"[2UB^?0N8C(P>B@MRX6Z>K:U]0UE13<YRZ.!X#/8
M"#CV*7VFY4EVH(JVWS-FII1EKV_4? ^A9:\B=-/22-EHS74@EZX86.LMD4%!
M&:&IA;B.=GG$GKY_Y7UK0T>I[_H:I90:LIY*VW$\L5:PY('K_&V[C@JV5T5M
M)3UU+)35D,<\$@PYCQD%<.DMX:,Y<.<=#IM%THKQ1,J[;4QSP._&8>A\".X^
M@KO954[YG0LGB=*WJP/!</6%2'$:P_N'GBGT_7U5-!< ^-\+7GS0,=_>-^_<
M>*KJ">6"=L\$KXYFGF$C7$.!\<JB>*<'EDM3AUG%V:/72*-\.[U-?M*4E95D
M&I\Z.5P& YS3C/M&%)%KBU)71<G=7"(BDD(B( B(@"(B (B( B(@"(B (B(
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M0L6EXO:=FK1 ^.MAB)P)Y(QR#TG#B0/8H;QGCM-;2VN]6:.%QJ7O9431C!)
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M4U$<='%&973.<.4- SG/AA:#B)HFVZYL1MMTYXW,=VD%1'\^%_3(\1C8CO\
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M=RM&!D]ZSEJ-(5U;<]+VJMNU.::OJ*9DD\)86=F\C<<IW&_<5MT("(B (B(
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M-:8W-)SXD]P\/4K_ .'$$E-H'3D,[2R6.WP-<T]QY @)$B(A 1$0!$1 $1$
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MBG'.QSFD!PR=PI#HFV2U5UCJBQPIX#S%W<7=P"L**D@BI8Z9D3.PC:&-81D
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MY$SM_>2M+'QCMS6--9:+C <X=CE(;OXDCZEGP\7=,2$\\E9$!WN@)S[B5Q+
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M$0$$T!9=<6VZ5$NL-1TEUHW0\L<4,(86R<P/-GE'<"/:IVB("JN&-,W26O\
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M:^CG!P0_YN?7W>U298-RM%#<6D5=.QY_+&SA[1NL_85*?Z4M.CU^>Y7V<H_
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MAT6NFTE8)L\UII!D8\QG+]2WB*28UJD?ADUYD0J>'6GIOFT\T6V/,F=[]\K
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MD:PY:X'((]JCFK]:WS1.MGS7NCGK-&U,([*>DI^9]+(,9#R.[J=_';H5:".
M<"' $'J"@*,KKP[B]J[3D%EMM=%IVTU0KZFOJ(^S#WM^:QGMVZYW.VV^^^$4
MXUFD[9I^'+JJ]7*"F8UHR<!W,7>H8&_I5J-:UC<- :!W 840;IBJK^(AU#>'
MQ&EH(>PM=.QQ=REW[Y*_;9QZ ;[! 2REA;34T,$9)9$P,;GK@#"[$1 $1$ 1
M$0!$1 $1$ 1$0$<XD4DM=P_U'2TS>::6WSL8WQ)8=E4'P2+M1BTWNT.E:VO-
M0*IL9."]A8UN1XX+=_6%Z"(!!!&05YEXD<&[]8]12W[A]VKH"\S-AIG]G-3.
M.<AGY3?#&^#C!0D]-*C/A87FDBTE;[.7@UM15"<,!W:Q@<"3[7 >_P %7(UQ
MQ@9":0PWOG^9S&U^?GU\G5;/0O"+4^L=01WK7SJJ*C)#Y15N)J)\'9G*=V-]
M>-N@0%Y<%J.6AX6Z;@J&\LGDHD(((P'$N'7T."FBXQL;%&V.-H:QH#6@=P"Y
M(0$1$ 1$0!$1 $1$ 1$0!$1 %2-__A2Z?_JT_9F5W*D;_P#PI=/_ -6G[,R
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M^R]6]2PMIJ:*!A<YL; P%QR2 ,;J/\0-'4&N+$VU76:IAIQ,V?FIW-:[F:"
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M.FD=X-:"2?<$!D(J'T_2:KXP0U%XJ]05=@TV9W,HJ6B')+(UIQS.<#]9.X.
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M-@\'H?7L54M33S4L[H:B)\4K3@L>,%3+2VA_C&@?47,STQ<X=DT  X[R0?\
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M,ZM>4&](O0(B+4>6$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M"MIV3B(NYN3F&<9[UM5C6N@IK7;Z>AH(A#24[!'%&"2&M'0#*R4("(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M:1I%5"3C)#=LC(SZ_1DU7PXM7#:.WU%IXB4++=J.@E='.:NHEB$HSD$8<!D
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MR\_*,9QDX]ZVZ$!$1 $1$ 1$0!$1 $1$ 1$0!4C?_P"%+I_^K3]F97<J3O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M[X9:^T%[#@F.C=(WV.:P@^PK&GXG<+(HG/%5;Y"/Q&6YY)]7F(23S15XDO\
MI*T7:>-D4M;3,G<QA):TN&<#*W2UFE[E2WC3UNN-NB,-'50-EAC+0TM81D#
MV&RV:$!$1 $1$ 1$0!$1 $1$ 1$0&@UQ=9K18))J4XGD>(F._)SG?W JF72/
M=(9'/<9"<EQ.^?'*N77D-/-IFJ;4NY<8=&1^7W?^_#*IJ2)\?SAMXKU^&UZ*
MO2;2F^7-GSW%XS[1/E8S*BOJ+E50OJW]I(R,1AQZD#.,^E1>JC=%+V;QAP.%
MNV.+'<S3@KI@I6W;4]#1O<8VU$C(W.;N1GO"\_C-"=.6>*]QI+SS7^=SZ/\
MV-QS52I1D]+.7I9%V: K)J[25OFJ2YTO(6%SNK@UQ /N"D"Z+?20T%%!2TS>
M2&%@8T>@+O5!U6DIU)2BK)MA$1"L(B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"+"ODE;%9ZU]JC;+7MB<8&.Z.?C8')'?Z56GQOQ2
M_P!BTGN9_P#,5M.DYJ]TO%E52LJ;M9OP185ZU)9[(]C+K<*>FD>,M8]WG$>.
M!OA9ELN-'=*1M5;JF*IIW;"2-V0O*FI:BX55^KI;T'"XF4B9KOQ2-N4>@=!Z
M%(N&E?JBDEKH])TK:KF#73,D Y6]<'=P&>JVRP"5/,I:_(PPX@W4RN.GS/2:
MUNI;M'8M/7*ZS .91T[YBTG'-R@D#V]%!['<^(LMXHV76TTL5 Z5HG>T,RUF
M=SL\_4I!Q5H)KGPYU%2TPS,^CD+1C.2T<V/;A8:E/([73\#?3J*HKV:\2L>%
M^A*;B!;GZQU]VUSJJ^5[J:F?(]L4$8<1@ $;;;#I@#O6RU#PMJM.:AM-]X71
M"CJFS<M9225!$$D6-\Y)VVQCT@C!&5(?@^W&"X<*K,(' NIFOIY&YR6N:X]?
M6"#ZBM_K[6ELT1:X*Z[]JYDTPA9'" Y[B03L"1L,*LM.W6VL+3HRT"X7N9S&
MN=R1PQ#FDE=^2QNV5$M/\9+/<+S2VV[6VZ6.>KQY,^X1!C)3X9SMW>C=:761
M9<^/.@X[E$YM#Y')40QR@#$V'$ ]V06LV] 6T^$O34<O"NMFJN43P3POIG=#
MSEX! _X2Y"# XX7"EM6O.'%?<)FPTE-55$DDCNC6@1K8V3C59+A?:*W5=LNU
ML97N#:2IK(0V.7)PWOR,[8Z]0M)Q*@;<=4\(8KG$)>UE<Z5CQL7<L)W'K[EL
MOA)1,.E;%(6-[1EYIPUV-V@M?G'N"$DYUQK*T:+M(KKU,X![N2*&(<TDSO!K
M<[_4%%-/<8[/<;W36JZVVZ6*IJL>3FX1!C)3TQG.V^P[EK-<10U?P@]$P7+>
MEBHY9J<.'FNG!>?:?-:<>@+*^$Q34DG#&HGJ T5-/40NIG=X>78./^$N0@E&
MNN(%FT3/11WORD>5LE?&Z)@</N8!(.2-SD >)/<J>XR\4Q>]!FBHK=?K/5SU
M(:YT\?9-<QH!<TN#L[A[=L;K?\2(S7:UX2"XQ\[Y)"^5KQCSL1'<>L+9_"D_
M!>?SZ'_U(23O0.IZ35FGX[A04]9!"UQA+:J,,?EH&3@$[;K5<6;'J#4=BI;7
MIVJ9213U+/+IA*62"#.X9@;GOZC88WRIE2?^$A_F-^I8U\NU#8K54W*ZU#*:
MCIV\TDC^[T#Q)Z =Z$%,\0.#^E=.:'N5WLOE=!=;=":B*L%4_F<]NX!R<#)V
MV .2%JN*UVJ+IPBX=W2[_<ZB6OII9G/VS]S?EY]8'-[5NH*2[<9KK#67&&:V
M:#I)6R0TLC>62X.'XSM]F^GP.V3N.SX3M-3MTCIJE+6Q4@NT41 V#6=F\>P
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M%;*&6N-55RMAB#Z<@<SC@9.=E&-6MI-><3KO;M17(TND--0Q^41F;LF2SO\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M'$\D8.0QS^_PR2>@V4_U%IZLFT@RRZ5N9L4L+8XX*B./G[-C,>;C(Z@84E1
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M#7MSOOC??U' 5@(@*OTSPWNKM54VHM=W\7NNHA_D<+(NSB@=^4!TST/0;^.
MN/&>)VIJ_3^B:21PEKZD5=86MSV5+'G+CX9=@#/>%:2U]+9J"FN]7=(:<"X5
M36LEG<XN<6MZ-&3YK>_ P,[H#/8UK&-8P!K6C  [@OJ(@"(B (B( B(@"(B
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M3O;/N<9 R#]!5&QU%5&T,9/(&@Y #MEX?$L!4K5%4@?2<(IJK1:3LTR:JR-
M2&33X'XK)7M!\=]_IR%1SKK6NCY.U:/]X-W5T<+9W3Z.I>8;QO>S.,9\XG/I
MZ]5/#.'U</4=2III8CBM%PH7?7\DL1$7MGS@1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M<GVE9%#204%)%34D38H(QRM8WN"[U#=S%C<?/%.STCR01$4& (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B ZJJGBJZ6:GJ8Q)!,PQR,=T<TC!'N4-^2?0W\
M6:#]$_WJ;H@(1\D^AOXLT'Z)_O3Y)]#?Q9H/T3_>INB Q[;0TULH*>BH(6P4
ME.P1Q1,Z,:.@"R$1 $1$ 1$0!$1 $1$ 1$0!$1 %2-__ (4NG_ZM/V9E=RI&
M_P#\*73_ /5I^S,@+N1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %2-_P#X4NG_ .K3]F97<J1O_P#"
MET__ %:?LS("[D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!4C?_P"%+I_^K3]F97<J1O\ _"ET_P#U
M:?LS("[D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!#L,GHBB?%B[/L?#G4%?"[DF92N9&[P<_P P'WN0$"U3QYHZ*\SVS3-DJKY-
M3O+))8W%K#C8\N&N) /?@!2+ACQ9M>MZR6VOI9[;>(F%YIICD/ ^=RN]'@0#
M]*P?@V:>I[3PXI*\0-;6W)SII9.4<Q8'$,;GPP,X_P!XJ)<<Z>'2G%#1VJZ&
M-M.^:?DJWQ[=IREH)('4ECW GP 0D]!+X]S6,<Y[@UK1DDG  7UIR 1T*@''
MFZR6GA9?)87<LDS&TP/HD<&GZ"4((=?>/].VYSTFEM/5EZ; XA\S7%K78VRT
M!KCCTG"F/##BC:=>&>FIX9J&YT[>:2EFW);G',TCJ,^H^A=7 33]/8^&MJ?'
M QE571"JGDY0'/+MVY/> T@!0'B+3P:/X_:4O5'&*>"Z.$=2(Q@/<7=F\D#T
M/8?20A)Z"5=Z[XHT&F=3VBP4T+:^XUM1'%,QLO**9KW  NV.YSD-\/#9;KB7
M^Z9VFG1:*$?QM-*V/GDP!'&0>9V3L"-O'U+SMJ_0CM%:VT.ZMN,EQNMQKQ/6
M5#LX<X31XQG?\8[GKGN0@]9HB( J1O\ _"ET_P#U:?LS*[LJD;__  I-/_U:
M?LS("[D3*90!$RF4 1,IE $3*90!$RF4 1,IE $3*90!$RF4 1,IE $3*90!
M$RF4 1,IE $3*90!$RF4 1,IE $3*90!$RF4 1,IE $3*90!$RF4 1,IE $3
M*90!$RF4 1,IE $3*90!$RF4 1,IE $3*90!$RF4 1,IE $3*90!$RF4 1,I
ME $3*90!$RF4 1,IE $3*90!$RF4 1,IE $3*90!$RF4 1,IE $3*90!$RF4
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 5?<?HWR<(]0B-I<0R-QQX"5A)]P5@K6:HM$5^TY<[5/CLZR
MG?"21GE)! /L."@(WP1D9)PJTV8W-<!3<I(.<$.((]A"KGX5(,TVCZ:+SZB2
MJDY(P?.=\P=/60M'PQXE/X94U7I+6]OK(O))G.@DC;S%N3DMP2,M)W!'B5WT
M%=5\9N+5JN%/0RT^FK(1('2CYV'!V">G,YP;L.C0A)Z1C&(V@]<!5=\)=CG\
M)Z\M!(;40.=Z!V@"DW$?7%#H.T4UPN5-4U$4\XIVMIPTN!+7.R<D;>:5VZUL
M[-9Z!K[?&.4U]+SP\^/-?@.9GVX0@<+I&2\.=-.C<'-^+X!D'.X8 1[U5/PA
M6FHXE<.Z:#[I/Y0'=FWK@S18./8?<M3PQXMQZ%LSM+ZVM]=!46Y[F1/8SF/+
MS$\K@2.AS@C8C'M[]&2U_%?C#3ZJ?124U@LX'8=J.I&2P9Z%W,>8XV  'K$G
MHQ4)\(7\(_#C\Z__ $T2OM4)\(3\(_#G\Z__ $T2$(OM1W7VF/W7:>?:_C&I
MMW-(V3MZ8^>.4]/45(D0%(_($/XZW[]+_%5Y<^&@IN,EKTO^Z"Y/\II#-Y<X
M_=6;2'E&_3S?I*]8JD;_ /PI=/\ ]6G[,R$CY A_'6_?I?XI\@8_CK?OTO\
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M"RD(*1^0(?QUOWZ7^*?(&/XZW[]+_%7<B I'Y Q_'6_?I?XI\@8_CK?OTO\
M%7<B I'Y Q_'6_?I?XI\@0_CK?OTO\5=R("D?D"'\=;]^E_BGR!C^.M^_2_Q
M5W(@*1^0(?QUOWZ7^*?($/XZW[]+_%7<B I'Y A_'6_?I?XI\@0_CK?OTO\
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M(B P;I9[;=F,;=;?25K6'+140MDP?1D%9%'2T]%3LIZ."*G@8,-CB8&M:/0
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$!!.,NN?W"Z3=64S&2W*I?V%*Q^[0[!)<1W@
M >\A5A3Z8XQUMH%].I7PUCF&9EO,G*XCN;RAO("1W'VK/^$"SXPXD\/;7,?\
MFDJ 7 [@\TK&[CIT'TJ^P,# 0DK7@?KZHUI9*N"\1MBO=ND$52UK>7G!SAW+
MW'8@CQ"LI4%PT<;;\(_6MNIMJ:HCDF>WIYW-&[H-NLCO>K]0@(B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MM:!@ ! =R(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( BCE]UK8['7NHKE5/CJ T.+1$YVQZ;@+7_*;I?_STG_(?_<JG
M6IIV<D;(</Q52*E"G)I]S)FBT.G=6VC4-1+!:JATLD3.=P,;FX&<=X6^7<9*
M2O%W,]6C.C+)4BT^C"(BZ*PB(@"(=ANNN"HAG!,$T<@'7D<#CW(39[G8B(A
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MK31#FF%J\I;\8&'//V/LWQX^Q1JD@L<6JK(-!R/-09,U@A>YT?8?C%_-W_\
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M/HPN-IT7146E:VRSRRU(KN=U54/^?)(X;N]'=CU*-G0FI*JBCLMSU,V73\9
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M2/YO%]J92<(O]$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M^)[W#\=G<<)V<+/FUTYO7<Z>'-NU)!?;E6ZFIP'U$8^[N<PN)!V:.4[-QG8
M*P5\9\QN>N%]6BG35..5.YY6+Q+Q-1U))+966VFAJ]2V2EU!:)J"MR&/W:]O
M5CAT<%6#N']V;6M?'JJ L;'V(E,KA((^]O7IZ,J7<765S](O% ]S6=JWR@M.
M_9;Y]F<$^A:"FX5V":GCD;>:F0.:#SL?'RGTC99:\<\[*-VN^Q[7#*WLV'SR
MK95)O3+FZ7\"<:-L5'I^SBCH)NW!>7RS$@E[SU.W3NV6\6CT=I^DTW:WT=!4
M23Q.E,I=(03D@#&P'@%O%KIJT4K6/$Q4\]:4LV:[W>E_((B+LSA4!Q"_A-Z1
M_-XOM3*_U0'$+^$WI'\WB^U,@1?Z(B (B( B(@"(B (B( B(@"(B JSA9^$/
M7OYT/[216FJLX6?A#U[^=#^TD5IK3B_U/)?1%=/X0B(LQ8$1$ 1$0!$1 $1$
M 1$0&!J#_,-R_-I/LE1;@Q]XT']-)]I2G4'^8;E^;2?9*BO!C[QH/Z:3[2SR
M_77@_L>G3_Y?4_JC])$Y1$6@\P(B( B(@*LI?X057_5X^RU6FJLI?X057_5X
M^RU6FM.)_9_2BNGS\0B(LQ8$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 4%QZ
M_"WPY_.8_P"WC5^J@N/7X6^'/YS'_;QJ_4)"(B$!$1 $1$ 736"0T<XA:'2F
M-P8#T)P<+N755QOEI9HXG\DCV%K7?DDC8J5N"BV\-]<R6:2V.KK?';I7]HZD
M,QY6NSG8<AQOX%3/A[HJ\VS4$][U/<(ZNM[#R:(1N+L-VW)('ATQWDK3#AWK
M7'WZ3?\ .F_O63PXIKS:=>5]KU!?9JR:.DYXX7RO>V1I(\]N>A&""#OOWKU*
MM1SA++-/P1GC&S5T6LB(O*- 1$0!$1 $1$ 1$0&'>!1&UU(NO9>0\A[;M?F\
MOI5!U$F@_C,]G#>_)>;\5S.7'H!\['MRK3XP0SS:)J.P#G-9*Q\H;WL!W^G!
M]BZK?JO13+"R)LM)%3"/!IGQ>=Z06XW/UK#B$ISRMI67,^CX7*>'P_:P4Y9G
M:T7:UK:O1ZN^A(])BU"PTO[GQ'\7\OF<O7/?S9WSXYW67>16.M56+6YK:XQG
ML2[& _NSG90K@TP_%EVG@B?%;YZUSJ5CNYG_ +P/8K!6FB\]-/8\K&T_9\5*
M-\UGSU[]?HRG+G<^(EOKZ2BDK*>6LJL]E#%'$YQ ZD^;@#TE=EXK>)%HI/*J
MRI@\G!'/(R.)PC'B[#<X]*D>OK)>S?*"_P"FN62LIHS"^%Q'G-R3MGKU.=_#
M"T%RJ]>ZFI'VN2SQ4%/,.663E+1R^DN<?H&5AG&47*-Y7Y'T-"K3K1IU%"EE
M_==)-:]/#;>Y9]EDFEM%%)52,EG="QTCV$%KG$;D8VPLQ8-BMXM5FHJ /+Q3
MQ-BYCWX'59R]*-[*Y\I5MGEEVN%JJW4%!27NBM,DA=756>2-@SR@ G+O ;%;
M.1I=&YH<6D@@$=RK6IT]26'6VE>P?-/4SR3NGJ9WETDI#!C)]I5=6<HVR]5]
M33@J%*LY*HW=)M)=R;U?D68CB&@EQ  W)*+5:BLL=]I8J6IJ*B*G#^>1D+^7
MM1@^:X^&_P!"L=TM#+34922F[+U%AO\ 0WWRLVV1TL=-+V3I,>:XXSEI[QZ5
MM5!^&5-#1U.IJ:F8(X(KD]C&#HUH& %*[Y<X+-9JZYU8>:>CA?/(&#+N5H).
M!X[+BE)R@G+<OQM*%&LX4]M-_!,CO&#\%^J/S"7ZEA\"?P3:<_H7?VCE76O^
M-VE[]HJ]6JBCN(J:RE?#&9( &\Q&V3S*Q>!/X)M.?T+O[1RL,Q.T1$("(B (
MB( M/JRJ@BT_=(Y9HV2.I)>5KG $^8[H%N%&-<V.EN%JKJR=THE@I).4-( V
M:X[[+BI?*[&G"*#K1SNRN:S@[4P#1=% 9HQ,9)?N?,.;YY[E.E6_!^R4K].T
M%T+I/*6OD &1R_.(Z8\%9"KPU^RC?HC3Q906,J9'?5W\;L(B*\\T(B( B(@.
M$W[S)_-*K'X/7WJ7'\^=]ABLZ;]YD_FE5C\'K[U+C^?.^PQ:J?Z$_%?<KE\:
M\RT41%E+ B(@"(B (B( B(@"(B (B( B(@"B6F/OLU!_/'UE;'5^IZ'2MOBK
M+F)C#)*(AV3>8Y()\?05 :'7]HM%?676J;5&EN)YH0R,%V-SN,[=4=&<G%Q6
M[^QJP\DJ56[Y+ZHMI%P@D;-#'*S/*]H<,^!7-#*$1$ 1$0!$1 0NW?A'KOZ,
M_9:IHH7;OPCUW]&?LM4T55+9^)NQWQ0_IB$1%:80B(@"(B *DKI_"KL_]5'[
M$JNU4E=/X5=G_JH_8E0%VHB( B(@"(B (B("IN,-;1VS5.F:^>F=6RP%[GTA
M8'-?'XY\0>[ZE7+KBVX6*Y6*CL=1--4UYJ+>[LO.IVN(YFC'H:!CIU/<KPUO
M<-44-92G2]EI;BQS#VLDI +#G8#SFJ'7;7&OK1%%+<=-6^GCDD$37N)Y>8]
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MQ]EJM)5;2_P@JO\ J\?9:K26G$_L_I173Y^(1$68L"(B (B( B(@"(B (B(
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M5TC0:ESFQ1%PR&N=WGU %0VS4&H;?JZ"FN%YDJZNLM\LK6N>[LXW]!WXV/>
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MC4_]*S[3U:BQ8.*5)/Q^I[/'JLIXN4&]$E]$$1%J/$"(B (B( HEIC[Z[_\
MSQ]96[O]\H+#2,J;I,887O$8<&%V78)[O457]BUS8*34%WJIZUS8:AP,9[%Y
MSN?0J*E2$9)-GIX/"UZE&I*$&TUR3ZHM)%QB>V6)DC#ECP' ^@KDKSS B(@"
M(B (B("J[)^'*[?T)^PQ6HJKLGX<KM_0G[#%:BS87:7BSU^,?'2_]./T"(BT
MGD!8EPMM'<&AM;3QS<O0N&X]1ZK+1&K[G49.+O%V9HK_ *;I;IIUUI:R-D Q
MR![><#!SW[^U5I-9M2<.I17V1GE-JYO\JI^T+HP,CSL=6]^XSCOV5T+67R^V
MVR4_:W2KB@:>C2<N=ZFC<KN%7LM7\/3D=K/6_P N*NV^EWZ[FFIM=VF:@?4/
M<]CF,Y^3YP=MT#AM[\*JJK79DUW#?V4S>6&,PB/Q;APS_P!RP]2"ANUTK:_2
M=JJ*>D9&\U4AVAQC=W+T9MZ=_!1DTDXJ!#R9D(R,'8CQSTQZ5X^-K-N/9.\>
MMN?0^UX-PVC",W7CEFU9K->T7]+]YZBT]=X+Y:H:ZFR&2#=I.[3X+8J'<)Z+
MR32%.>U$@E<7@M.6^&WN*YZZUU0:5A9'YM5<)" VF8_!:,CSG'?E&_M7JT(5
M*B2M[Q\9C(TZ5:<:;O%/0ER+$NUQI[5;*FOK7\E/3L,CSZ!W#TJ"'B)<Z:FA
MNERTM54UAE(Q5"8/>UIZ/<P#8?X*V%&=17BC,Y);EC(M#JO4U-I^U0U9BDJY
M:E[8J:GA^=,]W0#^]::U:TKVWRDM>IK#+:9*W(II1,)8WN'XI(&Q2-&<HYD@
MY).Q-T1%4=&CUE=*&VZ?KS7U<%/VE/(U@D> 7$M(  ZGV+S[I^>UUNF(K3#I
M>>ZWPN?BHBRSDYCYN2W<X].RM/BG4Z4H[U;)M54E952MB=V,<0!CQS#/,,C/
MU+%M_%C1]NIQ!;[=5TT(_$AIF-'N#EZF'4H4KPBVWKT1GG9RU9D<&]+W_3XK
M)+TXQ4TS (J4S<Y80<YP-AMX%%(]&ZZM6K:FI@MD=4U].P/?VS T8)QM@E%B
MQ$IRJ-U%9EL$E'W217&=]-05,\,9EDBC<]K!^,0,@*B+QJZMU)6&FN$=IMC<
MXYJBF+W#_B+7$?0KWN,[Z6@J:B.,ROBC<]K!^,0"<*K*VEUKK")K*JV6^W4K
ML',\32[_ +N9WT!>7BU)V46_"Q]'P25.&:=11_J;LUX*SOZ&XX6Z:MUHFJ*N
MAO4%REEB#'-AQA@R#XD^"L-0OA_H5FE)9JE]:ZIJ9H^S< SE8!D';O[E-%?A
MXN%-)JQY_%*T:V)E.,\ZZVM\C'N-;3VZBFJZV5L-/$WF>]W0!5V[B_:_*N5M
MOK#39QVOFY_1S^M;+C)3SSZ1#X6N?%!4,DG:#C+-Q]9"0:XT:VRM8)860"/'
MDA@.<?DXQA55:DL^524;=>9KP6$IN@JLJ4JC;:T=LMK=$]7?P)?:;C2W:WPU
MM!*):>49:X?2#X$++4 X-0R-L5?4-8Z*AJ:Q\E+&3GE9T_5CV*?J^E-S@I,\
M[&T(X>O.E%W2?\]#2:NOS+!:^V##/5RN$5- WK+(>@QX>*A.D[34VKB3%\8S
MF>X55L?4U+\[<[I.@]   4JU-I%E\NM+</C*LHYZ9A9'V! QG.2,C8[J*1Z<
MJH>)5+ Z]727EH.V-0]PYB!)^]YQ\T]<+/54W--K1-6/5P,J"P\X1G:3B\VC
M\EX+?O?@;W6/$[3&D+JVW7VLFAJW1"8-93O>.4D@'('H*IBX:KM.L/A#:4N-
MAG?-2L9'"7/C<P\P,A(P?0X+T77V*TW&<37"UT%5,&\O:3T['NQX9(Z;JB-9
M6^CMWPE-)0VZDIZ2$P1.+((VQM)YI=\ ==@MAX*/1"(B$!$1 $1$ 1$0!$1
M$1$ 55_"&D?'IBVF-SFGRT=#C_1O5J*IN/M1%5T=HLM.U\UTGJ1+%$SPP6[^
MLNP/4?!:L%^M$KJ_ RAQ+(TN+9'M+NI!ZJ\K7Q8DI;531SZ;N),436E[=VD
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MJ=2E%[Q4DTU:S9=#@V)6#KV2:;BTTT[I7NUZDF?2\5VL<X5UJ>0,AK0S)][
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M63L/4,E9]CX9PFH\MU16272L=N6EQY ?2>KOH'H5A0Q1P1-CAC9'&T8:U@P
M/0%S18=-WJ/,_EZ',^*2A%T\)%4X]WQ/QEOZ&GO=DCK-,7"TT#(:5M1 ^%G*
MS#6EPQG 7G'5ND;I8*_XHI(I+M7.C;*V.E8>9S3G. ?  E>IE6]=^'"W_F1^
MR]75*TJ<8QCMF3..'1SRK.6_9S^AG<%I+I^XB&FO=IGM<])*Z&.*8$.>S <'
MD>DN(]BU_%JRV^@TE<ZRDI8V5=750OFFZO>>T'>>[;IT5E*-<0['5:BTU+;Z
M%T39W2QO!E)#<-<">@*UT:K552D]WJ>5*/NV1K.-+GMX=7+D)W=$'8\.T;E;
M+7#(AP[O#&AO9-M[^0#ILS;'T+;:@M4-[LM9;:K:*IC,9(&2WP(]1P5 9-*:
MSK[5%I^Y7>WBSMPR2IB8[MY8AT:0=NF/=U/?W1<7&*;M9W^GX(E=-Z;G2Y\D
MLG"H5)<6N:7OYN]X@;RD^GJMUQ:#11:>>,=NV\TW9GO&YSA;+6&EWW>S45/:
MZKR&MMTC):.;&0QS1@ ^C"U%+IG4=YOMNK=7U=!Y+;G]K#2T0=A\HZ/<3X+N
M,XMJ=[6OIYM_<AIZKJ3]$182TJKB2 [B?HMK@""\Y!_G!6?Y+3_ZB+] *O\
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MY%#46_XQKWO$M/" ,M<#L[."0<],#Q4#KM14\]RCN&J]$N8TD--1RO8?1D$
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M*PRA4!Q"_A-Z1_-XOM3*_P!4!Q"_A-Z1_-XOM3($7^B(@"(B (B( B(@"(B
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M+#('LC';L.7$' V!.ZOV@N%'<&.?05=/5,:<.=#(UX!\#@KIQDMT+HR41%R
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MT?4WVJI:AVI:&"DF:\"-L1!#FXZ_./>JMU[JRU735MBK:&626GH9&NE=R$9
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MUO??87F]4=H;$ZL<\"3/+RL)Z+G;;M2W&BDJZ8R&*,D'+"#L,[#O6<YH=\X
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MGR-<X-. [&'> \%MI0782697=N?2Y5)^^M"Y41%B+0B(@"(B (B( B(@"(B
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MGVEGE^NO!_8].G_R^I_5'Z2)RB(M!Y@1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M_P F-;^E)^PK1T+15%MT98J&MC[*JIJ*&*5F0>5S6 $9&W4+>(04E\J'$/\
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MAA=JBW"Q]K=P_L;;#4OJ;?'3-C9)(WE>2W9W,.XYSLI2@"(B (B( 2&@EQ
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M$0-CZ.>UQV)(Q^,>IQE7ZB Q+1016NU4=!3_ +S2PLA9MC9K0!]2RT1 $1$
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M[BYP'H!.%*D0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$!67%>W7B@U#I[6&FK=)<JJV]I!5TL9PZ6G>-\=Y(.<#?<@
MX6JL4E^U_P 1K1>KEI^LLMALD<KH65K>62:=X#?FGN'4$#NZ[[7$B (B( B(
M@"(B (B("N.%-OK*/5'$"6KI)X(ZF[NDA?+&6B5N/G-)ZCTA6.B( B(@"(B
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M7"1\<]9-.7.<_P WSNFP\\[=,=R"QZB$C"\L#VEXZMSN%]>YK&ESW!K1U).
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M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!\?\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MWT("VD4=K=2FVU]C@NE$ZFAN@$0F[0.$-21D1.&._! =XC&-PI$@"(B (B(
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M\$M'-C&' ;.Z+?Z;O5)J&R4MTM[B:>=N<.&',<#AS7#N(((/I" V2(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (BXR.Y(W/.X:"4!R15%:>,===Z%E9:]!7^KI'DALT/*YKL'!P?6"%+-*:_
MH-1VBZU4-)64E;:VDUE!5,Y)8CREP'J.#@H"8HM/H^^QZFTS;[S!"^".LB[1
ML;R"6[D8)'J6X0!$1 $11RDU5#4:\K=+BFD;/2T;:PSEPY7!S@WE ZYW0$C1
M$0!$6GU-?X+%34Q?&^HJZN9M/2TT9 ?-([N&>@ R2>X H#<(@Z;H@"(A( R=
M@$ 11+2^O;3J;4]XL]G+IQ;&,,E4T@QO<206M\<8Z]%K];\11IO4=+8Z*Q7"
M\W">G-28Z/&6LSC)!]10$]10W3FL+G=[5=:N;2=UM\U$P.BIJDM:^IV)(8>F
M=N_Q"DEANU)?;/27.VR]K25+ ]CN_P!(([B#D$=Q!0&<B(@"(B (B( B(@"(
MB (B( B@FKN(T-GO?Q%9;36WZ^@!TE+2C#86GH9'G9N?_KA8-KXH21WVCM.K
MM-W#3U16O$=++*\30R/.,-YP!@[A 62BCLFJ86:]BTOY-(9WT!K^WYARAH?R
M\N.N5(D 1$)P"4 11O0.JX=8V66XTU+)3,CJ9*;DD<"26'!.WBI(@"*&V_B#
M;JWB#6:49#*VHIVGEJ#CLY)&AKGQCT@.!*V6MM3PZ5M]'5STTE0VIK8:,-8X
M M,AP';]PP@) BC=#JR&KUW<M,-I96ST-+'4NG+ARN#\; =>]21 $1:;5%_@
ML%'!))$^HJJF9M-2TT9 ?/*[HT9Z#J23L "4!N41N2!D8/>$0!$6EUAJ:VZ3
MLDMTO$I9 PAK6,&7RO/1C1WDH#=(J[T_Q2IZZ[4E!>[#=[ :UW)1S7"+ECF=
MW-YNYQ[@5*Z._P ,VI:VQSQ/IZV"-L\7.0140G;G9ZG9:1W;>(0&Y1$0!$1
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M9H*RADG=)&XN'FR#F)P1^H>E;5_#*XC1NDX:&Y046J-/,/D]4UI?$_/SF.R
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M:RJY0QC0T8:QH[F@+7<(*9];4:FU7+&6-OM<7TQ=U=31CDC)]>Y]1" L5$1
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MNB'8&1O-NSS3MC'*<=0I%^YVR_['MW_3,_N6=24M/1PB&D@B@B!)#(F!K1[
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M),=7Q3C#F^GYH/K 6$-,:UU==;4=<RVJCL]NG;5>2V\O<ZJE;\TN)Z 'N_\
MJ,_B/ ^_ZYT;I^$<S*>I-WJ]]F1Q;-SW^<YV![4!9"(B (B( B(@"(B (B(
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MRB.E;4]H7;GF<1RX]B1JQEL34P56E?,EI>^JTMO?U-LBCMRU(:*JO</DH?\
M%U&VJSSX[3/-YO3;YO58M)JBN;:IKO=;:REM?8B6 MFYY7Y(#6EN.IR.].UB
MG8+!5G',ETYK6^JMZDL10^34MYM[(:R]V6*FMDC@U\D51VCX XX!>W'3QPI@
M#D9'13&:EL5UL/.C9RM9]&FOD$1%V4!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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ML8WJ2MTBY5-*&0NGBI3Q'M#6M[]Q";?>KW262EHZ?2]<ZJA@9"UTLD;8^8-
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M;+HNK1IM9QOETE>8XF.>]U)(&M:,DGE.P"T5^IYGZ3TW&R&1TC*JB+VAI):
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M3XI9OK^2%P6N*KXCWB2NH63T_D<(8Z:$.;GOP2,94NI*2FHX^SI*>&!GY,3
MT>X+M<X-&7$ >E?20!D[!3""C<YKXB5:R>R27HK%;:;O<=@N6I(JZAN1,]SE
ME8Z*E>]KFDXSD#T+:6""KO>KY-0U5'/1T<%-Y/1QSCE>_)RYY'=X>U31I#@"
MT@@]X3F;S!N1S'NSNJXT6K)O1&FKCXRS2A"TI*S=[Z;:+O\ ,CG$>*2?1=SC
M@C?)(X,PUC22?NC>X+AJ6&22Z:6<R-[FQUA+R&D\H[)XR?!2=8]774E'R^5U
M4$'-T[60-S[RK'3S-^7RU**6*=."C;;-_P#))?8CQIY'\1II#&\0NM/9]IRG
MESVO3/3.%"**SVRT4SZ"\6*\3W")SFQOIC(Z.H&3REI:<#(QX*X&D.:"T@@[
M@CO15RH*6IHH\2G265+2R6C:VOS7CL5?745;;+99(*FDN%%:"R1U3!:Y'/>R
M5SLM#C\[&/#O7S3M'%'K:WU-IL]=24;J>9K9ZSGS*_ ZYR6CU]<E6BBCV=73
MOM;Y%G^*R<)1<=TT]7;6^K7-Z[MO[E/7"EAG?*ZCLEYM6J"\@"B#A"Z3J'<W
MS>7O)V[U)ZRHJK#JQESN%%55--/;XZ=\U+&9.65I).0-\%3I$CA\NJ>I$^)]
MI:,H75FMW?6VSW25M%J5I4R5ESFU?5/MM53-GM;&P,D9Y[P _N'0^CKT6\OU
MGGNW#N"BAC)J6T\$C8G'EYG,#3RGPS@A2]%TJ*LTW>Y5+B$LT90C;*TUY)+[
M%2.MMIKFQ4MMTS=G7![VMDCJWRLBB&?.+G<V"/5Z%;3&AC&M'0#"^HIITE3O
M^+%>+QDL39.]EU;>_B$1%:8PB(@"+YS#FY<CFQG"^H B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M)FOFS'(TM<,RO(V/H.5764+2RJUG^3J-]+DI1$64L"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( L:Y5U/;;?45M8_LZ:G89)'8)PT=3@;K)774015,$D-1
M$R6&0%KV/:'-</ @]5*M?4%3\1N(>G[MH^OHK1<I'5LG)V8$4C"</!.Y QL"
MJ1^,*S_S=1_S7?WKT=Q#T;1U6D:Z&PV.A%Q=R=EV,$<;_GC.';8VSWJE_DUU
M?_L27_G1_M+W,%4H1IM)VUYM&2K&;9)>#FL[;88[L-07"5AF,79<S7R9QS9Z
M XZA7+IG5%IU*R=]FJ3.V @29C<S!/3YP'@J\X0:&GH8[K^ZNQT^7F+L/*61
MR].;FQUQW*TK=:Z"VAXMU%34@?@O$$36<V.F<#=8<;*E*I)QW\K%M)225R!\
M:*%MSI].4#SAM3<F0D^',UP_6LFVZJ?!PLDN=2<U]'"ZED;W]NT]F ?23@^U
M9'$F&66OTB8HY'AEWB<XM:3RC?<^ 4=N-FK'<0G6<0R&U5E?'>'O#/,PUAYF
MD]-WM;MZ4IJ,J<8RY:_/4.ZDVC#X6NAT@[6!N;W<M"VG,Q'G%S^0D@>)+C@>
MM2Q^KKU0Q17"]Z=\DL[W .F94B26!KC@.D9C8>."<*,U5AK+Q6<1J6"%XDEG
MIY8>8%HE+/.Y0?3C&1XK"EH+'7TS:.W:?U#/=92(Y*2IGGCCBWPXO>26\H]N
M=E;*,*DG*6K=K^B[T<IN*LBQ+WJ&XQ7AEKL-H-?4]D)Y)9I>QA8PD@>=@Y.W
M0!8+-;3P6J_272U^37*SL;)+3MF#V/:X9:6OQWX/<M%JB1T6IIZ;4<E\ALHA
MC%&RVA_92 ##P\L\XG/=X+0PT+H[5KYE):*^AAGHH'00U(<^60>=EQSDY)WQ
MG(5<*$'%773ZKO\ MYG3F[DSJM;7>DH([Q5:<='87<I,OE ,[&'H\QXZ>W.Z
MGC'!S0YO0C(4/U_#)+PPN$4<;WR&D8 QK27$Y;W*5-D$-")'@\K(^8X&^P6:
MHHN*<5;5KZ'<;WU(#KNBDU;J:/3L+RR"BHY*R9V<#M7-+81MX'+EL+5=WWKA
M?55%0"*N.CF@J [J)6-+7?2,^U:/2&E9-0Q5VHKG67BW5ERJ'O$5/.Z$B('#
M X==@#[%UTENGTQ<M46*)M946^OH'UM/-)EY[7E(>"[O<3OX[+2U&W9IZQM_
M?^=QPF_BZDKX5?@]L7YO^LK5W?\ #-8/ZOF_6M=H/65ML^D+505T%S94T\/)
M(T4,I .3WAJ^ZDNL-'Q&T_>I8*QU ;=)YT=.]Y'-G ( R#Z%'9R56=UOF&99
M5Y%@WJN;;+/75SF\S::%\Q'CR@G]2A&A=*4%ZL<-\U+3QW.YW)O;O?4#G;&U
MQ):U@.S0 >Y;REOUKU;!76F!E:WMJ=[7F:EDB'*?-.[@-]^BCVE-41Z2M$5B
MU='/15%"#%#/V+GQU,8)Y7-+0>[ PJX1G&#C'XM/&QTVF[O8R-*L.FM>UFFH
M9I9+744@K:2.1Q=V!#N5S 3^+WJ7ZCO$%AL\]PJFO>R+ ;'&,ND<3AK1Z22%
M%M)PU5]UC6:IJJ.:DHQ3"CH63CE>]F>9TA'=GNSXK:\0[=57#3[3;XNWJZ2I
MBJXX<X[4QO!+?:,J)I2JQ4NZX5U%V,2BU->XKE00WW3QHZ:N?V<4L%0)C&[!
M($C0!C8==P%UG5EXN,]:_3=A974%)*Z%T\U4(C*]IPX1MP<^LX7V+6<]VJ:2
MBL=IK?*GR 51K:=T3*:,?.)/>[N &=UJM.7PZ,M\MCNULN3I:>:4TLE/3.D;
M5,<\N:01L#OC!QW+OL]+Y->GWW(S=^AM:S7L$=DM%QI+?4U'E]2:3R<$-D9(
M.8%N.\\S<>W*[:+4]U@OE#;M0V1M$*_F;3S05 F;S %Q:_88.!Z5&J:U5])2
MZ5?6TLD5147Z2MEB YNQ#Q(0#CIMA2C6$4DFI=(.8Q[FLK9"\M:2&CL7C)\$
ME"FGE2ZZ^%[!.6_@8T^K;O5SUSM.V 5]!12.B?/)4B(RO;\X1MP<X\3A=U1K
M)\U':FV:V3U5SN49FCI9CV/9,;@.=(XC8 G'3?N6FT_>_P!Q=+566[6VY.?%
M43/I9:>G=*VI8]Y<,%NP=OC!QW+7ZDM]765EIO\ JBU5?D[J9\%3!;GO[2F\
M_FC<[E.3L2'8Z%=*E#-9K3EW_/\ '0C,[;DOL^IJM]PJK;?;8*"Y10&IC:R7
MM(YXQU+78&X.,@CO6GI=<7JOL;+U;M,F2V-C[20R50;(['SNS;CS@-]SC.%K
M]+6RWSWJHK;-9[DRB@I)&MK:Z:4%[W#!:QC^HQU/BM]I6&5G"6DA?&]LHM9:
M6%I#L\AVQURN91IPUMT^_>2FWS-3?=1W&JU/HZHLU#+4457#)4,C\H$8F+HS
MD.!Z%@.=^N=EMI-5W6IU#<K59;&VJ=;Y&-GEEJ1&WE<UI'+L<G=VWH]*CD4D
MEIH>'5RJJ6J-+24SXYS'"Y[HB^$-&6C<;J4Z0CD;J;6$CHWM9)5Q.8YS2 X=
MBW<>*F<8*-[;+_\ U^"$VWO_ "QURZEOM96UK+#IX5%+22&%TU54]@97MZ\C
M<'(])QU6AU3JNX7&Q:;KK3;YVB>Y,CFC\H##VK'D=B?$.(._3S=^JU0DCJ:B
MKBU=#J:LNXG>&T-/VC:=PYCR=F6X&,=Y/>5]H8*BCX<V21]OJH_B^^^43T[(
MW/?%&V5Y.W4X!&ZLC2A&SMS^S[]?1$9FR=FXTL>LXF5= V&O%I-0^H,F>S8)
M!S1XZ'??*U3-:7J>VNO5+IHR6(-,@>ZI G?$.KQ'C&,;XROEQIS>]:/,#9!3
M5NG)(FRN80 7R;9R-C@]%A6[5,]NTK#8Y[)=#?H:84K:9M,7,>X-Y0X/^;R]
M^<^*J5--+2[T\OY\CIOO-W=-:&*JM%/:+=+<9+K2NJ*;E>&#;EP'9Z#!R3W8
M[UWV#4E=47Z6RWVUB@KQ!Y3$Z*;M8Y8\@'!P,$$],+1Z=L]19]1:0I)F.+J:
MSSQRO RUKRZ,D9Z=<^Y;>IBD/%6BE$;^R%ID:7\IY0>U;MGQ7,HTU[J7)N_F
MR4WNR7(B+(6!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
< $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g73463g01n39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01n39.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1=\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %U\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\
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MX6*"(T(D0_%R_]H # ,!  (1 Q$ /P#]4HB("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@P[N7POMW<OA6&,B(BJ"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(@
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$"($!$\$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!!WH@[T'HB(L68B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M##NY?"^W=R^%88R(B*H(B("!$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 "(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B!$!$1!A9'>B#O0>B(BQ9B(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B@.K]1ZAAU[B=-Z=^*XS;I2VGS78GOVY';;#E<
M%KYO,Z]TS0FRN1IX/,8^LTR6(:(D@F:P?*<WG+@=AUV06,BYM#.8^[A:.59:
MB92N,8^*21P:'<X\T=?'U+:BO5);<M2*S ^U$ Z2%KP7L![B1WA!L(M"[F<9
M1L,KW<C3KSOVY8Y9FM<=^[8$[K?!! (((/4$("+PO"R:4XH.B;;+#V1F!+ [
M;IS $$CV*M-4YO7^GABS-8TS-Y?>BHMY:LXY"_?SC_&=PV06DBB5*SJ;%,MW
M]5W,([%UH'RO\BKRLD'*-]]W/(VV!\%Q,%G-=:HQT68Q-/!XS&V1VE6&]VLL
MSX_Q7.+" W?O\=D%D(HE3U)D\;I3*9;6F,BQK\?SN<*\W:MF8T;AS?$;]VQZ
MKD8K)\0LY0CR=2G@,;5G:)8*EOM9)BP]1S.:0&DCU'9!8B*)5[.LK^GHGBGB
ML3F6S.9+'8<ZQ$Y@[G-+"TC?IWJ*NU#K\:[;ICMM,]NZB;W;^33<O+S\O+MV
MG>@M=%R--LSK*\WW23XV:?F_BS1B>QH;MX\SCUW770$1$!$1 1$08=W+X7V[
MN7P%88R(B*H(B("(B B(@(B("(B B\C/"'%IEC#M]MN8+U0$1$!$1 1?/.WG
M+>8<P&^V_5?2 B(@(B\K5B&I6EL696101-+WR/.S6M'4DGT(/5%K8V_4R=&&
M[CK$5FI,WFCFB<'->/2"%LH"+PO6Z]"G-;NSQP5H6E\DLCN5K&CO))[DHVZ]
M^G#;HSQV*TS0^.6-P<U[3W$$=Z#W1$0$1$!$6CE\MC\-4\JR]VO2K%X9VD[P
MQO,3L!N?%!O(@.XW'4(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B @1$!$0("(M(96@<L<6+</QB(NW-;F':=GOMS;>C?Q0;J(B B(@(B(
M"(B B(@(B("#O1!WH/1$18LQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!4'$
M#.0:?XU:<O6:UVS&,389V=.!TTFY>.O*.NW3O6_G->SZAQ%S$Z8TUJ";(W87
MP,DMTG5H8>8$<[WOZ #??Q)[E(<CINY8XH8C44;X11J8^:K(TN/.7O<"-AMM
MM]*EZ"E>)^ FP/!73V#CL\MFM;I0=NP=TG-U</I.ZFTN#Q.@-)9K)8*A$R[!
M3EFDL/'-+.YK2[>1YZNW/7J5[<3]-W-48"K2Q[X6RQ7Z]EQE<0.5C]SW ]=E
M*K5>*U6FKV&!\,K#&]I\6D;$(/S[I:334F AFSN@-3YS)W8VS6[]C$/F=,]P
MW):X]S?1ML-ME+^%V6O8K$ZG9)A=0LPF.E9)BZUJF\6#$YOG1,:>KN5P.W7N
M(6Y2P6O-+5X\7IJ[ALIAXARUSE.TCFKLWZ,)8"'@#N/0J9Z6J9BICG?=%DHK
M]Z1YD)AA$4<0.WF-'>0/2>I0<W2^LQG\BZH-/ZAQW*PO[;(470QG;;IS'QZ]
MRY/%_P"3I'^OZO\ WE8"BVO<!;SS<"*3H6^0Y2&[+VCB-V,WW V!Z]4$AR%.
M#(4+-.VSGKV(W12-WVW:X;$>XJNL3IS7&CZ[*.G\EC<SA:_FUZN0:Z&:*/P;
MVK00[;NZA6)DJ\EO'V:\%F2K++&YC)XP"Z,D=' 'IN%!'1<3Z.]>O/IG*Q@;
M,MV&RUY#ZW,;N-_84&[@\S3X@XC/X+,XRQ0MU_\ H>0I2/W+0\'9S7CH00"0
M1Z%R\9A^(&E8&5<=?Q>H<7 .2"&X#7L-C \UO. 0X^&Y73T]HS)4<9G9KF=?
M]T>:<V2>_7A ;"6C9C8V'<<K1N.O4[K3<SBC5YJ\,FEK[1T9;E[:%Q'I=&-Q
MO["@D&A]51ZHIW"^G-C\A1L.JW*<Q#G0R#KMS#HX$$$$*,/_ -H>+_X>/^,I
M+H33,NG:=U^0N^7Y;(V#;NV SD:Z0@#9K?!H#0![%JNTU=/%=FI>>#R 8HTN
M7F/:<_:<V^VVVVWK03!$1 1$0$1$!$1!AW<OA?;NY?"L,9$1%4$1$!$1 1$0
M$"(@(B(*'X[Z"TWBL+\?T,8R++3Y6!TE@2/)<7R;NZ$[=?8KX'<JN^$9]X%?
M^LZG^(K1"'<(B("\[$T=>O+/.]L<4;2][W'8- &Y)7HJOX]YV:IIZII_'PSS
MW<]*:Q9787RM@'65S6^)V('TH0@3;UVOD(.,'-,*-K(&K+ [\7&G:)KMO \S
M>;Z5^C&.:]K7,(<UP!!'<0JLEU/BI-*NT]]QNK!C#5\C$?Q=W,Y>7YW?ZUM\
M!-06<MH\XS*QRPY7"R"E/',WE?R ?Q;G#P);^PJ*-XP8.6.9E.AE[U^.S+6\
MAJ5NVF/9G8O(:2&M)/0DC?KZ%UM&\0\7J7*3XKR7(8K,1,[0T<E 892SYP'<
M0HS\'BA7@QFJ;L;-K%G-V6R/](:?-']Y]ZW.)S&P<0^&]R)H99.0EKF0#SC&
MZ,[M/J5$>X@<2LIC.)>G:%/#ZB;2BFL,L015=_C'9GFF+KYX:>OAT4_9J"IG
M]#9:_F<%DZ=!D,K;%+(0=G+)&UN[MF[]Q'=U4:XC?AEX8?I+W^$%->('WC:A
M_4)_\-R#RT):PXT)BK>&@&/PODHEBCE(;V4?4^<=SZR3NHM_#%BY^>;%8#4N
M3QK"0Z_4Q[G0].\@D@D?0H7J>:2+X,VF8^=S*ECR*&VYIVVA+_.W]70*^Z5>
M"I4AKU(VQUXF!D;&#8-:!L $$4R6H].:BX<9/+O;\9X'R:1UB$#9Y#1NYA:=
MBUPV[CLOJ'4&'T[PPKYVE2FAPE:A'8BK1@<[8R 0WJ=M^OI3B;6@K<,M5-KP
MQPM=1G>X1M#07%IW)V\3Z5#]3?[,)_J*#]QB#M6^+&+[=T6%Q&=SIBV$[\92
M,S(7$;\KG;[;CQ W4CT7K+$:OJ3RXF6035W<EFK/&8YH'>A[3W=Q]2SP]HT,
M?HG"08EK6TQ4C<PM'RMV@EQ]9)W44R,;:?'O$/Q[ V6]B9O+N4?*:Q[>1Q]>
M^XW0;N:XH8ZCE[>,QN(SN;MU']G8&-I.E;&[Q!=T&X]2Z>D-=XO5-;(''Q7(
MKM#_ %BA9A,=AAVW'F'OW[AZU'CKO4.7O7VZ%TI%D<=5L.KOO6;C:[99&]'<
MC=MR >F_BH_I&WG+/'YTNH\36Q5R3!D&*O8$PD:)1LXNV'7P^A0T:V+XK93^
M$?.METWJRQ0;5A['&LI;R5W==WN;OT#O J;\1,CI^QH?'Y#5V$M6*,]BN6TY
M6<LL4KSLWF&XV(WZC?T]ZT-,?A\UG_5E/_-8^$1]X5;^M:G^(@G6I,[C=,X6
M?)YFRVK2@ YG$;DGN#6@=23X *#_ ,,>+B:VQD,!J:ABW;$9"QCG"';TDC<[
M?0M?B,&W.+W#S'9$<V,<;5AL;OD/L,9NS<>D=X]JM&>&.>"2&=C7PR-+7L<-
MP0>A!"HYF1U!1IZ8LY^.06\?#6=:#ZY#NT8!OYIWV/10^?BWBGLB.'Q&=S;G
M1,EE&-J=L(>9H/*]P/+S $;@$[**:3Y8^!NNJM1[I,74FR,%%Q._\2-]MCZ-
MR59'"O'UL9P[T]7I1B.(THI"!XN<T.<3ZR24'OHG6.)UC1FL8F25LM=_96*T
M[#'+ _T/:>[]GN6=+:LIZCR&:IU*]N&3%635F,\?*USO2T[]0HMA(HZO'S43
M:[!&VSAZ\TP;^.\/+0X^O964 !OL!U[T1\696UZ\LSP2V-A>0._8#=5S'QAP
MMFC3EQ6-S.4N68C,:-&KVTL+ XM!DV.S=RT[#??93_+_ ,TW?T#_ -TJN/@V
MT,?5X7TK% -,]J:9]I^_4R"1S=CZ-FAO_HH)'H[7^)U->GQT<=W'9>!O/)C\
MA 89@WYP![Q["O+5'$;"Z9U <3E199/Y(+;71Q\X?N_D#&M!YB\GP 7!XS,;
M5S^@\E2'+EQF(ZT;F_*?"\$2-/I&RU\G1@M_"4Q,L[ YU7"/FCW\'<Y;O[G%
M%3;"ZMJWM.6LWD*=_"TJQ=VGQG#V+N0 'GV]!WZ*+#C%C',\JCT_J>3#[<WQ
MDW&N[#E^=OW[?0M#X1LEPX;35:I7;9BL9B%DL#Y.S9-T):QSO $K?&?XF!G(
M-#8D- VY1E1MMZ/DH:)O)G\?]S,V>JS"WCHZSK0? 0>=C6EW3U[#N*A8XOX:
MS6JNP^+S68M30,L25<?5[9]=KANT2$'E!]6Y7(TOA,W@N&.NZ^<Q\..CF;;L
MU:T,XE;&Q\1):"/ ']J[OP?J-"EPGP+\:UO_ $B(S3O'>^4N(=O[-MOH0=K1
MNNL1JJ:S4JBS3R=;K/0NQ&&>,>!+3WCUA:>J.(^-P>8DQ%?'Y?,92-H?)6QM
M1TQC!&XYCT Z==MUQN)$3:G$SA]?H, R<]N6K*6][ZY82X.'H'>MG*:ZR]O4
M.3Q>A]-LR\F/>([MN>TVO$R3K_%C<$N('N0T=;1FO\9J?(V<:RKD,9E:[!(^
MED8##+R'\8 ]X^U8U3Q#PFE\_'BLRZ:%[ZAN"4,YFD!W*& #SBXGN !5?27]
M2V^,^AY-3X.IB9#%<CC->T)S,WD!(=T&VQV]Y77U'CJ]_P"$=IEUI@D\EP\M
MB,'N#P]P!^C??VJ&B=:;U3!F<-:R=BAD,/5KN<'')P]@2P#<OV)^3Z_45%'<
M8,7)S3X[ ZER.,:3OD*N/<Z#8=[@202/7LL?"*DL-X9V(ZS.=DUNO%.TOY Z
M,R#<%W@"=@3ZUY4LUQ(JTX:]70N(97C8&1M;E0 &@; #S5318.GLUC]0XF#)
MX:TRU2G&[)&@CU$$'J"/$'JMC)WJV,Q]F]?F$-2O&999""0UH&Y/3JH#PHQ>
MH\?E]2SY[$UL54R$[+4->"R)FMD+=I-MN[<@'Z5,=5YNCIS3M_+Y7?R*K'SR
M -YBX;[  >))('THB$.XPT'1NLU=-:JLXQHYC>CQKNRY1WNW)WV^A3O3N;H:
MBPU7*XB<6*5EG/&\#;U$$>!!Z$*!5]6<0K]>.UCM"4XZ4S ^)MG)M;)R$=.8
M!O3IX)\'PS#2N9CLUHZLK,U<:ZO&[F9"><;L:?$ [A%T6'F,G3PV+M9')SMK
MTJS#)+*[N:T?^NY5ZWC#1?'Y5%IC5<F+V#A?;C7&(M^<.N^RE?$33(UAHW)8
M,V#7=:8WDEVW#7-<'-W'B-P-U#H=2:^TQ0:W4&DJF4HU(]I+>)M@.Y&MZN[)
MX!/0=P(1(2K/ZYQ>&TWC,Y*RQ+1R$T,,):SE<.U^2YP=ML/2N!-Q=QCWR/Q.
M"U'E\?&XM=?I8]SX.G?LX[;CUA1KCIE\7JCA'A,E7E=\4WLE6<7D<K@PEP=N
M/ CK[E=%.O#5J0UZK&QUXF!D;&C8!H&P 17.TMJ/%ZIQ,>2PEIMBLX\IZ;.C
M<.]KFGJUP]!48S/%#&4LK9QV*Q>;SUFJ_L['Q73,S(G>+2[H-QX@*+Q<^)XA
M<4(\ "T.Q,5Q[&=S;18_8CT$CJN7PDRFN:/#[#QX#2&,M4'1&1ME^3#'S.<X
MESG#;O)W4-%L:,UCBM6U9Y,8^9D]=W)8JV(S'- [T.:?V]RYFJ.(V*P>6=B:
M]3)9G+,:'RT\77,[X@>XOVZ-W]!ZJ-:>QVLKO%.AJ',:?I8FJ*<E2VZO=$QF
M;\IA(V'4.']ZBO"C)ZTKTLY9PFE\?D9+.4L.M6I\@(I#(';<I;MT &VWM0T6
MOH[7F*U/;GH1Q7<?EH&A\N/R$!AF:WYVQZ$>PK[UGKK$:4FK5;@M6\G:W,%"
ME"9IY .\AH[AZRH-=JZ_S>KM-92YI7'8UV-M;R68<@V1SH'#ED81L-QL=_:%
MT.&#&7N)/$+(9!@=E:]QE6,OZF.L&GD ] .WT[*FCL:>XFXO*9B#%9''9?!9
M&Q_J\.5JF'M_4T]03ZE%-1:@QVF>/-G(9>?LH&X!K&AK2Y\CS-T:UHZEQ] 5
MP3UH+#XGSPQROA=SQE[02QW=N-^X^M55/0KV_A+0SV&![ZF"[6+?\5QD+=_<
MXH0Z=7BYC!D*U?,874&$@LO$<5O)4C%"XGNW=OTW]:L<$$ @@@^A0KC7!%8X
M4ZG9.P/:VD^0 ^#F]0?H("[.@Y'S:)P$DCBY[J$!<X]Y/9M1'=1$0$1$!$1
M1$0$1$!!WH@[T'HB(L68B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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ME>>]_9O! <?$A!J2P0T^.<+<>T1NR&%D??;'TYN20"-Y]?5PW7-T]C=;</\
M'OQ.,PN.U%AX97O@E9:\FLEKG%VSPX%KG#<]=^JF6D=&4M.MN3&U<R.4N@"U
MD+<O--(!W-!&W*T;] -EP?X.LM7:ZOB]>ZAJX\D[0/[.9[!OOLV1S>;WDE!P
M>(VHZ&J."5O(XN&2O%Y97A?!(P-=%(VRP.:0.FX/H5L3NL,Q3W48XY;8AWB9
M([E:YVW0$^ W\5'OX/\ !C0LVDVQ2MQLS?/?VA,KI-P[M2X_C\P#M_2O31VF
M<A@7RG(:FR6988VQ1,M-8UL;0>_S1N7>LE!X:<OZVGRL<>H,)B*F/(=SRUKK
MI7@[=-FEH\?6N9QU^\B'^LZ7^.Q6$N%K33D6J,.S'SV'UV-L0V.=@!.\;P\#
MKZ=MD';9_)C?NV4"EX:5Z=ZS=TIF\I@)K#C(^*NYLE<N/4GLG@@$^HA3N6%D
MU=\$HYHWM+'#T@C8JOF\-[V/+XM-ZTSN+HGY-1Q999$/0PR N ^DH-C1&?S?
MW5YC2NJ75;=NE7CMPWZS.S;-"\ENSV;^:[<>'3O^GX/#2"A<L7-(YS)X"2P\
MRR0P.;-7<XDDGLW@@;^HA=;2^A\;@J61B?+:R5K)?Z[<N2<TTXV(Y21MLT G
M8#NW7$;PWOT-XM/:VS^-HGHVJ\LL-C'S6%X):![2@V-!ZBS,FJ<YI74IKVKV
M,CBG9?K,[-L\4GR>9FYY7=.H!V7/U/\ AZT7_5UW_NJ5:,TA2TO%9?%-8O9&
MV[GMW[;N>:=WAN? #N '0+.1TM#=UMB-2.LR-FQU>:NV$-'*\2;;DGU;()$H
M5Q%TYELI;P>7TY+2^-,1,^2.O>!,,S7MY7 D=6NV[BIJHYJ_2[\^:LU7-93$
M7*Q/9S4I=@0>\.8=VN'M&Z#@X[6>3K9_&8S6>F1BY[TAAIW*]AMF%\G*26[[
M!S"0#MT6E2U9J',7,F_0^EL=)BX+4D#K=RWV!L2M.SW!K6D[;]-SWKJ87A_)
M#GJF7U'J+)9^U2YC499#(XH7$;%X8P %VVXW/I7A9X<3P9.]8TYJK+X2M>E,
M]BI &21]HX^<YG."6$^KQ0<WA&[(C6FNH\M5K4K1L5Y9*U67M(FO="-R#L.I
MZ$].]:?"S\'&M/ZQR/\ FIGHG0]325[*V:=NU9=D#&Z4V7<[RYK=BXN[R7'<
MGPZ].B^M-:-@P6 R^*BMRRQY&Q8L.D<T L,O>![$$(P^ DU!\'["1TQMDZE5
MERB\=[9XR7-]_=]*^]0ZF.O]&Z7Q.(?V5C4Y'E8:=C#7CZV/9U!8/:K'TC@X
M]-Z:Q^'AF?/'3B$39'@ N'I(7"TKP\QVG-6Y;.U9YI'W=Q%7?MV=4.=SO#/1
MS.ZE!IZFU%/C]44M/:3T_6R.;CI]LZ2>40Q5J^_*!S;$G<@>:%%<C8U-)Q5T
M+/J/%8W'/<^S"Q].T972M[,$M=NT= 0"IWJ_1#,YEJN8QV6O87-5XS +=0M/
M/$3OR/:X$.&_5<['\-6Q:AQ.=R>?R>4RM"1[^VL\NSFN;R\C6@ ,:.IZ#<GQ
M[D')L8ZK=^$?'-:B;*^K@A+#S#<-<92W?V[$KN<7J,WW/09['Q\^3P$[<A"!
MT+V-Z2L^EA=[@NRW2\+=>/U/Y3)V[J(H]ARCEY>?FYM^_=>6I-;Z9P%B>EG<
MK6JSMA[4P3;[O8=QYH_&/0]!N4$6U'>CUYEM)8C'2AV-FC9F[WK@:1V;/_F>
M>O\ 1*L]5CP)TT<5A+^7FBFADRT[I:\,WRJ]4.=V,?J&Q+MO^)6<@K#@Q'#;
MR&LLG;;SYIV8FKS/>/.9&S;LV#T-V4XS%.*M7R64H58OC;R-[&2M8.=W*"6M
M]?5<'4>@(K^;=FL'E[^ RTC>2>:EREE@#N[2-P(<1X'OZK=TAI 8"U:O7<OD
M<SE++0R2S<>/-8#ORL8 &M&YW0<7@)!3;POP]JKM)/<8Z>U,>KI)BX\Y<?$[
MC;Z%IXAK,?Q\RU3%,:RK<P[+5Z-@V:)A)RL=ZB6D^U;]SAS)!?M6=*ZDRFGH
MK3C)-4K-9)!S'O<UC@>0GO.R[NC=)4=+5[ K2V;=VT_M+5VW)VDT[O#F/H'@
M!T""%<!,?68_6]]L3?*YM0VHG2>/(T@@>S=Q]ZV[/^T/2_\ A]_^,I7HO2\.
MEH,K%!9DL#(9";(.+V@<CI-MVC;P&RT]8Z*9G\G2RU#*7,-FJC711W*H:XNC
M/4L<UP(<-^J#E<:_YCP/]>T?\1>NK\!J"'6%;5&EFX^W8;3\BGI7G%@<SGYP
MZ-X!Y7=2#N/0NAD=&?&.GL7C+^7NVI*5R*Z;4P:Z25T;^;8[   ]WJ"SJC2%
MK+91N2Q6I<OAK8C$;A7>'PO .XWC>"W?J>HV0<BAK2]-=OXC+Z?DP^IA0ELU
MPV1D\<[6[[<CQL>_P("]N!M/'P<-<1/CPUTEN(6+4N^[I)W?++CZ=^BW-)Z&
M9ALQ-F<IEKV;S4D78"U;Y1V4>^_*QC0 W<]ZY]KALZM=LS:4U)E-/06GF2:I
M5#)("X][FM>#R$^I!KX2&OC^.6=KXMK60V\5%:O,9\D3B0M:[;P);O[5Z\!O
MO(L?UI=_QW*1Z-TE0TM7L>2OL6KUIW:6[UI_/-8<.XN/J'0 ; !?>BM-Q:5P
M\F/KV)+#'V9K/.\ '>1Y>1T]&Z#O(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(HKQ5D?%PWU+)$]S)&T)BUS3L0>4]Q48
MP/"C35W 8^Q/\:]M/6C>]PR4X\XM!)^5ZT%HHJKL29'AGG<+"_)6LII;*612
M+;K@^:E*[Y!#^]S#L00>Y2_56L\9IRW4I3LM7,I;W,%&E%VLT@'>=N@ ]9(0
M25%#L/Q Q]W.08;(T,GA<I8!->OD80SMP 2>1S7.:=MCTW7KJ#7-/%9OXGJ8
M[*9C*-C$TE?'PAYB8=]B]SG-:-]CXH)82 "2=@%Y5;$-N!D]6:.:%XW;)&X.
M:[V$+@X#4M;4%;(12XS)49:S0VQ6O0=F[9S2>A!+3N-^XKBZ9U#IW"<)HL]A
M<?9JZ?K5W3LJ@ RAO,=^A=MN3N?E()ZB@/\ "=2L576\1@\]EJ$8WDM4ZS3&
MP^(W<X%VWCR@]RE.F-08[4V#KY;#S]M2F!Y7%I:002""#U!!!"#JHH%!Q.H9
M":?[G\+G<W3@>8Y+E&LTPAP[P"YS2[;_ (05U-+ZZP^ILK-0Q+IWRPUVV)"]
MG)R;O<PL<">8/!:=P1Z.I02E$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$11OB1F'X#0F<R<)VF@JO,7],^:W^\A!WZUF"TQSZTT<S&N+"Z
M-P< X'8CIX@KU58Y/$.TQ\'W(4(7O98KX:5[Y 2'=J6%SG;^GF)ZKXP7"C35
MW XZQ,<KVTU:.1[FY*<><6@DCSO2@M%%6O#I]G$ZZU%I>+)6LEB*-:O/"^R_
MM)*SW\P,1?WGH 1OU77N:^B9=M5L5@,_E_)9'132TZK1&U[>\!SW-YB/5N@F
M:+@:7U=B=1X>QDJ$SV0UGNCLLG88WP/:-W->#W$*/P<3JUNNZYC-.:DO8H;D
M7H*C>S<!ONYH+PXCIWAJ"?HH[EM98?$Z;JYN]-+%4M!G8,,3NUE<\;M8&;;\
MQ]"Y5?B+4;?JULSA<WA&6WB."Q?KM;$]Q[FES7.Y2?0[9!,9K=>">"":>*.:
M<D11N> Z0@;GE'CL/0GE5?ROR7MXO*N3M.QYQS\N^W-MW[>M5QQ)_"KPN_6;
MO^ %VVSX#^%AU<8^7[I/BL2FYL.3L.?;D^5W[^KN\4$R10F_Q)Q-3/9#!QU<
MA;S%21L;:=:(/DGW8'\S/.V#0"-R[E&ZV=-Z[HYC-R8:S1R6(R[8^U;4R$(8
MZ1F^Q<PM+FD#VH):M:#'U*]ZU<@K11V[08)YFM =+RC9O,?'8$[+B:IUCC]/
MW*M%\-N_E;0+H:-*+M)GM'>[;< -'I)"U]/ZZHY3,C#VZ.2P^6<QTD=7(0AC
MI6CO+'-+FNV]102:M:KVNU\FGBF[)YCD[-X=R.'>T[=Q]2]E ,5$S!\8<K4A
M:6U\[0;?(WZ">)W9O(]&[7,^D*?H"(B B(@(B(,.[E\+[=\E?"L,9$1%4$1$
M!$1 "(B B(@(B((#ELUK7)9:_0TMA*E*O4D[(Y'+2$-E=L#_ !<; 26]1YRU
ML3J[46&U1B\!KJC1Y\H7MIY''O<8G2-&_(YKANT[=Q\??M8QV ))V'I54MLO
MXC<1,3;Q0YM+:<G?*ZYML+5O8M#6;]2UN_4]Q]R*M=$1$%7W%S5&:TZ-.U].
M"EY9E;XI\UMKG,;N.AZ'?O5@JI^.LK(<MP]DF>UD;,[&7.<=@!MWDH0WVQ<5
MX=Y'SZ1L!O7LFB9A?ZMR.B[N@-8#5,61@LT)<;E\9-Y/=IR.#N1Q[BUP[VG8
M['U+HV]6:?J5WSV<UCXXF#=SC.WH/>H-PHF.H]<ZOU?5CECQ%WL*E-SV\O;B
M,;.DV/7;NV]J*M)CFO;NQP</2#NA>T.#2X!Q[AOU*KCX/A)X=M)))\OM?XSE
M]ZQ)'&7AX-SL67]_J"B:/?56:R%/BSHG%5K3X\?>BN.L0@#:0LCW;OX]"IX)
M8S(8P]I>.]H/7W*F^,%._D.*_#^GBK;J5B>.Y&ZPP;NCC+1SEN_XW+S >LA=
MR;@MI0UB:C+U;) ;LR++<AG#_GDD[$[^I%335]J:EI3,VJKS'8@IS21O'>UP
M82#[U':<F=SO"&C+C,K'3SMO'PR-O3M!#7D-+B>G3<;C?;INN+@,UD<KPGU5
M5SLC9LMBF7,?8F:-A,6,.S]O6TA<[5!(^"X2#L1AJ_\ W%!;.(BM0XNG'D+#
M;-QD+&S3-;RB1X'5P'AN=UL=K&).S[1G/\W?K[E6&M]09+%:*TEB\%(R#*9U
MU>A%8<-^P:6#F>!Z0.Y>L7!+2(IAL\=^>_MYV0=<D[<N^=OOL#]"J+-1<[3M
M"QB\-5I7,A-D9X6<CK,S0U\GHW 5;<>[#XI=,0Y2>Y7TE-9D&6EJ<P< &CLP
MXMZAI/-OM]B"UXI8Y2>SD8_;OY3OLLE[0\,+@'GN;OU*J;26C>&V0O5;^C;P
MCM5Y&RAU&^_=^Q^2YI)W![B-EH<6*.0RG&/1>/QEV2B^S3LLEL1_+CB[WEOH
M<0" ?#=%T7.)8R\L$C"\=[=^H7VJSL\%M+>3<V.;>I91@YHL@RU(9FR#N<=S
ML>O>-E&K_$G,XWA#+8NS0,U'#DG822VX;1MD#B#,1W?)&_M1-%W&2,2",O:'
MGN;OU/T+[7Y_BQ'!QU4>7:HAMY(C=^1?DGB<O^<#OL.O<-ME,.$>HGZDP^HL
M)\<^7_%<QJU\K 1SRPO;O&_?N+QU&_I"+HLUTL;7ACI&!Y[FD[%?8[U1-S3?
M!ZDZ6KFL]#8R8Z2VK.2>9^8^.X.P/T*5< ,U/E=*7Z\V0.2BQN0EIUK;NIEA
M;L6$GQZ'O0T=#@UF+^;TQ>LY6R^S/'D[4#7N W#&OV:.GH"G1D8'AA>T//4-
MWZE?G_2G$/':!X:Y&:SM-DK&7O-IU=]NT<).]Q\&C<;E61P^TK-7G?J?4=B*
M]J:_$.TEB.\->,]T4(\&@>/>>J0.MI2EG:N3STF=R\&0JSV0ZC%%&&FM'L?-
M=T[^[T]V_BI$)&$.(>TAO1QW[O:JRX.'_P!I.(W]=N_=40X=Z.BU=G];MST]
MF3#5\W+V5.*4QMDE/RB\MZN '* -]NI07Y&]DC>:-[7-]+3N%]*ELSI^IPNU
M;IC(:4=/7Q^6O,QMV@Z5SXWA_P E[>8[AP/K76UY-;U3Q&Q^AH[DU/$"D[(9
M%U=W)+,WFY61AW>!OW[(FBT(Y8Y.81O:XCOY3OLLL<U[>9C@X=VX.ZK>;A%@
ML;6-G2?E6(S,#>>O:CL/=N\ ["1KB0YI\05Y_!P=,_A;4=9V$YMVN<#N#NV=
MOLAHL+,9"+%XNU>GZLKQ/E+=P"[E!.PW\>BYNB]35=4Z;Q^7KM[!MUA>V![P
M7MV)&QV]BT>*. QNH-&9&++5O*&589+,0YBWED;&[8]#ZRH-P&T%IQNCM,ZD
M&. S/9.D\H[5_P KF>W?EWV[O4@N0D ;D@ >)6(Y&2-WC>U[>[=IW526,=+Q
M,UYGJ&8LS,TK@I6UF4X)#&;-@M!<Z0CKRC?8#=:^M=&5.'.%FU9H;RBE8QO+
M+/2,[G06H>8![7-=OL=CN"/0AHN5"0 23L!XK5Q-UF1Q=.[$-H[,+)FCT!S0
M?\U#^)F!T[DFU;FL<S/4Q4 (\E-KL(97;[[NV\XG;IMN@F\<C)!O&]KQZ6G=
M?:_.MR?0NFL_I[(\-\Y V\_(0U;-&"TZ5EB&0\KB6N/>-P05^BD-'R7M:6M+
M@"[N!/>L=I&).SYV]I\W?K[E4G'.+)6-4</JV$L"M>GNV(F3$;]F'1@.?MZ0
MTDCUA=.3@KI)]<_Q>0&0VW^,/+).W#_G[[[;[^K9!9:^'2QM?R.D8'G\4D;^
MY5UPSRN2S6$U'I[-7I/C+#69,<<A%LU[V;>9)Z [;]BB%S3G!RH9:N5SL,N2
M'22U/DWF?F^=N#MO]"+HO=?':Q\A?VC.0=[M^GO5<\ <W8S.C+$=J\<@,?>E
MI0VSWS0LVY'$^)V/>H1P<T-!J[3-F?54D]K&PY"RRE3;,8XP.T)>]W*07$NW
M W/0#UHFB_F/:]H<QP<T^(.X7UX'T*H:&#CX=<4,!C]/S31X'4#+$<M&20R-
MBEB9SA[-^HWZ#WK1XAZAQ66XD3::U3GH\3IO'5F33P]OV+KLS^K6EPZ\K1W@
M$=471=,<C) 3&]KP/FG=0/BEFLAB<IHJ+'6GP1WLS'6L!H![2,@[M.ZK/.V^
M'^E*3\WPYU-4IY>F!(:<=MTD=Y@/6)S7$]2-]B/%3+BG=BR4_#"]7W[&UFJ\
M[-^_E<S<?W%0T6RB(J@B(@(B("(B B(@(B("(B B(@(B("#O1!WH/1$18LQ$
M1 1$0$1$!$1 11+5^O\ #Z4S%''9861+<ADEB=%'S@\I Y-@>8N)<-@ ?H6_
M7U/6&G+.;R]6YAJ=?F<\7V!CPP?C;-)Z'?H._P!2#O+#WM8QSWN#6M&Y).P
M4!=Q0I156W[> U%6PSO.&1EICL@WP<0'%X;X[EJXO'[.O;HEM.IC\A;I9"2O
MSVZO(8C&Z5N\>Y<';N'0;#;KWH+(BSN)F@EGBRE%\,1#7R-G:6L)Z $[]%T5
M16O*N.CX79>7'Z3M:=D$M.)WE$4;'3-$K=MN1[M]O7UZJV]6:FQNEL<RWE9'
M@2R"&&*)A?)-(>YC&CO)0=I%"Z?$*J<E4IYC#9K".MO$=>6_7:V.1Y[F\S'.
M )V[G;+KZMU7B]+5H)<K+)VEF3LJ]>&,R2SO^:QH[S_<@[J*%5.(=/XSIT<S
MB,S@Y+C^RK29"!K8Y7GN8',<X!Q]!V45M\0LU!Q;=C68#/2X]F.<_P A9'!S
MR/$NPF:3)\C;IW@]>Y!;Z*+:BUM1P%/%OOT\@;V2\VMCH81)8<[8$MV!V!&X
MW.^WK3 ZQ&3RS,;:P.<Q5F1CI&>6UVAC@-M_/8YS=^OB4$I1>5JQ%4K36+,C
M8X(F%\CW=S6@;DE02'B?6M5#>H:;U+<Q/4B_#4;V;FC?=S07AY'3OY4%@(JF
MXHZ_R6+.EW8/'9?R>[>K.=.R&,-L1OW)A >X.#R-N\#VJ;Q:IY=,Y'-9'#Y3
M&QT6/D?7M-C[5[6MYB6AKR/>0@D2*'Z6X@8_5%BNS"4<G9K/:#)<$($$#BT.
MY'.+NKAOL>7FV*QD]?TZ^8MXO%8K+YNY3V%EN.A:YL)(WY7.>YK=]O $E!,4
M4>TUJ_%:@HW;%9\U=U$\MN"U&8I*YVW\]I[N@/7NZ+@P<3JUNNZYC-.:DOXL
M;[7H*C>R<!ON6@O#B.G>&H)^BBV:UUBL3A\5?DCNSG*;"E5@KET\Q+>;8,.V
MW3OWVV7SA-9C(9>#&W,!G<58G:YT1NUV\CN4;GSV.< ?:@E:(H+_  E4;5NS
M%@<-F\Y!6D,4UK'UVNB:\=[0YSF\Q'_#N@FC;5=UM]5L\1LL:'NB#QSAIZ D
M=^WK7LJCT/G:&HN-N:OXJ4R0'"0L<'-+7,>)3S-<T]01Z%8&!U-3S69SF-JQ
M3LGQ$S()W2 !KG.;S MV)W&WIV0=Q>-BI6L/C?8KPROC.['/8'%I](W[ES,G
MJ&KC]18;#31S.LY7MNQ<T#D;V;.=W,=]^[NV!7(U)Q"Q&GM1,PMZ.X^])6%B
M%D$7:&;=_(&, .Y=ON=MMM@>J"56;5>JUCK4\4+7N#&F1X;S./<!OWGU+V4!
MUME<'9T]@;FK,%>[.QDH8Z]69K1+#.7.#'. ?MMTW[ST/<NSK#6N(TC9QL6;
M?)$R]VO9RM;S-:8VAQ!Z[[G<   [DH)*B@<G$RE3L5AFL'GL12LR".*]<K-;
M#S'HT.+7$MW_ .(!2?4NH<9IO#R9/,6FUZ;-AS;%Q<3W!H'4D^@(.JB@D?$J
MJR&.UD\!J'&8Q^VUZU4;V0W[BX-<YS1ZR %(-&:EIZMP$.7QK)F597R,:)@
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M6^74.6S\.&DPF'?5AH8VI+'V;S$PO<Y[F?B[N=T!Z^/B@LQ$1 1$0$1$!$1
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M%\3PX II)$Q/1OHB**(B("(B B(@(B("(B##NY?"^W=R^%88R(B*H(B("(B
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M-^BAJX/ **.+A+@.R8UG.R5[MAMS.,K^I]:TL\ /A :6( !.*L@GT]2IOI'
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M1$!$1 1$0$1$ (B("(B B(!OW("+/*4V*&C"(B B(@(@W6>4H,(L\I6$!$1
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MI?[W,]^A=^XY>'P?_P %V+_IS?XCEYNT?/9]'\/^C3TG^5B(B+G>@(B("(B
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M(;*QQ[@X$^]6>_4&*_A0AR(O1>0MI]F9M_-YN4]%O?P!:D_.&+_[3_\ E3^
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M;UNC(VW:959V3G$ASM]B=QW=%^C.&VD(-&:;CQ\4G;3O<99YMMN=YV[AX
M+')?>C5LV?%-)T\$J1$6AV"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B M7*TVY#'6*LAV;*WEW]!\"MI%)B)C22)TYH71R&4CIMQ
MU?LQD:+N5T3_ /KX_#8KH1:OI,')D8IZE@?*8YA.Q]1"Z&:PM?*-:YY=#9C_
M ).>,[.:N5Y!J*OYC+-.[&.XSQ^<N*:YL4Z1.L>_[<F^)I;J39ZSE@:^!KR>
M=T=9E'*U@]2YM2 S/DQ6$D+@3_TZ\>\^IO\ >ND["YC(CDR>2;#6/RH:S>7?
MZ5(,=1KX^LV"I&(XV^CO/K/I*5Q7RVUO_OI'=]^\FU:QI#&,H08VFRM5;RQM
M]/>3Z2MI$7;$16-(:)G41$5!$1 1$0$1$!$1 1$0$1$!:&=R4>)Q<]N3KR#S
M6_.=X!;Z@W%61PHT(AORND<X_0/_ !6[9\<9,D5ES[5EG%BM>.L(!D;T^1N2
M6K;^>5YZ^@>H>I:R(OI(B(C2'R<S,SK(IWPYS\C;#<5:?S1.![$GO:>_E]B@
MBV<;*Z'(5I&'9S96D>]:L^*,M)K+;LV:V')%X7PB(OFGUXB(@(B("(B B(@(
MB("(B B(@(B("J[07X8-?>R#]BM%5=H+\,&OO9!^Q91WL+=8:MSY#OTKOVE:
M:W+G\F[]*[]I6FO9CH^.R=4JTQ][F>_0N_<<O#X/_P""[%_TYO\ $<O?3'WN
M9[]"[]QR\/@__@NQ?].;_$<O,VCY[/I/A_T:>D_RL1$1<[T!$1 1$0$1$!$1
M 1$08=W+X7V[N7PK#&1$15!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M"(@($1 1<_,Y./&UVN[-\]F5W)!7C^7*[T#]I/< N>S#Y#)ELV=O20Q$=*--
MYC:WU/>/.<?80/4LXKRUF=&.O/2'9LW*U8;V+$47]-X"UF9K%O=RLR%0N] E
M;]JB?$67&Z+TI/D:&(I26W/;%$Z6(.V<[?SB3U.VWI5>7K&I=,8^OJ&_E:V2
MQ\SHC'5DJ@-F#ANX;<OF;?WK=CP1DC6)]/NEK36>:_8WMD;S1N:]OI:=U]L[
MRN)3Q&)R&/K78*@J&>)LH=7<87#F&_>W9#\989O,Y\F4H@]26CRB-OIZ='@>
MP'VK1I$\H9QR1;@;L[!9B1QWL/R<QD)[R>FVZL=5=IZ[#I7B#<HO>WXFU"?*
MZ5C?S.U\6;^O[%:*SVB/U[W=)CZ:"(BT,VKE6M=C+@>-VF%X/N*AG \N/#3&
M\W<'S!OK':N_\5L<5,\<;@CC*7\9E\KO6K1-^5YW0N]@W7;TEAF:?TSCL4PA
MWDT0:YP&W,[O<?>2M\1NXN??/\-<\[.NWY2KS0F[N*&NG3])PZNUH_\ V?*=
MBK"'0[JN-43?<?Q%IZ@>TC%9:,4[LGXL3P?,>?HZ?05<7/>K'68_[)Y:2LM%
MACVO8U['!S7#<$'<$+*YVP1%PM::BK:9P%B_9<.T Y88_&20]S0%:UFTZ0DS
MIS1+@]YN0UG'%UJMRCNS]IWW_P ET>)N:NT:V.Q.'<&9++S>3QR'_JV_C.'K
MV*V.%F!GP.E&-O[_ !A<D=;L;]X>_KL?8%Q.*?\ ^#]1:3S<P/D5:P^"P_PC
M#P '>KQ77&EL\]__ %#5TJC^B\)=O6K<&DIH<?B:TABER\L(FLW)1\HCF[F[
M_P#HK:UU@\KA\:;&>GAU'I]I M"2!L5F $[<['-]&ZW^&.;HZ9BM:7S=B*I:
M@G?+7EE<&LLQ//,US7'H>];_ !-U3CY]/6L)B)X<CE\BWR>&M7<)#YW>X[=P
M W6R;7XND1R_KQU2(C=<?1]2KEY+FC]1M&2H5XH[N,GD)#S [NZCKN-P/>NA
M=?<QVH*6B=$>38F%D!M3V7L[0M:3X ]Y/K6EPZK]MKLM@=VD&$Q4>.EF'4.E
M)W(!]6Q'T+H2RQUN.C38>V(38OEC+SL'GF[AZ^A4M\\Q]M=/OZ$=&,-H#4&'
M-LX_5PB-J4SS?_@]IYGGO/5W1>V8Q>M,1C+.0@U1!==6893!+1:QKP!N1N#T
M5@]K'_[QG_:"Y&K[=>#2V6?-/&QGDL@W<X#J6G9:(S7M:-=)_$,YI$1R?.CL
MT-0Z9Q^5[/LC9CYG,\ X$@_1N"NPH=P@8Z/AQ@P]I:>R<=CZ"]Q"F*PR1%;S
M$>*5G6($1%@R$1$!$1 1$0$1$!$0("(B B(@(B("(B B(@(B("(B @[T0=Z#
MT1$6+,1$0$1$!$1 59<%O]<UI_7,RLU5?P<D$4^MY';[-S$SCMZEE'26%N4P
MM!%PXM58I[=W3.8?0YA7T[5&*:-_*2?8PK+A7\):^U8>N_'NT.*?X.]0_J<G
M[%[<-_O#P'ZE%^Z%SM?WX<EPRU#/7YNS\ED;YPV[@NCPW^\+ ?J47[H6,Q,1
MI+.MHM.]7IHD:K3X0_X-K'ZS#^\K+5:?"'_!M8_68?WE*]5O\LK$Q_\ J%;]
M$W]B]UR)<O6Q=&CY47 21C8@;]P'VK U-B2-_*@/:T_8LHQVF-8AA.?%6=VU
MHB?5V%5=[_:)QW]4N_:Y3INIL:^>.&*5SWO<&C9IVW)4%O?[1.._JEW[7)N3
M7K!&6F3Y)UYK41$6#<K'BY]]F@/ZR/\ W59RK'BY]]F@/ZR/_=4ZR.<IXZT(
M+3G->6AVX;N-O_06<5FVD0U3>N/6;3I#J(N/]TN)_*Q_V3]B^J.H*-VXVM6>
MY\CMR#RD#H$X=^NB1M&*9TBT>Z \-?PK<0_TL/['*U%5?#3\*W$/]+#^PJU%
M+=6>/H*KM _ABU[[(/W5:*J[07X8M?>R#]U([RW6%HHN''JG&.<0^9T9!V/,
MPK[=J;%-:3Y5OZ@TK+A7\&OM6'SQ[O/7GWE9W]2E_<*Y'!C\&. _0']XK9U/
MDZ^3T+J&2J7%C*DK27#;KR%:W!?\&. _0']XJ3$Q&DLJVB\Q:LZQHFB(BP;1
M$1!&^)7W@:A_4I?W2M/A!^#33WZJ/VE;G$K[P-0_J4O[I7(X9Y"'&\+-/36>
M81^3M;N!OXE91$S&D-=K16=ZW31.T7&9J?%.;N;/+ZBTKXEU3BV?)F<\_P#"
MPK+A7\)8=JP]=^/=!^+?W\</OZP/^2M155Q8/-K;AZX=QOD_L5JK&>D-E>LB
M(BQ9B(B#4R_\U7?T+_W2H'\'W\&E+]-+^\IYEOYJN_H7_NE5WP-MQT>%5:Q/
MOV;)I-]AO^/LLHC6-(:[3%9UGP6>BXL>J,4]NYL\OJ<PK$NJ<4P;BP7_ -%A
M67"OX2P[5ATUWX]T.XZ_S7IS^N*_^:LMGR&^Q5AQMF;8P>F)6;\DF7KN&_H.
MZL]GR&^Q8ST;*SK,S#*(BQ9B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B#F8"U-;K67SN#G,LRQMZ;>:'; +IK6H4XJ
M4<C(>;:21TIYCOU<=RME:\46K2(MU96F)F9@1$6QB(B("(B B(@(B("(B B(
M@*+<1<<^[@^UB&[ZSNT(]+=MC]OT*4KPO6(:E2:>TX-@8TEY/H6S#>:7BU>K
M5GQUR8[5MTE0J*99?2K;K/C#3;FV*LOG&$'9S#Z!O^Q16>E:@D+)J\K'#ILY
MA7T6/-3)'*7RF7!?%/..7CW-==C26.?DL[6B:/,8X22'T-!W_P#!,5IO*9)X
M$%9S(]^LDGFM'V_0K"TK!BL/8?BZ]ALV1+>>5^W?ZO5MZ%HVG:(I68KSG^'3
MLFRVR7BU^5?OW_:$G1$7@/IQ$1 1$0$1$!$1 1$0$1$!$1 1$0%5V@OPP:^]
MD'[%:*J[07X8-?>R#]BRCO86ZPU;GR'?I7?M*TUN7/D._2N_:5IKV8Z/CLG5
M*M,?>YGOT+OW'+P^#_\ @NQ?].;_ !'+WTO][F>_0N_<<O#X/_X+L7_3F_Q'
M+S-H^>SZ3X?]&GI/\K$1$7.] 1$0$1$!$1 1$0$1$&']R^%]N[E\*PQD1$50
M1$0$1$!$1 1$0$1$!$1 1$0$1$! B! 1$0$1$!$1 1$0<:M R;5UN>;SI*U6
M-D._XH>Y_.1[>1H^A4]??8UMKS,U,QFO(ZE!TS(*0D>P^8T[/\T;$;C<D]5<
MN6ISBS%DL:T.NP-+#$YW*V>,G<L)\#X@^GU$J*Y31FFM:Y*>]S7*64BVCM-@
M?V4@)'<\;$=WB.\>E=6&\5F;3X>S"T:QI")\-S]U.'S^E]0WVY3&5&1R17VO
M=LW?KT<X ]"/'U^"U<%IG$9;/.H7M?#*UWO9ST@YS>WY/DMW)V.WJ4DU_I2O
MISAG8H:=KSBL)V27.1V\LD>_G'?W>K95CE7X6Q@,1#BXLLZR3(,<T20%S7\P
MWY^4<W?MLNK'_P#)K:DZ1,_;W:[?IY2[G$J_;S&K\AA9<W7PF,Q@CC@AE=(Q
MLF[0=_,!W^GPVV\5W^".8OQ:ANZ?DRS,OCXZPGCFC<YS8W;@<H+@#MU[NY2[
M.</,7JJCCI\ZV:+*15V,EG@>&N<=NH/0@]=TTYB,3I.&QCM)5G7,G)MVLDC]
MPWT&1_< /FCKZO%:;9J6Q<.(Y_MZZLXK,6WFI<HXK/Y3-:.M5K#F1.%R&Q&W
MS:SG@'8._%/,20/05Y5,GJO1<7D^<HS:@QC.D5VF-YF-'SV=Y]O]ZG."Q4>)
MJO8'F6Q-(9IYG#8R2'O/J'H'@%T5S3FCY=-8_P!YMD5[^] &<6],<O\ 'OO0
M2#OCDJ/YA[@O)W$&YF0ZOH_3]^W,X;-LVH^Q@9ZR3W^Q6"8HR=RQI/I(7V
M-@-@IOXXZ5_<TMWRK6GB3I&*UJW6$L^8S!V:Y\$?,VJP^#!X >)Z*>8S(5LK
M0ANT)FS5IF\S'M[B%N2,;)&YDC0YCAL6D;@A5E@6/T3Q ?@6G; Y8.GI _\
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MW/$QWI *\?)6(K%H^\>SWL5YFTUG[3[_ /\ 'TB(M+>(B("(B B(@(B("(B
MB(@(B("J[07X8-?>R#]BM%5=H+\,&OO9!^Q91WL+=8:MSY#OTKOVE::W+GR'
M?I7?M*TU[,='QV3JE6E_O<SWZ%W[CEX?!_\ P78O^G-_B.7MI?[W,]^A=^XY
M>/P?_P %V+_IS?XCEYFT?/9])\/^C3TG^5B(B+G>@(B("(B B(@(B("(B##N
MY?"^W=R^%88R(B*H(B("(B B(@(B("(B B(@(B("(B B(@(B! 1$0$1$!$1
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M6#<(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M]HT8Q\NO@L%%YUYH[%>*:%P='(T/:X>((W"]%QMHB(@(B("(B B(@(B("(B
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MG =P&_<>]=>7/6:S%9UF7E;+L.2N6+WC2(:W"T]OQ*XAV8SS0^4Q1AP[B1S
M_L5J*'<*]+R:7TR([KN?*7)#:N/WWWD=X?0-A[U,5YT]7T%(TCF*KM%?Q'&G
M7$,OFR2Q02L!_&;RCJ/>K158<4J&1PF>QNML'"Z=U)AAR$#/E2P;[[_1U_N]
M"M?!+^/@U[D#VR3P.'\;%([IZ>JT""#L00?6I;6=B=<48LOIZZP2O'GM/1P/
MH>WO!68M(S]H),E;A; SJXM/A[3MLO2KM%-W69?.9?A^7?TK&L>+GRGR3A=J
M2>?S(WUY>4GQ\S;]JZ_!Z)\/#33[9 0XU@[8^@DD?M4*U?DFZ[R5;16D7E^,
MKO#LG;C_ )-K ?D ^/\ F?I5PU*\52K#6K,$<$+!&QH[FM V 7!DMO3,^+W=
MFQ\.L5\(T>J(BU.D1$01[B)$Z;0F?CC!+G4I=@/'S2H=HYPM<%\%) ><0QMY
MMNNW*X@JT)&-EC?'( YC@6N!\0536F[S>&6?MZ6U "S3=V5TF.MN&\; [OC<
M?#_T?%;,=MV=?!SYZ;]9K/?&C9LQDN[1@W:[KN%XPL=)*QC1NYS@ %+IM*2N
M=VN)N1.K/\YH<=QMZB-]U\&KB]'U),MJ*] T1#F8-_'_ (1WN/J7H3M-(KK$
MO CX?FM?28TCOGN<+B:.WXB</:,1#IV672N:.\- '7^XJUE5/#FG=U7K*WKS
M)0OKU'1FMC()/E-C[B\^WK[RK67FV\'TE.^1$18LQ$1!KY%AEQ]J-G5SHG-'
MM(*JCA%_TC@W+#%UEAFE:]OB"'@_L5OJFF3OX6:VNMO,>[2.;E,K9@W=M68]
MX=ZO\MO05G2=):<U=Z)B>DQ,>[WL,,@;*P;@C8[>"U]O#Q4QFTXR]M=P-V!]
M:;SF[.YF_01NOF+"TL%&_)ZCO5XX(?//,[E;O]/?[%Z7::::ZOGI^'9IOII^
M>Y'^+K=L3HNAN/*I<I7Y6>/FCJ?HW"M9HV:!ZE46EO*.(FOX-520O@T_B0Z.
M@R4;&:0][P/1X_0/6K>7F6E]'CC2.0B(L6P1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0<W U):=>PR<-#GV))!L=_-
M<[<+I+2Q-XWX9GE@9V<SXMM]]^4[;K=6O%NQ2-WHROKK.HB(MC$1$0$1$!$1
M 1$0$1$!$1!\6).R@DDVWY&EVWL"@6B)I[SL_>L/YGO9L?<X^Y3F_P#ZC9_1
MN_85!.'/\UYOV#]UR[,$1P;SZ?RX-IF>/CCNY_PK]OR0K'X4?ZKD?Z;/V%5P
MWY(5C\*/]5R/]-G["O3V[Z-OQ_+Q_AO_ "*_G^$%S/\ .][]._\ >*DG#$;Y
MJT!XUS^T*-YG^=[WZ=_[Q4EX7?SY9_0']H66T?\ 'GT8[+_R8]77X97II!>I
M2N+HX2'LW/R=R00IRJ\X8?SGD_Z(_>*L->3ML1&:='N?#K3."-?O_(B(N1VB
M(B B(@(B("(B B(@(B("(B B(@+2H9".[8N11L<TU9.R<7>)V\%NKDX*A/3L
MY.2<-_Z18,C"#ONW99UBN[:9Z]S5>;1>L1T[W61$6#:(B("(B B(@(B("(B
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MW;^"V5FN[;7KW-5XMOUF.G/5O(B+6VB(B B(@(B("(B B(@(B(,.[E\+[?\
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M#>)EN2,SY,LL"%[F,E\SJ"-^HW\#NM/C7DL[1U5H6'34I;<M69X0QSR(G$L
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M5:GS<#Y*S#7KXZQV 8S8 %[MBY[G;!Q)/CLM3%R:QM:VR/#M^>F;CZ,8M/S
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M,KM<V#/8QC7.+R!*.I/4E>O\(>D?]X<=]:%C7%DTYU_8FU>Z4I11;^$+2/\
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M*(B(@B(@(B("(B L+*("!$0$1$!$1 1$11%A90$1$!$1$$1$41 B B(B"(B
MB(BB(B((B("(B B(@(B>E 1%A!E$1%$1$!/!$0$181&41$41$1!$1 6[A/YY
MH?IX_P!X+26[A/YYH?IV?O!8W^66>/YH7ZB(ODGVPB(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("^9(V2 "1C7@'<<PWV/I7TB B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B JOX!;G&:K
M=)_*NU!;Y_;NU6@JSX71NPVN->8&8!G-=;E*X/3GCF'4CT@.;L?6@X^C<=1M
M?")UY<L-:^Y5@JB ._%#HF\SAZ^C1]/K4QXR8^GD>&>HH[[0615'S,=XL>P<
MS2#X'<!5U7T[?S'&W7ES!9=^)R](4^QFY!)'(UT(YF2,/>T\K?6-E)\EHK5^
MK^SIZWSV-CP8<UT]'$5WL\J#3N ][R2!N!T"")\2A+G^#?#]N5+C)=N4&SGQ
M/,T@_205;^JW/Q.B,L[$1B*2K0E-=D8VY2UAY=AZMERN(>CY=1XO!TL;+7JL
MQV0@M<KP>7LX]_-&P[]NY3)[&O8YCVAS'#8M(W!'H045POS&L,-H;$U\'P^B
ML5'PME%D96-IL%PW,AZ;[G??JN[I*#55CB<<WD=)LP=2S1=7MEEQDPF>UP=&
MX@;'<><-^O>MRCHO5>DG35]"YS'NP[WE\6/R\+Y&UM]R1&]A#N7?N!4ET=AL
M_1M7;VI\\,E9LM8UM:"'LJ]<#?Y .Y)._>3X((^[5FOQ:+!P^88>?E[3XUC^
M3OW[;>CJK(1$%5<!OY;7?_Q!8_R4WUGI+$ZPQ8H9N!TD;'B2*2-Y9)$\=SFN
M'<5R^'&D[6EI-1NN6()AD\G+>C[+?S6.VV!W'?T\%ZZUTUF,M:J7].ZDM8:]
M6:6<G():\K2=_/C/0GUH(S8T?K73-(R:/U=-DF0-+FX_,Q-E$@^:)1LX'T?Y
M*2:2R=+B/P[K6\E0;Y/D8G1V*K^H#@XM< ?1N"0>_N7$OX/B5F*<N/OZAT_C
MJLK>1]G'5)3.6^.W.[9I/I'<NQ8T)%#HC'Z>P.5OX@T"U\%JN[SR\;DEX[G!
MQ))'B@X4'#')Z?B<W1&L<GCXAU94NM;;@;ZAS $#V%=;A?JG*YWXZQ>I:M>O
MG,-8%>PZL3V4H<"6O;OU&X!6E'C>*,,/DK=0:9G8!RB[+1E$Y]?(UW)NNWP\
MT:S2-&[VUZ;)93(3FS=NR@!TSSZAW > 01/BS^%#A9^O6?W&*UU#-::2M9[5
M^CLO7L010X2Q+-,Q^_-('M: &[#;P\5,R0 23L!WDH*UX<$CB=Q)8.C/*:KM
MO68CNK*58\$"<B=6ZBZF++9>1T#_  ?%'YC2/5WJSD!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$01/B?][#OTS/\U4*MWB?][#OTS/\U42]
M_P"&_1_+YGXM]?\ $"(B]!YHB(B"(B B(BB(B $1$01$11$1 1$0$1$!%A91
M!$1 1$0$1$41$0$1$!$1 1$0$1$!$1$$1$!$1 1$0$1$!$1 1%A!E$1 1$11
M$1 1$0$1$01$11$1$$1$!$1 1$11$1$$1$!$1 1$11$1$%NX/^>:'Z=G[P6D
MMW!_SS0_3L_>"QO\LL\?S0OU$1?)/MA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!<N7 T9-109SD>W(Q0.K=HQY ?&3ORN'<[8]1OW+
MJ(@X^-TYCL=J#*YJK&]M_)B,67EY(=V;>5NP[AT]"["(@(B("(B B(@(B("(
MB B(@+PR%5EZC8JRND;'.QT;C&XM< 1L=B.H/K7NB#2PF+IX7$U<;C81#3JQ
MB*)@\&C]JW41 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$
M3XG_ 'L._3,_S50JW>)_WKN_3,_S51+W_AOT?R^:^*_7_$"(B]!Y;"RB("(B
M*(B(,L:'. +@T$[$GN"WLYBIL1>-:PYCSR![7Q[EK@?$;K04KM[9C14%@;&W
MC'=E)Z3&>X_1T_O6K)>:6B>[I_AMQ4B];1WQS_S_ )_"*+H7<5-3QE*[-)&&
MV]S'&">;8>)\-E\X/'ORF6K4V;_QKP"1X-[R?<NCJN]'?SW8M<(Z5;:M&6C?
M9@Z$^OQ2UYWXK'K*UI'#F\^D?[_O5P$4D<[2U9W9=GD;FW0S!XC!]@^U:VHL
M56J0U+N,EDFH6@>0R#SF.'>T[)7+$S$3$QJ6PS$3,3$Z>#7FQ;8].U\GVI+I
M9W0]GMT&P[]U\LI4S@GVW7FBX).05=NI'I74M_@_H?KK_P!A6K'C:[M'S9(A
MWE+;0B!YNG*1Z%A%YTYSWZ-DXXUY1_\ 75Q$"[V$P]:3'2Y7+S/BQ['=FUL0
MW?*_T#T+8AATYDI/)JHN4;#ND4DS@]CG> =Z%E.:(F8B)G1KK@M,1,S$:]'-
MU)BVX?)>2ME,H[-K^8C;O&ZY:D_$9I;J1S7=XAC!]R\A]S%5C&O\OO2$ N>T
MB)H/J'>L<>6>'69C69AGEPQQ;5B8B(GO1U>T56>6"6>*%[X8MN=X'1N_=NNQ
MG,;0&-@R>&DF-5\ABDCFVYHW[;@=.\;+N:>FQ(TCE.:K9+6MC%D=IMSG?O;Z
M.J6SZ5WJQWZ?N4V?6\UM.G+7]M4%1=#("G:N11X>M/&U^S.21_,7.)Z;?W+L
MVJ&"PI%;)FU=O@ RM@<&,C/S=_$K.<L1IRG6>YKKAFVLZQI'>BRPI#E<51DQ
M9RF#EF=68\,FAF YXB>X[CO"8;#53BWY7-32140[LXV1?+E=Z!OW!.-7=WOQ
M]]5X%M[=_.O=IXN P<S@/2=ET]2XIN&RKZ;)3*&M:[F(V[QNNI6@T]DIFUZ?
MEE&TX[1.F<'L>? 'T;KYXC C5,X/?V<?[H6$99MDBO3E/],YPQ7%-]=><<X_
M*,HBF%S#87'8['7;\EC:Q UP@B(YI'][CN>X=RV7R132)[VK'BG)$S'<AZ*7
MT<-B-0PS,PGE%6]$.;LIW!S7-WV)W6N]NEJ<_D[VW[?*>5]ACPT;^/*/0L(S
MQ,Z1$Z^#9V:8C>F8TGO1A%VM3X>+%S5Y*<QFI6H^UA>X;';T'^Y;<.*Q>,Q]
M>UGI+#Y[#>>*K 0"&'N<XE9<:N[%H[V/ MO36>6GLC2*4PXO#YN&5F$-FOD6
M-+FUYW!PE []CZ5S-/X9V4LS"6005:S>>Q*?Q&^KU]$C-729GEH<"VL1'/7I
MHY*ZES%-KX&AD1*7.LO>TLY?D[>M=$NTIS]B(LGR=WE'.W?V\JWM6TA0TKAX
M&RMFC$LCF2-[G-/4'W+7.:9M6NDQK/\ 4ME<$12]M8G2.[QUA#$4AQN*HU\6
MS)9V280S$BO!#MSR[=YW/<%L5L=A,V'5\3Y54R&Q=''.X.9)MX;^!6<YZQKR
MG2._N81L]ITYQK/=WN3IK%MS&8AI.E,0D#CS@;[; GN^A<Z1O(]S>_8D*2<.
MVENKZK7 AP$@(/AYI4<G_EY/Z1_:K6TSDFO=I']I:D1BK;OUG^GP$6]A,9/E
M\C%4K;![NI<[N:!WDKL2_<K4D,!9D+G*=G3->&@G_A"MLL5G=B-9^R4Q3:-Z
M9TC[HRNWB\+!)BSD<G<\DJ&3LH^6,O<]WCL/0O3,XBK3CIY"E,^SBK#MNO1[
M".]I]>RD-J?!C1E%[Z5LTC9>&1B4<P=UW)/H[UIR9IF(W-><_P"]6_#L\1-N
M)IRC7_=.Y"<E#6@M%E&R;,&P(D+"P^S9:J]KCH'6I75(WQUR?,:]W,0/65N8
M:+%N[9^7GL,:S;DC@8"Z3Z3T'_BM^N[76?\ MS;N];2-(_C]W-12JA7TUE;+
M:<#+U*Q(>6*1[P]I=X A<&'&V9LJ,=&T&R9#%L3TW'^712N6)UUY:>+*V&8T
MF)UU\&FBE-JMIO%2NJV?+;UJ,\LKHW!C&N\0/2N7G*V,8(9\/:>^*4>=!*/X
MR(^O;ILI7+%IZ3S6^&:1/..7=JY2+MZEQM?'QXLU@X&Q5;*_F=OYQ]"SH[&U
M\KEG5[8<8Q$Y_FNV.X[DXM=SB=R<&W$X?>XT$$MB9L4$;I)7G9K&C<DK$C'1
MR.9(TM>T[.:1U!]"D>@)*(S-5MJ&9]ITH[%['[-;T\1XKXU)-AW3W6U:=IEW
MMG;R.EW;OS=>BG%GB;FC+@QPN)O(ZBD&+Q-&'%MR>=DF97D<6P0P[<\I'>>O
M<%M5:&"S9-;&&U3R!!,39W![)"/#?P*3GK&O*=([RNSVF(YQK/2.]%469&.C
M>YCP6O:=B#X%;F)BI36MLE8D@KAI),;.9Q/H'H6V9TC5IK76=&DBDL3]*2R]
MBZ#)Q-)Y1.9&DCUEJY&=QLF(R=BG*0XQG=KOG-/4'W+"N2+3NS&DME\,UKO1
M,3'V:**99/"87%UZ5N\^QV<]=CFP1.W<]^V[B2>YO4+P@Q>&S=:R,,+=:]!&
M9>RF(<V0#OV/I6N-HK,;VDZ>+9.RVB=W6-?!% BZ>GHJ-B^*V3+F1S#D9,UV
MW9N\"1XA;573=E^>EQ\_\7'7//--W!L?SOI"V6RUK,Q/<U5PVM$37GKR<S%5
MX+60A@MV6U8'G9TKAN&KSNQQ0VYHX)>VB8\M9(!MS#TKJU*V.OZJKU:C)1CY
M)A&.9WG.'IW6J<8^SJ"3'4ANXSNB9S'N )[S[ I%XWN?+EJRG'.[I$:\]'.0
M*468=,XV8U9VWKLT9Y998WAK0[Q#1XK4S.)JUX:V1QTLEC%S.Y3S[!['#O:?
M7MXJ5S1,QRF-2V":Q/.)TZN0:LXJ"T87^3%W()=O-+O1OZ5XJP)9\)]Q,#S2
MM^1>5D-C[4<P?L>N_H7 P='&Y?)7JL4<D)DC+J8=)N0X#N/IW6%-HUB9M&FC
M9?9M+5K6T3,H\BR]KF/<QX+7-.Q!\"NUJ#&P8JICX=G&_+'VTY+NC0?DMV6^
M;Q$Q'BYZTF8FW@XB(BR8"(B*(B(@B(BBW<'_ #S0_3Q_O!:2W<'_ #S0_3L_
M>"QO\LLL?S0OU$1?)/MA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$3XG_>P[],S_-5"K=XG_>N[],S_ #51
M+W_AOT?R^9^+?7_$"(B]!Y@B(@(B("(@[D!2#0]^.IF/)[1_Z)<::\H/=U[C
M[_VJ/HTD$$'8CJ"L+TB]9K/>V8[SCM%H[DSIX]^F<?F+U@$6FN-.J3TW)[WC
MZ/\ -1?$51?RM2J]W*)I6L+O0">JW=0:AN9QM9MOD:V ; ,W\X^D^M<F*1T4
MC9(W%KV$.:X=X(\5KQ4O%9FWS2VY<E)M$4^6/]G_  EF5S%+%9*Q3IX'']G
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MC_K7?:GW#8'\D?\ 6N^U29$[3F\T^YV3!Y(]D9^X; _DC_K7?:GW#8'\D?\
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MW3@LP[]E/&V1FXV.SAN-_>@]46EF\G5PN(N9/(/[.I4B=-*X#?9H&_3UJ):
MXIZ;UUD;%'!R6A9AC[4LL1<G,W?8[=3OMN$$Z1% M>\5M.:'RL6.SANBQ+$)
MF]C#SCE)([]QZ"@GJ*GA\(K0Q.Q=E #X^2_^93K1FO-.:QC><!DXK$K.KH';
MLE:/3RGKMZQT02<(H+K#BEI_2&H(,1GA>KS3AKHYA"'1.:3MS<P/<#OOT4Y8
MYKVAS'!S7#<.!W!'I"#**.:[UIA]$8AF0STTC(7R"*-D3>9[W'KT&_@!U70T
MUF8-082KE:<5B*M:9SQ"=@:\M\#MN=@4'31%R=5:@H:7P%O,9=[F4JK07E@W
M<=R  !XDDA!UD4.X>\1L!KTW1@)+'/4Y3*R>/D.SM]B.IW'0J8H"*$ZBXFZ?
MP&L*FF<@;GQG:,38^SBYF;R'9NYW]/J4@U9GZ6E]/W,SE.U\BJAKI.R;S.ZN
M#1L/:0@ZR*/Z'U=BM:8093!RO?7[1T3FR-Y7L</ C<[>!^E2! 11K7NML-H;
M%Q7\]+*V*:3LHV1,YWN.VYV&XZ#Q^A='2^<J:DP-/+XWM/([;.>/M&\KMMR.
MH^A!U$1$!$1$$1$41$1!$1 1$0$1$41$1!$1 1$11$0(@B(BB(B B(@(B("(
MB B(@(B! 1$0$1$!$1$$1$41$0 B(B"(B B(@(H-K_BCI[0F1K4LZ;G;6(NV
M9V$/..7<CKU'B%%A\(K0V_RLH/\ ^E'_ #(+B1171?$#36L@\8#)QS3L&[H'
M@LE ]/*>I'K&ZW=:ZJQVCL&_+9CMO)&/;&>Q9S.W/=TW"*[J*G?](K0WIRG]
ME'_,NYI?C1HG45V.G6R;JMF0[,9<C,0<?1S?)W^E!8R+&XY=P=QMON%"-&<3
M]/ZOS]O#X@W/+*S'/D[:'E;LUP:=CN?$H)PBB'$+B'A-!,I.SWE6ULN$781<
M_P G;??J-N\*38N]7R>.K7Z,HEJV8VRQ/'XS2-P4&RB*$:RXGZ=TCGJF'RTM
MAU^R&N:R"/GY0YVPYNHVW03=$!!&X[BN%K756,T;@I,MFY)&56/;'M&WF<YS
MCL ![S]"#NH%%>'^O,+KNC:M8"29S:T@CE9,SD<"1N#MN>AZ^Y2I 15EJGC;
MI/3.>N8?)G(>657!LG9U^9NY /0\WH*YL/PB-"OD#72Y*,'O<ZKT'N=N@M]%
MQM*ZHPNJJ'EF R,%R$='<AV<P^AS3U'TJ..XJZ;BUN=*7'6ZF5[;L!V\7+&7
M$;MV=N>CNFQ]803Q$4-U]Q(P&AK%*#-R6'6+@)BBKQ=H[8$#<C<;;D[#Z4$R
M1>5.8V*L4QBEA,C0[LY1L]N_@0"=BN?JK/4],:?N9G)]IY'4:'2=DWF=L7!H
MV'M(0=5%3O\ I%:'].4_LH_YD_TBM#^G*?V4?\R"X@BXV7U'1Q6E)=0V^U^+
MXZ[;+N5F[^0[;=-^_J%SN'^O<'KNG:L8":1WDSPR6*9G(]NXW!VW/0]>OJ*"
M5(G@5!=$<4M/:SSEG$X8W/*Z\;I7]M#R-V:X-.QW/B0@G2*'\0N(F#T$*)S_
M )4!<Y^R["+G^3MOOU&WR@H;_I%:&].4_LH_YD%Q(J^TIQAT9J6['3HY3L+<
MG1D5N,Q<Q] )\W?U;JP0@(JUU;QITII74%O#94Y#RRL6B3LH YO5H<-CS>@A
M<F+X1&AGR!KI,FP'\9U7H/<Y!<"+B:3U7A-643;T_D8;D;=@\-.SXSZ'-/4+
MM.<UC2Y[@UH&Y).P 0915;J3COHC"6GUA=L9&5AV=Y%%SM!_I$@'Z-U\Z=X\
MZ)S5R.JZW9Q\LAY6FY%R,W];@2!].R"U$6&/:]@?&YKF.&X<T[@A0C6G$_3^
MC\[4Q&8-SRNRUKX^QAYF[.<6C<[CQ""<(N=J#,U<#@;N7O\ :>25(C-)V;=W
M<H] 7&T#KW!:ZI6+&!L/<8'\DD4S>21OH/+N>A]/J*"5(G<"5"=%<3<!K'.7
M<3A_*_*ZC'/D[:+D;L'!IV.Y\2@FR*JLWQXT=ALO=QMPY+RFI*Z&3DK@CF:=
MCL>9:7^D5H?TY3^RC_F07$BK#37'#2.HL[2Q&..0\KMR=G'VE<-;OZSS>I6>
M@(B("(B B(B"(B B(BB(@0$1$!$1 1$1!$1%$1$!$1 1$0$1$01$0$1$!$1%
M$1$01$0$1$!$1%$1$01$0$1$41$0$1$! B("(B @1$01$11$1 0(B B(@(B(
M@$1$!$1 1$11$1 1$0 B(B"(B B($!96$0$1$41$0$1$01$13THB("(B B(B
M'@B(BB_/OPQ/O9T_^N/_ '"OT$OS[\,3[V=/_KC_ -Q!-N'&A=*W= Z?L6]/
M8R:>6C$^21]=I<XEO4D^E5%\)7A[A-(U,7G=-1.H2S6.Q?#&\\FX;S!S?$'I
MZ5MZ2XC<4:.F,74Q6A?*J$-9D<$_D-AW:, Z.W#MCOZEJ6]'<3.+><K2:OA?
MA\7"=VMEC[-D0/?R1_*+CZ3[T%L9+,3Y_P"#M;RES8V;.&<^4[;;NY=B?IVW
M5:?!3TUA,[@]029K%4KSXK$36.L1!Y:"T[@;JY>(N/KXK@_G:%)G)6JXMT,;
M?0UK=@OS+P2U;K33>.RD6C=,_',$TK'3O\FEE[-P! 'F$;;CTH+VXI\)-)7=
M(Y2U3Q<&.O5:\D\4U4<@W:TG9P[B#LH_\$/-VKVELQB[,CI(:$['0;]>5KP=
MV[^C=N_TE5MQ#XG:_P _,W3&9JQ:>\LY(Y(.R=7+VN.PYG2$D-/CU 7Z(X-<
M/V</M+NHOG;9O69.VLRM&S>;;8-;X[#_ #*"B:W^UP?ZR=_@E6-\+;\&]3^L
M(_W'JN:W^UP?ZR=_@E6-\+;\&]3^L(_W'H*[^#-K2?36?CTQF@8<?E@V:JZ3
MIRR$>;MZG@;>W;UK]3Y2_6Q>-M7KT@BJUHW2RO/XK0-ROS1J+09SW 73&HL2
MQXS6)IA^\0V?)"'$D;CQ;\H?2N'J3B;E^(^E=-:.Q<<XRUIXAR#@>DY;L&_0
M>KG>Q! N*&H[^M=1W-23PR1X^64UJN_R6-:.C?;L03ZW+]SZ9^]O$?J</[@7
MYH^$5I:IH[AWHK"T@UP@EG[64-V,LA:PN>?:?[M@OTEA;,%+2&/M6Y6Q5X:$
M4DDCCL&M$8))^A!3/PJ]33LQV*TCC"76LF\23L9WE@< QO\ \SOW57.8P-_@
M?KO3&7C+Y*TT#/*#ON'.VVGC'=Z=Q]"X\/$#&W>,TNK]2PV[5&&9SZM> -<0
M&](QYQ V'?[5*^,G%_2VO](.QL.,RD-^*5LU::5D?*UPZ$'9Y.Q!/]R#]65;
M$5JM%8KO$D,K ]CQW.:1N"ORS\)N-DO%W3L<K0]CX(&N:1T(,KMP587P6]7G
M.Z)?A[<W/>Q+N1O,[=SH3\D^P=6^Y5O\*>66#BE@Y:T?:SLJQ.C9L3S.$KMA
ML/24'Z&GX<Z-E:]C],XKE/S:[6GWA?FCBKAJW"?BSAKVDR^"-S&6A"YQ<&^<
M6N9Z2T@=WK*F.2XM\6*=&Q9M:$95AC87/G?0L 1CYQW=MT]:CG"?365XN:R.
MJM59*&Q6H3,[6'<<[MNK&!@Z-9O[^OCN@N+CSH5NN=$^45&'XVQ[#9K;#J\$
M;NC^D ;>L!<+X,NOV9K3#]/Y27ER.(CW:]_3GK@]#[6]Q]6RNX=.Y?D'X2&G
M)-&:Y^.,'.ZG7S44A<R!W)RN(Y96]/Q7;[_24'6=+-QSXQQ1ECQI7$[[\N^Q
MB![S_P 4A ]@]B_4L$3((610L:R-C0UK6C8- [@%!."6C*NC=#4X8BV2Y=8V
MU9F V+G.&X;[&@[#Z3XJ?("_./PG<[;SF?PN@<+M)-/(R6=H[S(X[1M/J )<
M?:%^@LSDJV'Q-S(WI!'5JQ.ED<3MT W7XMT'Q"Q]#BC<UCJRO<N3/,DD,< :
M[D>[H/E$=&M) ^A!*Z]*;@?QFQS#,YV#OQ,C?(X[\T;M@\GNZM>-_9MZ5^LP
M00"""#U!'BOQ_P <>*.FN(>$I14<?DJV2IS%\4LS(^4L<-G-)#B?!I^A7C\'
M75OW3\.JD=B7GR&-_P"B3\QW<0/D.^ENP]H*"J.-'^TGIS])1_Q%<7PA?P.Z
ME_1Q?XS%3O&C_:3TY^DH_P"(KB^$+^!W4OZ.+_&8@_-O 76TVA-3UW93M(\!
MEAV4KS\EI!V$@_HGH?5NOVHY[&QF1SVB,#F+B>@'IW7YAT5H)NNO@Z115FM&
M6IW+$]1VVY<=QO'['?MV4==Q=RMSA.W1PCM2:BDE%'M0#SN@^;Z>;\3V(.)Q
MRUE9UWJBW:J-+L%BG^2UW-^3YQ/GGUN+3]#0OT+P_P M:P7P=*&4QU86K=3'
M22QQ$$AQ#G=^W@._Z%6'%'0\.AN F+J.C;\96+\4UV3;JZ0QO\W?T-'3WGQ5
MU<" #PBTT"-P:Q'_ -[D$:^#OQ%SNNX<PW/PPN\D<PQV(8^1IYN;=AZ[;C8;
M*XEK8^G3IPEF.KUZ\)<26P1M8TN\3L/%;* B(@(B("(B B(B"(B B($!$1 1
M$0$1$41$1!$1%$1$!$1 1$1!$1%$1$!$1 "(B B(@(B(@B(@(B! 1$11$\$1
M!$1%?ECX6#6OXAZ::X!S35:"#XCM7*_'<.M'2PEC],XK9S=CM7:#[PJ ^%L]
M\>O=//B;SR-I@M;MON>U=L%('<4.+QCV;P]Y3MT<,?9/_>00CC3@:O"OB1AL
MEI OJA[!:;"7%P8X.((&_7E(\/:K@^$G.;/!ITY&QEEKOV]&_50/3/#+6FOM
M:5]0<2@ZO4@<TF&4!KI&M.XC:QOR6[]^^W?XE6%\* !O":RUH  LP@ > W*#
MD_!XT?IW+\*\9<RF#Q]NT^68.EF@:YQ D<!N3ZER_A$<,--8W0]K4&&HLQUV
MH^/=L!(9(USPT@M[M_.WW'H4/X5:[XB8/15.AIC1PRF+C?(8[7DD\G,2\EPY
MFN Z'<+E9[5&MN*^J:VD,K)6Q!?,0ZFYI@8U[03YW-NYQ'78>GP07U\'//VL
M_P +:CK[C)-3D?4$A[WM: 6[^D@$#Z%4?P9/POZB_03_ .,U?HK0>EZVC=(T
ML)3=VC:[#SRD;&1YZN<?I_NV7YU^#)^&#4/Z"?\ QFH.W\,C_5M+_P!*?]C%
MZ?!=UO+7?/HK.R&*:/\ C<>).AV/G.C_ +^8>TKX^&3_ *MI?^G/^QBT^+VC
MK532VD]>Z;88K]"E6-MT+>NP8WDE/IV[CZMO0@_0FKM0TM+:=O9C)R!E:LSF
MV\7N[FM'K)V"_"UO)Y//ZVIY[+AQER-ULC7'Y) D V;ZAW?0K-U5K#)\;\SI
MO3&'A?5K\K9KVWR1)MY[S_PM&^WK/L7M\(/%4\'KS1&-QD+8*E:O%'&QHVZ"
M8]3ZSWDH/U:SY#?8%^9OA!9.WK?B3A]!8CSV02M,W+U_C7C<D^IK.OJZJ_\
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M=W$#Q"M-$$2X48FYA>'>#QN5@["Y7KADL1(=RG<]-QN"N7HKA1@M)ZNRF?H
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M"/67,*">29*C%/6ADN5VS6?Y!AD =+TW\T;]>G7HLY')4L;!VV1N5ZL7SYI
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MM,W6M\.]1W<'DHIG0TIBV:K,"6.##U#FGH5L: ND\.L%>R-DD_%T4LT\S_\
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MAQN-C[&M5EF<V.8[ =8V_P H1R^@]Y]*"8XS.8K*2/CQN2IVWL^4V"9KR/:
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ML^_;U]^ZDFHW09S1N0^+\XRA!/ X-R<$@(A /5P=OMX;=X57PZ0TX>/]G&G
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M$4K;:MS*4H++NZ*6=K7'Z"=U461=F- \%ZS8GEFJ<Y:8VQ9DZ/CGL.)<X_\
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MNB"K]?:;&"X!Y+ XV.2PZM19$T1M+G2.YFEQ '7J=RIUI%CH]*85DC2U[:,
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M>I!,$5=MS.1/'AV'\KF^+/B46/)M_,[3M-N;;T[*P(9XIVET$L<K0>4EC@X
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M)Q7?O8&3TK&X^<*?82EH_P"$R=_T[*4:,R^8R=>U%J'"OQ=^K+V3RV020S=
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MB*(B("(B B(@(B("(B B(@+*PB B(B"(G@BB(B((B(HB(@+*PB(R%A$11$1
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MWL%D:KK.,\I<7R5G,.SXN8]2W8[A:4&,EXH:MS_QU:LMTIB;1HP4(93&+$S
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MC 0(B*>E9"(B,)XHB!XH$1%/%/!$0%E$0%CP*(B!0(B*RB(B,! B( [T\$1
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CG@LA$1& LA$0$1$&$"(BP>E/!$0@"#N1$#Q3P1$!9"(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g73463g02n39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g02n39.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1\>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'P$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0U6"DY3A-%9UE;,XI,+B\"5$15=C@_$H1F2$TZ/_Q  : 0$! 0 # 0
M        ! 4! @,&_\0 .!$!  (! @,#"0<$ P$!      $" P01!1(A$S%Q
M%3(T05%2D:'!%")"8;'1X2-R@? D,T,U\?_:  P# 0 "$0,1 #\ U2
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MFQNJEL]NIJ+RI_63=1&C$>[Q7 $F
M
M
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MM2UD+I'+$UB*C>Y.P":
M
M
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MFO8G$[A3*JJ8Y^!\DV6TQ1:LMU_L4+[;4TLR2NBC571/3&,<*]GR 6<
M$;J6R4>HK'66JYQI)2U,:L<F.:9[%3TIVDD ,Z61-P-FEFML=HEU7IGB62%\
M"NXX4\$3"JWQ5,*G@>JY;D;@ZTH7VK2NB:^S33YBEKJISDZEJ][55K<+Z>9H
M$ 5_LWMY'H*P21U,S:N\5CNMJZG':O<U%7FJ)Z>U553FMW-1:^M.O]/TVDZ&
M2HM4R-ZQ&0J]DC^)4<CW8\U$3'>A<H \]52Q5U!+2UL;9(IXUCE8O-%14PJ&
M?H;!K;9R\U3]*44FH]*5+UD\B:JH^!?K7.,<TSGO0T2 *%DWIU?<8G4]DVUN
MC*URHC'5"O5B>OS&_>36S&W=VMMXN&K];2MGU%<$RV)?.\F:O-4SV9[$PG)$
M0N        Y^@]U==\6GX'0'/T/NKKOBT_ #H
M
M
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M85.L1<KDW                          ("A]U==\6GX$^0%#[JZ[XM/P
MGP
M
M
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M GP
M
M
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M+M)9]OHG5$3G5MXE9P2U;TPB)WHQOZJ?660
M("A]U==\6GX$^0%#[JZ[XM/P GP                        #RW2OI[7;
MYZVM?U=- WC>[&<(!Z@<*FZ^D%3/Y37'Q+OY#^E?2'^TU_X3OY =T"'TSJ2U
MZEI9:BS5'7Q1/ZMR\*MPORDP
M
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MBT_ "?                        /#?;9%>+156^H>]D50S@<YGMD3T'N
M%):OVHM-BTO<;E35UPDFI85>QLCF\*JGCAIS^U>A:#6%)<):^IJH74TC6-2%
MR)E%3//**7)NE^CZ^_PR_>AQ'1S_ *MO7Q[/[H'>Z(TE1Z0H)Z2AGJ)V32=8
MJS*BJBXQRPB'1@
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M@                        .?H?=77?%I^!T! 4/NKKOBT_ "?
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MJ2.@H*>DA5RQ0,2-JN7*X1,<ST
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MK4MKJ;/-'-5<N;\BY3Y@+)Z7NKG0T-!I6F<BK4JE548PJHUJKPI\J\_D+)V
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M5%7GSPGUF;=O[]N)<]Q**RU%_N$553U#73TU54<"N:U<O;A>U<9Y&T0
M  ?QRHUJN<J(B)E54#^G\1[57".:J^LSU=-5:KW9U76V30-<ZU:<HU5E3<<*
MBR+S3DJ<\+W(GK4]TFP]RI(UJ[1K:ZQWAK<MDD<O"K\=^%SC(%\ I+:G<.^4
MNKZC0FX2M6]0I_F]6B<I^6<*J81<IS1<<_67: /RKV(N%<U%]9^C+%-I:?<K
M>W6M-/>*ZBI:-^6K"['-%1B-QX<E U+UC/VV_.?UKFN]JY%]2E%?Y.]/_P![
M+S])#NMK]NX]!_E#J[M6W'RO@SY0OM.'/9Z\@=X     $!0^ZNN^+3\"?("@
M]U==\6GX 3X                          Y;=+]'U]_AE^]#B.CG_ %;>
M_CV?W3M]TOT?7W^&7[T.(Z.?]6WKX]G]T"X
M !2?2/\ ;6/US?<A:&AO<A9_X9GW%7](_P!M8_7-]R%H:&]R%G_AF?<!.
M
M   "-N=CM]R7BJJ=JR?MMY.^<CH=&VJ-_$YDCTSV.=R.C!ZUSY*QM%IV>%]+
MAO;FM6)E\J6FAI84BIHF11IV-:F$/J ><SOUE[1$1&T  .'(     _CFHYJM
M<B*U>2HO>5#K_833&J*I]90\5GK7N5TCJ9B<$BKXL[$^3!;X S _HM3];^;U
M3'U?@ZD7/]X[32'1UTM9:IE3=99[Q(W"I'.B-C14[^%.WU+DNL ?&"EAIJ-E
M+2Q,A@8SJV,C:C6L3&$1$3L0H_1&P]1IK<&FU*^_15#(IY)NH2F5JKQ(O+/%
MZ2]@!YI:^CBK8Z.6J@95R-XV0ND1'N;XHG:J&=NF'56:6V66!)87WN.9RHUB
MHKVQ*G/B[T15Q@D-Z]G]5:KU=^7;)=H9$2-(XH)I%C= B9Y-5$[%557Y5.6T
M=T<K[67AM3K2M@CI6N1SV12K+)+CNSW(!W'1/TDEHT9-?*F-$J[F]4C56X5L
M35PG/P545?D0O,^-%204-)#2T<3(:>%B,CC8F$:U.Q$/L!A;4E/#5=(2X4]5
M$R:"6_*R2-Z9:YJS85%0N#5'1DH:VYS5%AO3K?3R+Q)3RP]8C/%$7*<B+N>S
M&K:C>&HU'%%1?DU]W\L1RU"([J^LXNS';CN-.@4'HOHV6:TUT57J"XONJQNX
MD@2+JXG?O<U5?47Q3014M/'!31,B@B:C&1L3#6M3L1$[D/H *'U=L+47[7\^
MHV7Z*%DLS)>H6F5RIPHG+/%Z"^$Y( !7F].W<NXUCH;?#<64"TU1UZO=$LG%
MYJIC&4\3RZ)VWN&E-L[AIFAO;$KJE\CHZUL*MZKBPG),YRF/$LT 4EM-L4S1
M.J/RW<;K'<IHV*D#4@X.!RY17*JJO/"EV@ "E=W-C6:XU/'>K?=8[9,L2,F:
ML''QN15P[**G/"X^1"Z@!7&H-O:^^;4TVDJV\1NK(F,C6M6%51Z,[,MSVXQW
MGXV3VTEVXH+E3S7)E>M7(UZ*R)8^'"*GBI90 J?>W::;<BLM4\-VCH$HHY&*
MCX5DX^)47Q3'8=KMUIM^D=&VRQR5*53J-BL69K.%'9<J]F5\3HP!PFY>U]@U
M]3YN,/D]P:B-CK843K&HG<OBG/L4IZ3HM/\ *?S>J$2FRG)U+YV/I8-. "L=
MM-F-.Z&J4K8^.XW-$PVIJ6I^;_=;V(OI[2S@         (G56H;?I>Q5-VO$
MW4T=.F7*B9557L1$[U53/4?2/NURU#2T]KL=-%;9JAL"23.<YZ\2^A<(N.XE
M.F+6RML%AHFO>R"6J<^3#L([#>64[\9R>3>"QVRP6';FCLU-%!3>61.RQ$S(
MJHBJYR]ZKVY MG6&YUBTIJ*S6:Z/D2JN*IS:WS86JN$<Y?!5Y'<M5'(BM5%1
M>Q4,Y=,"GI4LNF*OS&U[9WL8Y,(]6<**OIPBX^?TEYZ)EGGTC9Y:I7+.^EC5
MZN3"JO"@$T  /XKVHN%<B+Z5/YUK,*O&W">DHK>/:S5VK=9/N=@O,5)1+ R-
M(G5$C%1R9RN&I@X9VPFX;FJUVI(%:J85%JYN?U >G>"[457T@M*.L,T,M;3S
MP1SNC[./K.2*O>N%-3E%;/[#,TI>8KYJ.MBK[C#YT$,;%ZN)W[2JO-5\.28+
MU      !PN^%VDLVV%]J8'/9,Z'JF.9VHKN6?K.Z*WZ1%/)4;37M(DRK&M>O
MJ1W,#S=&RRQ6?:JVO8W$U<YU5*Y4YJJKA/J1"T3@=AZR.MVHT^^)S5X(.J<B
M+G"M544[X#/G2NH66]-+ZGID6.KI:U(G2LY*K?;-^96K\Y?M',E31P3IV2QM
M>GRIDHOI?SYT;9*)BM66HN"*UGZRX8Y.7TD^<N^T,6*U44;O;,@8U?6C4 ],
MKN")[E[$15,I[/[BZ=TKK/6UPU)6/@?<*K,7!"^3*(]ZK[5%\4-7.1'-5KD1
M45,*B]YSSM$:5<Y7.TU95<JY55H8N:_1 YJU[V:!N+T;'?XH7+V>41OC^]"P
MJ:>*JIXYZ:1DL,B<3'L7*.3Q13C;]M5HN]4KX:C3U!"KNR2FB2%[5\45N"K=
MF*JNT+NM>-OZRLFJ[:]%EH5>OM,>=G'=EO:B=Z :(     " H/=77?%I^!/D
M!0^ZNN^+3\ )\                          <MNE^CZ^_PR_>AQ'1S_JV
M]?'L_NG;[I?H^OO\,OWH<1T<_P"K;U\>S^Z!<
M    I/I']MC]<WW(6AH;W(6?^&9]Q5_2/]M8_7-]R%H:&]R%G_AF?<!.
M
M
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MY4^^I],VC4] M'?*"&KA[N-OG-]2]J' 4FP.@Z:N\I2@J9%XN+JY*A59ZL>
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MK'ZYON0M#0WN0L_\-']Q5_2/]M8_7-]R%H:&]R%G_AH_N G
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M!J*S3_Z&ZT+_ %3M_F>V.MI9$_-U,#OW9$4QHC6^"I]1_8W]6[,<CF+XHY4
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M5]=1*D4CU[7ICDX[P
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MJG3^[FU&F.NCL%)Y$UZ^>ZGHU3C^7MP!R6\-2S4'2(TQ;+?(R22DEABDX>?
M[CXE1?4AJ0HRW;G;67'6E)<J6B7\O3R)"RJ\E5'*YWFIE?EQDO,
M                0%![JZ[XM/P)\@*#W5UWQ:?@!/@
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M([T>DT&UR.:CFJBM7FBIW@?T
M                         /Q40QU$$D,[&OBD:K7-<F45%[4/V *2U;LU
M,D[Y],5#%C<N?)JA<</J=X>LYJEVDU5+,C)8:2%F<*]TR+A/%$3M-) #B-O=
MO:'2:+4ND=57-[>%TSDPC4\&IW';@         4MTH-)WS5FGK-3Z=MTM=-#
M5.?(V-6IPMX%3/-4[R2Z-FF[OI?0L]%?Z&2BJEJWR)'(J*JM5&\^2KX%K@
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MZUK%9[]-F@7E#4O556)?V7?V?N+Y8YKV-<Q4<UR914[%0#^@
M
M                                               %8])']$=Y]3/[
MZ%G'';N:9K=7:%N%FMDD,=5/P\+IE5&\G(O-4 YOHV5$#-HK.UTT;7(Z5,*Y
M$7VZE8[<RQLZ45[<^1C6JM1A5<B(O(B(.COKN"-&0W:WQL3GPMJ'HG]T_#>C
MCK=LZSMN=M29?UTG?Q?/P@=STP)8Y=*6+JI&/Q6NSPN1?U2Y-OO<18_X2/[C
M,DW1UUS.C6U%UMTK47*(^H>J?W34^E;?+:M.6V@J7-=-30,B>K.Q51,<@)0
M <GJ?0&D]05S[EJ"T4M34HQ&NFE54PU/'GV(5W66[8RBK?)*G\@-G1<*B2.<
MGTD7'UD'TG]67*HNUKT/897LFK.%]1U:X5_$JHQBKX=Z_(?FT=&"A2UM2[7R
M=;@J95U.Q$C;Z$1>:_4!9=@VXV[J%IKE9+1;)TC>DD4]._C1')S1<HI89DC;
MR>\[.[P1Z6N$RU%KN4K(E1B^:]'+ADJ(O8J+VIZ_0:W
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M_2/]M8_7-]R%H:&]R%G_ (9GW 3ASNMM)T.J[6ZFJT2.=O.&=J>=&[^7H.B
M&0M1V*NT_<Y*"YPJR1O-KL>;(W]I"P=I]QGVJ2*S7V5TE"]4;!4/=S@_LK_9
M^XMO6VE*'5=J=2UC4;,WG#.GMHW?R]!F/4EBKM.W26@N4?#(WVKT]K(W]IH&
MO(WMD8U\;D<QR91R+E%0_I0.U.X[[0^.T7Z5S[<N&P3+S6%<]CO[/W%^L<U[
M4<Q4<U4RBHN45 /Z
M
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M93T'?                         " H/=77?%I^!/D!0^ZNN^+3\ )\
M                  .4W/O2631EPG1V)I6+#%^\[D=641T@[RE1=;?:(GY;
M3M6:5$7]9>2)\R 5524TM7504L#>*6>1L;4\55<&O[+;X[7:J6AA3#((VL3T
MX3M,_;&V9+GK!:J5F8*"/K.:917JN&_+VJ:. Y;=+]'U]_AE^]#B.CG_ %;>
M_CV?W3M]TOT?7W^&7[T.(Z.?]6WKX]G]T"X
M !2?2/\ ;6/US?<A:&AO<A9_X9GW%7](_P!M8_7+]R%H:&]R%G_AF?<!.
M<_K72M#JJU.I*UO#*U%6&9OMHW>/J]!T  R)J:P5VG+K+;[E'PO;S8]/:R-_
M:0[S:G<9;-)%:;Y)FVN7$=0[*K"O@O\ 9^XN#6>E:#55J=25S$;(WG#.B>=&
M[Q3^1F/4^GZ[3ETDH+G&J.3FR3'FRM\4 US&]LD;7QN1S')EKD7**GB?HS_M
M3N*^S21VF]RNDMSW(V*9[O\ 0>A?[/W%_12,EC;)$]KXW)EKFKE%3Q10/T
M
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M<Y<(@%!;U[9:WU7K1UQTY70PT'4,C:Q]6Z-4<F<\D0X/^@W<_P#VI3?^8/\
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MW1Z8MD%5>:2.:*G8U['.YM5$[% [X'SIYXZF".:!Z212-1S')V*B]BGT
M0.L=+T&J;4ZDKV8>G.*9OMHG>*?R)X 9&U5IVNTU='T%R8F>:QR(GFRM\4.V
MVIW%DL;H[5>I'26M?-A?VK N>Q?[/W%SZOTS0ZHM+Z*O9A<9BE;[:-WBAF35
MFFZ_3-U?17&/EG,4J>UE;XI_(#6L;VR1M?&Y',<F4<BY14/T9ZVIW$?89([5
M>)..U.7S)G95T"KW?N_<:"AE9/$R6%Z/C>B.:Y%RBIX@?L
M
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MQ4LBUM5U,G7M5<-]&%0LJED66FBD=CB>Q'+CTH!]      @*'W5UWQ:?@3Y
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MQR)E8%5>W]TT-#+'/$R6%[7QO3B:YJY14 _8
M
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MG/J'22T_=[]3::;9;;4URP5O'*D#.+@;XJ7#1-5E' UR*CDC:BHO<N /L
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MBLO5(WRM_#Q8SVY+#T1H?5]LU5;ZRYSRNHXI,R(M8YZ*F/#/,"[@
M
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MY'JC6M;4-555>Q$YDX9OL?1L6T7NWW!VI&O2FJ(Y>#R;'%PN1<>V[\&D
M                     ! 4/NKKOBT_ GR H?=77?%I^ $^
M      (W4MR99[!<+A(O*GA<]/2N.2?/@R'4U$M5-+43*KIYG*]R]ZN52].D
M%>5I[/16F)V'5;U?*G]AO_4K#;6R_EW6-#3.:JPQ.Z^7]UJY^_ &A=NK&FG]
M(T%%PHDO!UDOI>[FIT@3EV
M            16IK!0ZCM4M!<HN.)_-KDY.8O<J+XDJ ,G:TTM7:4NBTE<G'
M"]56"=J>;(W\%]!/[8;@3Z7J6T5P<^:RR+C@3FL#E7VR>CQ0O[4MBHM0VJ:@
MN,?%&].3D]LQ>Y47Q,QZVTI7:4NKJ:K8KZ9ZKY/4=TB?@OH U92U$553QST\
MC9(9$XFO:N45#Z&;-L-?S:6J6T=>Y9++*[+^2JZ%5_6;Z/%#1M'4PUE+%4TL
MK98)6HYCVKE'(H'V     9W;^GN/^/3^X:(,[I^GN/\ CT_N&B
M
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MDM(                         0%#[JZ[XM/P)\@*'W5UWQ:?@!/@
M           $!KR\)8=)W&OSA\<?#'Z7+R3[P,][I7I;UK.N>UW%#3N6"/GR
MPU>?UY+$Z/EDZJ@K;S(WG.O4Q93]5J\U3UK]Q2#&RU,S6)E\TST1/%7.7^:F
MMM'VAMBTU;[<U$18(D1V.]R\U7Y\@3
M                        1FH['0Z@MDE#<H6R1.3S55.;%[E3P4DP!E#6
MVDZ[2=U6FJT=)3/YPU"-PUZ>'K]!-[9:_GTO5-I*Y7S6B5R(Y%7G!_:;Z/%#
M0.HK'0Z@M<M!<X4E@?S\%:O<J+W*9DUQI.MTG=/)ZM.LII558)T['IX+X*!J
MBBJX*ZEBJ:.9DU/*U',D8N4<A]C-.V>OI]*U*4M:Y\MG>O.-.:Q*J^V;Z/%#
M2%'505M+%4TLK)8)&HYCVKE%0#[  #.[?T]1_P >G]PT09W;^GN/^/3^X:(
M
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M15^P=D6ATY47*5N)*YZ*Q53]1O9]>2T
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M-$@
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MJ@KBGW9M,NZ,NC'P313M_--G>F&OF3GP(GACL7O+'
M      $!0>ZNN^+3\"?("A]U==\6GX 3X               .2W2OGY!T;6U
M#'8FE3J(OWG93[LF8J"CDKZRGHX$5TL[TC:B=N5+2Z05[\IN]'9HG9;2MZZ5
M$_:<G)/F(O8RRK<=8)7/;FGH&*_T*]>2?S O^R4$=KM%'0Q(B,IXFQICT)S4
M]H
M  #P7RT45\MLM#<H4FIY.U.Q47N5%[E/> ,KZ]T=6Z1N2QS?G:&956GG3L5/
MV7>#B)I+]=:2W.H*6X5$-&Y>)8F.PF2W.D57R1T5HM[<=7-(^5_^ZB8^\I$#
MZ13RQ5#9XY7MG:O$V1'+Q(OCDM/;G=*MIZ^&WZCF=4TLSDC94.1.*)5Y)Q+W
MH50?Q>Q0-HHJ*B*BY1>\'*;5W"2YZ"M%1.N9$BZM5\>%5;]R'5@
M
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MNLY9]./J-1&<]C]KKY5:J76^O5>ZM5>NIXY7?G'2+^N].["=B?R-&
M                  #GZ'W5UWQ:?@= 0%#[JZ[XM/P GP             ^
M55.RFI9IY51L<3%>Y5[D1,GU.#WGO?Y)T940QNQ/6_F&8\%]LOS?>!GW4UT=
M>M07"Y29S42JY$5<X;V(GJPA?NR%E6U:-9/*W$];(LSLISX>QIGZP6U]VO%%
M;X4RL\C6?)W_ %&O:2!E+2Q01)B.-B,:GH1 /J
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M$T
M                                     "B.EK1VE='T5;<I:GRUDRQ4
M<42HC7/5,JKLHO)$0Y+;_HWPW;3--<-37.KHZRI1)604R-5&1JB*WB547SON
M.@Z8=!4/TY9+A&BNIZ>J5DB(BX:KFKA5^;!9NW6X.G]3:7HZJFN-+!+'$ULU
M/-,UKXG(F%145>ST@95N^V%-I;="BTYJNKJ8[57OX:2MID:KG(Y>%JJU<X\[
M"+\YT$]KNVPVZ%M6FKW5-GKE:USG)A)(U<B.1S>SB;VHI([U:@I-=[PZ8M&G
M')5+13LA=40KQ(YRR(KL*G:C43M]9[NE/5Q5NL=*V*G59*N+A5^%RJ<;D1$Q
MX\L_*!J%CFO8U[%RUR91?%#^GSIH^JIXH\YX&HW/J0^@%,=(/=*MT:VBLVG&
ML=>ZS#U<YO%U;,X3#>]7+R^<M73=56UMAH*FZTBT==+"UTT"KGJW*G-#->^T
ML=CW^L-WNS56VK' _B5N41&N5%[?#M-/TM;2U=,VHI:B&:!R921CT5JIZP*3
MLN[-XH=YJ_2VJJ'R:@K*A(J#EYT?<Q<_K-?]2_*7F98W9KZ?4_2#TO16)[*B
M:DFACEDB=Q(CDDXEYI^RG::G          #*>*     /YQ-\4^<#^@_G$WQ3
MYS^HJ+V+D      $!0^ZNN^+3\"?("@]U==\6GX 3X             9XWWO
M:7'5,5OB=F*WL5'8_;=V_4B%^W:NBMEMJ:VH<C8H(UD<J^"&0;G627&XU==,
MJK+4RNE7O[5[ ++Z/UF6JU!6765GYJDCZN->Y7N[?F1/K+]..VDLOY%T30LD
M9PU%0BSRY3"Y=S1%]28.Q
M                            #.[?T]1_QZ?W#0E3!%4P203L;)%(U6N:
MY,HJ*9[;^GN/^/3^X:( SSN;MM-899+C9&/FM3E5SXTYN@_FW[CBM,7^NTY=
M65]LD1)$Y.8[VDC?!4-=/8U[',>U'-<F%14RBH49NGMFZBZZ\:=B5]-VS4;&
MY5GBYOH] %GZ&UA;]66[K:1W!5QHB3TZ]K%_%/2=*8]LMUK++<8JZVS/AJ(U
MSR7DY/!R=Z&D=O-=46K*)&JK*>YQI^=IU=]IOB@'8@
M
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MGN=XE;R9BGB5?'M=^ %V1L;&QK&)AK4PB>"']
M                                             #.[?T]1_P >G]PT
M09W;^GN/^/3^X:(   "G=TMLDF;-=]-Q-9*B+)/2I_K/%6>GT%,4%74V^MCJ
MJ*62GJH79:].3FJG<O\ (V25=NAMJR\];=;&Q&7/MDBRB-F_D[[P)+;/<*GU
M/"VCKN&"[L3SF]C943]9O\COS&J>44-9_K::K@?^Z]CD+[VOW*CO;8[9?'QP
MW-,-BD[&S_R<!9X
M                                             H/I=V6:LTG;+I3H
MK_(JG\ZS^PY%\[YT3YRRMOM;V'4&D[?64EQI(\0LCDB?*UCHGHU$5JHJG.[Z
M;<77<&EMT-IN--1I3N<LB3*[#T5,?JHI3[>C#J5N>&^VI/5UG^$#4OY:M?\
MM.B_X[/YGMC>R1C7QN:]CDRCFKE%,GMZ,FID5%_+]K__ .G^$T_I>W26C3UN
MM\[V22TT#8G/9G#E1.U,@28  R]OY21VC?#3E]O$*2V>;J6JY[?,:K'87*]G
M+DXT[!/#-"R6"1DD3T1S7,<BHJ+V*BF?-_\ ;K7&M-49LW!-8V1,6.*2H:U&
MR(BHY4:O9VG"T>TF[E'3LIZ2KDA@8F&QLN6&M3T)D#8'$GBGSG],J:<VUW9I
MM06V>X5TSJ.*IC?,BW+**Q'(J\L\^6358      *VZ14+YMI;UU:9X$8]?4C
MBR3PWRV07BSUMNJVHZ"JB=$Y%3/)45,@<CL54LJMJ=//C5%1M/U:X7.%:JHO
MW'>&<-E-4IMK>;CH#6;EI,5#IJ.J?RB<BIXKW.QE/3E"_:R^VJBHI:NIN-)'
M31MXW2+*W")X]H%,=,"=$T39J1.%9)[@BM3O7#'=GSH7=9V+'::%CN3FP,1?
MHH9S=5.WLWBHW4+9DTK8L2]:]N$D<CD7YW*B<O!"^-:ZMM.C+*MSOL[HJ5'I
M&B,;Q.<Y>Q$3O GR+U/8:'4MDJ;5=8W24=0B(]K7*U5PN>U"!U#N':;5H1FJ
MZ=D]PMTC6N8E.W+E15[\]F.><^!]M)[B:7U32-GM-VIU54RZ*9R1R-];54"O
M[_T=-+U-OD;8YJNV5R)F.;K%D:B^E%[O4IYNCQJF]17N^Z'U54K4UMI7$$LC
M^)RM:O"K?%4[%1?26QJ'5UBT_;9*ZZ7.FB@8BKRD17.]")GFI2^P--/JG<K5
M>NWTLD%OJ'+'2+(F%=E>[QPB)GTJ!H4     ("A]U==\6GX$^0%#[JZ[XM/P
M GP          (S4UUCLMAKKA*J(D$3G)Z5QR3YR3*DZ0=XZJT45HB=Y]1)U
MLB?V&]GU@47))+/))+(JOFE<KU]+E4U;M[9FV+2-MH^'$J1(^7ES5[N:Y^[Y
M#/6V%F2]ZUM]/(Q'4\;NOE1>SA;SQ\YJ=$PF$
M                                               ,[M_3U'_X@G]P
MT09W;^GJ/^/3^X:(      *^W,V\I]2PNK;>C(+LQO)V,),G@[T^DSQ54U5;
M:Y\%3'+35<#L*UWFN:J=Z?S-D'&;BZ$H]5T2R,1L-TB:O4SIRS_9=XH!R6UN
MYS:E(;1J25&3HB-BK'NY2+W-=X+Z2X$7*93L,=WBV5=GN,U!<8EBJ8EPYO<O
MI1>]"T]K=S74RQ6C4DKG1*O#!5N_4\&O]'I O$'\8Y'M1S%1S53**G8J']
M
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MV^)$1(8T1V.]W?\ 62H
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MZ -)@\]OK::X4D=513QST\B9:]BY13T
M                                                      !QVZNA
M*3<#326NJE6"2.5LT,R)E6.3*+R]**J'@U1ME07O;.'2/E,R-IHV)35,J\3F
MO;V*OBG:F/!3^[UZ_7;W227"GACGKZB5(*>.3/"KL*JJN.Y$0SS0:EWHU7 M
MVM'Y1DI)7*C5IHFLCY>"*!U>F.C360WVEGU'>J:JMU.]%6&%KN*1J+GAY]B&
MF(8F0Q,BB:C(V(C6M3L1$[C(R+OOE,QWK'[K#4^E5K5TY;5NO'Y?U#>OXTP[
MCQSR!* '+[EZMAT7HZX7F9$?)$SA@C7]>1>34]6>:^A .#Z0NUL^M:.FNMA1
MC;Y1)C"NX>NC[4:B]RHO-/6I43-V-U[# ^U5M'-)5Q8:DD]!Q2-3UHF%]:F@
MMD=97+7&B8;I=Z%M-4=8Z+K&)ADV%]LU,Y3P]:*=^!FW9';G4%YU>FNM>K+U
M[7)-3,F7$CW]SE;^JU$[$-)%,:-W?JKCNS=M*7^B9;XTD6&A:K5X^-O<]<X\
MY.:?]2YP                        ! 4/NKKOBT_ GR H?=77?%I^ $^
M        ?QSD:U7.5$:B955 I7I#WA7.MMFB?RYU$R)\S4^]3D=F[,EXUM Z
M5O%!1-\H=ZT7#?K(37%V6]ZKN=;G,;I59'^XWDA<^PME2BTS)<I&XEKGY15_
M8:N$^<"S0
M                                 $9J*QT.H+9+0W.%)8GIR7O8O<J+
MW*9IUYHVNTE<%9.BRT,CEZBH1.2^A?!35)Y+K;:6ZT$M'7PMFIY4PYKD^M/2
M!FK;O7-9I*K2-5=-:GNS+3IW+^TWP4TE9+K1WJVPUUNF;+3RIE%3M3T*G<IG
M'<7057I.I=/ CY[0]?,G7FK%7]5W\R.T-JZNTE<^OI%XZ654\HIW=CT\4\%]
M(&K016F;_0:BMD=;;9D>Q4\YJ\G,7P5"5
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M^!9.#M<J2X3*>HT\9.V=H[ONAN_+K*[,5*"WR]:F55&M=SZN-GCCM7_J:Q
M                       '/T'NKKOBT_ Z Y^A]U==\6GX =         <
MCNM>?R+HFOFC<C9YD2"+GA<NY?=DZXH7I WE:B^4=HB=F*FCZZ1$_;=V?5]X
M%8VVDDK[A2T<65EJ)6QIXY5>W\37EFH([7:J6A@1$C@C2-,>@H'8JR)<M6OK
MI&HL-N9QIG]MW)/Q-%
M                                               ?&MI*>NI9*:LA
M9-!(F'QO3**AGC<S;FHTY*^OM;9*BU/55<B-RZGY]B^+?2:-/Q-$R:)\4S$?
M&]%:YKDRBIX 9*TKJ2X:9N;*VV2JB<DEA5?,E;X*GXFF=&ZJH-56QM50O1LJ
M<I8'+Y\:^GT>DJ'=';66TOFNU@B62WJO%+3MRKH?%4\6_<5YI^]U]AN+*ZTS
M]5.WQYM>G@J=Z ; !RF@-:T6KK?Q1?F:Z)$2>G=VHOBWQ0ZL
M
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M!H+92R?DG1T4\C<35R]>[U?J_4=\?*C@92TL-/$B-CB8C&HB8Y(F#Z@
M       /-<ZMM!0353VJ]L3>)6IVJ<Q$VG:'%K16)M/=#T@XU->TOP*?Z2#V
M>TOP*?Z2%/V+/[J+REIO?_5V0(K3UZCO5/++%$^)(W<*HY47)*D]Z32>6W>K
MQY*Y*Q>D[Q( #J[@
M                         J(J*BIE%*4W3VS<WKKOIN%7?K3TC/K<Q/P+
MK &.;5<:JU7"&MH)715,+LM<GW*GX&C=M]?TFJJ=M-4*R"\1MS)#V(]/VF^/
MJ[CG]T=LV7!LUVT_$V.L1%=+3L;A)O2G@[[RCH9:F@K&R0OEIJN!_)4RU['(
M!LH%<[8[C0:AC9;[JZ."[-3#<KA)T\4]/H+&
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MBRO#RY9YFLBLMH-W;7N$V6E6):&[PMXW4SG<2/;WN8O?CP[2S0
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M7DI_3X4$'DM%! KN)8V(W.,9P?<S9VWZ-FLS,1,]X #AR
M                            5MN;MM!J!)+E:&L@N_:_*X;.B)V+Z?26
M2 ,:S15%#6.CE;)3U4#^:>U<QR=Y>6UFY;;GU5IU!*C:_DV&H7DDWH7P=]Y/
M;E: IM54RU5+B"[Q-Q'+V->G[+OYF<[E;ZNU5TE)7POIZJ)<.:O<OBB_B!L8
M%*[6[G</4V?4LJ(U$1E/5NSE5[FO_F74BHJ(J+E%[P
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MU5_F:K                         $!0^ZNN^+3\"?("A]U==\6GX 3X
M   5COS>_(--16Z)V):]W"Y$7GP)S7Y%["SC,^\=[6[ZTJ8F.58*'_-V^&?U
ML?*!!Z(LSK]JB@H&IECI$?)Z&-YJ:S:U&M1K41&HF$1.XI7H]655EN%ZD;YN
M/)XE].<N_ NL                "(U=[FZ_XO\ $@-LO]!7_O-^Y2?U=[FZ
M_P"+_$@-LO\ 05_[[?N4OQ^B7\?V96;T_'X3]7;  @:H
M       #@]SO;T'^_P#@=9IW^I*+XIIR>YWMZ#_?_ ZS3O\ 4E%\4TOS>BT_
MRRM/Z=E\(^B0 ! U0
M     Y/7^B:'5MO5KT2"OC1>IJ6MYHO@OBAU@ Q]?;-76*Y2T%T@=%/&N,X\
MUZ=SFKWH6/M=N8^V.BM6H97/HE7$=4]V5B\$=_9^XMK66D[?JJW+3U[,2MRL
M4S>3HW>/J]!F?5>FZ_3%T=071B95.*.5OM)&^*?R UM#(R:)LD+VOC<F6N:N
M45/%%/T9TVPW$FTY*RWW5\DUI<J(U>U8/5_9]!H:DJ8:RFBJ*61LL$C4<Q[5
MRBH!]0
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MY2?U=[FZ_P"+_%" VQ_[/7_OM^Y2_'Z)?Q_9E9O3\?A/U=L "!J@
M               .#W.]O0?[_P"!UFG?ZCHOBFG)[G>WH/\ ?_ ZS3O]247Q
M32_+Z+3_ "RM/Z=E\(^B0 ! U0
M                "(U3IZ@U+:I*&Y1\3'<VO;R<Q?%%)< 92UOI&X:3N'55
MC>.DD5>HJ$['IX+X+Z"2VXUY5Z3JD@E5T]ID=Y\*\UCY^V;_ "-&7RT45[ML
MU#<8&302MPJ.3FU?%/!3-FO]#UNDJQ5P^HMCW?FJGA[/[+O!?O TO:;E27:A
MBK+?.V>GD3+7M^X]9EC06M:_2-=Q1<51;WK^=I5=A%_M-\%-*:=OE#?[;'6V
MV9LD;D3*(O-B^"IW*!)@
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M3S6)A,*G%SSVEOF3M.;<;N4VH+9-<)*I:..IC?,BW-JIP(Y,\N+GRR:Q
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M65:J[SW<3:9J_JI_:^[L3TVX      " H?=77?%I^!/D!0>ZNN^+3\ )\
M#GMP+VVP:3N%<JXD1BQQ_ONY)_,#/.YM[_+NLJZH8[,,2]1%ZF]_RJ67T?+,
ML%LK[M*U.*I>D4:_V&]OUE&0Q2U$K(8DXIY7HUJ>+E4UWI:ULLVGK?;XTQU$
M+6+Z5QS^L"4                  $1J[W-U_P 7^) ;9?Z"O_?;]RD_J[W-
MU_Q?XD!ME_H*_P#?;]RE^/T2_C^S*S>GX_"?J[8 $#5
M       <'N=[>@_W_P #K-._U'1?%-.3W.]O0?[_ .!UFG?ZDHOBFE^7T6G^
M65I_3LOA'T2  (&J                     !%2:AM4;W,?6Q(YJX5/22JI
ME%0XVHT+#-42RK7R)QN5V.K3EGY3WP5Q6W[6=DNIOGK$=A6)\4Y[([3\.B/I
M37VVU,[(8*N-\CUPUJ=Y6:6IJZB2V=:[A67J^LQS]>#L[5HR*WW""J;6R/6)
MW$C58B9*\VFT^*.MIWF-X0Z?6:O-;I2-HG:?]W=6 #-;
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MG_V;<?HM_F!:P(/1VI*?5%H_*%)#-#'QJSAE1$7EZB<
M                                   <-O?=)+1M9J*H@D6.9U,L3'(N
M%17KP_<JG<G%[RV234&VE_H:=BOJ%IG21-1>US?.1/J XOHI61M!MNEQ5W%-
M<)GN7FJ\+6KA$]'>5GO"DVY6_%%I:EJ)(Z6G1*97=J,5$5\CT3QQR^0]FRV]
MMDTAH/\ (E\@K$K*1TCH5BC1S9$5<HU>:87/B?OHMT%;J'7M]UA7><U.-BN<
MF<R2+G"+Z$^] (;>';N#:6OTW?\ 2]=5*O7\+^M<F6O;A45%1$Y*F<H:PL->
MVYV:AKF>UJ(6R?.F2@.F!7MGCTO9*=$DJYIWR\"+YR)R:WEZ55?F+XTI1.MV
MFK91R91\-.QCD7Q1.8$J%5&IERHB>*@Y+=;3]QU/H:XVFRSLIZZ=&=7(]ZM1
M,/15YIS[$4#AM8[H7>S;R6W2M+#1.MM0D2OD>B\:<6<X7..[P+CZV/WQGSF#
M-1Z#U!;=Q*/35QKXI;K-U?5U"2N<U.+LYJF4+$_H$W$S_7]+_P W)_(#N-UM
MP+U8MX-,6JVW1BVR>2+RFEB:BN\Y_"J.7MYIS[B^C/&U>PE?9M607_5UQAJI
MJ61)88H7.?Q/3L<YRIV)X&AP      ?Q[6O8YCVHYKDPJ*F45#^@#/=3H?6&
MUVIJJ[[>,_*]BJG\<UJ<["HJ^">CN5.?H4]<F[.X%U9+16?;>NI:YR<+9JAS
MU9'W9YL:B_.7R *FV>VSKM/W2LU1JZN_*&IZ]JM>J^<D+55,HB]Z\D3ER1.2
M'JW]N6L;9IFEFT-%4/G6=$G=30];(UO=AN%Y9[>19X X"[ZBU)9MIH+M):9*
MW4JTL?'2PL5525V$RK4RO+.50SWH6]:FL6I*[45_T#>K_?JAWF5,\<C4A3^R
MWJUPO=Z$[#88 H7^F[5W_P"5UW^E)_\ ZCJ=N-R;]JG4"V^ZZ)N%EITB5_E,
MZOX<IW<V-[?66B       0%#[JZ[XM/P)\@*'W5UWQ:?@!/@  4ETA;TDDMO
MLD3O:+Y3,B+\C4^\NN1Z1QO>Y<-:BJJ^A#)NM[NM\U5<J_B5622<,?H8WDGU
M(!.[,V9;KK>GFD9Q4]$U9GY3*<78U/G^XTN5GL+9O(M+2U\K,35LJJBKV\"<
MD_%2S                 !S^I]216=J11-26K<F49GDU/%2;JYFTU++,_VL
M;5<OR(4O5U,E752U$SN*21W$JE^ATT9K3:W=#+XGK;:>L5IYT_)Z[A>[A<.-
M*FID6-W;&U<-QX8/C;[E66]ZNHYWQ<7:B=B^L\@-R,=8CEVZ/EYRWFW/-IW]
MJRM+:J9<I$I:UK8JI?:JB\G_ /4ZDHYCW1O:]BJU[5RBIW*6=;M66U]# ZJJ
MFLGX$XV\*]O>8^LT7+/-BCI+Z+AW$>TK-,\]8]<^MT8(3V4V?X8WZ*CV4V?X
M8WZ*D/89?=GX-/[5@]^/C";!">RFS_#6_17^0]E-G^&-^BH[#+[L_ ^U8??C
MXPFP0GLIL_PQOT5'LIL_PQOT5'89?=GX'VK![\?&$V"$]E-G^&-^BH]E-G^&
M-^BH[#+[L_ ^U8??CXPFP0GLJL_PUOT5'LIL_P ,;]%1V&7W9^!]JP>_'QA-
M@A/939_AC?HJ/959_AC?HJ.PR^[/P/M6'WX^,)L$)[*K/\-;]%?Y#V4V?X8W
MZ*CL,ONS\#[5@]^/C";!">RJS_#6_14>RFS_  QOT5'89?=GX'VK![\?&$VJ
MHB95<(<+J/63VRR4UJQAJ\+I^WG_ &3T:IU-236B2&VU*/FE5&KA%3#>\KXT
M=%HXG[^6/\,?B7$9B>SPSXS#T5E;4UKT=5SR3*G9QNSCU$C:=1W&W*QL<RRP
MMY=5(N4Q^!# U+8Z6KRS'1ATS9*6YZVG=<%@O-/>*3K8?-D;R?&J\VJ294>E
M;@^WWJG>CL1R.2.1/%%+<,#6:?L+[1W2^LX=JYU.+>W?'>  D7@
M           "LF_I ;_%(6:5DW](#?XI"S2_7?@\&5PO_P!/[I  0-4
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MDV;T?8K_ *5EJ[O;XZFH;4OC1[G.3S41,)R7TG7;X^X"J^-C^\\'1\]Q,_\
M&2?<T#O;'9J"QT7DEJIVT]/Q<7 U57G\I(
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MGUGEV(LWY0U;+7RLS!0Q9:JI_K'<D^K(%_6JBCMUNIJ.!,1P1MC;\B8/4
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M3S26^ES4[ZKL>NT^3S;Q^GZID'SBGBF3,4K'IXM<BGT)YC95$Q/<  .0
M      5DW](#?XHLTK)OZ0&_Q19I?KOP>#*X7_Z?W2  @:H
M                  "K]TMMH[TV2ZV1B1W-J9DB3"-G_D[TE".;4458J+UE
M/5P/_=<QR&RRO]RMNZ;4T#JRW]72W9B9X^'E-_9=_,#P;8;E17ID5LOCV173
MVL<F,-F3\'%GF-JRDJK=624]9%+3542X5KLM<U?%/YES[6;F).V.T:DF1LR8
M;#5O=A'^AZ^/I Z3?'W 57QL?WG@Z/GN)G_C)/N:>'>35MDKM-5-JHJ^*HK5
MD:O#$O$G)>?/L/SL'>;;3:<EMU16P15SJI[VPO>C7.143"IGM MT
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MS*N\E#26CI#Z:J;2U&U=3/3S3QQICS^LQGEXHAJH
M     0%#[JZ[XM/P)\@*'W5UWQ:?@!/F==YY6P;H,F>F61PP/5/0BJI96M]S
M[9IVHDHJ5JUUQC7#XVKAL:_VG>/H*(UAJ&HU1?'W.KABAE=&V+@BSC"9QV]_
M,#R:@N#[M>[A<)%RM1,YZ9_9[D^;!H;9:S?DO15/-(W$]8JSO7T*OF_5]YGO
M3U#^4[];J'B1J5$[&*JKC"9YFO*:%E-3Q00IPQQM1C4\$0#Z
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M88/Q!+'/"R6%Z/C>G$UR=BH?LQNY]%$[]8  '(
M         #C-Q-!T>K*19&<,%T8F(JCN7^R[Q0S5<J*:W7"JH:M&I44\BQ2(
MU<IE/!39"YPN.TQM7O?)<:R21561T\BN5?'B4#X)R[ G)R.3DY.Q4[4  OO9
M/6E1>(I;/=95EJX&HZ&1W:]G9A?2A:IE3;2N9;M=VBHGF;! DBMD>Y<(B*U4
MY_*:HAECGB;)"]LD;DRCFKE%^4#]@
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ME2FM&;P373=B[Z5O5$M!&DBPT+7-\_C;G*/7/ZR<T_ZER@
M          "M=P+^[3L=ZJ878JI8DA@7.,/7'/UIVEE%*[XTTDT$TL:*K()F
MO?Z$QC(%,JKG.<Z1SGO<N7.<N5<O>J@ #^L<Z-[7QN5LC51S7(N%14[T-2;7
MWZ34.CZ.JJ'<54S,,RYRJN;W_*F#+1H;8&GDBT7)*]%1DU2]S/2G),_4!90
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M>+]EWFK\Q@Z_!:,DWK'27U/"M56V&,=K=828 ,]K@
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M(C4^1W8!W /XQS7M1S'(YJ]BHN44_H
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MG"O-527"93U&GS)NT5+=]TMXI-8W2%[+?02]<W.58Q4SU<357MQVK_U-9
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M4G]7>YNO^+_$@-L?^SU_[[?N4OQ^B7\?V96;T_'X3]7;  @:H
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MQNF-R-/7U&L2K;1U*_ZFI5&+GT+V*=BUS7-16JBHO8J*!_0
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MJ875D34>^%')QM:O8JIX'J \%BL]OL-MAM]HI(J2DB3#8XTPGK]*^D]X
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M-:2TT-SIJ=7K(K$@1?.7M7GZ@-+ Y/;.:]S:;1^I6SMKNL7E,Q&NX>6.2'6
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M_'-:[VS47UH?T ?GJV?L-^8=6S]AOS'Z W<;0)R[  '(
M       "LF_I ;_%%FE9-_2 W^*+-+]=^#P97"__ $_ND ! U0        _,
MD;)&JV1C7-7M1R90_0!WN?N>DK96HJLB\FD7]:+E]78<M<M$UU.BNI)&5+4[
ML<+BR058M;FQ]T[Q^:#-PW3YNLUVG\E)U5)44KU;4P21*G[;50^E%<:RA<CJ
M2IEC]".Y?,7)44\51&K)XV2,7N<F3G+CHRW5**ZF1U-(O[*Y3YC0Q\1QWC;+
M'U9>3@^7'/-AMO\ *4+;M=5$:(VOIVRI^VQ>%?F.IMNI+97-3@J6QR+^I(O"
MO\CA[CHZYTB*Z)&5,:=[%Y_,<_-%)"]63,<QR=SDP=ITFGSQOCGX?L\ZZ_5Z
M6>7+&\?G^Z\&JCDRU45/% 4Y;[U<+?RI:I[6_LKYS?F4ZFVZZ5,-N5.J_P!N
M+^1'EX=DIUKU:.#B^')TO]V?D[H$;;;Y;[@B>35+.+]AWFK\Q)$-J6I.UHV:
M=+UR1O2=X  =7<        /XJHG:J)ZS^D!K"UU=UHXHZ)6(]K\KQ.X>1WQU
MB]HK:=H>>:]J4FU8WGV)WC9^TWYQQL_:;\Y55TT[<[92.J:IT?5-5$\V157F
M?FT6&XW:E6HHW1]6CE8O'(J+E"_[#CY>?M.G^_FRO*>;G[/L9W]F_P#"V45%
M3DJ*GH!"Z2MU3;+8L%8K5DXU7S7<28)H@O6*VF(G=JXKS>D6M&T^P !T>@
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MM@ $32
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M=.R"G8C(F)A$0^QG:K56SS^38T.AKI:^VT^L !(O
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M0M)%14147*+WF)J=/;!;:>Y]+H]9754YHZ3'?  "=8
M      _$T4<T;HY6->QR85KDRBG!:DVIT]=>.6DA=;ZIWZ\"^:OK;V%@ #->
MI-K-069KY861U],WGQ09XD3TM7\#A'-?!/A[7PSL7L5%:YJ_>;/(74.EK/J"
M%8[I112KW2(G"]/4Y.8&?]-[FZBLJLCDJO+J5O\ JZA,KCT.[2U=-[MV*Z*R
M&MZVWU#L)B5,L5?0Y#EM2;+21(Z33E:LGA!4JGU._F5C?-/76QR*R[4,U/\
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M7( "98
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MI7TS>)5[\<C*]NH:BYUT%#1,5]1.Y&,1/$US8+<RTV6BH(_:T\+8_F3F![P
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M
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MZ7A8]Z=CE;V*J<@.+W/UUH71^X;I+YIV:OOJ4\:^5-8UZ-;^JB<2\E^0\O\
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MQP  \5(
M
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M.5?V<>*FJP                        !S]#[JZ[XM/P.@("A]U==\6GX
M3V4\4*TUMSU8F/V8SWW[3-VK+O55%.YG4R.RW,N/J(Y=&WE5RY(57Q64UM)3
M%BGGF\=886NR9\]>SC%/2>_P_P +-:Y.%.:']*XI-)WF*KAD>Z/A:]'+^>7L
MR6.09\5,>W+;F:>ESY,T3STY=@ '@J
M
M                            Y_6-5<*2CA=;$E617X=U;.)<'0 [X[Q2
MT6F-WEFQSDI-(G;?UJIKZV_U].L%5%521*J*K>HQV?(?FW55]MT"PT<-5'&K
MN)4ZA5Y_*A; +OM\;<O9QLS/)5N;G[6=_;_LH72-36U5K5]R23KN-4\]G"N/
M430!#>T7M-HC9J8J3CI%9G?;U@ .CT                     !4SVGFJ*"
MDJ4Q/30R?O,13T@YB9CN<6K%NDP@*O25JGSPP+$Y>^-<$/4Z"C7*TU:YOH>S
M/W';@HIJ\U.ZR3)P_3Y.^D?I^BL:O1ES@15B2.=/["X7ZR(J;3<*;/7T4[?3
MP*J%R@IIQ/)'G1$HK\%PSYLS"C<*U<+EJ_,>FFN%93_]GJYHT_LO7!;U5;:*
MJ3%12Q2>MI$U.C[3-E60NB=W*QR\OD**\2Q6Z7K]4EN#9J=<=OHXVDU==8,(
MZ9LR)W2-/A?[_4WE(FS-2.-GZC%7"KXG0U6@\\Z2LQZ)&_R.-KZ5]%62TTJH
MKXW854[%*,,Z?);FQQ&\)-3&KPTY,LSRS^>[SH "MG!9&WMS?5T$M+,[B?3J
MG"JKS5J_R*W.QVS1?RA6*GM>J3/SDFNI%L,S/J:/"\EJ:FL1ZUA  ^=?7@
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M)                         $!0>ZNN^+3\"?("A]U==\6GX 3X
M
M
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M=\6GX$^0%#[JZ[XM/P GP
M
M
M           7L4K2T^[U_P#$/^]3T72'4RW&I6F2MZGC7@X7\L>CF14=FO\
M'4^4,I*EL^>+K$5,Y\<Y-?38:XZVWO'WH?/ZS47RWIMCG[L[]RV 5Y:H=3)<
M*=:E*WJ>-./B?RQ\Y89GY\/93$<T3X-?3:B<\3,UFNWM  >"D
M  "'U=IV@U5I^LL]UB22FJ6<*KWL7N<G@J+S)@ 99?T7[E^45C9J.F_)O&JH
MY8G=8C>[+>S/RFB]%Z9H-(Z=I;/:F<-/ G-R]KW+VN7TJI-@"FK/M-<TWDGU
MA?[I#74[7.FIF(Q<M=S1K<+V(U.:*G>7*               49TDM07":>Q:
M(L<CXZF^2I',]JXS&KD;P_*JY7T(6;H+15HT78J>W6NFB1S&_G:A6)UDSN]S
ME[?D[BH-6,2HZ56G&3.5S(J='L15Y(J->IH4#C]R=!6K6^GJFAK*>%E8K/\
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MTT'E])\)A^F@'I!YO+Z3X3#]-!Y?2?"8?IH!Z0$YIE.P
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M;[Q]I3^^QVV^\?:4E@!$>QVV^\?:4_J:=MJ*BI!V?VE)8 &HC6HB=B<@
M
M
M
M
M                         %3[H;LNL%[BTSI6WNN^IYN'$:)F.+/<["Y5
M<=W=WJ<[)4;[Q1/KEBLCXT3C\D1&*['[*=^?E OH%8;5;KT^KZZ:QW>AEM>I
M*9JK-32)AK\+SX<\_#DOUEG@
M             "J-RMX:?3=Z]CUAME1>-1+A.I8U49'GLRO:O:G)/G M<%"1
M2[\7&)*F)++0L?E4@D:SB:F>_*+]YZM+[NWNT:II]-;FVIM!65"MC@K(4Q&]
MV<97GC"KWIV> %X@%3;F[LOLE]CTOI*WON^IY<+U:)F.)%15YX7*KCGCL3O4
M"V04+Y3OO!"E?)%998FMZQU(C6<2IX>.?E.LVHW7I]8UDUFNE%+:]1TK56:F
MD3#787FK<\_D4"S@
M      !3.NMP;]<]?TFC-NY(6UT3N*X5DL221PMY<N>>S//TX0N.!KV01ME?
MUDB-1'/QCB7'-<=P'[!Y[E6T]MM]16ULK8J:GC621[NQK43*J42NY^M]>7*>
M+:^T116N%_#Y?7L1$<ORKA/5S4"_@9_K=;;J:"8ROUO:J*ZV='?G9*+".C3U
MM3"?*A<NC=3VW5UAI[O9Y5?32IS:[DYCN]KD[E FP
M                             <GN/KVT:!LS:^\+(]TKE9!!$B*^5V,X
M3/=V<_2591ZGWCU@QU=IRUV^S6YR9B2L:G&],]OG(OW(!?X*3LMUWCM-[M]/
MJ*W6RYT-5.V.26#"=2U5YJJMQCY44NP "E=<;NW&;4LNE]M[;^5;Q%E)JAR9
MBC5.W'/GCO5>7K(ZHN.^-EA?<J^FL]PI8DXWTL+6\?#WXQA<_*H%]@X':G<R
MW:_I)V10R45VI$3RJCE[6+E4RU>],I\AWP
M                 ")U;=FV+35SN;W-;Y+3OD17=F41<9^4ECB=ZVJ[:S4B
M-157R1W) *^Z*]B;-9+GJZXMZVZW.JD:DKDYM8G;P^&7*OS(7N5CT;'1NVCM
M'58Y.D1V$[^-2S@,]])VTK8*VQZ[LZ=5<J:J9#,Y.2/3"JW/S*GJ+[ME4E;;
MJ6J;C$\39$QV<T12H^EB]K=JE1S<JZNA1OH7SBQM -<S1-B:]JM<E%%R7M]J
M@$^                                                >)MIH&W=]
MT;20I<7QI"ZHX$XU8BYQGP/: !0/2X\G6S:;1'-_*/EJ]0B>V5,<_DS@N35^
MIK9I.Q5%UO-0V&FA3DF?.>[N:U.]5*7T'IV[;I:UBUYJV&2ELM(]%M5OE3B1
M[47*.Y]V<+G'-?0@%NW6[3V#;R>YUJM\KI+>LK^/DBR)'G'RN*OZ*UA;)I^X
M:MKTZVYW2ID1)7<U1B+SQX9=GYD.^WL:KMK-1HUJN7R1RX0B.C:Z-VT5GZG&
M$65%PF.?&N0+.,\])FU>QV[6#7EF3JKE!5,BG<GM7HG-JN\>S'J4T,4QTLGL
M;M=PN;ESJV+A7P[0+@M]2VLH*:J9CAFC;(F%SR5,GW(/0;5;HJP-<BHY*"!%
M1?BT)P                                              %5[X[AOT
MW0P6&P(E1J:[?F:>-JY6%'+CC5/'GA/3ZCJ=S-;4&A-,5%UKE8^9/,IZ=78=
M,]>QJ?>JE<;(:1GFN%1KK6T\4U[N'YREBF<BK31KV+S[%PN$3N3U@=ALSM[%
MH;3^:I>NOM:B25TZKQ+Q]O"B]Z(J_*O,L(X/>>YK2[97^:WUO4U+*=58^&7A
M>B^A47)YMB+HZKVLLD]QKEGJ7MDXI)YN)Z_G')S55R!QW2ENU2^DT[I6BD1J
MWJIX)D1?.X4<U$3U*J_46_I"PTNF=-V^T4+$9#2Q-9Z7+WJOBJJ4ET@58W=O
M;>25$ZKKT3*IE%7K6_S0T(!\ZF"*IIY(*B-LD,C5:]CDRCD7N4SSL\Q^A][=
M2:/A=BU5F9Z=CUYIA%5N/D5R?(:*,[W-R2]+:T]4Q?S=,J/5$_\ TI.?UH!H
M@                                             '8@/S+_HG_ +J@
M9XL]%!N1TA[Y-=&^46K3S4CAA<N6*]KL(N/2Y'+\B&@9:NEIO-EGABQRPYR(
M8_T;?KW;]<ZPL&E:9R7V]5ZPLJ53E3,;(_B>OJXL^C!:\71ZH:R)TNI-37JX
MW&1>)\R/1K<^I>)?K N^.1DK$?&YKVKV*U<HIQ.].I)=+;<W>X4KF-J5CZF)
M7=SG\LIZ4SGY"G]36#4FR%71WZP7FLNVF^L1E71U+EPQ%7"9[L+GDJ(F%P=5
MTB;E#?-CX+I1Y=3U3Z>=JISPUR9Y_/@"7Z->EHK#MW35TC46ONBK4S2+S7A5
M<-3/AA$7UJ6N<SMBZ-^WVGG0XX%HH\83^R=,!G#=ND=M_O+IS5EHQ%'=I^HK
M&K[1>;4=\[57Y4R:/1<IE.PS_P!+IR+:]*1(U5D=7N5JHGH3E]:%^P?Z"/\
M=3[@/V                                          !X;[;8;Q9JVW
MU+4=%4PNB<B^E%0]P SUT;;[[&;E=]O;_(D-Q@JG24K7<D>BIYR(OBN$<B>E
M30I7VYFU-CUY+%653YZ&[0M1L5;3*B.1$7*(Y/UOO3Q.)7:37<BK1S;AUJVQ
M6]6J(KN-68QCM[0(O?BYKKW6UDV_L3^N=#4)-7*U?-;Z%7Q:W/RJ:&I*>.EI
M8:>!.&*)B1L3P1$PAQFVFV=CT#!*MM26IKYTQ/65"HLC^><)X)Z$.X
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M/0@':4T$=-3100-X8HF(QC?!$3"(?0
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M)QJBRSRJCI)5_M+CZNQ#J
M                                              '\XDXL93/@!_0
M
M    JHB9541/2
M
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M9Y1HW.>SS<8)OH>^X2Z_QW_P-.;]F.HTZ2S[)^6Z[\D^7]6E)UB]7P\.<8\
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M[5:U5YKE780X_0B__P U%QY]MPJOO<:ZX6^"?,!_0
M
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M455:E99WUM1*VHZZ-45KE7A7"+GGGP-'@
M
M
M                             #X5T3IJ*>)F.)[%:F?'!]P!1NPVUU^T
M/JJ\7"\NI%@JHE8SJ9%<N>//@G<7D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
L                                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g73463g04c52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g04c52.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1N.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &W$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*/_  !$( Z$&CP,!(@ "$0$#$0'_Q  <  $  @,! 0$
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M[J4"=D#LH4CHF4$=U*)XH"#DH4A PF$0('1.R(@^H?ZP+U+S1?3:O2HN"(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@PU'[/O6
M!9ZC]E4O:S>I]/[.[[<J,[M3%!B-V?HEQ#<^[*J*-K';!5OU@S26@*"&XW@R
MF&2>HSP6.'TL8()W>>3TY=U:K=9->PTXJ*O5M%45N-[T5UN9Z/G[.\W#\>><
MKB'R2K=%7:RO%TJ?G*FFI_4<X9.\]W-V?' (]Z_5@[Y0<UT/JS4]TUU>]/ZB
MH:*@EMU(V1AI]Y\<SG.]60$\]W';/CGFJEH/:WJ.];5)]*76EM @@FG@?-31
M2-<XQDC(WI".>/!=J;;*47=US;&!6&#T=SQRWF;V\ ?85^1M&55;2_*'N[K7
M2-JZUUQK611O?N,WC(_FYV#AHZG )0?L9%P2S;4]46C:T-):SBM\C)I6Q-?1
MM($9>,L()P2.8SD95TVQ[3HMG]-;XHJ5E5<*YY$;9'ED<;!U>X@$GF1R'GX<
MPZ.J?M6O]TTOHZLO5E]!=+2 .=%5Q/>UX) Y;KVX/Q7-=HNT75VS>[V::Y5=
MLOEKN,;I R&F-.X!N[D [SNSA@_@K?MIK8KEL6NU;3YX512LE9GK@D%!X]DV
MT"^ZXT'>KM/%;*6XTDSXX0R&0Q$-C:[U@7YZDCD0M3L*VLWS7^HJ^@O%);8(
M:>EXS32QO:XNW@.>\]W+FM7\EL?_  MU+_BY?^0Q5#Y(/]M;Q_@/_,:@_6"!
M<FJMH%VU)M&K=':,]%I30-<ZLN52SC!I;@%K8P1G#B&\SURO5LQV@UUYU%>-
M*:CBIX[_ &W)XU/GA3-& 78."#D@X\#V0=/0+@#-M]]BVB3:7EL5'5215<E&
M'4SW-=(YI(!&\< $@9SG SU7S'M8U78MK4.F=506R2FJ:B* >B[V(A(0&N#B
M 78SW"#] *5S+;;M0;L]H*2.EI!5W.M#N"'NPR,-QESNYZC _%5K5VM]=Z$T
MI:]07E]IN4=<YL<E*V!T1IGN:7-&\''?Y-.>0P1W0=R"@*CV'654S9Y/JS4K
M;>VD%/Z7$+<][]Z/=R =\##\\L=/-4:'7VM;AH.IU[1LME/:8GN<RUOC<]\L
M+7;KG<7/(Y!Y8[(.Y>Q%RV\[7**GV3LUA;Z8RRS$0LIGNQN3'D0XCL.9\QCI
ME:ZV:IUL_35DO\=;:+I;J^J@;5""G+'T;'RM:0/6._R)!)QA!V+JJ+M@K]7V
M_3<<F@Z1M37.F#92&![XV>+6GD>> >1Y'WJ]KF>VS7UVV?6ZAN-#24-92U,W
M ='-OM>UVZ7 @@X(PT^'O07'14]XJM+6Z;4L#*>[OB!J(V8 #O8"0"MV.BYG
M-M N9V-LUI34E$*IL0GDII"[<+=[=(!!R#SSSRJEI':OJ[7&F[U/8;1;*6KM
MS>*^>:1_##-TG=:,$N><'P  \T'>%/=<@V [4:W7D5PHKS#"RX4;6R"6$8;*
MTD@Y;V(./;GRY]?0<;VX[1-3[.Y;=+0,LU725SI&M;-32B2/=QR)$N#R<.>!
M[%Y8=>;0Y-G,6LX:/3550\-T\U*R*9DK8VN(<03(1RP3[%HOEC<[?I;_ (M1
M^4:\=GVAV2W?)^AL,,KZV]5%%-2"DA87.8Y[G#+N70!V45U'8_M0H]H=%4M%
M,:.Y4H!F@SO-(/1S3X=N:Z,OSU\F#0UZLM/<[_7Q"C=6T_ I8IVG>//>WW-Y
M$#( \>J^].[=+Y<=83Z?DT_23U;7RP1-I9'?.2M) YNZ-Y$D]@"B/T [.Z2W
M&]CEE<LV;W?:-6ZVN\&KK;'3V-N_P7\-K PAV&AC@<O!&>9S[0HV;:EU[>;Y
MJ*@U':J:@%*P&FD?$[AB3/)N0?7!'/(6KV4[7[IK'7$]AK[914S(8Y'&6![B
M26''?L@[4H[+D%RVD7/4&TDZ-T2::!U-OFLN-3'Q0S=Y.#69&<$@=1D^'53I
M[:9<;9M*ET+K)E-+5N<!37&E:8V2;S=YH<P_1R.7(G!Y<^J#KY1<?VV;4;QL
MZN5OCIZ"WUM+7,>YA>7M>PL(R#@X/T@M3>-I6O*N+3MQTYID?HJO,8+BTR.E
M<0-[D/H,R3@GJ!E!W9<RVTZMU1HBSQWBR1VBJH>((I(JF"0R-)Z$%L@!'(]@
MNF-R6C>&#CF!XJG[3(V2TNGHY&AS'WNC:YKAD$%YY%!3-B6V3^F]7+:K[#34
MEYYO@%.US8Y6 <P-YQ.\.9]BN.TR\:AL%I97V!]J>#/# Z*M@D<?G'AF0YKQ
MW<.6%^;]M&@:W9OJJ&_Z;<^"UR3"2F?$3FFD'/</EX>(Y+J4&T*GU]LK;4%K
M8;G35]%'50Y!];CQ^N/NG\.80=HMK:QM(P7*6GEJ?VG01&-GN!<X_BO3V6AU
MOJ>DTAI:MO5>'/BIF@MC:><CSR:T>TKE53K_ %M3Z AU^YEK_1+Y 3:#&[?$
M)?N!W%SS).#C'0Y\D'<^R=ES;56T::#9?!K335/35%,X->^"KR' %VZ1EIZA
MW+S7@TIM*NNH-DUVU6RAHH:RADE IR7%CVL:T]<Y!.]U\D'6!Y*%RS8AM+K]
MHL%Z-70TM$ZBX0CX1<X.W]_KD]MT*J.VXWFBVA3:9KK)1U)AJ7TV]1N?ORN
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MVH+C&'OBI:9T9B=O<XVNR=YP&"/'P5VVN;28M!62WU+:/TFLN#BR".1VZU@
M!<YW? R.0\4'1!R[954VGWRY:;T7<;U9_0W343.(8ZJ)SVO&0,>JYI!Y^:Y=
MM VC:NT%-9+C55MJO-JN3.*(H:8PEHQG=#MXDC!&'''L5TVI7**\["[K=(&N
M;#6VV.H8UW4-?NN _%!YM@VT*Z[0;5=JF\4]#!)2S,C8*5CV@@MSSWG.YKJ]
M-U<OSO\ (\_L[J+_ !4?\!7Z(INKD&$H.B(.2 $3R1 4=5/9$$="I[(@Z<D!
M0.J=5/L0 B)W0%&5/9$!0I[( @(@1!"GR0)XH")XH@(B( 0=#E$!0.R(G9 /
M3*)CDH[()3Q0H@($4 H)0!% 02%"GS1 ]B($"!Y)CQ10@D>"!0I* 4[(GM0$
M4>2D>" H[(.ZD((4J IZ("(@00I1$$*5"E &,E$"!! [IV4J$$E0.JE @)XH
MG= [*%/L4()1%""4"!,=0@#DA3"((4A/%/$H'9$0("@(B I0=40$1/:@A2%
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M*ATZZ6IJ+E7W6Z2,X1K:V3?>QGV6@\FCD/;A!^;]-_[5,_\ G%5^4BS;6O\
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M*U['$=#]$$'KW5[INKD&)$\40.Y1%"">B)CJ@01R4H@Z\T =$PH'DI0$ZJ$
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M]971,#Y7N;@%K"<@8)QS'8KZV6W?7L&O+GI_5-+75EGAXO N<]-N;V'>J=\
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MF$#Q4CHB!  4!2B $Z*$03XJ%(4!!]P_U@7J7EA_K O4HN"(B B(@(B("(B
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M6-C:UCXW&3(RT8+QNC/M![JB\HH4A 3JH4H"A/%2@)CDH"=D$A/8H4H"=T1
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M]R5T% @I.O-F.FM;RQSWFED;61C=%33OW)"WP/(@CVA>_1NAK'I&/_W12O\
M2"SANJ9Y#)*YN<XR>@\A@*S]T04FY[+-'72[272OM!GN$CQ(Z=]7/O;PZ'._
MRQ@+ZONS#2-_K!5WFU.K:EL8C$DM7,2&CH/IJZ*$'FME!3VN@@H:-KF4T#0R
M-KI'/+1X9<23[RO4G90@!2@1 3LH]JE 4*4]J @[HH!02410@GNH4CS1 '1
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M4>*GL@C'9%*('O105/LZH 10B"44*4!$3W("A3XIXH">*@*4#S[(H"()">U
MHR@E$1!"GV*%.4 >:8Z\T]Z! 6:FZN6%9:8<W(,7CT1"G) **%/O01V4IV1
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M*6"JX< DS&R02;S1DG>:3E=*(#FEI (/(@]"N;;=860;-W0PM#(XYH6,:.@
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ME]+41PN>R5C6N((!/1P([+D6J+W?:'1-HU90ZAK'RU4C6R4TC&"+)WOHM R
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MV$IMGFEJ-D-;-40F&:2.![XCU8XN:2WW'DKB+5I>2JKM$6YYJ7BLFHFGCO\
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MS2L?&)GAF^.9Y9Z\B%.QT@[1MH1:00:Y^,?\5ZZ!>]%Z=OEP977:TT]35L
MD=D$@=,X//WH8YA+>;>_Y0]/5FKB92^@<-LTCMQCCNNYAQY$>![J6W^GT'M>
MU"R_QEMKO?#FAJBPEK2!^67.!/D%U4Z6L9NL=R=:Z5U='&V)DI9G<:WH .@Q
MY++?]/6G4%,RGO5!!61,.\T2#Z)Z9!',)1J8-862LN='0V*:FN57.[+A3.#A
M#&/I/<1T [#N2JA7$'Y2%O /2U'_ ,Q=!T]IBS:=C>RR6Z"C#_I%@.\[VN/-
M>.30^GY+L+H^BD-Q!R*GTF7B#V.WLH*5MK/_ .MFSH9Y_I4?\R)>3:S45&E]
MIFF=7/A?);8XC25!:TNW 2_/L.)"1X[JZ%>=%6"]5K*NZT)JJB/FQ\D\GJ?N
M^MR]RVM9:J*NMC[=70-JJ-[=UT<Y,F\/,NR2?-**_/M T^ZBC?;;C35U74 -
MIJ6)^9)'GHW R1SZDCDMOJ6SQ:@TW76RL8-VJA+#]UV,@CV.P?<O)8-$Z<L%
M4:FT6FGIJ@C'$&7. \B2<>Y?%ZUQIVRW-]ON=T@IZMD?$,;ST!&0/:?!%<NV
M:FXWFJM^C[U X1Z:J75,[C_O0W^I;[G.)]C0NZJI;/:1\L-QOU7!P:N\5''W
M"S=<R)H#(P?<W>_[RMJ:8Y_MULM5>MGU7'0L=)+3R-J=QO5S6YR ._(Y]RVF
MRV]4MYT+:9J:5I=#3L@F:3SC>P;I!';IGV*V*N2Z'TW)535!M,#))CF7AES&
MR'[S6D ^\(*3LGM9J-?ZSU)&#Z%45#J>FD'T9AOY<YOB,M;S\RIM#FGY1-[
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MJC4Z?</]&%*<C=_1G7_\V57_ ).Y'^C*GP>E1-_$KE#I>TPV4VB*GE9;3RX
MJ9=W'A]+..?3HL5HT?9+/23TMKI)*2GF&)(XJF5H/3G]+D>74<\<D'/_ ).A
M!I-4D'(-R/Y*=(G/R@-58(/^J-_\M7ZQ:-L5A?,ZS43J,RC$G"GD =[1O=?/
MLOB@T1I^@NKKG1T+HK@\DOJ&U$N^[)R<G>YY\TJ*1?'#_P!H&RC(SZ$[\BM;
MK>Y2:*VT4E_KXG_H>OI6T\DP;O!N.1]XPTX\"NDU.B-/U-W%UGH7ON0(<*DU
M,N^".F#O<L+:7>SV^\6\T-UI(JNE./4E&]T[YZY\^J4:>76]EEEIJ:TUU/<:
MVI>UL4%._?.">;CC. !S)*J6L;YZ9M1H=,W2N]!L?HO&E;O\/TEYSACG=F]L
M \U=].Z0L&G)'R66UP4DKQASVY<XCPR23A3J'25BU%+#+>K9!5RQ##'OR' =
M<9!'+R0<IKZ^PT6W#2K[9/106R"CEC=+&0V(.+)1C>Z$\P.JV>W^5CX=(2,>
M"QUR:X'Q'+FN@U.CM/54M!)/:*1SJ 8IO4P(QG. !R//GS4:@T=8M0S1RWJA
M]+?&,,WYI &>P!V![DHWT?T&^P+G^VO4U=IK3%,^V2^CRU=4RG=4XSP6D$DC
M/? _-7NDIHZ2G9!#O\-@PW?>YYQ[7$E8+S::"]4#Z*ZTL552O(+HY!D9'0^1
M45Q7:T-.4NSSA6BIIJJOFD@DEF;)Q97@'F][N9'/V#)PN@U5WT]7:8L]%<W4
MM;;K@8Z-SN("QK^'O $CH>6.O(E;.'0^FH;-/:HK/2LH)R'2Q 'UR#D$NSGD
M1XK/5Z2L-7:*:UU%KIWV^G.]%!@AK#C&>7?F54<CU/IBLV9W>W7;1UPG-!6U
M;*=]N>[>SO<\#Q'(\^HY<RN@ZKMFF]97B?3M\@'I]/ R>&0/W9 U^02P^1',
M'(YCDM[;]+6:@G@FIJ)O$@!$)DD?)PL]=W>)W?<OF[:2L=VN+:^X6]DM:UH:
MV??<UX S@ @C'4I1S?0E#>=*;0JC2+[E)<;/+1&H8YXYP9R!D<\'(QC/-:[9
M)JNW:4DN.E-5%E#54]4]\<\PPQP..63T\1V.5V6UV6WVN2:2AIFQRS8XDI)>
M]^.F7.))Q[5X-0Z-T_J*=LUZM5/53-&Z)' AV/#((*4?-EU+;KQ=I*6PF*L@
MA9O5%5"?FV$_18".3B>9P#RQYJD7/16G]HE$Z_6:1ULO7$<'S0OR1(PEN'M\
M>0YC!PNEV:TT%EHFTEJI(:2F:<B.)N!GQ/B5IX-"Z<IY99*:VB!\N>(8II&;
M^3D[P#N?O04O0.IJG_1Y6NUD!5T]-6_HYT[^8EC+@S>)QS )(SY+1Z^T0W15
M&_5FA+E)0LB<POI1)O,>'.#?4)SG.1ZISW]B[#4:?M-191:)J" VP8_U<##.
M1ST'GS7BI-&:?I1"(;<SAPO$D<;Y'O8QPZ.#7$@$>.$I'.]O53+4[.M-5%6P
M13RUU/)(P_LN,3R1[B5>-K?ZMM0_X5WYA;#4.DK+J)S'7NB]+$?T&OF>&M\P
MT. !\\+[K=,6JNM3;;60S34+1C@OJI2TCL#ZW,# P#T0:G9"X?Z-K"<C IAS
M7--D-ODNVR_65OI<&HG?*Q@\7%G(>\KL%NTK:+;:Y+;04\L%#)]*%E3*!YX]
M;EGOCJOG3NDK)IR25]DHO0S+_6!DKRU^.F07$'JE'.=D6OK)#IR&R:@D@MER
MMWS!;58:'@>9[CF"%T;3FH*.]RUC[4P/MT!#!6#DR5_/>#?$#ESZ<UY[SH33
M-ZKC67.S4T]4?I2'+2[VX(S[UMGV>A=:A;6TXBH0W=$,+C$,>'JD<D5S7Y-O
M]C[G_F,G\+$V=D';-KW'/E&KS8]'6.Q-G;9Z-]&V88D$-1*T.\_I=?/J%\VO
M15@M5R=<+=0N@K7'+Y6U$N7\\^MZW,>12I%!M%?26[;]J:2X54-+&^WL#73/
M# 3\V< GR!^"W^H;1I?:#<:ZV5\8;<J*.,PU#'[LNY(P/#FCN.>,'/XJRW;2
M5BN]T@N-SM=/4UL( 9*\'( .1D=#[U\5^C[#7W1URJ;>PUYQ_K#'O8_D,#FT
MC'((*'LMBO>G=>7?2==<'W&UTU(*B&5W,QY<T-;Y$@GEGMGNNMKP6JST%I$H
MM],R$S.WI'#)<\^+G')/O*]ZBN-V>LIK=M_U')<*B&FC=1-W73/# >3#U/DO
MO:M*R;:#L^DC.6OE<X9&#@EO9=%NNDK#=;K#<KC:Z:HKHL;DKV\^73/8^]8;
MOHJP7BX,K;G0&HJF'+)'SR99W]7UN7N5J13OE'X_H%#_ (V+\G*=I6H:BWUF
MD;,*PT%ON;@VKJ6G=(8-T;H=^SG/57.]Z0LE]CACO%))6,A'J-FJ)7 >>-[K
MY]5]7'2-CN5KAM]QM[*JDA.8FS/<\L]CB=X?%!R+:>_3EOOFB8;))1MBI[FV
M2IDB>'!HWV'+W\^?(GF5:MOM1#6;+*B>EE9-"Z>(M>PY:?6QR*ME1H73-1;*
M>WS66D-'3OXD<0:0 [N>7,Y[YZK;UUIH*ZU/MM720RT#V",P%OJ[HZ#';'DE
M'BTI=:&NM5%%15<-1)'2Q%XB>';N6]\=/8MTM98+#:]/T9I;+114D!=O%K,\
MSXDGF5LU%$1$!:N^_0A_>*VBUE\^C#^\4&S;T"(.@1 1$0%Q_:)I^NL.OZ#7
M5JIY:N!A#*Z&)N7M;N[I<!W&[^2[ A&1@]$&HH=362NH&UM+=:)],6[V_P 9
MHQ[<GE[US34U(_:?K&V4U#&Y^F+8\R3UA!X<S_LL/[70#(\_?TF?2M@J*@SS
MV6W23'F7NIV$GWX6WABCAC;'"QK&-& UHP J.0?*,D;#1Z8D><,9<6N)\  K
MIKR_V^'1-PGAJ(*DU,!BIXXWAQG>\8:UH'7.52OE%3PQQZ79)(QKOT@)"TGG
MNCJ?9S"Z=2V&S1U8KZ6VT+:EWK"=D+=XY[Y 1'/J;3M38-@E?;JB-WIIHI)9
M8P,EKG<R.7@%L=BU_MM5HJRVVFJ1+604Y$T; 3PL$_3\,]L]5T0@$$$ @\B"
MM926"T4=)44M);*.&FJ/ZZ*.%K6R?O #FE'+MA4\4FJM;\.5CM^J:YN' Y&7
M\QY+-H.HA?MTUJ&RQDOB8&X</6P&9Q[%T*DTAIVCEXM)8[;!)@C>CIF-.#UY
M@+Y@T=IN"H;/!8;9',T[PD;3,#@?'.$I'/-?3PQ;=]%F26-H;"02YP&"3(!\
M2LGREI8V:3M#'/:'_I.-^">>!')D^SFN@5.C].550ZHJ;%;)9W'>,CZ9A<3X
MYPLE=I6P5[HS766WU!C8(V&6G:[=:.0 R.@2BG;;IHCLDJB)&8D;!N'>^EZS
M3R\>2VM+J6@TWLPMEVK96&&.BA#&M=SD?N@!H\\_S6[GTGI^HIX:>>RVZ2"$
M$1QOIVEK 3DX&.2@Z2T\ZA%&ZR6TT@?Q!":=FYO8QG&,9P@YULKMT=TNM5K?
M5%13FY5KBZBADE ]&BY@<L^& /+VKW;7(GZMT362V ^DRVFN#L1'?XA8WUL8
MZXWNGD5<AHK3 &!I^U ?X5G_ *+:VNV4-JIC36RCIZ2G+B_AP1AC<GJ<#N@Y
MQIS;5IRMM<;KK)-1W$#$E,(G/)=]T@<\^"Z%8*NIK[;'5UE.:9TQ+XX7?39&
M?HA_@['4=NBPLTU8X[AZ<RT4#:W.>.*=N_\ '&5MD47(MD%53S;0]?\ !GCD
MXE9OLW7 [S=]W,>(75ZVDIZZF?3UD,<\#^3HY&AS7=^8*TT&C--4\@D@L%KC
MD',.93,!_)0<_P!H]5!'MHT/Q)HV\,/W\N W<Y SX95IVQV*HU%H"OIJ .?4
MQEM1&QO,O+3D@>T9QYK<U.C].550ZHJ;%;)IW'>=(^F8YQ/CDA;FF@BI8(X*
M:-D4,8W6,8,!H\ %:CE.CMLEA-EIZ?4$DM!=*9@BFB,+G!SF\LC ZG'3LMEK
MJFN&MME]S?3T<L$DA%124[VXD>QA!]8=B<.('L5RETU8Y;@*Z2T4#ZT.WA.Z
M!I?GQSC*VW3H@Y9L\VGV&33EOM]PGDI;K2PMIY*9T;BY[FC=]7 YDXZ=5Y=A
M4CI=1[0)'QOB<^Y[QC?C+"7R\CCN%TJ.P6>"Y/N4=LHHZ\Y+JD0M$ASUR[&5
MS38;40S:JV@F*5CQ)<S(S=<#O-WY?6'ES'-!Y-GMXMVF-H&N*6_5D5!+458E
MA](.X'MR\Y!/7J%AMUYI3\H&6KF+Z>":W[D1E:07YQ@XZC..65UVOL-IN%9%
M5U]LHZFJBY,FEA:Y[?82,KT,MM$RO?7,I(&UKVACIQ&-]S1T!=UPE(XK;M2'
M9GM#U#2:AIY6VB[U3JR&J:PD-+B3VZCG@@<QA='L&MZ+4UUCI].,EJZ2/+JJ
MK=&YD;.7)H)ZN)Q[ K!=+3;[M"V*Z45-61-YAL\8>!\5]V^W45NI!2T%)!34
MPZ11,#6_ (.7>D0O^48T-FC)%MX> X?2P[E[5YML,\0VEZ :96!S*V-SAO#U
M1Q6<SX+HIT7IDRF4Z?M?%)SO^BLS\<+[K-(Z=K:IU366.VSU#CETDE,QSB?:
M0E',=HL]5HG:I0:O=3RS6>H@%-4NC&=T\Q@__*1XXPKG2[1K3>IZ>BTO(^XU
M\Y;ZK8G!D+/VGR$@ 8';J3@*W26^CEMXH9*6!]$&"/@.8"S= P!CIA8+39;9
M9V/9:;?2437\W"GB:S/MP$'SJ6T07ZPUUKJQF&IC+#Y'J#[B 5R38_%=[A<(
M;)?(B*;2CWM]?GOS..(_<UN_CR</)7;4>TRQ:?U!+9J\59K6,:YHCA+@\N&0
MT8[E;/0=OJZ6TR5EV8&W6XRFJJ6_8)^BS_NM ;[D%D7--ONG:R_:-9);8W2U
M-#,)^&P$N<W!!QY]#[ETM%%532NMK/=M,4]REKZ6G<V%IJ8Y)0TPO ]9I!.>
MN?:J[L1L$]%!>KY5PN@==ZDR0QO&'"(%VZ2.V=X\O(>*N[M,V-U?Z<ZT4!K-
M[>XQIV[^?'.,K8U--!54SZ>IB9+ \;KHWMRUP\"%4<EV95$,NV+7G#EC?OEI
M9NN!WL'GCQPNOJOLT5IB-Y='I^U-<>I%*P'\E8  !@= HN./;:(J^Q:JT_K2
MC@=44UO^9J&M'-K23S/@"'$9\58J;:KI^Y001V22:MN=2 (J-D3MX//9QQAH
M'<],!7V6-DT;HY6-?&X8<UPR"/8M=:M/V>T2ODM5KHJ.1_TG00M83[2 JCG/
MRC).'H"A9421F<UT1..6]AK\D#P5VKJB%NSV:9TK!";82'EPP<Q<N:]]WT]9
M[Q*R6[6NBK9&-W6NJ(6O('@,CS*AVF[*^VMMSK30F@:_B"G,+>&'8QG=QC.$
M52-@\\/^BV \5F(G2\3UAZG///P7B^3K-')8KX&2,<?TB]V [/(@8/L5]ATA
MIV"*2*&Q6V..08>UM,P!P\QCFOJBTGI^A<]U%9+=3F1I8\Q4[6[S3U!P.B5'
M-=F\\4FVW7!CE8\.;ZN' YPYN<>Q9:N>'_VDJ,<5F?T:8\;P^EAQQ[<=ET.D
MTCIVCJF5-)8[;!4,.\V6.F8UP/CD!?+M&::=.9W6"UF8G/$-,S>S[<)1RW6=
M14Z"VOC5513RRV2XQ-AGDC;D,.Z&X/F-QI\U>Z+:%:K[604&EYG5]9(6N>X1
M.X<,>?6<\G&#@' \<*VUE%2UM(ZEK*>&>F<,.BD8'-(]A6"T6:V6>-\=IM]+
M1,><N;3Q-8#[<!!RJY7^B?MDN%#K.IB@M5'3M=015)W82\AI+SV)YNQG^2U=
M%J&VLV^OKB]\5%-1"*!SHG-XAW !NC&2#@X\>R[1<;):[E413W"W4E5-%_5O
MFB:]S/82.2^Y+1;I+A%7R4-,ZMB;N,G,0+VCP#L9 2D<GVRU$+-I.S\/E8TQ
MU)+\NQN@R1X)\.A795I:_2FG[C5OJJ^RVZIJ7G+I9:=KG'WD+;4T$5-!'!3Q
MLBAC:&L8P8#0.@ 17,]N%YGMC=-TLDLM/9*VMW+E-'D'A MRS(Y@.!>>7/U5
M3MLUTL$MDL=/IPQ/HJ:L#GRTS"86\AR+QR+O+.5WBXV^CN5*ZFN-+#54[NL<
MS ]I]Q7EDT_:);:RW26NB=0,(<VG,+3&TCH0W&$S4:/4.J;'Z);&W'@36:ZR
M.@,TPQ&?5R#SZM/BN;ZETQ3Z5UEIROT!5EC[A5MCDH8I#(QS,C+NOT,=<]/%
M=JK[3;[A#'%74--411_09+&'!O;D#T6.UV*TVISG6RVT=(YPP3#"UA/P""HW
MJ72^KK_=],ZC@IO2Z!T8A+Y-U[VOB:_>8>1R"2".?0*N;+K-4VG5>J=.TE?+
M6:<93@1R'UA'(['J@]-X-)SCP"Z97Z;LEPJ'SUUIH:B=Y#G22P-<YQ #022/
M  >Y>ZAHJ6@@$%#3Q4\(.=R)@:,^P(.'[.-<PZ %5I364<M'Z-,]U//PR06N
M.>8';.2"/''9=.L.KXM0&LJ[/"^6T4T+CZ5(TLXLHY[K >9:!G)\5N+K8;3=
MW,==;;1UCF?1,\+7X^(7MAI8(:44T,,;*=K=P1M: T-Z8QX(.47JQ:-V@V"2
M]P3TU!=N%Q'U$4H:^)X',2-SSYCJ>?FLVA]2U=LV5VZOU<TRP23BG+Y@<F!Q
MP'NSU_F%>_Z):>XHE%CMO$'1WHS,_DME6T%)74PIZRFAG@!!$<C YN1TY%*.
M';3=*V>S4=+J3056VEN#IV,9!1R;[9RX_L 'KY#EA;?;54\.Y:"%=)#'4MK6
M23-W@ WFW>/LSGFNG6_3EEMU1QZ"TT---]N*!K3\0%CN.E;!<ZIU3<;-;ZJH
M=UDFIVO<?>0E(J7R@7M&RZY9<WUI(0W)Z_.-/);>R5,'^BBEF$T?";:1E^\,
M#$7/)6VJ=*V"J@A@J;-;Y8801&Q].US6<\\@1R1NEK"V@=0MLUO%&YP>Z 0-
MW"[&,XQC."@X[L]M#]1_)^O-KHW!U2Z:1S6#F2YCF2-;[]T#WK;;/=K-HH+!
M#:]5&:VW*@;P7-?"\[X;T. ,@^174K3IZSV>1[[3:Z*B>\8<:>%K"1YX"^*W
M3=DKJT5E9:*">J!#A-) US\CH<D92C3R7M]WT7?;E+":6WOIY?13,-Q[X^&1
MO.!Z9.<>6%H/D[RQG9G3@/;F.>;?&?H^MGGX<ET&Y6J@NE,*>Y45/54X.1'-
M&'M'N*\-+I33]+#-%2V6W0Q3-W961T[6AXR#@@#GS ^"*YML+FBEU5KDQR,=
MO5[WMPX'+=]W,>2\>@KO163:MK:.Z3>CRSS$PQN!WI?7Z-'<G(P!U75K=I6P
M6RJ;4VZS6^EJ&])(:=K'#W@+UR6>W27-EQDH*5UP8-UM28@9&CP#L92HI5S9
MI+7=;<;3?H*=EQH9#$S?DX<P:0"'-/7OS',<EJ-B5-<+7?-46@5KZZQT,K(Z
M:=W,;W/(:>G(=<=\+H=;IBQ5T[IJRST$\SG;SGR0-<XGQR0MC24L%' V"DAC
MAA;R:R-H:![@E&9$111$1!YKGRH9?9_-1:_J,7L_FET^H2^P?FEJ^HQ>_P#-
M!CN76/WKPA>ZY]8_>O%S6W#QER]1V0=.280=%TB>RCQ\$1!/9!S/DH4A 4<D
M\<J0@84#S*=E.$$(@4CN@!1W*E0@#R4@J%/;F@!$480%("*.G3J@93Q3\40/
M%.6$1 ">U2%""2H[J4_-!"!%/<H"A$0>^V?[WW?S7M7AMG^]]W\U[ECR]:<?
M!$1<NA$1 1$0$1$&MO=AM=\A$5WH*>K8.G%9DCV'J%YK)I.PV.7BVFU4M++C
M&^QGK#WGFMVB B(@(B("(B B(@+%5TT57324]0TNBD&ZX D9'M'-9405ZU:+
MT]::[TRVVR*FJLY,D;G GV\^?O5A1$!$1 1$0$1$!:FXZ;LURN5/<*^VTU16
MP8X<KV9+<<PMLB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B M7?1ZD/[Q6T6KOO
MT(<?:*#:#H$0= B B(@(B("(B#P5-FME5,Z:IMM%-*[Z3Y(&N<?:2%ZJ6F@I
M(1#2PQ01#HR-@:T>X+*B B(@(B("(B B(@(B("(B B(@(B("(B#'400U,+H:
MF*.6)WTF2-#FGV@KR4]EM=-,V:FMM%#*WFU\<#6N'L("]Z("(B B(@(B("(B
M#!)14LE2RIDIH'U#!ALKHP7M'D>H6=$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!Y;G]1E]@_-+
M5]1B]_YI=/J$WL_FEK^HQ>S^:#'<_P#=^]>'FO=<NL?O7B[+?AXRY>H4IV49
M50[8[HI4=T!%I]77^FTS8:FZ5H<Z.+ #&]7N)P /_OQ7/KGM!U%!I*GU/2TU
MF=;II.'P#Q'2LYD<W9 SR\/BE6.LJ<JJZ;UE27?13]0OB?#% Q[IX^I:6#U@
M/$>"K%AUMJ?4%EKKO9Z&TS0P/<T41<\3X'<G./=CFE2.H#NBH>K->_H#1-IN
MQ@CFK;C%&Z./F& N8'$GGG S[>866COFI8;A967&"TU%NN#]UU71;^(SNDAN
M"3U..?M2JNZ*EZ\UM_1ZOH+5;Z9M7=ZYP;%&]VZQH)P"X]>J\4>M;G9]8T=A
MU9!0-].:TT]51[X;O$D!K@XD]1CX)4CH/53A<]U)KFJBUQ!I>R"A95D RSUV
M\8VDMW@T!I!SC'Q6TTY?[M)<[U1ZBI*:F_1\;)6OI]XME8=XEP)/3U>G4)56
MY%R[3>N]0:ICN=98:.UNIZ1Y#*2=SQ42CJ#D'='+RZJPU.IKE#L^CO[:.G?5
MLBXM13O<Y@&"0X#KS!'?S2D6]2N4Z5VC7[5E%7BRV*E%73[IWYICP6@@]>A+
MN7(#SYA8=%[4KG?:FHMDMGCDNXY0M@);%RY.+R22T#Q&<Y2D=;['FGL7*+'M
M)N[-?'3>HZ"AC<9> 'TA<=UQYM.2>8(\AU5JVB:TAT?00.X!J*VJ<6P0YP"1
MC))[#F$J1;E!7-Z_6UZTS>+73ZLIK<*.OZ2T>^#"[P<'$YQRR0L^TW7E;HR:
MA=%;Z:KIJMKMQQE<UP+<9R,8QZPQ[TJNA>U%R/4.TG4%'IZWWVBM%$RVU!##
MZ0YSI'.[D $8;U )Y\NBLTNJJZX[-QJ"R00"H? Y[FSO.[$6Y#L8',@CD.25
M(M<%QI9[C44,4S7U-.UKY6-Y[@=G&?/DO4%P+8C<-055?>JFB92ULTIC=425
ME0YCN_,8:<J]ZBUS60ZVIM+6>.ACK'-!EJ*W>,;26;X: T@DX_-3-6.A>Q/<
MJUI6ZWFLNMWH;]14U,^CX1B?3EQ;*U^_ZP)[>KT[<U954 F5*CQ02B#DH"#W
M6S_>^[^:]R\5L_WON_FO:L>7K7CX(B+E1$1 1$0$1$!$1 1$0$1$!$1 1$/0
MXZH"+FM1KV]4^T+^CDEEB=FF,T;(I-^20G.[ZQ(:T<CG([+R7/7NIM,ZJME!
MJFUVYU#<';L3[<7O>'9P&^L>9R1V'56)7547+]7ZRUCIJE9>:VQVT6/B-;+$
M)G.J8FN. 7'Z(/08&>9"L6MM9QZ?TI37>EIS5/K#&RF9S#27C(+NX&$BK<BY
MQJ[5NH]&PVVLO,-IJZ*IG;3RMI6R,?&XC.07.(<.1[!>[:GJ'4&F;&+O8H;?
M4TL9 FCJ(WE[0<^L"UP&.G+S2"\HM-IFXU%TTM0W&:>E=-4T[9M^*-PC:2,X
MW2XDX]O;LM=LZO%XO]G?<KNRCCAED<*5L$3F%T8) >[><[KU&%!:D6&NJ64=
M%454H<8X(W2.#1DX:"3@>/)<\M>K-3WG1U1J:W4]HAHP))8::=LCI'QL)!WG
M!P )W78Y$=$'2454T=JFIU3HB&\T%%&*UX<WT=\A:S?:<8WL'E[E7-&:XU)J
MZQ5,]KM- VM94/B#IGO;!&T 8R>;G..3TP/''=!TY%R[36T#4-?7W6PUMC@?
MJ6C> &T[RVGW3^VYSB2 .73).1R6>RZUU#2Z]@TSJVWVZ-]7&9*:>A<\M. 3
M@[QY]".W-6%=*1<TU+KZ\V;7EML1LL4L-6Q\C.%(7RR@!^Z&] T[S1G.0 M5
M?-HNKM*7*DFU7I^BALE0_=XE,\OD9RZ$[V-X>P9P<)"K7M8U%=M,:7GN-H@I
MGEA:'22N.6Y..3<8/;J?<MWI^NK+AH^WUWJ/KYZ-DO,8:Z0LST'0954VYS1U
M&RVNFA>'Q2<-['#H03D%;>P5591;-;146ZECJIX[?$\1ODW 0(P>N"B/5L^G
MU#4:>:_5]/'!<^*X;K,<V=B<<O%>2ZZAJ:S5ITS9)HH*F.F](J:I[-_A \FM
M:WH3T//LOC9OJ>X:OT8ZZ214E-6ODDCC:&N,;<=,C.3Y\PJ)IQE\.VC4(BJ+
M:*\4S=][X)#$1RZ-W\CXH+[I"?5L5ZN%!J:&GJ**,!U/<80(Q)Y%@/)7!<QV
MB:MU7I*KMD@CLTMKJI60R5#H9<PO)YY'$Z=2%<]3W26TZ3K+FRHI6RT]/Q1)
M+&XQ../LAV<$\AS[]T5NT6ITM-=*FQTM1?A2-KIF"1S*9CFL8",AOK$DGQ7E
MUY>ZS3VF*VZ6^CBJY*9F^YDDA: ,]>0Y^SDH+ OB=TC87F!C9)0/5:YVZ"?,
MX./@N5VS6FM[_IBCN>G[!;Y'&-SYWSN<UDC@XC=B;O9/(#F3URK#LPUW'K*B
MJ65%/Z)=:1VY44_/ YXR,_\ V%8/%H#5=YO6M]46F[LIHH[86,C9!S&<D$[Q
MYG. >:Z&N3;-/UO;0?WX_P RM]2ZJN]]U;>+1I^&BIX+5ADT];&]Y>\YY-:U
MPY<NI*(O:*DZ U?6WV\7VSW>EIX;A:9 Q[Z9Q,<@)(R >8Z+T.U+67;4-?:-
M,QTCC;L-K*JJWBQCSG#&M;@N/(YY@!2*MR+G^F-;7";7=PTGJ"DIVUT#.+%4
M4C7".1N [F'$D<B._BMP^^5]UO%=0:;%&&V]PCJJFJ:YS1(1G<:UI&2!C)SY
M(+._>#3N %V.0)P"?:N=:/U;>KGM,OMANL=)%3T$.\QD&79.\W!+CS/)W@/8
MLNF-=5C]:5>D]34]-#=8QO0RTF]PIF[N]T<20<<U3[975]%MOUA^B* UU=)
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M*ZS27B*X0OAW:F!],V-K&DC+HRWGR^\2F(NNSNOJ;IHBRUM?*9JJ>F:^20@
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MK0W>FJ:J",S26YU(T0O &2UCAZ^>N,NYK:[/-64^LM-Q7.G9PGAQBFBZ[D@
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M(/=:_P#>^[^:]R\-L_WON_FO<L>7K7CX(B+E1$1 1$0$1$!$1 1$0$1$!$1
M1$0<HF_VC(?\J_\ YEY]MW]K=!_YBS^-JL;MGA.K?Z2#4-S_ $F&E@=NQ%H9
M@C=W=W&.:R:OV?,U1<Z.MK;U<(GT;@^G9"V-HC<"#GZ.2<CNJCR[?OU67?\
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M#0 <>>#\ K32Z L=+$^")M9Z"XDFB-5(:?GVX><8\E:V,;&QK&-#6-& T#
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MSR4*4$$=4"?!$$CHB*!W02H4J /! 0=TPIZ=T$)V0(@]UL_WON_FO<O%;/\
M>>[^:]JQY>M./@B(N70B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("U=]^A#^\5M%J[Y]"'VE!M&]
MB#H$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0>6Y_49?9_-+5]1B]G\TNGU"7V#\TM?U&+W_
M )H,=SZQ^]>);&MA?+N;@'+.>:\PHYO ?%:\=R,^6;7F4X7H]#F\!\4]#F^R
M/BNNV)->?VJ"%Z?0YOLCXIZ'-X#XIVPFO-V1>GT.;P'Q3T.;P'Q3MA-><*%Z
M?0YO ?%1Z'-X#XIVPFO.B]!HYOLCXJ?0YL\VCXIVPFO,@7I]#E^R/BH%'-X#
MXA.V$UYQT*=EZ/0YOLCXJ?0YO ?%.V$UYQW4!>GT.7'T1GVH*.;P'Q3MA->=
M0O3Z'-]D?%0*.;GR'Q3MA-8%"]/H<V.@^*@4<W@/BG;":\Z=5Z!1S> ^*>AS
M> ^*=L)KSJ5G]#F\!\5/H<WV1\4[837F_-2%Z/0YO ?%/0YOLCXIVPFO-W1>
MGT.7P'Q3T.;P'Q3MA->92,]UZ/0YOLCXJ/0YOLCXIVPFO.@\5Z?0YN?JCXIZ
M'-X#XIVPFLMK_P![[OYKW+R4C#3[_%Y;V,8YK/QF>)^"RY>M./C(B^.*SQ_!
M.,SQ_!<J^T7QQ6>*<5GB@^T6/C,\2G&9XGX(,B+XXK/%.*WS^"#[1?'%9XIQ
M6>*#[18^,SQ_!3QF>*#[1?'%;Y_!.*SQ/P0?:+'QF>*GBL\?P0?:+'QF>*GC
M,\2@^T6/C,\3\$XS/$_!!D1?'%;XGX*.,SQ/P09$7QQ6>)^"<5GB@^T7QQ6>
M*<5GB@^T7QQ6>)^"<5GB?@@^T7QQ6>*<5OB@^T7QQ6>)3BL\?P0?:+XXK/%.
M*SQ_!!]HL?&9XGX*>,SQ0?:+XXK/'\$XK/%!]HOCBL\3\$XS/%!]HOCC,\4X
MK/$_!!]HOCBM\2G&9XH/M%\<5GB4XS/%!]HOCBL\4XS/'\$'VB^.*WQ/P3BL
M\4'VB^!,SQ3BL\4'VB^.*SQ4<9GB?@@R(L?&9XGX*>*SQ/P0?:+XXK/$IQF>
M)^"#[1?'%9CJG&9XGX(/M%\<5F.JCC,\3\$&1%\<5GB?@G&9X_@@^T7QQ6^*
M<5OB4'VB^.*SQ3C,\3\$'VB^.*SQ3BL\3\$'VBQ\9GB?@IXK/'\$'VB^.,SQ
M3BL\4'VB^.*SQ4<9GB4&1%\<5GC^"<5GB@^T7QQ6>)^"<5GB@^T7QQ6>*CC,
M\3\$&1%\<9GBG%;Y_!!]K5WWZ$/[Q6QXK/'\%X+HPU#8Q&,[IR4&R;T"+&)6
MXZJ>,SQ0?:+XXK/%1QF>)^"#(BQ\9GB?@IXK?$_!!]HL?&9XGX*1*SQ0?:+X
MXK/%!*SQ0?:+'QF>)^"GC,\_@@^T7QQ6>/X)Q6>*#[1?'%;XIQ6>*#[1?'&9
MXGX)Q6>)0?:+XXK/$_!.*SQ/P0?:+'QF>)^"GBL\?P0?:+XXK/%.*SQ/P0?:
M+'QF>*GC,\4'VB^.*SQ/P3BM\3\$'VB^.,SQ3BL\4'VBQ\9GC^"GC,\3\$'V
MB^.*SQ/P3BL\3\$'VBQ\9GBI$K#W_!!]HOCBL\4XK/%!]HL?&9XGX)QF>)^"
M#(BQ\9GB?@IXK?$_!!]HL?&9XGX*>*WQ0?:+'QF>)^"GBL\4'VBQ\9GB?@IX
MK/$_!!]HOCC,\?P3BL\4'VB^.*WS3BL\?P0?:+'QF>)^"GBL\4'VB^.*SQ/P
M3BL\3\$'VB^.*SQ4<9GB?@@R(OCBL\_@G%9XGX(/M%\<5GBG%;XE!]HOCC,\
M?P4<9GB@R(OCBM\_@G%;XH/M%\<5GC^"<5GB@^T7QQ6>*<5GB4'VB^.*SQ4<
M9GB@R(OCC,\4XK/%!]HOCBL\2HXS/%!D1?'%9X_@HXS/%!D1?'&9X_@G%9XH
M/M%\<5GBG%9X_@@^T7QQ6>*<5OB?@@^T7QQ6>)3BL\3\$&"Y_49?9_-+7]1B
M]G\U\W*1IHI0#SQ_-?5K^HQ>S^:#ZKG%L!+20<]05KQ-+_>/^*]]P^KGVK6!
M:\/&?+UD$TN/ZQ__ (DXTG]X_P"*QA%W,<UD$\O>1_Q3C2_WC_\ Q+&%*3"O
ML32X_K'_ !*<:7^\?\5C4I,*^Q-+_>/_ /$4XTH_WCS[RL?1 DQ:R<:4_P"\
M?_XDX\@_WC__ !+XZJ!T*3"LG&E_O'_%.-+_ 'C_ (K'V4^U(E?8FE_O'_$I
MQI?[Q_\ XBL?BB0K)QI?[Q__ (DXTN/ZQ_Q*^%"0K)QY<?UC_BIXTO\ >.^*
MQ!2DPK[XTO\ >/\ _$G&ES_6/^)6/HGM2#)QI?[Q_P 4X\G]X_XE?')1A)BL
M@FEQ_6/^*<:7^\?\5\!$F)7WQI?[Q_Q3CR_WC_BL8Y]T2*R\>3^\?\5'&E_O
M'_%8QW4]$F%??&E_O'_$IQI>O$?\5C[I[4F%9.-+_>/^*<:7']8_XK'T4I,2
MMK3>O PO]8^)YK+N-^R/@L5%]68LRPWUKGB-QOV1\$W&_9'P4HHJ-QOV1\$W
M&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;
M]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W6_9'P4H@C<;]D?!-QOV1\%
M*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<
M;]D?!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3=;]D?!2B"-QO
MV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4
MH@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-UOV1\$W&_9'P4H@C<;]D?!-Q
MOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_
M9'P3<;]D?!2B"-UOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2
MB"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W6_9'P3<;]D?!2B"-QOV1\$W&
M_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;]
MD?!-QOV1\%*((W&_9'P3<;]D?!2B"-UOV1\$W&_9'P4H@C<;]D?!-QOV1\%*
M((W&_9'P6MO!,;(N&2W).=WDMFM9??ZN']XH-B&MP/5'P4[C?LCX*6] B"-Q
MOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P
M4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C=;]D?!-
MQOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&
M_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!
M2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W
M&_9'P4H@C<;]D?!-UOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;
M]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-QOV1\$W6_9'P4H@C<;]D?!-QOV1\%
M*((W&_9'P3<;]D?!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<
M;]D?!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%*((W&_9'P3<;]D?!2B"-UO
MV1\$W&_9'P4H@C<;]D?!-QOV6_!2B"-QOV1\$W&_9'P4H@C<;]D?!-QOV1\%
M*((W&_9'P3<;]D?!2B"-QOV1\$W6_9'P4H@C<;]D?!-QOV1\%*((W6_9'P3=
M;]D?!2B"-QOV1\$W&_9'P4H@\ET:!0RD 9P.WFIM7U&+W_FET^H2X\!^:6OZ
MC%[/YH)N'U<^T+6CNME</J_O"U@[^*VX>,^7J?$J/-$'1=.1$Z%,("*4\T$!
M2H'-!TY("E.APHZ("=DYH@(B802H_-$"!T3MYIR4CKV00.G-3V4<T03R\4"!
M._5!&.:<PG=$! @Y*4$>U2% _%!T0$0#*=$#'BB!.HYH-M1?5F+,L-%]68LR
MPWUKG@B(HHB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MC=:<E7?:+M$N6C;C34\ENI*EE1%Q&N$K@1CD0>7BI?\ %=)IC(ZGB=.T-F+
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M?D@TFA1_\;M<?\*+\F+'K7]?>BO\-)^4BW5DT'=+7K"NU"W4<<E17$"IA-
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M_5M//.'$'F/' &4'3+5+336ZG?0-:RD+!P@UNZW<[8'88Z*G[;OU:7G]QO\
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M-TIZ*9M1%"RE; '2M^BYY!.<9/(8"\6T?0=3K62C:^]>A4M(_B1Q,I=]V_\
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M<3S(YC&?#HK9IW2D6F[)/26>I=Z?,=^2NJVF9\C^F\X9&>7( $ ?'(4;8/\
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M+8H@UE1IZSU%+34T]JH9*>F.]!$Z!I;$?%HQR7JK[?1W&D=2U]+!4TSNL4K
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MR]=\4D8=\<+;M:&-#6@-:!@ # "J--#I33\+BZ*RVYA)R=VG8,GX+=    #
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MH(KQ32&%[*ASHXGN'<$ GW>/=5/3FMM<:MTC55VGZ&C],BJ7!SG@!I9AN(V
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MM%:GM5-?JZENEGN3C&V>.$120.! )(!((]8*0=21%6]4:B_1]PM]GH3$Z[7
MGA"7Z$48YND=X@ <AW/)!9$7+-8:NO>@ZZW55TKZ6\6:JDX4HC@$,L)YG(P3
MD8\?#'FO7M4UE>M-T5!5VFGHW4-5*QC9R\ODP1GZ! 'XGW*P=(1<KUOJ'7%G
MLW](H8;;3VR'=,E"[,DQ878!<[& 3D$@'EYK;ZOUA<J/9]%J6QTM')"ZG9-)
MZ1([>9OX')H&"03W/9(+ZBY?;+]KN[0:=N=NH*-UKJ&L]):_#9'Y WG\_HMS
MG&.?BM_+J&LO6JJ^PZ>FA@;;HVNK:Y\?%W)'?1C:W(R<!V2>F,=4@N*YCMBU
M1J+3)MCK5-1PTE74MA+^&7R]L_2]7'7MGHONIUA>-):OH;1JMU/5VRX'=I[E
M''P=QV?HO;DCERY^>?%:SY1G_9VG/\P'Y)B+?M-NUZL>E:NYV1U$/1HM^0U#
M7.=U &Z!R[]UL]#U]3<](VFMKI.+4ST[7R/W0W><>^!R"U.U_P#5C?\ _##^
M(+S:<K;A;]D]JJ[534U1/#0B0MGD+&[K6DGH#D\NG+VI\%[1<HT3JG6.L]*F
MIM;+?35)FD#JNI:>&T#&&,:,DGGS)Y>TKXT3KK5-^9<[-^C:1U^H9N%+4O=N
M0,:<C><!S)RWD!U2%=:1<VTAJG4--KV;2FL/0Y*B2F-52U-,T@2#/3'L#NN/
MH^:WM;?:FY:AK+)9*FGI'4+&NK*N9F_N.>,L8QA(!) )))P%%6Q%S.V:RNEH
MV@1Z6U)-2UK:QG$HJV!FYO9)PUS1D#Z)'M'FO)<-<:GI=J$6G1;J.5CH'21P
M0RD\3+26ETC@-T#!)Y=N_)6%=76OO]XI+%;)*ZO<6P,+6X:,ESG$  >9)7/'
MZGU7IO7-EMNJ)+?54%X?PH32,+>$_(&,G!/,CXK3_*(BKVRV)[;D\4DU6UK*
M81@-8X8]<GJ[V'HD2NUHO#9Z:NI:=S+E<!72EV1((!%@>& 2O!KF_G3&EJZ[
M-I7U3Z=K=V%O[3G.#1D]ASR5%;U%RV_7[5EBT5%JB>NHYG89)+;G4NXT-<0,
M!^=[(R.OFK#JK4MSH] MU!9Z2ED)I&U+VSRD;@<T'U0!ZV,]R.G=6%7%%RFS
MW[7.I-$4USM#;=2RB(R.FJ&Y-003D,8 0T<L9/4^7-6;9AJQ^J=),N%>QD%7
M YT52!R:'-_:\LCFD%O?O;CMS&]CEGIE<VTMJ?4%7M8O&G[S)2-I:.DXC(Z:
M/ ))86N+CEV=UW3./)>S3^H+OK8UE98:F*V6:&4Q4\\D'%?5$=78) :W\54M
MGTMQEV[ZC-YCB96MH1&_A9W7!O"#7#/3( ./-,1VM5?:%JMNE;/%-'&V:MJI
M13TT;CAI>>[O(=U:%P[;_2W!E=IU\MR$D,M>>!%Z.!P.G?/K>],%VO%'KR@K
M:2HLMTI+K#(X,J*:KA9$V+/[;2T!Q \"2?:MCHG^E8TU4?TH]%-YXC^#C&YN
M_L[VYRZYZ<\>:SU(O]HL==4"KIKO5QM,C&S,]&:UH:21ZH=D\AUQ[0M7L?U-
M7ZKTK)<;KP^/Z2^,"-NZ T8P/Q0:_9UJ:^7?6NJ;9?)J9S+<6,C93Q[K <G)
M!/K'/+J5>9[K2PW>EMCW$U=0Q\C&CLUO4GXKF>S,$[5=H0:<'BMP<9P<E:J*
MCO+MNM13"^N])%#O-G=3-<&-/[ 9G 'FD';T52NE_GBO-'INAJ8G75\'&J*N
M5@W(6#]K<R,N)Z#*K=QUE=M(ZPMMNU!6TMSM-Q]5E5'$(GPNSC!:"01G'Q\E
M(KJ*+E^M]:Z@L6M[+:HJ2C-'7.<6<)QDDE'0 Y #3G'3(&>O);[1T^LW7^XQ
MZIIZ%EN#0ZFDICD;V?HCN>7B$@N2*'N:QCGO<&M:,DDX "HUBO=VUM1U=?8:
MZ"UVQD[H::1]-QGU&[U>02 UN>@Z]>B"](N>Z/UE<:C5%=I34\,-/>8&;\,\
M/T)V8SO 'H<8./;X+S:<U)>SM:N&F;A6QU=#!2&=CN V-^<LQDCVE6#I:\%Y
MNU+:(8)*UY:)YV4\8'5SWG "HNIM07RR[2M-VIEPCGMMT>[?B=3M#F =@X=>
MRKFV>GN7]-]) 75XAFK&\"'A#=@<'-];[QY]T@[8B\=JIZNFI!'<*T5L^23*
M(A%R[#="]B@(B("(B B(@(B(/+<_J,OL'YI:OJ$7L_FET^HR^P?FEK^HQ>S^
M:";A]7/M"UOBME</J_O"UJVX>,^7J$1%TY3A.B*$#Q4_DGO1 \5Q7Y2WU2P?
MOS?DQ=I5#VEZ$JM:R4;?TI%24]+O%C?1R]Q+L9R=X> [)OBXKVH?]G^A_P +
M M;LPC:W8OJB0- D<:@.=CF0(FX'XGXJYUVB+A5Z!@TRZZTX;%NL](%,<EC>
M@W=_KYY7FT]H"XV72%UL,5XIY(:W>(D=2D%F\T-=^WSY *05?Y-7T;[[8O\
MJ6KV$5Y=KZZ-K"'553$\[SCSW@[)70MFF@:G1=15N_2D59!4AN\ST<L((S@@
M[Q\5I-2[+*YFIVWS1M?!0U/$XW#FR&M?W((!R#SR",<U(.E4-DM=!7SUM'04
MT%7.,22QQ@.<"<\S[@N"VO\ V@C_ (Z3^!R[38+;>XG>DW^Z1554(RR.*GB,
M<+">YYY<>7?'D%3:?9A<8=9_TD%]I_2^.9]ST,[O/(Q]/P*IBJ?*#.=:6;_#
M-_YCEF^4-]5TQ_P9/R8KEM4V?56KI:*MMU5!#74S>&1+D,<W).<@$CF?#NO!
MJ39G=]44=M_3.H(154K"S$=-F, XZ<P<\N9/7R4AC9RZ=&J-D5IMO&$,SJ2!
M\+G' WPT8!\NJY?9]07S9_7.L>IJ0U-J>X!T$OK-#<_2C/AT./R*[#/IBZ?T
M.M]HI;G"RMHGQ&*K$1;NAG0[N3DX[9YK2ZET5?M736ZGU#/:V4=(XN?-3!W%
ME![8(PWIV)5ABM_*1D;+2Z:DC(+'\=S3X@B-:S:O)*W9UHV-I(A=&2X>)#1C
M\RNA;1=G]1K!U"P7.&CI:)KA$ST<O/K8SD[P^R.R]=7H9MST-%I^[U4<TD
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M(B B(@(B("(B B(@(B("UE\^A#^\5LUK+Y]"']XH-F.@1&] B B(@(B("(B
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M;=H>-238WFY(((.001T(*BN4[3;3##LMJKE=KE)<+I4,B>V267# 7.;RC9T
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MFM;I'1E%I2AGH[/65[*:4EVY(]KPUY&-YN6\CR'EY(*9LQ_6OM!_XS/S*4Q
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M3A^^QDI)W6!W<\L^0*[&FF"(BBB(B B(@(B("(B B(@(B("(B B(@(B("(B
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M6:Z[.J+]+T4=6:DF4N<YP<,.( #@01CGT\5J_E%PQTVG;%!"P,BCF<UK6CD
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M:MJI1#3"-Q+Y!N[H.\!G/3J%O]L-Q@J]&S6:WR1U5RNSF04T,1WR[UP2[ [
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M#!!Y'LL6LMH=%I>]6ZW5=#5O=62!G'(W8V@G!.3UQG. $%V142V[0GUEZN-
M[3EWB%+!Z0QY8"96Y&,#/+.\#U\<X7GL&T^#4%JFJK+9+A5U#93&VE86[VZ
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M:YK=,"CJF5-- )S.YHX;@<=/_$/Q069$1 1%7M;:LI-(VE]?74U9/&WM!%O
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MN]CEG'Q7MNVF7Q:'DTYIOT:EADIW4I=.'.PQS2USN75W/J4&EV!,#=F=NPT
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M3.I'.,CHVL ^ER ;T'Q6[O\ L[N3]3T6H--WH6^XQ4[*:7B1[['M:W=Z8YY
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M21QF&*<MD&&G/5O<\U\[.=+7W1^G9+2:BV53&ETD+\2-.^XCD[RZ]/)!H]C
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M95BVF7^Z1;/!=;&^&&*>%CI9"X\1C7[H 9RQGUCDDC&.7E3/E%_U6GO^&_\
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M5UGJ+A;*6K8R&1T1BG#6O<X ' PXCOW*Q:9UI27Z_P!TL\=#74E;;@#,*AK
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MT% S:51U[FBPTU6Z/F<#<!E:<?\ =#4%X_TD4+[1/=Z>TW>>T0N(=6,B9N$
MX+@"\.+?/"M5CNM)>[337*W2<2EJ&;['8P<>8\5S&:2MJMFE8-.TL-KTQ'12
M<(U ,D\[,'F!G#0?$Y/DMYL#_579O;/_ ,YZ#0?)Y^EJ_P#S(_\ 4KM)K6D?
M=ZZVVN@K[I44./2#2M86QDY]7+G#GR/(*D_)Y^EK#_,C_P!2VVGIH9+S?X-
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M:S>M/7&V"3A&K@?"'_9R,945SJT2MBV?W&WZ-HGRV"*FJ!^D:^3^M]4[Q8P
M%W?GR')>WY.Q)V:4V3TJ)OXEXM)6#7-/I=^F*QEJHJ"*%\#*P.,DDC79Y  X
M'7J1[BMKL8T]?],Z??;KXRDB@CE>Z)D;M][MXY))!P!X#KXJICH:XC3W;4>R
MJIK*>Y6M]TTW-4NFBK(G>O'O')WNOP./:NW*@:6?JNVV1EKO-@CKVL:6,ECJ
MX\.9SPUX<>H'+(RF*]VGZRSW'9W53Z?<76Y\%00QPP6..\7-([<R57_DW_JY
M'^,E_)JV&F=*5FD- 5]NHJ=M=<:Q\LKHHGM8QKGMW0 7$>J &^:\>R*UZ@TC
MI.HMESLDCYV2NFB,-3$1)G=&[S=R/(GPP/'DB-5\GVCI^-JNIX+..RXOC:_'
M-K>?(>"^M#Q,IMO.KXH6AD;Z<2. [N)82?B2O?LELNH-,.O;+M9G!M=4NJF/
MBJ8G <CZI&]G)Y#/GV6+3%EU'1[4KOJ*ML;HZ*X1\%H;51.=& 6X)&]X-[?B
M@PT\SM-[=KG57QPBH[Q2".CJ'G#,L#,MSV^B>OEXKY?3.OFWNDN=DD$M!0T0
M;65$9RPO]<;F\.1/K,Y>2:C.KI-H-YJ=-4]NO%-!#%!P*D\J;+=XM&2!O$C)
MQGJU(=8:YL+1/?=(TS+4SG,ZB^DQO=V,D=$#Y1G_ &;IS_,!^2]NU^NJ8[]H
M6W4\T<,=57F1SI6ES-]FYN;S01D9?G&1T4;8[%?M51VF"Q6OC14LPJ7323QL
M#N0PT G/Q"W.OM(R:\TI!!/&ZV7.!_&@,CFOW'@$8):3ZI\O (,.L]'7S5UD
M=:[I=[6R!SVR;\%O>'@CP)E/Y*VZ:M\EJL%!0351JY*:%L1G(P7X&,XR5SBP
MT6U-\++7<:FW4U,!NNN!Q)-N^0!P7>9"ZA;***VV^GHZ?>X,# QN\<G \451
M]O;0[9?=LC.'1$>7SC5[M$6"V5.SN@I)J.$Q5=*#-EH)<7-P3D]UXMO/ZK[O
M[8O^8U?.CJW44>A[734MHAFG-(T158J&MA&1ZI<T^MRY9 !Z)\17?D[&>D?J
MBTN<74M%6%L>3T.2#_"%Z]A/_:>N?\U=_$]6W1VF_P"AVG)XZ>-UPN4SW5%0
MYA#3/*X\\%Q  'GV59V5V+4%CN.H&WJT&&"[5+J@31U,;^%G>." <]QTR@].
ME#26ZZWVET/2RW&26L+Z^JJIPV&&4Y]5I#<NQX#/F5I]@!>RIUJ)-TO;</6#
M!@9R_./)9]%:<UMI6LN-KH8K6^UU%0Z:.NG>7%F<]6 @DXQR\3U7JV7Z3U'I
MC4>H!6&E-JK*DS-F<=Z6;F[& .3<AV3GW(/G8?6BZ5.K:^H>77"6XD2!QR6,
M&=QOL',>Y6RW:+M5NUG6ZFIW5(N%;&8I&%XX?/=)(&,Y]4=U1;MHC5&F-755
M\V?R034]<\OJ:&=X:W>))/7 (R>7/(5TTG;=02UGZ4U=/2^E-C,=/24H/#@#
MB-XDG.\XX SV&?%!2MB]3?[SIVX7"CN%MBDJ+A+).VII'ROWR&_M"1O+&,#"
ML.E=!5=FUS7ZCJ;M#*^N8X2TT%.8F$G',9<>F/Q5:KM#:MTIJJMNN@)J::CK
MGF26BG(:UIR3C!(&.9P01CHKQI&TWQ]7^E]75,#[CN&*&FI1B*!IZ^UQP,G*
M"B;(*&FJ=I.O9JB".62&J:(R\9W<ODSCX!8MIULBLFU31]WL\;8:NKJ6PRL8
M,"3+@TG'FUQ"WMJTSJ+2&L+Y=+124UXH;O())(C,(98B"XC!=R/TBMS2:8KK
MQJ^EU)J1L,#J%I914$3M\19SE[W="[PQR')!6],W%]WV_7]M8T?^[:$PTK"/
MHC>9EP\SO'W%??RCJ)ITC1W2(!M;0U;#'(.H!S_, ^Y;35>C;C%K.GU=I1U.
M+BQG#JJ64[K:EN,=>SL8Z^ 7HOUDNNMX:&DO="RTVR"=M1/'Z0V62<M!PT;H
MP&\SDDY\D%KTW535NGK9550(GFIHY) ?M%H)7-]O5?PYM(VR=Q905EPWZAV<
M AA: T^1WR?<NL1L;&QK(VAK&@  =  JGM+T7!K6PBC?+P*N!_%IYL?1=C&#
MY'O[ F*V>KM-4.J;'+:KEQ6TSRUV87!KFD=",@C\%R_;5(VUT>C=.0/<;4^H
M:)"X[Q>UA:UH)[_2.5L[#2[4>!%::^2VP4K!PW7)Q$DI8.60 >;L=R/:M_KO
M9]2:DTK26NFD%-4T.#25#ADL(&"#Y'EGV)G^(M%^ME/=['6VZJ:#!40NB/+I
MD$9'F.JX[LJK:JKV):DI:L%T-&RIAA>>F[P]XM]Q)^*OE%4ZT?9G6ZIM=)'<
M1$8A<?2FF$G&!)N ;V>^,+'-IB73VS>;3NGJ*2OFE@DB+S(R/+W@Y>XN(\>V
M>@"#P?)_HZ>+9O1RLB8)9WR&1V.;L.(&?):CY.X$3=64T8W88KB=QOAU'Y +
M?;+Z*^:9T4RUW"R2NJJ7>+.'4Q%LN\[. =[EC/?_ .B\&QZP7_3==>VWJT\&
M.XU'I#965$;PSZ1P0#GN.@*#S[(?[=ZZ_P 6/S*\4])#4_*3''C#Q'1-D:#T
MWA'R*VUFTQJ:Q:\OM1;643K3=7\8U,CLOB^Z&YYNZCPZ>Q>1UDU,W:X-41V-
M[J#@"G<QU5#Q"-S=WL;V.O/&4'UMX?%I_04T-JIXJ5MSJVLJ7Q-W2X8+CT[G
M='X^*Z+8::G.F+=3-C:ZE-)&P,(Y%NX!C'L7DUOIFFU=INHM=9\V9,/CDQDQ
M/'1P_$>PE:'2@U?8K3#9JVUTUQ-*T105[*IL;',')N^TC>Y#'0'*?!6=@;9K
M;?-9V)F^^@H:S$3G'Z/K/;CWAH/N7IV+_P!LM?\ ^/'\3U;M&Z:=I2TU\QWK
MA=ZZ5U55NC(;Q93DD-WL #).,JM;,;)J&QZGU#57:SF*FNU1QFO94QOX7-QP
MX!V3]+ME!U%<[8;?;-?WA^FZ:HNFH:N-AK(W3!D%,W/(EV.1/AS/+LNB+D]#
MIC5VF=<WFNT_#;JV@NSP]\E5(6F'!.,@<SC)Z9Y)BO#L\])&W#5PK>$*@PL,
M@ASN9PSIE>FJI8:CY1D)EC#N';A(T'IO .P5EL6D=66K:A<;T9*">CKHV\>H
M(P3@-RUC,Y!R,#/+&#E?4UKU-_I89J>.P/- *;T9T9JH>(1@^L!O8ZGIE$;K
M:G;*&@V9ZF]#I((.+%Q'[C -YV\WF?/D%GV8VZD&S&TQB!F[4T+3-RR7DMYY
M6;:A1W2[:/KK59[<:FHK8Q'O.F8QL8R"2<GG[EBT6V]6?0]';JRQ3&NHH&P!
MD=1"6RXY9!WN7;.?=E/@J'R9:6#^B=95&)IJ?271"0CU@W#3C/AE?6SMH@VV
MZUAA&Y$6;Y8.0WMYISCWGXKW[%K%?](V:LMMXM#@'RNGCEBJ(G ^J!NXWLY.
M.O3V+'H^QZCM^TZ]7ZNLICH;F-P;M3$YT0R,%PWN?3GA!U9<@NO^T?;/\N__
M )UU]<PUII?40VE6S5&FX:2J#*?T:6*HDW SF[UO,8=VY\DQ7CUC7OJ]N&E[
M54@^ATT9J&#LZ0YP?=NA6C;#;*>Y;.[T*A@<ZG@=41N[M<P9R%X-<:'K[TZS
MWBWU=/%J6V.$@D+"V*;GG</<#/(>1*]%V@U-JBPRV>MM=/:6U+1%55)J6R@L
M/TN&UN3DC.-[&,]T1ZMD%=4W'9Q8ZFM+G3NB<TN=U(:]S6GX +/M1:UVSZ_;
MP!_U5W4+?6>W4]IM=+;Z)FY34\8C8WR"TFT>FN-PTG7VZT4)JZFKC,0^=8QK
M,]R7$?AE%:38C0TS=F5L(A9O5,;^*<<W^LX<_<J]\GJ@I6?TEF; SC0W!\,;
MR.;6> \.@5GV;TU[T[HBFMEPLDQJZ-I#1'41$2Y<3R.]RP#SS^*U6R6S:@TS
M->8KM9G-BKJIU4R6.IB=N9!]4C>S[PB/#IL"#Y0NHXX1PV24;7/:WD''##DK
M-J-H'RA]-$  NMKR3CK_ %RFT6;4E/M:KM2S6)S;?5Q"#=%5$7L&&C>(WL?L
M] 5]WNTZDJ=K%LU)!8G.M]# ZF+?2H@^0'?]8 NP/I]"@\&V6FAJMHFA8:A@
M?')*]KFGN-YO)>OY1L$3=#T+FL:TPUT8CP,;OJN&![E][0K+J.\ZUT_<K=9'
M/I+3(7.+ZJ)IER1]$;W+IW7HVP6F_P"J]/TMMM-E?O<5E1(^:HB:&X!]7Z1R
M>?7I[4P;#;!\YLHNCG@.)@8[F.^0O/:6AVP-H(!Q89",C_\ (N677E'?;[L_
MDM5%9)&UU2P1N;)41!L8:1S)WN>>V/?A8J&AO\&R@V%UD?\ I(41H !4Q;AW
MF.;Q,[W0<N77F@P?)]HJ>/9U33-B;Q9WO$CR,EP#C@'RZ\O-:C87;Z6.^ZM>
MV"/?@K7,B)&=P$]!X=E8-E=!?-,:-%LN=EE-33N<YG"J(G"4$] =[D>9Z\N7
MN7AV7V;46G[U?)+I97,I[E4&=KXZF)QCZ\G#>_)!K[<T0?*/N+(?FVRT37/:
MWD''AM.3[U]ZX _T^:*.!GT=W/\ _BK+3674K=KTNIY+&YMNEB$&YZ5$9&C=
M#=[&]CMTROO5MEU)7[4;)J"BLADH+8SAD.J8FOE!+LEHWN7)W+/AV0= NK[;
M9!77^N<(N' &2RD_L-)( 'M*YEL]MM9KO53];:@A,=% 2RUTSNF ?I^[\3S[
M+W;4+-JG55?0T,%K=_1V,LEJ&,JHV2S.QDM.78 !Y=^?-6":NU'!9G45FTD:
M1S(N%!FMAW(AC Y YY(*WJ6LKJG;E:;?2U-- ZGM[Y:<U$1E9ONSO>J'-Y[H
M//*V&MM WG5QM[[E?*"GDH)#+#+2T+V.!Y=S*? %8]H^S^X:@IK3<[16^C:B
MMT30)"<<4X'[78YSS\U%GMVT"^!M#JZ2WT5J;@3FFPZ6J:.K<@D-#NYY'P0=
M-8"&-#G;S@.9QC)4HT!K0&C  P BBB(B#RW3ZC+[!^:6OZC%[/YI<_J,OL'Y
MI:_J,7L_F@FX?5_>%K.ZV=P^K^\+6+;_ ,_&?+T\?%.@.$4]ETY0I4*1S0%'
M9%*"!R0)[^:=\E!/FOB:5D,4DLK@R-C2YSG<@ .I*^U5MJ$LL.@+X^GSO^CN
M:<#G@\C^&4&GM&T2:_7&NCT[8IJ^AH\<2I](;&7?NM(YGETR%RW9;,VHVQNF
M8'!DDU2\!PP<$./,=E=ODW;O]&[J!C>]+'MQN!4[9M^NN?\ Q%5_UKET[-K'
M65'IN6DI3#)67.K<&P4D1PYV3@$D\@,\EX[9KG>U,VPWZVFU7"1@=#F<2LDS
MSP' #FN5[1JFI=MNIVOJ74HAEIF03;@/#:0T[P!Y'UG.ZKH=?LWFN=]HKO<]
M1U5354KF.8X4\<?)KLX]7"J1LKSK<4^J6:>LUO%RN6YOR--0(6QC&<9(.3CG
M@+VZ<U-47B:[TTMHFHZNWEC'0R2@EY<">1Z8Y<CW7.-JVB[I#?IM4Z7E>^1A
M#IXX79EB>!C> [C&,CKSZ86_V-ZT?J8UT%SAC;=X(V&29K<&=@)&2.Q!./>G
MT>[3NTFAN^J7606NJIJX/?&]TA80US,@@D$^"RZBVB4]OU)#8;30ONMU>[<,
M;)1&UAQG!<0>>.O@N8:%_7G7?XVK_C<MA=K54Z0VQTUZJX9I[=4SRS-?"WB.
MPYI#LM'/D7#LE(NDFTJ6FOPLE;IVICNI(#8HZF-S7YZ8<XM!7NUEM CTDVB=
M<[36%M4S+2Q[#NN'5IY]1D>2I-1:ZS6NUFEO%NI:JGM5$Z)SJFHB=$).&[.&
M@C)SX?%??RE?JUB_?E_)J4;Z[[56T=FI+O1V"KJ;;.6L=.^41-8\C)8.1+B,
M=>F<C*O&F+W3:BLM-<Z+>$4PSNNZM/<%<DULUK-@E@#!@?ZN>7B6N)5NV$?J
M^I_^-)^:8.@HBE5$)SPB( YY3"*4 ?!1V*E$#OR4(,*4&UHOJS%F6&B^K,69
M8;ZUSP1$441$0$1$!$1 1$0$1$!$1 1$0$/(<T0@$$'F"@U U-93=!;FW.E?
M6[CI#&QX=NM;U+B.3??A>.U:XTU=;JZVV^\4T]:"0(VDC>Q]DD8=[B5SFLL5
MMEV^QT1I8V4;[:'OAC&XUY];J!UZ#VX6/;-::&FUGHJ6DIV4[YJMD$A@'#WF
M%[1CU<=B>?FK$=)FUUIB&[MM<E[HA6D[NYOY /@7?1!\B<K>5U;34%')55M1
M%!31C>?+(X-:![2N8;<=.VBBV85<E';Z>&6D?"Z%[&8<TF1K3SZGD3U6SU1;
M[?>]FMF?J*ZR4-,R*FJ)9&X)E=N [N.Y)/0=T%AI-;Z=JJJ*F9<V1RS?U7'C
M?")/W7/ #O<5DU)K"QZ:DC;?*UU)Q/HN=!(YI\MYK2,\NF5RO;9<JJYZ8L]4
M+2^WT3*^,0/J"&S.Y.QA@^BW [G/3DNEZ_TS'JW2%1;9/ZXM$L+OLR <C^)'
MO0;F@NU)<+4VXTCII*1S2]KN!('.;XAI&\?+ Y]EYM/:EM6H?2/T1423B!V[
M(3!)&&N\,N:.?EV5%T%K=QV55-55,_\ >EF8:.2G=ZKW2- ;&".V>0]H/@KI
MH:QMT_IJDH2/G\&6=V<[TKCEQ^)16^5:J==:;II96271A$3^'))'&]\;'<N3
MGM!:.HZE;VXPMJ+?4P/E="V2)S#*TX+ 01O ]B.JY9;74M#LZN5ATO32W:@I
MZ>H$USJ (X'DY<[=/,O(SCD,<AS3!U!ERH7VX5[*VF=0EN\*@2MX>/'>SC"U
M?],M._HR>X"[TAHH9#"^8.]4O&#AOVNO;*J.P:&.MV6TL%9&R>'BRMX<C0YN
M-[.,'S*T_P GJT4%7IJMJ*JECGDCKI6,XHW@P8;G /(>U(CI-JU=8;K:9KG0
MW6EDH821+*YVYP_W@[!'OZKXT]K'3^HJB:GLUUIZF>+Z48RUWM < 2/,9"YA
MHVP6R7;+JV@DI(S00!D\=-SX8?ZOK;O0_2/7ES7KU%04MJV\Z6?;H(Z<U=._
MBB-H:'<GCH/()!TN?4]D@ND%MDNE+Z=,7!D+9 YWJ@DYQ]'D#S..B\-#KS3%
M?=_T71WJEEK<[H8"<./@'8W3[BN=:[L=NGVW:5I'4K&4]732<=L7J<3E+UQC
MKT/B%FVWZ'M%%H]][LU)'05UM=&YKH!N[S2X-P?,9!!\D@L.WR*-^S>X/<QI
M>UT>'$<QZRWVD:FEI= 622OFAAI_08@YTS@UN-P=<JG;3*Z6Z;"X*^IY3U-+
M332<L>LX G\2K19*.FK=F%MCK((IXQ;&$-D:' 'A=>:?![-*U.G*73<D^FN$
MVT0O>7&GC<X;P^D0,9=[L^2YS:M7T,^V.Z5M5+4FCAHFPTY]%E<6C.3Z@;O#
MF3S(6]^3M^K>#_$2?R7BTM^OG4W^%9_)!O)]4:&LVHY*N:04EYK&-:YQI)VO
ME;^S@;O/MT5OK[M24%J=<JMTL=&U@D<[@O+FM/<M WAYY'+NJ1MMTXZYZ:%W
MH(V_I6T.%5$_',M:<N;Y],^Y?-TU5_239Y;OT1,&W"^%M$W R8WG^MR/)H<?
M9A!=K#>J&_4 K;5*^:E<2ULCHGQAWF-X#(\QRZ^"SW*XT5KI75-RJX*6!O62
M9X8/B5]6^DBH*&GI*=H;#!&V-@\@,*L;6Z2GJMGUZ-1#'(8Z<O87-R6G(Y@]
ME%9JW:#I:BM])6U-YIV4]7DPNPXEX!()W0,XR#S(PM];ZZBN]"RIH*B"KI)1
MR?&X/:5S;9'I*QW'9M;)Z^W0U,U5"]LCY<N.-]P 'V1[%I]AXGLVN=6::8][
MK?22.?$TY.Z0_ Z^(Q\%8C8[,&-CVM[06QM:UO$C.&C ZE=!N^J+-::IM+75
MK15%N]P(HW2R!OB6L!('F0J!LT_6]M!_?C_,K943+?I_6][EM3JR]WRY.:Z6
MGCW=RD:"<![^C1Y'G@=$%VLE\ME\IS-:*Z"K8WD[ANRYA\'-ZM/+H0$NU[MM
MH#?TC61PO=S9'S=(_P#=8,N/N"YAL?XK-I&OF3QQ0R<6-SXH3EC7;S\X.!^2
MV&R>M;?M6:QN]6=^KBJ_1(0_&]# TNW6CPSSSXX2"]V+45IOS93::Z*H=$<2
M1C+7L/WF.PX>\+[O%]MUG#/TA4B-[_HQM:Z21P\0QH+B//"T='H:EH]H%7JJ
M"LJ&S5,>Y)3 #AD[H&?'L#[55=!7"]WC4.J[C1-MTDK*TTH-4]X='&T>JQNZ
M,8[^W**Z'8=0VG4$,DEHKH:IK#NR-;D.8?!S3@CWA<NTK44ELVXZTGJ98*2E
MCI6ESWN#&-SP^IZ=5O+)H>]4FTF34\M7;Z>GJ&EM124N_A_JXSS [X*KMAM%
M#=]O&K8KE VHACA9((W_ $2X"/!([XSW1'3=/:RT]J*9\-FNU-4S,ZQ@EKCY
M@.P2/,+;7"OI+=3&HKZF*GA!QORN#1GL.??R7%=LNGZ/2=TT]J;3L#:.J%:V
M"2.$8;)D$CE[ X'VK>7>Y.NVW:VV:JYT5NIS41QGZ+Y2W(=CN0#R]B07>WZR
ML%?7BB@N4;:HC+8IF.A+_P!W? WO=E6!<UV^VB&MT+-7AN[6VY[9X9F\G-YX
M(SX'\P%:] 7.>\Z+LUPK/K,],UTAQC>=T)QYXS[T5O9'LCC<^1S6,:,N<XX
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M*;_LYBH3=A:H701.EJ",C< !(/,<C[5SS:W66^79] ZP6>3T2CEAX5T$386
M@X]0'#SGQ QYK>;4[===1[,[8RRT=<Z2G?$ZHHGP/CD> W&[N$ G!P>7@O)M
M*K+]K#9[-#;=*7*DC8^)SXZEA;,2#TCB )<!XG'+LF#;;6+]66[0MDIZ2H?!
M4766&F?.TX<UA;EQ!['I\2M_J/05KO.CG66EAIZ([K3#.V$.<QX_:\23SR<Y
MYK0ZMTQ7Z\V9T=.^B?;;C3".6GBJ'>L7-9ND. ^CG)QWZ9QT7BTSK;6D5!!:
M:S1-PFN<0$/I<A=% ['(.<XM(^!.4'IU]-<=.Z4TOI]E6ZLFJZB.CGG>XQ&9
MC1DC>YEN< $\^65\:YTI=]2:?;;Z72]IM\\3VO@J(ZT9B(\,1C\UL=HVB[GJ
M#1%'#3U>]?Z*453)"X@/DY[[6D_1'/E^Z![-1I[7>N9:>"W5>B*Q]Q ##63%
MT,)[;SLLQ[@>:##M;@N5+L3I:>^2-EN,3X63/:[>WB,C.>Y5AFV8:=O-B;Z=
M3OEKZB%KG5SWDRAV.1SGD/NCDHVEZ7NUYV:FUT\HKKFQS)7N<=WB$$EV[\>0
M\%Z*#6-:;)'#!I:_-NC(VQ-AFI2R/?QC)D/J[OF@H6@]87&R[)M2B>5TE=9Y
MG4M,]YWMTD8;U[-()Q[%T#9O9+?5:!MSZZE@K)JZ'C54T[ ]\SG$DEQ/,]>7
MA@+Q6#9T:?9O<+!<:AKJZY%\\\S>8;,X#!'B!@>U>79S=;KIBQ1:?U'8KJ9J
M'+(:FDIG3Q3,R2/6:.1&<<_!#&LV832Z=VG:DTC')(ZUL'I%)&XEPB^B<#P&
M'8]H78E1M$:?J6ZJOVJKE"ZFGN1;%!3/^G%"W R[P+MT''97E-7'(M%76Z:B
MNVH+I^A*.Z/BK74D3JFJ$? C:!ZC6ECN1YDGN2O3H_2>HK1M%K+M%2T5ML-<
M#QZ&&HX@WMWD0-T#.]SY8ZE:2IHM4[.=:W*ML-HJ+UI^XO,IIJ<.)8X\R2 #
M@@YYX.1^%[TI<=0ZCKH;A<[9-8;?3@[E)(\F6H<1C+Q@;K1V&.OL1%3US30-
MVX:*8V"(,?%)O-#!@_3ZA=(U-24W]&KFWT>'=92S%HW!ZIW#T7--:35=3M>T
MS<J6S7F:@M[3'/.R@E+027#(]7F!D+H>JKDP:5KGPTMPJ'ST\D<<4-'*Z0N(
M+>;=W(Z]\(*IL$@@&S>AG,,9E:^0[^Z-[Z7BM=H*XW6_/O%Y_05'='R5LL$<
MU36!ABC;C=C:WANP!G/F5M-AQGH=%4UKN5ON-'61R/WF5-')&""<YWBW'XJJ
M14VK-F>JKH^T66HOMAN$IF;%3-<2PDD]@2",XZ8*"Q:!TGJ"Q:\N=P=3TM!8
M*YKB:&&I,C8Y.1! W0.H/N.%&QR5FK8;QJ6[MCJZR2M?3P<1N\((6M:0UH/3
M.]SQU5AT?<-17^N%QO%M?9+?$QS(J)[RZ65QQZ[^0P ,X'B?(+GEMH-2[*]3
MU[;99JN_6"X.XH;2L<Y\9R<9P#@C./ C'-!?],:&_0&K;Q=*6O\ _=MP&?T<
MV+=8QW+)ZX/?MW58TE2T[MNFK(W01&-M&S=86# YL[*X:3K+Y?*S]*7:@EL]
M&QCHX*&1Y,CR2,R2# QTP![53^'=].;8[M<FV&X7&CNE.R.*6D9EK#EOTW'
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M0(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=.>JV&P!ACJ-9,<]TA;<BTO?C+L;W,X[KXV8?K@U]^^/XT'7QTY]5RKY1_\
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MIYV"$@MF;*3*?+)SR\L8\%>/:I2#2V[3-KH=/NLL5.7V]S"Q[)'EQ>#UR?\
MT6GTWLXL.G[F:Z@94ND#B]C)9BYD9[$#EG . 3E7+NGO2"JW39_IFZW&2OK[
M<Z>K>=YTCJF4'/EAW+W+->M$:?O;H'7:B?5&!@CCWZF7U1_XOQZJR(D%<J]%
M6&KM%/;*FCEDH*<YB@=52X;_ /-__1>K3FFK5IR&:&RTIIHI3O/9Q7O!/CAQ
M./<MP.:E!1;SLMTW<[D:_A5-'4.=ON-++N!Q\<$''NPK%;M.6RW6B2VTD+XZ
M:4'B$2O#WD]27YWLGVK<>]04@JUHV?Z:M%8*JV6YU-4 %H>RIF!P>1_;7S2;
M/=,4EQ;<*:W/CK6O+Q,*J;>WCU/TU;$RD%9UCHFSZM;"ZZQRB:'DR:%^ZX#/
M3H1CW+8Z<L5%I^W"CMS'B/.7.D>7.>?$DK:!!T02G90B I\4'4J/'F@E$"A!
MMJ+ZLQ9EAHOJS%F6&^M<\%AKH/2:*H@WMWBQN9GPR"%F115(L>D;MIBTPT.G
MK[OPL: (KC#Q6,.<G<+2UP!.>1)66UZ,D?J6/4.I*X7&Z0Q\.!L<?#A@'7U6
M\SGF>9)ZJY(@YW>-&7ZOUU0ZD9<[;&^C:8XH#3O(+3G.3O=>:^MHFB[WJ]UO
M9^DK?2P44S:AC> ]Q=(!W.]TZ\ET)%:*KJO2$.L+!'0W]S6U4;M^.HI06\-W
MBT'/7OE>5NF]15=H?9[O?:>6@>SA230TQ9421^!<7%H)'(D!71%!5-5:7GKM
M'G3MADI*"C?%P'&2-S]UG+Z.".?7F?%?>SVPW+3-A@M-?5TM5!3-W87Q1.8[
M&2?6R2#U5H1!0M7:#JKIJZAU'9+NZV7&%AB>XQ"0%F".0/+.">N5]ZXV;T&J
MK31P3U52RX48/!K2[>>23D[WB">?+&.RO2)1SC3>SRZ030?THU-67>DIGA\5
M(?5C)&<;^<EV.1QY++K?1=[U'J6S72&YT%,RT3&:FC=3N<7$N:?7.]S^@.F%
MT)%:1AHA4BEC%<Z)U2!ZYB:0TGR!)*S(B@YY2;/:V@U?=KG;;[-36ZZR":KI
M61C?D=EQP'_LCUCS&#SZK"W0^H&[0GZK%UMO'='P>!Z,_=W,8QG>SGEG*Z2B
MM(U>I+'1ZCLE1:[JPOIIV@.W#@@@Y!![$%<WLVRJ]VH^@TFLJV&QEQWJ:)NZ
M\M)Y@'H,CR77$4I%.UCH*@U!HV#3\3W4D5,YKZ>0>L6.:",GQR'.S[5H[ELX
MN]ZTI-;+]JBHK*C=:V B)L<3-TC!<UH!><#&25TU$HJE+I%SM"R:=NMRGK3-
M3^COG(#=T   - & !@>?B2M=H[2%\TW9FT8OL=::=ICHXYH=V&)I.22&X<YW
MAD\LE7Q$% V::-O.BK546X7&@JZ5\CIFDP/:YKRT#KO<V^J/-8=/:+OUIUG<
MM0.N=ME=<,":$4[P  >6Z=[JNBHE'.=1:(OEUUU;]217.W0R4#>'#":=[@YF
M\X^L=[KZW99]H6S>FU9/2W*&J?;[W3@!M5$.3L<QD=>1Z'/=7]%:10]*:&KZ
M.K@J]47^JO<],<T\<G**,_:QW=YE>:[Z+O\ 7:^H=3MNEM9)1,,4,!IWENX=
M[J=[KZQYKHJ)2.?;0M&7K5L]MQ<K?2P4,S:B-O >YSG@#.3O=,YY+8ZXTC-K
M'23;;<*J."O8\3,F@:>&'@G'JDYQ@^*N"*4:72MKN%LH2V\W:6Z5K\!TKF-8
MT = UH'F>9R2ME<:*GN-!/1UL8EIIV&.1AZ$%>A$',]-[/+WIF::EL>JI8++
M(XNX#Z=LDC/-KCR!]RV&A]G\NF+Y<[C^FZNH]-E+WQ%K,/&3C?)!)//J,*^(
MK1SFKV>7&FUC6WS3.H)+4+@X.JXN V7>/<MWACQ//N5E;LX+-;1ZAAO5;#,R
M%L66AKY)#@AQ<7@CGY#EV7042D<XK]%:@J=?TFJ676W,GIH?1V0^CO+7,];.
M\=[J=X]%8M>Z4BUCII]KJYC#(7-D;*P9W7CR\.JLJ*#F5=LXNUXTE/:=0:GG
MK9@UK:8B(1Q1EI!#G-&"\X!',]#X\U8K7I%\>B'Z?NUSJ*[B0"!TV W=:!@!
MH Y  #KDGNK6B44706C[QI:U&DEO@K60-<RCA,6Y%'DDDNQZSCS\<+S:#T3>
M=,Z@NE?/<Z&JAN4IEGC; YI:<D^J=[S[KH:(*3?M#OEU0-2Z=K_T=>2T1S%[
M.)%.WER>W(/8=".B]L6F)J^\4-TU+4PU=309-+#!&8X8W''KX))+N7<X'@K2
MB#GNIM&WV\ZQM=\9<[=$+:XFGA-.\Y!.3O'>Z\NR^=I6B;SK:AHZ-]RH*2"%
MPE=NP/<7/Q@\][Z/-=$16D>>WBJ%)&+@Z!]4/IN@:6L//L"2>B\.K+'#J/3U
M=::E[XXJIFZ7LZM.<@_$+;(H*%IW2%\LVGG4#[['6RQQN@IA-#NQ0QD$9PW!
M<[GU)7SLVT=>M%V6JMK+C05<+WNFB+H'M+7G='/UN;<-/GDJ_HE'/=%:*O.G
M]1WJXU%SH:F&[R\6JB; YI!RXC<.]RQOD<\KQZ;V:7+3U95T]JU/4TMAJ)3*
MZEBB9Q,^ >0<<L#(\%TY%:10=!;/YM*7NZU++O-+05<QE92!N.?/!>XY+B ?
M$ ]\K"-GE92ZZK[Y:;[-14EQ'^MP,C:7OYY(:XCU?;C(Y\UT1$I$-:&M#1T
MP%1-J.CKKK.EIJ*FN5)14<$K:@;T+GO,@#@.><8PX]E?$4%1U98;WJ'2$UG?
M6V^":I;PYYFPO(W<@^J-[D>7?*\=HTM?K;H3^CD=PMSRV)U.RH,#^4;@[.1O
M=>85Z1!2-G^E[UI+3OZ)%=;ZJ./>="\PO:0YQSZWK<QU7DT5HR^:<U!=+@^Y
M6^HBN4O$GB%.]I:<_LG>_-="1*.;R:'OSMHK-6?I2W"9K."*?T=^[N;I;C.]
MG//.5EU1HN]WG6MKO\-SH(1;#_J\+H'NW@3SWCO=?8NAHK13-HFBWZRLM'$^
ML%)<J20313,;E@?RSZIYXY<N:QW'25YJK5;VC44IN]-5MJW5;X@6DACV[@8,
M -]97=%!3+CI2X:B?;VZIK*.:FHYA/PJ2%T?%>.F\7./+R"N:(@JFT31%OUM
M:HZ:N<^*> EU/.SJQQZY'<' R/)5S3^S>[POA@U#JJLN5JA(+:(9:U^#D!YR
M21GLNG(E%/VC::N>J;'):*"MHZ.BE#>(Z2%SW^J<@#!  Y!>O1]IO-DL4-MK
M*NAJA30<.&1D3FDD=-X9Z>Q65$'-[9HK45#KRXZH_2MLEJ*V+@R0&F>&!H#0
M,'>SD;C?Q7MVFZ/NNL[;2T$5PHZ2GBD;,\F%SW.> 1RY\AS5[16BN5FFQ?=)
MFS:G,%27-#3)3M+,$#DX9)PY4JQ[+[[;&BWMUE6LL+2<4T#-U^"<XWN>._1=
M812BE:ZT#3:BL%NH+?4&VRVU[7T<C!O"/ P ?+H?'DM-J39M=-16"*"[ZFGJ
MKI%*V2.=T3611@9SAC<9)Y<SD\ETY$HK=7I.GNNDS9+_ %$UQWV^O4/PU^_V
M<T 8;CL,?%4VQ[,;[;FBW/UC6?H $@4L3=QY8?V=[MGOCS75D2C!04D%!1PT
ME)&(X(6!C&#L N??H*W77;0^YP1N$UJI&^D/QZKIG AH]H8?R6XVAZ0JM51T
M!H+W56F:ED+]^$G#@?($<_-;G2UAI]/6QM+!)+/*X[\U1,XNDF?W<XE4;=$1
M0%J[[]"']XK:+5WWZ$/M*#:-Z!$'0(@(B("(B B(@(B(.9Z^T'?M67:VUOZ7
MH*+]'/,E,(Z=Y<';P())=U]4+>.HM=%I O-@:2,9%!)D?_\ 17!$HJ>BM-7"
MU/NM3J"YMNM?7N;OR"/<:&-! 8&] .96MM6B+AI>X5C](7."GM]6_BR459"9
M6,=XL(<".PYY5^1!7;%IH6VMN-UFF%7?*T 25+V[K6@ !K&M'1HQ[?-5RR:+
MOUNU[<-327.VRR5[!%-"*=X 8-T#=.]UPP=<KHJ(.=WW1E^N>N;;J,7.VQNM
MP+((#3O(+3O9WCO=<.[+7ZWM=7J77=MIK%>G4%ZME&Z6:6,!\<0>=W&[UWCD
M]?V5U1474^S\7"_.OMBNU39;R]H9)-"-]DH'+UF'D>@^"N(T0TMM,I,R0ZVH
MY@PD[L]. UP\_5*W5ST[3[2M!VUU[:*>M?&)F2P=(Y,$$C/5I\/8ONWZ-O<Q
M#-3:MK+E2YR:>&%M.U_DXM]8CR!"O$4;(8F1Q,:R-@#6M:,!H'0 (.7V+9G=
MX@RDO^K*VOL\9!;1LRP/P>0<<DX\@MOM/T;<M8VV"V4M=1T5#%(V7UH7.>7-
M! '(@ <_!7M$JQX+'%7P6]D5VEIIJEGJ[].PL:0!RY$GGU7O1%!0+SH&KFUW
M_22RWN2W2SL$54P1->7-  ]3(P#@#KGFO'J?0%XN^I[-=J:ZT=/^B2/1VOA>
M]S\.SZYWN9/DNEHK2/'-1BOM3Z2ZLBF$T?#G:P$-=D<\9YX7+:+9)=;)72#2
M^K*RW6V5V\^'=WG?'IGSPNO(H*E7Z&H:K0]5ILSU'#J/6DJ7NWI7R;P=ON)Z
MG('NY+00[.;O4Z6GLE[U1/54K8.!2QQQ-C8P 8:7X]9^,#D3A=,1**IHO2<U
MCTM^A[E<Y;@#$81EH:R-F"-UH]_4Y*U.B-#7;2U-+2LOWI5#$XOHZ5\(:QKC
MWD(]9WL! 7042CGVA-&WO3%ZO%;+<K?4Q76H-341B![2UQ+CZAWOO=\K!'HF
M_LVA/U7^D[9QW1<$P>COW=S&.N]G/)=(16CGVN=&WO4M\L]?#<K?2MM4QFIV
MF![BXDM)WO6Z>J.F%Z=>[/Z?6=OI7U\PIKS3-Q'54X( YY(P>WORKPBE(YSI
MG9]=8*BG=JG4M5>*:E>'PTI!;'O#H79R78[+)M"T3=]5W>UU,%RHJ6GMLPFA
M8Z!SG.<"#ZQWARY=ET)%:11MH&EKYJ[3HM+J^W4L<A:Z=[8'N+BTYPWUN0Z+
MT7'2$][T(=/7JJAWVQL8R>F86C+!ZI(<3X<U<44%7T+IVX6&W10W:\27*6&)
ML$0#!'''&,8 :.IY#F22K.YH<TM< 6D8(/<*40<QH]FURT]>:FHT7J$VR@JG
M[\M'-")F@Y/T<^ Z=_:O19]F]50ZXJ]12ZCK9)IFL:<,9OR -:'!Y+<8);RW
M0,!=&16D<^U+H*OJ-7?TBTS>C:*^6,15&81*V0#R/L'P7Q<-FTE9JBTWIU^K
M&U=%'AT^ZTRROR>?,;H&#C ;C"Z(B4CG.IM$7V[ZMM-[AN]%$^U@B!KX'.+Q
MGF7X(&3Y *U:FL U+I6IM%TD#'5$8#Y(1@->""" <\LCNMXB@YG2;.;O+IBH
ML=YU3455"(3#30Q1-C:P8PW?(&\X#D<9PM]H/24^G=+FT7"Z2W!A88F^J&-C
M8<\FCK^T>9)[>"MR*T<_V?Z"N&E'OIW7Z6IM,4CI::D$89AQ[O=U/L&!E8K=
MHS4%+KZJU0^Z6V2:IB$,D'H[PT,  &#O9R-T+HJ)13-6Z'9=[W27ZU5K[;?:
M4;K)VMWF2-^R]O<=>F.166;2]9>ZBBDU95TM7!1R<6.EI871QR/QR<_+B3CJ
M!T\<JW(H*#M(T;=]734+:>XT5)2T<PGC:^!SWN<,?2.\.7L7HUMIJ^:HTN;,
M^OMU.)@T3R-@><[KLC=&]RZ#KE79$&DT9;*ZS6"FMUQGIJAU,P1QR0,<S+1X
M@D\UL;M0Q7.V5=#4;PBJ(G1.+3@@$8R%ZD0479UHJX:5I_1*R^25M! YQI:9
ML0C:S>/,N/5QYGEG'/IT7Q#H6JLFHJR[:1N4=&*UV]4T=5$987'KO-P00<^?
M<J^HE(KMFTV8+Y-?+K4-K+M)$(6O:S<C@C'5K&Y/7D222?8K$B(.>ZTT7>M0
MZGM-UAN=!3QVN7B4\3H'.+N8/K'>\NRG:3HR\:TME'0NN-#21Q.$LA;"YQ<_
MR];D/Q7045I%3OMEOMVTC/9WUEM9/4PNIYIA"\C<(QEHWNO58M&V"^Z;TM':
M!76VH=3-W::4P/&,N).^-[GU[85Q10<]V=:+NNCHKE%47&CK*6LD=42;L+F/
M#R,<CG&%4]A5/=G6_4$UIK:>,&XO:Z&IB+V9P/6!!!![>')=BNT59/02Q6V>
M&GJ'C DFB,C6CV!PY^]4[9KHBYZ,=51OO%-6T=5*9Y6>B%C]\C&6NWR!V[%6
MHV^GM+"VW2X7JMG;67RM&Z^<LW61L'1C&]F\AXD^*KU#HK4-+KZJU3^E;8^>
MIC$,D!IG[H8-WD#O9SAHYKHZ**T^K-.4&J;++;+LQSH'D.#F'#F.'1P\QE:&
MV:;U+0VD6<:AIW6]D?!CG-*?261XP!O;V[D#OA79$&MTY9*'3UH@MMKBX5-"
M.0)R23S))[DE:;6FB:#5-QLM;5X$MNJ!*>61+'U+#Y9#3\?%6M$!<JO6R>>/
M44]XT??)K)/49,K&MWFY)YXQCD? Y75405S1^EQ8633U==47*ZU  GK*AV7.
M Z- [-'@K&B("(B B(@(B("(B#RW3ZA+[!^:6KZA%[/YI<_J,OL'YI:_J,7L
M_F@FX?5_>%K%L[A]7/M"UJUX>,^7J.V$4XYIA=N10 B()4>84H.Z".2D810@
M=\*5K[]455):*NJH>"9H(W2ALP):[ )QR.1TZ\_8J3LKV@5>LZRX0U=%!3"F
MC:]IB<3G)(YY2CHN41!T5$CNBCN@4!$'DGCX()480+S4MPIJFJJJ:GE;)-2N
M:V4#]@D9 SXH/4,>*+G5\U/JFEVAT5KH[3OVB21C72[A=O,)&\[>Z-QSY>2Z
M*$P1V4J/@B >ZE0@Z()491$#L@3Q4CH@* B=D!2%!1!MJ+ZLQ9EAHOJS%F6&
M^M<\$1%%$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1>*\W6DLU!)6W"1
MT=/&,N<UCGX]S02O!H[4]#JRTNN-K;,*83.A!E:&EQ;CF!D\N??F@WB(H<0U
MI<>@&2@E%5[3KJS7;5$UAM[JB6LAC,DCC$6,;@CEZV#GF.@PK0@(B("(B B\
M-[NU)9;=+77&1\=/&,N<V-SSTST:">R\.CM34.K+2ZY6L3"F$KH@96AI<6]P
M,GES0;Q$5=9J^VNUH[3 %1^D6P<?>,?S9'AG/7'/ICS06)%5+UKZRVF_45FG
M=425]5,V%K(XCAI)QDN.!C/AE;#66IJ+2=CENER9/) QS6;L# YQ).!U('Q*
M#=HL%!515U#3U=.289XVR,)&#@C(Y+.@(B("(B B+YD>R.-SY'-8QH+G.<<
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MNB*K:4UW9=4W:OH+1)-(^D8R0R.CW62-=W:>O+(Z@>65:4!$1 1$0$1$!$1
M1$0$1$!$7BO-TI+/;Y:ZX2.CIHAE[FL<\CW-!*#VHM#HS55!JZV2U]I;.*:.
M9T.96AI<1CF!D\N??!6^0$1Q#02>@YJK6C75GN^J);#;W5$M7%$97O,18QH&
M.7K8.>8[806E$1 1$0$1:Z_7FBL5MEKKD][*>,$N+(W//P:"@V*+3:2U%1ZI
ML[;G;6S"F>]S&\5H:3@XSC)Y+<H"*NT>K[;5ZSK=,0BH_2-)")Y'%F(\'=Y
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MG=,RJ+@,]P-P94:EVG55BUB+%/9XI-Z2-K9FU1YM?C!QN=>?14.J_P!H-O\
MF#/X0HVL?K@IOWZ;^275CJ^TK655HREIJMENBK*:9_"R:@QN:_!/3=/+ ZY5
M:K-J=UFTW372S:<DE8XXGD<2Z*-V2 T$8+CTY]!G"GY1W]D[=X^G#_EO5CV,
MQM9LXM!9^TU[G>WB._\ 17ZGQ]:IUU#IK35ON%PHW^FUC6[M)O8+7%N3DGH!
M[%7-4;1+[IC]%U5QM]KJ*"X,,D?HTKRX- :3ZQY$X<.RVVV.LT]1V*)VHJ+T
MZ;?_ -6@:\L<7=SO#F!CK[ERK:H+E)IW2U7<70Q0SQR&FHX6^K3Q 1[HSU)(
MQE-,=BUIJ.LBT ^]Z>C8YLM.)N)*[=,3'#J!W<,CDJ%L+K[Y)3W22EHX*YL]
M2UU1//5%CP2#DXW3O=^X5DKVEVP3#?\ \,8?R6K^3=RLEW_X[/X2GT^-E<-I
MM9;=:P:=K+-!Q)*B*#C1U9< 'N WL%@\>BWNT;7-/H^E@8V(55PJ?ZF#>QR^
MT[RS\5R;7'Z]*'_&TO\ &U9-NC7#:1;C4;W =3P[N<XQONSA2D7V]ZYOFE)K
M=)JFVT7H%8<%]$]Y?">X(=U5@UKJF2P:8;>Z"EAKZ4AKCF8LRUV-TM]4YZJF
M?*.<!IZV-)]8U!(_\*\]\$P^3U2BIW^)PH_I=<<7E^&%1L+;M-NUZTS<;E:;
M#&):(N=-Q9RZ-K T'D< EW7EY=>:WVR[7'],[?4NGIF4]93. D8QQ+7 ]",\
MQ[%1]E0_^#&JCWWZG_D,7S\FKZ=\]D?\TS1W#"GNH"GLJB!A B8[! 3J$ZH4
M#VHB#JJ-M1_5F+,L-']68LR\^^M<\$1%%$1$!$1 1$0$1$!$1 1$0$1$!$1
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M?%/74]SB87OCJ(@T 8SU!/94NRPQP_*)O)B8&\2WA[L=W'<R?P7Q1_[25?\
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M8I76Z@U[>OZ)4DMQO]5NFXOEF+8*49Y G'4]=T9/+LBK9IC55JU)Z2VVS/\
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M7K6U5UW%JF%5;[DX9CIJZ$Q/D'/FWL>A5'T56/N>W/53ZX[TE'%Z/3 _L,!
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M=#J6VRVC4E'OL@8_.Z\O&'@<N6=T<O)(+*=H^F/TI4T+;DQ\E/"Z>61H^;8
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M]XH-FWH$1O0(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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2"(B B(@(B("(B B(@(B(/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g73463g13a34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g13a34.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1:(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %FL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9 ,!(@ "$0$#$0'_Q  =  $  @,! 0$!             08$!0<# @@)_\0
M8A   00! @,$ PL(!@8%"@ /  $" P0%!A$'$B$3,4%1%&%Q"!8B,E)3@9&2
ML=$5-D)R<W2ALB,S-3=BP30X=;/A\"1#5)/"%Q@E)T1%8X*B\295*$=69&6#
MA(64TG:CT__$ !H! 0 # 0$!               ! @,$!0;_Q  Q$0$  @(
M! 0#" ,! 0$      0(#$002%"$3,4%246%Q(H&1H;'!T>$R,_ %\2/_V@ ,
M P$  A$#$0 _ /U2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     '/L[J'*
MP9ZU4J2_!;(C(V(Q%5=T3H=!.79B5D&N)9I5VCCLL<Y?)$1IV\#6+6MN-]GG
M?^C>U*5Y9UW9OY3U5_V>Q_W!DXS(:EDR-9EF&=('2(CU6'9$;X]3?>^S#_\
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MM-9I':&'&8LG#UBT9)G<_%FKD]5[+_06/^X-WJ7*7J&GZ,\;^SLO<U).9O\
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M$<;GQ.YF*Y.K5]1D'+FR4R:FM=2[.'Q9,6XO;FCT  8.D
M
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M(B>/12B:#QUVIFGR6JD\+.Q<G,]BHF^Z=#/AYB,.2);<569XC%,0Z <PU?\
MG7)^LS_(Z><ZU1C+T^I9)H:<\D2JSX;6*J>'B. F(R3N?1'_ *=9MBC4>O\
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MJ\W(7M$RMLPRNNOVWCY-G+\-/#V&=>'G%>MIF/.&MN*C/2]8K,=I\X8_#/\
ML^]^V3^5#3\1]ORY%OW>CI_,XW_#ZI8J4;C;4$D+G3(J)(W;=.5#5:_QUVWE
MF/JU)YF=@C>9C%5-]W=#HQVCJYG;ERTMT-8UW_N7G#:U:D+$BBE[-&IR[1L[
MO ^&X+/9JTUV4>^-B?I2JG1/4U#H%)JMIP-<BHY(VHJ+X=#V.>>,FLSRUB)^
M.G5' 1:(Y[VF/AMB8RA#C:$=6LBI&Q.]>]5\54YSI+\[HOUY/N4ZBO<ISK3&
M,O0:GCFFISQQ(Z1>=S%1.J+MU+<+?=,DVGO,?RIQF/63%%8[1/\ #>\1?["9
M^V;]RGQPW_L6?]NOW(9&NZT]K#,CJPR3/25J\K&[KMLI4\8NHL; Z&G4LLC<
M[F5%AWZE\5?$X;DB8B=L\UYQ<7XDQ,QKT=/.=\1<A'/=@JQ.YNP15?MX.7P^
MK[SY?8U7;3LNRM,1W3I'R?Q\#9Z:TB^O8;;RJL=(U>9L2+S(B^:KXC%CIPT^
M)>T3/I$)S9<G%QX6.LQ$^<RL>G:KJ6$I5W_'9&F_J5>IL #S[6YIFT^KU*5B
ME8K'HY?K17)JN98_ZQ.S5OMV38S_ $O5_P U-_W;"-38V[/JM9H:D\D/-%\-
MK%5.FV_4Z$G<AZ.3/%,=(U$]O5Y.'AK9,N2>::]_3MOS<ZJZ:R^6NI-F'N8S
M?X3GN17;>2(G1"^-KQU<>L$#>6..-6M3U;&2?$Z*L$B(FZJU=OJ.3+Q%LLQ$
M]HCT=^#A:8(F8[S/K+D6 DR,=M5Q#7.L<FRHU$7X/TFVR.3U-6K*ZZZ:")R\
MO/R-3JOK0R]!8Z[4S#WVJD\+%A5.9[%1-]T+Q>JQW*DM>=J.CD:K5W^\[N(X
MFE,NIK$Q\7F<+PE[X=Q::S\/11=#X2.[*F1L3-D[-_2/?=4=YN^\R>)59RI3
MLHBJQN\:KY;]4,3#5<II[./1*EF>JJ\CW1L54<WP=[4_$OERK#=J206&(^*1
M-E1?^>\SS99QYXR;W#7!@C+PUL6M6]?JU.B[T=O!P1M<G:0-2-[=^J;=QO3G
M%K3V8PMQT^*626/P?$OPMO)S?$^G9K4T[.R;7G:[S;75%*WX6,EIOCM&I7Q\
M9.*L4RTG<?FS^)%YJ15Z+517JO:N]2=43_,VFE*[J^E&\Z;+(QTB>Q=]C283
M2=JW9]+SBN1%7F6-SN9S_P!9?!/47BPS_HDC&-_05$1$]17->E*5PTG>O.5N
M'QWR9+<1>-;C40YQP\_.!?V+_O0Z8<HQM3.8ZPL]2C99+LK=^R5>BK_P-F[(
MZK<FR0645?%(#?BL'C7YJVC\7-P7$^!CY+5G?T637%^.I@YHG*BRV$[-C?'U
MJ:OAI55M>Y:<G1[DC;Z]N_[S7TM+Y7*6FSY=[HXU^,LCMWJGDB>!?J=:*G6C
MKUV(R)B;(B&.2U,.+P:SN9\W1AIDSY_'O&HCR<QU(LK=7V5K(JSI,Q8]OE;)
MM_$V,U[5L43Y)63,8U%5SNS9T3S)R6-NOUIZ0RI.Z#TF-W:(Q>79.7==SH2H
MBHJ*FZ+T5%-<N>M*TCEB>S'!PULE\D\TU[SY.5X*@_4F4?Z;<<KD3F>KEW<Y
M/)#I<]=K<9+7@;LU(5C8U/#ILB%&S&%O8C.,MX:"62)R\[4C;ORKXM7;P+W0
MG=:J13/BDA<Y-W1R)LYJ^1EQ=^;EO6?L_#X-N IR<^.\?:^/Q<[X<RI!G'Q/
MZ.DA5J;^:*B[?>=+*%J+3%ROD'7\.BO17]IR,79['>:>:&,F9U.L?8=A/S]W
M-Z.O-]>QIFQ1Q,^)2T,N'S3P=9Q9*SV\M//B)(C\XQC.KF0M:J)YJJ]"UYVB
M^72#ZZ(O:10-<B>MJ(O^1HM.:8MV+S;^9141'<_9R+NY[O-WJ+XJ(J*B]44S
MSY8IR4I.^5KPV"V3Q,EXUSJ#PVNLCGM4WJB.EVD9OXJG14^XOQ1M0:2G996Y
MA5Z\W-V2+RJU?-J_Y&'%E]3U&]D^O.]4[ED@5R_67RX:\3/B8[1W])4P9[<)
M7PLM9[>4P].):JF0I[*J?T+NY?67?%?V;5_9M^XYZN'SV>M,?=C>Q$3;M)DY
M4:GJ3O.CU(>PK10[\W(U&[^>Q3B>6N*F/>YA?@^:^;)EU,1.O-Z@ X'I@
M
M
M
M
M
M
M
M                                            &/;O5:;>:W9A@3SD
M>C?O R 8].[5NLYJEB*=OG&]'?<9
M
M
M
M
M                                         %7XDZJCT=I.YEGM1\D:
M<L3%_2>O<ARC2O#+(\0:#,_K[+WN:XG:14Z\G(V-B]QO_=1PRR</(7QHJQQ7
M8WR;>#>O>=*TG9KV]-8R>F]KX'UV<KF]W<!Q?4_#+(\/:+\_H/,7]J7]++2G
MDYVR,3JIUKAUJB+5^DZ67B1&NE;RR-3N:].]#,UE/#6TGF);+FMB;5DYE<O3
MXJG-O<MP31\/)9)&N;%+<D?$BI^B!V$
M
M
M
M
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MO78C&IY[>*FP
M
M
M
M
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M4]*8EM:LG:69/AV;+NKYG^*JOB6,
M
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M%14Z*BDA(
M
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MT!$;48QK6_%:FR$@
M                                           *NR;KW %79-U[C$EM
M[+M'U]:GE8G6151N_)]YX%HAG-O@^GO<_JYRJ?(!90"!$W  D@  "4 @D@D"
M !]X0!/4!W!( @0 20-P" =P10 'M $@@($ "#P"0D@ /,  2U5:NZ*J+ZC(
MBMN1=I$W3S,8$$3,-LQR/;NU=T)-9#*L3MV]WBGF;&-Z2,1S5Z%9C36MMOH
M$+
M
M                                               #YD<UC'/=W-3<
MK6F-7Q:AR-RO5QUZ&&NY6^D3,1K'JB[=.NY9S59'-8_%WZ=&PY66+CN6)K6*
MJ*OK5.X#:@(    \K<"6:LL"N5J2-5O,WO3<H&/X704\I#=3.9*18I>T[-SO
M@KU[E]1T1>Y2EXO3.H*V?],M:HN6*7.KO17(WEVWZ)W 71.B;    >=B>*M$
MZ6Q(R*)J;JYZ[(GT@>@*OA->Z<S.1EHT,G$^PQ539WP4=M\E5[RT
M
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MOQ7?>8X((G3;@^('<\357OV/LHW
M
M
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M^LL]HY65->4G6:V^S<I2;NQ4\WM_1 ZB#"Q&4I9BE';QEF*S7>FZ/C=NAF@
M
M             !YSKM"]?4:Q#96_ZAQK=BU6=_," %E K/$;3B:ITG<QS=DL
M*WG@<OA(G<68*@'%]&\37Z<I,PNO*-RG:J)V;;/9JYLB)W'QK3B1/JFF_!Z"
MHW+4UM.S?:6-6M8U>\[#>QU*^U&WJD%A$^<8CB:5"I18K*5:&NU>](V(T@:+
M0. BTMI2AB'2-2=&;R+OLKI%3X6WF:&Y#JS2EV:W3DDS^(D<KGUGK_31>Q5\
M/4635^F8M1U(F^EV*=JNJO@FA?MRN]:>*%9CU+G](HV'6%5;U%/@LR--NZHG
M^-G^8%FTUJW$Y]G+5G[*TG1]6=.25J^7*O52P>HI61T]I[7%1N3QMA&6D3=E
MVF[E>U?)VWW&N@SFH]'M2'4]9<IC&KRLOU&_#:W_ !L_S)'1@G5=D*S:UUIZ
MMB&Y%V1B? [XK&+O(J^2-\RMR7=4ZX;RXEBX'"NZ.GG;_3RIZD_1 L>I-;8C
M"O\ 1DD6[D7=&5*R<[U7R7;XOTFKXG:<GUEH;LJ\:PY"-6V86.^,CD1?@[_2
M;K2VD,5IR/>G#VEMW]9:F^%(]?%=RP;>L@<>TGQ;K8['Q8W6M2YC\A51(G/6
M)RI)MTW0P-2:QR?$'+4,+HJ"[!2;,V2Q?Y58G*B]>IV2[B<??7FNTJ\[OE2,
M15/6G2K4H^SIP101_)C;L@%>U9BLQ;P]>AA\CZ)&UBI9L.W616HG@OFI7^ 4
M7HVDK\*O=)V>3G:KWKNKMMNJG1+7^BSHG7^C7I]!0^"L$T&F\LR:-\4CLG.K
M4>W;=%VV7V$CGO-4=F]07\UHNWFY'VW)VCXE_HXVN5-TW3KT\BYYNWA+O!?*
MR:9@9!1[%R=@QO*L;M^J*AZ2\2I\1/>Q^H,'?].CD<V!:T//'.W?X/7P,[A3
MIZ>EIVX[,UF,=D9G3.JNZHQJJNR*0)X$[IPOPR+NB\KN_P#6,;CZBKP]LHB*
MJ]JSN_60Z!4K04X&P5860PM^*QB;(@MU(+D*Q6X8YHE[V/3= *9-IEFIM%X&
MK;L2Q4XHV2S1,54[5$3XJ^HI.#CQ4?%6E%@*3]/P5V/CE;(U8V6U\.7?O.CZ
MUR^1T[0IV\3CO3*<;^6S#&GPVL\%:A1,SE7<1-0X.+!8NW!#1G;8GMVHNS5B
M-7=6I[0-SQ;Q><R.'R[VY!*>%KUG2+%%NDDSD\%7R]1;="_FCBMN[L4/CB*Q
M\VA\\R)KGO=5>B-:FZJ>FB&N9I/%M>US')"FZ*FRH!O !L2  0   )("#S
M #/HKO"J>2F08N/^(_VF44EK7R  0L
M
M
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MMW3Q12Y'+>"W]IZK_?G?>H'4@
M                                      !Y6_ZAQK396_ZAQK2U65_,
M!)!94'B20 '@  ]I\R1LDC<R5C7QN39S7)NBIZT/H 4+):"=4O29+1UY^)N_
M&6!.L$B^MO<AI,YQ&OX?"9"EJ+&K2S"1\D,O)S5YW*NW15^XZP5'BQ!#-H'+
MNFBCD='&CF*YJ*K5YDZIY$#3\/\ ASAL=#'E[4:7;]E$E<LC4[-BK\EG<AT9
M$Z)MW)X(:W3/73^._8M^XV1(#O  (  '>?+6-9OR-:U/)$V/H ?+HXW*BO8U
MSF]RJFZH?7F.X ![  &VY\LC8QJI&QK$5=UY4VW/H!"%:CFJBHBIY*G>2UJ-
M39$V3R0 )/O   )W D"        9N/\ B/\ :91BX_XC_:912?-K7R  0L
M
M
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M<7/^@W=>B&"K>,7*N[\1MLO>W_B8WN6.V_)^JO2MO2?RBO:[=W-UW_B!W(
M#EG!7^TM5_OSOO4ZF<LX*_VGJO\ ?G?>H'4P   -#J[)Y?&T&RX+$KD["NV6
M/G1FR>?4#? H6 U-J^YE88,GI-U*HY?AS]NUW+]&Y?47?N
M                                                     #RM?U#S
M6FRM_P!0XUI:K*_F>8 +*@0(  \P " DCP >95>*?]WV;_8I_,A:BJ\5/[OL
MWO\ ,I_,@(;C3/YO8[]BW[C9&MTS^;V.V[NQ:;, " !) 0      !   )\"
M '@ !) 0( )W"?Q $> 0     )\R$[@,VA\1_M,HQ<?\1_M,HI/FUKY  (6
M
M
M                                       >%ZI#>IS5;4;9()F*Q[')
MNBHO13F.C[%G06J7Z6RLKG82VJR8NS(OP6+XP[KW;>!U4KFO=+P:KP$M&5RQ
MV&KVM>9.^.1/BJ!8P47ACJ6U?K6,)GF]EG\8J13-7_KFIW2)ZE+TB[IN
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M[6Q"K6^S=4+D5?2&ML9JJ:>+&QVV.A1%=VT7(A:
M                                               \K7]0XUILK?\
M4.-<6JROYH"=P!94 ">L"2 $  ! !2]4:\T=227'YG)5I4=\&2%O](B]>Y=C
M5\<M26L%I=E3&.5M[(R)78Y.BM1?%#UT-PPP.'Q,#[M1E_(2L1\\T_PMW*FZ
M[;D"PZ6U;IW.QMAP61KR*Q-FPHJ-<B>II8CC?%?0%+%8U=2Z58M#)T7)(Y(E
MV;(U.]-D.BZ"SR:ETGCLFJ;231IVB)X.\0-^@)()0>  "0  $'L \P"!   \
M  )("=  !) $H0   0D"    ">(&;0^(_P!IE&+C_B/]IE%):U\@ $+
M
M
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M'Q'^TRBDM:^0 "%@
M
M                                                          #%
MR="MDZ,U.]$V:M,U6/8Y.BHIE #28'2>#P,?)BL;7KIYHW=?K4W:(B)LG1
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MK5Y)IW(R*-JN<Y?!$.?2:LS.J^>OHBHD51%5CLE;39G_ ,B)U+5K;\T\IO\
M,.^XP.%7]W> _=D[O:I \-+Z!Q^)L?E#(/?E,P[X3[5CJJ+X\J>1<4[M@$)$
MD      3O'< !) $D(    #P)\"!X "4(  ! @   /N!)  ( !) \    &;0
M^(_VF48N/^(_VF44EK7R  0L
M
M
M              "K)JG!Y74]S2<K5FNQQ<\L4D>[%;_F9":,TS$J/;@<:U6?
M"14KMZ;?0<:;G\9ISW1>9MYJVRI7=51J/?W*NQTJ3BSHIT;VIGJNZHOB!MM*
MZSQ&H\AD*&*=(LN/=V<J.9RHB^HLQP/W.5F&YJW6-FL])();',QR=RIT.^
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MB20  ]@  (20$"  )$  0S<?\1_M,HQ<?\1_M,HI+:OD  A8
M
M
M                                      'YY_(&,U'[HK,T\U49:KMJ
MHY&/[D7;O.DOX2:*;&]4P5?HB^*GWC=!K3XFWM6>E\R68>R[';N]9>7MYF.;
MYIL!P3W.5:&EJW6-:JSD@BL<K&^2=#OA0^'V@5TGG,WD%MI/^49>TY=OBE\
M  #G7#K\^];_ +Q%_*=%.=<.OSZUO^\1?RG10 7N4!>X#\V\*-*875/$#7:9
MVC';[&X[L^??X.[UW.F93A1HR#&6I&8.!'-C<J+NO1=C+X?:!72>H=0Y-;?;
MIE9EE1FWQ.JK_F72]!Z52G@WY>T8K=_+<#CON6FHS2658WHUM^1J)Y(AVDI?
M"W1*Z(Q-RFMI+"SV'3\R)W;^!= !\R_U3_U5/H^9?ZI_ZJ@<_P""7YNY3_:E
MG^<Z$<\X(_F[E/\ :EG^<Z&         -1K'\T\S^YR_R*;<U&L?S3S/[G+_
M "*!H^#?]VV"_8(63-_Z"OZR%;X-?W:X+]@A9,W_ *"OZR$U\R%? 0&ZX
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MQUET,=JPC)43]).I Z1[ &]6I[$!(  #-Q_Q'^TRC%Q_Q'^TRBDM:^0 "%@
M
M
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M).DB;DX8Z]2-.5C6JJ]7>:G8H>D,?ZJ$C/Q_Q'^TRC%Q_P 1_M,HI/FUKY
M(6
M
M
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M)^@L$M=6]EZ,U$Y3*_FVQ^3F^;T)JG1E5^8TQJ.Y>2LG:2U;#U5'-3JO0O\
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M[3*,7'_$?[3**2UKY  (6
M
M
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M,]?\2]YO"$       ,3+4(,ICK%*VWF@F8K7&6 .4U:VL=%<U3&UF9C$HO\
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MH?$?[3*,6A\1_M,HI/FUKY  (6
M
M
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ML^?=]E#; <TFVI_(S?GW?90?D5GS[OLH;8#FDVU/Y%9\^[[*#\BM^?=]E#;
M<TFVI_(K?GW?90?D5OS[OLH;8#FDVU;<-&B_"E>J>I$0S:U2&NG]$S9?->JG
MN")F90  @>$E2%Z[\NR^H\_0(O-_UF6"W//Q4Y*_!B>@1?*?]8] B^4_ZS+
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M"P
M
M
M           *B*BHJ;HIXUJE>JCDK010HY=W)&U&[KY]#V $2,;(QS)&HYCD
MV5JINBH?%:O#5B2*M$R*-.YK&HU$^A#T
M                                        0]O,U4\TV-5MLJHO>;8P
M+C.63F3N=]Y:JEX]6.@\ "S,"    !/@020  0    ^\  /  (!)'@ !QSC%
M>MYO56#T;1G?#!;>C[BL7959OW?4I?\ #:&TWB:+:E;#TW,:FRNDB1SG>M54
MYOQ-3WM\5]/:DM(OY/F5(9)/"/JB;J=HKSQ686S5Y&21/1'-<U=T5%('#^*N
M CT%E,;JS2K/0VI,D=JO$NS'HJ]ZHAVVA9;<HU[+%W;-&UZ?2AR+W0^6ALX_
M'Z;HJDV2N3M7LV=5:W?O7ZCJ^$J>@X>E57JL,+6+[40#-0D$$B2/   @  D@
M  /  (21X > 2 'W#'VDB-3N\?8"&?5;RPM]?4]0B;)L@,V\=@
M
M
M
M
M              ^98TD8K5/H :M[%8Y6N[T/@VDL39&[+W^"FOEA?'OS)NGF
MA>)VRFNGGW@("53P  !  @ > )0(0  D )\0(  0D@D@):O4>!H:BQ$V.RT*
M35I/#Q:O@J+YG-(^$V8QO-!I_5UZM15?ZI[MU1/).AU\$"@:(X88[3F0=E+=
MB?)Y=>OI%A>;D7_"7] "00D@D(0 $"0E"  \    " $ /J-CGKLQ-P(1%5=N
M]?(V%:'LF=?C+WBO72+JO5WGY'L4F6E:Z[R  A<
M
M
M
M
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M0W_*:$IN\7I]1F@;DY(8[*D;?C*KCW:B-39J(B$@C:8B(  $@
M
M
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MM:YC)1>Z:J4XLA;947(TVK"V9R,V5K-TY=]NH'ZE
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M^G#(CT3V[=P&:
M
M
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ML+^V-._N\O\ ,@'Z*TG^:V&_<H?Y$-J:K2?YK8;]RA_D0VH
M    _)7N@_[\L;^K4_WBGZU/R1[HA[(N-U"21R-8R.JYSG+LB(CUW50/UN0[
MXJ^PK7O_ -(__I-A_P#^K9^)G8C4^#S4TD&'R]&],QG.YE>=KU1O=NJ(O=U
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MB=_E])8?<<_V;J/]I!_*XRO=8:;=Z%B=54$<RW3D2O*]B;*C5W<QV_J<G_U
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M7R _0%.Q';J0685WBF8V1B^:*FZ'J>5.M%3J05J[>2"%C8XV^3439$^I#U
M
M
M
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MKU53=@#G5OA'@[6OV:ODMY%,BVPVPD39&=ES-3HFW+OM])T4
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M8H/3Z,=1JHB5Y6[R*J[JYZN:JJIU5M>-*J5W-1\2,[-4<F_,FVW4]0!R?47
M/1>9MOLQ0W,;(]>9R4Y4:Q5_5<BHGT&XT-PBTIHZVVYCJDMB^SXMFV_M'L_5
M39$3Z$.@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*L;/EO7HU/KV./>YNRFHM039G4.I,W<GQU;>-D4DJ]FCU^$Y=O)J;;>T#]
M_,NH^.6J-0:@EQO#S&\T+%<V-Z0K-+,B+MS[=S4_$QO_ "G\6-.31R9_!OFK
MJY$Y9J2L1=U[N=O<H'ZC!S3C3K#,Z3X=5LQC6Q5<E)-"R1DC4E:SF1>9O7OV
M7IN:O06>U!K_ (.92W/>=!FE69L$]1O9JCF=6[;>OH!U\'Y[]S/Q R^8RV4T
M_J.Y-;L-9Z1!+.[=[514:]GLZHOUGZ$
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M5711SM<YNW?NB+OT,FAD:6125:%RO:2)W)(L,B/Y7>2[+T4#*
M
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MD>R)CGR.:QC4W5SEV1$ ^@:NMJ+"VK/H];+X^6QOMV;+#%=OY;(IM
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M9["-_-'$K>:665W3N3=$1$^]3HO%+3\FE_<X5,3.N\]=8.UZ[HCU=NY$^E5
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M4_BJ'ZY/R-BT;FO=12OAV=&W*2/1R=VT;5Z_6A^N0
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M'MCA[B,C3M7XKKK4Z3(Z-BMY=F[;=3A' W_6$G_7O?YGZ[
M
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MHC)V<KDYU;XM5R]6[JNR@=(
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MUE8K5?*]4<Y4W\D^\_31#6HU-FHB)ZD)
M                        #Y<]C5:CG-17+LB*O>?0  CF;S<NZ<VV^V_4
M"0?*O8CT8KF\ZINC=^JDJY$5$5415[O6!(    "OYC1>FLS>?=RV#Q]RV]$1
MTLT*.<J(FR=5,+_R;:+_ /T7Q/\ _3-_ MH T,&CM.P8BQBH<+09C;#TDEK-
MA1(WN3;953Q7HGU&7B,!B<-1EI8K'5:E2555\,,:-:Y539=T3U&S &DPFDM/
MX*V^UAL/1I67M5CI((D:Y6JN^RJGK1#WSVGL1J".*/-XVK?9$JNC;8C1Z-5>
M]4W-H -:F!Q281<.F/K?DM6\GHO9IV?+Y<O<?.!T]B-/Q31X3&U:$<SD=(VO
M&C$<J=$5=C: #19O2&GL[;2UF,+0NV4:C$EGA1SN5/#=?:;2O0J5\>RC#7B9
M38SLFPHU.1&;;<NWEMX&2 *R[0&DG64L.TWB5F1=^;T5GX%B@ABKPLA@C9%$
MQ-FL8U&M:GDB(>@ T6-TAI[&91<EC\-1K7U5RK8BA1K_ (7QNOK-Z
M                                 0Q[7[\CFNV79=EWV4D
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MQC4V1K4V1$)          $-<CDW:J*GFBD@
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MEH?3KTL3]GN@1-^S14\TW_@!TR+4V"EN^AQ9K&OM[[=BVTQ7[_J[[E$TVO\
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M^".9R$U7.:=S-A]NY@+CJB67KNZ6/]!5]>R =,
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M[=YTO2"Q2X*O9AQ"X=;#>T=4<QK',5?E(GCL;%E&JR=9F58&S+WR)&B.^LR
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MD[FKNBOW^%LOMW.LGQ##%"CDAC9&CE5RHQJ)NJ]ZKZS[
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ME:2TW;=4RV9@CM-79T,>\CF^U&[[&XTWJ;#:EJNL8+(U[L;5V=V3MU;[4[T
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M>FYZ;L8]=WN3U-3JI@Z9XCZ4U+9;6Q&9KRVG?%@?O&]WL1VVX%M
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M2X')U[B-3=[&.V>SVM7J@&\!K,YGL?@UHIDY^Q]-L-JP?!5>:1R*J)T[NY3
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MDL([HF^V_=]!U72FI<7JO%?E'!V?2*G:.BY^16_"3;=-E]J ;@
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MQQ,WVW<J=$W'#O'6<1H;!8^_'V=NM4CBE9OOLY$V5-RP@
M            -'K2GG+V#?%I?(PX_*->U[)9H^=CD1=U8J>"+YE19G^)-5B0
M6=)8RW8VV](KWN6)5\]G)NATH <XT%I'.MU9>U=K6S6DR\\/HM>K5W6*K#OO
MLBKWK_Q.C@            *CQ9P]W/</\QC,7$DMRQ$C8V*Y&[KS(O>I;@!B
M8B%]?%4X94VDCA8UR>2HB(IE@
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MW)MWG00
M
M
M
M
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M9\U;^PGXCI<WME/68/?"U JOOYQGS5O["?B/?SC/FK?V$_$=+F]LG68/?"U
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M]@W[W%8+/Q$_MZ/]@W[W%8/:X7_57Z/GN+_WW^J"2 ;N9)   $D $!)  $D
M "0(!( $ D"   !) $@@ 2020 )!  D$  20@$D$H0 )!   D 020!)!("4$
MD (2020 )  @$D(    $D 2020!)!*$ "2  "$D 2020!)!( $  "00  ) @
MDCP $D  "2  !)" "2$) @D@ 20  '@   0D" 20!(  @ D" 20!) ) $  "
M00!) ) @D@ $ ) A"4() @D$     ) @ D "$ $D$D "2  !)  $D  "0! )
M @D@D" GB20!)!)    "00 !( A  !) )    020 )(   D @ 0" 20
MD" 20      20"0! ) @ D 0 !(()   " 20 !)  (20!)!(0  0 )(  E 0
M!) ) @$D 2 @ @ D""2"0( ) @  "00 !( @ D" 2 ()!" 20 !*=P( $D$@
M ""0! ) A"2"0() "4?2!T 0M'$3^WH_V#?O<5@L_$7^WH_V#?O4JYAPO^JO
MT=/&?[[_ %  ;N9((    "00!)   D@ 202 !!( @ D 02 (   D@ 21X  2
M0"0(!( (0"0!  $D   "0()()  @       D@D" 20!)   D@ 2/,$  @
M 2" @ D@ 20$) @D  020  )    0"0()()  $ 2 0!)!)   D 020@$@@ 2
M""0( ) @$D  2 (   ! !((  D   $ @D@D 0 !)   ! !(! $D$H0!(() $
M$D  "0    @ 2""0(!( @  /,$H (!)    2""0("  "2"0()  $$CP @D@
M"2"0 ( $A""0(!) $@@(  ) $   "0 () @ D" "0(!( @D@D $! $@$ "2
M )  $$D 2""0(   D " 2A $D$D "0  () $$D  2 ()( $D D 0       "
M0 !!) $H02 ()() @E/$@ 2 0 )() @D "  !:.(O]O1_L&_>XJY:.(G]O1_
ML&_>XK!APO\ IK]'3Q?^^_U02 ;N9!)  D$  $) $$D$@0 -P!)   ^XHGRJ
MJ11O>J)NJ-15V3S/@   !)  D@]'Q21M:Z2-[$<F[5<U41R>H^ G2 20$!)
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M)5V1ZM7E5?:$Q#X!!(0$$@  0!)"$@" "0 (    "2    $D D" 2 ()()
M(&HKE1&HJJJ[(B>($$GU)&^)ZLE8YCT[VN394#HI&,:]\;VL=\5RM5$7V*-I
MU+X!(" 'TV*18W2-C>L;5V<Y$Z(OK4^ E)  0 D@   !)  D$ "0  ! 0
M /MD4CVO<R-[FLZN5$54;[?(^0E )("$@  02 ()( $@@]'0R-B;*Z-Z1.79
M'JU=E]BA+S!("$ ]&12/C=(R-[F-^,Y&JJ)[5/,)T$D ("0U%<Y&M15<O1$3
MQ/J6*2)ZLE8Z-_R7)LOU!.GP20 @)! $D'VD4G8]KV;^RWVY^5>7?RW/@)
M$)(!($$D$@"/,$@0202 !  $D "2"4 $ ^F-<YR-8U7.7N1$W53[F@F@5$GA
MDCW[N=JMW^L;3J?-YD ! "2  )( $@@"0"  0$@0"0! )  @$@" 2!"$^!
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MUCK1.^+NGBJ?6?"ZNRCI-W.@='W+$L?P53R-/$M:9BD;TS\*E8B;VU,_+?\
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M=%0M.H&^FZ:Q-RONYD#5BD1.O(NR=_U?<5<V&'R]G%2/6!6OBDZ/B>F[7?\
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M.NU:M2>LZ%&/=)%SK&Y.]%7P--[YIO\ L.-Z_P#ZO_Q,3#YJUBT>R+DDKO\
MCPR)NU?P-@W4-*)SI:N#J1V.]'JNZ(OGML5C#R=N3?\ WJM.?G^USZ^6OT8&
M;RMK(=C%<@BA6!%Y6LC5BHB[>"^PU9D7KD]^T^Q:?SRN[UVV3;R0QSJI7EK$
M:TX\EN:TS,[ 20642""4  ! ()0@ "2    %HXB?V]'^P;][BKEHXB_V]'^P
M;]ZE7,.%_P!-?HZ>,_WW^H #=S!)    "2 2 (     "0! )( ! 2! )( D
M 0"0! 0   2!!)  D$$@0"2 )(  $@ 0  !G7LG/=J4Z\S8TCJMY8U:B[JG1
M.OU&"")K$SN?1:+3$3$>H "50D$ $ )\ ()! $D$@)0"2 @  $@@D" "0!!)
M     20 !) $@@ 2     @D@ 2""0(  $^! )\P!   D$ "2!Y@"2  !)
MD""2 !*$$D  "0(!( A   !) $@$   !) ) @D@D  0 !)   D" 2@ @ D"
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M"  0  0$D  "0(!( $  2A" D""2  )(  ! !)     20"0(!(0" 20!)!(
M @  20 \P"0! )  $  "0(\"2"0()(  $@ 0  !( @> ) ( 0 !( @!  )
M@$@""2"0!" D 0    $D$D  "0!!( @E  ()  $       $D#S)3N @$@" "
M0! 'F!)    E !"  2  ( ) @D ""0 ! ) @  "00!(() @(  )  @D@  20
M 0D@ "2"0(!( @D$ 2""0!   D@  20 )(  D@D""2"0()() $!"0(!)
M$!( @!"0 0 " "0()( $D$D  2$ @ D" 20 )( $D   20 )("       $D
M2""0 (0 202 !!) $A" !) 0  20!*  "S\1/[>C_8-^]Q5RT<1?[>C_ &#?
MO<5<PX7_ $U^CIXS_??Z@ -W,D@$@0"0$H )" @D@  2!!)!( $$@ 0  )
M$( )(   D 02" )!  $D "2  !(( D$  $  $D  "2 " D " @ D$$@02"
M  D @ 202! )( GV @ "2 !(  @D$ 2020 )( $D D""2"?,"   "  "2 !)
M!) $D$D 2 0    $D    )! $D$@" 2$ @$D 2"$)    " !(!  D@  20!)
M!)"    0  20"0!!( @D "   )(  D@D 0"0()(  $@""2 !)   E" !)!(
M$ D"  !(( $D$@""2"4 @$D "2 !(!   D 02  () @$@""2 !((  $@""0
M()(0 "00 )0#P  $ 2" !(()  @D""2"0()  !"$"   !* $ 20"0()( $@$
J(!*$ D""0  (     2  () @D@ 20$  D " 20   $D$@ 020   '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g73463g14k41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g14k41.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1B44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &'<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  #_X4#G:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L
M(#(P,C O,#<O,3 M,C(Z,#8Z-3,@(" @(" @("(^"B @(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @
M(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N
M=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HQ831A-C(W-2UF.3-A+3@T-#,M
M.#$V-"TV8S)D.#9E93EE83(\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z838T.# V-F4M8S)D9BUB.#0T
M+6(T83$M864P9F8R-# Y86-B/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/CDS,S@S-CDY14(V-4(S-$-$
M1C!"-T9%-SDS0S-".$5!/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#ID,SDY,3%E82TW-C0S+6$Y-#@M.&$P92TT.3@R-&8X8S,Q
M.#8\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C4M,3$M,3A4,38Z,3 Z,SDK,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY,&1E-&)E82TQ93(T
M+34P-#$M8F5C,RUC864V-#9C8V8P,#@\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,3$M,3A4,38Z,3 Z
M,SDK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z86,Y-F5D,3,M9#4P."TX-C0X+3DV,3(M
M-6$P,CDW9C8W,C R/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(U+3$Q+3$X5#$V.C$P.C4Y*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z838T
M.# V-F4M8S)D9BUB.#0T+6(T83$M864P9F8R-# Y86-B/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3$Q
M+3$X5#$V.C$P.C4Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N
M," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#IA8SDV960Q,RUD-3 X+3@V-#@M
M.38Q,BTU83 R.3=F-C<R,#(\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3!D931B96$M,64R-"TU
M,#0Q+6)E8S,M8V%E-C0V8V-F,# X/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/CDS,S@S-CDY14(V
M-4(S-$-$1C!"-T9%-SDS0S-".$5!/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QD
M8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \<&AO
M=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @
M(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4O/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C R-2TQ,2TQ-U0Q-SHQ,SHS,BLP-3HS,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(U+3$Q+3$X5#$V
M.C$P.C4Y*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-
M971A9&%T841A=&4^,C R-2TQ,2TQ.%0Q-CHQ,#HU.2LP-3HS,#PO>&UP.DUE
M=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  8$!08%! 8&!08'!P8(
M"A *"@D)"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH
M,"4H*2C_VP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" ,M!V0# 2(  A$!
M Q$!_\0 '  !  $% 0$               $"! 4&!P,(_\0 8Q   00! @0#
M! 0)!P<'" 0/ 0 " P0%!A$'$B$Q$T%1%")A<14R@9$((S5"4G.AL;(6,S9B
M<G3!%R0T4X*ST24W59*3HO!#8W64M,+2X1@G.$149(/Q5F6$PR9&1TAVQ.+_
MQ  : 0$! 0$! 0$              0(#! 4&_\0 -!$! 0 ! @0$ @H" P$!
M 0    $" Q$2(3%!!#)181-Q!2(S@9&AL<'1\$+A%"/Q4A4T_]H # ,!  (1
M Q$ /P#ZI1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1>=BQ#6B,MF
M6.&,=WR.#0/M*M/IK%_])4O^W9_Q07Z*F.1DC&OC>U['=0YIW!52 B(@(B("
M(""B B(@(B("(K7)Y&GBJ,MW)68JU2(;OEE=RM:/F@ND6IZ9XBZ5U-DCC\'F
M(+5P N$3002!W(W'5;8@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B BMH
MLA3FL&"*W7?.-]XVR N&W?IONKE 1:+DN*FF,=K>/2MFV]N3>]D1(83&U[OJ
ML+O(G<?>MZ0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!%;5\A3L3.BKVZ\LK?K,9('.'S *N4!%HS>*>F':Z.DQ;?\ 2@?X._(?
M#\3]#F]?+YK>4!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!RO\)TEO!_+$$@^+!U'ZQJY)
MP>X+8K6^AZ^9O92_!8DDD86Q$<HY7$#NNM?A/?\ ,]EOUL'^\:N'\-<UQ5Q>
MA!)H_'QRZ?A,L@E,<3CN"2_H3S'8[^2D[E[+S"6LWP=XQUM-C*37</;EB:Z-
MYW:]DAV#N7\UP/F/3XKZ"XD\3,#H"O%]+222W9F\T52$;O</4^@^)7SWP&P\
MG$7B19U)J?*,L7:#FV#7=OXDCAT:=MM@QOP\]EZZN;5L_A3LCU?R#&"Q&U@F
M^H6>'O&#\"__ !5VZ0]:W_!?A+:<O9&.OD<;=Q\+W!OCN<)&M^) Z[+I'$'7
ME'1VD6:@?"Z_3D?&QG@/'O!X)#@>VW1:-^$U3P#.&$\EJ*I%=9)'[ 6- >7;
MC<-V\N7??R7+KAN2_@F4_:@]S&9/:$N_U7,[;[-]U-^JQ]+</M4PZSTK4SE6
MO)6BL%P;'(02.5Q'<?):?@N,F.R^KLUI^/&68YL9'8D?*Z1I:\0G8[#XKR_!
MIOU3P?QWX^,"L^5LQ+MO#/.3U].A!7)> ]B"]^$/J"Q7>V6O.+CV.'9S3(-C
M\B%KOLSVW87(\;+\_%2//06<M%I]KV%V+%H\A 9RD<N_+U/7LOIK0>O\=JK1
MDVI71NQU"%\C9#8>#R!FQ+B?3JN!ZGBKQ?A:58W1Q,@\> <I: WK /+MW70_
MPJ!-7X6"/&1MCJF]&+(B  #=G$;@?UN7]BS+]5K;FQ^4_"9T[6R#X:6*O7*S
M7;"?F:SF'J&GJNI</]=8376*==P<Y<8R&S02#EDB)[<P]#Y'LOG[A58X@.T5
M!#I+3VG+>++2V1\DL7/(?/Q 7;[_ #6=_!^T/J?!:_R68R-*E6Q=F*6*05+<
M<C&2<[2& -<2-NOR6MD?1NZY1Q$XY:;T=DI,:UD^2R$1VFCKD!L1]"X^?P"Z
MA<+Q4G\$?C.1W+\]NB^4/P78<;:XAYU^H1$_-!A= VR 3SEY\0C?\[M\>I69
MSNQVW=:X?<>-.:NRL6-EAGQ=R8\L(G<"R1WZ(<.Q/D"N6?A6:Z^D<JW2=:.:
M)N/F$EAQ<.68N8"WI\.8KV_"XK8>OE\')CA#'FR'^,V  .+!MR%VWGOOMYJO
M\*9DO\E-$378VLOR0DV'<H#B_P -F^Y^>Z=8L9S\&6UHV]F)1@,#9IYJKCVB
MS<FL.D$N[FAQ#2=F[G;MMTZ+Z*6M<-ZT$6A]/R10Q,D?CH.9S6 $_BV]RME6
MJS!$111$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MB6-KP/3<;KYW_!'T]BKFF<ME+=&O8N>U^ U\S _E8&-.PW[=25]'- :T!H
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M;9IV+DS(?'&_N-,0YNW?IOT72=4XG_(3PHR;=/Y"Q:OY.RR(6)6@&)Q:07-
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M6 TGBY75F9&-EB=[7$%_.XL8S?T!!)]>GHO:?\&/'?R?9[%G;@SH:'&:1K?
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MJQV*D)QF1/M]0$<O*X'WF[?)W_=75;MW!Z8QM:*Y)1QE"1[:\,98&,<X]F@
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MPED3^1V_=5UV.CA8Q[N9P&Q/JO.Y")H"POY.N^ZKK,\.!C.;FY1MOZH/1$1
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MXFZO8VW@H*F!Q$OO0.L.'B/8>Q/0D_<%[_A%L><#@II@YV/CR+?:@/0CIO\
M9S!=1A?&^G')0$;H71!T !V:6[>[U]-MD'+8I>+&GG":S%C]0U6_7CB>!)M\
M.C3^];?HO76)U4Y]6N)J>6A!,^/LMY9(]NY'D1\?V+3K/%;+Z<R'LNMM+OI1
M%^S;55Y<PC?N-^COL(*Z+A9,+F S/8EM2P^=G(+<;!XA'FTGN#Z@H-1XXX)V
M2TB,I4>(\EA7^UP/WV/*-N8?L!^Q;;I'+LU%I3&90M:6W:X=(PC<;_5>"/3<
M%8+7G#O'ZQMQ6K5_(4YXX_"/L[QR/;Y;M(VWZK1++M3<&JT8@ECS^FIGEC(Y
M&F-T$AZ@#;<C?KVZ$^009[$Z7S^A]9@:5KMO:4R,H=8K/D#33)[N&Y[ =MM]
MQT*R?%W3^3SSM+#$5C8]CR@FG<'!OAQ[#WNI[=/)8MMSBQEFB6"EAL-"X;M9
M*.=X'QW)6%U+JK7^BF-FSF5T[:WZBL6CQ'#X!NQ'S0;IQOOWL=P_NV\3:EJV
M631;21'9P!=Z_<LGIW6V(NX#&VK&7I16)J\;Y6/G:TM?RCF!&_3KNN,:QXL#
M5^A[>+=A)H+DKF'Q87F2+W7;D]MQV[+VT'C>%6:H4Z>1-B#,<C6S&S.Z(/D\
M]B.@&_8=$'6M8X;$Z_P,E*OD*S[<)\:K8AE#G02#L[H=]CYK4\?J;B'IFM['
MJ#2QS;(ARLNU902\#L3MOO\ : 5M6EN'&FM+9;Z2Q%>Q':$98'26"]K6GN0/
MEYK(Y#6NFL8UQMYZ@PM[M9*'N^YNZ#ENBK,_%#B&<EJ".&M5P; Z'%[G?G)Z
M.<#U.QZD_ !;QQSDC;PNSAG(]]K&LW\WEXV_Q6MZ(MQZNXP7=48."2'"UJ9J
MRSN;RBS*>W3[C]@]5/%2X=5ZRP.AL<3(QD[;>2<WJ&-;^:?D-S\R$'2M*"1N
MF,.)]_%%.'FW]>0+*JEH:T!K  UH  'D!V52@($1%2B(B"E0I0$1%1(10%*
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M(@(BU&:7*:AS%ZK1R#\7CZ$@B?)"P.EFDVW/5W1K1OZ;E2W8;<BU7^2^2_\
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M1^AS2 O;\@[K]JW99PY[VI!$1;5Y2UH)F[30QR#T<T%6APF*)).,I$_J&_\
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M/ :>W.%Q%.J__6-9S/\ ^L=S^U!K'#'3%R+(Y'5VHV<F<RVY97\JD)ZAGS(
M'P V70@B!!*(B JME2I""41%%2B(@*0H4A$$1%0"E0%* @1 @E$1 "K;]8?-
M4*MOUA\T'.N%OY8S_P Q_&Y=$7.^%WY8SWS'\;ET18T_*QAT2.RE0.R+;8J@
MH4CL@(B(B6^:PVKO?Q<4).S9K=>,_(R#_@LR%AM5$"K0)&X]OK_QA9RZ4;8$
M1%I1$1 1$0$1$&$R^T.?PMC\Y[I*WV.;S?O8%FU@=3;^VX';O[>/]V]9Y9G6
MI!$1:41%B-1Y1V/K1Q5@'Y"V[P:L??=WFXC]%HZGX*6[<QYYG+RQVVXW%,CE
MR3V\[C)OR0,[<[]N_7LWH2O#'8*"O/[7<D?D,B?K69P-Q\&-[,'P'WE>^%QD
M>,KO:'&6S,[Q+$[NKII#W)^'D!V Z+(*2;\ZAYH$1:5*!$02$4*4!$1!*(BJ
M+<S 7!#X?7;?G5R%;F63VP1<GXLC?GV^"N!V4!$]4\E1(1 I0$"($$HB( [J
MHJE8766>9I[!372WQ)R1'!'YOD/8?X_8I;)-Z,I<N5J41EN3Q01#\Z1P:/VK
M%1:PT]++X;,Q3+]]MO$V_:OG?-Y;(9FXZQE;$D\W8!W0,^ ;V"L-AZ+R7Q-W
MY1SXWUFQ[7L:]CFN:[J"#N"%R36NG(L1->]I+AI[)3B8R,;N:-CL'[>;#UW6
MJ:$UK<TW:CAFD?/BG.VDA=U\,?I,]/EV*[Y#)2S&,#XS%:I66?VFO:5TF4UL
M?=J691\RYK%V,/?=5M!I.P?'(P[LE8>SFGT*L%U?5^G*^%8VK>9(_3;W;5[(
MW<_&R'RW[F,GR*YKF,98Q-]]6T 2!S,D;U;*P]GM/F"O+GAPUSLV62(O6K!+
M:LQ5ZT3Y9Y7!C(V#<N/HN;+?>&VO9,+)%C,LXR8U[@V.0GK 3^]O[EW*-[9&
M->QP<UPW!!W!"T+27#C'4<-*S,0,LW;47)*X]1&#^:STV]>ZL,=>O</LK'C,
MQ,^?3DYY:MIW7P#^BX^G_@>:]VG<L)MGT=L=Y.;IR*&.:]C7L<'-<-P0=P0I
M7=L1$0$1$!$1 1$0$1$!$1!:W+ ADA:8N?G.V_HKI6UN:6)\0BCYPX[..W97
M* B(@(B("(B M;T3WS__ *6G_P#=6R+7-&])=0 [=,K+^UK"LWK$;&B(M*(B
M("(B B(@+6] [#%7F@[M;D;8'_;.6R$@ DG8#J5K?#T<VF(;![VIIK/S#Y'.
M!^XA9OFB=VR(BUKB%J'^3FG9;,1'M<I\* '](@]?L'56V2;U6>@N5K$TT4$\
M4DL)Y9&,<"6'T(\E[KYGT?J*?3^HH\B7N?'([:T#U,C2=W'Y^:^DX[,,E1ME
MDC37<SQ!)OTY=M]_ELN>GJS.,XY<2QU#EAB* E;$ZQ9E>(H(&]Y)#V'P'<D^
M0!7CIO$24(YK-^46,I;=XEB7;H#Y,8/)C1T ^WS5AIP29R^_/6VN$ YH\=$X
M?5C\Y?[3]NGH/F5M"W.?-1$1:41$0$1$!$1 1$0>-R5T,!>V/Q#O]555WF2!
MCW-Y"1OR^BHN/E9 3 WF?OV5=9SW0,,HY7D=1Z%!Z(B("(B B(@(B("P^L_Z
M)9G^Z2_PE9A8?6?]$LS_ '27^$J9=*EZ+>QJ'&X''8L92QX GB 8XM)&X:-]
M]OFH_EKIS;?Z8J;?VES_ (S?D/37]EW\#5RH +S9Z]PRV8N>W)]$Y//X[/Z1
MU [%S^,R&M(QSN4@;\A/3=;%AOR33_4L_<N0\-_^;[5OZM_^Z*ZY@W<V&HGU
M@9^X+KIY<7.M8W?FO41%U:$1$!<<XUZD$]B/!53NR$B6PX'\[\UGV;[G[%TG
M66<CT_IZW?>1XC6\D+3^=(>C1_C]B^:+$\MFQ+/8>9)I7%[W'N2>Z\WB,]IP
MQSSNW)L>E-%Y'4M*:S0D@;'%)X3A(2#OL#Z?%9#2&1L:'UO)0NO:Z"1S8+(:
M?=&_U7CY;_<2MTX$?T<R']\/\#5SCB5UUSE_U@_A"Y7&88S.=6=MI+'TBTAP
M!!W![%%S_A!J9V8P[\?<DYKU( ;GN^/LT_9V/V>JZ O9AE,IO'67>;B(BTHB
M(@(B("(B B(@QFJ/Z-Y/^[/_ (2M7X,_T4F_O3_X6K:-4?T<R?\ =W_PE:QP
M;_HK-_>G_N:L7SQG_)O2(BVT(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B#55*A2H"(BHD(@1 0(I'= 1$02%*@*
M4$*0B!!*(B I4*0@+6M=:/Q^L,:VO<YH;</O5;<?UX7?XCMT6RH@Y11O<3-*
M#V6_BH-3T(^D=F&4-D(^/YWW@_-6EWB/JS-Y-VG=/:8.-S$D?,Y]N7<PL\W]
M@ /B=_DNQ@KG6DS[5QEUM8=U->O7K-/W$_N058VC!PJX=9&[:F;<R+B;%B5V
M^T]AW1K1Y[;_ &]RL)C-&ZCUVZIDN(EX0XT$2PXFN.7?T+]N@Z?$GY*\UP9-
M6\3,)I6+\G8S;)WSY/(VY6'[-A_M+J?F@HABCAACBA8V.*-H8QC1L&M'0 !5
MHB I4*4 (B!!*(B %([* I'902B)ZH)1 B**0H4A$$1%0"E0%* @1$$HB("K
M;]8?-4*IO<(.>\+Q_P KY[YC^-RZ$N>\,/ROG?F/XW+H2QI^5C#HD=E*@*5M
ML4CLJ54.R"5"(@EJPVJ^E"J[I[MVN>OZP+,A876)VP3G'8<MB!W4;]I6K.72
MI>C;40(M*(B("(B B(@PF;'BYK"0CZS9GS?8UA'_ +P6;6OP.-W6]APZPX^H
M(C^LD/,1]C6M^]; LX]ZD$18K*YZECI! Y[I[COJ58!SR.^P=A\3T5MV5D+=
MB*I6EL69&QPQ-+WO=T#0.Y6MZ?@?;M6,Y;#O&MCEKM<-O!K[[M&WD7?6/V>B
M/IW,W-%-FF-KTHR'MQ[7<W.X=0Z5WGM^B.FXZDK.A2<[N@%*@*5H$1$5*(B(
M*5"E%$1$$H@1$>'-/[6&AOXC;O\ %7 5N6S^U[AP\#;M\5<! 1$5$CLI4#S4
MH"! @02B>J("YUQ#E=)K73,#OYJ%DUL ]B]K21_#^U=%6D<2\?(WZ,SU>-TI
MQDA,\3>[X'='[?(?XKGJR\*7HX-)(Z61\DAW>]Q<X^I)5*RVH,1]&RQ35I!8
MQEH&2K8:.CA^B?1P[$+$KYUEG*N MLT!K";3%XMEYY<9,?QL0Z\I_3:/7X>:
MU-%<<KC=XLNSZHJ6:69QC9J[X[5.PSOMN' ]P1_@N7ZLTV,/#)4NM=+IJ1Q=
M7L-'-)C9#VZ=S'\%J>@M9V-+VG1O:9\;*[>6'?JT_I-^/P\UWRO-3S6*$L19
M9I68_/J'-([$+V2S5Q]W6691\OUJ<UNZVI28;,SW<D8C'U_B-^P^:[UPYT7'
MING[1<#)<K*/?>.HC'Z#3^\^:UFQBAPVSYS%>O[9A;'XI_3>2KN=^A\QT_P7
M4L==KY&E#;I2MFKRMYF/:>A"SHZ<QO/JF&.W5<*TRN.JY6A+3OPME@D&SFG]
MX^*NT7IVW=',<9<M\.\DW&9=\D^G9W_YK<(W,!/YCOA_^?Y=,BD9-$R2)S7Q
MO <US3N"#YJVRN.JY7'S4K\39:\K2US2/VCT*T/A_:M8+4U[2-^9\T,3/&I2
M/[\GZ/W'?["N4^I=NS/1T=$1=6A$1 1$0$1$!$1 1$06UMUAKXA7:"TGW_@%
M<JVMML.?%[.X!H/O[^85R@(B("(B B(@+6](G;):F9T]W)$[?.*,K9%K>GAX
M.JM3P?I206!\>:/E/[6+-ZQ&R(B+2B(B B(@(B(,/K"Z<?IK(3L_G/"+(QZO
M=[K?VD*[P5(8[#4:;>T$#(_GL %B=2!F0S.(Q6^_XPW96_U(^V_S<YOW+8UF
M<[NB'N#&.<X@-:-R3Y!?.G$G4G\H=0221/)H508X!Z_I.^T_L 73>+VIAB<*
M<;5</;;S2T['^;C_ #G?,]A_\EP9X_%N^2\WB-3_ !CGGEV;;!P^U)-29;BI
MP&O)&)6N\=H):1N#M\EL7#;*6,_5ATS9LLBIP@RO[^)8C!_FAY >OGMT]5T_
M"G?1=$__ *O9_NPOF["9";%9*I?K$B6N\/ !VYO4?(CI]JSE)I66=RR8OJJ-
MC8V-8P!K6C8 =@%*L<%DX,QB:U^J=XIV!P'H?,?85?+V3FZB(BH(B("(B B(
M@(B(/"YXW@'V;^<W5=?Q/ 9XW\YM[WS5-MDKX2V!_(_?NJZ[7MA8V5W,\#J?
M4H*T1$!$1 1$0$1$!8?6?]$LS_=)?X2LPL/K/^B69_NDO\)4RZ5+T<VXS?D3
M37]EW\#5RI=5XS?D337]EW\#5RI>#6\[CEU=-X;_ /-]J[]7)_NEUO ?D2A^
MH9_"%R7AL">'^K0._AO_ -T5UK ?D2A^H9_"%Z='I/DZ8=%\B(N[8B+2^*6I
MS@,&8:KMK]P&.(@]8QYO_P"'Q4RRF,WJ6[<W,N*NHSF]0.K0/WI428V;'HY_
MYSO\%I2>2+YN65RN]<+=^;M' 9X^A,HSS%D.^]@_X+FVOI/%UIF7>E@M^[HM
M]X"R>YEXO0L=^\+G.K7\^JLR[_\ &Y?XBNN=_P"O%J^6&ELU-@,Y6R$/4,/+
M(T?G,/UA_P"/1?3./MPWZ4%NK()()F!['#S!7R@NM<$]1@"3 VG]=S+6)/E^
M<P?O^TK7A\]KPU=.[<G7$1%['41$0$1$!$1 1$08S4_]'<G_ '=_[BM8X.?T
M6F_O3_W-6SZG_H[D_P"[O_A*UG@Y_1:;^]/_ '-6+YF?\F\HB+;0B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(-5
M4A0I"@(B*B0B!$! B!!*(B .ZJ5(52 B(@E%"E 4A0@02B(@D+G7#4"7B#Q$
MG=T_Y09'\@ 5T4*B*&*)\KXHF,?*[FD<UH!>=MMSZG9!S3@XPY3-:RU/)[WM
MU\UJ[C_JHR>WWM^Y=."\X(8J\?AP1,BCW)Y6- &Y.YZ+T""41$!2H4H"(B"4
M1 -R@*H=E2002"-BI'902B(@D=D0(@*0H0()1$5 *5"E 1$02B(@*MO<*A5,
M[A!S[AC^5\[\Q_&Y=!7/^&7Y7SOS'\;ET!8PZ,8=$A2H"+;:5+52I:@E$4H
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MB3:FKTS;T[:)?<J1_P Y6?\ ZZ+_ ! 7EU=+O&,L7&$63S>(DQ<D;VR"Q0L
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M6 .#>;H"-]]_@4G2G>.C;';?;HH"^<<[I+B[A\59S<VKYI9:S#/-7BOO+FM
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MF\=Y=Q$1:41$0$1$!$1!;WFQ/KD6'%L>XZA>E4,;7C$)WC ]T_!>=XPBN?:
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MHMX#</FN!&&DW!W'^=R__$D*U"JX/_"WLN80YIQS2".Q'A-6(X*X#%YCC#Q
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MDTTMYX]Q'H9G]?VK;J\,=:".&!@9%&T-:T=@!V"[Z.&6&\K>$L>B(B[-B(B
MB(@(B(/"Z^*. NG;S,W'3;=5UG,?7C=&.5A&X'H%1=F$$!>8_$ZCW576?XM>
M-X;R\PWY?1!Z(B("(B B(@(B("\+U9ERE8K2_P W-&Z-WR(V*]T0<SFQC<[A
M1I/-3>R9F@>:K*X;MF8.C7M]00=B.X*TUO"W4IM>$8Z;8]]O'\?=NWKMMO\
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MF(/1[7^0;TW'_@<QGFEL<"M)R6'E\GM--I<3OT;8+1U\^@ 6YYG_ )Y\!O\
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MOVGGB]GVY=_?W]%<JWM1SO?$8) UH/O#U"N$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0>-MLSH2*[N63?NJZX>(6"4[R >\
M?BJ+<<DL);"_D?OW5==KF0L;([F>!L7>J"M$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$08[4?Y R/ZA_[BM=X3_P!&I?[R[]S5
ML6H_R#D?U#_W%:]PH_HW+_>7?N:IW8OF;DB(JVUC7>L*NCJF/LY"&22"U:;6
M)CZEA()WV[GMML/58.WQ(GQ'@6=3:;R&(Q$S@QMZ1[9!&3]7Q&MZMW^WT3BZ
MUK[>B0\ CZ>KG8_[2N^-#6NX=WPX @SU00?[Q&IORM.^RSL\1[5.HW)W]+Y.
MM@"X;WGN:7,8>TCHA[P;^U;)JC55#3^,KVY_$LOM.;'4KUV\\EA[NP:/V[]@
M%:\2&M_R;:@&PY?H^7I_L%:/D)/HB+AMJ2^U[\/3IB&S+L7"L9(FALKMNPWZ
M$^6ZOL-GKZ\M5;U*#4^G+V%@N2-AAM/D9-&)'?58\M^J3VZ]-U<ZKURS :DJ
M81N,MW[MRJ^Q797VW>YK@WDZ]!T)/,3L-EAN).I,-FM/-P.%OT\IE<K+%'6A
MIRMF+??:XRGE)Y6M +N8].BNIX^7C5A6OV>YF G',?7QHQNH+["ZUEGU!#A<
M]AK.&OV6&2KXDC963@?6 <W\X>BI%K'Q<1<NRGB/$SL6+9*ZR)-C,SF/+'UZ
M#J!U5EQ) &LN'I'?Z3D&_P#^1<JL=_SWY?\ ]#0_[QRL/[^;$<,M7ZGRV6SM
M?(X::6O%EY8#*ZQ'M3:&M/A[ ;NVW[_%;/G-9RULW)A\'A[6:R$+&OL"%[8X
MZX<-VASW?G$==N^Q"UOAIE\;B<]K?'Y2_4IWIL_))%!8E;&^1LC6<A:"=R#L
M=ME[Z4RE'2^L-68S4-R"E:OY Y&K+9D$;;$+V- #7'8$M+2W;OT3T/5L^D]6
MPYZS;H6*=C&Y>GL9Z5C;F:T]G-(Z.:?4+#Z5XAOU/<$&*P=V2.*>2"Y8<]K8
MZQ:X@#<_6) !V'8$;JPPUJ#4W& YC!N;/B\9C7TI[L1WCFE>\.$;7=G<H!)(
M[%7G UK1HB1S6@%V0MEQ'F?&>.OW)!E=*3XQ^H=7,QV/]FM076-MR\V_M#S"
MQP=MY="!]BP.'XEW<]B8LAI[2>1OUO#YI7^,R,->.[&\WUR/AT5_H7^EW$/_
M -)1?^RQ+UX*L:WA;IOE:!O5!.WKN5)_"LK@]78O+:7=GF3&O2C:\S^..5T)
M9T<UP]00M?K\0<C:K#(U-'Y>;"GWFV0Y@D?'^FV'?F(^'<K4JF&M9W0?$C'8
MQ@?8=G++HX=]A)RECN3[=MOM6WXWBEI3Z$BDGR#:MV-HB?C'L(M,E'3PQ%MS
M$[].@V51GM#ZHK:NPTF3H,<VL+$L+"X[\X8X@.^ .V^R\M<ZOK:0J8^S>@FF
MBMVA5 A&[@XM<1L//<MVV^*P7 R5T^D;LSZSJCY,K<>ZNX;&(F9QY"/4=E=<
M36M?D-%->T.;].1]"/\ S,J;=B+Q^LOH_3$^9U'C+.):V41Q57N;+-,3MRAK
M6_G$G;E^"L(M>7:L]4ZBTS?Q%"S(V)ER21DC6/<=FB0-ZLW) W[;D*QXVTK3
ML;A<G5FLPU\7?;8LR5HA+)%'L090P@AW+OOV/3<K#94X[)8R.K>XK27:F0+8
M&UXHZCWS%Q  #6,YP=R.H[=^FR0;WJO5S,)?J8VC1GRN9M-,D=*N0TB,'8R.
M<>C6[]-SW6%'$A];-XK#9G!6\=D\A8$,<;Y&O:6$$^(UPZ$ C8CH58R6*^DN
M+,]S.SM@Q^4QD%:I>L.Y8V21./-$7GHTN!#NO?98_B!J3%9;7VA*6*FAOR09
M+GEL5R)(X=V.V87C<!QVWY=]]NJ3L7NZ%'J.-^MIM."N\2QTA<\;F'*07\O+
MMZKURN=9C\]AL8^%SWY(RAL@.P9R-!ZCSWW6FYB]6T]QF@O9F9E.AD<5[+!:
MF=RQ>,V3F+"X] 2.HW[KRS&I<;F.*6D:>(M1WA6]J=-/ >>)CBQNS.<="[8$
MD;[CHI!M.*?C3KW.QUZ BR;:]=UBUS?SS3S!HV\MMEB\#Q DSV6DI8G!7)XZ
MUN2K;LE[6QP<KRW?<_6.PWV"]\'_ ,Z6IO[E4_\ ?7EPA8T:>RA: "<Q>)('
M<^.]6"N_KF=^6N4--8*WG'4G<EJ:*1L44;]M^0.=]9WJ!V63P&KJ&5PUW(3>
M)C_8'.9>AM#E?5<T;D.^&VQ!'0@KE>BX;&'GRN#R>N;.G;\%R:;V::*LUDT;
MWES98WR,)>"#UZG8CRZ*_P A@6:@T)K=^G=13ZDR-QC8))A&QC9'Q<KN1I8T
M-<2WW=QOWVWZ*=COLV>#B%?L51DX=)Y-V!(YQ=YV!QB[^*(OK<NW7UV\EX\
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MFL#8RMN*26&$L!9'MS'F<&C;?YJ*S"* I02B>2(@I4*0BB(B"W\2+VT1F/\
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M&_3ZH\EN3=4,OZ3N9?"TK=F>#GC?3<UL<T,K?K->''8%O<^H[+$\(@!A\Z0
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M4I6>S10/YF[L.Y?N & =SOMV]5<:@REBAI_2=<99V$H6X8V6<BU@<8]HFEK
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M6 B(@(B("(B B(@(B(+>T+!?%[.X!N_O[^BN%;6X999(C%(&!I]X>JN4!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0>-MDKX2
M('AC]^ZKKM>V%C97<SP.I]2O.[$9H"QLGAG<>\JZS#' QA=SD#;F]4'HB(@(
MB("(B B(@(B("T[B?<Q\&*H5;V&CS=BY<9%4HRD!CY>I!<3TY0-R=]_DMQ6)
MU/I_'ZDQOL64B<^(/$C',<6/C>.SFN'4$(.3YZ+-T=::'NW\%A,3([)MJ"?'
M3ETDD;HW<T;AR-W9TW\]B%G/H:AE>/63?D:\=EM7#5WQQRCF8'^(\!W*>A(&
M^Q\MRLW7X:X=F0H7[-C(W;]*PVQ%8M672/!:#LWKT#>O4#OL%L$. J0ZGM9Y
MAD]MLUF57[N]WD:XN&P]=R41IKJ\.)XW4H<9#%5BR&(EDM1Q-#&RO9( UQ _
M. )&_?95<,L/B\E2RV6R5.M<R]N]9BN26&"1S0V0M$7O;[-  &W9;A/I^G/J
M>KGG^)[=6K/JLV=[O(X@G<>NX6'S'#_%9#*3Y&";(8ZU8_TAU&RZ$3_V@.A/
MQ[J16L\,L=C\5Q2U[2PY J11TMHFNW;"2V0EC?0 GMY;[+*<=?Z!._OU3_?-
M6>TOHW$::O7+6(B?$ZW%%%(TN)!\/FV/7J2>8[D]U>:GP-34F+./R!D\ RQR
M_BW;'F8X.'7Y@*^AZM6U /\ ZY])[]OH^[_[BQ6/R\7#N[JS$VFGV""$YC%L
M\G,>[E?"/E*1T_KK?[>!J6M28_-RF3VRE#)#%L[W>5^W-N/L"M]2Z3Q6HKV*
MMY.)SYL;-XT!:[;KZ.]1N =O4!0<HU+BLGB]):6QUB.&Q9SV4-C,-L3&**Q/
M(TO$3W@'9NX:T =^4!9;*:<U1=?C9(-,::Q5JC/$^O;IVG,?"UKAS, $8W:6
M[M+3T.ZZEFL32S6-FH92NRQ4F&SF/'W$>A'JM9QG#O%4K]2S+;RMT4WA]6&W
M<?)'"1V(!/4CRWW5&!LXBGEN/<IR=>.RRO@8I612#F9S^.\!Q:>A(!.WIN5U
M!C6L:&L:&M V  V "Q,> IQZIFSX\3VZ6HVD[WO=\,/+AT]=RLNAW$1$!$1
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M0B(B"!$"HE-D1!(Z(H52 B(@E% 4H'DI:H"D()"(@02%*I"J4!$1 1$11$1
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M+8B(@E2H'92@*5"D("(B"6]-U(4#NI0$'=$05(B(@%4J5([("E$5$A H:I"
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MBRV(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M8Z.!C)'<S@-B?5478O&@+#)X?4>\JZS/#@C8'<W*-N;U0>B(B B(@(B("(B
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M9C\E7/U3OW%8C07Y%D_7._<%N>6L7S-C1$6&Q$1 1$0$1$!$1 1$0$1$!$1
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MQ]2H'FB&ZH$]>I^]-SZG[U \U*B[@)]3]ZD$^I4(AND$^I4[G](_>J0I0E5
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M[Q]%<H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@\;<KHH2YD?B'?ZJJKO,D#'N;R$C<M]%3;?*R$N@8'OW[*N!SW0L=*WE>1
MU'H4%:(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@M,O^2[?ZIW[EB-"_D>3]<[]P67RWY+M_JG?N6)T-^1W_KG?N"W/)6+YFPH
MB+#8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B(++(R;-$8/?J?DK#R7O<=S6'_#HO!>C";1X]2[Y(5/JJO-1ZK<8
M0GJB("A2H1! B>2L1"@=BI4>JHA$1$% \U*CU1!/-$\U1")Y(@* I0=!N>WJ
M@!/50TAP)80[;T.ZL\GDZ.+B$N1MPUF'L9';;_(*SGRALO"BUVOK;3=F41Q9
MBJ7D[;.);^TA9\S1-@,QE8(=M_$+AR[>N_96XW'K%V5H%KMG6VFZTA9+F*O,
M.GNDN_<%D<1FL;EP3C;L%G;N&.ZC[.ZMPRDWL39D$1%E!%*A 1$0$]41 1/-
M$! B! "($0 B!$$CS1!YJ$5(1$0 I'E\T"#N@PNG_P#2;GV?O*S2PN _TFW]
MG[RLT5&LNH/-$'FB,@[E/5 B"0I4#NI0$0(% "E0I]46)1P):0#L2.A]$4^2
M*Q7+F(?JRU+0_K@QN_9T5I?CRLTC)V4(XK48V9-%8:3MZ$'N%L"+<U-KOM'*
MZ.\VXK_?FPM?+7((@,MCK$9'>6%O.T_8.RR5*]6NM+JL[)=NX'<?,=PK@+'Y
MBE6EKR6)&EDL+2]LL?1[=AOW4WQR[;+)GA.N_P _Y_TR(WV4KEWTK>-T6S8>
MZ8'?<GH1Z;>BZ72L-MU(;#/JRL#P/3==-;P^6EM:QX?Q6.OO)-MGN$4!5>J\
M[TQ*E4JI%$"(BQ(4A0%(4$A2% [J5%%(\U"D(J5(\U 4CS4$H$0**\MY?:-@
M/Q6W=7 5ORR^T[@_BMNRN!V4C5 I'90I18D*1YJ I"@*L=RJ J@HL2I'FH"D
M>:BQ(505*GR"BJD1$5*K'94*L=E*L$1%&A$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$%M;=8:^(5V[M)]_X!7*M;C;!DB]G.S0??Z^2ND!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0>-SQO /LVWB;^:JK^)X#/&
M_G-O>^:IN,E? 6P.Y7[]]]E57:]L#&RGF>!U/J4'HB(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(+7+?DRW^J=^Y8C0_P"2)/US
MOW!9?*_DRW^J=^Y8G1'Y(?\ KG?N"W/)6+YFP(B+#8B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(,(X[O<3YE1Y*
M52O4\-/-1ZJ?,JGU50\D1$!0I4(@@[(@[*Q!4^14J/540GJB(@H4J!YH@GFB
M>:HA%*U;4VN<-@#)#+/[1?:.E6$<SM_(./9JN.-RNV,W)%>M=5Q:;KPLCA-O
M)67<M>JT]7>6Y\]M_O6O#1>;U$&VM69RQ"YW44J@#61CT]/V'YK$\,[]?4&M
M+^5S4[3F>7:K7<W8,9Y\OQ Z;=^I*ZT'MYPSF;SGKR[]?N7?+?0O#CU]?X:Z
M.>NX9,J#Q<'G<E3M-ZM<Y_,TGX[;+7M&8&',ZMRM36ILW<M4 (CED/(YO3KT
M[]QL.VQ6Z:%S.0S66U'+8E#\=7L^!5:&@;;$[]1WZ;=_58_(%L/&G'F+8/FQ
MY$OQVYMOV +I,]3ZV.5Y[#-9+1^E31D-S%48*[&[NE'XKD'KS ]%KE?A=4DD
M:'YN]/B">>*JUW38]O>WV(^("W+6%&/)Z9R5!Y;S6('",$[;O YAMZ]0L'P^
MD?FN'%:!\LD$GA/JF2,[.9MNW<?'9<L<\YAQ3+NFZ)L3H3 M]GMPXF!^VQ;.
M[G>?GN25BLAH/$91K<IHN^RC89U:ZM(71%WV'=I_\;+V.B-'Z?@B?FB9I)Y!
M$V2S(XE[SV #5CM3XQG#W)T<W@>>&A+*(+E4O+FN'??K\ ?D0NF-Y[897?WZ
M57K@,1KVY!-+=U!-0EBD+&Q2QMDY]OSM]NRNWZISVEK,46L:T5BA([D;D*K=
MMC_6;_\ F^U;/-J[3T+F-ES-)CG@$ R==CVWV[*]LPX_/8J2"0PW*-AO*2QP
M<#\B.Q6+G;?KX\OEM^";KRO-%8@CFKR-EAD:',>T[AP/8A5KE\]+/<.XS8QD
MIRFG6.YI:[Q[\()[CX?$=/4+H>%R5;,8RO?I/YH)F\S=^X]0?B%SSPX9O+O$
ML7I[(A[(L((B("(B @3R1 "($0 B>J('JI'90%(0/)%(4(1*#N@\T'=%8; _
MZ3;^?^)68/98C!?Z1;_\>968\DK67410/-2HR#NI4#NI0 I4!2H"(B HD+FQ
MN+&\[@.C=]MSZ;^2%8V2/)R/<7V8JL6_NMB9SN(^)/162=[L6WI)NA^6EKG>
M]CYX6?IQD2@?/97U6Y7M1>)6F9*SU:>WS"QYH/<=Y+]UQ/F).7]P5L[ UC-X
MHFLME_3$FQ4N>E9UV6:6MC>F\][-_P FP-<'#H=U4L(VE:9_-9.R/[36N_>%
M92W,B)G5Z-XW)Q]8"%@:S^T[LF&,SZ7]?X-2W3YW&_E_+:5XW(A/3L1.<&M>
MQS2X]AN.ZP-7&YQ]XSV\BV,<NVT7O#Y<I&RO+N.K1UWV<G-8MLB'.6O>>7I_
M5&P73@F-Y9;_ "<YJ998W?';YN>/;X;W,W:2T[;@[CY[^BZEB86U\96BCD;(
MQD8;SM.X*TRC-$V?$SL:T-DGE\1NW0!S@-OEL0MK;A:T3W.I.FJ./4^"\@?]
M7LO3XK/BVEY?W9XO Z?#Q98\_P"[LDI6M7\?F#:CDJ97G#/*0ANQ^( V*\Q<
MR<4PAR=PU'NZ->(6.C?\G>1^:\OPI9O,H]WQK+MEA9^'\MJ7G9L0U(C+:E9#
M'ZO.W_YUAS6N.!#\I9_V6M;^X*U=@:TDHEFGM22CJ'/DW(^2YRZ??+\':XZN
MWU<?QO\ &Z_;FC9<1C:-BRW],[1M/R)64K/D?"QT\8BE/=@=S;?:L**#FG=E
M^ZUP[$R;_O7L(<O&T/K7(K3?..=@:?\ K!7?#+EC^_\ XSMJ8<\Y;^'_ *S0
M4CLJ&<Q:WF&SMNHWWV*K"PZ)"GU4!2%%%(\U"D(HJAW5(50[E14H$0*#S#)/
M:.</]S;;E7L.R\/"WL^)S[>7*O=O8J1I*D*%*"0@0*0HH.RJ'=0%(45([*5"
MD**E3Y!4A5>0454B!$5*K'94*H=E*L2B(HT(B("(B B(@(B("(B B(@(B("(
MB B(@M[44TCXC%*6!I]X>JN%;7*_C/B=XI9R'?;U5R@(B("(B B(@(B;H"+$
M7<LX6'5<; ;EP?6 .S(O[;O+Y=U3'B[-EG_*MV5_-WB@/AL'PW'O'[2MS#:;
MY79RNKO=L)O^B]NY.E2'^=VX(CZ.> ?N[JQ_E#!+_H-6Y;]#'"0W[W;!7=+$
M4*76K3AC=^ER[N^\]5?A7?"=M_[_ 'NFVK>MD_/^_@P[;V5>?Q>):UI_UM@
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MYQ$TN^9ZG]I5OJ4.GKUJ33_I4S6._L#=SOW?M5WE+\&*Q\MJR[:.,= .[CY
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M_P"LN4K[GT9CMIW+W?F_IC*W5F/I$(I39?1?)0JXHWS2,CB87R//*UK>Y*I
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M[%^G_H\\C-W1]=^A\NJRR(*)HHYHGQ3,;)&\;.:X;@CXA:[CM!Z5QN2^D*.
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M(^U>H0=UG+'BFS>&=PN\8'4W/]$2&-A<YKFNW'=NQ^LJJ=Z2+!QV[YWE+=P
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M/M,+PQUD&"5I[$;?6^87IQO'J<'OR_ON\>4^%I?$]N?W_P //'/DBQ>)L3
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M08>O,[E'<;>1/16FHN$N?R/!;3VDH)J(R6/F=)*]TCO#(+GGH>7?\X>27O\
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M/HNT/AA=/XSH8G3>4A8"[[]MU7\^I5FG>MK%U9MMC'S+^# ".(6?W!_T1_\
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M?<CRZ+J@[(@\UUDVFSCEE<KO1/)/5!YJH%!YHB B! @($1 1$]4$J%*A")1
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M$<G- QYY2V/GW/7IU/S5%QIWBAQ"UF;5[2M33452&4QMH6K!]I?MU]1WW[[
M+/\ $KBAG]-W-.X*GC\=#GLI R26:Y,16@>3L6[]-]COUW^]<SU1H_5N;%FI
M/PMH09F9W3)TYO#8#OOS='\FZWC5^ UA5TSIK&V])X[5]>G2$=M\TF\K9?ZA
MW#M@ !N-]_-!OO#;):XN7+,>L:V&--L0=#;QTI<)'$_5VW/8;]?DM^7 > ^B
M=28C6F3S=W$#3F#G@\-F,%@R<S^FQY221ML3N=CUZ=%WX("(B B(@\;;)7PE
ML#^1^_=55VO9"QLKN9X'4^I5-R)TT)8R0QG?ZP55=AC@8QSN<M&Q=ZH/1$1
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M02B#LB B*45AL!_I%O\ \>9686'P'^D6_G_B5F5O4\S&GY0)YH%!7-L"E B
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M*OSW<!-$]_AROY_ <&<XZ^H^J?7==!X@<'L9JO/#.4\C=PF9Y0U]FF=O$VZ
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M,.V^]/5)'S-B-:9[5/#;B+#E9?I'&UH![/DS5$!E/,!L0/,@;^H6;T15K_\
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M4JD("I514)$0B(@I>T.:6N <UPV((W!5I1Q>/H/>^ACZ=5[_ *SH(&1EWS(
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MWW5S#-'/"R6"1DD3QS->P@M</4$=U9M4YQA\IBIK.I,'>B,8KTA.)6D]2'M
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M!WLT7-'LY]7>\01\._HM7_RH:TU)GLG7T92P<%2C,81'D)FMFE(.V^SGCOZ
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M("(B B(@(B("(B B(@M;L[89(0Z(2<QV!]%=*VMS2Q/B$47.''9Q]%<H"(B
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0(@(B("(B B(@(B("(B#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g73463g14k43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g14k43.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2;N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )M$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQ  : 0$  P$! 0               0(#! 4&_\0 -!$!  (" 0," P8& P$
M P    $" Q$$$B$Q05$3,F$4(B-Q@:$%,T*1L=%BP>%2-/#Q_]H # ,!  (1
M Q$ /P"U(
M
M
M
M
M
M
M
M
M
M                    X/5#)[U8JG'Z''(:*2MNM4M,U:OBX&\M^Y37\>K/
M^%BOSR_B!)@(SX]6?\+%?GE_$<>K/^%BOSR_B!)@(SX]6?\ "Q7YY?Q''JS_
M (6*_/+^($F C/CU9_PL5^>7\1QZL_X6*_/+^($F C/CU9_PL5^>7\1QZL_X
M6*_/+^($F C/CU9_PL5^>7\1QZL_X6*_/+^($F C/CU9_P +%?GE_$<>K/\
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M\J@LJT]T;,K7T?'Q-ZMN_>OH E0
M
M
M         1GJK[M-.OVM_(I)A&>JONTTZ_:R_<4DP
M                                           $99QY9]/O@ZW[B$FD
M99QY9]/O@ZS[B 2:
M
M                                                          (S
MU5]VFG7[67[BDF$9ZJ^[33K]K+]Q23
M                                 1EG'EGT^^#K?N(2:1EG'EGT^^#K
M?N(!)H
M
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M.M^X@$F@
M
M                                                 ",]5?=IIU^U
ME^XI)A&>JONTTZ_:W\BDF          >)'MC8Y[W(UK4W5579$(^R#4ZBHYG
M06JG6ND;R63BX6(OI[S7%AOEG5(VSR9:XXW:4A AQNJEVZS=U!2*S^[Q+O\
M.=7C.HMONLS:>MC=0U+N3>-V['+YE-K\+-2-S#.G*QVG6W< (NZ;IS0'(Z
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MR7[4+8:#YA)F.!4M35OXZZF7J)W>+D[%^5 )$
M
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M(
M                                                     !&>JONT
MTZ_:W\BDF$9ZJ^[33K]K+]Q23    Q*FV4-3*LM1202R*FW$]B*I\OR);/>^
ME^K0V +1>T>JO37V:_\ (EL_W"F^K0?D2V>]]+]6AL .NWN=%?973+K:ZTY'
M74CF\+$?QQ\NUB\TV-03MJ!BB9%0LDIE:RX0?V;E[')WM4A&Y4-5:ZEU/<8'
MT\R=STY+YT7L4^@XO(KFI'O#Q^1AG';Z,<'CB3;?=-C/LEHKKW4]1;*=TSN]
MW8UOG53IF8K&Y81$SVAO--+3^5,GB66-'TU,U9)$<FZ+W(BDT?D2V?[A2_5H
M8&%8Y%C=I2G1W65$B\<TG]YWF\R&_/ Y7(G+DW6>T/8X^"*4U:.[7_D2V?[A
M2_5H/R);/]PIOJT-@#EZ[>[?HK[,2FME#2R];34D$4FVW$QB(NQE@$3,SY3$
M1'@ !"0 BWI YK+C&)I06N3:]75WJ:F1OMFHO)SD\_/9/.H$@VB^6V\/JF6N
MLAJG4LG53=6[?@=X+YSYR9'9HY',DNM$U[5V<U9FHJ+X=IJ-+,7CQ'";;;49
MPU*1I)4N[W2N3=RJOIY%7]/L&MV>:L9/;KM-410POFF:L#MEW23;^(%MFY)9
M7.1K;M0JY>Q$F;^)LX9HYV(^&1DC%_6:NZ$'R=&K%E:J,N-T8[N7C:NW[B/K
MI;\IT%RBCK:>NEKL8J94C<CEW:].U6N;W.V1514 MH#"LESIKS::2XT,B24U
M3&DD;D[T4R*FHAIHUDJ9HX8T[72.1J?.H'U!BT-RHJ_?U#64]1MV]5(C]OF4
MR@ ,6MN-%0HBUM73TZ+V=;(C-_G4^E)5TU9%UE'413Q_WHGHY/G0#[ &)6W.
MAH51*VMIJ=5[.ME:W[5 RP?.FJ(:F))::6.6->Q['(Y%^5#Z  #UD>V.-SWJ
MC6-1555[D Q*R[6^BG9#65M/!,_FUDDB-5>[DBF:G-.12G.HZ[4C)LSR2CD=
MZELK&]5P=BL:[A3;][BS6A^5?G;IW;:R1_%5P-]35'CQM1$W^5-E [>KJ(J2
MEEJ*EZ1PQ-5[WKV-:B;JICV:ZT-ZH&5MJJHJJE?NC9(W;HNQER,;)&Z.1J.8
MY%:Y%[%0@3#I5TSUJK\8ED5EAOB>J:)J]C)%7L3P[T^8"?0       ",LX\L
M^GWP=;]Q"32,LX\L^GWP=;]Q )-                               !S
M6I%A7)<(O%J9_:SP.2/_ #(FZ?O*/8-?ZO3[.H:Z:G?UM)(L<\#O8JK=]G(?
MH,1?J;HQ8,VF?6^RH+J[MJ(DY/\ \S>_T@<UF>O^+OQ"I_([YJBX5,*QL@<Q
M6\"JFR\2^8@_H]X[5Y#J7;ZB)BK!12)532;<DV7DF_BI)U#T7F-JF+79#QTZ
M+[)L<.SE3TJ3I@V&6;"K4E#8Z9(VKLLDCN;Y%\54"*.EMCDUPQ.ANU,Q7K0R
M[2HU-]F.1>?SD:]''4^VX6M=;+\KXJ*I<DK)FIQ(UVVVRI\A;ZMI8*VDEIJN
M)DT$K58]CTW1R+W$!Y;T:K5<*]U1C]R?;HWKNL,C>L:WT=X$2](34*DSO(J5
MEHXW6^B:K(WN397N7M7;Y"P/1FQ>;'M/8YZMCF5%Q?ZH5CDV5K>Q/W&DP;HY
MV:RU\5;?*U]SDB<CF1(W@CW3Q3M4G6-C8V-9&U&L:FR(G8B >0  ,2[?HJL^
M!?\ 8IEF)=OT56? O^Q0*'Z>>5NV?M'^<OVWL0H)IYY6[9^T?YR_;>Q
M
M                                                (SU5]VFG7[67
M[BDF$9ZJ^[33K]K+]Q23         !CUM#2UT2QUE/%.SPD:BF0"8F8[PB8B
M>TM W#<?;)QI:Z;B_P O+YC=4U-#2Q)'311Q1I^JQJ(A]06MDM;YIVBM*U\0
M  HL        %<,R<F5=)^QVQZ\5-:V,>YJ]BJU%D7^!8\K=C7L>EI=N/9%6
M.3AW^#3L LB5>Z/'EPRW_+/_ -U"T)5[H\>7#+O\L_\ W4 M"1GTC:""NTFO
M*SMW=3HV:-=N:.1W_JI)A#_2CO\ #:M-)Z%7(M3<I6PL;OSX4YN7;PY?O ^.
M@F1LM^A+;G<%7J;;UR=O:UJ[HB?.1YA^.7K7:Z7"^Y'=9Z.R0S+%#2P]GCPI
MW<D5-U.JL^/U%KZ+553JQ4GGI7U;F\]T1R[_ &&ZZ)\T<FEW!&J<<=9(CT[T
M7V*_8!R6;:*3X7;)LDP.\5L-7;V]>^![O;M;S794]'8O:2!IUJ:_)M+:^_R4
MZ?E&VQO;/$WL<]K=T5/,O:=QFTL4.'7R2H5$B;13*[?LVX%(-Z)$4;<5R:HK
M',;0/J48Y)%V;MP\]]_,H'-Z6872:NON5^S"_P!1+6^J',2D9(B*QNR*BIOV
M)SV1$3N-_<M*,FT_R6UW/3BKK*ZE?,B5%*^1&HC=]UXN>RM5.79R,Z^:"V^X
M5$UVT^R%]O=(]52-CU?$B[\T1S5W3T<SEKK>]5=)IZ>HOE6ESLO6HQ7.5)&/
M3?LXMN)JJB 3/K5G4^#X)ZO@C:ESJ7-@A:J[HQZHJJOGVV(UPW1-V6VN._Z@
M7BMGN5>U)DB:_G&U>:;JO?S[$[#X=*2X?EW ,2O%,BMHZF3K%1>UJN9NG\39
MV'1*HN5CM];2Y[=T@GIV2,1B<D16HNR>R[@.=R.RWG0F_6Z[V2ZSUV-5,Z13
MTTB\F]^RIV=F^REG;=5Q5]!35<"[Q3QMD8OF5-T(!OVA$"4D<=]U KO4[WIP
M-JFIPJ[S;N[2<L5MS;1CMNM[*I:ME- V-LZHB<:(G)>0&T. UUR5N,:;76HW
M_KZEBTD*(NR\3T5-_D3=3ORKG2,N%9FFHUGPJR.17P.3B1R[-ZUW>OH0"0^C
MOA<=LTM<ERC:^6]<4TS7)_Y;DV:B_)S^4XC0:LEP;5*_8/<55L=1*Y],J]BJ
MG-%^5OV&?3X;K7301P09-0LBC:C&-16[(B<D3VA&VIECSK#,CL^6916PU=:D
MK$9/"O9P<T:[9$[4W NB0#TM:):>TX]D%/[&JH:Q&(Y.W945R?O:39C5VBOM
M@M]TI]NJJX&3(B+V;IOL1/TM7,33*)'[<2UT?#]%P$KXQ<6W?';9<&KNE33Q
MR_.U%4V9Q^CK7MTOQE)-^+U#'V^@[       $99QY9]/?@ZS[B$FD99QY9]/
M?@ZS[B 2:                                             &)=OT5
M6? O^Q3+,2[_ **K/@7_ &*!0_3SRMVS]H_SE^V]B%!-//*W;/VC_.7[;V(
M
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M^E-C,       !&6<>6?3[X.M^XA)I&6<>6?3WX.M^X@$F@
M                              !B7;]%5GP+_L4RS$NWZ*K/@7_8H%#]
M//*W;/VC_.7[;V(4$T\\K=L_:/\ .7[;V(
M
M                          !&>JONTTZ_:R_<4DPC/57W::=?M9?N*28
M                          'R@IH('2.@ACC=(O$]6-1.)?%?$^H
M                 !ZR,;(QS)&HYCDV5JINBH>((8J>)L4$;(HV\D:QJ(B?
M(>X         $99QY9]/O@ZS[B$FD99QY9]/?@ZW[B 2:
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MLQ+M^BJSX%_V*!0_3SRMVS]H_P Y?MO8A033SRMVS]H_SE^V]B
M
M                                           1GJK[M-.OVM_(I)A&
M>JONTTZ_:R_<4DP
M                 $99QY9]/O@ZW[B$FD99QY9]/O@ZW[B 2:
M           &(VVT3:]]:E+#ZK>B-=-P)Q*B=VYE@   !SNH&3,Q#%*Z]24[
MJAM,U%ZMJ[*NZ[=IT1''2&\DU\_R)]H&HTIUI@S[))+3%:9*16P+-UCI$=V*
MB;?O);FBCFC=',QKV.396N3=%0IWT2/*54?$G_>:7' ^-'2P4=.V"DB9#"WV
MK&)LB'V             8EV_159\"_[%,LQ+M^BJSX%_V*!0_3SRMVS]H_SE
M^V]B%!-//*W;/VC_ #E^V]B
M
M                1GJK[M-.OVLOW%),(SU5]VFG7[67[BDF
M                                                   C+./+/I]\
M'6_<0DTC+./+/I]\'6_<0"30                      K7TILLON/9':(K
M+=*FCCDIE<YD3MD5>)4W4"R@/S]]<_,_^(J_Z8]<_,_^(J_Z8'Z!$<](7R37
MSX-/M*A^N?FG_$5?],Q+MGV47:WRT-RO=944DOMXGOW1WI D;HD>4FH^)/\
MO-+CE..B3Y2I_B3_ +S2XX              ,2[?HJL^!?\ 8IEF)=OT56?
MO^Q0*'Z>>5NV?M'^<OVWL0H)IYY6[9^T?YR_;>Q
M
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M,LQ+M^BJSX%_V*!0_3SRMVS]H_SE^V]B%!-//*W;/VC_ #E^V]B
M
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M(KO8JJ;]OH.W(@TIUIAS[))+3':7TBM@6;K%EXM]E1-MMO.2^
M   #$NWZ*K/@7_8IEF)=_P!%5GP+_L4"A^GGE;MG[1_G+]M[$*":>>5NV?M'
M^<OVWL0
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M^G]VOQJIK!&>"YY>[[D,=#<;*ZDIW,<Y9>%R;*B<NU"3#GRXK8IZ;+UM%HW
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M OZDS$<G[SF[7I=A=LK&U5'CU$V=J\37.:KN%?%$4[, &HC41&HB(G8B
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M9\"_[% H?IYY6[9^T?YR_;>Q"@FGGE;MG[1_G+]M[$
M
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MV%OZK)57\=T^5 +         $99QY9]/O@ZW[B$FD99QY9]/O@ZW[B 2:
M           \.<UC5<Y41$[54UM3D%HIE5*BYT<:IW.E:B_:!LP:2'++#,NT
M=WHE7X9#:TU73U*;T\\4J?\ (Y% ^P   %?-7=9[W@VH,MLI:6EJ;>V%C^"1
M%1VZ[[\P)<U.I9ZW +]3TD3Y9Y*21K&,3FY=EY(4<];_ "YW-<>N2^F%2QV/
M=):PU?5QW>W55'(OMI&JCF?B2;C^I.)W[9+?>:9SU3?A>[@5/G I'ZWN6_\
M#UQ^I4>M[EW_  ]<?J5/T'@GBG9Q02,D;XM7<^@%4NC#BM]LVH4U1=K35TD'
MJ-[4DEC5J;JYO+<M:               #$NWZ*K/@7_8IEF)=OT56? O^Q0*
M'Z>>5NV?M'^<OVWL0H)IYY6[9^T?YR_;>Q
M                                             "&=3:W5*#*I68=3
M1R6GJV\*JUJ^R[^TXF[9'K7:;;45]?30QTL#>.1W Q=D LX"K.,9GK%DUI;<
MK-%#44;G*Q']6Q.:=IUN'5^L,F3V]E^I(VVM9$]4+PL39OR 3R
M                           C/57W::=?M9?N*281GJK[M-.OVLOW%),
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M8A033SRMVS]H_P Y?MO8@
M                               .-UB\FU^^+..R.-UB\FU^^+. Y3HL
M^2FG^,2_:A+I$719\E-/\8E^U"70
M     ",]5?=IIU^UE^XI)A&>JONTTZ_:R_<4DP
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M? [W+D6)VVZU,38I:J))',:NZ(JF^-3B=DCQW'J*U02.DCI8TC1SNU=C;
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M^BJSX%_V*!0_3SRMVS]H_P Y?MO8A033SRMVS]H_SE^V]B
M                                      !%NJ6HU[Q&]P45JQN>Z0R1
M=8LK$79%W[.1Q<FNF4Q1/DDP>J;&Q.)SE1VR)\P%A@5QMW2!O]S@=-;\.FJ8
MFNX5?$JN1%\.PV]CUER>OO%'23X750Q32(QTBH[V*+W]@$[@)S1%
M    #C=8O)M?OB[CLCC=8O)M?OB[@.4Z+/DIIOC$OVH2Z1%T6?)33_&)?M0E
MT                                      C/57W::=?M9?N*281GJK[
MM-.OVLOW%),                           !L
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MM?V[@=>#P]S6,5SW(UK4W557DA$&7Z_XK8:^2CI^ON,T:[.= B<"+X;]X$P
MBK!]<\6RFOCH>.6AJY%1K&U"(C7+X(I*J<TW3L    8EV_159\"_[%,LQ+O^
MBJSX%_V*!0_3SRMVS]H_SE^V]B%!-//*W;/VC_.7[;V(
M                                   'AS&N]LU%]*&GR]C6XM=MFM_\
M-)W>93<FHS#W*W;XM)]B@13T3VH[ J_B1%_VY_<36D;$7=&-W]!"O1.]P=?\
M>>38              #C=8O)M?OBSCLCC=8O)M?OBS@.4Z+/DII_C$OVH2Z1
M%T6?)33_ !F7[4)=                                      (SU5]V
MFG7[6_D4DPC/57W::=?M9?N*28
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MQBMWZ_Q3T 1-IYY6[9^T?YR_;>Q#\_M,9O5&J%FF5.'K*YK]O#=VY^@+>Q
M                                                  &HS#W*W;XM
M)]BFW-1F'N5NWQ9_V*!%71.]P=?\>>380GT3O<'7_'GDV
MXW6+R;7[XNX[(XW6+R;7[XNX#E.BSY*:?XQ+]J$ND1=%GR4T_P 8E^U"70
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M9'TU2V9$2!N_)%W7=NQ:.PT]1266AIZZ7KJJ*%C)9/[SD395 S@
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M_P!O8A033SRMVS]H_P Y?MO8@
M                #3YA[E;M\6?]BFX-/F'N5NWQ9_V*!%?1.]P=?\>>380G
MT3O<'7_'GDV               XW6+R;7[XLX[(XW6+R;7[XNX#E.BSY*:?X
MQ)]J$ND1=%GR4T_QB7[4)=
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M_:/\Y?MO8@
M #49A[E;M\6?]BFW-1F'N5NWQ:3[% BKHG>X.O\ CSR;"$^B=[@Z_P"//)L
M             /G4SQ4M/)/42-CAC:KG/<NR(B$*ZEZEVZ\66XV2V022LJ&+
M$M2J[-3SHG>>=><EG6KBL-*]60HU)*C9?;[]B$/ILG9R0]?A\&MJ=>3U<N7-
M,3JJ0='<YH\(QZ&QUU/)+"V5S_5#.[B_Y2P-JN-+=:&*LH)FS4\B;M<U2GI(
M6B^23VK)8K8^15H:U>'@5>3']RH7Y7 I%)MC[3",>:=ZLL6 #Q76
M                          ",]5?=IIU^UOY%),(SU5]VFG7[67[BDF
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M1U;9I%6*9O"Y$5>2[$3=)_#\BOV>4E59;-75U.VB8Q9((E<U'<3N6Z>E"T@
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M<OVWL0H)IYY6[9^T?YR_;>Q
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M5GP+_L4"A^GGE;MG[1_G+]M[$*":>>5NV?M'^<OVWL0
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M5ZKN=L#.W+S6_J6C'6/1@4-FMM"QK:2AIXD3LX6)N9Z)LG( PF9GRO$:  0
M  '%ZQQL=IS?'N8U7MIW*URIS3T':'&ZQ>3:_?%W")UX')=%MC7Z84\SFM69
M:B1%>J>R7FG>2'E^,T.3VJ2DKXTXME6*5/;1N\4(^Z+/DII_C$OVH2Z6K>U9
MZHGNB8B8TA?$\CN6"7Q,=RI[GVYR[4U2O8WGRY^'V$S1O;)&U\;D<QR;HY%W
M14-+F&,T646E]%7-Y]L<B=K'>*$9XGD-?I_=OS=RI7+;WNWIJI>:-3L3Y/L.
MRU8Y4==.UO6/?ZPRB9QSJ?": >L4C)HF21.1\;T1S7(NZ*A['"V
M                       1GJK[M-.OVLOW%),(SU5]VFG7[67[BDF
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M@4/T\\K=L_:/\Y?MO8A033SRMVS]H_SE^V]B
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MLM6.3'73M:/,>_UAE$SCG4^$S@]8WMDC:^-R.8Y-T5.Q4/8X6P
M                   C/57W::=?M;^123",]5?=IIU^UE^XI)@
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MJM:Z67T)S_$NX5.Z(%BDJ<GNM[D:O44T'4-<J=KW*B_8G[RV(
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M?M'^<OVWL0H)IYY6[9^T?YR_;>Q
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MK]K+]Q23",]5?=IIU^U5^XI)FZ>*  -T\4&Z>*  -T\4&Z>*  -T\4&Z>*
M-T\4&Z>*  -T\4&Z>*  -T\4&Z>*  -T\4&Z>*  -T\4&Z>*  -T\4&Z>*
M-T\4&Z>*  -T\4&Z>* #09UBM#F6-55FNG$D,R(J2-]M&Y.QR><W^Z>*#=/%
M (]TKTQI].WUK;?=ZRJIJI$5T$S41J.3]9-N_;D2$-T\4&Z>*  -T\4&Z>*
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M(4$T\\K=L_:/\Y?MO8@
M        T>;W9MDQ:XUJN1KV1*D?^94V0WA$6L]<^ZWBS8Q2/573S-?,B=R*
MO+^)OQL?Q,D1/CU4R6Z:MEH99G4F.RW2I;_M-P>K]U[>'?\ $[3,/<K=OBTG
MV*9]MI&4-!3TL2(C(F(Q$3S&!F'N5NWQ9_V*5S9/BWF_NFE>F-(JZ)WN#K_C
MSR;"$^B=[@Z_X\\FPR6              XW6+R;7[XNX[(XW6+R;7[XNX#E.
MBSY*:?XQ)]J$ND1=%GR4T_QB7[4)=      !H\OQFAR>UOI*Z-./95BE3VT;
MO%#> M6TTGJKY1,1,:E#&)9%<L%O?YNY4]SK>Y=J:I7L;X<_#["98WMDC:^-
MR.8Y-T5.Q4-)F&,T646E]%7-V=VQR)VL=XH1IB.15^ W;\W,K5RT+EWIJE>:
M(G8GR<OD.RU8Y,==.UH\Q[_6&43..=3X30#UBD9+&V2)R/8Y$<UR+NBH>QPM
M@                       '-YGAMORUM#^4):J&2BEZZ"2FE6-S7;;;[FC
M]:ZB]_\ (_\ 7N_ D  1]ZUU%[_Y'_KW?@/6NHO?_(_]>[\"00!'WK747O\
MY'_KW?@/6NHO?_(_]>[\"00!'WK747O_ )'_ *]WX#UKJ+W_ ,C_ ->[\"00
M!'WK747O_D?^O=^!Y]:ZB]_\C_U[OP)  $?>M=1>_P#D?^O=^!Y]:ZB]_P#(
M_P#7N_ D  1]ZUU%[_Y'_KW?@/6NHO?_ "/_ %[OP)! $?\ K747O_D?^O=^
M ]:ZB]_\C_U[OP)  $?>M=1>_P#D?^O=^!Y]:ZB]_P#(_P#7N_ D  1]ZUU%
M[_Y'_KW?@/6NHO?_ "/_ %Z_@2" (^]:ZB]_\C_U[OP'K747O_D?^O=^!((
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M3+,2[?HJL^!?]B@4/T\\K=L_:/\ .7[;V(4$T\\K=L_:/\Y?MO8@
M                                        'K+(V*)\CUV:Q%<J^9"'
M-.(79/J->,AFW6"F>K(-TW1=UV3YD.OU?OJV7#ZA(G*E15?U,>W:F_;^X^^E
M-F2S8;1,5NTT[4FDW[=W<SLQ_A8+7];=H_[96^]>(]G7FHS#W*W;XL_[%-N:
MC,/<K=OBS_L4XVJ*NB=[@Z_X\\FPA/HG>X.O^//)L              !QNL7
MDVOWQ=QV1QNL7DVOWQ=P'*=%GR4T_P 8E^U"72(NBSY*:?XQ+]J$N@
M  #0YCB]#E%K?25S$1_;'*B>R8OBAO@6K::3U5\HF(F-2AC%,EN&"7EN-Y1Q
M/H5=PTU4O8U-^7R?83+&]LD;7QN1S')NBHNZ*AH\QQBARBUOI:Z-.L1%6*5/
M;1N\4(VQ#)+E@][_ #<RMSEH57:FJ5[$3NY^'V'9:L<FO73M:/,>_P!891,X
MYU/A,X/$;VR,:^-R.8Y-T5%W14/)PM@
M
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M\"_[% H?IYY6[9^T?YR_;>Q"@FGGE;MG[1_G+]M[$
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M.8Y-T5.Q4/8X6P
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M+8WI1T<+E=)MR5R[(C=RY)BV^AHK;$E/04\%-'VI'$U&_N0R@
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MZQ[_ %AE$SCG4^$S@]8I&2QMDC<CF.3=KD7DJ'L<+8
M
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M$_;K7JK4]DWN["UQ6'HG9$VGNUPQBMIH6U#&NDBF1B(_DNSFJO:I9X
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M8
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MVC_.7[;V(4$T\\K=L_:/\Y?MO8@
M          #TGE;!!)+(NS&-5RKYD/<X76.^K9\1FBA=M4UB]3'MV\^W]QIB
MQSDO%(]5;3TQMRNF5.[),^O.1SIQP1/6.%5\Z\MO0B$R'*:7V9++AU#$J;2R
ML2:3ESW=S.K-.5DB^2=>([1^B,<:J  YUP                  #C=8O)M?
MOB[CLCC=8O)M?OB[@.4Z+/DII_C$OVH2Z1%T6?)33_&)?M0ET
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M+&K=T3MYJ!W(
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M%3=5_B!7;^D7F7_N?U0_I%YE_P"Y_5$O?T;<0_WBX_6)^ _HVXA_O%Q^L3\
M(A_I%YE_[G]4/Z1F9?\ N?U1+W]&W#_]XN'UB?@/Z-N(?[Q<?K$_ #4:#:M9
M#FV9RVV\>I_4S:9TJ=6S9>)%1/XEA2-]/M'[!@U[?=+3+5OJ'1+%M*_=-E5%
M_@20              #$NWZ*K/@7_8IEF)=_T56? O\ L4"A^GGE;MG[1_G+
M]M[$*":>>5NV?M'^<OVWL0
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M.-UB\FU^^+N Y3HL^2FG^,2_:A+I$719\E-/\8E^U"70
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M1#R5XY\5:=P
M                               !S>>8;:LVLCK;>8N)F_%'(WVT;O%%
M-/I%I['IY::ZABK%JTJ*A94>K.%439$1%^8W6>9A;,*L,ETO$BI&B\,<;>;I
M'=R(5:R?I%Y5<*MZV9(+;2]C6(Q)'?*J@2?JYH)%E-XFO&/U<='63KQ30R-]
M@]WBBIV*<OAO1IJF7.*?)KC"M'&Y'+! BJLFR]BKW(;;HX9[D&2U]^6_7!U5
M'3P)*Q'-1.%>?AZ#TT[Z0#ZG+*BU92V-M)-.YE-5,3;@Y[(CO-YP+$4E-%1T
ML5-3,2.&)J,8QO8B)R1#ZGAKD<U'-5%:J;HJ=YY   #PYR,:KG*B-1-U5>XK
M3JUT@YJ6X5-IPUC/ZERL?7/Y[JG;PI_$F/66ZRV?3:^U5.JI+ZG=&U4[4XN6
MY5?H\8+09QEE2EZXI**DBZUT:.VZQRJB(BKX <W4ZF9A7U+75-^K%5SD5>%_
M"G;YBPNMVH=VQ#&L/DL]7PUL[&RSHY-^L:C$Y+Z5(YZ3V/6G'LDLD%DH(:.)
MT&[DB3;B7B[5)MSS K3F.F]+-7QJVNH[<DE/.U516JD:+LOBG(#/T:U,I-0K
M1(Y8TIKG3;)/!ONGF<WS$BE+.B]6S4.J3*=CO83POB>G<O-/P+I@>'N:QCGO
M<C6M3=57L1""\]Z1-GL=PFH;'2.NDL2\+YD?PQ[]Z)XG<:X5ERIM.[G'9*>>
M:LJ&]2G4INYJ+VK\Q6/173"7)LT=2Y-154-#3Q++(UR*Q7KNFS=_E [FAZ4$
M_7IZNQ]BP[\^KFY[?*A/.G^;VC.+.E?9YMU;LDL+O;Q.\%0BK6?1W%Z7!ZZY
M66B2AK:*-'M<QZ[.1%YHJ*1#T9;Q56W4NEIH'OZBL:L4K$[%\%^0"Z==5P4%
M)-55DK8:>)JO>]R[(U$*]97TF*2DKY8,?M2U<+%5$GEDX4?YT3;L-GTMLBFM
MV)4-JII%8M=+O+MR56-1>7SD>=&C3:U9:EPNM_@6IIJ9Z11PJJHBNVWW7;M
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M57(G'16Q.%FW9NB[(OVDS'9R/P\=<7ZS^K+']Z9L  XVH  !I\Q]RMV^+/\
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M6P1ATDO)/=O^G[23R,.DEY)[M_T_:!M]$/)7CGQ5IW!P^B'DKQSXJT[@
M
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MMQ25K7KMXJ[<_0)O8A0'3>-L6JUICC39C+@C6IX(CB_S>Q
M                           !SFH5X;9,2N%4KD;(L:LC\[E39#HR(-6Z
MM]\RJRXQ3+NU96OFV[N??\AT<7'\3)$3XCO*F2VJMYHE8UMN+^K9V;5-<[K5
M5>U6]Q(9\:*G924D-/$U&QQ,1C43P0^QGFR3DO-Y]4UKTQH !FL   :C,/<K
M=OBTGV*;<T^8>Y6[?%G_ &*!%?1.]P=?\>>380GT3O<'7_'GDV
M#'K*VFHHG25<\<3&\U5SMB8B9[0B9UWED X2[ZE6V!ZQ6R*6OF[$ZM.1K.MS
M3)D7JXVVND=WKVJGVG37B7UN_P!V/JQGD5WJO>?HY?5.1S\QG1R[HV-$3S')
MG?95I_5VZUK7Q54E?4-YSHY.>WBAP"*B]A[?&M2V.(I.]=GDYJVB\S:-;>3;
M8@^1F4VQT._'UR)R\-^9J%5$3FIT.-QUUEJ*6_RVV6:A8NW%M^\TR3]V85Q_
M-"P2 U&.Y%;[_3)+03-<[;V4:K[)OI0VY\Q:LUG5H[O>K:+1N  %4@
M               :#,\7HLIM+Z.L;L].<4J=K'>)OP6K::3U5\HF(F-2AC#\
MCKL#NOYN98KO4;G?[-4KS1$[$Y^'V$RQ2,EC;)$Y'L<F[7(NZ*AHLRQ:ARFU
MOI*UB)(G.*9$]DQ?$C?$\FN&#7E,;RE'.HE=PTU4O8B;\OD^P[+5CDQUT^;U
MCW^L,HF<<ZGPF<C#I)>2>[?]/VDFQO;(QKXW(YCDW147=%0C+I)>2>[?]/VG
M"V;?1#R68Y\5:=P</HAY*\<^*M.X
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MG#]+,4Q2I2IM=L9ZK3LFE7B<GHW[#N    &)=OT56? O^Q3+,2[?HJL^!?\
M8H%#]//*W;/VC_.7[;V(4$T\\K=L_:/\Y?MO8@
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MF^.-:7Q9IWJR?0 >*ZP
M                                 :+._<9>_BDGW5/SJ=[9WI/TOGBC
MGA?%,Q'QO16N:O8J$;W_ $1PF\(]5M?J25VZJ^G>K5W]'8!3K'*/&JM6LO=S
MK*%R]KHZ=)&I^\DVQ:2X7?$:ENU!IW/=_P"6^!&N3Y%<=3DG1B55?)CUY1$3
MLBJ6[JORH19D&CN:X^YSWVR2>-.R2F=Q;_-S E6+HPTTK>*+*%>U>]M.B_S'
MLO1<BV7;)7[_ !;_ /D0;;\MR[%*A8:>Y5]%(WMCD5?L<=_C_2+RRWJQMQ;2
MU\2=O$SA<ORH!;##K&F.8U06ELZSI2QI'UBIMQ;>8W)I<,OGYQXS;[MU*P>J
MHDDZM5WX=S=   !@WVV07FS5MMJTW@JHG1/\R*FVY32T7J?1+4^X0TLL%UI4
M3JI4C?MQ,5=TY]SD+4:OWJ>P:=WJNI%5M0V!6L<G:U5Y;E',6QJ]9I>GTEG@
M?5UCT61[G.[$WYJJKZ0+1TG24Q22)%J*6OAD[V\"./M_20P[_"N'U1"S>CSF
MRM15AI$7PZT\_P!'G-O\&D^M L;I_J]C^<7M]KM#*IM0V)9=Y6;)LBHG\21B
MNV@6E&1X7FDMRO4<#:9U,Z)%8_B7B54_ L2              #$NWZ*K/@7_
M &*99B7;]%5GP+_L4"A^GGE;MG[1_G+]M[$*":>>5NV?M'^<OVWL0
M                                &MR.YQV>R5E?+[6&-7>E>XFL3:=0
M3.NZ+,G1<NU:HK8Q56DMR(Z7O3B1=U_@A,C6HUJ-:FR(FR(A%FAEODFI;E?J
MO=U163*B.7^[V_Q)4.KESJT8X\5[?[98H[=4^H #D:@    #F<]R5,=M2/B1
M'U<R\$35[O.057UM5<:EU173OFE<N^[E[/0=MK+(]V0TL:JO V'=$^4X(]_@
MXJTQQ;UEX_*R3:\U](>4<Y'H]KG->G8Y%V5"2L!SU8&/HK]/O&QN\<[EY^A2
M-#(MD;9;G21R,21CI6HK5[TW.C-BIEKJS'%DMCMNJ5*S4E:F9:?'[9/62+R1
MRILFY\$L>79'L^Z5WY/IW=L<?;MZ"0;;;J.@@:RCIHX6[=C4,P\/[16G\JNO
MK/>7J_!M?^9;;C;)IY9[<Y))V+5S][I>:+\AUT$$5/&C((V1L3L:U-D/H#"^
M6^2=WG;:F.M/E@ !FN     !QNL7DVOWQ=QV1QNL7DVOWQ=P'*=%GR4T_P 8
ME^U"72(NBSY*:?XQ+]J$N@  !X>QKV*U[4<U4V5%3=%."R/ D6I6XXW,M#7(
MO%PMY-=^!WP-<6:^*=UEGDQUR1JR.K%G<]%5);<K@=2U*+LDZI[%WG4D*&6.
M>)LD+VO8Y-T<U=T4UM^L%OOE.L5P@:_E[%Z<G-]"D?STN0X).LE$]U?9M]UC
M7FK4-^C'R/D^[;V])_)CU7P_-WCW2J#18QE-OR"!'4LG#,B>SA=[9IO3EO2U
M)Z;1J716T6C=0 %5@                  5=U2H9:#.KFDS51)G=:Q?%JG*
M%F-2\(BRN@;) K8KE!_9R+V.3^ZI7J^6*YV*5[+K2O@1B\Y%3V'SGT?#Y-<N
M.(WWAPY<<UEK#NM%:1U5G4#VJB-@B=([[/XG.X_C5UO\T;+92/D8_LF5-F(G
MCN2G+I-5VVV4]58KD^.]PIQ/=OLUZ^">!/)S8XK..;:F48Z6F=Z3$")<8U*J
MK;6):<WIWTU2U>%*CAV1?3^*$JTU1#50,FIY&R1/3=KFKNBG@Y<%\4_>=M;Q
M;P^H ,5@
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M;V(4$T\\K=L_:/\ .7[;V(
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M3^GK^GNK%YKVO_=,8,.U7.CNM&RJM]0R>%Z;HYJ[F8<DQ,3J6OD !
M
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MBIH(G<44,;'>+6HA]2#.C/J5491;I;%>I>MN5$SBBE7MEC[.?G3D3F
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M+2?8IMS3YA[E;M\6?]BG$ZD5]$[W!U_QYY-A"?1.]P=?\>>38
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MG-JING<=QI<FIR9$_P#/9\*VSJUVX4:B\7=V(=UIQ[@\?^)1?=0Z(
M
M     "/]>YI8-*[ZZ!51RP\*[>"]I7?HG6VBKM0YY:UC'RTU*Z2!KO[W$B;_
M #*6OS*S-R#%[I:G;;U4#XVJO<Y479?G*%T=7?-.\Q>^G<^DN=%(K%1S>3D\
M%1>U% _0TY+5BVT5ST]OL5R:Q8F4LDC7._5<UJJBI\I"MFZ3T:4B)>+&Y:E$
MYN@?[%?/S.!U2UQN^9V^2UTD#;?;)%_K&M7=\B>"KW)Z /ET8I9(=5:5L3E1
M'Q/:[;O3D7:*M=$;$JA]SK<EJ8U;3,C6"!7)[=RJFZIZ-OWEI0
M    8EV_159\"_[%,LQ+M^BJSX%_V*!0_3SRMVS]H_SE^V]B%!-//*W;/VC_
M #E^V]B                                  <WEF<8_B<L$=_N,=(^=
M%6-'(O-$-!Z\V"^_L'S*!(9\:RH924DU1*O#'$Q7N7S(<%Z\V"^_L'S*<IJ9
MJ_C-9C$U#8[LR:JJE2-4:B\FKVE\=>N\51:=1MGZ24CK[E=[R>I3=JR+'#OZ
M>U/D)?.:TYM++/B%NIVHG&Z)LCU3O54W.E->3DC)DF8\1VA7'750 '.N &-<
MJ^GMM%+55DB1PQINJJ3$3,ZA$SKO+TN]RIK502U=9(C(HTWY]_F0C2AI:[42
M[>K*]KZ>R0._JX_[ZGK2Q5^HEZ6:IXX;#3O]BSLX^9*='2PT=-'3TT;8XF)L
MUJ=QVSKBQJ/GG]O_ %RQOD3N?E_R\TM/%2P,AIV-CB8FS6M3DB'U .'RZ_ :
M?,/<K=OBS_L4W!I\P]RMV^+/^Q0(KZ)WN#K_ (\\FPA/HG>X*O\ CSR;
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M.2;+W_*3]8[M27JV0UU!(CX96HJ>*>9?.4S\7)@^;PM3)6_AG@ YEP
M
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MV?M'^<OVWL0H)IYY6[9^T?YR_;>Q
M .<RO";!E<L$E^H(ZI\"*C%=W(IS5?H_A$5!4O;8X$<V-RHOR$D&+=?T95_!
M.^Q0*P='7!\>R6?)FWFWLJ4IJA&1<7ZK=U-X[3[&;MJO%;;3;614%"B.GX>Q
M7-YK_ Q.CQ<V6:U9[<)?:PS;IZ>>Q(^A5MD6VU][JMUJ*Z9=E5.?"G?^\Z\%
M8KCMEG\H_.6=YW:*PD^&-D,3(XT1K&(C6HG<B'L <C0 /A75<-#22U-2]&11
MM5SG*3$;[03.N[UN-=3VZCDJ:R1L<,:;JY2+^"MU&O*2+QP6"G=LG=Q['E\E
M;J/=UBCXZ:Q4[MU=_B*2?;:&GMU'%2TD;8X8TV1$0[>W%C_G/[?^N3OR)_X_
MY>U#20T-)%34K$CAC:C6M0^X!Q3.^\NN(UV@ ! &GS#W*W;XL_[%-A4U])2O
M1E3500N5-T221&JOSFCRRZVZ3&+JUE?2*JTS_P#SF^"^<"-^B=[@Z_X\\FP@
MKHK5U)38)7-J*NGB<M<]=GR(U?WDTLNMOD>C&5]*YR\D1)6JJ_O S
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M"9%[$:]-_F/G<G'R8_FAWUO6WB6S !BL
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M;+7=Z2N9>[A(ZGD21&JO)=B;P 1-D1
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MHG=OVG8$7I:DZM&DQ,3W@ !1(
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M/@7_ &*99B7;]%5GP+_L4"A^GGE;MG[1_G+]M[$*":>>5NV?M'^<OVWL0
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MFELMNCHZ)B-C8G->]R^*FP .*9FT[ETQ$1&H  0D
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MYW]]NW)2MY+/1[9(MVN;T1>J1B(J]VYR\_'%L,S/F&F&TQ;2=  ?.NX
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M_IR_M& 9O1ZTDOV'W^2]7U88..G=$E.UW$Y%547=53EW%@P
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MFY]CR;6FTS,^7HUB(C4  *I
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MS9SQTUC4+XL/1WGR  X&P
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M%EO;ON(=/20I3TL,+=D;&Q&)MYDV/J >"]<
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MK6*QJL  *K
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M@J$\8=?XLBLT=6Q."5/82L\')VF7)X=L$=43N&F#DQE[3VEO  <3J
M
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M5=JS2INN_F\#J$Y=@!S7R6R3NT[;UI6D:K  "BP
M
M              #AM1,-6^,2MM^S:^--E:O))$\/20_<*"KMLBLN-.^F5%VW
MDY)\YO<BU)U)HK_<:6WX>L]'#.YD,O5N7C:B\E^8X;46_P"H^<6%+778A-3Q
MI(DG611.XN6_+]YW<?G6Q5Z9C<.3-Q*Y)ZHG4NGLV/W2\2-;04CW,=_YKN34
M3QW)QP['H<=M+:=B\<[O92R?WG?@0'9-0M3[3:*.@APMSF4T38D<L3MW(B;;
MJ=YI=F^;W_(W4F38VMNH4C5W7<*I[+N3F5Y',MGCI\0M@XU<4[\RET '&Z7A
M6HO:B'QDHZ:3^TIXG>EJ'W!,3,>$:AJYL?M,V_66^F7?_D0U=1@6/3JO%0-3
M?^ZNQU +QFR5\6E6<5)\PX2?2ZPO55B2HB7S/,&32YC%_P!DO%7"GAN22#6.
M9FC^IG/&Q3Z(P=@F14VZ4603*WNXG*>JVK/J!CG0U\,[6IO[)=U)1"INFREO
MMEY^:(G]%?LM8\3,?JK#4ODDJ9GSKO,KUXU_YM^9\SH\_L4ECOLVZ*M+4.62
M-^W+FO-#G#WL=XO6+5\/(M6:VF)"2-%9GI6W"%%_JU1'*GG(V5=OX(G>33I1
M89;7:'U=6S@J*I>)&JG-K>XYN=:*X9B?5OQ*S.2)CT=T #Y][(
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M_P# "5P<YA&9V?-+?-66&=\T$3^K<KF*W9?E.C
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MBB">E[[@K?\ '4^ZX#A^B99;9=YKZESH8*K@1G"LK>+A]!8S\Q\9]XZ'ZI"
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MEVV[";/S'QGWCH?JD(FZ('N+N?QK^!/8'.?F/C/O'0_5(>?S'QGWCH?JD.B
M'._F/C/O'0_5(/S'QGWCH?JD.B '.?F/C/O'0_5(>?S'QGWCH?JD.B '._F/
MC/O'0_5(>/S'QGWCH?JD.C '._F/C/O'0_5(/S'QGWCH?JD.B '._F/C/O'0
M_5(/S'QGWCH?JD.B '._F/C/O'0_5(/S'QGWCH?JD.B '._F/C/O'0_5(/S'
MQGWCH?JD.B '._F/C/O'0_5(/S'QGWCH?JD.B '._F/C/O'0_5(/S'QGWCH?
MJD.B '._F/C/O'0_5(>/S'QGWCH?JD.C '._F/C/O'0_5(/S'QGWCH?JD.B
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M_P JGYPY3[IKO\;E^^H%I^A_[A[G\<_E0GD@;H?^X>Y_'/Y4)Y
M                       '.7_!\:O]1U]XLU)53;;<;V<_G0Z, :7'\5L>
M/(Y++:Z6CXNU8V<U^4W0    #$NWZ*K/@7_8IEGSJ86U%/+"]51LC58JIX*F
MP%"-//*W;/VC_.7[;V(0W9.C_8+3DE/>8;C<'SPS]>UCE;PJN^^W83(G)
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MJ(FZ]@ 'Q950/?P,FC<_P1R;GV
M'A[FL:JO<C43O5=@/(/E%4P2NX8YHWKX-<BGU
M             #Y35,$+D2::-BKW.<B'T8]KVHYCD<U>:*B[HH'D
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MFKL4=TFN+K1J39:AKU8UM2C'>=%78#] @&JCD14[%Y@
M             U&67ZEQK'JZ[UR[04L:O5.]R]R(4GR7/,NU%R+J*:>J=U\B
MMIZ.F56HB*O).7;Z5+B:EX='G&,R6>:KDI&/>U_&Q-^SN5#BM)]%*; LBFNK
MKCZO>L?5QM=#PJSQ7?=0*S7W&<\PV".XW.&XT,7$C4F27=$7S[*3]T<-5ZK)
MW/Q_(9DEN,;5?!,J;+(Q$YHOG0[7I!5M#1Z6WA+@K/ZYJ1Q-=VN>J\MBLW1G
MI)ZK56@= B\,+'O>J=R; 7?                                -9DM\
MHL=LM5=+G*D5+3L5SE7O\$3SJ;-51$5579$*C=)'4)^57V/%;"JRT=-,C7NC
M7?KYNS9/,F_S@1EJ#G%RR[**RZRSRQ1R.X88FN5$9&G8A='19[GZ7XZY[G.<
MM*W=7+NJE)<^Q.HPV\0VVND:^J=3QS2-1/:*Y/:_(78T2\EN.?%&@=N
M                          #FM1,OH\)QBIN]?[+@]C%&G;(]>Q"FMTRC
M-M4<C=%2OJIY7JJQTM,O"R-O_P#O>I*G3&O#N.R6=KE1J<50Y/'M1#&Z.%YQ
M_"L,NM_O]3#!+/4=5'WR.:B)R:G;V@1/<&9MIS>*:2N?76ZJWXX^*3B:_;Y=
ME+>Z+9\S/L3;5RHUEQIUZJJ8WLXNY4\RG'7/-=,=4IJ2V7:H5LD<F\*SM6/=
MR\MD7SDFX9AMCQ&GF9C](V!DZHYZM7?B\ .C
M       !!?20U1K<2B@LEA?U5PJH^LDGVW6-FZILGG4@''<0SW-::6YVZ.NJ
MH=U_KGS;(Y?!-U.XZ6UAJZ?,::[\$CZ*I@1G6;>Q:Y%7V.Y)FA&I&+1:?4-!
M67&FM]711\$L<SD;Q;?K)X@0'AV?Y5IOE"T]?+4K'$_@JJ*H<KDV[]M^Q?07
M<L-T@O5FH[E1KO!51-E9Z%3<I%K;?J/-=2)Y\>B6:-W# QS&\YG>/[RXFF-H
MGL>"66WUF_JB*G8DB+^JNW- .G                             >LO\
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M$\%<C45S)E]ELO82IH-C&5-S3'KF^AKDLW%QI-O_ %?!MZ>P"Y8
M                      *B],#?\^+7X>H_YE.<T-TP?J'55$EPJI(+11KP
MNX%]DYR\]D\"1^F+97NBLMY8Q5:U74[W)W=JH>G0_P @H(*:[66>=D=9+*D\
M;7+MQILB+L!Q6NFD#,!@I;I9JF6>VR/ZMR2>WB=W<_ ECHL9S5Y!8ZNRW69T
M]30;.AD=VK&O+95[]E/KTLKQ108#%;7S,6LJ:AKF1HNZ[-WW4X7H<T4RW^]U
MJ,7U.VG2)7=W$KD7;]P%JP                               5]Z3FI$
M5IA_->DI:>IJ9X^.:25J.2)%WVV3^\0[@6BN2YE9UNE*M/2TKMUB6=519/0G
M@?'I$13Q:L7E:K=>)S7,5?[NW(MMH[=*"Y:=6)UOEC<V*E9$]K5]HY$1%1?E
M I[:*F[Z29YO<K;#)5P<G1S-XFN:J^V:OR=I=S#,CH\KQRBO%O7^IJ&(JM7M
M8[O:OH*L]+:YT-=F]#3T<L<L]+3<$RMY\*JJJB*2_P!%6&:+2Z-TJ*C)*F1S
M-_#D!,(                            #UE_LG_Y5/SBRGW37?XW+]]3]
M'9?[)_\ E4_.+*?=-=_C<OWU M-T/_</<_CG\J$\D#=#_P!P]S^.?RH3R
M                                      *QZX:&U]7=ZB^XC&V9LZ\<
M](G)S7<]U;X^@LX *%MP[4&ZM@M4MONTD+%X61R\21M^?D60T#TD=@S);I>'
MLDO%1'P<#>R%O:J;]Z\B9                                 !%/2*M
MF07O#H[5C5+).Z>5.OX';>P3N*R)HWG/O)+])"^( HCZT&>^]$_TT.XT6TVR
MZR:B6VONMMFAI(N)7O<_DG(ML
M JMT@M.LHR/46HK[/:Y*FD=!&U)&JG-41=T)^TJMU7:=/K'0W&)8:J"G:R1B
M_JKX'5@                                #0YOB]#E^.55HN;5ZF9/8
MN3M8Y.QR%/\ +=',QQ"ZK+;()ZV!CMX:JDWXOF3FBEW@!1NSZ89YFEV8MQI:
MMB*J(^IK55.!OCS[?06WTQPBAP/&H[71+UDJKQSSJFRR/\3K0
M                     !$&NFD3<\;'<K9,R"[P1\"(Y/8S-YJB*O<OG*YQ
MXCJ1B=1/2T-'=:?B]B[U*JJUWS%ZP!2W!=$,IRFZ)47V.6WT3G<4LT_.1WBB
M)V[^<N%CUHI+#9J2V6^-(Z:FC2-B>.R=J^<V
M       /67^R?_E4_.+*?=-=_C<OWU/T=E_LG^A3\X<I]TUW^-R_?4"T_0_]
MP]S^.?RH3R0-T/\ W#W/XY_*A/(
M           1;1:L4E1J[/B/"Q(&LZMDV_;,G:TE(
M
M
M                                        /67^R?Z%/SARGW37?XW+
M]]3]'I?[)_H4_.'*?=-=_C<OWU M/T/_ '#W/XY_*A/) W0_]P]S^.?RH3R
M                                        .1U5RR+#L*N%T>Y$G1G5
MP-_O2+V'7'!ZG::T&H"4B72OK((:9%5(X%1&N5>]=P*-4M[K(,A9>6RKZM;4
M>J./?M=Q;E_]/<EI\LQ*WW>F<B]=&B2(GZKTY.3YRDMNQ&CJ=54QA\TJ4?JU
M:;K$]MPHNV_I+CZ9:>T> 4E736VNJZBGG<C^"=45&+YM@.U
M
M
M                                             'K+_9/]"GYPY3[I
MKO\ &Y?OJ?H]+_9/_P JGYQ93[IKO\;E^^H%INA_[A[G\<_E0GD@;H?^X>Y_
M'/Y4)Y                                         'AWM5]!Y %)[(
MUR=(E%X7;?E5W/9?[REV$[#5LQVT,KO5K;=3)5\7%UJ,3BW\=S:
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M\P>L,C)HF21N1S'HCFJG>BGL
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MF$W.IO&*6NX5\"T]740-?+&J;*UW>!N@
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MV*I<N[VT[8G+YVIM_ [4B'HM2NDTNIVNWV9,]$^<EX
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M]L]4[U,H
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MBUVY$1%IJ9D:[>*-3<VX
M                                   >LO\ 9/\ 0I^<64^Z:[_&Y?OJ
M?H[+_9/_ ,JGYPY3[IKO\;E^^H%I^A_[A[G\<_E0GD@;H?\ N'N?QS^5">0
M
M
M          $0=)?#'Y-A*UM%'QUUM=UR(B<W,V7B3^)+YXD8V1CF/:CF.394
M7L5 *U]$+*&=1<<;J'[2H[U1"BKW<D5$+*G%V73#$[+?4O%KM;:>O1RO21LC
MMD5>WEOL=H        !Q&LN4LQ+ ;C7<6U1(WJ($\7N1=OXE=^B]A;[_ )9)
MD5<SBH[>Y5;Q-W1\J_AON6@R_#[+E]+#37^D]50Q.XV-XW-1%\>2F3B^.6O%
M[6VW6.D92TC7*[@:JKNJ]ZJH&V
M                                           >LO\ 9/\ \JGYPY3[
MIKO\;E^^I^CTO]D__*I^<.4^Z:[_ !N7[Z@6GZ'_ +A[G\<_E0GD@;H?^X>Y
M_'/Y4)Y
M
M
M                                                    ]9?[)_\
ME4_.'*?=-=_C<OWU/T>E_LG_ .53\XLJ]TUW^-R_?4"TW0_]P]S^.?RH3R0-
MT/\ W#W/XY_*A/(
M
M
M                                                           '
MK+_9/]"GYPY3[IKO\;E^^I^CTO\ 9/\ \JGYPY3[IKO\;E^^H%I^A_[A[G\<
M_E0GD@;H?^X>Y_'/Y4)Y
M
M
M
M     ]9?[)_^53\XLI]TUW^-R_?4_1V7^R?_ )5/SARGW37?XW+]]0+3]#_W
M#W/XY_*A/) W0_\ </<_CG\J$\@
M                                                ##NEUH+3"V:Y
MUE/21.7A1\TB,15\.8&8#56S([-=*A:>VW6BJIT;Q=7#,USMO'9%-J
M   !'FI6K>/X%60T5QZZIKI&\?40(BJUO<JJO9V&YT]SNS9W:GUMDE<JQ*C9
MH9$V?&J^*?Q ZH                   ?&MJZ>AII*FLGC@IXTW?)(Y&M:G
MG535T65V"MJ8Z>CO-OGGD79D<<[7.<OF3<#=
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MI^<65>Z:[_&Y?OJ!:;H?^X>Y_'/Y4)Y(&Z'_ +A[G\<_E0GD
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M#'DKJ5O4UD.S*JG_ ,-^W=XHO<;/.\OM>%6*2Z7F56Q(O#'&U-W2/VY-1/D
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M^53\XLI]TUW^-R_?4"TW0_\ </<_CG\J$\D#=#_W#W/XY_*A/(
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M*OH1'<P*O:9WN;'L]LU?2N<O!4M8Y$7;B8Y>%47Y%+)=+Y>+ ;6J=BUJ+_\
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M%'%65"SNAIV3-1S&(U$W=LO+?=2.ND]Y7;E\#%]TGOHI>2J/XW+_   ^^O.
M6&YX!=*^.WTU+7T$+IX9X(T8OL>:M7;M12K6C5=-;]3,?FIW*USJIL;MEVW:
M[DJ%TM7?)EDOQ&3[%*1Z5^47'?CL?V@60Z7.0U%OQ&@M-,Y[&W"55E5J[;L;
MSX5^54^8K[I'<<5L^1K<,RIYJJ"!J.@@8Q'M=)OVN1>Y/ L+TML>GN6'4-UI
MHW2?D^5>MV_58[EO\Z(5XTEK<6ILF2'-Z!*JUU#>KZWB<G4.WY.Y*FZ=R@6
MKM==.J^@?15EHFFI7MX5B=2MX=O1W%8\L=:$R2KEQATZ6M9..!)4X7,3MV^3
MQ+:PX%H]-2)51QVQ8%3?C]6NV^\:3&K)HQD>45%BM5!'+5Q-W:_K7HR7Q1B\
M7/8"5=*KK+>M/+!75"JLTE(Q'JJ[JJHFRK^XZLP;'::*QVNGMUKA2"CIV\$<
M:*J\*?*9P                   >LO]D_\ RJ?G#E/NFN_QN7[ZGZ/2_P!D
M_P#RJ?G#E/NFN_QN7[Z@6GZ'_N'N?QS^5">2!NA_[A[G\<_E0GD
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MXY_*A/(
M   'A[6O:K7M1S5[45-S$6U6]7<2T%*KO'J6_@9@ ]8XV1L1L;6L:G8C4V0]
M@
M
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M_'/Y4)Y(\T/P.? <3=0UTZ2UL\JRS<"[L:O8B-^0D,
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M]2V"6>H6.171H_=.%5[SG.CCJ3DN:9'<Z6_UC)X(*9)&-;$UNSN+;M1 +!
M    /"N1.U43Y3RBHO8NX \2/;&QSY'-8QJ;N<Y=D1/%3R01TM<EJ[5B=!:Z
M*5\7Y1E7KG-7;BC:G-ORJJ?,!TU_UVP>SUCJ;\H25DC%V<M+&KVHOI[%^0Z+
M!=1L;S9TD=AKNLJ(V\;X)&*U[4\=E*>Z0Z85VHU95MIZN.CI*1$ZV9[5<JJO
M8B(6=T/TK73K\K25=1#6555(C8YF-5%2).Q%W[%WY@2H   '8>$<B]BHOH \
M@*J)VJ@3GV  -T\4  #L"*B]BH  "JB=JH@ 'A'(O8J+Z#R  5=NT(J+V*@
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MN3?3&_#J(WMDC:^-R.8Y$<U4[%13V/6-C8XVLC:C6-1&HB=R(>VYHY0#L
M  %7;M  X^PZA66\Y?<<9A6>&[47%Q1S,X4>B+LJM7O\?0=@5XU_I'XCJ'BV
M;T#>K1T[8*I6_K;+W^ENZ 6'!\J2=E52PSQ+O'*Q'M7S*FY$^?39UAUYK<DM
MEPI[MCR_UD]NJ%;&Z%J)S1B]_) .^Q;*[=DL]UAMO6\=MJ5I9^L;M[-/#Q0W
MY4K3/4&]5UTR"UX50117.]5SZQ)ZN5J-IXU\W>Y-RR>!VB[66P,IK_>'W>O5
MZR/G<U&HF_ZJ>9 .B
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MR\'ZK5\=O$Z"*&*)7+%&QBO7=W"U$W7Q4]P
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MJ2"AI(J6CB9#3Q-1C(V)LC43L1"#-9M%;KG>9.O%#<J.GA6!D2,E1W%NW?P
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M)O34S&+MX[<_WF[)5
M
M         5'Z0^#Y/>]2ZRMM%BN%92.AC1LL,2N:JHG/F3CT?+37V73.@HKM
M1S4=6Q\BNBF;PN1%<NW(D<
M                        $%ZJXU>[+JG8LWQ:VU%>G*&M@IF*YRIS157;
MQ:O[B<8).M@CDX7,XVH[A<FRIOW*>X
M                ! U?C=\SK76"ONMMJZ/';&N\#YV*C9G-7DK?'=>?H0GD
M
M
M
M
M
M
M
M
-              '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
